https://clival.com/news/mannkind-reports-phase-3-inhale-1-results-for-afrezza-in-youth daily 0.8 https://clival.com/news/sapience-therapeutics-begins-patient-enrolment-in-phase-2-study-of-st316 daily 0.8 https://clival.com/news/tenayas-tn-201-shows-promise-in-mypeak-1-trial-for-mybpc3-hcm-treatment daily 0.8 https://clival.com/news/mannkind-reports-phase-3-inhale-1-results-for-afrezza-in-youth? daily 0.8 https://clival.com/news/abbisko-therapeutics-announced-the-entry-into-a-licensing-agreement-for-pimicotinib-absk021-with-merck? daily 0.8 https://clival.com/news/tenayas-tn-201-shows-promise-in-mypeak-1-trial-for-mybpc3-hcm-treatment? daily 0.8 https://clival.com/news/category/certificates-accreditation?page=2%29%2BAND%2B2014%3D5165%2BAND%2B%286361%2BBETWEEN%2B6361%2BAND%2B6361 daily 0.8 https://clival.com/news/pfizer-launches-pfizerforall-a-digital-platform-that-helps-simplify-access-to-healthcare? daily 0.8 https://clival.com/news/overland-adct-biopharma-announces-biologics-license-application-for-zynlonta? daily 0.8 https://clival.com/news/us-fda-accepts-bla-for-sobis-nanoecapsulated-sirolimus-plus-pegadricase-for-patients-with-uncontrolled-gout? daily 0.8 https://clival.com/news/truenorth-launches-sensibiotics-in-india? daily 0.8 https://clival.com/news/gsk-launches-shingles-vaccine-shingrix-in-india? daily 0.8 https://clival.com/news/gefurulimab-meets-primary-and-secondary-endpoints-in-phase-iii-prevail-trial-for-generalised-myasthenia-gravis? daily 0.8 https://clival.com/news/valneva-reports-positive-phase-1-results-for-second-generation-zika-vaccine-candidate-vla1601? daily 0.8 https://clival.com/news/new-tb-trial-data-shows-sorfequiline-could-dramatically-shorten-treatment-time? daily 0.8 https://clival.com/news/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema? daily 0.8 https://clival.com/news/uk-mhra-approves-bridgebios-beyonttra-for-treating-attr-cm? daily 0.8 https://clival.com/news/arrowhead-pharma-gets-fda-approval-for-plozasiran-in-chylomicronemia-syndrome? daily 0.8 https://clival.com/news/ingrezza-shows-nearly-two-fold-higher-vmat2-target-occupancy-vs-austedo-xr? daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-f2gs-olorofim daily 0.8 https://clival.com/news/cbc-group-backed-hasten-biopharma-successfully-completes-acquisition-of-five-cardiovascular-and-metabolism-drugs-from-takeda daily 0.8 https://clival.com/news/astrazeneca-announces-approval-of-calquence-in-china daily 0.8 https://clival.com/news/us-fda-grants-priority-review-status-to-astrazenecas-snda-for-calquence daily 0.8 https://clival.com/news/new-frontier-group-acquires-hong-kong-integrated-oncology-centre daily 0.8 https://clival.com/news/cellistic-to-acquire-celyad-oncologys-gmp-cell-therapy-manufacturing-operations daily 0.8 https://clival.com/news/merck-eisai-provide-updates-on-two-phase-3-trials-evaluating-keytruda-plus-lenvima-in-patients-with-certain-types-of-metastatic-nsclc daily 0.8 https://clival.com/news/merck-cctg-announce-phase-23-trial-of-keytruda-plus-chemotherapy-improves-os-vs-chemotherapy-alone-to-treat-advanced-malignant-pleural-mesothelioma daily 0.8 https://clival.com/news/china-nmpa-accepts-astellas-bla-for-zolbetuximab-to-treat-patients-with-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-gej-adenocarcinoma daily 0.8 https://clival.com/news/us-fda-advisory-committee-backs-up-abbotts-triclip-system daily 0.8 https://clival.com/news/hong-kong-science-and-technology-parks-corporation-inks-strategic-collaboration-with-roche daily 0.8 https://clival.com/news/fda-approves-ionis-tryngolza-for-familial-chylomicronemia-syndrome daily 0.8 https://clival.com/news/botswana-national-hiv-reference-laboratory-designated-who-collaborating-centre-of-excellence daily 0.8 https://clival.com/news/eli-lilly-japan-and-mitsubishi-tanabe-pharma-corporation-announce-new-launch-of-mounjaro daily 0.8 https://clival.com/news/x-trodes-receives-clearance-for-wearable-skin-solution daily 0.8 https://clival.com/news/atea-pharmaceuticals-announces-us-fda-fast-track-designation-granted-to-bemnifosbuvir daily 0.8 https://clival.com/news/mesoblast-gets-dsmb-recommendation-to-continue-remestemcel-l-phase-3-trial-in-covid-19-ards daily 0.8 https://clival.com/news/sun-pharma-gets-sec-nod-for-phase-iii-clinical-trial-for-antipsychotic-drug-pimavanserin daily 0.8 https://clival.com/news/leqembi-approved-for-the-treatment-of-alzheimer-disease-in-china daily 0.8 https://clival.com/news/doer-biologics-announces-first-patient-dosed-in-phase-2-study-of-dr10624 daily 0.8 https://clival.com/news/gsk-seeks-fda-approval-for-investigational-hiv-treatment daily 0.8 https://clival.com/news/vivavision-biotech-announces-positive-topline-results-of-vvn001-in-the-phase-2-clinical-study-for-the-treatment-of-dry-eye-disease daily 0.8 https://clival.com/news/canariabio-achieves-significant-milestone-with-fda-orphan-drug-designation-for-mab-ar205-targeting-pancreatic-cancer daily 0.8 https://clival.com/news/biophytis-seeks-us-fda-approval-to-initiate-sara-31-phase-3-study-in-sarcopenia daily 0.8 https://clival.com/news/qiagen-gets-us-fda-nod-for-therascreen-kras-kit-as-companion-diagnostic-test-to-mirati-therapeutics-krazati-in-nsclc daily 0.8 https://clival.com/news/dr-reddys-labs-launches-generic-syprine-capsules-in-us-market daily 0.8 https://clival.com/news/boehringer-gets-bta-by-fda-starts-phase-iii-trials-in-mash-for-survodutide daily 0.8 https://clival.com/news/axsome-speed-up-completion-of-advance-1-phase-23-trial-of-axs-05-in-alzheimers-disease-agitation daily 0.8 https://clival.com/news/cellenkos-receives-approval-for-second-cohort-in-als-trial daily 0.8 https://clival.com/news/the-china-nmpa-approves-selpercatinib-for-the-treatment-of-patients-with-ret-driven-lung-and-thyroid-cancers daily 0.8 https://clival.com/news/roches-phase-iii-empacta-study-of-actemraroactemra-in-hospitalised-patients-with-covid-19-associated-pneumonia-meets-primary-endpoint daily 0.8 https://clival.com/news/sandoz-to-appeal-district-court-of-new-jersey-ruling-in-biosimilar-erelzi-us-patent-case daily 0.8 https://clival.com/news/beijing-tide-pharmaceutical-and-insilico-medicine-enter-into-a-strategic-partnership-agreement-for-cancer-therapy daily 0.8 https://clival.com/news/xencor-and-atreca-enter-strategic-collaboration-to-discover-develop-and-commercialize-novel-t-cell-engaging-bispecific-antibodies daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-novartisa daily 0.8 https://clival.com/news/us-fda-accepts-for-review-mercks-nda-for-gefapixant-to-treat-refractory-chronic-cough daily 0.8 https://clival.com/news/desai-pathology-introduces-rt-pcr-testing-for-over-20-infectious-diseases-in-kolhapur-in-partnership-with-mylab daily 0.8 https://clival.com/news/abbisko-therapeutics-announces-that-us-fda-has-granted-fast-track-designation-for-its-csf-1r-inhibitor-pimicotinib-absk021 daily 0.8 https://clival.com/news/antengene-receives-us-fda-clearance-of-ind-application-for-phase-i-trial-of-small-molecule-erk12-inhibitor-atg-017-in-patients-with-advanced-solid-tumors daily 0.8 https://clival.com/news/glenmark-receives-orphan-drug-designation-for-its-antibody-candidate-for-multiple-myeloma daily 0.8 https://clival.com/news/astrazeneca-and-daiichi-sankyo-recommend-for-approval-of-enhertu daily 0.8 https://clival.com/news/cstone-announces-european-commission-approval-of-sugemalimab-cejemly daily 0.8 https://clival.com/news/roche-already-prepping-2021-launch-charts-big-expansion-plans-for-lucentis-eye-implant daily 0.8 https://clival.com/news/innovent-announces-phase-2-study-of-mazdutide-in-chinese-patients-with-type-2-diabetes-meets-primary-endpoint daily 0.8 https://clival.com/news/syros-receives-fda-orphan-drug-designation-for-tamibarotene-for-the-treatment-of-mds daily 0.8 https://clival.com/news/ema-accepts-anavexs-blarcamesine-application-for-alzheimers-treatment daily 0.8 https://clival.com/news/us-fda-approves-crenessity-for-classic-congenital-adrenal-hyperplasia daily 0.8 https://clival.com/news/eisai-and-biogen-announce-the-traditional-approval-for-leqembi daily 0.8 https://clival.com/news/lilly-announces-agreement-to-acquire-disarm-therapeutics daily 0.8 https://clival.com/news/nona-biosciences-inks-hcab-based-drug-discovery-collaboration-agreement-with-dragonfly-therapeutics daily 0.8 https://clival.com/news/chimeric-enters-strategic-manufacturing-partnership-with-wuxi-advanced-therapies daily 0.8 https://clival.com/news/ferring-announces-new-collaboration-for-development-of-olamkicept daily 0.8 https://clival.com/news/eyenovia-and-arctic-vision-announce-exclusive-collaboration-and-license-agreement-to-develop-and-commercialize-micropine-and-microline-in-greater-chin daily 0.8 https://clival.com/news/astrazeneca-and-serum-institute-of-india-sign-licensing-deal-for-1-billion-doses-of-oxford-vaccine daily 0.8 https://clival.com/news/ipsen-phase-iii-napoli-3-trial-of-onivyde-regimen-meets-primary-endpoint-demonstrating-statistically-significant-improvement-in-os-in-previously-untreated-mpdac daily 0.8 https://clival.com/news/neurobo-pharma-signs-exclusive-license-agreement-with-mthera-pharma-for-nb-01 daily 0.8 https://clival.com/news/yisheng-biopharma-receives-approval-from-china-nmpa-for-rabies-vaccine-production-facility daily 0.8 https://clival.com/news/nsg-biolabs-and-eppendorf-group-form-alliance-to-enhance-biotech-support-in-singapore daily 0.8 https://clival.com/news/dr-reddys-labs-launches-generic-venlafaxine-er-tablets daily 0.8 https://clival.com/news/keymed-biosciences-gains-approval-for-stapokibart-to-treat-chronic-rhinosinusitis daily 0.8 https://clival.com/news/jb-pharma-board-approves-acquisition-of-4-paediatric-brands-from-dr-reddy-for-rs-98-crore daily 0.8 https://clival.com/news/pharmacyte-biotech-successfully-completes-manufacturing-of-clinical-trial-product daily 0.8 https://clival.com/news/strides-pharma-gets-usfda-nod-for-generic-product daily 0.8 https://clival.com/news/phylex-biosciences-announces-nipah-virus-vaccine-initiative-with-its-nanoparticle-mrna-vaccine-technology daily 0.8 https://clival.com/news/glenmark-launches-tiogiva-tiotropium-bromide-dry-powder-inhaler-in-uk daily 0.8 https://clival.com/news/flagship-pioneering-introduces-a-new-bioplatform-company-abiologics daily 0.8 https://clival.com/news/syneurx-announces-final-results-of-phase-2-clinical-trial-of-covid-19-oral-antiviral-candidate-pentarlandir daily 0.8 https://clival.com/news/ptc-therapeutics-ptc518-huntingtons-disease-programme-receives-fta-from-us-fda daily 0.8 https://clival.com/news/ptc-therapeutics-announces-strategic-financing-collaboration-with-blackstone-with-up-to-1-billion-in-funding daily 0.8 https://clival.com/news/fda-approves-ryoncil-for-steroid-refractory-agvhd-in-young-children daily 0.8 https://clival.com/news/biocytogen-pharmaceuticals-and-myricx-bio-enter-into-licence-agreement-for-adc-development daily 0.8 https://clival.com/news/lipella-pharma-completes-dosing-for-first-cohort-in-phase-2a-trial-of-lp-310-for-oral-lichen-planus daily 0.8 https://clival.com/news/ucb-collaborates-with-veeva-systems daily 0.8 https://clival.com/news/brainomix-launches-full-suite-of-us-fda-cleared-modules-in-its-brainomix-360-platform-for-stroke-care-in-us daily 0.8 https://clival.com/news/roche-late-stage-trial-of-two-lung-cancer-drugs-fails daily 0.8 https://clival.com/news/innovation-pharma-to-begin-patient-screening-for-phase-1-trial-of-oral-brilacidin-to-treat-ulcerative-colitis daily 0.8 https://clival.com/news/ricoh-and-ers-genomics-enter-into-crisprcas9-license-agreement daily 0.8 https://clival.com/news/kimera-labs-responds-to-fda-warning-letter daily 0.8 https://clival.com/news/armgo-pharma-begins-patient-enrolment-in-phase-2-trial-of-arm210-to-treat-catecholaminergic-polymorphic-ventricular-tachycardia daily 0.8 https://clival.com/news/abbvie-partnered-calico-unveils-first-licensing-deal daily 0.8 https://clival.com/news/ethris-receives-uk-mhra-nod-to-begin-phase-i-study-of-eth47-a-first-in-class-inhaled-mrna-for-respiratory-viral-infections daily 0.8 https://clival.com/news/laurus-labs-receives-eir-from-usfda-for-visakhapatnam-units daily 0.8 https://clival.com/news/icmr-set-to-collaborate-with-pharma-companies-to-develop-dengue-vaccine daily 0.8 https://clival.com/news/us-fda-approves-braeburns-brixadi-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder daily 0.8 https://clival.com/news/hillstream-biopharma-signs-option-agreement-to-advance-next-generation-anti-muc1-c-agents daily 0.8 https://clival.com/news/arecor-trx-biosciences-partners-for-oral-glp-1-therapy daily 0.8 https://clival.com/news/radiopharm-gets-hrec-nod-for-177lu-rad-202-study-in-her2-solid-tumors daily 0.8 https://clival.com/news/genscript-probio-and-neoletix-signed-a-letter-of-intent-on-clinical-and-commercial-production-of-recombinant-human-coagulation-factor-viii daily 0.8 https://clival.com/news/larimar-reports-positive-ole-data-advances-nomlabofusp-for-ataxia daily 0.8 https://clival.com/news/bespak-and-medicines-evaluation-unit-partners-for-climate-friendly-inhalers daily 0.8 https://clival.com/news/abbott-gets-cdsco-approval-for-marketing-of-estradiol-dydrogesterone-fdc daily 0.8 https://clival.com/news/scopio-labs-receives-fda-clearance-for-its-ai-powered-full-field-peripheral-blood-smear-full-field-pbs-application daily 0.8 https://clival.com/news/sentiar-announces-second-fda-clearance-for-commandep-interface daily 0.8 https://clival.com/news/glenmark-pharma-gets-us-fda-approval-for-generic-elidel-cream daily 0.8 https://clival.com/news/wuxi-biologics-and-bayer-enter-into-acquisition-agreement daily 0.8 https://clival.com/news/spains-pharmamar-says-covid-19-treatment-drug-shows-clinical-efficacy-in-trials daily 0.8 https://clival.com/news/dante-labs-in-partnership-with-the-renato-dulbecco-foundation-to-advance-personalized-drugs-for-cancer daily 0.8 https://clival.com/news/insilico-collaborates-with-bi-for-discovering-therapeutic-targets daily 0.8 https://clival.com/news/aurobindo-pharma-gets-us-fda-nod-for-generic-antifungal-injection daily 0.8 https://clival.com/news/arisglobal-acquires-boehringer-ingelheims-digital-innovation-brass daily 0.8 https://clival.com/news/hikma-celltrion-healthcare-ink-exclusive-licensing-agreement-for-vegzelma-for-mena-markets daily 0.8 https://clival.com/news/eurofins-discovery-and-immunoprecise-announce-collaboration-to-expand-their-antibody-discovery-platform daily 0.8 https://clival.com/news/phanes-therapeutics-pt217-gets-to-fast-track-designation daily 0.8 https://clival.com/news/beigene-enter-into-agreement-with-novartis daily 0.8 https://clival.com/news/mediwound-announces-positive-results-in-us-phase-iii-study-of-mw005-for-the-treatment-of-basal-cell-carcinoma daily 0.8 https://clival.com/news/mhra-grants-marketing-authorisation-to-lupin-zentivas-generic-raltegravir daily 0.8 https://clival.com/news/united-biopharma-gets-taiwan-fda-nod-for-phase-2-ind-for-ub-221-to-treat-chronic-spontaneous-urticaria daily 0.8 https://clival.com/news/dca-telangana-raids-pharma-unit daily 0.8 https://clival.com/news/telix-to-expand-by-acquisition-of-isotherapeutics daily 0.8 https://clival.com/news/aurobindo-gets-licence-for-supply-of-pfizers-covid-pill daily 0.8 https://clival.com/news/fda-takes-additional-action-in-fight-against-covid-19-by-issuing-emergency-use-authorization-for-second-covid-19-vaccine daily 0.8 https://clival.com/news/gilead-looks-to-redefine-hiv-prep-market-with-2025-launch-of-long-acting-sunlenca daily 0.8 https://clival.com/news/us-fda-approves-recarbrio-to-treat-hospital-acquired-bacterial-pneumonia-and-ventilator-associated-bacterial-pneumonia daily 0.8 https://clival.com/news/chugai-receives-japanese-mhlw-approval-for-piasky daily 0.8 https://clival.com/news/phase-iii-aranote-trial-of-darolutamide-adt-reduce-risk-of-death-in-mhspc daily 0.8 https://clival.com/news/phase-iii-trials-of-covid-drug-movfor-show-positive-results-says-hetero daily 0.8 https://clival.com/news/mabwell-announces-fda-fast-track-designation-to-9mw3011 daily 0.8 https://clival.com/news/everest-medicines-enters-into-agreement-with-calliditas-therapeutics-expanding-territory-license-to-develop-and-commercialize-nefecon-in-south-korea daily 0.8 https://clival.com/news/ginkgo-bioworks-signs-definitive-agreement-to-acquire-fgen-ag-a-leading-bioengineering-company-and-its-proprietary-ultra-high-throughput-screening-platform daily 0.8 https://clival.com/news/emas-human-medicines-committee-recommends-approval-of-henlius-hansizhuang daily 0.8 https://clival.com/news/citius-pharma-completes-enrollment-in-pivotal-phase-3-trial-of-mino-lok-therapeutic-to-salvage-catheters daily 0.8 https://clival.com/news/us-fda-awards-26-million-orphan-products-development-grant-to-soligenix-for-expanded-study-of-hybryte-to-treat-ctcl daily 0.8 https://clival.com/news/torus-health-joins-hand-with-tata-1mg daily 0.8 https://clival.com/news/pfizer-rings-in-new-year-with-hemophilia-b-gene-therapy-nod-in-canada daily 0.8 https://clival.com/news/amrita-vishwa-vidyapeetham-receives-cdsco-approval-to-initiate-clinical-trial-of-synthetic-jaw-bone-graft daily 0.8 https://clival.com/news/prolongation-of-coronavirus-outbreak-in-china-could-hit-indian-pharma-sector daily 0.8 https://clival.com/news/ge-healthcare-partners-with-osf-healthcare daily 0.8 https://clival.com/news/melinta-therapeutics-acquires-us-rights-to-toprol-xl daily 0.8 https://clival.com/news/inflarx-announces-fda-emergency-use-authorisation-for-gohibic-vilobelimab daily 0.8 https://clival.com/news/lupin-to-acquire-two-inhalation-brands-from-sunovion-pharma-for-us-75-million daily 0.8 https://clival.com/news/rising-demand-for-salicylic-acid-in-pharmaceuticals-and-personal-care-products-drives-market-expansion daily 0.8 https://clival.com/news/who-issues-alert-on-substandard-syrup-and-suspension-medicines-detected-in-maldives-and-pakistan daily 0.8 https://clival.com/news/moderna-announces-emergency-use-listing-granted-by-the-world-health-organization-for-its-covid-19-vaccine daily 0.8 https://clival.com/news/pfizer-completes-acquisition-of-biohaven-pharmaceuticals daily 0.8 https://clival.com/news/imfinzi-and-tremelimumab-granted-orphan-drug-designation-in-the-us-for-liver-cancer daily 0.8 https://clival.com/news/lupin-launches-generic-drug-used-for-prevention-of-organ-rejection-in-kidney-transplant-in-us daily 0.8 https://clival.com/news/us-fda-approves-azurity-pharmas-zonisade-for-treatment-of-partial-seizures daily 0.8 https://clival.com/news/pyxis-oncology-announces-worldwide-licensing-agreement-with-pfizer-to-develop-and-commercialize-multiple-antibody-drug-conjugates daily 0.8 https://clival.com/news/lonza-soon-to-acquire-genentech-manufacturing-facility-in-vacaville daily 0.8 https://clival.com/news/gsks-jemperli-dostarlimab-plus-chemotherapy-receives-approval-in-singapore daily 0.8 https://clival.com/news/eisai-furthers-oncology-research-in-gastrointestinal-cancer-treatment-with-new-data-at-asco-gi-2024 daily 0.8 https://clival.com/news/emd-serono-presents-data-from-phase-ii-trial-of-btk-inhibitor-evobrutinib-at-aan-meeting-shows-reduced-blood-neurofilament-light-chain-levels-in-pati daily 0.8 https://clival.com/news/applied-biomath-llc-announces-collaboration-with-gritstone-oncology-inc daily 0.8 https://clival.com/news/pfizer-and-biontech-commence-global-clinical-trial-to-evaluate-covid-19-vaccine-in-pregnant-women daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-travoprost-ophthalmic-solution-usp daily 0.8 https://clival.com/news/ricoh-ers-genomics-collabs-in-us-and-japan-for-crisprcas9 daily 0.8 https://clival.com/news/iktos-and-almirall-announce-research-collaboration-in-artificial-intelligence-for-new-drug-design daily 0.8 https://clival.com/news/lumosa-therapeutics-announces-positive-results-from-lt3001-phase-2a-clinical-trial-in-acute-ischemic-stroke daily 0.8 https://clival.com/news/regeneron-announces-positive-results-from-phase-12-trial-of-regn5678-in-combo-with-pd-1-inhibitor-libtayo-in-advanced-mcrpc daily 0.8 https://clival.com/news/nasal-covid-vaccines-of-bharat-biotech-and-senotize-enter-final-phase-of-clinical-trails daily 0.8 https://clival.com/news/pag-led-api-platform-completes-acquisition-of-controlling-stake-in-optimus daily 0.8 https://clival.com/news/novartis-inks-typhoid-vax-licensing-deal-with-biological-e daily 0.8 https://clival.com/news/bayer-and-mammoth-biosciences-to-collaborate-on-novel-gene-editing-technolog daily 0.8 https://clival.com/news/evolus-submits-premarket-approval-application-to-fda-for-two-evolysse-dermal-filler-products daily 0.8 https://clival.com/news/merck-loses-bid-to-revive-254-bln-patent-verdict-against-gilead daily 0.8 https://clival.com/news/gland-pharma-receives-us-fda-tentative-approval-for-latanoprostene-bunod-ophthalmic-solution daily 0.8 https://clival.com/news/sn-bioscience-gets-odd-for-snb-101-on-pancreatic-cancer daily 0.8 https://clival.com/news/sinovac-biotech-starts-phase-trial-for-hfmd-bivalent-vaccine daily 0.8 https://clival.com/news/insulin-pumps-market-grow-significantly daily 0.8 https://clival.com/news/samsung-biologics-and-astrazeneca-expand-strategic-manufacturing-partnership-to-include-covid-19-and-cancer-therapy daily 0.8 https://clival.com/news/prospection-and-novotech-partner-to-accelerate-clinical-trials-with-real-world-evidence daily 0.8 https://clival.com/news/us-fda-accepts-for-priority-review-bristol-myers-sbla-for-opdivo-as-adjuvant-treatment-for-patients-with-muscle-invasive-urothelial-carcinoma daily 0.8 https://clival.com/news/ema-approves-roches-vabysmo-prefilled-syringe-for-retinal-diseases daily 0.8 https://clival.com/news/quest-northern-light-health-form-laboratory-collaboration-to-improve-access-to-affordable-diagnostic-services-in-maine daily 0.8 https://clival.com/news/china-nmpa-approves-astrazeneca-daiichi-sankyos-enhertu-to-treat-her2-positive-metastatic-breast-cancer-treated-with-one-or-more-prior-anti-her2-based-regimens daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-gsks-jemperli-plus-chemotherapy-to-treat-dmmrmsi-h-primary-advanced-or-recurrent-endometrial-cancer daily 0.8 https://clival.com/news/4moving-biotech-begins-patient-enrolment-in-lasare-phase-i-trial-on-osteoarthritis daily 0.8 https://clival.com/news/acasti-pharma-announces-patents-for-gtx-104-in-europe-gtx-102-in-the-us-and-gtx-101-in-japan daily 0.8 https://clival.com/news/daiichi-sankyo-announces-clinical-research-collaboration-to-evaluate-ds-1062-in-combination-with-keytrudaa daily 0.8 https://clival.com/news/us-fda-approves-adaptimmunes-gene-therapy-tecelra daily 0.8 https://clival.com/news/merck-completes-tender-offer-to-acquire-imago-biosciences-inc daily 0.8 https://clival.com/news/carsgen-therapeutics-and-huadong-medicine-announce-collaboration-agreement-for-zevorcabtagene-autoleucel-in-mainland-china daily 0.8 https://clival.com/news/harbour-biomed-announces-approval-for-phase-i-trial-of-b7h4x4-1bb-bispecific-antibody-in-australia daily 0.8 https://clival.com/news/taigen-enters-exclusive-license-agreement-with-joincare-for-tg-1000-in-china daily 0.8 https://clival.com/news/ovid-therapeutics-receives-fda-rare-pediatric-disease-designation-for-ov101-for-the-treatment-of-angelman-syndrome daily 0.8 https://clival.com/news/lupin-zydus-ink-agreement-to-co-market-liver-diseases-drug-saroglitazar-mg-in-india daily 0.8 https://clival.com/news/bristol-myers-squibb-2seventy-bio-to-discontinue-enrollment-in-phase-3-karmma-9-study daily 0.8 https://clival.com/news/merck-moderna-begin-phase-3-trial-of-mrna-4157-in-combo-with-keytruda-for-nsclc daily 0.8 https://clival.com/news/sprouts-female-libido-drug-addyi-back-in-fdas-crosshairs-years-after-controversial-approval daily 0.8 https://clival.com/news/fda-grants-orphan-drug-status-to-uniqures-huntingtons-disease-treatment daily 0.8 https://clival.com/news/aitia-and-ucb-announce-strategic-drug-discovery-collaboration daily 0.8 https://clival.com/news/hoth-therapeutics-announces-development-of-ht-kit-to-treat-multiple-orphan-diseases-including-rare-cancers daily 0.8 https://clival.com/news/solasia-pharma-darvias daily 0.8 https://clival.com/news/zydus-cadila-has-received-final-approval-from-us-food-and-drug-administration-fda-to-market-macitentan-tablets-10-mg-macitentan-is-used-to-manage daily 0.8 https://clival.com/news/pfizer-begins-phase-23-study-of-novel-covid-19-oral-treatment-in-paediatric-participants daily 0.8 https://clival.com/news/brii-bio-announces-strategic-partnership-with-sinopharm-to-advance-commercialization-of-long-acting-covid-19-neutralizing-antibody-therapy-amubarvimabromlusevimab-combination-in-china daily 0.8 https://clival.com/news/samsung-bioepis-partners-with-sandoz-to-commercialize-ustekinumab-biosimilar-candidate daily 0.8 https://clival.com/news/tavros-therapeutics-and-vividion-therapeutics-announce-strategic-collaboration-to-discover-and-enhance-targeted-oncology-programs daily 0.8 https://clival.com/news/adagene-announces-interim-data-demonstrating-safety-and-confirmed-clinical-responses-of-anti-ctla-4-safebody daily 0.8 https://clival.com/news/fda-grants-approval-for-samsung-bioepis-epysqli-as-a-biosimilar-to-soliris daily 0.8 https://clival.com/news/uk-approves-fifth-covid-vaccine-with-novavax-approval-lilly-delays-timeline-for-submitting-alzheimers-drug-application daily 0.8 https://clival.com/news/abbvie-seeks-us-fda-and-ema-approvals-for-skyrizi-to-treat-active-psoriatic-arthritis daily 0.8 https://clival.com/news/simcere-and-zaiming-announce-nmpa-approval-for-cetuximab-beta-in-china daily 0.8 https://clival.com/news/alembics-jv-aleor-receives-us-fda-approval-for-generic-axiron-topical-solution daily 0.8 https://clival.com/news/the-university-of-queensland-and-oxford-nanopore-technologies-announce-research-partnership daily 0.8 https://clival.com/news/akesos-cadonilimab-receives-second-indication-approval-from-nmpa daily 0.8 https://clival.com/news/china-nmpa-accepts-for-review-chi-meds-nda-for-surufatinib-to-treat-advanced-pancreatic-neuroendocrine-tumors daily 0.8 https://clival.com/news/marksans-pharma-to-acquire-100-stake-in-dubai-based-access-healthcare-for-medical-products-llc daily 0.8 https://clival.com/news/genscript-probio-congratulates-xlifesciences-on-the-start-of-taest16001-early-phase-clinical-trial daily 0.8 https://clival.com/news/polaris-group-submits-bla-for-adi-peg-20-to-us-fda-for-malignant-pleural-mesothelioma daily 0.8 https://clival.com/news/alligator-bioscience-completes-patient-enrollment-for-600-mg-dose-cohort-phase-i-trial-of-ator-1017-to-treat-advancedmetastatic-cancer daily 0.8 https://clival.com/news/gracell-biotechnologies-acquisition-completed daily 0.8 https://clival.com/news/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine daily 0.8 https://clival.com/news/foresee-pharma-gets-positive-recommendation-from-dsmb-to-continue-casppian-phase-3-study daily 0.8 https://clival.com/news/xenpozyme daily 0.8 https://clival.com/news/gerresheimer-aptar-digital-health-collaborate-to-develop-integrated-solution-for-cancer-therapy daily 0.8 https://clival.com/news/syncromune-inc-enters-into-an-exclusive-worldwide-license-agreement-with-eucure-biopharma-co-ltd daily 0.8 https://clival.com/news/aparna-group-gains-us-fda-clearance-for-pharma-entry daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-to-market-generic-kerydin-topical-solution daily 0.8 https://clival.com/news/nanox-partners-with-ahealthz-scl-science-for-s-korean-market-entry daily 0.8 https://clival.com/news/harmony-biosciences-partners-with-bioprojet-for-tpm-1116 daily 0.8 https://clival.com/news/cipla-gets-usfda-nod-for-cancer-drug daily 0.8 https://clival.com/news/orion-partners-with-jemincare-for-novel-non-opioid-drug-candidate-for-pain-treatment daily 0.8 https://clival.com/news/hanchorbio-announces-first-patient-dosed-in-the-phase-1-multi-regional-clinical-trial-of-hcb101 daily 0.8 https://clival.com/news/neurophth-announces-first-patient-dosed-in-phase-iii-clinical-trial-of-second-gene-therapy daily 0.8 https://clival.com/news/phase-1-trial-of-cln-978-of-cullinan-therapeutics-gets-us-fda-clearance daily 0.8 https://clival.com/news/sensorion-begins-patient-enrolment-in-phase-2a-proof-of-concept-trial-of-sens-401-in-cisplatin-induced-ototoxicity daily 0.8 https://clival.com/news/abbvie-announces-positive-data-from-phase-2a-study-of-abbv-3373-to-treat-rheumatoid-arthritis daily 0.8 https://clival.com/news/orum-therapeutics-announces-acquisition-of-orm-6151-program-by-bristol-myers-squibb daily 0.8 https://clival.com/news/glenmark-receives-fda-approval-for-esomeprazole-magnesium-delayed-release-capsules-usp daily 0.8 https://clival.com/news/nurexone-biologic-secures-fda-orphan-drug-designation-to-expedite-development-of-exopten-therapy-for-treating-acute-spinal-cord-injuries daily 0.8 https://clival.com/news/pluristem-announces-positive-results-from-phase-iii-study-of-muscle-regeneration-following-hip-fracture-surgery daily 0.8 https://clival.com/news/sanyou-bio-biogeometry-partners-to-make-antibody-drug-discovery-platform daily 0.8 https://clival.com/news/isotopia-usa-partners-with-e-solutions-to-build-its-gmp-manufacturing-center daily 0.8 https://clival.com/news/dyadic-advances-its-partnership-with-iibr daily 0.8 https://clival.com/news/genesis-medtech-collaborates-with-penumbra-to-expand-neurovascular-market-in-china daily 0.8 https://clival.com/news/ping-an-inks-agreement-with-shionogi-to-launch-joint-ventures daily 0.8 https://clival.com/news/entera-bio-announces-fda-approval-of-ind-application-for-eb613-an-oral-human-parathyroid-hormone-1-34-for-the-treatment-of-osteoporosis daily 0.8 https://clival.com/news/merck-ervebo-gets-european-commission-expanded-indication-approval-for-active-immunization-of-individuals-1-year-of-age-or-older-to-protect-against-evd daily 0.8 https://clival.com/news/menarini-reports-positive-phase-3-results-for-obicetrapib-and-fdc-trials daily 0.8 https://clival.com/news/ono-enters-into-a-definitive-agreement-to-acquire-deciphera-pharmaceuticals daily 0.8 https://clival.com/news/india-poised-to-ramp-up-remdesivir-production-as-mylan-and-jubilant-life-sciences-soon-to-launch-the-drug daily 0.8 https://clival.com/news/iktos-announces-a-collaboration-with-ono-in-artificial-intelligence-for-new-drug-design daily 0.8 https://clival.com/news/himachal-pradesh-asked-to-submit-revised-bulk-drug-park-proposal-for-dop-approval daily 0.8 https://clival.com/news/alphamab-oncology-cspc-achieved-a-licensing-agreement-on-adc-jskn003 daily 0.8 https://clival.com/news/bms-investors-bet-big-on-3-newly-acquired-celgene-drugs-for-cancer-and-ms daily 0.8 https://clival.com/news/strides-pharma-gains-after-arm-receives-us-fda-nod-for-pregabalin-capsule daily 0.8 https://clival.com/news/tevard-biosciences-and-zogenix-announce-collaboration-to-advance-novel-gene-therapies-for-dravet-syndrome-and-other-genetic-epilepsies daily 0.8 https://clival.com/news/sii-partners-with-univercells-for-personalized-oncology-to-people daily 0.8 https://clival.com/news/tigermed-completes-acquisition-of-marti-farm daily 0.8 https://clival.com/news/takeda-receives-us-fda-approval-of-fruzaqla-fruquintinib-for-previously-treated-metastatic-colorectal-cancer daily 0.8 https://clival.com/news/daiichi-sankyo-obtains-japanese-approval-for-additional-indication-dosage-administration-of-antiplatelet-agent-efient-375-mg-25-mg-tablets daily 0.8 https://clival.com/news/amgen-and-bushu-pharma-announce-expanded-supply-chain-partnership-across-japan-and-asia-pacific-region daily 0.8 https://clival.com/news/roches-covid-19-antibody-test-receives-fda-emergency-use-authorization-and-is-available-in-markets-accepting-the-ce-mark daily 0.8 https://clival.com/news/ono-pharmaceutical-enters-into-drug-discovery-collaboration-agreement-with-adimab daily 0.8 https://clival.com/news/pfizer-valneva-update-on-phase-3-trial-evaluating-lyme-disease-vaccine-candidate-vla15 daily 0.8 https://clival.com/news/kelun-biotechs-trop2-adc-sacituzumab-tirumotecan-gets-china-nmpa-marketing-approval daily 0.8 https://clival.com/news/lupin-gets-us-fda-tentative-approval-for-dolutegravir-tablets-for-oral-suspension daily 0.8 https://clival.com/news/abbotts-triclip-transcatheter-gets-approval daily 0.8 https://clival.com/news/bristol-myers-banks-on-25-plus-label-expansions-to-help-weather-ira-revlimid-generics-and-more daily 0.8 https://clival.com/news/teva-and-medincell-announce-positive-results-from-phase-3-rise-study-of-tv-46000mdc-irm-to-treat-schizophrenia daily 0.8 https://clival.com/news/serum-institute-seeks-inclusion-of-covovax-on-cowin-as-heterologous-booster-dose-for-adults daily 0.8 https://clival.com/news/insilico-medicine-uses-ai-to-transform-drug-discovery daily 0.8 https://clival.com/news/biosight-launches-a-phase-12-clinical-trial-of-aspacytarabine-in-combination-with-venetoclax-for-first-line-aml-induction-therapy-followed-by-aspacytarabine-consolidation daily 0.8 https://clival.com/news/cadila-healthcare-gets-eir-from-usfda-for-baddi-facility daily 0.8 https://clival.com/news/sandoz-launches-generic-revlimid-in-19-countries-in-europe daily 0.8 https://clival.com/news/fresh-tracks-therapeutics-announces-data-from-pre-clinical-studies-of-frtx-02 daily 0.8 https://clival.com/news/oncosec-announces-exclusive-license-agreement-for-cliniporator-gene-electrotransfer-platform-developed-by-igea-clinical-biophysics daily 0.8 https://clival.com/news/renalytix-ai-collaborates-with-astrazeneca-to-develop-and-launch-precision-medicine-strategies-for-cardiovascular-renal-and-metabolic-diseases daily 0.8 https://clival.com/news/taigen-enters-exclusive-license-agreement-with-ysp daily 0.8 https://clival.com/news/laurus-labs-to-acquire-the-subsidiary-company-of-aspen-pharmacare-south-africa daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-lindis-biotechs-korjuny daily 0.8 https://clival.com/news/nuvig-launches-to-develop-novel-immune-therapeutics-for-chronic-inflammatory-and-autoimmune-diseases daily 0.8 https://clival.com/news/neumora-initiates-phase-1-study-of-nmra-266-to-treat-schizophrenia-other-neuropsychiatric-disorders daily 0.8 https://clival.com/news/novartis-completes-spin-off-of-its-generic-drug-division-sandoz daily 0.8 https://clival.com/news/antibe-therapeutics-inks-licensing-deal-with-nuance-pharma daily 0.8 https://clival.com/news/roche-gets-a-green-light-to-challenge-biogen-novartis-with-sma-med-evrysdi daily 0.8 https://clival.com/news/maharashtra-fda-soon-to-make-provision-for-issuance-of-e-licensing-of-cold-storage-delivery-vehicles-for-drug-distribution daily 0.8 https://clival.com/news/biontech-autolus-enter-strategic-car-t-cell-therapy-collaboration daily 0.8 https://clival.com/news/quantoom-collaborates-with-stevanato-to-elevate-mrna-production-with-nfinity-platform daily 0.8 https://clival.com/news/roches-personalized-cancer-treatment-wins-fda-approval daily 0.8 https://clival.com/news/diagnostear-a-subsidiary-of-biolight-life-sciences-ltd-signed-a-binding-letter-of-intent-for-merger-capital-raise-and-listing-on-the-canadian-securities-exchange daily 0.8 https://clival.com/news/jj-nabs-fda-nod-for-ponvory-joining-novartis-bristol-myers-in-crowded-ms-market daily 0.8 https://clival.com/news/leo-pharma-inks-agreement-to-acquire-clinical-stage-biopharma-company-timber-pharma daily 0.8 https://clival.com/news/celcuity-announces-worldwide-licensing-agreement-with-pfizer-to-develop-and-commercialize-gedatolisib-a-first-in-class-pi3kmtor-inhibitor-for-breast daily 0.8 https://clival.com/news/japanese-pmda-approves-microport-crm daily 0.8 https://clival.com/news/china-approves-genuine-biotechs-hiv-drug-for-covid-patients daily 0.8 https://clival.com/news/cancer-research-uk-and-sosei-heptares-sign-agreement-to-advance-cancer-immunotherapy-candidate-into-clinical-trials daily 0.8 https://clival.com/news/clearpoint-neuro-gets-us-fda-clearance-for-clearpoint-prism-neuro-laser-therapy-system daily 0.8 https://clival.com/news/lupin-receives-us-fda-tentative-marketing-approval-for-generic-descovy-tablets daily 0.8 https://clival.com/news/pfizer-scores-fda-nod-for-braftovi-duo-in-colon-cancer-as-investors-await-more-lucrative-triplet daily 0.8 https://clival.com/news/philogen-gets-france-ansm-nod-to-begin-new-a-phase-ii-study-to-evaluate-nidlegy-in-several-non-melanoma-skin-cancers daily 0.8 https://clival.com/news/otsuka-announces-positive-top-line-results-from-two-phase-3-studies-of-centanafadine-for-the-treatment-of-attention-deficit-hyperactivity-disorder-ad daily 0.8 https://clival.com/news/santheras-agamree-approved-for-duchenne-muscular-dystrophy-care daily 0.8 https://clival.com/news/dyno-therapeutics-announces-ocular-collaboration-with-novartis-to-develop-improved-gene-therapies-with-aav-vectors-based-on-ai-technology daily 0.8 https://clival.com/news/astrazeneca-inks-760-mln-deal-with-swiss-firm-neurimmune-for-antibody-drug daily 0.8 https://clival.com/news/genentech-gets-us-fda-nod-to-begin-clinical-trial-for-actemra-to-treat-hospitalized-patients-with-severe-covid-19-pneumonia daily 0.8 https://clival.com/news/jazz-pharmaceuticals-receives-european-commission-approval-for-enrylaze-a-recombinant-erwinia-asparaginase-or-crisantaspase-for-the-treatment-of-acute-lymphoblastic-leukemia-and-lymphoblastic-lymphoma daily 0.8 https://clival.com/news/us-fda-approves-amneal-pharmas-biosimilar-fylnetra-to-treat-neutropenia daily 0.8 https://clival.com/news/i-mab-receives-fda-orphan-drug-designation-for-cancer-drug daily 0.8 https://clival.com/news/us-fda-approves-gsk-jesduvroq-to-treat-anaemia-of-ckd-in-adults-on-dialysis daily 0.8 https://clival.com/news/novavaxs-covid-19-vaccine-nuvaxovid-granted-full-approval-in-singapore daily 0.8 https://clival.com/news/roche-enters-partnership-with-the-global-fund-to-support-low-and-middle-income-countries-in-strengthening-critical-diagnostics-infrastructure daily 0.8 https://clival.com/news/scientists-identify-new-types-of-a-blood-cancer-and-potential-targeted-treatments daily 0.8 https://clival.com/news/lilly-and-asahi-kasei-pharma-announce-license-agreement-for-chronic-pain-drug-candidate daily 0.8 https://clival.com/news/gilead-offers-its-newest-hiv-drug-candidate-to-patent-pool-for-low-cost-production daily 0.8 https://clival.com/news/alebund-ap303-granted-fda-orphan-drug-designation daily 0.8 https://clival.com/news/keros-therapeutics-ker-050-gets-fast-track-designation daily 0.8 https://clival.com/news/indoco-remedies-receives-eir-from-usfda daily 0.8 https://clival.com/news/golidocitinib-granted-priority-review-by-china-nmpa-for-the-treatment-of-rr-ptcl daily 0.8 https://clival.com/news/european-union-recommends-approval-of-astrazenecas-tagrisso daily 0.8 https://clival.com/news/us-fda-clears-inversago-pharmas-ind-application-for-phase-2-study-of-inv-202-in-diabetic-kidney-disease daily 0.8 https://clival.com/news/scisparc-launches-new-jv-targeting-discovery-of-potential-drugs-for-cancers-and-infectious-diseases daily 0.8 https://clival.com/news/novavax-updated-covid-19-vaccine-receives-emergency-use-authorization-in-taiwan daily 0.8 https://clival.com/news/ema-committee-recommends-acoramidis-for-transthyretin-amyloid-cardiomyopathy daily 0.8 https://clival.com/news/european-commission-approves-bavencio-avelumab-for-first-line-maintenance-treatment-of-locally-advanced-or-metastatic-urothelial-carcinoma daily 0.8 https://clival.com/news/pfizer-and-biontech-receive-us-emergency-use-authorisation-of-omicron-ba4ba5-adapted-bivalent-covid-19-booste daily 0.8 https://clival.com/news/incyte-and-cms-announce-collaboration-and-license-agreement-for-ruxolitinib-cream-in-greater-china-and-southeast-asia daily 0.8 https://clival.com/news/us-fda-approves-lynparza-for-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer daily 0.8 https://clival.com/news/innovent-first-phase-3-trial-of-mazdutide-in-chinese-adults-with-overweightobesity-meets-primary-and-all-key-secondary-endpoints daily 0.8 https://clival.com/news/roche-bid-to-recycle-gayzva-for-lupus-nephritis-wins-fda-breakthrough-tag daily 0.8 https://clival.com/news/alvotech-and-fuji-pharma-expand-partnership-adding-a-new-biosimilar-candidate daily 0.8 https://clival.com/news/bioarctics-antibody-abbv-0805-to-treat-parkinsons-disease-receives-us-patent daily 0.8 https://clival.com/news/jazz-pharmaceuticals-announces-agreement-to-divest-sunosi daily 0.8 https://clival.com/news/boehringer-ingelheims-phase-ii-data-of-bi-1015550-shows-reduction-in-rate-of-lung-function-decline-in-patients-with-ipf daily 0.8 https://clival.com/news/bristol-myers-gets-european-approval-for-opdivo-with-chemotherapy-to-treat-unresectable-advanced-recurrent-or-metastatic-escc-with-tumour-cell-pd-l1-expression-1 daily 0.8 https://clival.com/news/huadong-becomes-strategic-partner-in-asia-for-heidelberg-pharma-strikes-deal-worth-09b daily 0.8 https://clival.com/news/astrazeneca-to-buy-us-based-clinical-stage-biopharma-company-icosavax-for-11-billion daily 0.8 https://clival.com/news/maat-pharma-completes-recruitment-in-ares-phase-3-trial-for-maat013-to-treat-acute-graft-versus-host-disease daily 0.8 https://clival.com/news/lutris-pharma-receives-odd-for-lut014 daily 0.8 https://clival.com/news/sanofi-and-innate-pharma-expand-collaboration-for-natural-killer-cell-therapeutics-in-oncology daily 0.8 https://clival.com/news/arexvy-the-first-rsv-vaccine-for-older-adults-granted-approval-by-has daily 0.8 https://clival.com/news/seastar-medical-selective-cytopheretic-device-receives-us-fda-breakthrough-device-designation-for-hepatorenal-syndrome daily 0.8 https://clival.com/news/porton-advanced-and-ascle-therapeutics-have-established-a-strategic-partnership-to-enhance-the-utilization-of-nk-cells-in-cancer-prevention-beauty-and-anti-aging daily 0.8 https://clival.com/news/exelixis-and-bioinvent-establish-exclusive-option-and-license-agreement-to-develop-novel-antibody-based-immuno-oncology-therapies daily 0.8 https://clival.com/news/hist-pharma-announces-us-fda-approval-to-initiate-phase-iii-clinical-study-with-tc-cream-worlds-first-botanical-small-molecule-drug-that-treats-psoriasis-vulgaris daily 0.8 https://clival.com/news/asieris-unveils-cevira-phase-iii-subgroup-analysis-at-the-2024-csco-meeting daily 0.8 https://clival.com/news/vedistry-part-of-charak-pharma-launches-fortyfitt-woman-tablets daily 0.8 https://clival.com/news/hutchmed-completes-enrollment-of-phase-iiiii-trial-of-fruquintinib-in-combo-with-sintilimab-for-advanced-renal-cell-carcinoma-in-china daily 0.8 https://clival.com/news/hutchmed-announces-results-of-sovleplenib-phase-iii-eslim-01-study daily 0.8 https://clival.com/news/pieris-pharma-begins-patient-dosing-in-phase-2-gastric-cancer-trial-of-4 daily 0.8 https://clival.com/news/legochembio-signs-license-agreement-to-acquire-first-in-class-antibody-from-elthera daily 0.8 https://clival.com/news/taiwans-premier-health-brand-unveils-best-quality-pineapple-enzyme-for-digestive-health daily 0.8 https://clival.com/news/obi-pharma-partner-biosion-announces-fda-approval-of-ind-application-for-phase-12-trial-of-obi-992-trop2-adc daily 0.8 https://clival.com/news/novartis-acquires-china-based-startup-sanreno-therapeutics-to-enhance-kidney-diseases-treatment daily 0.8 https://clival.com/news/agomab-therapeutics-completes-acquisition-of-origo-biopharma daily 0.8 https://clival.com/news/karuna-therapeutics-and-zai-lab-announce-strategic-collaboration-for-development-manufacturing-and-commercialization-of-karxt-in-greater-china daily 0.8 https://clival.com/news/immunocore-and-gadeta-announce-agreement-to-develop-first-gamma-delta-tcr-immtac-for-solid-tumors daily 0.8 https://clival.com/news/abbott-launches-its-tactiflex-ablation-catheter-for-abnormal-heart-rhythm-treatment daily 0.8 https://clival.com/news/rapid-medical-receives-fda-breakthrough-device-designation-for-vasospasm-treatment daily 0.8 https://clival.com/news/china-nmpa-approved-the-ind-application-for-new-glutamate-modulator-troriluzole-signalling-fresh-hope-for-ocd-patients daily 0.8 https://clival.com/news/sumitomo-pharma-oncologys-investigational-ebp-inhibitor-dsp-0390-receives-us-fda-orphan-drug-designation-to-treat-brain-cancer daily 0.8 https://clival.com/news/resilience-keeps-expansion-spree-rolling-with-buyout-of-biologics-maker-ology daily 0.8 https://clival.com/news/limacorporate-gets-us-fda-nod-to-begin-clinical-trial-of-smr-stemless-reverse-shoulder-system daily 0.8 https://clival.com/news/union-therapeutics-receives-fda-fast-track-designation-for-oral-orismilast-for-the-treatment-of-moderate-to-severe-atopic-dermatitis daily 0.8 https://clival.com/news/innocare-pharma-collaborates-with-arrivent-biopharma daily 0.8 https://clival.com/news/bio-thera-begins-patient-dosing-in-phase-1-study-of-bat2606-a-proposed-biosimilar-of-nucala daily 0.8 https://clival.com/news/mannkind-to-acquire-v-go-insulin-delivery-device-from-zealand-pharma-for-10-million daily 0.8 https://clival.com/news/entera-bio-announces-collaboration-with-opko-biologics daily 0.8 https://clival.com/news/carterra-launches-sensitive-platform-ultra-advances-fragment-and-small-molecule-discovery daily 0.8 https://clival.com/news/polypid-announces-750th-patient-enrolled-in-shield-i-phase-3-clinical-trial-of-d-plex-in-abdominal-surgery daily 0.8 https://clival.com/news/engitix-signs-collaboration-and-licensing-agreement-with-takeda-to-develop-anti-fibrotic-therapies-in-advanced-liver-diseases daily 0.8 https://clival.com/news/affamed-therapeutics-dextenza-receives-macau-china-approval-to-treat-ocular-inflammation-and-pain-following-ophthalmic-surgery daily 0.8 https://clival.com/news/hugel-receives-marketing-approval-for-botulinum-toxin-letybo daily 0.8 https://clival.com/news/amerisourcebergen-completes-acquisition-of-pharmalex daily 0.8 https://clival.com/news/who-certifies-cabo-verde-as-malaria-free-country-marking-a-historic-milestone-in-the-fight-against-malaria daily 0.8 https://clival.com/news/everest-medicines-has-received-approval-for-the-new-drug-application-nda-for-nefecon-in-taiwan-aimed-at-treating-primary-iga-nephropathy-in-adult-patients daily 0.8 https://clival.com/news/prozomix-ginkgo-collaborate-on-next-gen-enzyme-development daily 0.8 https://clival.com/news/nuance-pharma-announces-strategic-licensing-deal-with-antibe-therapeutics-in-china daily 0.8 https://clival.com/news/us-fda-approves-jazz-pharmas-ziihera-to-treat-adults-with-biliary-tract-cancer daily 0.8 https://clival.com/news/sun-pharmas-us-subsidiary-acquires-galdermas-companies-in-us-japan-and-canada daily 0.8 https://clival.com/news/cipla-receives-eua-for-oral-antiviral-drug-to-treat-mild-to-moderate-covid daily 0.8 https://clival.com/news/us-fda-grants-accelerated-approval-to-janssens-rybrevant-to-treat-nsclc-with-egfr-exon-20-insertion-mutations daily 0.8 https://clival.com/news/everest-medicines-and-kezar-life-sciences-gets-cde-approval daily 0.8 https://clival.com/news/todos-medical-to-launch-eua-authorized-cpass-sars-cov-2-neutralizing-antibody-kit-through-agreement-with-fosun-pharma daily 0.8 https://clival.com/news/clover-biopharma-begins-patient-dosing-in-phase-1-trial-with-scb-2020s-a-potentially-broadly-protective-chimeric-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/theriva-achieves-target-patient-enrollment-in-virage-phase-2b-trial-of-vcn-01 daily 0.8 https://clival.com/news/merck-partners-with-hansoh-in-19b-deal-for-cardiometabolic-treatments daily 0.8 https://clival.com/news/brukinsa daily 0.8 https://clival.com/news/merck-completes-acquisition-of-harpoon-therapeutics daily 0.8 https://clival.com/news/gracell-biotechnologies-announces-china-nmpa-clearance-for-ind-application-for-phase-12-clinical-trial-of-fastcar-t-gc012f-for-treatment-of-relapsedrefractory-multiple-myeloma daily 0.8 https://clival.com/news/eylea-hd-aflibercept-injection-8-mg-demonstrate-continued-durable-vision-gains-and-anatomic-improvements-with-extended-dosing-intervals daily 0.8 https://clival.com/news/clarivate-expands-partnership-with-verisim-life-to-accelerate-and-de-risk-research-and-drug-development daily 0.8 https://clival.com/news/pulmatrix-announces-fda-acceptance-of-ind-application-for-pur3100-to-treat-acute-migraine daily 0.8 https://clival.com/news/zydus-life-receives-final-usfda-approval-for-insomnia-drug daily 0.8 https://clival.com/news/lilly-and-iabl-collaborate-to-ensure-patient-access daily 0.8 https://clival.com/news/unum-therapeutics-inc-announces-acquisition-of-kiq-llc daily 0.8 https://clival.com/news/novo-nordisk-enters-pharma-acquisition-deal-for-rnai-therapies daily 0.8 https://clival.com/news/exelixis-and-cybrexa-therapeutics-establish-exclusive-collaboration-providing-exelixis-the-right-to-acquire-cbx-12-a-potential-first-in-class-peptide-drug-conjugate-of-exatecan daily 0.8 https://clival.com/news/century-therapeutics-and-bristol-myers-squibb-enter-into-a-strategic-collaboration-to-develop-ipsc-derived-allogeneic-cell-therapies daily 0.8 https://clival.com/news/inspira daily 0.8 https://clival.com/news/merck-to-buy-clinical-stage-immunotherapy-company-harpoon-therapeutics-for-680-million daily 0.8 https://clival.com/news/citing-significant-violations-fda-slams-ohio-drug-repackager-with-warning-letter daily 0.8 https://clival.com/news/algiax-pharma-begins-patient-dosing-in-phase-iia-cure-study-of-ap-325-to-treat-chronic-neuropathic-pain daily 0.8 https://clival.com/news/mission-bio-and-sequmed-sign-collaboration-agreement-announcing-partnership-to-provide-tapestri-services-and-co-develop-clinical-applications-in-china daily 0.8 https://clival.com/news/cstone-pharmaceuticals-receives-national-medical-products-administration-approval-for-gavreto daily 0.8 https://clival.com/news/huidagene-therapeutics-gets-us-fda-clearance-for-crisprcas13-rna-editing-hg202 daily 0.8 https://clival.com/news/applied-biomath-llc-announces-collaboration-with-antengene-for-systems-pharmacology-modeling-in-oncology daily 0.8 https://clival.com/news/cipla-gets-eir-from-us-fda-for-bommasandra-api-facility daily 0.8 https://clival.com/news/single-use-rhinolaryngoscope-now-distributed-exclusively-by-olympus daily 0.8 https://clival.com/news/mercks-welireg-gains-positive-eu-chmp-opinion-for-vhl-rcc-tumors daily 0.8 https://clival.com/news/kelun-biotechs-trop2-adc-sac-tmt-secures-second-nda-for-egfr-mutant-nsclc daily 0.8 https://clival.com/news/greenlight-biosciences-samsung-biologics-partner-to-advance-new-rna-covid-vax daily 0.8 https://clival.com/news/si-bone-receives-us-fda-clearance-for-expanded-rod-compatibility-with-ifuse-bedrock-granite-implant-system daily 0.8 https://clival.com/news/aiviva-biopharma-completes-patient-enrollment-in-phase-1-trial-of-aiv007 daily 0.8 https://clival.com/news/fda-clears-wearable-ecg-patches-from-samsung-spinout-wellysis-smartcardia daily 0.8 https://clival.com/news/encompass-healths-home-health-unit-attracts-acquisition-interestsources daily 0.8 https://clival.com/news/bio-thera-launches-first-humira-biosimilar-in-china daily 0.8 https://clival.com/news/genosity-enters-into-an-agreement-with-gemini-therapeutics-to-develop-a-diagnostic-and-implement-testing-to-support-geminis-age-related-macular-degene daily 0.8 https://clival.com/news/zealand-pharmas-glepaglutide-receives-fda-response-for-short-bowel-syndrome daily 0.8 https://clival.com/news/anvisa-grants-marketing-approval-for-zylox-tonbridges-zenflow-tiger-ld-pta-dilatation-catheter daily 0.8 https://clival.com/news/evotec-and-bayer-announce-new-alliance-focusing-on-drug-discovery-for-polycystic-ovary-syndrome-with-novel-targets-from-celmatix daily 0.8 https://clival.com/news/astrazeneca-daiichi-sankyo-seek-fdas-accelerated-approval-for-datopotamab-deruxtecan daily 0.8 https://clival.com/news/diagnamed-holdings-launches-cervai-brain-health-ai-solution daily 0.8 https://clival.com/news/dr-reddys-acquires-cardiovascular-drug-cidmus-in-india-from-novartis-ag daily 0.8 https://clival.com/news/novo-nordisk-recalls-insulin daily 0.8 https://clival.com/news/wuxi-sta-launches-new-parenteral-formulation-manufacturing-line daily 0.8 https://clival.com/news/purple-biotech-expands-pipeline-of-first-in-class-therapeutics-with-acquisition-of-immunorizon-and-its-portfolio-of-tri-specific-antibodies-for-the-treatment-of-cancer daily 0.8 https://clival.com/news/biomimetic-innovations-gets-us-fda-breakthrough-device-designation-for-osstic-synthetic-injectable-structural-bio-adhesive-bone-void-filler daily 0.8 https://clival.com/news/dr-reddys-laboratories-announces-the-launch-of-regadenoson-injection-04-mg5-ml-in-the-usa daily 0.8 https://clival.com/news/sanofis-consumer-healthcare-unit-launches-the-shared-care-collective-an-advisory-group-working-to-advance-sustainability daily 0.8 https://clival.com/news/agastiya-biotech-receives-fda-orphan-drug-designation-for-ab001-for-pancreatic-cancer-and-acute-myeloid-leukemia-aml daily 0.8 https://clival.com/news/arch-biopartners-doses-first-patient-in-canada-for-phase-ii-trial-of-lsalt-peptide daily 0.8 https://clival.com/news/biohaven-to-seek-fda-approval-for-second-migraine-drug daily 0.8 https://clival.com/news/raysearch-laboratories-and-ge-healthcare-collaborate-to-improve-radiation-oncology-treatment-planning daily 0.8 https://clival.com/news/new-drugs-and-clinical-trial-rules-to-promote-local-trials-in-india-to-develop-new-drugs-vaccines-dr-naresh-sharma daily 0.8 https://clival.com/news/gsk-pharma-board-approves-sale-of-vemgal-plant-to-hetero-labs daily 0.8 https://clival.com/news/navrogen-and-levena-announce-collaboration-to-develop-antibody-drug-conjugates-adcs-to-treat-humoral-immuno-suppressed-cancers daily 0.8 https://clival.com/news/okyo-pharma-announces-categorical-data-from-ok-101-phase-2-clinical-trial-in-dry-eye-disease daily 0.8 https://clival.com/news/lilly-and-breast-cancer-advocacy-organizations-collaborate-to-drive-awareness-of-complexities-of-early-breast-cancer-and-risk-of-recurrence daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-inovios-ino-3107-to-treat-recurrent-respiratory-papillomatosis daily 0.8 https://clival.com/news/gilead-sciences-to-acquire-uk-based-biotechnology-company-mirobio-for-405-million daily 0.8 https://clival.com/news/neuraxis-gains-fda-510k-clearance-for-red-in-chronic-constipation-test daily 0.8 https://clival.com/news/ucb-completes-acquisition-of-zogenix-inc daily 0.8 https://clival.com/news/usfda-grants-final-approval-for-zydus-seizure-injections daily 0.8 https://clival.com/news/wuxi-atu-announces-licensing-agreement-with-janssen-biotech-for-tessa-technology daily 0.8 https://clival.com/news/fda-grants-fta-to-biomarker-guided-db104-liafensine-for-treatment-resistant-depression daily 0.8 https://clival.com/news/nanox-partners-beilinson-hospital-to-study-nanoxarc daily 0.8 https://clival.com/news/roche-introduces-next-generation-qpcr-system-to-advance-clinical-needs-in-molecular-diagnostics-and-address-public-health-challenges daily 0.8 https://clival.com/news/yiling-pharmaceuticals-patent-depression-resolving-drug-approved-for-marketing-in-china daily 0.8 https://clival.com/news/bioarctics-partner-eisai-gets-approval-for-leqembi-to-treat-alzheimers-disease-in-israel daily 0.8 https://clival.com/news/sanofi-tevas-relieve-uccd-phase-2b-study-meets-primary-endpoints daily 0.8 https://clival.com/news/everest-medicines-announces-china-center-for-drug-evaluation-of-nmpa-recommends-priority-review-for-cefepime-taniborbactam-for-the-treatment-of-complicated-urinary-tract-infections-including-pyelonephritis daily 0.8 https://clival.com/news/us-fda-denies-nrx-pharma-request-for-breakthrough-therapy-designation-for-zyesami daily 0.8 https://clival.com/news/innovent-announces-acceptance-and-priority-review-designation-for-ibi351-new-drug-application-by-china-national-medical-products-administration daily 0.8 https://clival.com/news/johnson-johnson-acquires-ambrx daily 0.8 https://clival.com/news/guardant-health-in-collaboration-with-samsung-medical-launches-shield-blood-based-screening-test-for-colorectal-cancer-in-south-korea daily 0.8 https://clival.com/news/cms-incyte-collabs-to-develop-povorcitinib-in-china daily 0.8 https://clival.com/news/beigene-announces-health-canada-approval-for-brukinsa daily 0.8 https://clival.com/news/nexturn-bio-inc-decided-to-invest-in-the-development-of-a-new-drug-pipeline-for-diabetes-treatment-using-mirna daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-ideaya-biosciences-darovasertib-in-combo-with-crizotinib-to-treat-metastatic-uveal-melanoma daily 0.8 https://clival.com/news/sanofi-and-gsk-to-join-forces-in-vaccine-collaboration-to-fight-covid-19 daily 0.8 https://clival.com/news/zebiai-and-tb-alliance-announce-collaboration-to-apply-ml-driven-discovery-platform-to-tuberculosis-targets daily 0.8 https://clival.com/news/reviva-pharmaceuticals-receives-european-patent-for-brilaroxazine daily 0.8 https://clival.com/news/galderma-has-received-regulatory-approval-for-restylane-shaype-a-novel-hyaluronic-acid-injectable-designed-for-enhancing-the-chin-region daily 0.8 https://clival.com/news/roche-partners-with-pathai daily 0.8 https://clival.com/news/roche-to-acquire-telavant-including-rights-to-novel-tl1a-directed-antibody-rvt-3101-to-treat-ibd-from-roivant-for-us-71-billion daily 0.8 https://clival.com/news/ono-pharmaceutical-announces-collaboration-agreement-with-molcure daily 0.8 https://clival.com/news/chemdiv-inks-partnership-with-utmb-to-expand-its-high-throughput-screening-research-capabilities daily 0.8 https://clival.com/news/acer-relief-win-fda-approval-for-rare-metabolic-disease-after-clearing-inspection-hurdles daily 0.8 https://clival.com/news/soligenixs-suvax-gets-us-fda-odd-for-prophylaxis-against-sudv-infection daily 0.8 https://clival.com/news/ypsomed-inks-deal-to-manufacture-glp-1-autoinjectors-for-novo-nordisk daily 0.8 https://clival.com/news/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout daily 0.8 https://clival.com/news/astrazenecas-evusheld-long-acting-antibody-combination-recommended-for-marketing-approval-in-eu-to-treat-covid-19 daily 0.8 https://clival.com/news/hong-kong-developes-blood-test-for-alzheimers-mci daily 0.8 https://clival.com/news/roche-and-prothena-will-advance-prasinezumab-into-late-stage-clinical-development-study-in-parkinsons-disease daily 0.8 https://clival.com/news/rafarma-pharmaceutical-discloses-recent-partnerships-with-kelun-lifesciences-pvt-ltd-in-sri-lanka-and-el-salvador-university daily 0.8 https://clival.com/news/torrent-pharma-recalls-over-27k-bottles-of-blood-pressure-lowering-drug-in-us daily 0.8 https://clival.com/news/china-based-startup-harbour-biomed-enters-into-collaboration-with-moderna daily 0.8 https://clival.com/news/tg-immunopharma-gets-us-fda-clearance-to-begin-clinical-trial-of-tgi-6-bispecific-antibody daily 0.8 https://clival.com/news/cipla-receives-us-fda-approval-for-generic-durezol daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-prestige-biopharma-pbp1510-to-treat-pancreatic-cancer daily 0.8 https://clival.com/news/greenlight-biosciences-receives-approval-to-initiate-phase-iii-clinical-trial-of-covid-19-mrna-vaccine-candidate daily 0.8 https://clival.com/news/arvinas-novartis-comes-in-agreement-for-protac-ar-degrader-arv-766 daily 0.8 https://clival.com/news/orion-corporation-glykos-ink-licensing-agreement-to-develop-next-generation-adcs-by-using-glykos-proprietary-adc-technologies daily 0.8 https://clival.com/news/tackle-phase-iii-trial-shows-astrazenecas-evusheld-significantly-prevented-covid-19-disease-progression-or-death daily 0.8 https://clival.com/news/vapotherm-signs-definitive-merger-agreement-with-an-affiliate-of-perceptive-advisors daily 0.8 https://clival.com/news/novo-nordisk-hit-by-wegovy-supply-issues daily 0.8 https://clival.com/news/fda-grants-accelerated-approval-for-astellas-seattle-genetics-bladder-cancer-drug daily 0.8 https://clival.com/news/biotheus-enters-into-strategic-partnership-with-biontech-to-develop-and-commercialize-bispecific-antibody-candidate-targeting-pd-l1-and-vegf-in-multiple-solid-tumor-indications daily 0.8 https://clival.com/news/novavaxs-updated-protein-based-covid-19-vaccine-is-now-an-option-for-all-194-world-health-organization-member-states daily 0.8 https://clival.com/news/ascletis-presented-positive-phase-i-clinical-data-for-broad-spectrum-antiviral-double-prodrug-asc10-at-croi-2023 daily 0.8 https://clival.com/news/insightec-receives-fda-ide-approval-and-breakthrough-designation-for-nsclc-brain-mets-study-and-ide-approval-for-liquid-biopsy-study daily 0.8 https://clival.com/news/cholesgen-collaborates-with-astrazeneca-to-advance-rd-in-hypercholesterolemia-and-related-metabolic-diseases daily 0.8 https://clival.com/news/xilio-therapeutics-initiates-enrollment-in-phase-1-trial-of-tumour-activated-fc-enhanced-anti-ctla-4-xtx101-in-combo-with-atezolizumab daily 0.8 https://clival.com/news/japanese-health-ministry-approves-merck-eisais-keytruda-plus-lenvima-for-radically-unresectable-or-metastatic-rcc daily 0.8 https://clival.com/news/23andme-begins-phase-1-trial-for-23me-01473-antibody daily 0.8 https://clival.com/news/bristol-myers-lag-3-blocking-antibody-combination-opdualag-receives-us-fda-approval-to-treat-unresectable-or-metastatic-melanoma daily 0.8 https://clival.com/news/nrx-pharma-to-begin-phase-3-trial-of-nrx-101-to-treat-bipolar-depression-with-acute-suicidality daily 0.8 https://clival.com/news/novartis-completes-acquisition-of-washington-based-biopharma-company-chinook-therapeutics daily 0.8 https://clival.com/news/aptar-pharma-announces-exclusive-collaboration-with-fluidda daily 0.8 https://clival.com/news/role-of-pharmaceutical-database-companies daily 0.8 https://clival.com/news/sanofi-announces-phase-3-trial-of-sutimlimab-in-people-with-cold-agglutinin-disease-meets-primary-and-secondary-endpoints daily 0.8 https://clival.com/news/us-fda-approves-kindred-biosciences-zimeta-for-control-of-pyrexia-in-horses daily 0.8 https://clival.com/news/clario-acquires-ai-company-artiq daily 0.8 https://clival.com/news/haleon-india-partners-with-sevamob-to-launch-primary-healthcare-mobile-van-in-hosekote-bengaluru daily 0.8 https://clival.com/news/novartis-soon-to-acquire-ifm-for-sting-antagonist-programme daily 0.8 https://clival.com/news/orgenesis-announces-agreement-to-acquire-koligo-therapeutics-a-leader-in-personalized-cell-therapies daily 0.8 https://clival.com/news/laurent-pharma-gets-us-fda-approval-to-begin-phase-2-resolution-study-to-treat-covid-19 daily 0.8 https://clival.com/news/alnylam-reports-interim-phase-1-data-of-nucresiran-showing-ttr-post-single-dose daily 0.8 https://clival.com/news/norgine-bv-submits-maa-for-eflornithine daily 0.8 https://clival.com/news/tiumbio-begins-patient-dosing-in-phase-2-trial-of-oral-immuno-oncology-drug-tu2218 daily 0.8 https://clival.com/news/ascletis-announces-ind-approval-of-oral-3clpro-inhibitor-asc11-for-covid-19-by-us-fda daily 0.8 https://clival.com/news/tryngolza-olezarsen-approved-in-us-for-adults-with-fcs daily 0.8 https://clival.com/news/syngene-concludes-the-acquisition-of-biologics-manufacturing-facility-from-stelis-biopharma daily 0.8 https://clival.com/news/hummingbird-bioscience-and-merck-enter-collaboration-to-evaluate-hmbd-001-in-squamous-non-small-cell-lung-carcinoma daily 0.8 https://clival.com/news/ema-recommends-marketing-authorization-for-sparsentan daily 0.8 https://clival.com/news/enterobiotix-reports-positive-results-from-phase-1b-impulce-study-of-ebx-102-in-liver-cirrhosis daily 0.8 https://clival.com/news/antengene-announces-ind-approval-in-china-for-the-phase-i-study-of-atg-101-pd-l14-1bb-bispecific-antibody-for-the-treatment-of-solid-tumors-and-non-hodgkin-lymphoma daily 0.8 https://clival.com/news/caliway-gains-fast-track-designation-for-cbl-514 daily 0.8 https://clival.com/news/visus-therapeutics-expands-ophthalmic-drug-development-portfolio-with-acquisition-of-viewpoint-therapeutics-assets daily 0.8 https://clival.com/news/preveceutical-enters-into-license-option-agreement-with-endosane-pharmaceuticals daily 0.8 https://clival.com/news/equillium-acquires-bioniz-therapeutics-significantly-expanding-pipeline-of-novel-immunomodulatory-drug-candidates daily 0.8 https://clival.com/news/lilly-and-evotec-aim-1b-deal-at-kidney-disease-and-diabetes daily 0.8 https://clival.com/news/beigene-announces-us-fda-acceptance-and-priority-review-of-supplemental-new-drug-application-for-brukinsa-zanubrutinib-in-marginal-zone-lymphoma daily 0.8 https://clival.com/news/wuxi-biologics-aravive-ink-collaboration-to-develop-novel-high-affinity-bispecific-antibodies-targeting-cancer-fibrosis daily 0.8 https://clival.com/news/boehringer-ingelheims-jardiance-gets-cdscos-approval-for-treating-heart-failure-with-preserved-ejection-fraction daily 0.8 https://clival.com/news/tmc-collaborates-with-tcd-to-validate-diagnostic-test-for-oral-cancer-screening daily 0.8 https://clival.com/news/redhill-biopharma-announces-presentation-of-positive-oral-opaganib-phase-2-data-in-covid-19 daily 0.8 https://clival.com/news/health-groups-ask-india-to-rescind-gileads-patents-for-covid-19-drug-remdesivir daily 0.8 https://clival.com/news/bayers-phase-iii-quasar-study-positive-results-for-aflibercept-8mg daily 0.8 https://clival.com/news/everest-medicines-enters-partnership-with-china-resources-pharmaceutical-for-its-mrna-vaccine-business daily 0.8 https://clival.com/news/acelyrin-inc-affibody-ab-and-inmagene-biopharmaceuticals-announce-positive-interim-results-from-global-phase-2-trial-of-izokibep-in-patients-with-psoriatic-arthritis daily 0.8 https://clival.com/news/y-trap-enters-collaboration-with-merck-kgaato-develop-novel-antibody-ligand-traps-for-immuno-oncology daily 0.8 https://clival.com/news/sibylla-partners-with-ono-pharma-for-developing-cns-disorder-therapeutics daily 0.8 https://clival.com/news/shimadzu-medical-acquires-california-x-ray-imaging-services daily 0.8 https://clival.com/news/health-ministry-issues-draft-amendment-to-ndct-rules-for-deemed-approval-of-clinical-trials daily 0.8 https://clival.com/news/daiichi-sankyo-begins-patient-dosing-in-phase-12-trial-of-ds-3939-to-treat-several-types-of-advanced-solid-cancers daily 0.8 https://clival.com/news/caris-partners-with-merck-kgaa-for-adc-development daily 0.8 https://clival.com/news/halozyme-announces-us-fda-approval-of-roches-tecentriq-hybreza-with-enhanze daily 0.8 https://clival.com/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairs-positive-response daily 0.8 https://clival.com/news/aura-biosciences-announces-positive-results-from-phase-2-for-early-stage-choroidal-melanoma daily 0.8 https://clival.com/news/mabwell-gets-china-nmpa-approval-to-begin-phase-ii-trial-of-novel-nectin-4 daily 0.8 https://clival.com/news/fda-denies-approval-of-regenerons-linvoseltamab-for-multiple-myeloma-cites-third-party-issues daily 0.8 https://clival.com/news/ibio-and-planet-biotechnology-enter-into-exclusive-worldwide-license-agreement-for-the-development-of-a-covid-19-therapeutic daily 0.8 https://clival.com/news/merck-to-buy-caraway-therapeutics-for-total-consideration-of-up-to-610-million daily 0.8 https://clival.com/news/us-fda-grants-priority-review-to-amgen-tarlatamab-application-for-advanced-small-cell-lung-cancer daily 0.8 https://clival.com/news/endeavor-biomedicines-acquires-global-rights-to-hmbd-501-a-next-generation-her3-targeted-antibody-drug-conjugate-adc-in-licensing-agreement-with-hummingbird-bioscience daily 0.8 https://clival.com/news/gsk-announces-positive-topline-results-from-ruby-part-2-phase-iii-trials-of-jemperli-in-combo-with-zejula-to-treat-endometrial-cancer daily 0.8 https://clival.com/news/us-fda-approves-roches-companion-diagnostic-for-her2-targeted-ziihera-treatment daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-to-market-generic-synjardy-xr-tablets daily 0.8 https://clival.com/news/pfizer-and-biohavens-vydura-gets-european-marketing-nod-for-both-acute-treatment-of-migraine-and-prophylaxis-of-episodic-migraine daily 0.8 https://clival.com/news/sellas-life-sciences-receives-idmc-recommendation-to-continue-phase-3-regal-trial daily 0.8 https://clival.com/news/halozyme-therapeutics-inc-and-chugai-pharmaceutical-enter-global-collaboration-and-license-agreement-for-enhanze daily 0.8 https://clival.com/news/pharmacosmos-group-acquires-boston-based-clinical-stage-abfero-pharmaceuticals-inc daily 0.8 https://clival.com/news/who-and-eu-renew-partnership-for-universal-health-coverage daily 0.8 https://clival.com/news/ionis-pharma-announces-positive-results-from-halos-study-of-ion582 daily 0.8 https://clival.com/news/enveric-biosciences-evm301-portfolio-receives-five-additional-us-patents daily 0.8 https://clival.com/news/merck-announces-collaboration-with-mersana-therapeutics-to-develop-novel-immunostimulatory-antibody-drug-conjugates daily 0.8 https://clival.com/news/astrazeneca-announces-positive-results-from-flaura2-phase-iii-trial-of-tagrisso-in-combo-with-chemotherapy-to-treat-egfr-mutated-advanced-lung-cancer daily 0.8 https://clival.com/news/novartis-highlights-96-week-scemblix-asc4first-kisqali-natalee-trial-results daily 0.8 https://clival.com/news/menarini-asia-pacific-enters-into-an-exclusive-licensing-agreement-with-astellas-to-commercialize-smyraf-in-taiwan-and-select-south-east-asian-markets daily 0.8 https://clival.com/news/iktos-and-astrogen-announce-a-research-collaboration-to-use-artificial-intelligence-platform-for-drug-design-against-a-novel-parkinsons-disease-target daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-device-designation-to-cordance-medical-neuroaccess-for-liquid-biopsy-in-brain-tumours daily 0.8 https://clival.com/news/wockhardt-and-serum-life-sciences-uk-announce-collaboration-for-manufacturing-multiple-vaccines-in-the-united-kingdom daily 0.8 https://clival.com/news/icra-revises-domestic-pharma-industry-outlook-to-negative-due-to-coronavirus-outbreak daily 0.8 https://clival.com/news/ultima-genomics-collaborates-with-genome-insight daily 0.8 https://clival.com/news/abbvie-seeks-us-fda-ema-approvals-for-upadacitinib-to-treat-adult-with-giant-cell-arteritis daily 0.8 https://clival.com/news/nouscom-inks-clinical-trial-collaboration-supply-pact-with-msd-to-evaluate-nous-209-in-combo-with-keytruda-in-phase-2-trials-in-dmmrmsi-high-metastatic-crc daily 0.8 https://clival.com/news/health-canada-approves-sqi-diagnostics-rali-dx-severity-triage-test daily 0.8 https://clival.com/news/co-diagnostics-inc-completes-submission-to-fda-for-co-dx-pcr-pro daily 0.8 https://clival.com/news/nanosmart-receives-second-fda-orphan-drug-designation-for-treatment-of-pediatric-cancer daily 0.8 https://clival.com/news/sanofis-hercules-phase-3-study-of-tolebrutinib-for-secondary-progressive-ms-meets-primary-endpoint daily 0.8 https://clival.com/news/us-fda-fast-tracks-sanofis-combo-vaccines-for-flu-covid-19 daily 0.8 https://clival.com/news/vyne-therapeutics-reports-positive-phase-1a-sad-data-for-vyn202 daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-status-to-glycostems-onkord-to-treat-multiple-myeloma daily 0.8 https://clival.com/news/alvotech-and-fuji-pharma-expand-partnership-for-additional-biosimilar-candidate-in-japan daily 0.8 https://clival.com/news/marius-pharmaceuticals-announces-kyzatrex-ciii-testosterone-undecanoate-capsules-hero-campaign-empowering-men-to-be-the-hero-of-your-life-again daily 0.8 https://clival.com/news/phase-3-ikema-trial-of-sarclisa-combination-provides-unprecedented-median-progression-free-survival-in-patients-with-relapsed-multiple-myeloma-receiving-proteasome-inhibitor-therapy daily 0.8 https://clival.com/news/pfizers-prevenar-20-gets-approval-for-pneumococcal-disease-in-infants daily 0.8 https://clival.com/news/index-pharma-receives-korean-patent-for-for-cobitolimod-to-inflammatory-bowel-disease daily 0.8 https://clival.com/news/revir-therapeutics-kennedys-disease-association-partner-for-rare-neuromuscular-disorder daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-pfizers-ervogastatclesacostat-combination-to-treat-nash daily 0.8 https://clival.com/news/histoindex-inks-partnership-with-vcus-stravitz-sanyal-institute-for-liver-disease-and-metabolic-health-in-the-study-of-liver-diseases daily 0.8 https://clival.com/news/cepheid-seeks-approvals-to-manufacture-point-of-care-covid-19-rt-pcr-diagnostic-test-in-india daily 0.8 https://clival.com/news/medilink-therapeutics-and-roche-establish-worldwide-partnership-and-license-agreement-for-the-development-of-advanced-oncology-antibody-drug-conjugate daily 0.8 https://clival.com/news/compugen-secures-fda-approval-for-ind-application-of-com503-in-solid-tumor-treatment daily 0.8 https://clival.com/news/zydus-cadila-starts-supply-of-covid-19-vaccine-to-govt daily 0.8 https://clival.com/news/biosyngen-receives-us-fda-fast-track-designation-for-brg01 daily 0.8 https://clival.com/news/cellipont-bioservices-and-diakonos-oncology-corporation-collaborate-to-develop-groundbreaking-therapy-for-glioblastoma daily 0.8 https://clival.com/news/mhra-approves-fosdenopterin-for-molybdenum-cofactor-deficiency-type-a daily 0.8 https://clival.com/news/adaptive-biotechnologies-corporation-announces-translational-collaboration-with-takeda daily 0.8 https://clival.com/news/us-fda-grants-eua-to-pfizer-and-biontech-covid-19-vaccine-booster-dose-in-children-5-through-11-years-of-age daily 0.8 https://clival.com/news/sun-pharma-to-acquire-daiichis-1128-stake-in-zenotech daily 0.8 https://clival.com/news/abbvie-inks-deal-worth-156-b-with-chinas-futuregen-to-develop-ibd-therapy daily 0.8 https://clival.com/news/novo-nordisks-semaglutide-delivers-in-phase-3-mash-study-teeing-up-filings daily 0.8 https://clival.com/news/regeneron-pharmaceuticals-announces-collaboration-with-sonoma-biotherapeutics daily 0.8 https://clival.com/news/neuberg-diagnostics-launches-clinical-laboratory-operations-ncgm-in-north-carolina-usa daily 0.8 https://clival.com/news/us-fda-grants-eua-to-pfizer-and-biontechs-omicron-ba4ba5-adapted-bivalent-covid-19-vaccine-booster-in-children-5-through-11-years-of-age daily 0.8 https://clival.com/news/brickell-biotech-announces-sale-of-sofpironium-bromide-to-botanix-pharmaceuticals daily 0.8 https://clival.com/news/raysearch-acquires-druglog daily 0.8 https://clival.com/news/lillys-bebtelovimab-receives-emergency-use-authorization-for-the-treatment-of-mild-to-moderate-covid-19 daily 0.8 https://clival.com/news/stemcyte-reports-positive-phase-iia-results-for-hpc-cord-blood-in-post-covid daily 0.8 https://clival.com/news/affamed-therapeutics-announces-approval-to-initiate-a-phase-3-registrational-clinical-trial-in-mainland-china-for-dextenza daily 0.8 https://clival.com/news/seagens-tivdak-receives-us-fda-approval-for-treatment-of-metastatic-cervical-cancer daily 0.8 https://clival.com/news/indoco-remedies-gets-us-fda-approval-for-lacosamide-injection daily 0.8 https://clival.com/news/kempharm-announces-strategic-acquisition-of-arimoclomol-from-orphazyme-expanding-its-rare-cns-diseases-pipeline daily 0.8 https://clival.com/news/medgenome-partners-with-twist-teams-in-india-to-diagnose-rare-disease daily 0.8 https://clival.com/news/gsk-spero-ink-licence-agreement-for-tebipenem-hbr-a-late-stage-antibiotic-that-may-treat-complicated-urinary-tract-infections daily 0.8 https://clival.com/news/stada-gets-european-marketing-authorization-for-kinpeygo daily 0.8 https://clival.com/news/ocugen-completes-dosing-in-phase-12-gardian-trial-for-ocu410st-gene-therapy daily 0.8 https://clival.com/news/inozyme-pharma-receives-us-fda-uk-mhra-approvals-to-start-phase-12-clinical-trial-of-inz-701-to-treat-enpp1-deficiency daily 0.8 https://clival.com/news/cepi-partners-with-bharat-biotech-consortium-to-develop-variantproof-covid-19-vaccine daily 0.8 https://clival.com/news/genelux-corporation-announces-first-patient-dosed-in-phase-2-trial-for-lung-cancer daily 0.8 https://clival.com/news/sukino-healthcare-gets-nabh-certification daily 0.8 https://clival.com/news/merck-halts-phase-3-keyvibe-trials-for-nsclc-with-vibostolimab-fdcs daily 0.8 https://clival.com/news/fda-issues-warning-letter-to-inopak-ltd-for-significant-cgmp-violations-in-drug-manufacturing-facility daily 0.8 https://clival.com/news/inovio-ivi-seoul-national-university-hospital-partner-to-begin-phase-12-trial-of-inovios-covid-19-dna-vaccine-in-south-korea daily 0.8 https://clival.com/news/mercks-phase-3-trial-of-subcutaneous-pembrolizumab-berahyaluronidaseshows-positive-response daily 0.8 https://clival.com/news/annovis-bio-gets-us-fda-approval-to-start-pivotal-phase-3-studies-on-buntanetap daily 0.8 https://clival.com/news/moderna-rovi-expand-collaboration-to-manufacture-mrna-medicines-over-next-ten-years daily 0.8 https://clival.com/news/sanofi-receives-health-canada-approval-for-dupixent-to-treat-severe-chronic-rhinosinusitis-with-nasal-polyposis daily 0.8 https://clival.com/news/us-fda-grants-de-novo-marketing-authorization-to-labcorps-pgdx-elio-plasma-focus-dx daily 0.8 https://clival.com/news/pfizer-and-biontech-conclude-phase-3-study-of-covid-19-vaccine-candidate-meeting-all-primary-efficacy-endpoints daily 0.8 https://clival.com/news/ema-grants-orphan-drug-designation-to-neoimmunetechs-nt-i7 daily 0.8 https://clival.com/news/bdr-pharma-launches-new-drug-palbociclib-to-treat-advanced-breast-cancer daily 0.8 https://clival.com/news/glenmark-usa-acquires-andas-for-four-otc-drugs-from-wockhardt daily 0.8 https://clival.com/news/ajinomoto-bio-pharma-buys-indian-api-plant-from-jv-partner daily 0.8 https://clival.com/news/sana-biotech-obtains-non-exclusive-clinical-commercial-rights-to-use-maxcytes-flow-electroporation-technology-and-expert-platform daily 0.8 https://clival.com/news/taletrectinib-gets-second-nda-for-ros1-positive-lung-cancer daily 0.8 https://clival.com/news/takeda-drops-cancer-candidates-axing-immunocytokine-and-car-ts-amid-shifting-treatment-landscape daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-abbvies-upadacitinib-to-treat-adults-with-moderate-to-severe-crohns-disease daily 0.8 https://clival.com/news/ema-recommends-approval-for-cstone-pharmas-cejemly-with-chemotherapy daily 0.8 https://clival.com/news/junshi-biosciences-oncology-drug-toripalimab-obtains-marketing-approval-in-india-and-hong-kong-sar daily 0.8 https://clival.com/news/jama-oncology-publishes-phase-1b2-study-data-on-iaso-bios-equecabtagene-autoleucel-fucaso daily 0.8 https://clival.com/news/junshi-biosciences-and-wigen-biomedicine-enter-global-development-and-commercialization-collaboration-for-four-small-molecule-cancer-drug-candidates daily 0.8 https://clival.com/news/ema-validates-henlius-organons-maa-for-prolia-and-xgeva-biosimilar daily 0.8 https://clival.com/news/bristol-myers-squibbs-sbla-accepted-by-fda-for-first-line-treatment-of-advanced-liver-cancer daily 0.8 https://clival.com/news/lemonex-mrna-degradaball-vaccine-lem-mr203-clinical-phase-1-trial-ind-submission daily 0.8 https://clival.com/news/gsk-announces-phase-iii-anchor-trial-positive-results-for-depemokimab daily 0.8 https://clival.com/news/triumvira-reports-updated-positive-data-from-ongoing-tactic-2-phase daily 0.8 https://clival.com/news/lianbio-enters-into-an-agreement-transferring-rights-for-nbtxr3-in-china-and-other-asian-markets daily 0.8 https://clival.com/news/china-beigene-expands-collaboration-with-novartis-for-oncology-medicines daily 0.8 https://clival.com/news/novo-nordisk-wins-us-approval-for-first-of-its-kind-oral-diabetes-drug daily 0.8 https://clival.com/news/oncternal-updates-status-of-phase-12-study-of-ror1-targeting-autologous-car-t-onct-808-in-patients-with-relapsed-or-refractory-aggressive-b-cell-lymphoma daily 0.8 https://clival.com/news/oscotecadel-announce-fda-clearance-of-ind-application-of-adel-y01-for-the-treatment-of-alzheimer-disease daily 0.8 https://clival.com/news/pfizer-to-buy-biohaven-pharma-for-116-billion-in-cash daily 0.8 https://clival.com/news/cactus-communications-collaborates-with-indian-society-of-cell-biology-to-empower-researchers daily 0.8 https://clival.com/news/oculis-holding-accelerates-enrollment-in-both-diamond-phase-3-trials-of-ocs-01 daily 0.8 https://clival.com/news/astrazenecas-selumetinib-with-breakthrough-designation daily 0.8 https://clival.com/news/uk-mhra-trains-worldwide-laboratories-in-early-detection-of-polio-using-breakthrough-advanced-technology daily 0.8 https://clival.com/news/smithnephew-gains-fda-clearance-for-aetos-stemless-shoulder-system daily 0.8 https://clival.com/news/sun-pharma-receives-australian-tga-approval-for-winlevi daily 0.8 https://clival.com/news/alvotech-and-teva-secure-usa-license-date-for-avt04-a-proposed-biosimilar-to-stelara daily 0.8 https://clival.com/news/processa-pharma-announces-positive-results-from-pcs12852-phase-2a-trial-in-patients-with-moderate-to-severe-gastroparesis daily 0.8 https://clival.com/news/c2-pharma-receives-approval-of-china-dmf-for-digoxin daily 0.8 https://clival.com/news/us-fda-accepts-dynacures-ind-for-dyn101-to-treat-myotubular-and-centronuclear-myopathies daily 0.8 https://clival.com/news/altos-biologics-files-approval-of-aflibercept-biosimilar daily 0.8 https://clival.com/news/nclt-okays-merger-of-monsanto-india-with-bayer-cropscience daily 0.8 https://clival.com/news/sheba-medical-centers-assistance-urgently-requested-by-world-health-organization-who-for-deadly-samoan-measles-outbreak daily 0.8 https://clival.com/news/engrail-therapeutics-acquires-neurocycle-therapeutics-to-improve-and-optimize-drugs-to-improve-the-lives-of-patients-with-central-nervous-system-disea daily 0.8 https://clival.com/news/daiichi-sankyo-board-passes-resolution-to-carry-out-an-absorption-type-merger-of-its-wholly-owned-subsidiaries-daiichi-sankyo-propharma-daiichi-sankyo-chemical-pharma daily 0.8 https://clival.com/news/cytomx-regeneron-sign-research-collaboration-in-the-area-of-bispecific-cancer-therapies-utilising-probody-veloci-bi-platforms daily 0.8 https://clival.com/news/tevard-biosciences-collaborates-with-vertex-pharma-to-develop-novel-trna-based-therapies-for-duchenne-muscular-dystrophy daily 0.8 https://clival.com/news/the-worlds-first-recombinant-anthrax-vaccine-gc-biopharma-applies-for-mfds-approval daily 0.8 https://clival.com/news/biogen-and-samsung-bioepis-byooviz daily 0.8 https://clival.com/news/novo-nordisk-launches-safe-pharmaceuticals-disposal-initiative-for-employees daily 0.8 https://clival.com/news/china-based-jiangsu-hengrui-pharma-launches-new-subsidiary-luzsana-biotech daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-device-designation-to-sooma-medical daily 0.8 https://clival.com/news/bharat-biotech-announces-phase-3-results-of-covaxin-indias-first-covid-19-vaccine-demonstrates-interim-clinical-efficacy-of-81 daily 0.8 https://clival.com/news/transcenta-gets-china-cde-south-korea-mfds-approvals-to-initiate-transtar-301-global-phase-iii-pivotal-trial-of-osemitamab-in-combo-with-nivolumab-and-chemotherapy daily 0.8 https://clival.com/news/cepi-and-gsk-announce-collaboration-to-strengthen-the-global-effort-to-develop-a-vaccine-for-the-2019-ncov-virus daily 0.8 https://clival.com/news/china-approves-gloria-biosciences-drug-for-cervical-cancer-treatment daily 0.8 https://clival.com/news/aurigene-announces-phase-1-study-for-indias-novel-autologous-car-t-cell-therapy-trial daily 0.8 https://clival.com/news/prilenia-receives-positive-ema-opinion-on-orphan-drug-designation-for-pridopidine-in-als daily 0.8 https://clival.com/news/eli-lilly-incyte-announce-updates-on-phase-3-development-programme-for-olumiant-in-adults-with-active-systemic-lupus-erythematosus daily 0.8 https://clival.com/news/itm-gets-us-fda-fast-track-designation-for-radionuclide-therapy-candidate-itm-11-to-treat-gastroenteropancreatic-neuroendocrine-tumours daily 0.8 https://clival.com/news/genetx-ultragenyx-receive-uk-mhra-approval-to-begin-phase-12-study-of-gtx-102-to-treat-angelman-syndrome daily 0.8 https://clival.com/news/insilico-medicine-discovers-industry-first-preclinical-drug-candidate-using-ai daily 0.8 https://clival.com/news/astellas-provides-update-on-zolbetuximab-biologics-license-application-in-us daily 0.8 https://clival.com/news/zevra-therapeutics-to-acquire-acer-therapeutics-for-91-million daily 0.8 https://clival.com/news/corcept-therapeutics-plunges-after-loss-in-patent-battle-with-teva daily 0.8 https://clival.com/news/sillajen-to-acquire-rights-for-basileas-novel-kinase-inhibitor-bal0891 daily 0.8 https://clival.com/news/alexion-enters-agreement-with-pfizer-to-acquire-a-portfolio-of-preclinical-rare-disease-gene-therapies daily 0.8 https://clival.com/news/biontech-and-oncoc4-announce-strategic-collaboration daily 0.8 https://clival.com/news/china-nmpa-approves-micurxs-contezolid-for-treatment-of-drug-resistant-bacterial-infection daily 0.8 https://clival.com/news/incyte-and-innocare-announce-collaboration-and-license-agreement-for-tafasitamab-in-greater-china daily 0.8 https://clival.com/news/kineta-reports-positive-kva12123-monotherapy-safety-and-biomarker-data-from-phase-12-vista-101-trial-to-treat-advanced-solid-tumours daily 0.8 https://clival.com/news/south-korea-approves-novavax-covid-19-vaccine daily 0.8 https://clival.com/news/polaris-group-announced-the-acquisition-of-genovior-biotech-initiating-dual-engine-growth daily 0.8 https://clival.com/news/nicox-grants-japanese-rights-to-develop-and-commercialize-ncx-470-to-kowa-company daily 0.8 https://clival.com/news/fda-grants-priority-review-to-mercks-sbla-for-keytruda daily 0.8 https://clival.com/news/pasithea-therapeutics-acquires-allomek-therapeutics daily 0.8 https://clival.com/news/everest-medicines-announces-acceptance-of-nefecon-new-drug-applications-for-the-treatment-of-primary-iga-nephropathy-in-adult-patients-in-south-korea daily 0.8 https://clival.com/news/curium-completes-patient-enrollment-in-phase-3-eclipse-trial daily 0.8 https://clival.com/news/lipella-pharma-reports-positive-results-from-phase-2a-trial-of-lp-10-for-haemorrhagic-cystitisn daily 0.8 https://clival.com/news/novartis-phase-iii-trial-of-beovu-versus-aflibercept-to-treat-diabetic-macular-edema-meets-primary-key-secondary-endpoints daily 0.8 https://clival.com/news/china-nmpa-accepts-and-grants-priority-review-status-to-hutchmeds-nda-for-sovleplenib-to-treat-primary-immune-thrombocytopenia daily 0.8 https://clival.com/news/chugai-pharma-inks-joint-research-pact-with-ncc-for-asian-international-collaborative-prospective-study-a-train daily 0.8 https://clival.com/news/sp-launches-sp-hull-lyostar-40-rd-freeze-dryer-to-enhance-speed-to-market-in-drug-development daily 0.8 https://clival.com/news/lupin-launches-turqoz-tablets-usp-in-the-united-states daily 0.8 https://clival.com/news/meridian-bioscience-receives-fda-emergency-use-authorization-for-revogene daily 0.8 https://clival.com/news/fda-delays-approval-of-novo-nordisks-once-weekly-insulin-icodec daily 0.8 https://clival.com/news/gilead-sciences-to-acquire-german-biotech-company-myr-gmbh-for-approximately-eur115-billion daily 0.8 https://clival.com/news/gilead-sciences-gets-european-marketing-authorization-for-sunlenca-injection-and-tablets-to-treat-hiv-infection-in-combo-with-other-antiretrovirals daily 0.8 https://clival.com/news/soligenix-reports-positive-results-from-phase-2a-study-of-sgx302-in-patients-with-mild-to-moderate-psoriasis daily 0.8 https://clival.com/news/persephone-biosciences-and-ginkgo-bioworks-announce-collaboration-to-develop-novel-therapeutics daily 0.8 https://clival.com/news/lupin-gets-us-fda-approval-for-bromfenac-ophthalmic-solution-007-and-tentative-nod-for-canagliflozin-tablets daily 0.8 https://clival.com/news/marketing-pfizers-lorbrena-breaks-into-front-line-alk-lung-cancer-jostling-with-novartis-roche-and-takeda daily 0.8 https://clival.com/news/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups daily 0.8 https://clival.com/news/lennham-pharmaceuticals-announces-issuance-of-us-patent-covering-deuterated-psilocybin-products daily 0.8 https://clival.com/news/bayer-curadev-ink-pact-to-discover-drug-candidates-for-lung-cardiovascular-inflammatory-diseases daily 0.8 https://clival.com/news/johnson-johnson-runs-into-vaccine-supply-issues-in-europe-threatening-second-quarter-delivery-pledge-reuters daily 0.8 https://clival.com/news/bcbstx-ht-enter-collaboration-aimed-at-culturally-aligned-healthcare-and-improving-texas-maternal-infant-health-outcomes daily 0.8 https://clival.com/news/bio-thera-solutions-initiates-integrated-phase-i-phase-iii-clinical-trial-for-bat3306 daily 0.8 https://clival.com/news/accuray-cyberknife daily 0.8 https://clival.com/news/sec-recommends-approval-for-boehringer-ingelheim daily 0.8 https://clival.com/news/positive-outcome-from-a-phase-ib-study-in-australia-treating-patients-with-androgenic-alopecia daily 0.8 https://clival.com/news/vertex-gains-fda-fast-track-designation-for-diabetes-stem-cell-therapy daily 0.8 https://clival.com/news/bayer-soon-to-collaborate-aignostics-for-precision-oncology daily 0.8 https://clival.com/news/lupin-completes-acquisition-of-afdils-brands daily 0.8 https://clival.com/news/samsung-biologics-and-stcube-enter-into-development-and-manufacturing-agreement-for-novel-target-anticancer-drug daily 0.8 https://clival.com/news/zydus-lifesciences-gets-usfda-nod-for-generic-drug daily 0.8 https://clival.com/news/lupin-introduces-generic-prolensa-ophthalmic-solution-007-in-us daily 0.8 https://clival.com/news/healis-partnerns-with-massachusetts-hospital-for-neuroscience-research daily 0.8 https://clival.com/news/onyx-pharmaceuticals-has-received-a-fast-track-designation-from-the-us-fda-for-its-multiple-myeloma-drug-carfilzomib daily 0.8 https://clival.com/news/psyence-and-filament-health-announce-worldwide-licensing-agreement-of-psilocybin-capsule-for-palliative-care daily 0.8 https://clival.com/news/merck-launches-lanexo-system-to-enhance-productivity-of-scientists-in-laboratory daily 0.8 https://clival.com/news/mylan-launches-remdesivir-in-india-under-the-brand-name-desrem-for-covid-19-treatment daily 0.8 https://clival.com/news/glycomine-begins-patient-dosing-in-phase-1-study-of-glm101-for-treatment-of-pmm2-cdg daily 0.8 https://clival.com/news/karyopharm-inks-clinical-trial-collaboration-with-bristol-myers-squibb-to-evaluate-novel-celmod-agent-cc-92480-mezigdomide-in-combo-with-selinexor-in-patients-with-rr-multiple-myeloma daily 0.8 https://clival.com/news/jacobio-pharma-receives-ind-approval-for-kras-g12c-in-china daily 0.8 https://clival.com/news/eris-lifesciences-expands-to-injectables-by-acquisition-of-biocon-biologics daily 0.8 https://clival.com/news/china-nmpa-grants-breakthrough-therapy-designation-to-jw-therapeutics daily 0.8 https://clival.com/news/lupin-collaboration-with-yabao-pharma-for-paediatric-formulations-in-china daily 0.8 https://clival.com/news/novavax-nuvaxovid-covid-19-vaccine-approved-in-south-korea-as-an-adult-booster daily 0.8 https://clival.com/news/sun-pharma-canada-launches-prwinlevi-clascoterone-cream-1-ww-a-novel-topical-treatment-for-acne daily 0.8 https://clival.com/news/glenmark-gets-usfda-approval-for-theophylline-er-tablets daily 0.8 https://clival.com/news/kite-and-daiichi-sankyo-announce-changes-to-yescarta daily 0.8 https://clival.com/news/glenmark-gets-usfda-nod-forgeneric-drug daily 0.8 https://clival.com/news/granules-india-gets-us-fda-approval-for-generic-mitigare-capsules daily 0.8 https://clival.com/news/novavax-highlights-science-supporting-protein-based-vaccine-technology-at-idweek-2023-and-world-vaccine-congress-europe-2023 daily 0.8 https://clival.com/news/raysearch-announces-raystation-9-receives-chinese-regulatory-clearance daily 0.8 https://clival.com/news/enterobiotix-completes-patient-recruitment-in-phase-2-triumph-study daily 0.8 https://clival.com/news/luye-pharmas-risperidone-gets-priority-review-by-cde daily 0.8 https://clival.com/news/trexbio-announces-collaboration-with-janssen-to-discover-novel-targets-for-immunology-and-inflammation daily 0.8 https://clival.com/news/japanese-mhlw-approves-chugai-pharmas-vabysmo-for-neovascular-amd-and-diabetic-macular-edema daily 0.8 https://clival.com/news/astrazeneca-advances-response-to-global-covid-19-challenge-as-it-receives-first-commitments-for-oxfords-potential-new-vaccine daily 0.8 https://clival.com/news/astrazenecs-imfinzi-approved-in-us-for-an-additional-dosing-option-in-the-unresectable-stage-iii-nsclc daily 0.8 https://clival.com/news/accord-biopharma-announces-fda-approval-of-420mg-strength-of-hercessi daily 0.8 https://clival.com/news/omega-therapeutics-gets-us-fda-clearance-to-begin-phase-12-study-of-otx-2002-to-treat-hepatocellular-carcinoma daily 0.8 https://clival.com/news/china-sonoscape-receives-fda-510k-clearance-for-hd-550-endoscopy-system daily 0.8 https://clival.com/news/cipla-receives-usfda-nod-to-market-lanreotide-injection-in-american-market daily 0.8 https://clival.com/news/kintara-therapeutics-granted-fast-track-designation-from-the-fda-for-val-083-for-newly-diagnosed-glioblastoma daily 0.8 https://clival.com/news/docdoc-kaitaiming-technology-to-bring-doctor-discovery-services-to-china daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-allopurinol-tablets-and-tentative-approval-for-sitagliptin-tablets daily 0.8 https://clival.com/news/solasia-and-nippon-kayaku-announce-license-agreement-in-japan-for-new-drug-candidate-darinaparsin-sp-02 daily 0.8 https://clival.com/news/us-fda-approves-heron-therapeutics-zynrelef-vial-access-needle daily 0.8 https://clival.com/news/telix-gets-chinese-nmpa-approval-to-begin-pivotal-phase-iii-study-of-tlx591-cdx-for-prostate-cancer-imaging daily 0.8 https://clival.com/news/basilea-seeks-us-fda-approval-for-antibiotic-ceftobiprole-to-treat-sab-absssi-and-cabp daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-merck-investigational-anticoagulant-therapy-mk-2060 daily 0.8 https://clival.com/news/abbvie-join-hands-with-ose-immunotherapeutics-for-ose-230 daily 0.8 https://clival.com/news/novartis-phase-iii-appear-c3g-study-of-iptacopan-to-treat-c3-glomerulopathy-meets-primary-endpoint daily 0.8 https://clival.com/news/correvios-heart-drug-fails-to-get-fda-approval daily 0.8 https://clival.com/news/roche-announces-positive-results-from-phase-iii-study-of-gazyvagazyvaro daily 0.8 https://clival.com/news/alembic-pharma-subsidiary-aleor-dermaceuticals-gets-usfda-nod-for-acne-gel daily 0.8 https://clival.com/news/fda-approves-eli-lilly-drug-for-thyroid-lung-cancers-driven-by-a-genetic-mutation daily 0.8 https://clival.com/news/taho-pharma-begins-patient-dosing-in-us-phase-iii-trial-of-tah3311 daily 0.8 https://clival.com/news/roche-expands-collaboration-with-janssen-to-advance-personalised-healthcare daily 0.8 https://clival.com/news/abbvie-shares-promising-late-stage-results-for-parkinsons-disease-candidate-tavapadon daily 0.8 https://clival.com/news/inventiva-and-sino-biopharm-ink-nash-deal-for-more-than-300-m daily 0.8 https://clival.com/news/alloy-therapeutics-signs-collaboration-and-license-agreement-with-takeda daily 0.8 https://clival.com/news/mercks-phase-3-keynote-412-trial-of-keytruda-to-treat-patients-with-unresected-locally-advanced-hnscc-fails-to-meet-primary-endpoint daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-to-market-generic-renagel-tablets daily 0.8 https://clival.com/news/lilly-mounjaro-injection-to-treat-adults-with-type-2-diabetes-receives-us-fda-approval daily 0.8 https://clival.com/news/takeda-and-protagonist-therapeutics-announce-global-license-and-collaboration-agreement-for-rusfertide-an-advanced-rare-hematology-asset daily 0.8 https://clival.com/news/bayer-announces-exclusive-licence-agreement-with-cedilla-therapeutics daily 0.8 https://clival.com/news/cassava-sciences-phase-3-study-of-simufilam-fails-to-meet-co-primary-endpoints daily 0.8 https://clival.com/news/donaldson-company-acquires-solaris-biotechnology daily 0.8 https://clival.com/news/eu-grants-marketing-authorization-to-vertexs-casgevy daily 0.8 https://clival.com/news/endos-paladin-labs-announces-launch-of-xcopri-cenobamate-tablets-in-canada daily 0.8 https://clival.com/news/hikma-junshi-biosciences-ink-licensing-and-commercialization-agreement-for-cancer-treatment-drug-toripalimab-for-mena-region daily 0.8 https://clival.com/news/opko-health-acquires-modex-therapeutics-gains-proprietary-immunotherapy-technology-with-a-focus-on-oncology-and-infectious-diseases daily 0.8 https://clival.com/news/pfizer-elranatamab-gets-us-fda-breakthrough-therapy-designation-to-treat-relapsed-or-refractory-multiple-myeloma daily 0.8 https://clival.com/news/sun-pharma-inks-licensing-distribution-pact-with-hikma-for-ilumya-in-mena-region daily 0.8 https://clival.com/news/novavax-announces-initiation-of-prevent-19-pivotal-phase-3-efficacy-trial-of-covid-19-vaccine-in-the-united-states-and-mexico daily 0.8 https://clival.com/news/iicon-supports-new-phase-ii-trial-of-novel-pneumococcal-vaccine-pnubiovax daily 0.8 https://clival.com/news/organon-launches-as-new-womens-health-company daily 0.8 https://clival.com/news/viva-biotech-accelerate-the-early-drug-discovery-through-ai-technology daily 0.8 https://clival.com/news/bausch-health-glenmark-receive-health-canada-approval-for-ryaltris-to-treat-seasonal-allergic-rhinitis daily 0.8 https://clival.com/news/novartis-kisqali-receives-european-approval-in-patients-with-hrher2-early-breast-cancer-high-recurrencex daily 0.8 https://clival.com/news/sandoz-completes-acquisition-of-aspens-japanese-operations-strengthening-its-position-in-worlds-third-largest-market-for-generics-and-off-patent-me daily 0.8 https://clival.com/news/kangpu-completes-patient-enrollment-for-phase-iia-clinical-trial-of-kpg-818-in-sle-in-the-us daily 0.8 https://clival.com/news/boisar-facility-successfully-renews-eu-gmp-certification daily 0.8 https://clival.com/news/ionis-olezarsen-gets-orphan-drug-designation daily 0.8 https://clival.com/news/astrazeneca-ionis-wainua-gets-us-fda-approval-for-treatment-polyneuropathy-hattr-pn-in-adults daily 0.8 https://clival.com/news/lyell-immunopharma-inks-agreement-to-buy-immpact-bio-usa daily 0.8 https://clival.com/news/dr-reddy-acquires-menolabs-a-women-health-and-dietary-supplements-portfolio-of-brands daily 0.8 https://clival.com/news/moderna-and-the-european-commission-agree-on-amendment-to-covid-19-vaccine-supply-agreement daily 0.8 https://clival.com/news/hutchmed-completes-planned-enrollment-of-fresco-2-a-global-phase-iii-trial-of-fruquintinib-in-metastatic-colorectal-cancer daily 0.8 https://clival.com/news/anheart-therapeutics-and-innovent-announce-china-nmpa-has-granted-taletrectinib-ros1-inhibitor-priority-review-designation daily 0.8 https://clival.com/news/sun-pharma-gets-us-fda-nod-for-generic-mesalamine-er-capsules daily 0.8 https://clival.com/news/kura-oncology-mirati-therapeutics-ink-clinical-collaboration-supply-agreement-to-evaluate-ko-2806-and-adagrasib-in-krasg12c-mutated-nsclc daily 0.8 https://clival.com/news/i-mab-announces-china-nmpa-clearance-for-phase-1-clinical-trial-of-lemzoparlimab-in-relapsed-or-refractory-advanced-lymphoma daily 0.8 https://clival.com/news/eisai-seeks-us-fda-traditional-approval-for-leqembi-for-treatment-of-alzheimers-disease daily 0.8 https://clival.com/news/cytovation-begins-patient-dosing-in-phase-iiia-cicilia-trial-of-cypep-1-in-combo-with-keytruda-in-patients-with-a-range-of-solid-tumors daily 0.8 https://clival.com/news/indias-first-chemo-syrup-has-finally-arrived-expected-to-help-10000-children-each-year daily 0.8 https://clival.com/news/acko-acquires-digital-health-platform-parentlane-to-strengthen-its-content-and-healthcare-delivery-capabilities daily 0.8 https://clival.com/news/amgen-inks-collaboration-with-beigene-to-expand-oncology-presence-in-china daily 0.8 https://clival.com/news/ono-pharma-begins-drug-discovery-collaboration-with-epsilon daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-sanofi-and-astrazenecas-beyfortus-for-prevention-of-rsv-disease-in-infants daily 0.8 https://clival.com/news/remegens-rc88-obtained-fda-fast-track-designation-heralds-new-hope-for-ovarian-cancer-patients daily 0.8 https://clival.com/news/glenmark-pharma-receives-us-fda-approval-for-generic-firazyr-injection daily 0.8 https://clival.com/news/context-therapeutics-menarini-enter-clinical-trial-collaboration-and-supply-pact-to-evaluate-ona-xr-and-elacestrant-combination daily 0.8 https://clival.com/news/iontas-teva-announce-new-antibody-optimisation-agreement daily 0.8 https://clival.com/news/dca-raids-unearth-10-units-illegally-producing-alprazolam-on-city-outskirts daily 0.8 https://clival.com/news/sanofi-intends-to-sell-its-equity-investment-in-regeneron-confirms-no-change-to-ongoing-collaboration daily 0.8 https://clival.com/news/asahi-kasei-medical-to-acquire-bionova-scientific-us-based-biopharmaceutical-cdmo daily 0.8 https://clival.com/news/akeso-begins-patient-enrollment-in-phase-3-trial-of-ivonescimab-combination daily 0.8 https://clival.com/news/gilead-mercks-phase-2-data-shows-promising-weekly-treatment-for-viral-suppression daily 0.8 https://clival.com/news/impact-biotech-secures-fda-approval-for-ind-application-of-padeliporfin-vtp-in-pancreatic-cancer daily 0.8 https://clival.com/news/astrazeneca-kym-biosciences-ink-global-inc-have-entered-into-a-global-license-agreement-for-claudin-182-adc-cmg901 daily 0.8 https://clival.com/news/sanofi-and-innovent-biologics-enter-strategic-collaboration-to-accelerate-development-of-oncology-medicines-and-expand-presence-in-china daily 0.8 https://clival.com/news/epicentrxs-adapt-001-tgf-inhibitor-gains-fda-fast-track-for-sarcoma daily 0.8 https://clival.com/news/novavax-and-commonwealth-of-australia-announce-agreement-in-principle-for-acquisition-of-novavax-covid-19-vaccine daily 0.8 https://clival.com/news/haleon-completes-demerger-from-gsk-launches-as-an-independent-company-focused-on-consumer-health daily 0.8 https://clival.com/news/gc-cell-and-biocentriq-accelerates-us-entry-of-immuncell-lc-inj daily 0.8 https://clival.com/news/paratek-pharma-announces-positive-top-line-data-from-phase-2b-study-of-oral-omadacycline daily 0.8 https://clival.com/news/beyond-air-terminates-commercial-licensing-agreement-for-lungfit-ph-for-use-in-the-hospital-setting-in-the-united-states-and-china daily 0.8 https://clival.com/news/biosion-licenses-bsi-060t-anti-siglec-15-to-pyxis-oncology daily 0.8 https://clival.com/news/innovent-announces-nmpas-breakthrough-therapy-designation-for-ibi351-kras-g12c-inhibitor-as-monotherapy-for-previous-treated-advanced-non-small-cell-lung-cancer daily 0.8 https://clival.com/news/mallinckrodt-presents-new-data-on-terlivaz-terlipressin-for-injection-at-the-society-of-critical-care-medicine-sccm-2024-critical-care-congress daily 0.8 https://clival.com/news/akeso-and-remegen-collaborates-on-clinical-study-exploring-the-potential-of-pd-1ctla-4-bispecific-antibody-with-her-2-adc-combination-therapy-in-gastric-cancer daily 0.8 https://clival.com/news/alnylam-peptidream-ink-pact-to-discover-develop-peptide-sirna-conjugates-for-for-targeted-delivery-of-rnai-therapeutics-to-tissues-outside-liver daily 0.8 https://clival.com/news/us-fda-approves-medtronics-minimed-770g-insulin-pump-system-with-smartphone-connectivity-for-people-with-type-1-diabetes daily 0.8 https://clival.com/news/ani-pharmaceuticals-announces-fda-approval-and-imminent-launch-of-clorazepate-dipotassium-tablets-usp daily 0.8 https://clival.com/news/us-fda-approves-pfizer-nasal-spray-for-migraine daily 0.8 https://clival.com/news/novartis-biopharm-manufacturing-starts-in-singapore daily 0.8 https://clival.com/news/hcltech-olympus-expand-engineering-and-rd-partnership daily 0.8 https://clival.com/news/mercks-treatment-for-urinary-abdominal-infections-gets-fda-approval daily 0.8 https://clival.com/news/pfizer-litfulo-receives-european-marketing-approval-for-adolescents-and-adults-with-severe-alopecia-areata daily 0.8 https://clival.com/news/glaxosmithklines-nucala-targets-rival-astrazeneca-with-fda-nod-for-rare-white-blood-cell-disease daily 0.8 https://clival.com/news/rznomics-to-commence-rna-editing-therapy-trial-for-retinitis-pigmentosa daily 0.8 https://clival.com/news/acepodia-receives-us-fda-clearance-to-initiate-phase-1-study-of-ace1831-in-patients-with-non-hodgkins-lymphoma daily 0.8 https://clival.com/news/lupin-launches-rufinamide-tablets-in-us-market daily 0.8 https://clival.com/news/fda-fast-tracks-lipocines-lpcn-1148-for-sarcopenia-in-cirrhosis daily 0.8 https://clival.com/news/pharmabcine-announces-first-patient-dosed-in-phase-1ab-clinical-trial-of-pmc-309-in-combination-with-keytruda-pembrolizumab-in-patients-with-advanced-or-metastatic-solid-tumors daily 0.8 https://clival.com/news/granules-pharmaceuticals-inc-gets-usfda-nod-for-colchicine-tablets daily 0.8 https://clival.com/news/esperion-and-daiichi-sankyo-europe-announce-amendment-to-license-and-commercial-collaboration-agreement daily 0.8 https://clival.com/news/merck-receives-fda-approval-for-ebola-vaccine daily 0.8 https://clival.com/news/telix-granted-fda-orphan-drug-designation-for-bone-marrow-conditioning-treatment daily 0.8 https://clival.com/news/cdsco-approves-german-pharma-firms-drug-to-help-reduce-cardiovascular-deaths-in-india daily 0.8 https://clival.com/news/praxis-precision-medicines-and-tenacia-biotechnology-have-entered-into-a-licensing-and-collaboration-agreement-for-ulixacaltamide-in-the-greater-china-region daily 0.8 https://clival.com/news/alivecor-gets-us-fda-nod-for-algorithm-suite-for-personal-ecg-a-new-gen-ai-powered-remote-cardiology-device daily 0.8 https://clival.com/news/zydus-settles-revlimid-patent-litigation-with-celgene daily 0.8 https://clival.com/news/roche-launches-ocrevus-in-india daily 0.8 https://clival.com/news/daiichi-sankyo-receives-japanese-approval-for-delytact-to-treat-malignant-glioma daily 0.8 https://clival.com/news/be-the-match-biotherapies-and-cryoport-partner-to-accelerate-the-development-of-cell-and-gene-therapies daily 0.8 https://clival.com/news/eisais-fycompa-receives-chinese-approval-to-treat-primary-generalized-tonic-clonic-seizures daily 0.8 https://clival.com/news/foresee-pharma-gets-positive-recommendation-from-dsmb-for-phase-iii-trial daily 0.8 https://clival.com/news/us-fda-grants-fast-track-status-to-aura-biosciences-belzupacap-sarotalocan-to-treat-nmibc daily 0.8 https://clival.com/news/biophore-india-receives-licences-from-mpp-to-market-molnupiravir daily 0.8 https://clival.com/news/aurobindos-buyout-of-sandoz-assets-delayed-on-ftc-query daily 0.8 https://clival.com/news/ema-human-medicine-committee-recommends-approval-of-sanofis-sarclisa daily 0.8 https://clival.com/news/natco-pharma-kothurs-formulation-facility-gets-eir-from-us-fda daily 0.8 https://clival.com/news/halesaga-launches-new-health-and-wellness-products daily 0.8 https://clival.com/news/akebia-therapeutics-provides-update-on-commercial-launch-of-vafseo-tablets daily 0.8 https://clival.com/news/edigene-enters-strategic-rampd-collaboration-with-haihe-laboratory-of-cell-ecosystem-to-develop-hematopoietic-stem-cell-regenerative-therapies-and-platform-technologies daily 0.8 https://clival.com/news/icmr-completes-trials-for-worlds-first-injectable-male-contraceptive-data-shows-its-safe-and-effective daily 0.8 https://clival.com/news/orsini-specialty-pharmacy-selected-as-distribution-partner-for-adzynma-adamts13-recombinant-krhn-a-newly-approved-treatment-for-an-ultra-rare-blood-clotting-disorder daily 0.8 https://clival.com/news/nppa-to-fix-ceiling-prices-of-225-formulations-based-on-market-data daily 0.8 https://clival.com/news/phenomics-health-inc-acquires-patented-drug-metabolome-technology daily 0.8 https://clival.com/news/saniona-ion-channel-research-collaboration-with-boehringer-ingelheim-advances-to-next-stage daily 0.8 https://clival.com/news/roche-launches-institute-of-human-biology-to-accelerate-breakthroughs-in-rd-by-unlocking-the-potential-of-human-model-systems daily 0.8 https://clival.com/news/advanco-and-vantage-partner-to-offer-first-interoperable-pharma-traceability-solution daily 0.8 https://clival.com/news/precigen-receives-orphan-drug-designation-for-prgn-2012-for-the-treatment-of-recurrent-respiratory-papillomatosis-from-the-european-commission daily 0.8 https://clival.com/news/torrent-pharma-acquires-4-brands-from-drreddys-laboratories daily 0.8 https://clival.com/news/lemonexs-mrna-degradaball-vaccine-lem-mr203-ind-application-approved-for-phase-1-clinical-trial daily 0.8 https://clival.com/news/world-rabies-day-awareness-campaign-is-launched-by-corning-serum-institute-sewa-india daily 0.8 https://clival.com/news/cgbios-novosis-putty-attains-fda-breakthrough-device-designation-paving-the-way-for-expedited-entry-into-the-us-market daily 0.8 https://clival.com/news/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china daily 0.8 https://clival.com/news/novartis-brings-on-first-tigit-drug-in-massive-billion-dollar-biobucks-deal-with-beigene daily 0.8 https://clival.com/news/astrazeneca-inks-billion-dollar-deal-with-chinese-startup-eccogene daily 0.8 https://clival.com/news/kintara-therapeutics-to-present-at-the-ld-micro-main-event-xvi-conference daily 0.8 https://clival.com/news/phanes-therapeutics-pt217-receives-fast-track-designation-from-fda daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-status-to-mercks-new-hif-2a-inhibitor-mk-6482-o-treat-von-hippel-lindau-associated-renal-cell-carcinoma daily 0.8 https://clival.com/news/pfizers-phase-3-clover-trial-of-clostridioides-difficile-vaccine-fails-to-meet-its-pre-specified-primary-endpoint-of-prevention-of-primary-cdi daily 0.8 https://clival.com/news/entod-pharma-launches-synthetic-snake-venom-based-facial-gel-serum-in-india daily 0.8 https://clival.com/news/menarini-and-sciclone-partner-for-orserdu-in-china-to-address-advanced-breast-cancer daily 0.8 https://clival.com/news/ridgeback-biotherapeutics-lp-announces-receipt-of-breakthrough-therapy-designation-from-fda-for-mab114 daily 0.8 https://clival.com/news/biotheryx-announces-research-collaboration-and-licence-agreement-with-incyte daily 0.8 https://clival.com/news/sun-pharma-to-market-pharmazzs-cerebral-ischemic-stroke-drug-tyvalzi-in-india daily 0.8 https://clival.com/news/evotec-biologics-and-alpine-immune-sciences-expand-partnership-for-commercial-process-development-of-alpn-303 daily 0.8 https://clival.com/news/eu-chmp-recommends-approval-of-mercks-winrevair-to-treat-pah daily 0.8 https://clival.com/news/gc-biopharma-receives-who-pre-qualification-for-barycela daily 0.8 https://clival.com/news/glenmark-gets-usfda-nod-for-generic-derma-smoothe-topical-oil daily 0.8 https://clival.com/news/evonik-phathom-pharma-partner-to-produce-novel-acid-blocker-vonoprazan daily 0.8 https://clival.com/news/enesi-pharma-imperial-college-london-collaborate-to-develop-thermostable-rna-vaccines daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-status-to-bristol-myers-squibbs-investigational-lpa1-antagonist-to-treat-progressive-pulmonary-fibrosis daily 0.8 https://clival.com/news/lupin-gets-usfda-nod-for-generic-drug daily 0.8 https://clival.com/news/novartis-issues-voluntary-us-nationwide-recall-of-two-lots-of-sandimmune-oral-solution-cyclosporine-oral-solution-usp-100-mgml-due-to-crystallization daily 0.8 https://clival.com/news/ge-healthcare-announces-ionic-healths-ncommand-lite-technology-receives-us-fda-clearance daily 0.8 https://clival.com/news/jacobio-announces-fda-approves-ind-application-to-develop-kras-g12c-inhibitor daily 0.8 https://clival.com/news/hanalls-licensed-partner-in-china-enters-sublicense-agreement-with-cspc-to-further-accelerate-development-of-batoclimab daily 0.8 https://clival.com/news/tg-therapeutics-seeks-us-fda-approval-for-ublituximab-in-combo-with-umbralisib-to-treat-chronic-lymphocytic-leukemia daily 0.8 https://clival.com/news/innovent-and-sanegenebio-enter-strategic-collaboration-to-develop-sirna-drug-for-the-treatment-of-hypertension daily 0.8 https://clival.com/news/pfizer-to-acquire-foldrx-pharma daily 0.8 https://clival.com/news/astellas-pharma-gets-us-fda-nod-for-cresemba-to-treat-invasive-aspergillosis-invasive-mucormycosis-in-paediatric-patients daily 0.8 https://clival.com/news/meftal-advisory-why-has-government-issued-a-safety-alert-against-painkiller daily 0.8 https://clival.com/news/moderna-merck-announce-us-fda-grants-breakthrough-therapy-status-to-mrna-4157v940-in-combo-with-keytruda-for-adjuvant-treatment-of-patients-with-high-risk-melanoma-following-complete-resection daily 0.8 https://clival.com/news/adma-biologics-gains-approval-storage-conditions-for-asceniv-bivigam daily 0.8 https://clival.com/news/merck-keytruda-plus-trastuzumab-and-chemotherapy-gets-european-nod-to-treat-her2-positive-advanced-gastric-or-gej-adenocarcinoma-expressing-pd-l1 daily 0.8 https://clival.com/news/innocare-gets-us-fda-nod-to-begin-clinical-trial-of-novel-shp2-allosteric-inhibitor-icp-189-to-treat-advanced-solid-tumors daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-expanded-label-for-mercks-anti-pd-1-therapy-keytruda-in-certain-patients-with-relapsedrefractory-classical-hodg daily 0.8 https://clival.com/news/us-fda-ema-accepts-bristol-myers-regulatory-filings daily 0.8 https://clival.com/news/us-fda-issues-crl-for-zealand-pharmas-dasiglucagon-in-chi-for-up-to-3-weeks-of-dosing-due-to-inspection-findings-at-third-party-manufacturing-facility daily 0.8 https://clival.com/news/fda-grants-tentative-approval-for-sq-innovations-lasix-onyu-gerresheimer daily 0.8 https://clival.com/news/i-mab-novel-antibody-gets-ind-approval-in-china daily 0.8 https://clival.com/news/merck-introduces-innovative-ai-solution-for-seamless-integration-of-drug-discovery-and-synthesis daily 0.8 https://clival.com/news/us-fda-granted-orphan-drug-designation-for-benlysta daily 0.8 https://clival.com/news/gilead-drops-remdesivirs-orphan-drug-designation daily 0.8 https://clival.com/news/gsk-and-wave-life-sciences-announce-collaboration-to-drive-discovery-and-development-of-oligonucleotide-therapeutics-focusing-on-novel-genetic-targets daily 0.8 https://clival.com/news/cardiff-oncology-in-collaboration-with-mit-presents-gene-signature-analyses-data-from-phase-2-trial-of-onvansertib-in-mcrpc-at-aacr-meeting daily 0.8 https://clival.com/news/who-launches-biosafety-risk-assessment-app daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-generic-chantix-tablets daily 0.8 https://clival.com/news/nihr-cambridge-brc-lifebit-partner-to-launch-cynapse-platform-for-next-generation-genomics-research daily 0.8 https://clival.com/news/boehringer-ingelheim-announces-plans-to-advance-new-treatment-for-geographic-atrophy daily 0.8 https://clival.com/news/innovent-biologics-and-anheart-therapeutics-receive-nmpa-breakthrough-designation-for-taletrectinib-in-ros1-positive-non-small-cell-lung-cancer daily 0.8 https://clival.com/news/jazz-pharmaceuticals-to-present-latest-advancements-in-sleep-medicine-at-world-sleep-2023 daily 0.8 https://clival.com/news/lupin-launches-us-fda-approved-generic-zyflo-cr-tablets daily 0.8 https://clival.com/news/sanyou-biopharmaceuticals-and-sinorda-biomedicine-enter-into-agreement daily 0.8 https://clival.com/news/bergenbio-announces-selection-of-2nd-dose-in-phase-2a-first-line-stk11m-non-small-lung-cancer-trial daily 0.8 https://clival.com/news/hitachi-chemical-advanced-therapeutics-solutions-and-ori-biotech-announce-a-joint-development-agreement daily 0.8 https://clival.com/news/dr-reddys-launches-generic-fulvestrant-injection-in-us daily 0.8 https://clival.com/news/phase-2b-transform-trial-of-setanaxib-meets-primary-endpoint daily 0.8 https://clival.com/news/roches-itovebi-in-combo-with-palbociclib-fulvestrant-gets-fda-approval daily 0.8 https://clival.com/news/tagrisso-approved-in-china-as-a-1st-line-treatment-for-egfr-mutated-non-small-cell-lung-cancer daily 0.8 https://clival.com/news/cde-approved-single-arm-pivotal-clinical-study-of-lbl-024 daily 0.8 https://clival.com/news/i-mab-announces-first-two-patients-dosed-in-us-phase-2-combination-trial-of-uliledlimab-with-atezolizumab-in-patients-with-selected-advanced-solid-tumors daily 0.8 https://clival.com/news/novo-nordisk-to-acquire-dicerna daily 0.8 https://clival.com/news/spt-life-sciences-announces-acquisition-of-lbd-life-sciences daily 0.8 https://clival.com/news/glenmark-launches-biosimilar-of-anti-diabetic-drug-liraglutide-in-india daily 0.8 https://clival.com/news/csir-launches-national-mission-to-develop-sustainable-packaging-solutions daily 0.8 https://clival.com/news/helix-covid-19-ngs-test-receives-us-fda-emergency-use-authorization daily 0.8 https://clival.com/news/vimian-group-acquires-heiland-gmbh-an-online-platform-for-veterinary-pharmaceuticals daily 0.8 https://clival.com/news/codeine-linctus-reclassified-as-prescription-only-medicine daily 0.8 https://clival.com/news/simcere-zaiming-collaborates-with-targetrx-to-introduce-a-third-generation-alk-inhibitor daily 0.8 https://clival.com/news/hkbus-aptamer-for-x-linked-hypophosphatemia-gets-fda-orphan-drug-status daily 0.8 https://clival.com/news/aldevron-announces-agreement-with-ziopharm-oncology-for-neogmp-production-of-sleeping-beauty-plasmid-dna-to-express-tcrs-for-treatment-of-solid-tumo daily 0.8 https://clival.com/news/sanjivani-paranteral-hal-ink-agreement-to-manufacture-iv-formulations-iv-sets daily 0.8 https://clival.com/news/keytruda-wins-fda-nod-to-tackle-early-bladder-cancer-with-gene-therapy-rival-closely-behind daily 0.8 https://clival.com/news/dcgi-approves-zyduss-oxemia-for-ckd-induced-anaemia daily 0.8 https://clival.com/news/novo-nordisk-partners-with-aspen-to-support-insulin-production-in-africa daily 0.8 https://clival.com/news/bayer-invests-250-million-usd-in-new-cell-therapy-manufacturing-facility-in-the-usa daily 0.8 https://clival.com/news/transthera-announces-that-the-ind-application-of-tt-01488-b-cell-lymphomas-has-been-approved-by-the-fda daily 0.8 https://clival.com/news/daiichi-sankyo-sarah-cannon-announce-initial-results-from-phase-1-study-of-ds-6000-to-treat-advanced-ovarian-cancer-or-renal-cell-carcinoma daily 0.8 https://clival.com/news/pfizer-to-buy-biopharma-company-global-blood-therapeutics-for-54-billion daily 0.8 https://clival.com/news/starpharma-announces-positive-interim-results-from-phase-2-trial-of-dep-cabazitaxel-to-treat-metastatic-prostate-cancer daily 0.8 https://clival.com/news/olix-pharmaceuticals-receives-ind-approval-from-fda-to-develop-rnai-therapeutic-olx10212-for-age-related-macular-degeneration daily 0.8 https://clival.com/news/mercks-phase-3-trial-of-pembrolizumab-sc-with-berahyaluronidase-alfa-meets-primary-endpoints daily 0.8 https://clival.com/news/novo-nordisk-wegovy-gets-approval-for-cardiovascular-risk-reduction daily 0.8 https://clival.com/news/novo-nordisk-will-cut-production-of-victoza-to-boost-supply-of-ozempic daily 0.8 https://clival.com/news/alexion-completes-acquisition-of-achillion daily 0.8 https://clival.com/news/compugen-expands-clinical-collaboration-agreement-with-bristol-myers-squibb-with-phase-1b-combination-study-of-com701-with-opdivoa daily 0.8 https://clival.com/news/china-nmpa-grants-breakthrough-therapy-designation-to-innovents-parsaclisib-to-treat-relapsedrefractory-follicular-lymphoma daily 0.8 https://clival.com/news/awakn-life-sciences-begins-patient-screening-in-more-kare-phase-3-trial daily 0.8 https://clival.com/news/ausperbio-completes-first-patient-dosing-in-phase-1-trial-of-ahb-137-to-treat-chronic-hepatitis-b daily 0.8 https://clival.com/news/syngene-launches-platform-for-rapid-enhanced-potein-production daily 0.8 https://clival.com/news/philips-partners-with-syntheticmr-for-ai-based-brain-imaging daily 0.8 https://clival.com/news/daiichi-sankyos-quizartinib-plus-chemotherapy-improves-os-compared-to-chemotherapy-in-patients-with-newly-diagnosed-flt3-itd-positive-aml daily 0.8 https://clival.com/news/gsk-completes-acquisition-of-sierra-oncology daily 0.8 https://clival.com/news/iaso-bio-announces-ct103a-granted-regenerative-medicine-advanced-therapy-rmat-and-fast-track-ft-designations-by-the-fda daily 0.8 https://clival.com/news/geneos-announces-positive-trial-data-for-gt-30-trial daily 0.8 https://clival.com/news/pathways-to-progress-how-orphan-drug-designation-sparks-biotech-transformation daily 0.8 https://clival.com/news/us-fda-grants-de-novo-marketing-authorization-for-invitae-common-hereditary-cancers-panel-a-dna-test-to-assess-predisposition-for-dozens-of-cancer-types daily 0.8 https://clival.com/news/padcev-enfortumab-vedotin-ejfv-with-keytruda-pembrolizumab-approved-by-fda-as-the-first-and-only-adc-plus-pd-1-to-treat-advanced-bladder-cancer daily 0.8 https://clival.com/news/innovent-begins-dosing-in-phase-i-of-ibi3002 daily 0.8 https://clival.com/news/xeris-pharma-receives-european-approval-for-ogluo-injection-to-treat-severe-hypoglycaemia-with-diabetes-mellitus daily 0.8 https://clival.com/news/janone-inc-completes-acquisition-of-soin-therapeutics-llc daily 0.8 https://clival.com/news/jpm-with-tesaro-staff-and-expertise-in-the-mix-gsk-gears-up-for-3-oncology-launches-in-2020 daily 0.8 https://clival.com/news/archimed-completes-acquisition-of-natus-medical-incorporated daily 0.8 https://clival.com/news/amarin-launches-vascepa-in-all-important-europe-as-it-slowly-bleeds-share-to-us-generic daily 0.8 https://clival.com/news/nabh-issues-notification-to-mis-centres-to-implement-nabh-accreditation-standards-for-mis-2nd-edition daily 0.8 https://clival.com/news/eu-eyes-autumn-approval-of-pfizer-jab-for-covid-variants daily 0.8 https://clival.com/news/china-nmpa-approves-tislelizumab-for-patients-with-second-line-esophageal-squamous-cell-carcinoma daily 0.8 https://clival.com/news/beigene-announces-btk-inhibitor-brukinsa-approved-in-50-markets daily 0.8 https://clival.com/news/mdxhealth-acquires-oncotype-dx-prostate-test-from-exact-sciences daily 0.8 https://clival.com/news/keytruda-redeems-itself-in-head-and-neck-cancer-as-merck-lands-potential-19b-ii-collab daily 0.8 https://clival.com/news/clarivate-extends-partnership-with-verisim-life-to-accelerate-and-de-risk-research-and-drug-development daily 0.8 https://clival.com/news/catabasis-pharmaceuticals-and-the-jain-foundation-announce-a-preclinical-research-collaboration-to-study-edasalonexent-in-dysferlinopathy daily 0.8 https://clival.com/news/ono-submits-supplemental-applications-for-approval-of-braftovi daily 0.8 https://clival.com/news/astellas-and-peptidream-enter-into-research-collaboration-and-license-agreement-to-discover-novel-targeted-protein-degraders daily 0.8 https://clival.com/news/ingenium-therapeutics-novel-nk-cell-therapy-receives-odd daily 0.8 https://clival.com/news/trevena-announces-approval-of-olinvyk-in-china daily 0.8 https://clival.com/news/ziopharm-oncology-announces-first-patient-infused-in-cd19-rpm-car-t-phase-i-clinical-trial-being-conducted-by-joint-venture-partner-eden-biocell daily 0.8 https://clival.com/news/roches-phase-iiiii-skyscraper-06-study-of-tiragolumab-plus-tecentriq-chemotherapy daily 0.8 https://clival.com/news/celltrion-usa-completes-submission-of-biologics-license-application-for-ct-p47-a-biosimilar-candidate-of-actemra-tocilizumab daily 0.8 https://clival.com/news/takeda-gains-approval-for-adzynma-intravenous-injection daily 0.8 https://clival.com/news/pfizer-to-acquire-arena-pharmaceuticals daily 0.8 https://clival.com/news/us-fda-approves-avita-medicals-recell-go-mini-disposable-cartridge-to-treat-smaller-wounds daily 0.8 https://clival.com/news/charles-river-laboratories-acquires-explora-biolabs daily 0.8 https://clival.com/news/astrazeneca-tops-sales-forecasts-on-china-new-drug-boosts daily 0.8 https://clival.com/news/biolinerx-announces-starts-of-dosing-in-phase-2-trials daily 0.8 https://clival.com/news/astrazeneca-gets-uks-competition-and-markets-authority-clearance-for-proposed-acquisition-of-alexion-pharma daily 0.8 https://clival.com/news/adamis-pharma-reacquires-us-rights-to-symjepi-injections-from-sandoz daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-mythic-therapeutics-mytx-011-for-patients-with-nsclc-with-cmet-overexpression daily 0.8 https://clival.com/news/revive-therapeutics-receives-fda-orphan-drug-designation-for-bucillamine-in-the-prevention-of-ischemia-reperfusion-injury-during-liver-transplantation daily 0.8 https://clival.com/news/amgen-announces-positive-results-from-phase-2-ocean-a-dose-study-of-olpasiran-in-adults-with-elevated-lipoprotein-a daily 0.8 https://clival.com/news/mankind-pharma-to-acquire-panaceas-formulation-brands-for-india-and-nepal daily 0.8 https://clival.com/news/granules-india-receives-us-fda-approval-for-generic-micro-k-er-capsules daily 0.8 https://clival.com/news/uk-mhra-approves-advanced-melanoma-medicine-opdualag-for-patients-from-the-age-of-12 daily 0.8 https://clival.com/news/sellas-granted-fda-rare-paediatric-disease-designation-for-acute-myeloid-leukemia daily 0.8 https://clival.com/news/mindmed-collaborators-report-positive-topline-data-from-phase-2-trial-evaluating-lsd-in-anxiety-disorders daily 0.8 https://clival.com/news/citius-resubmits-lymphir-biologics-license-application daily 0.8 https://clival.com/news/junshi-biosciences-announces-approval-for-marketing-of-vv116-in-china daily 0.8 https://clival.com/news/arcutis-and-sato-partners-for-roflumilast-in-japan daily 0.8 https://clival.com/news/china-nmpa-approves-chi-meds-surufatinib-to-treat-non-pancreatic-neuroendocrine-tumors daily 0.8 https://clival.com/news/sciwind-biosciences-announces-positive-topline-results-from-20-week-phase-2-clinical-trial-of-xw003-ecnoglutide-a-novel-long-lasting-glp-1-analogue-in-adult-patients-with-type-2-diabetes-in-china daily 0.8 https://clival.com/news/bioxodes-begins-phase-2a-trial-of-biox-101-for-intracerebral-stroke-treatment daily 0.8 https://clival.com/news/us-fda-lifts-clinical-hold-of-astellas-fortis-phase-12-trial-of-at845-to-treat-adult-patients-with-late-onset-pompe-disease daily 0.8 https://clival.com/news/roche-vabysmo-receives-us-fda-approval-to-treat-retinal-vein-occlusion daily 0.8 https://clival.com/news/who-launches-consolidated-guidelines-for-malaria daily 0.8 https://clival.com/news/sun-pharma-and-sparc-enter-into-a-license-agreement-for-commercialization-of-phenobarbital-for-injection-in-the-us daily 0.8 https://clival.com/news/fosun-pharma-gets-fda-eua-nod-for-covid-19-detection-kit daily 0.8 https://clival.com/news/ipsen-to-acquire-biopharmaceutical-company-epizyme daily 0.8 https://clival.com/news/milvexian-granted-us-fda-fast-track-designation-for-all-three-indications-under-evaluation-in-phase-3-librexia-programme daily 0.8 https://clival.com/news/venatorx-everest-medicines-accept-new-drug-application-for-cefepime-taniborbactam daily 0.8 https://clival.com/news/sirnaomics-doses-first-patient-in-phase-2-study-of-stp705-for-keloid-scar-prevention daily 0.8 https://clival.com/news/taro-shareholders-approve-merger-with-sun-pharma daily 0.8 https://clival.com/news/boehringer-ingelheim-zealand-pharma-begin-phase-iii-trials-investigating-survodutide-for-obesity daily 0.8 https://clival.com/news/inspira-technologies-collaborates-with-israeli-medical-center daily 0.8 https://clival.com/news/abbvie-receives-european-marketing-approval-for-elahere daily 0.8 https://clival.com/news/vanda-pharmaceuticals-announces-a-us-patent-allowance-for-ponvory-ponesimod-in-the-us daily 0.8 https://clival.com/news/askbio-begins-phase-ii-genephit-trial-of-ab-1002-to-treat-congestive-heart-failure daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-approval-for-perforomist-inhalation-solution-dabigatran-etexilate-capsules daily 0.8 https://clival.com/news/lupin-alliance-partner-caplin-gets-us-fda-nod-for-thiamine-hydrochloride-injection-usp daily 0.8 https://clival.com/news/bharat-biotech-intranasal-vaccine-incovacc-receives-cdsco-approval-under-restricted-use daily 0.8 https://clival.com/news/us-fda-grants-marketing-approval-to-theragnostics-radiodiagnostic-imaging-drug-nephroscan-for-evaluation-of-renal-parenchymal-disorders daily 0.8 https://clival.com/news/jubilant-therapeutics-and-onethree-biotech-collaborate-to-advance-precision-oncology daily 0.8 https://clival.com/news/aesthetic-medical-international-holdings-group-limited-announces-openings-of-two-new-satellite-clinics daily 0.8 https://clival.com/news/merck-keytruda-plus-chemotherapy-gets-us-fda-approval-to-treat-locally-advanced-unresectable-or-metastatic-her2-negative-gastric-or-gej-adenocarcinoma daily 0.8 https://clival.com/news/gracell-biotechnologies-initiates-phase-1b2-trial-for-gc012f-in-relapsedrefractory-multiple-myeloma daily 0.8 https://clival.com/news/brii-biosciences-vir-biotechnology-and-vbi-vaccines-announce-initiation-of-phase-2-clinical-trial-of-brii-835-vir-2218-in-combination-with-brii-179-vb daily 0.8 https://clival.com/news/datar-cancer-genetics-gets-us-fda-breakthrough-designation-for-blood-test-trinetra-glio-to-help-diagnose-brain-tumours daily 0.8 https://clival.com/news/aurisco-launches-manufacturing-facility-for-glp-1-peptides daily 0.8 https://clival.com/news/gujarat-govt-to-set-up-bulk-drugs-park-in-state-based-on-in-principle-approval-from-centre daily 0.8 https://clival.com/news/eisai-launches-anti-cancer-agent-halaven-in-china daily 0.8 https://clival.com/news/dizal-seeks-us-fda-approval-for-sunvozertinib-to-treat-relapsed-or-refractory-nsclc daily 0.8 https://clival.com/news/lianbio-announces-first-patient-treated-in-phase-1-trial-of-shp2-inhibitor-bbp-398-in-combination-with-osimertinib-in-patients-with-non-small-cell-lung-cancer-with-egfr-mutations daily 0.8 https://clival.com/news/regeneron-and-cytomx-announce-strategic-research-collaboration-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer daily 0.8 https://clival.com/news/panbela-therapeutics-inc-closes-acquisition-of-cancer-prevention-pharmaceuticals-inc daily 0.8 https://clival.com/news/us-fda-grants-fta-to-ionis-astrazeneca daily 0.8 https://clival.com/news/antengene-announces-clinical-collaboration-with-bristol-myers-squibb-to-evaluate-atg-017-in-combination-with-opdivo daily 0.8 https://clival.com/news/astrazenecas-ace-ly-004-phase-ii-trial-of-calquence-shows-long-term-efficacy-and-tolerability-at-3-years-for-patients-with-relapsed-or-refractory-mant daily 0.8 https://clival.com/news/lynk-pharmaceuticals-announced-first-patient-dosed-in-phase-ii-clinical-study-of-lnk01001 daily 0.8 https://clival.com/news/ironwood-pharmaceuticals-and-astrazeneca-amend-linzess-collaboration-in-china daily 0.8 https://clival.com/news/beigenes-anti-pd-1-antibody-tislelizumab-gets-china-nmpa-approval-to-treat-patients-with-locally-advanced-or-metastatic-nsclc daily 0.8 https://clival.com/news/sandoz-completes-acquisition-of-antifungal-agent-mycamine-from-astellas daily 0.8 https://clival.com/news/bayer-and-archerdx-announce-global-collaboration-to-develop-next-generation-sequencing-ngs-based-companion-diagnostic-cdx-for-vitrakvi-larotrec daily 0.8 https://clival.com/news/bellus-health-announces-design-for-phase-2b-soothe-trial-of-blu-5937-to-treat-refractory-chronic-cough daily 0.8 https://clival.com/news/biovie-completes-patient-enrolment-in-phase-2-trial-of-ne3107s-pro-motoric-activity-in-parkinsons-disease daily 0.8 https://clival.com/news/medijourn-enters-partnership-with-8chili-hintvr-to-bring-forth-patient-centricity-in-medical-value-tourism daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-for-biomarins-vosoritide-to-treat-children-with-achondroplasia-from-age-2-until-growth-plates-close daily 0.8 https://clival.com/news/lupin-launches-generic-aravat-tablets-in-us-market-to-treat-active-ra daily 0.8 https://clival.com/news/luye-pharmas-class-1-innovative-antidepressant-targeting-netdatgabaar-approved-for-clinical-trials-in-china daily 0.8 https://clival.com/news/south-korea-approves-pfizers-covid-vaccine-for-ages-5-to11 daily 0.8 https://clival.com/news/merck-to-discontinue-phase-3-keynote-991-trial-of-keytruda-in-combo-with-enzalutamide-and-adt-to-treat-mhspc daily 0.8 https://clival.com/news/pfizer-biontech-update-efficacy-results-from-phase-23-trial-of-3 daily 0.8 https://clival.com/news/ind-approval-for-phase-iii-study-of-anti-her2-bispecific-adc-jskn033 daily 0.8 https://clival.com/news/health-canada-approves-medmiras-multiplo-rapid-tphiv-test-for-syphilis-and-hiv daily 0.8 https://clival.com/news/gsk-signs-pact-for-shingles-vaccine-with-chinas-zhifei-for-3-bn daily 0.8 https://clival.com/news/lilly-to-expand-injectable-manufacturing-capacity-with-planned-25-billion-site-in-germany daily 0.8 https://clival.com/news/fujifilm-india-launches-campaign-films-which-encourage-regular-health-screenings-for-early-disease-detection daily 0.8 https://clival.com/news/olix-pharmaceuticals-receives-hrec-approval-to-initiate-phase-1-clinical-trial-of-nash-and-obesity-drug daily 0.8 https://clival.com/news/novus-therapeutics-announces-acquisition-of-anelixis-therapeutics daily 0.8 https://clival.com/news/jb-pharma-to-acquire-glenmarkrazel-brand-in-india-and-nepal-for-rs-314-crore daily 0.8 https://clival.com/news/wuxi-biologics-and-aravive-form-strategic-collaboration daily 0.8 https://clival.com/news/phebra-and-university-of-wollongong-enter-into-collaboration-agreement daily 0.8 https://clival.com/news/lupin-launches-generic-depakote-er-tablets daily 0.8 https://clival.com/news/biocon-biologics-just-evotec-biologics-ink-licensing-pact-for-biosimilar-asset daily 0.8 https://clival.com/news/sarepta-therapeutics-gains-approval-for-an-efficacy-supplement daily 0.8 https://clival.com/news/akeso-announces-ind-approval-from-china-nmpa-for-phase-ii-clinical-trial-of-cadonilimab-in-combination-with-docetaxel-to-treat-nsclc daily 0.8 https://clival.com/news/sk-bioscience-enters-into-partnership-with-sanofi-to-develop-pneumococcal-conjugate-vaccines daily 0.8 https://clival.com/news/pfizer-initiates-phase-1-study-of-novel-oral-antiviral-therapeutic-agent-against-sars-cov-2 daily 0.8 https://clival.com/news/molecular-templates-establishes-multi-target-collaboration-with-bristol-myers-squibb-for-the-discovery-and-development-of-next-generation-engineered-t daily 0.8 https://clival.com/news/european-commission-grants-conditional-marketing-authorisation-to-roches-columvi-to-treat-rr-diffuse-large-b-cell-lymphoma daily 0.8 https://clival.com/news/tilt-biotherapeutics-collaborates-with-msd-on-immunotherapy-trial-in-checkpoint-inhibitor-refractory-nsclc daily 0.8 https://clival.com/news/ractigen-therapeutics-begins-patient-dosing-in-phase-i-trial-of-rag-17-in-sod1-als daily 0.8 https://clival.com/news/diamyd-medical-to-pursue-accelerated-approval-pathway-in-us daily 0.8 https://clival.com/news/eisai-merck-seek-japanese-approval-for-additional-indication-of-lenvima-in-combo-with-keytruda-to-treat-advanced-uterine-body-cancer daily 0.8 https://clival.com/news/gsk-and-zhifei-announce-exclusive-strategic-vaccine-partnership-in-china daily 0.8 https://clival.com/news/jud-care-launches-international-partner-program-for-its-portable-ward-sroom-a-revolutionary-solution-for-patient-isolation daily 0.8 https://clival.com/news/harbour-biomed-announces-ind-approval-for-next-gen-anti-tslp-fully-human-monoclonal-antibody daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-secura-bios-copiktra-to-treat-relapsed-or-refractory-cll-and-fl daily 0.8 https://clival.com/news/wuxi-biologics-acquires-drug-substance-facility-from-bayer daily 0.8 https://clival.com/news/cohbar-and-morphogenesis-enter-into-merger-agreement daily 0.8 https://clival.com/news/pfizer-announces-european-approval-for-velsipity daily 0.8 https://clival.com/news/akeso-receives-china-nmpa-approval-to-begin-phase-ibii-trial-of-ivonescimab-in-combo-with-drebuxelimab-to-treat-advanced-solid-tumours daily 0.8 https://clival.com/news/clearsky-medical-diagnostics-and-shanghai-accurature-diagnostics-strike-licensing-deal-for-the-commercialisation-of-pd-monitor-in-china daily 0.8 https://clival.com/news/moderna-receives-us-fda-approval-for-spikevax-vaccine-to-prevent-covid-19-in-individuals-18-years-of-age-and-older daily 0.8 https://clival.com/news/fda-grants-orphan-drug-designation-to-reneo-pharmaceuticals-for-ren001-for-treatment-of-fatty-acid-oxidation-disorders daily 0.8 https://clival.com/news/vanda-pharma-receives-us-patent-for-ponvory-to-treat-multiple-sclerosis daily 0.8 https://clival.com/news/gilead-phase-2-evoke-02-study-of-trodelvy-in-combo-with-keytruda-demonstrates-promising-clinical-activity-in-first-line-metastatic-nsclc daily 0.8 https://clival.com/news/eris-lifesciences-enters-licensing-deal-with-biocon-for-insulin-glargine daily 0.8 https://clival.com/news/cipla-gets-eir-from-usfda-for-invagen-manufacturing-facility daily 0.8 https://clival.com/news/sanofi-partners-with-big-eortc-aft-to-initiate-phase-3-ameera-6-study-of-amcenestrant-in-adjuvant-setting-for-patients-with-estrogen-receptor-positi daily 0.8 https://clival.com/news/celltrion-submits-investigational-new-drug-ind-application-to-initiate-a-global-phase-iii-clinical-trial-evaluating-an-inhaled-covid-19-antibody-cocktail-therapy daily 0.8 https://clival.com/news/oncternal-therapeutics-announces-fda-granted-fast-track-designation-for-onct-534-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-bayers-asundexian-stroke-programme daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-status-to-editas-medicines-edit-301-to-treat-beta-thalassemia daily 0.8 https://clival.com/news/astrazeneca-announces-agreement-with-quell-therapeutics-to-develop-manufacture-and-commercialise-engineered-t-regulatory-cell-therapies-for-autoimmune-diseases daily 0.8 https://clival.com/news/lilly-announces-the-receipt-of-nrc-consent-in-connection-with-its-proposed-acquisition-of-point-biopharma daily 0.8 https://clival.com/news/sumitomo-pharma-oncology-receives-orphan-drug-designation-for-tp-1287 daily 0.8 https://clival.com/news/lyell-immunopharma-announces-initial-data-from-phase-1-trials-of-lyl797 daily 0.8 https://clival.com/news/maxcyte-signs-strategic-partnership-with-prime-medicine-to-advance-next-generation-gene-editing-therapies-for-patients daily 0.8 https://clival.com/news/us-fda-approves-vertex daily 0.8 https://clival.com/news/gsk-to-acquire-california-based-late-stage-biopharma-company-sierra-oncology-for-19-billion daily 0.8 https://clival.com/news/indias-drug-regulator-approves-study-on-mixing-of-covaxin-and-covishield-doses daily 0.8 https://clival.com/news/chugai-gets-japanese-approval-for-foundationone-liquid-cdx-cancer-genomic-profile daily 0.8 https://clival.com/news/flightpath-biosciences-begins-dosing-of-hygromycin-a-in-phase-i-trial daily 0.8 https://clival.com/news/biocon-biologics-partners-with-sandoz-australia daily 0.8 https://clival.com/news/alteogen-receives-ministry-of-food-and-drug-safety-mfds-approval-for-tergase daily 0.8 https://clival.com/news/ilya-pharma-acquires-nordic-bioanalysis daily 0.8 https://clival.com/news/merck-begins-phase-3-trial-of-mk-1084-keytruda-combo daily 0.8 https://clival.com/news/gilead-novo-nordisk-announce-positive-results-from-phase-2-proof-of-concept-trial-in-nash daily 0.8 https://clival.com/news/mercks-keytruda-receives-european-approval-for-two-new-indications-in-gynaecologic-cancers daily 0.8 https://clival.com/news/lysogene-inks-agreement-with-satt-conectus-to-develop-commercialize-gene-therapy-candidate-to-treat-fragile-x-syndrome daily 0.8 https://clival.com/news/japanese-mhlw-grants-orphan-drug-designation-to-menarinis-elzonris-to-treat-bpdcn daily 0.8 https://clival.com/news/us-fda-grants-permission-to-restart-phase-iii-trial-of-astrazeneca-oxford-coronavirus-vaccine-azd1222 daily 0.8 https://clival.com/news/merck-launches-new-lab-water-purification-system-milli-q-eq-7000 daily 0.8 https://clival.com/news/zielbio-begins-patient-dosing-in-phase-12-trial-of-zb131-in-patients-with-solid-tumours daily 0.8 https://clival.com/news/us-judge-rules-for-sanofi-in-amgen-patent-fight daily 0.8 https://clival.com/news/gsk-receives-approval-for-arexvy-as-the-first-rsv-vaccine-for-older-adults daily 0.8 https://clival.com/news/alnylam-completes-enrollment-in-illuminate-c-phase-3-study-of-rnai-therapeutic-lumasiran-to-treat-advanced-primary-hyperoxaluria-type-1 daily 0.8 https://clival.com/news/boehringer-ingelheim-launches-new-sglt-2-inhibitor-esgliteo daily 0.8 https://clival.com/news/sophia-genetics-and-karkinos-healthcare-forge-strategic-partnership-to-advance-cancer-research-in-india daily 0.8 https://clival.com/news/cipla-says-usfda-issued-7-observations-after-inspecting-bengaluru-api-unit daily 0.8 https://clival.com/news/ascendis-pharma-and-teijin-limited-establish-strategic-collaboration-in-japan daily 0.8 https://clival.com/news/senestech-signs-expanded-distribution-agreement-for-evolve-soft-bait-sales-into-the-united-arab-emirates-uae daily 0.8 https://clival.com/news/radiomedix-receives-btd-for-alphamedix daily 0.8 https://clival.com/news/malaysian-patent-granted-for-cytomed-therapeutics-licensed-allogeneic-car-gamma-delta-t-cell-technology daily 0.8 https://clival.com/news/astrazeneca-partners-with-mankind-to-distribute-asthma-drugs-in-india daily 0.8 https://clival.com/news/king-faisal-specialist-and-research-centre-achieves-world-first-fully-robotic-liver-transplant daily 0.8 https://clival.com/news/wuxi-apptec-to-expedite-early-drug-discovery daily 0.8 https://clival.com/news/stevanato-group-and-owen-mumford-sign-exclusive-collaboration-agreement-for-the-innovative-aidaptus daily 0.8 https://clival.com/news/skye-bioscience-gets-australian-hrec-nod-to-begin-first-in-human-phase-1-study-of-sbi-100-ophthalmic-emulsion daily 0.8 https://clival.com/news/sanyou-launches-advanced-intelligent-rd-platform daily 0.8 https://clival.com/news/biocon-enters-us-market-for-bmab-1200 daily 0.8 https://clival.com/news/molbio-diagnostics-forays-into-breast-cancer-screening-through-partnership-with-niramai-health-analytix daily 0.8 https://clival.com/news/amgen-files-breakthrough-leukaemia-antibody-in-us daily 0.8 https://clival.com/news/junshi-biosciences-and-coherus-announce-us-fda-breakthrough-therapy-designation-granted-for-toripalimab-for-1st-line-treatment-of-nasopharyngeal-carcinoma daily 0.8 https://clival.com/news/mirati-krazati-gets-european-marketing-nod-for-targeted-treatment-option-for-patients-with-advanced-nsclc-with-a-krasg12c-mutation daily 0.8 https://clival.com/news/phanes-therapeutics-pt886-granted-orphan-drug-designation-for-the-treatment-of-pancreatic-cancer-by-the-fda daily 0.8 https://clival.com/news/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate daily 0.8 https://clival.com/news/hepagene-therapeutics-receives-fda-clearance-for-hpg7233-thr-beta-agonist-ind-application daily 0.8 https://clival.com/news/uk-mhra-authorises-enzyme-inhibitor-anastrozole-to-prevent-breast-cancer-in-post-menopausal-women daily 0.8 https://clival.com/news/bristol-myers-squibb-to-present-new-clinical-and-heor-data-in-schizophrenia-at-psych-congress-2024 daily 0.8 https://clival.com/news/usfda-issues-2-observations-after-inspection-of-lupins-pithampur-unit daily 0.8 https://clival.com/news/arct-032-gets-orphan-medicinal-product-designation daily 0.8 https://clival.com/news/astellas-announces-strategic-collaboration-with-mass-general-brigham daily 0.8 https://clival.com/news/generian-and-astellas-enter-into-collaboration-and-exclusive-license-agreement-to-discover-and-develop-novel-small-molecules-for-undruggable-targets daily 0.8 https://clival.com/news/ema-grants-orphan-designation-to-midatech-pharma-mtx110-to-treat-glioma daily 0.8 https://clival.com/news/sun-pharma-to-sell-second-brand-of-bayer-kidney-drug-finerenone-in-india daily 0.8 https://clival.com/news/eli-lillys-reyvow-wins-fda-nod-for-migraine-relief-but-side-effects-could-limit-sales daily 0.8 https://clival.com/news/sanofis-phase-2-study-of-frexalimab-shows-reduction-of-key-biomarker-of-nerve-cell-damage daily 0.8 https://clival.com/news/novartis-regeneron-wage-acrimonious-patent-fight-over-eyleas-prefilled-syringe daily 0.8 https://clival.com/news/ampio-pharma-begins-patient-dosing-in-ap-019-phase-ii-study-of-inhaled-ampion-in-covid-19-respiratory-distress daily 0.8 https://clival.com/news/dr-reddys-laboratories-announces-agreement-to-acquire-mayne-pharma-us-generic-prescription-product-portfolio daily 0.8 https://clival.com/news/antengene-seeks-regulatory-approvals-from-singapore-and-australia-for-xpovio-to-treat-rrmm-rrdlbcl daily 0.8 https://clival.com/news/bavarian-nordic-inks-agreement-with-government-of-canada-to-supply-imvamune-smallpox-vaccine daily 0.8 https://clival.com/news/everest-medicines-announces-that-licensing-partner-venatorx-pharmaceuticals-reports-positive-results-from-pivotal-phase-3-cefepime-taniborbactam-trial daily 0.8 https://clival.com/news/cadila-launches-thrabis-worlds-first-novel-three-dose-rabies-vaccine daily 0.8 https://clival.com/news/narayana-hrudayalaya-to-acquire-bengaluru-based-orthopaedic-and-trauma-hospital daily 0.8 https://clival.com/news/revive-therapeutics-receives-us-fda-nod-to-begin-phase-3-trial-of-bucillamine-to-treat-covid-19-in-asia-pacific-and-canada daily 0.8 https://clival.com/news/amgen-completes-acquisition-of-horizon-therapeutics-for-278-billion daily 0.8 https://clival.com/news/madrigals-rezdiffra-receives-approval-to-treat-nash daily 0.8 https://clival.com/news/immviras-oncolytic-product-mvr-c5252-targeting-malignant-glioma-obtained-nmpas-approval-for-clinical-trial-in-china daily 0.8 https://clival.com/news/bergenbio-announces-positive-interim-data-from-phase-ii-trial-of-bemcentinib-in-combo-with-keytrudato-treat-refractory-nsclc daily 0.8 https://clival.com/news/rigel-pharma-buys-us-rights-for-gavreto daily 0.8 https://clival.com/news/eu-chmp-recommends-approval-of-mercks-keytruda-regimens-for-gynaecologic-cancer daily 0.8 https://clival.com/news/fda-approves-new-drug-treatment-for-chronic-weight-management-first-since-2014 daily 0.8 https://clival.com/news/lupin-introduces-darunavir-tablets-in-us-market daily 0.8 https://clival.com/news/immuneoncia-announces-phase-2-results-of-pd-l1-immune-checkpoint-inhibitor-at-esmo-asia daily 0.8 https://clival.com/news/palantir-expands-partnership-with-us-cdc-for-disease-monitoring-and-response daily 0.8 https://clival.com/news/minghui-pharma-soon-to-present-phase-iii-study-results-of-mhb088c daily 0.8 https://clival.com/news/gujarat-fdca-approves-seven-more-units-to-manufacture-remdesivir daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-anthos-therapeutics-abelacimab-to-treat-thrombosis-associated-with-cancer daily 0.8 https://clival.com/news/leo-pharma-announces-fda-approval-of-adbry daily 0.8 https://clival.com/news/lupin-atlantis-holdings-completes-acquisition-of-two-brands-from-sanofi-in-europe-canada daily 0.8 https://clival.com/news/bristol-myers-squibb-to-present-data-from-innovative-cardiovascular-portfolio-at-the-aha-scientific-sessions-2023 daily 0.8 https://clival.com/news/bioarctic-begins-patient-dosing-in-exist-phase-2a-study-in-parkinsons-disease daily 0.8 https://clival.com/news/merck-keytruda-meets-primary-endpoint-of-dfs-in-patients-with-muscle-invasive-urothelial-carcinoma daily 0.8 https://clival.com/news/cipla-launches-leuprolide-acetate-injection-depot-225-mg-in-us daily 0.8 https://clival.com/news/bayer-announces-mirena-approved-in-europe-for-extended-duration-of-use-in-contraception daily 0.8 https://clival.com/news/bioinvent-receives-ind-approval-for-clinical-trial-with-anti-tnfr2-antibody-bi-1910 daily 0.8 https://clival.com/news/clover-begins-patient-dosing-in-phase-3-trial-of-scb-2019-as-heterologous-covid-19-booster-following-prior-vaccination-with-inactivated-mrna-or-viral-vector-vaccines daily 0.8 https://clival.com/news/major-breakthrough-for-severe-asthma-treatment daily 0.8 https://clival.com/news/nuvox-pharma-gets-health-canada-approval-to-begin-phase-iia-trial-of-nano2-in-covid-19-subjects-with-ahrf daily 0.8 https://clival.com/news/kubota-vision-announces-collaborative-research-agreement-with-china-medical-university-hsinchu-hospital daily 0.8 https://clival.com/news/amarin-corporation-receives-saudi-food-and-drug-authority-approval-for-vascepa daily 0.8 https://clival.com/news/design-therapeutics-launches-with-45-million-to-develop-a-new-class-of-disease-modifying-therapies-for-serious-degenerative-disorders daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-priotheras-mocravimod-to-improve-the-outcome-of-allo-hsct-in-patients-with-hematologic-malignancies daily 0.8 https://clival.com/news/gilead-announces-positive-data-from-phase-3-tropics-02-study-of-trodelvy-versus-comparator-chemotherapies-in-patients-with-hrher2-metastatic-breast-cancer daily 0.8 https://clival.com/news/oman-to-expedite-registration-process-of-indian-medicinal-products-approved-by-us-fda-uk-mhra-or-ema daily 0.8 https://clival.com/news/forendo-pharma-signs-important-license-and-collaboration-deal-with-leading-pharma-company daily 0.8 https://clival.com/news/glenmark-pharma-gains-fda-approval-for-brimonidine-tartrate-timolol-maleate-ophthalmic-solution daily 0.8 https://clival.com/news/genscript-biotech-and-ligand-pharmaceuticals-enter-into-global-omniab-licensing-agreement daily 0.8 https://clival.com/news/sk-bioscience-introduces-new-partnership-model-to-establish-regional-vaccine-hubs daily 0.8 https://clival.com/news/zydus-saroglitazar-mg-to-treat-primary-biliary-cholangitis-receives-us-fda-orphan-drug-designation daily 0.8 https://clival.com/news/kyowa-kirin-presents-real-world-findings-at-asbmr-annual-meeting-highlighting-progressive-disease-burden-of-x-linked-hypophosphatemia-xlh daily 0.8 https://clival.com/news/zydus-gets-usfda-nod-for-prochlorperazine-maleate-tablets daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-topiramate-er-capsules daily 0.8 https://clival.com/news/ayala-pharmaceuticals-and-biosight-enter-into-definitive-merger-agreement daily 0.8 https://clival.com/news/advaccine-announces-first-participants-dosed-in-phase-2-study-of-adv110-evaluating-respiratory-syncytial-virus-rsv-vaccine-candidate-in-australia daily 0.8 https://clival.com/news/sanofi-completes-closing-of-collaborative-agreement-with-janssen-to-develop-commercialize-vaccine-candidate-for-extraintestinal-pathogenicecoli daily 0.8 https://clival.com/news/astrazeneca-amgen-announce-successful-phase-3-results-of-tezepelumab-to-widen-treatment-options-for-severe-asthma daily 0.8 https://clival.com/news/lantheus-and-point-biopharma-announce-fast-track-designation-grant-by-fda-for daily 0.8 https://clival.com/news/covaxin-to-be-evaluated-as-covid19-vaccine-candidate-in-us-asusfda-lifts-clinical-hold daily 0.8 https://clival.com/news/novogene-launches-clinical-sequencing-services-for-european-customers daily 0.8 https://clival.com/news/lupin-gets-us-fda-approval-for-generic-uloric-tablets daily 0.8 https://clival.com/news/oxford-nanopore-fabric-genomics-collaborate-to-launch-an-integrated-whole-genome-sequencing-solution-to-advance-the-future-of-paediatric-patient-care daily 0.8 https://clival.com/news/panel-recommends-retail-price-of-dapagliflozin-generic-drugs-even-as-astrazeneca-fights-for-patent-protection daily 0.8 https://clival.com/news/serenity-bioworks-acquires-dc-tab-for-lupus-nephritis daily 0.8 https://clival.com/news/us-fda-approves-new-bristol-myers-cancer-immunotherapy daily 0.8 https://clival.com/news/venatorx-pharma-announces-cefepime-taniborbactams-phase-3-study-publication daily 0.8 https://clival.com/news/todos-medical-and-nlc-pharma-announce-primary-and-secondary-endpoints-met-in-nlc-v-01-phase-2-clinical-trial-of-oral-antiviral-3cl-protease-inhibitor-tollovir daily 0.8 https://clival.com/news/mankind-pharma-to-acquire-combihale-and-daffy-brands-from-dr-reddys-laboratories daily 0.8 https://clival.com/news/remedee-labs-endorphin-stimulator-gets-us-fda-breakthrough-device-designation-for-management-of-fibromyalgia daily 0.8 https://clival.com/news/ge-healthcare-novo-nordisk-collaborate-to-advance-novel-non-invasive-treatment-for-type-2-diabetes-and-obesity-with-ultrasound daily 0.8 https://clival.com/news/sedana-medical-seeks-us-fda-approval-to-begin-phase-iii-trials-with-sedaconda-products daily 0.8 https://clival.com/news/european-medicines-agency-ema-grants-orphan-drug-designation-odd-to-gc-biopharmas-treatment-for-sanfilippo-syndrome-type-a daily 0.8 https://clival.com/news/nephroplus-gets-rs-323-crore-investment-from-bahrain-based-investcorp-to-expand-services-in-west-asia-and-south-east-asia daily 0.8 https://clival.com/news/boehringer-ingelheim-to-advance-survodutide-into-three-global-phase-iii-studies-in-obesity daily 0.8 https://clival.com/news/cognisant-collaborates-with-boehringer-ingelheim daily 0.8 https://clival.com/news/pfizer-and-clear-creek-bio-to-collaborate-on-a-research-program-targeting-sars-cov-2-papain-like-protease daily 0.8 https://clival.com/news/sirnaomics-launches-phase-i-clinical-trial-of-rnai-therapeutic-stp705-in-adults-undergoing-abdominoplasty-for-medical-cosmetology-treatment daily 0.8 https://clival.com/news/kerala-medical-services-corporation-ltd-to-buy-20-lakh-vaccine-doses daily 0.8 https://clival.com/news/splicebio-spark-therapeutics-enter-exclusive-collaboration-to-develop-gene-therapy-targeting-an-inherited-retinal-disease daily 0.8 https://clival.com/news/nigeria-tightens-regulations-on-indian-pharma-exports-new-standards-may-spark-industry-concerns daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-and-rare-paediatric-disease-designations-to-ionis-pharma-ion582-to-treat-angelman-syndrome daily 0.8 https://clival.com/news/anokion-announces-expansion-of-exclusive-collaboration-with-bristol-myers-squibb-to-develop-novel-treatments-for-autoimmune-diseases daily 0.8 https://clival.com/news/ascletis-announces-ind-approval-of-oral-3clpro-inhibitor-asc11-for-covid-19-by-china-nmpa daily 0.8 https://clival.com/news/qualigen-signs-contract-with-sta-pharma-for-gmp-production-of-as1411-for-clinical-trials daily 0.8 https://clival.com/news/pfizer-and-biontech-sign-new-global-collaboration-agreement-to-develop-first-mrna-based-shingles-vaccine daily 0.8 https://clival.com/news/pfizer-lianbio-collaborate-to-bring-novel-therapeutics-in-greater-china daily 0.8 https://clival.com/news/scynexis-closes-exclusive-license-agreement-with-gsk-to-commercialize-the-novel-antifungal-brexafemme daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-zielbios-zb131-to-treat-pancreatic-cancer daily 0.8 https://clival.com/news/novo-integrated-sciences-completes-acquisition-of-clinical-consultants-international daily 0.8 https://clival.com/news/dr-reddys-lab-inks-licensing-pact-with-slayback-pharma daily 0.8 https://clival.com/news/us-fda-approves-glaukos-nda-for-a-single-administration-per-eye-of-idose-tr daily 0.8 https://clival.com/news/eli-lilly-announces-positive-results-from-phase-3-trials-of-lebrikizumab-to-treat-atopic-dermatitis daily 0.8 https://clival.com/news/drugmakers-must-ensure-good-manufacturing-practices daily 0.8 https://clival.com/news/dr-reddys-launches-generic-bupropion-hydrochloride-extended-release-tablets-in-us daily 0.8 https://clival.com/news/charles-river-partners-with-pluristyx-for-stem-cell-research daily 0.8 https://clival.com/news/torrent-pharma-enters-into-voluntary-licensing-agreement-with-eli-lilly-for-baricitinib-for-covid-19 daily 0.8 https://clival.com/news/j-j-announces-positive-results-from-phase-23-vibrance-mg-study-of-nipocalimab daily 0.8 https://clival.com/news/ionis-partner-biogen-announces-that-results-from-phase-3-valor-study-and-open-label-extension-of-tofersen-showed-clinical-benefit-in-sod1-als-patients daily 0.8 https://clival.com/news/us-fda-grants-510k-clearance-to-polarisar-stellar-knee daily 0.8 https://clival.com/news/pfizer-covid-19-vaccine-scores-fda-nod-in-adolescents-enabling-a-wider-rollout daily 0.8 https://clival.com/news/beyondspring-receives-us-patent-covering-methods-of-treating-brain-tumor-by-administering-plinabulin daily 0.8 https://clival.com/news/orum-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-orm-5029-in-development-to-treat-her2-expressing-advanced-solid-tumors daily 0.8 https://clival.com/news/cell-biotech-acquire-european-patent-for-anticancer-protein-p8-originated-from-lactobacillus-rhamnosus daily 0.8 https://clival.com/news/ayush-ministry-launches-rrdr-for-ayush-at-national-institute-of-siddha-in-tamil-nadu daily 0.8 https://clival.com/news/curia-announce-collaboration-with-corning daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-leads-biolabs-lbl-034 daily 0.8 https://clival.com/news/sanofi-regeneron-to-restructure-antibody-collaboration-for-kevzara-praluent daily 0.8 https://clival.com/news/china-nmpa-accepts-shenzhen-chipscreen-biosciences-phase-iii-trial-ind-submission-of-anticancer-drug-chiauranib-to-treat-sclc daily 0.8 https://clival.com/news/tessa-therapeutics-baylor-college-of-medicine-execute-agreement-for-global-commercial-rights-to-off-the-shelf-car-t-platform daily 0.8 https://clival.com/news/illumina-sequoia-capital-china-partner-to-launch-sequoia-capital-china-intelligent-healthcare-genomics-incubator-in-china daily 0.8 https://clival.com/news/fda-approves-cancer-therapy-by-jj-partner-legend-biotech daily 0.8 https://clival.com/news/inspira-receives-israeli-regulatory-approval-for-the-inspira-art100-system daily 0.8 https://clival.com/news/ose-immunotherapeutics-announces-artificial-intelligence-antibody-drug-development-collaboration-with-mabsilico daily 0.8 https://clival.com/news/ema-approves-dupixent-for-add-on-maintenance-treatment-in-uncontrolled-copd daily 0.8 https://clival.com/news/telix-pharma-to-acquire-us-based-clinical-stage-company-qsam-biosciences-and-its-lead-therapy-candidate-cyclosam daily 0.8 https://clival.com/news/lupin-launches-generic-hypertension-drug-in-us-market daily 0.8 https://clival.com/news/china-approves-use-of-roche-arthritis-drug-for-some-coronavirus-patients daily 0.8 https://clival.com/news/mercks-phase-3-keynote-590-trial-of-keytruda-in-combo-with-chemotherapy-meets-primary-endpoints-of-os-and-pfs-to-treat-locally-advanced-or-metastatic daily 0.8 https://clival.com/news/pharmaessentia-enters-into-global-licence-agreement-with-wuxi-biologics daily 0.8 https://clival.com/news/chugai-refiles-patent-infringement-lawsuit-against-sawai-pharmaceu-nichi-iko-nissan-chemical-on-edirol-capsules daily 0.8 https://clival.com/news/tocagen-inc-has-secured-orphan-drug-status-for-its-investigational-gene-therapy-treatment-for-glioblastoma daily 0.8 https://clival.com/news/irish-oncology-care-platform-announces-collaboration-with-nccn daily 0.8 https://clival.com/news/viiv-healthcare-apretude-receives-european-approval-for-hiv-prevention daily 0.8 https://clival.com/news/senhwa-biosciences-begins-phase-ii-study-of-silmitasertib daily 0.8 https://clival.com/news/south-rampart-receives-us-fda-fast-track-status-for-non-opioid-analgesic-candidate-srp-001-for-treatment-of-acute-pain daily 0.8 https://clival.com/news/boehringer-ingelheim-collaborates-with-cdr-life-to-develop-antibody-fragment-based-therapeutics-for-geographic-atrophy daily 0.8 https://clival.com/news/us-fda-grants-accelerated-approval-for-ipsens-iqirvo-to-treat-primary-biliary-cholangitis daily 0.8 https://clival.com/news/nimbus-therapeutics-lilly-enter-alliance-for-therapeutics-for-metabolic-diseases daily 0.8 https://clival.com/news/cidara-therapeutics-and-wuxi-xdc-expand-collaboration-for-ind-enabling-cmc-development daily 0.8 https://clival.com/news/sandboxaq-collaborates-with-mayo-clinic-to-explore-ai-powered-mcg-technology-for-cardiac-diagnostics daily 0.8 https://clival.com/news/hutchmed-announces-inmagene-to-license-2-drug-candidates-img-007-and-img-004 daily 0.8 https://clival.com/news/bayer-invests-130-million-eur-in-new-production-facility-for-innovative-parenteral-products daily 0.8 https://clival.com/news/fibrocor-therapeutics-collaborates-with-msrd daily 0.8 https://clival.com/news/eris-lifesciences-acquires-trademark-zomelis-from-novartis-ag-for-india-market daily 0.8 https://clival.com/news/clobetasol-propionate-ophthalmic-suspension-gets-approval daily 0.8 https://clival.com/news/bioivt-announces-global-e-commerce-collaboration-with-charles-river-labs-avian-vaccine-services daily 0.8 https://clival.com/news/revolka-ltd-announcement-of-milestone-achievement-in-the-collaborative-research-with-sumitomo-pharma-co-ltd daily 0.8 https://clival.com/news/strides-receives-us-fda-approval-for-generic-suprep-a-bowel-prep-ki daily 0.8 https://clival.com/news/merck-animal-health-veterinary-wellbeing-study-indicates-progress-in-addressing-mental-health-challenges-among-veterinary-professionals daily 0.8 https://clival.com/news/johnson-johnson-initiates-second-global-phase-3-clinical-trial-of-its-janssen-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/nmpa-approves-new-drug-application-for-henlius-anti-pd-1-mab-serplulimab-combined-with-chemotherapy-in-first-line-non-squamous-nsclc-treatment daily 0.8 https://clival.com/news/jjs-multidrug-resistant-tb-treatment-sirturo-granted-full-ec-and-fda-approvals daily 0.8 https://clival.com/news/usfda-issues-warning-letter-to-cipla-for-goa-manufacturing-facility daily 0.8 https://clival.com/news/calypso-enters-into-agreement-to-be-acquired-by-novartis daily 0.8 https://clival.com/news/novartis-signs-initial-agreement-to-provide-manufacturing-capacity-for-pfizer-biontech-covid-19-vaccine daily 0.8 https://clival.com/news/porton-advanced-and-sinorda-biomedicine-enter-strategic-collaboration-to-accelerate-cell-therapy-development-for-solid-tumors daily 0.8 https://clival.com/news/seegene-obtains-iso-45001-certification daily 0.8 https://clival.com/news/merck-moderna-begin-interpath-002-phase-3-study-of-v940-in-combo-with-keytruda-for-adjuvant-treatment-of-patients-with-certain-types-of-resected-nsclc daily 0.8 https://clival.com/news/essa-pharma-announces-clinical-trial-support-agreement-with-janssen daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-device-designation-to-explore-use-of-abbotts-deep-brain-stimulation-system-to-manage-severe-depression daily 0.8 https://clival.com/news/bayer-acquires-german-biotech-start-up-targenomix daily 0.8 https://clival.com/news/formosa-enters-licensing-pact-with-cristalia-to-commercialize-app13007-to-treat-inflammation-and-pain-following-ocular-surgery daily 0.8 https://clival.com/news/notice-concerning-application-for-partial-revision-of-manufacturing-and-marketing-approval-of-companion-diagnostic-reagent-for-the-amoydx daily 0.8 https://clival.com/news/biocon-inks-exclusive-licensing-supply-pact-with-biomm-sa daily 0.8 https://clival.com/news/biogen-execs-blame-critics-the-media-for-spurring-misinformation-as-aduhelm-launch-lags-expectations daily 0.8 https://clival.com/news/tessellate-bio-omico-cmri-collab-to-accelerate-discovery-of-synthetic-lethal-precision-therapies daily 0.8 https://clival.com/news/uk-mhra-grants-conditional-marketing-approval-for-vertex-crispr-therapeutics-casgevy-to-treat-scd-and-transfusion-dependent-beta-thalassemia daily 0.8 https://clival.com/news/doh-abu-dhabi-partners-with-pfizer-to-advance-research-in-sickle-cell-disease-and-beyond daily 0.8 https://clival.com/news/merck-and-xtalpi-collaboration-optimizes-drug-formulations-with-ai-powered-techniques daily 0.8 https://clival.com/news/zydus-receives-final-approval-fromusfda-for-vigabatrin-tablets daily 0.8 https://clival.com/news/basilea-pharma-receives-us-fda-approval-of-antibiotic-zevtera daily 0.8 https://clival.com/news/acelyrin-affibody-and-inmagene-biopharma-presents-phase-2-trial-of-izokibep-in-patients-with-psoriatic-arthritis-at-eular-congress daily 0.8 https://clival.com/news/imaginab-announces-license-and-supply-agreement-with-pfizer-for-cd8-immunopet-technology daily 0.8 https://clival.com/news/agios-pharma-gets-us-fda-nod-for-mitapivat-to-treat-hemolytic-anemia-in-adults-with-pyruvate-kinase-deficiency daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-myovant-sciences-orgovyx-to-treat-advanced-prostate-cancer daily 0.8 https://clival.com/news/who-launches-global-network-for-coronaviruses-covinet daily 0.8 https://clival.com/news/lupin-injectable-facility-in-nagpur-receives-eir-from-us-fda daily 0.8 https://clival.com/news/saol-therapeutics-announces-positive-results-from-the-sl-1002-raise-limb-spasticity-trial daily 0.8 https://clival.com/news/biocytogen-enters-into-bispecific-antibody-drug-conjugate-agreement-with-radiance-biopharma daily 0.8 https://clival.com/news/knight-inks-exclusive-license-and-supply-agreements-with-rigel-pharma-to-commercialize-fostamatinib-in-latin-america daily 0.8 https://clival.com/news/sun-pharma-completes-merger-of-taro-pharma daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-nod-for-mesalamine-er-capsules daily 0.8 https://clival.com/news/jubilant-pharma-ltd-and-aavis-pharmaceuticals-launch-hydroxychloroquine-sulfate-tablets-in-the-us-market daily 0.8 https://clival.com/news/sihuan-pharma-acquires-antibody-technology-firm-combio daily 0.8 https://clival.com/news/pharmala-red-light-collaborate-for-psilocybin daily 0.8 https://clival.com/news/soligenix-starts-phase-3-trial-of-hybryte-for-cutaneous-t-cell-lymphoma daily 0.8 https://clival.com/news/gt-medical-technologies-inc-gammatile-therapy-awarded daily 0.8 https://clival.com/news/bayer-initiates-patient-enrolment-in-phase-iii-soho-02-trial-of-bay-2927088 daily 0.8 https://clival.com/news/eli-lillys-migraine-treatment-wins-us-fda-approval daily 0.8 https://clival.com/news/sophia-genetics-enters-into-collaborate-with-astrazeneca-to-expand-global-access-to-liquid-biopsy-testing daily 0.8 https://clival.com/news/arthur-d-little-and-begin-india-launche-iaa-to-boost-ancient-medical-practice-of-indian-ayurveda daily 0.8 https://clival.com/news/us-fda-approves-epkinly-as-first-and-only-bispecific-antibody-to-treat-adult-patients-with-rr-dlbcl daily 0.8 https://clival.com/news/roche-introduces-elecsys-hbeag-quant-test-to-help-clinicians-diagnose-and-monitor-patients-with-acute-or-chronic-hepatitis-b-infection daily 0.8 https://clival.com/news/qiagen-launches-neumodx-flu-a-brsvsars-cov-2-vantage-test-in-europe daily 0.8 https://clival.com/news/us-fda-grants-tentative-approval-to-lupin-generic-formulation-for-type-2-diabetes daily 0.8 https://clival.com/news/meiji-seika-pharma-announces-positive-findings-from-phase-ii-study-of-me3183-in-plaque-psoriasis-patients daily 0.8 https://clival.com/news/venus-remedies-oncology-wing-expand-with-marketing-approvals-from-gcc-asean-balkan-caribbean-regions daily 0.8 https://clival.com/news/nordic-nanovector-receives-us-patent-covering-use-of-betalutin-to-sensitise-b-cell-cancer-cells-to-cd20-immunotherapy daily 0.8 https://clival.com/news/astrazeneca-to-launch-once-daily-anti-diabetes-drug-in-india daily 0.8 https://clival.com/news/viracta-therapeutics-begins-patient-dosing-in-phase-1b2-trial-of-nana-val-in-patients-with-advanced-epstein-barr-virus-positive-solid-tumours daily 0.8 https://clival.com/news/lupins-subsidiary-novel-labs-receives-us-fda-approval-for-fluocinolone-acetonide-topical-oil daily 0.8 https://clival.com/news/exelixis-and-nbe-therapeutics-enter-into-exclusive-collaboration-and-license-option-agreement-to-discover-and-develop-novel-antibody-drug-conjugates-f daily 0.8 https://clival.com/news/usfda-approves-aleor-dermaceuticals-lidocaine-and-prilocaine-topical-cream daily 0.8 https://clival.com/news/halda-therapeutics-raises-126m-in-series-b-extension-to-advance-two-cancer-candidates daily 0.8 https://clival.com/news/pfizer-has-failed-to-convince-the-us-fda-to-remove-a-black-box-warning-on-its-quit-smoking-drug-chantix daily 0.8 https://clival.com/news/gsk-signs-agreement-to-support-pandemic-preparedness-in-europe daily 0.8 https://clival.com/news/bayers-phase-iii-finearts-hf-cardiovascular-outcomes-study-of-finerenone-meets-primary-endpoint daily 0.8 https://clival.com/news/antengenes-xpo1-inhibitor-xpovio-receives-malaysian-regulatory-approval daily 0.8 https://clival.com/news/novo-nordisk-pours-11b-to-meet-escalating-demand-for-obesity-drugs daily 0.8 https://clival.com/news/zymergen-expands-agreement-with-octant-to-scale-next-generation-drug-discovery-platform daily 0.8 https://clival.com/news/ptc-seeks-european-marketing-approval-for-sepiapterin daily 0.8 https://clival.com/news/naprod-life-sciences-renews-eu-gmp-certification-for-its-palghar-facility daily 0.8 https://clival.com/news/lupin-achieves-significant-milestone-with-iso-14001-iso-45001-certification-in-india daily 0.8 https://clival.com/news/thermo-fisher-scientific-opens-new-gmp-certified-ultra-cold-facility-in-eu daily 0.8 https://clival.com/news/huadong-medicine-announces-positive-phase-i-results daily 0.8 https://clival.com/news/eli-lilly-invests-additional-53b-for-production-of-diabetes-obesity-drugs-in-indiana daily 0.8 https://clival.com/news/pfizer-announces-positive-results-from-pivotal-phase-3-trial-of-abrysvo daily 0.8 https://clival.com/news/agilent-technologies-and-national-cancer-centre-singapore-enter-into-research-collaboration-agreement daily 0.8 https://clival.com/news/epam-acquires-odysseus-to-transform-the-life-sciences-value-chain-with-advanced-analytics-data-methods-and-ai daily 0.8 https://clival.com/news/thermo-fisher-to-cut-the-lights-at-california-plastics-plant-lay-off-74 daily 0.8 https://clival.com/news/who-issues-warning-on-falsified-medicines-for-diabetes-and-weight-loss daily 0.8 https://clival.com/news/lynk-pharmaceuticals-announces-first-patient-dosed-in-phase-clinical-study-of-lnk01003-in-patients-with-ulcerative-colitis daily 0.8 https://clival.com/news/merck-reports-positive-phase-3-results-for-hiv-1-treatment-doravirineislatravir daily 0.8 https://clival.com/news/rivus-pharma-to-present-topline-results-from-phase-2a-trial-of-controlled-metabolic-accelerator-hu6-at-aasld-2022-meeting daily 0.8 https://clival.com/news/amgen-inc-fails-to-secure-us-fda-expert-advisers-support-for-lumakras-approval daily 0.8 https://clival.com/news/evotec-announces-progress-in-neuroscience-collaboration-with-bristol-myers-squibb daily 0.8 https://clival.com/news/dr-reddys-gets-vai-status-for-two-facilities daily 0.8 https://clival.com/news/raybow-pharmaceutical-acquires-pharmagra-labs daily 0.8 https://clival.com/news/european-medicines-agency-grants-orphan-drug-designation-to-zydus-cadilas-saroglitazar-mg daily 0.8 https://clival.com/news/point-biopharma-announces-first-patients-dosed-in-phase-3-study-of-pnt2002-for-mcrpc daily 0.8 https://clival.com/news/pfizer-to-acquire-arena-to-boost-chronic-disease-management daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-zambons-cms-i-neb-in-patients-with-ncfb daily 0.8 https://clival.com/news/lupin-launches-difizma-to-treat-inadequately-controlled-asthma daily 0.8 https://clival.com/news/crownbio-acquires-ocello-bv-to-expand-its-preclinical-in-vitro-drug-development-service-offerings daily 0.8 https://clival.com/news/biocon-foundation-with-iisc-lead-expert-for-phase-1-of-the-project-the-ai-center-of-excellence daily 0.8 https://clival.com/news/mabwell-therapeutics-9mw2821-receives-us-fda-orphan-drug-status daily 0.8 https://clival.com/news/comprehensive-review-highlights-importance-of-leukine-in-combination-with-anti-gd2-immunotherapy-for-treatment-of-high-risk-pediatric-neuroblastoma daily 0.8 https://clival.com/news/merck-begins-tender-offer-to-acquire-imago-biosciences-inc daily 0.8 https://clival.com/news/kintor-pharma-begins-patient-dosing-in-phase-iii-trial-of-proxalutamide-to-treat-male-patients-with-mildmoderate-covid-19-symptoms daily 0.8 https://clival.com/news/chugai-seeks-additional-indication-approval-from-japan-mhlw-for-vabysmo daily 0.8 https://clival.com/news/new-drug-approval-for-in-house-developed-anti-insomnia-drug-dayvigo-lemborexant-in-hong-kong daily 0.8 https://clival.com/news/marchesini-group-acquires-sea-vision-group daily 0.8 https://clival.com/news/shanghai-fosun-pharmaceutical-group-partners-with-ifc daily 0.8 https://clival.com/news/moderna-and-thermo-fisher-scientific-announce-long-term-strategic-collaboration daily 0.8 https://clival.com/news/airs-medical-receives-eu-mdr-ce-certification-for-ai-powered-mri-enhancement-solution-swiftmr daily 0.8 https://clival.com/news/mankind-pharma-combats-leprosy-with-lepra-society daily 0.8 https://clival.com/news/us-fda-accepts-pfizer-genmab-tivdak-sbla-for-patients-with-recurrent-or-metastatic-cervical-cancer daily 0.8 https://clival.com/news/scibase-collaborates-with-johnson-and-johnson-consumer-to-develop-ai-based-screening-tool-to-detect-skin-barrier-dysfunction-in-infants daily 0.8 https://clival.com/news/biocytogen-enters-into-antibody-agreement-with-adc-therapeutics daily 0.8 https://clival.com/news/sirnaomics-announces-a-partnership-with-gore-range-capital-for-establishment-of-sagesse-bio daily 0.8 https://clival.com/news/ascletis-announces-us-ind-approval-of-asc22-envafolimab-for-immune-restorationfunctional-cure-of-hiv-1-infected-patients daily 0.8 https://clival.com/news/sandoz-acquires-us-biosimilar-cimerli daily 0.8 https://clival.com/news/sanofi-acquires-provention-bio daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-henlius-biotechs-hansizhuang-to-treat-sclc daily 0.8 https://clival.com/news/biontech-inks-1-b-oncology-deal-with-chinese-startup-biotheus daily 0.8 https://clival.com/news/merck-gets-eu-panel-nod-for-ebola-vaccine daily 0.8 https://clival.com/news/medicagos-plant-based-covid-vaccine-secures-first-approval-in-canada-bms-sues-xspray-to-block-sprycel-generic daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-final-approval-for-cyclophosphamide-capsules-25-50-mg daily 0.8 https://clival.com/news/carsgens-nda-for-zevorcabtagene-autoleucel-gets-chinese-approval daily 0.8 https://clival.com/news/nxera-pharma-antiverse-collaborate-to-design-novel-gpcr-targeted-antibody-therapeutics-using-generative-ai daily 0.8 https://clival.com/news/cortexa-started-manufacturing-gmp-laneo-mdma daily 0.8 https://clival.com/news/biocytogen-subsidiary-eucure-biopharma-completes-first-patient-dosing-for-phase-i-clinical-trial-of-yh003-anti-cd40-mab-triple-combination-therapy daily 0.8 https://clival.com/news/aum-biosciences-enters-in-a-strategic-collaboration-with-handok-and-cmg-pharm-to-develop-chc2014-new-pan-trk-inhibitor-for-cancer-treatment daily 0.8 https://clival.com/news/us-fda-approves-perioperative-treatment-of-neoadjuvant-opdivo-chemotherapy daily 0.8 https://clival.com/news/us-fda-grants-accelerated-approval-to-novartis-scemblix daily 0.8 https://clival.com/news/astellas-to-present-positive-findings-from-phase-3-spotlight-trial-of-zolbetuximab-during-2023-asco-gi-cancers-symposium daily 0.8 https://clival.com/news/pfizer-canada-recalls-bp-drug-on-potential-cancer-causing-impurity daily 0.8 https://clival.com/news/us-fda-grants-fda-emergency-use-authorization-to-roches-four-in-one-molecular-test-for-sars-cov-2-influenza-ab-viruses-and-rsv daily 0.8 https://clival.com/news/mercks-keytruda-gets-japanese-approvals-for-certain-patients-with-nsclc-and-urothelial-carcinoma daily 0.8 https://clival.com/news/immutep-announces-positive-results-from-tacti-003-phase-iib-trial-of-efti daily 0.8 https://clival.com/news/biocon-becomes-first-to-obtain-approval-for-liraglutide daily 0.8 https://clival.com/news/cresemba-gets-approval-for-odd-pediatric-exclusivity daily 0.8 https://clival.com/news/bayer-initiates-phase-i-study-with-novel-targeted-radionuclide-therapy-225ac-psma-trillium daily 0.8 https://clival.com/news/natus-medical-completes-acquisition-deal-with-micromed daily 0.8 https://clival.com/news/genfleet-beigene-partners-for-gfh009-and-brukinsa-combination-trial daily 0.8 https://clival.com/news/opus-genetics-announces-acquisition-of-the-rights-to-two-gene-therapy-product-candidates-for-inherited-retinal-diseases daily 0.8 https://clival.com/news/teva-and-biolojic-design-announce-exclusive-license-agreement-for-the-development-of-a-therapeutic-antibody-for-atopic-dermatitis-and-asthma daily 0.8 https://clival.com/news/kyowa-kirin-announces-acquisition-of-orchard-therapeutics daily 0.8 https://clival.com/news/cumberland-pharmaceuticals-secures-orphan-drug-and-rare-pediatric-disease-designations-for-ifetroban daily 0.8 https://clival.com/news/uk-mhra-extends-licence-of-cystic-fibrosis-medicines-kaftrio-kalydeco-for-children-aged-two-to-five-years-old daily 0.8 https://clival.com/news/us-fda-accepts-for-priority-review-sbla-for-sanofi-and-regenerons-dupixentto-treat-adults-with-prurigo-nodularis daily 0.8 https://clival.com/news/manipal-healthmap-acquires-100-stake-in-hyderabad-based-medcis-pathlabs daily 0.8 https://clival.com/news/ec-approves-tepmetko-for-patients-with-advanced-nsclc-with-met-mutations daily 0.8 https://clival.com/news/merck-announces-organon-to-acquire-commercial-stage-medical-device-company-alydia-health-for-240-million daily 0.8 https://clival.com/news/lilly-deepens-research-ties-in-china-with-biotech-deal daily 0.8 https://clival.com/news/ioncturas-cambritaxestat-gets-orphan-drug-designation daily 0.8 https://clival.com/news/merck-orion-ink-collaboration-to-develop-commercialize-investigational-steroid-synthesis-inhibitorodm-208-to-treat-mcrpc daily 0.8 https://clival.com/news/shockwave-medical-and-genesis-medtech-obtain-regulatory-approval-in-china-for-intravascular-lithotripsyapprovals-cover-both-coronary-and-peripheral-ivl-catheters-and-generators-manufactured-by-shockwave daily 0.8 https://clival.com/news/hikma-announces-us-launch-of-combogesic-iv daily 0.8 https://clival.com/news/jazz-pharma-sunosi-gets-european-approval-for-excessive-daytime-sleepiness-in-adults-with-narcolepsyosa daily 0.8 https://clival.com/news/abbisko-therapeutic-announces-that-ema-has-granted-orphan-drug-designation-for-its-csf-1r-inhibitor-pimicotinib-absk021 daily 0.8 https://clival.com/news/bioivt-acquires-carlsbad-california-based-provider-of-biospecimens-for-neurology-and-oncology-research-precisionmed daily 0.8 https://clival.com/news/memo-therapeutics-ag-and-northway-biotechpharma-collaborate-on-the-fast-track-manufacturing-of-a-sars-cov-2-neutralizing-antibody-for-the-therapy-of-c daily 0.8 https://clival.com/news/neurocrine-biosciences-and-xenon-pharmaceuticals-announce-agreement-to-develop-first-in-class-treatments-for-epilepsy daily 0.8 https://clival.com/news/legochem-biosciences-announces-license-agreement-for-lcb84-trop2-targeted-adc daily 0.8 https://clival.com/news/sec-recommends-waiver-of-phase-iii-and-iv-trials-for-sanofi-healthcare-olipudase-alfa-powder daily 0.8 https://clival.com/news/novartis-sickle-cell-drugs-approval-formally-revoked-by-eu-regulators daily 0.8 https://clival.com/news/cadila-launches-generic-versions-of-type-2-diabetes-drug-sitagliptin-in-india daily 0.8 https://clival.com/news/lupin-launches-luforbec-1006-to-treat-adult-asthma-and-copd-in-germany daily 0.8 https://clival.com/news/jacobio-licenses-glecirasib-and-jab-3312-to-allist-for-china-market daily 0.8 https://clival.com/news/fda-faults-biocon-small-molecule-api-facility-during-preapproval-review daily 0.8 https://clival.com/news/biocardia-enrolls-first-patient-in-cardiallo-phase-iii-clinical-trial-of-bcda-03-to-treat-ischemic-heart-failure-of-reduced-ejection-fraction daily 0.8 https://clival.com/news/chugai-pharma-obtains-japanese-approval-for-foundationone-cdx-cancer-genomic-profile-as-cdx-for-pemigatinib-in-patients-with-biliary-tract-cancer daily 0.8 https://clival.com/news/bristol-myers-squibb-announces-approval-of-sotyktu-deucravacitinib daily 0.8 https://clival.com/news/poseida-therapeutics-p-bcma-allo1-receives-us-fda-rmat-designation daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-boehringer-ingelheim daily 0.8 https://clival.com/news/astellas-announces-update-on-preliminary-safety-and-efficacy-data-from-fortis-phase12-study-of-at845-in-adults-with-late-onset-pompe-disease daily 0.8 https://clival.com/news/indias-first-mrna-based-omicron-specific-booster-vaccine-from-pune-based-gennova-gets-dcgi-approval daily 0.8 https://clival.com/news/neurobo-gets-aaprroval-to-advance-phase-2a-trial-for-mash-treatment daily 0.8 https://clival.com/news/boehringer-ingelheim-announces-collaboration-with-mabgenesis-to-discover-and-develop-novel-monoclonal-antibodies-in-canine daily 0.8 https://clival.com/news/merck-animal-health-to-acquire-elanco-aqua-business daily 0.8 https://clival.com/news/mindmed-acquires-exclusive-license-to-eight-clinical-trials-of-lsd-partners-with-world-leading-psychedelic-research-laboratory daily 0.8 https://clival.com/news/eversana daily 0.8 https://clival.com/news/azurity-pharma-gets-us-fda-approval-for-danziten-tablets daily 0.8 https://clival.com/news/melodia-therapeutics-alivexis-ink-license-agreement-for-mod-a daily 0.8 https://clival.com/news/fujifilm-initiates-us-phase-ii-trial-of-avigan-tablet-to-treat-patients-with-covid-19 daily 0.8 https://clival.com/news/gileads-biktarvy-gets-approval-for-expanded-indication daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-status-to-dupixent-to-treat-eosinophilic-esophagitis daily 0.8 https://clival.com/news/forge-enters-into-collaboration-with-roche-to-develop-novel-antibiotic-to-treat-lung-infections daily 0.8 https://clival.com/news/gsk-enters-agreement-to-obtain-exclusive-license-for-jnj-3989-to-expand-the-development-of-bepirovirsen daily 0.8 https://clival.com/news/biocon-mylan-launch-insulin-biosimilar-in-australia daily 0.8 https://clival.com/news/t-maximum-pharmaceutical-unveils-car-t-breakthrough-for-solid-tumours daily 0.8 https://clival.com/news/myricx-bio-enters-into-an-exclusive-antibody-license-agreement-with-wuxi-biologics daily 0.8 https://clival.com/news/torrent-pharma-to-acquire-curatio-healthcare-for-rs-2000-crore daily 0.8 https://clival.com/news/innovations-acquires-controlling-stake-in-us-based-avra-medical-robotics daily 0.8 https://clival.com/news/darolutamide-meets-primary-endpoint-in-phase-iii-aranote-trial daily 0.8 https://clival.com/news/lilly-to-buy-biopharma-company-dice-therapeutics-for-24-billion daily 0.8 https://clival.com/news/oscotec-adel-begins-trial-for-adel-y01-in-alzheimers-disease daily 0.8 https://clival.com/news/sandoz-announces-positive-results-from-mylight-phase-lll-study-for-biosimilar-aflibercept daily 0.8 https://clival.com/news/gracell-biotechnologies-doses-first-patient-in-phase-2-portion-of-registrational-phase-12-clinical-trial-evaluating-gc007g-for-treatment-of-b-cell-acute-lymphoblastic-leukemia daily 0.8 https://clival.com/news/limacorporate-orthofix-medical-partner-to-provide-solution-for-patients-with-high-hip-dislocation-for-us-market daily 0.8 https://clival.com/news/ucb-announces-positive-results-from-phase-3-be-sure-study-of-bimekizumab-as-compared-to-adalimumab-in-adults-with-moderate-to-severe-plaque-psoriasis daily 0.8 https://clival.com/news/krystal-biotech-receives-fda-approval-for-vyjuvek daily 0.8 https://clival.com/news/cage-bio-tagcyx-and-peptistar-execute-license-agreement-to-develop-and-commercialize-tagx-0003-to-treat-alopecia-areata-and-vitiligo daily 0.8 https://clival.com/news/search-complete-to-reverse-alzheimers-disease-impact daily 0.8 https://clival.com/news/entasis-therapeutics-and-zai-lab-complete-patient-enrollment-in-the-attack-phase-3-registrational-clinical-trial-of-sulbactam-durlobactam daily 0.8 https://clival.com/news/eton-pharma-introduces-ultra-rare-disease-product-nitisinone-capsules daily 0.8 https://clival.com/news/puretech-acquires-lyt-100-to-treat-lymphedema daily 0.8 https://clival.com/news/kintor-pharma-completes-patient-enrollment-in-phase-ii-trial-of-kx-826-in-china-to-treat-female-patients-with-androgenetic-alopecia daily 0.8 https://clival.com/news/glenmark-to-conduct-phase-iii-trial-nasal-spray-meant-to-treat-covid-19 daily 0.8 https://clival.com/news/lji-scientists-in-collaboration-with-institut-pasteur-researchers-capture-new-high-resolution-view-of-rabies-virus-revealing-potential-vaccine-targets daily 0.8 https://clival.com/news/bayer-sun-pharma-enter-agreement-to-market-and-distribute-finerenone-in-india daily 0.8 https://clival.com/news/aktivolabs-gets-hipaa-certification-launches-us-operations daily 0.8 https://clival.com/news/sangamo-therapeutics-gains-fda-approval-for-st-503-ind-in-idiopathic-small-fibre-neuropathy daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-nanoscope-therapeutics daily 0.8 https://clival.com/news/prism-biolab-and-lilly-enter-into-a-drug-discovery-collaboration-on-a-protein-protein-interaction-target daily 0.8 https://clival.com/news/sabin-vaccine-institute-initiates-phase-2-clinical-trial-for-sudan-ebolavirus-vaccine daily 0.8 https://clival.com/news/nurix-therapeutics-extends-collaboration-with-gilead-sciences daily 0.8 https://clival.com/news/biocon-biologics-gets-european-marketing-approval-for-yesafili-biosimilar-aflibercept daily 0.8 https://clival.com/news/abbisko-therapeutics-announces-worldwide-collaboration-with-lilly-to-discover-and-develop-novel-molecules daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-moleculin-biotechs-annamycin-to-treat-soft-tissue-sarcomas daily 0.8 https://clival.com/news/lynk-pharmaceuticals-announces-positive-topline-data-from-phase-ii-clinical-trial-of-lnk01001-in-the-treatment-of-ankylosing-spondylitis daily 0.8 https://clival.com/news/kelun-biotech-announces-oncology-research-collaboration-and-license-agreement-with-msd daily 0.8 https://clival.com/news/krystal-biotech-receives-fda-acceptance-of-kb407-ind-application-for-cystic-fibrosis-clinical-trial daily 0.8 https://clival.com/news/angle-announces-agreement-with-bioview daily 0.8 https://clival.com/news/even-healthcare-healthily-collaborate-to-empower-users-with-personalized-ai-assessment-and-verified-medical-content daily 0.8 https://clival.com/news/merck-to-acquire-clinical-stage-biopharma-company-imago-biosciences-for-135-billion daily 0.8 https://clival.com/news/serum-institute-of-india-to-launch-indigenously-made-vaccine-to-treat-cervical-cancer daily 0.8 https://clival.com/news/innovent-laekna-begin-patient-dosing-in-phase-12-trial-of-three-drug-combination-to-treat-solid-tumours-who-were-resistant-to-prior-anti-pd-1pd-l1-therapy daily 0.8 https://clival.com/news/glenmark-cediprof-enter-supply-and-distribution-agreement-for-us-fda-approved-generic-version-of-adderall-tablets-in-us-markets daily 0.8 https://clival.com/news/eyepoint-pharmaceuticals-announces-first-patient-dosed-in-phase-2-davio-2-clinical-trial-of-eyp-1901-for-the-maintenance-treatment-of-wet-amd daily 0.8 https://clival.com/news/pharmazz-and-sun-pharmaceutical-industries-enter-into-agreement daily 0.8 https://clival.com/news/pfizer-in-talks-with-india-over-expedited-approval-for-covid-19-vaccine daily 0.8 https://clival.com/news/health-ministry-to-waive-clinical-trials-for-eu-approved-medical-devices-soon daily 0.8 https://clival.com/news/johnson-johnson-files-for-european-approval-of-ebola-vaccine daily 0.8 https://clival.com/news/astrazeneca-india-launches-trastuzumab-deruxtecan-for-her-2-positive-metastatic-breast-cancer-patients-in-india daily 0.8 https://clival.com/news/pfizer-resumes-production-at-tornado-hit-plant-in-north-carolina daily 0.8 https://clival.com/news/penpulimab-monoclonal-antibody-pd-1-obtains-marketing-approval-in-china daily 0.8 https://clival.com/news/minoryx-therapeutics-announces-positive-results-from-phase-2-frames-trial-of-leriglitazone-to-treat-friedreichs-ataxia daily 0.8 https://clival.com/news/chinese-startup-jacobio-pharma-partners-with-merck-for-cancer-clinical-trial daily 0.8 https://clival.com/news/beigene-to-host-investor-conference-call-and-webcast-to-discuss-clinical-study-results-presented-at-the-2020-american-society-of-clinical-oncology-as daily 0.8 https://clival.com/news/pharming-announces-positive-phase-iiiii-leniolisib-clinical-trial-data-presented-at-the-2022-society-for-clinical-immunology-annual-meeting daily 0.8 https://clival.com/news/protalixbiotherapeutics-announces-positive-results-from-bridge-phase-iii-trial-of-pegunigalsidasealfa-to-treat-fabry-disease daily 0.8 https://clival.com/news/jj-pares-down-vaccine-partnership-with-bavarian-nordic daily 0.8 https://clival.com/news/moderna-us-clash-in-patent-dispute-over-origins-of-covid-19-vaccine daily 0.8 https://clival.com/news/takeda-presents-positive-results-from-phase-12-trial-from-mobocertinib-in-patients-with-egfr-exon20-insertion-mnsclc-who-received-prior-platinum-bas daily 0.8 https://clival.com/news/cbm-inks-partnership-with-achilles-to-expand-cell-therapy-manufacturing-capabilities daily 0.8 https://clival.com/news/antengene-announces-xpovio-regulatory-approval-in-macau-for-the-treatment-of-relapsed-andor-refractory-multiple-myeloma daily 0.8 https://clival.com/news/relive-biotechnologies-has-completed-the-acquisition-biotech-company-codon-ag daily 0.8 https://clival.com/news/usp-collaborates-with-gujarat-fdca-to-adopt-best-practices-on-regulatory-compliances-and-drug-standards daily 0.8 https://clival.com/news/chainese-nmpa-accepts-astellas-nda-for-oral-once-daily-therapy-xospata-to-treat-relapsedrefractory-am daily 0.8 https://clival.com/news/entod-pharma-launches-the-third-annual-national-myopia-week-awareness-campaign daily 0.8 https://clival.com/news/talvey-talquetamab-gets-fda-approval-for-multiple-myeloma daily 0.8 https://clival.com/news/assembly-biosciences-and-beigene-announce-license-and-collaboration-agreement-in-china-for-assemblys-portfolio-of-three-clinical-stage-core-inhibitors daily 0.8 https://clival.com/news/boehringer-to-invest-eur-120-million-to-expand-production-site-in-greece-for-new-medicine daily 0.8 https://clival.com/news/biontech-begins-phase-i-study-of-vaccine-candidate-for-malaria daily 0.8 https://clival.com/news/enhertu-granted-breakthrough-therapy-designation-in-the-us-for-her2-mutant-metastatic-non-small-cell-lung-cancer daily 0.8 https://clival.com/news/fdc-launches-2-variants-of-favipiravir-in-india-at-rs-55-per-tablet daily 0.8 https://clival.com/news/hutchmed-received-snda-for-savolitinib-in-china daily 0.8 https://clival.com/news/portage-biotech-collaborates-with-merck-to-evaluate-two-next-generation-adenosine-antagonists-in-combo-with-keytruda-in-solid-tumours daily 0.8 https://clival.com/news/mgi-announces-partnership-with-ngenebio daily 0.8 https://clival.com/news/lupin-collaborates-with-mark-cuban-cost-plus-drug-company-and-copd-foundation-to-expand-access-to-medication-for-copd-patients daily 0.8 https://clival.com/news/cynata-therapeutics-reported-positive-results-from-phase-i-trial daily 0.8 https://clival.com/news/cnmpa-approves-eisais-antiepileptic-drug daily 0.8 https://clival.com/news/veeda-acquires-a-european-cro-heads daily 0.8 https://clival.com/news/strides-gets-us-fda-approval-for-levetiracetam-oral-solution daily 0.8 https://clival.com/news/affinity-biosensors-lifescale-ast-system-gets-clearance daily 0.8 https://clival.com/news/orion-corporation-acquires-inovets-veterinary-business daily 0.8 https://clival.com/news/novo-nordisk-collaborates-with-life-edit-therapeutics daily 0.8 https://clival.com/news/verseon-acquires-edammo daily 0.8 https://clival.com/news/proteonic-announces-licensing-of-its-premium-2g-unic daily 0.8 https://clival.com/news/ultradx-receives-first-clinical-approval-of-single-molecule-analyzer-in-china daily 0.8 https://clival.com/news/taurx-to-present-24-months-data-from-phase-iii-clinical-trial daily 0.8 https://clival.com/news/ascletis-opens-clinical-development-shanghai-center daily 0.8 https://clival.com/news/remegen-obtains-positive-phase-iii-results-for-new-drug-telitaciceptrc18 daily 0.8 https://clival.com/news/astar-enter-collaboration-to-launch-joint-labs-for-cellular-immunotherapies daily 0.8 https://clival.com/news/industry-oncology-research-new-gsk-closer-to-first-us-approval-with-anemia-drug-for-patients-on-dialysis daily 0.8 https://clival.com/news/gsk-manufacturing-review-prompts-scynexis-to-pull-brexafemme-halt-trials-over-contamination-concerns daily 0.8 https://clival.com/news/ema-committee-recommends-conditional-approval-of-hansa-biopharmas-idefirix-for-kidney-transplant-patients daily 0.8 https://clival.com/news/bio-thera-begins-patient-dosing-in-phase-1-study-of-bat8007-an-adc-targeting-nectin-4-to-treat-advanced-solid-tumours daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-status-to-tc-biopharms-omnimmune-to-treat-acute-myeloid-leukaemia daily 0.8 https://clival.com/news/astrazeneca-and-saint-lukes-mid-america-heart-institute-initiate-phase-iii-dare-19-trial-with-farxiga-in-covid-19-patients daily 0.8 https://clival.com/news/pfizer-launches-an-accord-for-a-healthier-world-to-improve-health-equity-for-12-billion-people-living-in-45-lower-income-countries daily 0.8 https://clival.com/news/bioivt-acquires-southeastern-europe-based-fidelis-research daily 0.8 https://clival.com/news/bighat-biosciences-completes-first-stage-of-research-collaboration-with-amgen daily 0.8 https://clival.com/news/c4-therapeutics-and-merck-kgaa-partners-for-oncogenic-proteins daily 0.8 https://clival.com/news/luye-pharma-seeks-us-fda-approval-for-antidepressant-drug-ly03005 daily 0.8 https://clival.com/news/immunofoco-gets-approval-to-begin-trials-for-imc001 daily 0.8 https://clival.com/news/eli-lilly-files-patent-litigation-against-20-indian-companies-on-baricitinib daily 0.8 https://clival.com/news/sumitovant-biopharma-acquires-myovant-sciences-in-17b-deal daily 0.8 https://clival.com/news/epimab-biotherapeutics-and-almirall-announce-bispecific-antibody-license-agreement daily 0.8 https://clival.com/news/cartesian-therapeutics-doses-first-patient-in-phase-2-clinical-trial-of-descartes-08 daily 0.8 https://clival.com/news/roche-announces-positive-phase-i-results-of-its-oral-glp-1-receptor-agonist-ct-996 daily 0.8 https://clival.com/news/israels-icecure-says-gets-fda-nod-to-treat-tumours-in-liver-kidney daily 0.8 https://clival.com/news/united-states-orphan-drug-designation-for-treatment-of-soft-tissue-sarcomas-granted-to-spear-t-cells-targeting-mage-a4 daily 0.8 https://clival.com/news/microbion-drug-candidate-pravibismane-gets-second-us-fda-orphan-drug-status-for-treatment-of-non-tb-mycobacterial-infections daily 0.8 https://clival.com/news/cmp-pharma-introduces-liqrev-the-ready-made-us-fda-approved-liquid-suspension-of-sildenafil daily 0.8 https://clival.com/news/ocugen-gets-dsmb-nod-for-phase-12-trial-with-medium-dose-of-ocu410 daily 0.8 https://clival.com/news/ubiquigent-enters-agreement-with-nanna-therapeutics daily 0.8 https://clival.com/news/strides-pharmas-singapore-arm-gets-usfda-nod-for-generic-version-of-oseltamivir-phosphate daily 0.8 https://clival.com/news/us-fda-approves-myovant-and-pfizer-myfembree-a-once-daily-therapy-for-management-of-moderate-to-severe-pain-associated-with-endometriosis daily 0.8 https://clival.com/news/biocina-expands-partnership-with-gpn-vaccines daily 0.8 https://clival.com/news/carthera-enters-strategic-collaboration-with-accord-healthcare-for-supply-of-carboplatin daily 0.8 https://clival.com/news/bdr-pharma-launches-first-generic-apalutamide-to-treat-prostate-cancer-in-india daily 0.8 https://clival.com/news/gaurav-burman-of-dabur-acquires-strategic-stake-in-health-start-up-mitsu daily 0.8 https://clival.com/news/novo-nordisk-introduced-weight-loss-drug-in-germany-first-big-eu-market daily 0.8 https://clival.com/news/abbvie-announces-phase-3-cll14-trial-of-venclyxtovenclexta-fixed-duration-combination-demonstrates-sustained-pfs-in-cll-patients-after-3-years-off-tr daily 0.8 https://clival.com/news/nanox-announces-strategic-manufacturing-agreement-with-varex-imaging-corporation-to-advance-the-nanox-arc-medical-imaging-system daily 0.8 https://clival.com/news/credence-medsystems-schott-ag-collaborate-to-make-syringe-injections-safer-for-benefit-of-patients-worldwide daily 0.8 https://clival.com/news/abvc-biopharma-receives-taiwan-science-park-administrations-approval-for-gmp-production-facility-plan daily 0.8 https://clival.com/news/biocon-biologics-introduces-hulio-a-humira-biosimilar-in-united-states daily 0.8 https://clival.com/news/kdx-diagnostics-urogpo-partner-to-offer-uro17-non-invasive-urine-test-for-bladder-cancer daily 0.8 https://clival.com/news/diamyd-medical-to-receive-european-patent-for-prevention-and-treatment-of-autoimmune-diabetes daily 0.8 https://clival.com/news/seegene-collaborates-with-microsoft-to-realize-a-world-free-from-all-diseases daily 0.8 https://clival.com/news/xeris-commercialization-partner-for-ogluo daily 0.8 https://clival.com/news/ipsen-sutro-biopharma-enter-agreement-for-adc daily 0.8 https://clival.com/news/apeiron-announces-phase-2-trial-of-apn01-shows-clinical-benefits-for-severely-ill-covid-19-patients daily 0.8 https://clival.com/news/vertex-obsidian-therapeutics-ink-research-collaboration-to-discover-new-therapies-that-regulate-gene-editing daily 0.8 https://clival.com/news/abbvie-launches-strategic-collaboration-with-hotspot-therapeutics-to-further-expand-immunology-pipeline daily 0.8 https://clival.com/news/abbvies-select-choice-phase-3-trial-of-rinvoq-versus-orencia-meets-primary-and-key-secondary-endpoints-in-rheumatoid-arthritis-patients daily 0.8 https://clival.com/news/sensorion-announces-research-partnership-with-institut-pasteur-to-accelerate-gene-therapy-programmes-targeting-hearing-disorders-extended-for-5-years daily 0.8 https://clival.com/news/genentech-nvidia-ink-ai-research-collaboration-to-accelerate-drug-discovery-and-development daily 0.8 https://clival.com/news/tigenixs-crohns-disease-drug-granted-swiss-orphan-drug-designation daily 0.8 https://clival.com/news/acurx-pharma-reports-positive-comparative-microbiology-and-microbiome-data-from-phase-2b-trial-of-ibezapolstat-in-patients-with-cdi daily 0.8 https://clival.com/news/moderna-announces-emergency-use-authorization-for-its-covid-19-vaccine-granted-by-government-of-india daily 0.8 https://clival.com/news/biolexis-and-akston-biosciences-announce-encouraging-top-line-results-from-phase-iiiii-trial-of-their-thermostable-2nd-gen-covid-19-vaccine daily 0.8 https://clival.com/news/help-therapeutics-announces-ind-approval-of-first-universal-ipsc-derived-cardiomyocyte-therapy-for-end-stage-heart-failure-in-china daily 0.8 https://clival.com/news/merck-partners-with-vector-institute daily 0.8 https://clival.com/news/us-fda-approves-eiger-biopharmas-zokinvyt-to-treat-hutchinson-gilford-progeria-syndrome-and-processing-deficient-pl daily 0.8 https://clival.com/news/astrazeneca-msd-lynparza-in-combo-with-abiraterone-recommends-for-marketing-approval-in-eu-to-treat-metastatic-castration-resistant-prostate-cancer daily 0.8 https://clival.com/news/bc-platforms-and-ntt-group-soon-to-inaugurate-debut-of-japanese-precision-medicine-platform daily 0.8 https://clival.com/news/bengaluru-hospital-launches-third-phase-of-covaxin-trials daily 0.8 https://clival.com/news/anges-receives-japanese-marketing-approval-for-zokinvy-for-hutchinson-gilford-progeria-syndrome-pdpl daily 0.8 https://clival.com/news/vifor-pharma-to-spearhead-development-of-vascular-calcification-field-through-acquisition-of-sanifit-therapeutics-and-inositec-ag daily 0.8 https://clival.com/news/merck-keytruda-gets-four-new-approvals-in-japan-including-in-high-risk-early-stage-triple-negative-breast-cancer daily 0.8 https://clival.com/news/us-fda-places-clinical-hold-on-clinical-trials-of-pha121-in-us-under-two-pharvaris-ind-applications-for-hae-treatment daily 0.8 https://clival.com/news/who-issues-medical-product-alert-refers-to-falsified-covid-19-vaccine-bnt162b2 daily 0.8 https://clival.com/news/alx-oncology-to-present-results-from-phase-1b2-trial-of-evorpacept-zanidatamab daily 0.8 https://clival.com/news/innovent-dosed-first-participant-in-phase-3-clinical-study-glory-2-of-mazdutide-ibi362-higher-dose-9-mg-in-chinese-adults-with-obesity daily 0.8 https://clival.com/news/cdsco-approves-bharat-biotechs-intra-nasal-vaccine-for-covid-19-in-adults daily 0.8 https://clival.com/news/sciwind-biosciences-announces-initiation-of-dosing-in-phase-1-clinical-trial-evaluating-xw014-an-oral-small-molecule-glp-1-receptor-agonist-for-the-treatment-of-obesity-and-type-2-diabetes daily 0.8 https://clival.com/news/nurexone-biologic-initiates-european-odd-process-following-us-grant daily 0.8 https://clival.com/news/alligator-biosciences-ind-for-cd40-targeting-antibody-mitazalimab-gets-us-fda-approval daily 0.8 https://clival.com/news/china-nmpa-grants-breakthrough-designation-to-innovent-biologics-anheart-therapeutics-taletrectinib-in-ros1-positive-nsclc daily 0.8 https://clival.com/news/cipla-health-launches-maxirich-vitamin-c-zinc-chewable-tablets-and-maxirich-gold-supplement daily 0.8 https://clival.com/news/us-fda-approves-beigenes-brukinsa-to-treat-patients-with-mantle-cell-lymphoma-who-have-received-at-least-one-prior-therapy daily 0.8 https://clival.com/news/roche-seeks-fda-nod-for-columvi-combo-in-relapsed-dlbcl-treatment daily 0.8 https://clival.com/news/bio-techne-announces-launch-of-kappa-and-lambda-rnascope-ish-probes-as-analyte-specific-reagents daily 0.8 https://clival.com/news/us-fda-clears-ecential-robotics-surgical-robotic-platform-for-spine-surgery daily 0.8 https://clival.com/news/luye-pharma-partners-with-korea-based-myung-in-pharm daily 0.8 https://clival.com/news/sparc-receives-us-fda-orphan-drug-designation-for-phenobarbital daily 0.8 https://clival.com/news/uk-mhra-grants-marketing-authorization-to-oncopeptides-pepaxti-in-combo-with-dexamethasone-to-treat-multiple-myeloma daily 0.8 https://clival.com/news/lupin-gets-us-fda-approval-for-generic-edecrin-tablets-to-treat-edema daily 0.8 https://clival.com/news/penn-medicine-and-childrens-hospital-of-philadelphia-announce-partnership-with-costa-rica-for-car-t-cell-therapy daily 0.8 https://clival.com/news/mustgrow-and-bayer-sign-exclusive-agreement-to-develop-sustainable-organic-biologicals-in-europe-asia-pacific-middle-east-and-africa daily 0.8 https://clival.com/news/ksq-therapeutics-and-takeda-expand-strategic-immuno-oncology-collaboration daily 0.8 https://clival.com/news/jjs-balversa-gets-us-fda-full-approval-to-treat-locally-advanced-or-metastatic-bladder-cancer-with-select-genetic-alterations daily 0.8 https://clival.com/news/i-mab-announces-ind-approval-by-fda-to-initiate-phase-1-study-for-protollin-for-the-treatment-of-alzheimers-disease daily 0.8 https://clival.com/news/kalivir-announces-us-fda-clears-ind-application-to-initiate-phase-1-study-of-asp1012-to-treat-locally-advanced-or-metastatic-solid-tumours daily 0.8 https://clival.com/news/pfizer-biontech-regeneron-sued-for-patent-infringement-with-covid-19-products daily 0.8 https://clival.com/news/china-approves-fosun-diagnostics-covid-19-antigen-detection-kit daily 0.8 https://clival.com/news/the-european-medicines-agency-approved-pierre-fabre-laboratories-marketing-authorization-application-for-the-combination-braftovi-encorafenib-and-mektovi-binimetinib-for-patients-with-advanced-non-small-cell-lung-cancer-nsclc-with-brafv600-mutati daily 0.8 https://clival.com/news/alembic-pharma-receives-usfda-nod-for-fulvestrant-injection daily 0.8 https://clival.com/news/mimivax-granted-fast-track-designation-from-fda-for-survaxm-for-newly-diagnosed-glioblastoma daily 0.8 https://clival.com/news/harbour-biomed-announces-positive-results-from-phase-iii-trial-of-batoclimab-to-treat-generalized-myasthenia-gravis daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-ionis-astrazenecas-wainzua-for-amyloidosis daily 0.8 https://clival.com/news/evotec-se-and-variant-bio-collaborate-for-diseases-caused-by-fibrosis daily 0.8 https://clival.com/news/wuxi-biologics-and-gsk-enter-into-license-agreement-on-multiple-novel-bi-multi-specific-t-cell-engagers daily 0.8 https://clival.com/news/i-mab-announces-first-patient-dosed-in-phase-2-clinical-trial-of-tj107-in-glioblastoma-multiforme-in-china daily 0.8 https://clival.com/news/ascletis-announces-completion-of-180-patient-enrollment-for-phase-ii-clinical-trial-of-fasn-inhibitor-asc40-for-acne daily 0.8 https://clival.com/news/ionis-announces-enrollment-completion-of-phase-3-lpa-horizon-cardiovascular-outcomes-study-of-pelacarsen daily 0.8 https://clival.com/news/boehringer-ingelheim-cbmed-partner-to-translate-novel-cancer-therapy-approaches-faster-into-new-medicines-for-patients daily 0.8 https://clival.com/news/lupin-announces-resolution-of-us-fda-warning-letter-for-its-goa-pithampur-facilities daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-pitavastatin-tablets daily 0.8 https://clival.com/news/us-fda-approves-label-update-for-novo-nordisk-rybelsus-allowing-use-as-a-first-line-option-for-adults-with-type-2-diabetes daily 0.8 https://clival.com/news/astrazeneca-india-4basecare-collaborate-to-enhance-access-to-genomic-testing-for-cancer-patients-in-india daily 0.8 https://clival.com/news/emcure-launches-otc-portfolio-of-galact-for-new-mothers daily 0.8 https://clival.com/news/evotec-enters-a-drug-discovery-collaboration-with-janssen daily 0.8 https://clival.com/news/philochem-ag-seibersdorf-labor-gmbh-and-isotopia-announce-supply-development-and-manufacturing-agreements daily 0.8 https://clival.com/news/synthetica-pioneering-completes-series-a-funding-round-to-advance-oncolytic-bacterial-treatment daily 0.8 https://clival.com/news/rhythm-pharmas-phase-3-trial-of-setmelanotide-to-treat-bardet-biedl-and-alstrom-syndromes-meets-primary-and-all-key-secondary-endpoints daily 0.8 https://clival.com/news/roche-enters-into-a-definitive-agreement-to-acquire-telavant-including-rights-to-novel-tl1a-directed-antibody-rvt-3101-for-the-treatment-of-inflammatory-bowel-disease-from-roivant daily 0.8 https://clival.com/news/roche-acquires-test-maker-tib-molbiol daily 0.8 https://clival.com/news/biocytogen-enters-into-antibody-agreement-with-merck-kgaa-darmstadt-germany daily 0.8 https://clival.com/news/nona-biosciences-and-genequantum-healthcare-forge-strategic-alliance-to-enhance-early-discovery-of-next-generation-bioconjugates daily 0.8 https://clival.com/news/new-york-structural-biology-centre-and-syncell-partner-for-microscopy-guided-proteomics daily 0.8 https://clival.com/news/merck-scores-fda-approval-for-ebola-vaccine-ervebo daily 0.8 https://clival.com/news/merck-keytruda-plus-chemotherapy-gets-european-approval-for-new-first-line-indications-in-advanced-her2-negative-gastric-or-gej-adenocarcinoma-in-tumours-expressing-pd-l1-cps-1-and-advanced-biliary-tract-cancer daily 0.8 https://clival.com/news/arctic-vision-announces-first-patient-dosed-in-phase-iii-study-of-arvn001-for-treatment-of-macular-edema-associated-with-uveitis-ume daily 0.8 https://clival.com/news/teva-pharmaceuticals-and-alvotech-announce-update-on-strategic-biosimilars-partnership daily 0.8 https://clival.com/news/synaptixbio-gains-second-orphan-drug-designation daily 0.8 https://clival.com/news/lupin-gets-approval-from-health-canada-for-hypertension-drugs daily 0.8 https://clival.com/news/amneal-receives-first-product-approval-in-china daily 0.8 https://clival.com/news/sanofi-to-acquire-clinical-stage-mrna-therapeutics-company-translate-bio-for-us-32-billion daily 0.8 https://clival.com/news/repare-begins-phase-i-trials-dosing-for-rp-1664 daily 0.8 https://clival.com/news/sequence-bio-inks-collaboration-with-leo-pharma-to-identify-novel-dermatologic-drug-targets daily 0.8 https://clival.com/news/radyus-research-southern-research-forms-partnership daily 0.8 https://clival.com/news/akeso-announced-nda-acceptance-of-il-12ll-23-monoclonal-antibody-ebdarokimab-for-moderate-to-severe-plaque-psoriasis-by-china-nmpa daily 0.8 https://clival.com/news/european-commission-approves-contract-with-curevac-to-ensure-access-to-a-potential-vaccine daily 0.8 https://clival.com/news/biovaxys-expands-patent-coverage-on-covidth-by-filing-international-patent-application-through-pct daily 0.8 https://clival.com/news/boston-scientific-agent-drug-coated-balloon-demonstrates-superiority-to-uncoated-balloon-angioplasty-in-the-agent-ide-trial daily 0.8 https://clival.com/news/akron-biotech-signs-agreement-with-synairgen-plc-to-supply-interferon-beta-for-covid-19-treatment daily 0.8 https://clival.com/news/pfizer-challenges-roche-blockbusters-with-3-biosim-launches-at-discounts-from-22-to-24 daily 0.8 https://clival.com/news/us-fda-approves-daiichi-sankyo-and-astrazenecas-enhertu-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-cyanocobalamin-nasal-spray daily 0.8 https://clival.com/news/enzymit-receives-iso-9001-quality-management-system-certification-for-sustainable-enzyme-development daily 0.8 https://clival.com/news/ironwood-pharmaceuticals-enters-into-agreement-to-acquire-vectivbio daily 0.8 https://clival.com/news/nuclixbio-announces-a-collaborative-research-agreement-with-pharmabcine daily 0.8 https://clival.com/news/merck-reports-positive-results-from-phase-3-trial-evaluating-efficacy-and-safety-of-gardasil-9 daily 0.8 https://clival.com/news/orange-health-diagnostic-lab-acquires-gurugram-based-rapidx-to-enhance-ncr-footprint daily 0.8 https://clival.com/news/dksh-lactalis-signs-agreement-for-distribution-in-asia-and-europe daily 0.8 https://clival.com/news/synaptogenix-gets-us-fda-authorization-of-ind-application-for-clinical-trial-for-bryostatin-1 daily 0.8 https://clival.com/news/eli-lilly-completes-acquisition-of-radiopharmaceutical-company-point-biopharma daily 0.8 https://clival.com/news/exscientia-and-sanofi-establish-strategic-research-collaboration-to-develop-ai-driven-pipeline-of-precision-engineered-medicines daily 0.8 https://clival.com/news/daiichi-sankyo-astrazeneca-enhertu-receives-two-breakthrough-therapy-designations-in-us-for-patients-across-multiple-her2-expressing-cancers daily 0.8 https://clival.com/news/johnson-johnson-expands-cardiovascular-business-with-166b-abiomed-acquisition daily 0.8 https://clival.com/news/us-fda-accepts-innovent-lillys-bla-for-sintilimab-in-combo-with-pemetrexed-and-platinum-chemotherapy-to-treat-nsclc daily 0.8 https://clival.com/news/ema-tests-maas-for-datopotamab-deruxtecan daily 0.8 https://clival.com/news/ascletis-announces-first-patient-dosed-in-the-phase-ii-clinical-trial-of-asc42-an-in-house-developed-best-in-class-fxr-agonist-for-chronic-hepatitis-b-indication daily 0.8 https://clival.com/news/caped-trust-and-astrazeneca-india-launch-ganga-godavari-cancer-screening-programme-in-mathura daily 0.8 https://clival.com/news/bristol-myers-squibb-announces-positive-results-from-phase-2-pilot-study-of-breyanzi-to-treat-refractory-or-relapsed-lbcl-after-first-line-therapy daily 0.8 https://clival.com/news/shepherd-therapeutics-and-oncoheroes-biosciences-to-partner-for-the-discovery-development-and-commercialization-of-oncology-therapeutics-for-rare-can daily 0.8 https://clival.com/news/us-fda-approves-merck-welireg-to-treat-patients-with-advanced-renal-cell-carcinoma daily 0.8 https://clival.com/news/invo-enters-distribution-agreement-with-onesky-holding-for-mainland-china daily 0.8 https://clival.com/news/hansa-biopharma-enters-preclinical-research-collaboration-with-argenx daily 0.8 https://clival.com/news/mallinckrodt-receives-reimbursement-approval-in-japan-for-cellex-ecp-system-to-treat-chronic-graft-versus-host-disease daily 0.8 https://clival.com/news/astrazeneca-receives-european-commission-clearance-for-acquisition-of-alexion-pharma daily 0.8 https://clival.com/news/sanofi-completes-acquisition-of-amunix daily 0.8 https://clival.com/news/aurinia-pharmaceuticals-and-its-collaborative-partner-otsuka-have-jointly-filed-a-new-drug-application-nda-for-lupkynis-voclosporin-in-japan daily 0.8 https://clival.com/news/abbotts-fast-5-15-minute-easy-to-use-covid-19-antigen-test-receives-fda-emergency-use-authorization daily 0.8 https://clival.com/news/china-cde-grants-breakthrough-therapy-designation-btd-to-neurophths-nr082-in-lhon daily 0.8 https://clival.com/news/uk-mhra-grants-cta-for-mission-therapeutics-to-begin-phase-1-study-of-mtx325-to-treat-parkinsons-disease daily 0.8 https://clival.com/news/cipla-health-to-acquire-endura-mass-from-medinnbelle-hervalcare daily 0.8 https://clival.com/news/johnson-johnson-biopharma-turn-to-china-for-innovative-collaborations daily 0.8 https://clival.com/news/glenmark-receives-russian-marketing-approval-for-ryaltris-nasal-spray daily 0.8 https://clival.com/news/daewoong-pharmaceuticals-bersiporocin-receives-orphan-drug-designation-in-europe-to-treat-idiopathic-pulmonary-fibrosis daily 0.8 https://clival.com/news/vertex-expands-reimbursement-agreement-with-nhs-england-to-include-kaftrio-in-combo-with-kalydeco daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-kintara-therapeutics-rem-001-to-treat-cutaneous-metastatic-breast-cancer daily 0.8 https://clival.com/news/cabenuva-shows-superior-efficacy-for-hiv-treatment-in-phase-iii daily 0.8 https://clival.com/news/australian-tga-accepts-gsk-mmvs-filing-for-single-dose-tafenoquine-in-paediatric-populations-with-plasmodium-vivax-malaria daily 0.8 https://clival.com/news/everest-medicines-announces-partner-providence-reports-positive-top-line-data-from-phase-2-primary-immunization-trial-for-mrna-covid-19-vaccine-candidate-in-adults daily 0.8 https://clival.com/news/madrigals-rezdiffra-gets-approval-as-first-mash-drug daily 0.8 https://clival.com/news/orsiro-coronary-des-receives-market-approval-in-china daily 0.8 https://clival.com/news/pharmaron-acquires-state-of-the-art-biomanufacturing-site-in-the-united-kingdom-from-abbvie daily 0.8 https://clival.com/news/japan-pmda-approves-aurion-biotechs-novel-cell-therapy-vyznova-to-treat-corneal-endothelial-disease daily 0.8 https://clival.com/news/bioxcel-completes-patient-enrollment-in-safety-portion daily 0.8 https://clival.com/news/elicio-therapeutics-begins-patient-dosing-in-randomized-phase-2-pancreatic-cancer-study daily 0.8 https://clival.com/news/beigenes-brukinsa-gains-approval-for-refractory-follicular-lymphoma daily 0.8 https://clival.com/news/nurami-medical-artifascia-dura-substitute-receives-fda-clearance daily 0.8 https://clival.com/news/bengaluru-based-med-tech-start-up-inito-gets-us-patent-for-home-diagnostics-technology daily 0.8 https://clival.com/news/heres-why-nepal-banned-16-indian-pharma-companies-including-patanjalis-divya-pharmaceuticals daily 0.8 https://clival.com/news/g-niib-launches-the-worlds-first-antiviral-gut-microbiome-formula-in-singapore daily 0.8 https://clival.com/news/nextgen-genetics-joins-hands-with-luminary-life-sciences-to-launch-genetic-testing-services daily 0.8 https://clival.com/news/qilu-pharmaceutical-and-peptron-sign-license-agreement-for-anti-muc1-adc daily 0.8 https://clival.com/news/ab-sciences-masitinib-receives-orphan-drug-status-from-swissmedic-to-treat-amyotrophic-lateral-sclerosis daily 0.8 https://clival.com/news/angelini-pharma-cureverse-enter-exclusive-global-option-agreement-to-develop-cv-01 daily 0.8 https://clival.com/news/rnaimmune-secures-fda-approval-for-investigational-new-drug-application-of-mrna-based-respiratory-syncytial-virus-vaccine-rv-1770 daily 0.8 https://clival.com/news/boston-scientifics-agent-drug-coated-balloon-gets-approval daily 0.8 https://clival.com/news/evaxion-and-afrigen-biologics-to-develop-mrna-vaccine-for-gonorrhoea daily 0.8 https://clival.com/news/piramal-pharma-solutions-to-collaborate-with-epirium-bio-on-exclusive-integrated-development-manufacturing-program-for-orphan-drugs daily 0.8 https://clival.com/news/alvotech-fuji-pharma-expand-commercialization-partnership-by-adding-a-new-biosimilar-candidate daily 0.8 https://clival.com/news/guide-sensmart-launches-ai-powered-thermal-camera-to-streamline-industrial-inspections daily 0.8 https://clival.com/news/molina-healthcare-to-acquire-my-choice-wisconsin daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-status-to-neoimmunetechs-nt-i7-to-treat-progressive-multifocal-leukoencephalopathy daily 0.8 https://clival.com/news/pfizer-asks-uk-regulator-to-approve-vaccine-for-teenagers daily 0.8 https://clival.com/news/telix-acquires-optimal-tracers daily 0.8 https://clival.com/news/astrazenecas-voydeya-gets-approval-as-add-on-therapy daily 0.8 https://clival.com/news/bayer-thermo-fisher-collab-for-companion-diagnostic-assays daily 0.8 https://clival.com/news/chugais-enspryng-receives-japanese-approval-to-treat-neuromyelitis-optica-spectrum-disorder daily 0.8 https://clival.com/news/cyient-partners-with-massmedic-for-medtech-innovation daily 0.8 https://clival.com/news/certas-investigational-therapy-ft011-receives-approval daily 0.8 https://clival.com/news/sensorion-gets-australian-nod-to-start-proof-of-concept-clinical-trial-of-sens-401-for-residual-hearing-preservation-during-cochlear-implantation daily 0.8 https://clival.com/news/sciwind-biosciences-announces-positive-results-from-phase-1-clinical-trial-of-xw004-an-oral-formulation-of-long-acting-glp-1-analog-ecnoglutide daily 0.8 https://clival.com/news/mylan-working-with-dcgi-to-launch-new-tb-drug-in-india daily 0.8 https://clival.com/news/china-approves-anti-epileptic-monotherapy-for-partial-onset-seizures daily 0.8 https://clival.com/news/junshi-biosciences-and-coherus-announce-toripalimab-granted-orphan-drug-designation-in-the-united-states-for-esophageal-cancer daily 0.8 https://clival.com/news/kleiner-device-labs-awarded-patent-for-kg2-surge-flow-thru-interbody-system daily 0.8 https://clival.com/news/ucb-to-buy-biopharma-company-zogenix-for-us-19-billion daily 0.8 https://clival.com/news/vifor-pharma-and-angion-sign-license-agreement-for-ang-3777-in-nephrology-indications daily 0.8 https://clival.com/news/nrx-pharma-enrolls-first-patient-in-phase-ii-study-of-bipolar-depression-with-sub-acute-suicidality daily 0.8 https://clival.com/news/jazz-pharma-seeks-us-fda-marketing-approval-for-xywav-oral-solution-to-treat-idiopathic-hypersomnia daily 0.8 https://clival.com/news/fda-approves-alyglo-10-for-adult-primary-immunodeficiency daily 0.8 https://clival.com/news/gsk-sanofi-announce-positive-preliminary-booster-data-for-covid-19-vaccine-candidate-and-continuation-of-phase-iii-trial-per-independent-dsmb-recommendation daily 0.8 https://clival.com/news/us-fda-and-nih-launch-ppp-for-rare-neurodegenerative-diseases daily 0.8 https://clival.com/news/gujarat-fdca-collaborates-with-usp-for-knowledge-sharing-on-drug-standards daily 0.8 https://clival.com/news/the-china-nmpa-approved-cyramza daily 0.8 https://clival.com/news/j-j-announces-new-results-from-phase-1b-redirectt-1-study-of-talvey-tecvayli daily 0.8 https://clival.com/news/chemomab-therapeutics-receives-fda-fast-track-designation-for-cm-101-for-the-treatment-of-primary-sclerosing-cholangitis daily 0.8 https://clival.com/news/teijin-pharma-and-transthera-biosciences-form-strategic-rd-collaboration daily 0.8 https://clival.com/news/tron-group-inc-and-nanopharmaceutics-inc-announce-definitive-merger-agreement daily 0.8 https://clival.com/news/bleeding-warning-in-merck-drug-trial daily 0.8 https://clival.com/news/solvias-to-perform-release-testing-on-worlds-first-crispr-based-gene-editing-therapy daily 0.8 https://clival.com/news/ionis-announces-positive-data-for-etesian-phase-2b-study-of-antisense-medicine-targeting-pcsk9-at-2022-american-college-of-cardiology-scientific-session daily 0.8 https://clival.com/news/archimed-group-to-acquire-medical-device-solutions-provider-natus-medical-for-12-billion daily 0.8 https://clival.com/news/fogsi-announces-launch-of-mahila-kavach-kendra-a-comprehensive-walk-in-vaccination-center-for-girls-and-women daily 0.8 https://clival.com/news/mediwound-expands-global-presence-as-nexobrid daily 0.8 https://clival.com/news/themis-collaborates-with-abl-europe-in-france-on-the-production-of-its-sars-cov-2-vaccine-candidate daily 0.8 https://clival.com/news/bharat-biotech-seeks-nod-for-phase-3-trials-of-intranasal-covid-19-vaccine-as-booster-dose daily 0.8 https://clival.com/news/abbvies-elezanumab-to-treat-spinal-cord-injury-receives-us-fda-orphan-drug-and-fast-track-designations daily 0.8 https://clival.com/news/us-fda-grants-fast-track-status-to-dynacures-dyn101-to-treat-myotubular-and-centronuclear-myopathies daily 0.8 https://clival.com/news/probiogen-lava-enter-agreement-for-cell-line-development-for-manufacturing-of-novel-bispecific daily 0.8 https://clival.com/news/oxford-biomedica-signs-new-deal-to-make-astrazeneca-covid-shot daily 0.8 https://clival.com/news/ray-therapeutics-and-forge-biologics-announce-viral-vector-contract-development-and-cgmp-manufacturing-partnership daily 0.8 https://clival.com/news/roche-announces-collaboration-with-atea-pharmaceuticals-to-develop-a-potential-oral-treatment-for-covid-19-patients daily 0.8 https://clival.com/news/india-to-demand-faster-inspection-of-pharma-firms-by-us-fda-raise-export-regulations-at-tpf-on-friday daily 0.8 https://clival.com/news/lupin-receives-approval-from-usfda-for-hypertension-tablets daily 0.8 https://clival.com/news/health-canada-accepts-for-review-a-nds-for-tofersen daily 0.8 https://clival.com/news/gsk-gets-positive-phase-iii-results-for-gepotidacin daily 0.8 https://clival.com/news/beactica-therapeutics-collaborates-with-ncats-to-focus-on-translation-of-novel-proteolysis-targeting-degraders-of-tead-to-treat-cancer daily 0.8 https://clival.com/news/xcell-biosciences-and-acgt-vector-collaborate-to-accelerate-development-of-cell-and-gene-therapies daily 0.8 https://clival.com/news/astrazeneca-announces-approval-of-lynparza-in-japan daily 0.8 https://clival.com/news/johnson-johnson-submits-supplemental-biologics-license-application-and-new-drug-application-to-us-fda-seeking-approval-of-rybrevant-amivantamab-vmjw-plus-lazertinib-for-the-treatment-of-patients-with-egfr-mutated-non-small-cell-lung-cancer-nsclc daily 0.8 https://clival.com/news/luye-pharma-launches-zepzelca-in-regions-of-china daily 0.8 https://clival.com/news/simcere-pharma-novel-inhibitor-of-covid-19-3clpro-sim0417-received-a-second-clinical-trial-approval-in-china daily 0.8 https://clival.com/news/innovent-biologics-announces-fda-acceptance-of-nda-for-pemigatinib-in-patients daily 0.8 https://clival.com/news/biocytogen-eucure-biopharma-announce-the-completion-of-first-patient-dosing-for-phase-i-clinical-trial-of-yh004-anti-4-1bb-monoclonal-antibody-in-australia daily 0.8 https://clival.com/news/nuance-pharma-acquires-sino-health-to-further-strengthen-its-commercial-capabilities-and-expand-pipelines daily 0.8 https://clival.com/news/glenmark-launches-sacubitril-valsartan-tablets-in-india daily 0.8 https://clival.com/news/signpath-pharma-inc-announces-an-out-license-agreement-of-its-correqttm-technology-for-mitigation-of-qt-prolongation-with-rain-therapeutics-inc daily 0.8 https://clival.com/news/china-nmpa-approves-neurophths-ind-of-nr082-for-leber-hereditary-optic-neuropathy-gene-therapy daily 0.8 https://clival.com/news/moderna-escalating-dispute-with-nih-claims-government-had-no-role-in-key-vaccine-patent daily 0.8 https://clival.com/news/veranex-expands-european-medtech-capabilities-with-acquisition-of-medidee daily 0.8 https://clival.com/news/harbour-biomed-announces-strategic-partnership-with-viva-biotech-to-collaborate-on-incubating-innovative-biotech-start-ups daily 0.8 https://clival.com/news/ascletis-announces-poster-presentation-of-phase-i-single-dose-study-of-asc43f-for-nash-at-aasld-annual-meeting-2022 daily 0.8 https://clival.com/news/vividion-therapeutics-starts-phase-i-clinical-trial-in-advanced-solid-tumors-with-keap1-activator daily 0.8 https://clival.com/news/boehringers-spevigo-gets-expanded-indication-approval daily 0.8 https://clival.com/news/venus-remedies-receives-philippines-marketing-approval-for-six-chemotherapy-drugs daily 0.8 https://clival.com/news/zydus-gets-us-fda-approval-to-market-generic-colestipol-hcl-tablets daily 0.8 https://clival.com/news/akesos-ivonescimab-pd-1vegf-bispecific-antibody-ak112-granted-breakthrough-therapy-designation-for-i-o-resistance-nsclc-patients-in-china daily 0.8 https://clival.com/news/karnataka-directorate-of-ayush-expedites-process-for-online-issue-of-manufacturing-licenses daily 0.8 https://clival.com/news/mannkind-completes-phase-1-trial-of-nintedanib-dpi-for-pulmonary-fibrotic-diseases daily 0.8 https://clival.com/news/galdermas-regulatory-filing-acceptance-for-nemolizumab daily 0.8 https://clival.com/news/ema-recommends-marketing-approval-for-abbvies-mirvetuximab-soravtansine daily 0.8 https://clival.com/news/astrazeneca-daiichi-sankyos-tropion-breast01-phase-iii-trial-of-datopotamab-deruxtecan daily 0.8 https://clival.com/news/dxvx-plans-to-make-a-license-in-agreement-of-ovm-200-and-conduct-clinical-trials-in-asia daily 0.8 https://clival.com/news/johnson-johnson-innovation-announces-collaboration-with-singapore-economic-development-board-to-help-transform-singapore-life-science-innovation-ecosystem daily 0.8 https://clival.com/news/telix-to-acquire-british-columbia-based-burnaby daily 0.8 https://clival.com/news/life-molecular-imaging-and-sinotau-pharmaceutical-group-announce-regulatory-approval-for-amyloid-pet-imaging-radiopharmaceutical-neuraceq-in-china daily 0.8 https://clival.com/news/nih-launches-clinical-trial-of-mrna-nipah-virus-vaccine daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-morphosys-tulmimetostat-to-treat-patients-with-endometrial-cancer daily 0.8 https://clival.com/news/merck-gets-us-fda-approval-for-keytruda-plus-pemetrexed-platinum-chemotherapy daily 0.8 https://clival.com/news/neotx-announces-successful-first-stage-completion-of-its-phase-2a-clinical-trial-of-naptumomab-estafenatox-nap-in-combination-with-docetaxel-in-advanced-non-small-cell-lung-cancer-nsclc daily 0.8 https://clival.com/news/realta-life-sciences-announces-fda-orphan-drug-designation-for-pic1-for-the-treatment-of-hypoxic-ischemic-encephalopathy daily 0.8 https://clival.com/news/highfield-biopharmaceuticals-announces-first-patient-dosed-in-phase-1b2-trial-of-hf1k16-for-recurrent-and-refractory-glioma daily 0.8 https://clival.com/news/new-antibiotic-drug-by-researchers-in-hong-kong-receives-approval-for-clinical-trials-in-humans daily 0.8 https://clival.com/news/fractyl-glp-1-obesity-gene-therapy-outdoes-semaglutide-for-weight-loss-in-mice daily 0.8 https://clival.com/news/opiant-pharma-completes-enrollment-in-phase-2-trial-of-opnt002-nasal-naltrexone-in-patients-with-alcohol-use-disorder daily 0.8 https://clival.com/news/amylyx-gets-first-approval-for-als-drug-from-canada daily 0.8 https://clival.com/news/daiichi-sankyo-submits-snda-to-japan-mhlw-for-ezharmia-to-treat-patients-with-peripheral-t-cell-lymphoma daily 0.8 https://clival.com/news/novartis-key-multiple-sclerosis-product-gilenya-gets-approval-in-china daily 0.8 https://clival.com/news/jazz-pharma-inks-agreement-with-redx-pharma daily 0.8 https://clival.com/news/cerecin-inks-partnership-with-agency-for-science-technology-and-research-institute-of-molecular-and-cell-biology-to-advance-rd-in-neurological-disorders daily 0.8 https://clival.com/news/cancervax-enters-agreement-with-flashpoint-therapeutics-for-research daily 0.8 https://clival.com/news/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-in-the-us daily 0.8 https://clival.com/news/dr-reddys-pat-up-76-in-q4-soft-launches-hcq-in-india daily 0.8 https://clival.com/news/allergan-molecular-partners-announce-us-fda-accepts-bla-ema-validates-maa-for-abicipar-pegol-in-patients-with-neovascular-wet-amd daily 0.8 https://clival.com/news/novartis-phase-iiib-exchange-expand-trials-show-mayzent-to-be-safe-treatment-option-in-patients-with-spms daily 0.8 https://clival.com/news/teva-jiangsu-nhwa-partners-to-distribute-austedo daily 0.8 https://clival.com/news/eisai-biogen-announce-us-fda-grants-traditional-approval-of-leqembi-to-treat-alzheimers-disease daily 0.8 https://clival.com/news/recbio-announces-phase-iii-trial-progress-of-recombinant-hpv-9-valent-vaccine daily 0.8 https://clival.com/news/china-pharma-holdings-inc-announced-the-acquisition-of-dry-eye-disease-therapeutic-device-project daily 0.8 https://clival.com/news/orgovyx-relugolix-tablets-intended-for-the-treatment-of-advanced-hormone-sensitive-prostate-cancer-will-be-included-in-swedens-medical-benefit-system daily 0.8 https://clival.com/news/hexagon-nutrition-gets-sebis-nod-to-garner-rs-600-cr-via-ipo daily 0.8 https://clival.com/news/us-fda-grants-510k-clearance-and-ce-mark-approval-for-norlase-echo-green-pattern-laser daily 0.8 https://clival.com/news/chimeron-bio-selects-mfg-partner-fujifilm-diosynth-biotechnologies daily 0.8 https://clival.com/news/sk-biopharmas-european-partner-angelini-pharma-introduces-cenobamate-in-france daily 0.8 https://clival.com/news/aimil-pharma-launches-ayurveda-based-beauty-product daily 0.8 https://clival.com/news/biotheus-and-hansoh-pharma-prolong-partnership-for-egfrcmet-antibody daily 0.8 https://clival.com/news/new-mpox-vaccine-being-tested-in-the-uk daily 0.8 https://clival.com/news/lebanon-health-ministry-grants-emergency-use-authorization-to-russian-sputnik-v-vaccine-against-coronavirus daily 0.8 https://clival.com/news/inoviq-and-promega-enter-into-global-joint-marketing-agreement daily 0.8 https://clival.com/news/aurisco-collaborates-with-cytiva-to-build-first-oligo-flexfactory-in-china daily 0.8 https://clival.com/news/celgene-steps-back-from-1bn-sutro-acquisition daily 0.8 https://clival.com/news/over-2900-drugs-found-to-be-substandard-422-spurious-in-tests-conducted-in-2022-23-govt daily 0.8 https://clival.com/news/eli-lilly-daiichi-sankyo-ink-commercialization-agreement-in-japan-for-anti-cgrp-antibody-galcanezumab-to-treat-migraine daily 0.8 https://clival.com/news/ono-pharmaceutical-enters-into-drug-discovery-collaboration-agreement-with-twist-bioscience daily 0.8 https://clival.com/news/hetero-launches-generic-bictegravir-combination-therapy-in-india daily 0.8 https://clival.com/news/unichem-labs-gets-us-fda-approval-for-generic-cordarone-tablets daily 0.8 https://clival.com/news/domain-collabs-with-chime-for-new-anti-ccr8-antibody daily 0.8 https://clival.com/news/eu-drug-regulator-approves-use-of-bavarian-nordics-mpox-vaccine-imvanex-for-adolescents daily 0.8 https://clival.com/news/sonivie-gets-ide-approval-from-us-fda-for-reduced1-pilot-study-to-treat-hypertension-with-renal-artery-denervation-tivus-technology daily 0.8 https://clival.com/news/nurexone-secures-eureka-grant-for-collaborative-partnership-to-expand-to-chronic-spinal-cord-injury-therapy daily 0.8 https://clival.com/news/alexion-completes-purchase-and-licence-agreement-for-early-stage-rare-disease-gene-therapy-portfolio-from-pfizer daily 0.8 https://clival.com/news/eisai-new-fine-granule-formulation-of-anti-epileptic-drug-fycompa-launched-in-japan daily 0.8 https://clival.com/news/addex-terminates-phase-2b3-study-of-dipraglurant-in-patients-with-dyskinesia-associated-with-parkinsons-disease-due-to-slow-recruitment-rate daily 0.8 https://clival.com/news/ascletis-announces-phase-iib-trial-results-of-subcutaneous-pd-l1-antibody-envafolimab-in-patients-with-chronic-hepatitis-b-chb-at-an-oral-parallel-session-of-ilc-2022 daily 0.8 https://clival.com/news/xeltis-receives-ide-approval-from-fda-for-initiation-of-us-pivotal-trial-for-axess daily 0.8 https://clival.com/news/senhwas-silmitasertib-receives-us-fda-orphan-drug-designation-for-the-treatment-of-medulloblastoma daily 0.8 https://clival.com/news/china-nmpa-approves-harbour-biomeds-ind-application-to-begin-phase-1-trial-of-b7h4x4-1bb-bispecific-antibody daily 0.8 https://clival.com/news/roche-blueprint-take-on-lilly-with-fda-approval-for-ret-cancer-drug-gavreto daily 0.8 https://clival.com/news/blacksmith-medicines-to-merge-with-forge-therapeutics-to-create-leading-company-developing-medicines-targeting-metalloenzymes daily 0.8 https://clival.com/news/european-commission-grants-marketing-approval-for-modernas-mresvia daily 0.8 https://clival.com/news/us-fda-approves-oncosecs-ind-application-to-initiate-phase-1-trial-of-corvax12-to-treat-covid-19 daily 0.8 https://clival.com/news/dr-reddy-s-acquires-trademark-rights-of-breast-cancer-drug-primcyv-from-pfizer-to-use-in-india daily 0.8 https://clival.com/news/novartis-expands-zolgensma-manufacturing-capacity-with-approval-of-multi-product-north-carolina-facility daily 0.8 https://clival.com/news/lilly-sales-surge-on-obesity-diabetes-drug-demand daily 0.8 https://clival.com/news/amgen-presents-new-research-in-early-psoriatic-arthritis-at-acr-2023 daily 0.8 https://clival.com/news/dare-bioscience-reports-positive-topline-results-from-dare-pdm1-phase-1-clinical-study daily 0.8 https://clival.com/news/pharmakure-receives-uk-mhra-nod-to-begin-phase-2a-study-of-pk051-to-treat-mild-cognitive-impairment-due-to-alzheimers-disease daily 0.8 https://clival.com/news/ec-approves-roches-xofluza-to-treat-and-prevent-influenza-in-children-aged-one-year-and-above daily 0.8 https://clival.com/news/modalis-announces-partnership-with-ginkgo-bioworks daily 0.8 https://clival.com/news/twist-bioscience-signs-antibody-discovery-collaboration-with-medisix-therapeutics-to-develop-t-cell-therapies daily 0.8 https://clival.com/news/lumos-pharma-inks-clinical-collaboration-with-mgh-to-evaluate-oral-lum-201-in-nonalcoholic-fatty-liver-disease daily 0.8 https://clival.com/news/aleph-farms-increases-production-capabilities-with-vbl-therapeutics-facility-acquisition-and-esco-aster-partnership daily 0.8 https://clival.com/news/cellorigin-biotech-collaborates-with-qilu-pharma-to-develop-off-the-shelf-car-imac-cell-therapy daily 0.8 https://clival.com/news/denovo-biopharma-receives-us-fda-fast-track-designation-for-liafensine daily 0.8 https://clival.com/news/veru-reaches-full-enrollment-for-phase-2b-quality-study-of-enobosarm-for-obesity daily 0.8 https://clival.com/news/lupin-digital-health-introduces-digital-therapeutics-certificate-for-cardiologists-in-india-in-collaboration-with-acc daily 0.8 https://clival.com/news/teva-announces-launch-of-a-first-generic-version-of-revlimid daily 0.8 https://clival.com/news/zydus-gets-dcgi-approval-to-market-novel-rabies-vaccine-twinrab daily 0.8 https://clival.com/news/bone-therapeutics-signs-definitive-subscription-agreement-for-a-maximum-of-eur-5m-convertible-bonds-facility-with-abo daily 0.8 https://clival.com/news/oscotec-announces-topline-results-for-phase-2-trial-of-cevidoplenib daily 0.8 https://clival.com/news/bsv-collaborates-with-fogsi daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-midatech-pharma-mtx110-to-treat-recurrent-glioblastoma daily 0.8 https://clival.com/news/natco-launches-cut-price-versions-of-cancer-drug-ibrutinib-in-india daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-approval-for-lastacaft-ophthalmic-solution daily 0.8 https://clival.com/news/glenmark-launches-sitagliptin-for-adults-with-type-2-diabetes daily 0.8 https://clival.com/news/proteros-expands-oncology-collaboration-and-license-agreement-with-astrazeneca daily 0.8 https://clival.com/news/arkbio-soon-to-publish-phase-3-clinical-trial-results-of-ziresovir-for-rsv-infection daily 0.8 https://clival.com/news/neurop-receives-fda-orphan-drug-designation-for-np10679-for-treatment-of-subarachnoid-hemorrhage daily 0.8 https://clival.com/news/daiichi-sankyo-begins-patient-dosing-in-tropion-breast02-phase-3-trial-of-datopotamab-deruxtecan-in-patients-with-previously-untreated-metastatic-tnbc daily 0.8 https://clival.com/news/sgs-receives-who-pqt-approval-for-its-navi-mumbai-laboratory-bolstering-support-to-the-global-pharma-industry daily 0.8 https://clival.com/news/astrazenecas-imfinzi-plus-chemotherapy-gets-us-fda-approval-to-treat-patients-with-advanced-biliary-tract-cancer daily 0.8 https://clival.com/news/respirerx-pharmaceuticals-announces-collaboration-with-university-college-london-ucl daily 0.8 https://clival.com/news/novavax-receives-full-marketing-authorization-for-prototype-covid-19-vaccine-nuvaxovid-in-united-kingdom daily 0.8 https://clival.com/news/jjs-erleada-scores-metastatic-prostate-cancer-nod-in-battle-with-pfizer-astellas-xtandi daily 0.8 https://clival.com/news/malaysia-ew-group-enters-china-market-partnering-with-sinopharm daily 0.8 https://clival.com/news/roches-actemraroactemra-receives-us-fda-priority-review-status-to-treat-covid-19-in-hospitalised-adults daily 0.8 https://clival.com/news/micurx-pharma-receives-china-nmpa-approval-for-contezolid-to-treat-drug-resistant-bacterial-infection daily 0.8 https://clival.com/news/zumutor-biologics-inc-announces-fda-clearance-of-ind-application-of-zm008-a-novel-monoclonal-antibody-drug-against-multiple-solid-cancers daily 0.8 https://clival.com/news/dedalus-ibex-ink-partnership-to-bring-power-of-artificial-intelligence-to-digital-pathology daily 0.8 https://clival.com/news/merck-keytruda-gets-us-fda-approval-for-patients-with-resectable-nsclc-in-combo-with-chemotherapy-as-neoadjuvant-treatment daily 0.8 https://clival.com/news/hillstream-biopharma-announces-collaboration-with-sapien-biosciences-in-cancer-treatments daily 0.8 https://clival.com/news/forge-biologics-receives-us-fda-approval-to-initiate-phase-12-trial-of-aav-gene-therapy-fbx-101-to-treat-krabbe-disease daily 0.8 https://clival.com/news/sanofi-and-gsk-sign-agreements-with-the-government-of-canada-to-supply-up-to-72-million-doses-of-adjuvanted-covid-19-vaccine daily 0.8 https://clival.com/news/genprex-in-licenses-additional-gene-therapy-technologies-for-treatment-of-lung-cancer daily 0.8 https://clival.com/news/pfizer-begins-phase-3-study-of-mrna-based-influenza-vaccine daily 0.8 https://clival.com/news/everest-medicines-announces-new-drug-application-approval-by-the-pharmaceutical-administration-bureau-of-macau-for-nefecon-for-the-treatment-of-primary-iga-nephropathy daily 0.8 https://clival.com/news/japan-becomes-first-country-to-approve-ronapreve-casirivimab-and-imdevimab-for-the-treatment-of-mild-to-moderate-covid-19 daily 0.8 https://clival.com/news/usfda-issues-response-letter-for-new-drug-application-for-insulin-glargine-biocon daily 0.8 https://clival.com/news/gujarat-becomes-first-state-to-issue-online-licenses-of-medicines-through-newly-launched-fdca-mdmla-mobile-app daily 0.8 https://clival.com/news/nuvalent-announces-preliminary-phase-1-clinical-data-from-alkove-1-trial-for-patients-with-alk-positive-nsclc daily 0.8 https://clival.com/news/lupin-gets-eir-from-us-fda-for-its-api-manufacturing-facility-in-vizag daily 0.8 https://clival.com/news/nextcure-updates-interim-results-from-phase-2-portion-of-nc318-monotherapy-phase-12-trial daily 0.8 https://clival.com/news/us-fda-accepts-alnylams-nda-for-lumasiran-and-grants-priority-review-status-for-primary-hyperoxaluria-type-1 daily 0.8 https://clival.com/news/medlern-collaborates-with-aster-mims-calicut-to-provide-novel-resuscitation-training-to-hospital-staff daily 0.8 https://clival.com/news/innovent-presents-phase-ib-clinical-data-update-of-ibi110-anti-lag-3-monoclonal-antibody-at-the-2022-european-society-for-medical-oncology-immuno-oncology-congress daily 0.8 https://clival.com/news/astrazeneca-announces-approval-of-soliris-in-china daily 0.8 https://clival.com/news/sec-recommends-approval-for-johnson-johnson-tremfya-with-phase-iii-clinical-trial-waiver daily 0.8 https://clival.com/news/novartis-kymriah-car-t-cell-therapy-receives-us-fda-approval-to-treat-relapsed-or-refractory-follicular-lymphoma daily 0.8 https://clival.com/news/regor-begins-phase-2-trial-for-rgt-075 daily 0.8 https://clival.com/news/us-fda-approves-cognota-healthcare-blood-pressure-monitor-device-cognohealth-blood-pressure-monitor daily 0.8 https://clival.com/news/hightide-therapeutics-announces-end-of-phase-2-meeting-with-fda-and-agreement-to-proceed-to-phase-3-for-htd1801-for-the-treatment-of-psc daily 0.8 https://clival.com/news/healx-and-ovid-therapeutics-to-enter-strategic-partnership daily 0.8 https://clival.com/news/fda-approves-penbraya-the-first-and-only-vaccine-for-the-prevention-of-the-five-most-common-serogroups-causing-meningococcal-disease-in-adolescents daily 0.8 https://clival.com/news/zosano-pharma-announces-agreement-to-collaborate-with-mitsubishi-tanabe-pharma-corporation daily 0.8 https://clival.com/news/fda-approves-biogen-and-alkermes-multiple-sclerosis-drug daily 0.8 https://clival.com/news/evotec-completes-acquisition-of-central-glass-germany daily 0.8 https://clival.com/news/vazyme-signs-global-strategic-cooperation-agreement-with-azenta daily 0.8 https://clival.com/news/merck daily 0.8 https://clival.com/news/european-medicines-agency-validates-type-ii-variation-for-astellas-xtandi-enzalutamide-for-treatment-of-non-metastatic-hormone-sensitive-prostate-cancer-with-high-risk-biochemical-recurrence daily 0.8 https://clival.com/news/fda-approves-label-revision-for-brukinsa-zanubrutinib-in-chronic-lymphocytic-leukemia-cll daily 0.8 https://clival.com/news/ahammune-biosciences-in-partnership-with-veeda-clinical-research-announces-first-in-human-studies-for-new-vitiligo-drug daily 0.8 https://clival.com/news/us-fda-approves-astrazeneca-new-tablet-formulation-of-calquence-for-all-current-indications daily 0.8 https://clival.com/news/bdr-pharma-introduces-dcgi-approved-bdenza-oral-solution-for-treatment-of-prostate-cancer daily 0.8 https://clival.com/news/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-pivotal-study-of-alpha-dart daily 0.8 https://clival.com/news/ascletis-announces-ind-approval-of-oral-pd-l1-small-molecule-inhibitor-asc61-for-treatment-of-advanced-solid-tumors-by-china-nmpa daily 0.8 https://clival.com/news/granules-india-receives-us-fda-approval-for-gabapentin-tablets daily 0.8 https://clival.com/news/alembic-pharmaceuticals-gets-usfda-nod-for-anti-depressant-drug daily 0.8 https://clival.com/news/agilis-robotics-launches-groundbreaking-advancements daily 0.8 https://clival.com/news/redhill-biopharma-announces-positive-results-from-phase-23-study-of-oral-opaganib-to-treat-severely-ill-hospitalized-covid-19-patients daily 0.8 https://clival.com/news/roche-announces-positive-results-from-phase-iii-archway-study-of-pds-with-ranibizumab-to-treat-neovascular-amd daily 0.8 https://clival.com/news/allecra-therapeutics-and-shanghai-haini-pharmaceutical-announce-exclusive-licensing-agreement-for-cefepimeenmetazobactam-for-greater-china daily 0.8 https://clival.com/news/pfizer-reports-positive-results-from-phase-3-benegene-2-study-of-gene-therapy-fidanacogene-elaparvovec-to-treat-haemophilia-b daily 0.8 https://clival.com/news/alembics-associate-company-rhizen-pharma-inks-licensing-pact-with-curon-biopharma-for-tenalisib-in-greater-china daily 0.8 https://clival.com/news/canbridge-announces-approval-of-can108-for-rare-liver-disease-alagille-syndrome-under-early-and-pilot-implementation-policy-in-boao-lecheng-international-medical-tourism-pilot-zone daily 0.8 https://clival.com/news/sun-pharma-us-based-rockwell-medical-enter-into-licensing-pact-for-triferic-in-india daily 0.8 https://clival.com/news/us-fda-approves-darmiyan-prognostic-test-brainsee-for-predicting-likelihood-of-progression-to-alzheimer-dementia daily 0.8 https://clival.com/news/gardp-and-sumitomo-pharma-announce-partnership-in-search-for-new-antibiotics daily 0.8 https://clival.com/news/china-nmpa-approves-clinical-trial-of-innocares-btk-inhibitor-orelabrutinib-in-combo-with-r-chop-for-previously-untreated-patients-with-mantle-cel daily 0.8 https://clival.com/news/sanofi-to-acquire-clinical-stage-biopharma-company-inhibrx-for-approximately-17-billion daily 0.8 https://clival.com/news/bristol-myers-squibb-car-t-cell-therapy-breyanzi-gets-us-fda-approval-for-relapsed-or-refractory-lbcl-after-one-prior-therapy daily 0.8 https://clival.com/news/merck-announces-us-fda-acceptance-of-biologics-licence-application-for-keytruda daily 0.8 https://clival.com/news/indica-labs-collaborates-icaird-to-develop-ai-based-algorithm-for-automated-reporting-of-lymph-node-status-in-colon-cancer daily 0.8 https://clival.com/news/bristol-myers-phase-3-checkmate-67t-trial-of-subcutaneous-nivolumab-shows-noninferiority-compared-to-intravenous-opdivo-in-advancedmetastatic-ccrcc daily 0.8 https://clival.com/news/tonix-pharmaceuticals-enters-into-exclusive-worldwide-licensing-agreement-with-oyagen daily 0.8 https://clival.com/news/harbour-biomed-signs-strategic-collaboration-agreement-with-vir-biotechnology-to-develop-novel-therapies-for-immuno-oncology-and-infectious-diseases daily 0.8 https://clival.com/news/alembic-gets-usfda-nod-for-tizanidine-hydrochloride-capsules-used-to-treat-spasticity daily 0.8 https://clival.com/news/nemeras-preservative-free-multi-dose-eye-dropper-approved-in-brazil-for-aches-nsaids-and-dry-eye-formulations daily 0.8 https://clival.com/news/rhythm-pharmaceuticals-and-genpharm-announce-collaboration-to-provide-imcivree daily 0.8 https://clival.com/news/rallybio-announces-preliminary-phase-1-mad-data-of-rlyb116-to-treat-patients-with-complement-mediated-diseases daily 0.8 https://clival.com/news/eurolife-healthcare-acquires-intravenous-infusion-business-of-teva-hungary daily 0.8 https://clival.com/news/dyno-therapeutics-enters-collaboration-and-license-agreement-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-cns-diseases-and-liver daily 0.8 https://clival.com/news/bioarctic-announces-research-collaboration-with-eisai-regarding-ban2401 daily 0.8 https://clival.com/news/agomab-receives-us-fda-orphan-drug-designation-for-agmb-447-in-idiopathic-pulmonary-fibrosis daily 0.8 https://clival.com/news/logicbio-therapeutics-announces-strategic-collaboration-and-option-agreement-with-canbridge-pharmaceuticals-leveraging-gene-editing-and-gene-delivery daily 0.8 https://clival.com/news/sec-seeks-clinical-trial-data-on-indians-for-approval-of-astrazeneca-breast-cancer-drug-trastuzumab-deruxtecan daily 0.8 https://clival.com/news/specialised-therapeutics-partners-with-akeso-and-cttq-akeso-to-commercialise-new-anti-pd1-antibody-in-australia-southeast-asia daily 0.8 https://clival.com/news/pfizer-and-biontech-announce-collaboration-with-biovac-to-manufacture-and-distribute-covid-19-vaccine-doses-within-africa daily 0.8 https://clival.com/news/usgi-medical-gets-us-fda-nod-to-conduct-pivotal-study-of-pose20-incisionless-procedure-for-primary-obesity-treatment daily 0.8 https://clival.com/news/merck-announces-positive-results-from-phase-3-keynote-859-trial-of-keytruda-plus-chemotherapy-to-treat-patients-with-her2-negative-gastric-or-gej-adenocarcinoma daily 0.8 https://clival.com/news/dr-reddys-open-to-making-pfizer-covid-pill-post-deal-with-merck daily 0.8 https://clival.com/news/samsung-biologics-collaborates-with-pfizer daily 0.8 https://clival.com/news/us-fda-approves-neurocrine-biosciences-ingrezza-capsules-to-treat-chorea-associated-with-huntingtons-disease daily 0.8 https://clival.com/news/biovica-enters-partnership-with-it-health-fusion-to-commercialise-divitum-tka-assay-in-italy daily 0.8 https://clival.com/news/modex-therapeutics-inks-license-and-collaboration-agreement-with-merck-to-develop-epstein-barr-virus-vaccine-candidate daily 0.8 https://clival.com/news/gujarat-fdca-approves-59-product-licenses-to-37-new-cos-to-produce-azithromycin-for-sustainable-supplies-to-covid-19-patients daily 0.8 https://clival.com/news/peptidream-announces-new-research-and-collaboration-agreement-with-lilly-for-the-discovery-of-novel-peptide-drug-conjugates daily 0.8 https://clival.com/news/lexaria-bioscience-corporation-seeks-us-fda-nod-to-begin-phase-1b-hypertension-trial-hyper-h23-1-of-dehydratech-cbd daily 0.8 https://clival.com/news/lupin-introduces-cyanocobalamin-nasal-spray-in-united-states daily 0.8 https://clival.com/news/innovent-enters-into-clinical-trial-collaboration-with-remegen daily 0.8 https://clival.com/news/innovent-and-union-therapeutics-announce-first-subject-dosed-in-a-chinese-clinical-phase-i-study-of-the-novel-pde4-inhibitor-orismilast-ibi353 daily 0.8 https://clival.com/news/pci-biotech-and-mdimune-announce-research-collaboration-agreement daily 0.8 https://clival.com/news/roche-announces-positive-results-from-phase-iii-katherine-study-in-people-with-her2-positive-ebc-with-residual-invasive-disease-after-neoadjuvant-treatment daily 0.8 https://clival.com/news/nppa-to-fix-retail-price-of-certain-off-patent daily 0.8 https://clival.com/news/bayer-relaunches-antifungal-brand-canesten-in-india daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-to-market-for-penicillamine-tablets daily 0.8 https://clival.com/news/biocytogen-collaborates-with-fineimmune-to-develop-tcr-mimic-antibody-based-cell-therapy daily 0.8 https://clival.com/news/eurofins-launches-multiple-serological-assay-solutions-to-detect-antibodies-against-nucleocapsid-protein-of-coronavirus daily 0.8 https://clival.com/news/johnson-johnson-announces-collaboration-to-expand-manufacturing-capabilities-for-its-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/hitgen-and-mtpc-enter-into-license-agreement daily 0.8 https://clival.com/news/a-new-drug-could-revolutionize-the-treatment-of-neurological-disorders daily 0.8 https://clival.com/news/mahana-therapeutics-signs-agreement-with-consumer-health-division-of-bayer-to-commercialize-digital-therapeutics daily 0.8 https://clival.com/news/zenas-biopharma-launches-as-a-cross-border-biopharma-company daily 0.8 https://clival.com/news/alnylam-nets-fda-nod-for-oxlumo-its-3rd-rare-disease-drug-and-plans-unique-value-based-deals daily 0.8 https://clival.com/news/connect-biopharma-and-simcere-forge-exclusive-licensing-and-collaboration-deal-in-greater-china daily 0.8 https://clival.com/news/gilead-sciences-and-arcus-biosciences-expand-partnership daily 0.8 https://clival.com/news/roche-tecentriq-approved-by-european-commission-as-a-first-line-monotherapy-treatment-for-people-with-a-type-of-metastatic-non-small-cell-lung-cancer daily 0.8 https://clival.com/news/gsk-announces-125-bn-settlement-between-viiv-healthcare-gilead-on-patents-relating-to-dolutegravir daily 0.8 https://clival.com/news/avrobio-announces-agreement-to-sell-cystinosis-gene-therapy-program-for-875-million daily 0.8 https://clival.com/news/lupin-launches-generic-drug-to-treat-wilsons-disease-in-us-market daily 0.8 https://clival.com/news/coronil-has-been-awarded-copp-licence-as-per-who-gmp-patanjali daily 0.8 https://clival.com/news/cstone-pharmaceuticals-announced-the-ind-approval-of-cs5001-a-potential-global-best-in-class-ror1-targeting-adc-by-the-us-food-and-drug-administration daily 0.8 https://clival.com/news/ryvu-therapeutics-signs-a-grant-agreement-for-the-development-of-targeted-immuno-oncology-therapy daily 0.8 https://clival.com/news/ingenza-and-amplifica-collaborate-to-advance-novel-alopecia-treatments daily 0.8 https://clival.com/news/lifera-enters-into-strategic-collaboration-with-centogene daily 0.8 https://clival.com/news/tempus-announces-companion-diagnostic-collaboration-with-kartos-therapeutics daily 0.8 https://clival.com/news/laurus-labs-launches-pregabalin-caps-in-the-us-market daily 0.8 https://clival.com/news/bioduro-sundia-and-x-chem-enter-partnership-to-launch-del-services-in-china-for-the-discovery-of-new-small-molecule-drugs daily 0.8 https://clival.com/news/us-fda-approves-expanded-mri-labelling-for-abbotts-eterna-scs-system daily 0.8 https://clival.com/news/bristol-myers-announces-positive-results-from-phase-3-checkmate-816-trial-of-neoadjuvant-nivolumab-in-combo-with-chemotherapy-to-treat-resectable-nsclc daily 0.8 https://clival.com/news/roche-pd-l-cancer-immunotherapy-subcutaneous-injection-for-multiple-cancer-types-tecentriq-sc-receives-european-marketing-approval daily 0.8 https://clival.com/news/iontas-enters-new-antibody-optimisation-agreement-with-teva-pharma daily 0.8 https://clival.com/news/pfizer-opko-announce-us-fda-accepts-bla-for-somatrogon-to-treat-pediatric-patients-with-ghd daily 0.8 https://clival.com/news/eu-approves-enhertu-as-monotherapy-to-treat-adult-patients-with-her2-mutant-advanced-nsclc daily 0.8 https://clival.com/news/newomics-and-bruker-announce-collaborations-on-high-throughput-bioanalysis daily 0.8 https://clival.com/news/thermo-fisher-to-acquire-clinical-research-organization-ppd-for-us-174-billion daily 0.8 https://clival.com/news/bioshin-gets-china-nmpa-nod-to-begin-clinical-trial-of-new-glutamate-modulator-troriluzole-to-treat-obsessive-compulsive-disorder daily 0.8 https://clival.com/news/astrazeneca-says-lynparza-gets-eu-nod-to-treat-early-stage-breast-cancer daily 0.8 https://clival.com/news/fosun-kite-gains-first-car-t-cell-therapy-approval-in-china daily 0.8 https://clival.com/news/merck-announces-phase-3-trial-initiations-for-four-investigational-candidates-from-its-promising-haematology-and-oncology-pipeline daily 0.8 https://clival.com/news/gilead-galapagos-ink-10-year-global-rd-collaboration daily 0.8 https://clival.com/news/iovance-biotherapeutics-amtagvi-gains-fda-approval daily 0.8 https://clival.com/news/thermo-scientific-e-cfeg-enables-accelerated-cryo-em-discovery-with-high-resolution-data daily 0.8 https://clival.com/news/henlius-accord-receive-ema-approval-for-zercepac-trastuzumab-biosimilar daily 0.8 https://clival.com/news/enlivex-therapeutrics-receives-chinese-patent-for-allocetra-immunotherapy daily 0.8 https://clival.com/news/biogens-alzheimers-treatment-aduhelm-limited-to-clinical-trial-participants-in-the-us daily 0.8 https://clival.com/news/salipro-biotech-receives-european-patent daily 0.8 https://clival.com/news/us-fda-approves-leo-pharma-tralokinumab-ldrm-to-treat-atopic-dermatitis-in-paediatric-patients daily 0.8 https://clival.com/news/granules-india-gets-usfda-nod-for-generic-antidepressant-drug daily 0.8 https://clival.com/news/novartis-first-in-class-sirnatherapy-leqvio-gets-us-fda-approval-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year daily 0.8 https://clival.com/news/sensorion-receives-approval-for-cta-to-initiate-phase-12-trial-of-gene-therapy-candidate-sens-501-in-france daily 0.8 https://clival.com/news/suspected-fake-ozempic-linked-to-three-us-cases-of-hypoglycemia daily 0.8 https://clival.com/news/eu-approves-astrazeneca-and-daiichi-sankyo-enhertu-to-treat-patients-with-unresectable-or-metastatic-her2-low-metastatic-breast-cancer daily 0.8 https://clival.com/news/teijin-and-neurosigma-enter-into-exclusive-license-agreement daily 0.8 https://clival.com/news/boehringer-ingelheim-to-acquire-nbe-therapeutics-for-eur-118-billion daily 0.8 https://clival.com/news/mandaviya-virtually-launches-medtech-mitra daily 0.8 https://clival.com/news/nrx-pharma-seeks-us-fda-breakthrough-therapy-status-for-zyesami-in-patients-at-immediate-risk-of-death-from-covid-19-despite-treatment-with-remdesivir-and-other-approved-therapies daily 0.8 https://clival.com/news/gilead-sciences-soon-to-acquire-cymabay-therapeutics daily 0.8 https://clival.com/news/icmr-to-launch-adjunct-faculty-scheme-to-promote-bio-medical-research-in-the-country daily 0.8 https://clival.com/news/ahammune-biosciences-veeda-clinical-research-partner-to-initiate-first-in-human-studies-with-ab1001-to-treat-vitiligo daily 0.8 https://clival.com/news/european-union-approves-cidara-therapeutics-rezzayo-to-treat-invasive-candidiasis-in-adults daily 0.8 https://clival.com/news/astellas-pharma-seagens-padcev-receive-european-approval-to-treat-locally-advanced-or-metastatic-urothelial-cancer daily 0.8 https://clival.com/news/toragen-reports-positive-safety-data-update-from-cohort-2-of-its-phase-1-clinical-trial-of-tgn-s11 daily 0.8 https://clival.com/news/tyra-biosciences-initiates-patient-dosing-in-surf201-phase-1-study-of-tyra-200-and-provides-positive-updates-on-tyra-300 daily 0.8 https://clival.com/news/hummingbird-bioscience-merck-collaborate-to-evaluate-hmbd-001-in-combo-with-cetuximab-in-squamous-nsclc daily 0.8 https://clival.com/news/medgenome-announces-strategic-collaboration-in-parkinsons-disease-with-denali-therapeutics daily 0.8 https://clival.com/news/remegen-collaborates-with-innovent-bio daily 0.8 https://clival.com/news/novartis-pulls-out-of-mesoblast-deal daily 0.8 https://clival.com/news/biosyngens-bst02-the-worlds-first-til-therapy-for-liver-cancer-is-granted-an-ind-approval-by-fda daily 0.8 https://clival.com/news/cybin-announces-approval-of-first-in-human-dosing-of-its-proprietary-dmt-molecule-cyb004 daily 0.8 https://clival.com/news/hong-kong-regulatory-approves-antengene-s-nda-for-xpovio-to-treat-rr-multiple-myeloma daily 0.8 https://clival.com/news/zydus-cadila-receives-us-fda-tentative-marketing-approval-for-tofacitinib-er-tablets daily 0.8 https://clival.com/news/netris-pharma-orano-and-clb-ink-scientific-collaboration-to-develop-novel-antibody-radio-conjugate-therapies daily 0.8 https://clival.com/news/us-fda-approves-astrazeneca-imfinzi-in-combo-with-imjudo-plus-chemotherapy-to-treat-metastatic-nsclc daily 0.8 https://clival.com/news/boehringer-ingelheim-acquires-amal-therapeutics-significantly-enriching-its-cancer-immunology-portfolio-with-novel-cancer-vaccines-platform daily 0.8 https://clival.com/news/aurobindo-pharma-gets-usfda-nod-for-its-expectorant-tablets daily 0.8 https://clival.com/news/european-commission-approves-contract-with-biontech-pfizer-alliance daily 0.8 https://clival.com/news/northern-ireland-could-lose-half-its-veterinary-medicines daily 0.8 https://clival.com/news/fuzionaire-radioisotope-technologies-kk-and-nihon-medi-physics-enter-feasibility-study-agreement daily 0.8 https://clival.com/news/anti-cold-drug-combination-banned-for-kids-under-4-years-all-you-need-to-know daily 0.8 https://clival.com/news/sun-pharma-lupin-recall-drugs-in-us-over-manufacturing-issues-usfda daily 0.8 https://clival.com/news/dr-reddys-laboratories-announces-the-launch-of-lenalidomide-capsules-in-the-usa-with-two-of-six-strengths-eligible-for-first-to-market daily 0.8 https://clival.com/news/azd1222-us-phase-iii-trial-met-primary-efficacy-endpoint-in-preventing-covid-19-at-interim-analysis daily 0.8 https://clival.com/news/gsk-acquires-san-diego-based-elsie-biotechnologies-for-50-million daily 0.8 https://clival.com/news/merck-to-acquire-ophthalmology-focused-biotech-company-eyebio-for-3-billion daily 0.8 https://clival.com/news/orna-therapeutics-acquires-renagade-therapeutics-to-solidify-leadership-in-circular-rna-therapies daily 0.8 https://clival.com/news/everest-medicines-announces-that-spero-therapeutics-entered-into-licensing-agreement-with-pfizer-inc-for-spr206-in-ex-us-and-ex-asia-territories daily 0.8 https://clival.com/news/seres-therapeutics-receives-breakthrough-therapy-designation-for-ser-155 daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-johnson-johnsons-nipocalimab daily 0.8 https://clival.com/news/fda-grants-orphan-drug-designation-to-can-fites-namodenoson-for-pancreatic-cancer daily 0.8 https://clival.com/news/aurobindo-pharma-and-covaxx-sign-an-exclusive-agreement-to-develop-and-commercialize-covid-19-vaccine-ub-612-for-india-and-unicef daily 0.8 https://clival.com/news/akoya-neracare-partner-to-develop-immunoprint-test-for-melanoma daily 0.8 https://clival.com/news/biolinerx-ayrmid-ink-exclusive-license-agreement-to-commercialize-aphexda-through-gamida-cell daily 0.8 https://clival.com/news/kura-oncology-kyowa-kirin-ink-global-strategic-collaboration-to-commercialize-ziftomenib daily 0.8 https://clival.com/news/harbinger-health-announces-new-partnership-with-leading-cancer-center-to-accelerate-clinical-evidence-generation daily 0.8 https://clival.com/news/lokon-pharma-announces-collaboration-to-combine-load703-with-beigenes-tislelizumab daily 0.8 https://clival.com/news/chinese-medicine-drug-for-myofibrillar-myopathy-receives-orphan-drug-designation-by-us-fda daily 0.8 https://clival.com/news/gliapharm-sa-and-the-wyss-center-enter-collaboration-to-develop-new-therapies-for-alzheimers-disease daily 0.8 https://clival.com/news/sosei-group-announces-marketing-approval-for-pivlaz-clazosentan-sodium-150-mg-in-south-korea daily 0.8 https://clival.com/news/teva-reaches-agreement-with-rhode-island-to-settle-opioid-related-claims daily 0.8 https://clival.com/news/theralase-technologies-announces-update-on-phase-ii-bladder-cancer-clinical-study daily 0.8 https://clival.com/news/shandong-fontacea-announces-license-agreement-with-janssen-to-develop-and-commercialize-anti-il17a-monoclonal-antibody daily 0.8 https://clival.com/news/astrazeneca-launches-call-for-entries-to-the-2023-global-rd-postdoctoral-challenge daily 0.8 https://clival.com/news/us-fda-grants-emergency-use-authorization-to-roches-cobas-sars-cov-2-test-to-detect-novel-coronavirus daily 0.8 https://clival.com/news/alnylam-and-peptidream-enter-into-collaboration-agreement-to-discover-and-develop-peptide-sirna-conjugates-for-targeted-delivery-of-rnai-therapeutics daily 0.8 https://clival.com/news/boehringer-ingelheim-and-carthronix-announce-partnership-to-pursue-small-molecule-therapeutics-in-canine-oncology daily 0.8 https://clival.com/news/ractigen-secures-fda-rare-pediatric-disease-designation-for-rag-18 daily 0.8 https://clival.com/news/teva-concludes-nationwide-opioids-settlement-agreement daily 0.8 https://clival.com/news/fusion-pharma-partners-with-heidelberg-university-and-euratom daily 0.8 https://clival.com/news/combination-of-opdivo-cisplatin-and-gemcitabine-gets-approval daily 0.8 https://clival.com/news/cyxone-inks-api-deal-with-european-cdmo daily 0.8 https://clival.com/news/vizient-completes-acquisition-of-next-generation-cloud-based-pcm-software-preftech-or daily 0.8 https://clival.com/news/keymed-and-lepu-biopharma-jointly-announce-global-exclusive-licence-agreement-with-astrazeneca-for-cmg901 daily 0.8 https://clival.com/news/clivaligis-phase-1-treat-antibody-shows-high-response-rate-in-study daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-sobi-and-sanofi-efanesoctocog-alfa-for-haemophilia-a daily 0.8 https://clival.com/news/johnson-johnson-nipocalimab-granted-us-fda-breakthrough-therapy-designation-for-the-treatment-of-individuals-at-high-risk-for-severe-hemolytic-disease-of-the-fetus-and-newborn-hdfn daily 0.8 https://clival.com/news/pharmabcine-announces-first-patient-enrolled-and-dosed-in-the-phase-ii-clinical-trial-for-the-treatment-of-mtnbc daily 0.8 https://clival.com/news/pharmabcine-receives-ind-approval-from-the-korean-mfds-for-phase-i-clinical-trial-of-its-novel-tie2-agonistic-antibody-in-namd daily 0.8 https://clival.com/news/aldeyra-therapeutics-initiates-phase-2-clinical-trial-of-adx-2191-for-the-treatment-of-retinitis-pigmentosa daily 0.8 https://clival.com/news/micurx-receives-fda-qualified-infectious-disease-product-qidp-and-fast-track-designation-for-contezolid-and-contezolid-acefosamil daily 0.8 https://clival.com/news/palisade-bio-updates-on-strategic-collaboration-with-strand-life-sciences daily 0.8 https://clival.com/news/cipla-arm-to-acquire-remaining-stake-in-cipla-pharma-lanka daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-device-designation-for-spectral-medicals-toraymyxin-to-treat-endotoxemic-septic-shock daily 0.8 https://clival.com/news/hovione-partners-with-ripple-therapeutics-to-expand-epidel daily 0.8 https://clival.com/news/astellas-ramps-up-ma-buys-us-biotech-xyphos-for-as-much-as-665-million daily 0.8 https://clival.com/news/sun-pharma-launches-cequa-to-treat-dry-eye-disease-in-us daily 0.8 https://clival.com/news/repare-therapeutics-reports-updated-positive-safety-and-tolerability-results-from-phase-1-mythic-trial daily 0.8 https://clival.com/news/biocon-gets-usfda-nod-for-generic-product daily 0.8 https://clival.com/news/us-fda-accepts-nuvation-bios-ind-application-for-nuv-422-to-treat-highgrade-gliomas daily 0.8 https://clival.com/news/boehringer-ingelheim-eli-lilly-announce-ema-committee-recommends-approval-of-jardiance-to-treat-adults-with-heart-failure-with-reduced-ejection-frac daily 0.8 https://clival.com/news/european-commission-approves-abbvies-aquipta-for-preventive-treatment-of-migraine-in-adults daily 0.8 https://clival.com/news/ono-enters-into-a-multi-target-rd-collaboration-agreement-with-precisionlife daily 0.8 https://clival.com/news/pfizer-completes-acquisition-of-trillium-therapeutics daily 0.8 https://clival.com/news/sandoz-acquires-uk-based-medical-and-drug-delivery-device-company-coalesce daily 0.8 https://clival.com/news/apprehensions-loom-large-on-msmes-to-shutdown-units-with-revised-schedule-m-implementation-fope daily 0.8 https://clival.com/news/suven-pharmaceuticals-and-cohance-set-for-merger daily 0.8 https://clival.com/news/fda-approves-lupins-sevelamer-hydrochloride-tablets-800-mg daily 0.8 https://clival.com/news/roquette-soon-to-acquire-iff-pharma-solutions daily 0.8 https://clival.com/news/fda-grants-profounda-orphan-drug-designation-approval-for-treatment-of-treatment-of-invasive-candidiasis-with-miltefosine daily 0.8 https://clival.com/news/pacira-biosciences-agreement-with-premier-inc daily 0.8 https://clival.com/news/genfleet-therapeutics-announces-gfh009-granted-with-fda-fast-track-orphan-drug-designations-for-treating-rr-peripheral-t-cell-lymphomas-and-acute-myeloid-leukemia daily 0.8 https://clival.com/news/despite-trial-scare-traveres-filspari-gains-full-fda daily 0.8 https://clival.com/news/cst-and-cell-press-launch-cell-mentor-in-china daily 0.8 https://clival.com/news/supernus-announces-fda-approval-of-qelbreea daily 0.8 https://clival.com/news/charles-river-completes-acquisition-of-samdi-tech daily 0.8 https://clival.com/news/cipla-launches-generic-remdesivir-for-covid-19 daily 0.8 https://clival.com/news/rice-university-breakthrough-could-make-automated-dosing-systems-universal daily 0.8 https://clival.com/news/us-fda-clears-immpact-bios-ind-application-for-novel-bispecific-car-to-treat-aggressive-b-cell-lymphoma daily 0.8 https://clival.com/news/us-fda-accepts-precision-biosciences-ind-application-for-pbcar19b-to-treat-rr-non-hodgkin-lymphoma daily 0.8 https://clival.com/news/dksh-inks-agreement-to-acquire-two-pharma-brands-myonal-and-merislon-from-eisai-for-nine-markets-in-asia-pacific daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-q-biomeds-uttroside-b-for-liver-cancer-treatment daily 0.8 https://clival.com/news/sun-pharma-to-acquire-remaining-stake-in-taro-pharma daily 0.8 https://clival.com/news/antengene-announces-research-collaboration-with-celularity-to-evaluate-the-potential-therapeutic-synergy-of-combining-antengenes-best-in-class-bispecific-antibody-with-celularitys-natural-killer-cell-platform daily 0.8 https://clival.com/news/leo-pharma-gains-fda-nod-for-eczema-drug-adbry daily 0.8 https://clival.com/news/concr-launches-trial-using-digital-twins-for-outcome-prediction-in-breast-cancer daily 0.8 https://clival.com/news/innovent-anheart-announce-china-nmpa-accepts-nda-for-ros1-inhibitor-taletrectinib-to-treat-nsclc daily 0.8 https://clival.com/news/us-fda-accepts-and-grants-priority-review-status-to-astrazeneca-daiichi-sankyo-sbla-for-enhertu-to-treat-metastatic-her2-positive-solid-tumours daily 0.8 https://clival.com/news/scisparc-receives-approval-to-conduct-its-phase-iib-clinical-trial-for-sci-110-to-treat-tourette-syndrome daily 0.8 https://clival.com/news/china-approves-inhaled-vaccine-as-covid-19-booster-dose daily 0.8 https://clival.com/news/iterum-therapeutics-seeks-us-patent-for-composition-of-bilayer-tablet-of-sulopenem-etzadroxil-and-probenecid-and-its-related-uses daily 0.8 https://clival.com/news/takeda-partners-with-biological-e-for-dengue-vaccine daily 0.8 https://clival.com/news/cytodyn-gets-us-fda-nod-to-begin-phase-ii-oncology-trial-of-leronlimab daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-precigen daily 0.8 https://clival.com/news/astrazeneca-gets-into-partnership-to-enhance-respiratory-care-for-severe-asthma-patients daily 0.8 https://clival.com/news/novartis-receives-fda-breakthrough-therapy-designation-for-rare-disease-med daily 0.8 https://clival.com/news/totient-a-viva-biotech-portfolio-company-has-been-acquired-by-absci daily 0.8 https://clival.com/news/wuxi-advanced-therapies-partners-with-singapore-group-on-cell-therapy-production-tech daily 0.8 https://clival.com/news/kindeva-drug-delivery-to-acquire-ipharma-labs daily 0.8 https://clival.com/news/neutron-therapeutics-and-cosylab-announce-strategic-collaboration-to-bring-boron-neutron-capture-therapy-to-patients daily 0.8 https://clival.com/news/mercks-keytruda-snags-fda-nod-for-esophageal-cancer-as-stomach-cancer-label-hangs-in-the-balance daily 0.8 https://clival.com/news/bharat-biotechs-partner-ocugen-to-seek-full-approval-for-covaxin-in-us daily 0.8 https://clival.com/news/mtpa-gets-orphan-drug-exclusivity-for-radicava-ors daily 0.8 https://clival.com/news/evoq-therapeutics-and-amgen-expanding-collaboration daily 0.8 https://clival.com/news/pfizer-completes-acquisition-of-global-blood-therapeutics daily 0.8 https://clival.com/news/new-study-found-preventive-impact-in-adolescents-who-frequently-used-nerivio-for-abortive-treatment-of-migraine daily 0.8 https://clival.com/news/innovent-first-new-drug-application-of-mazdutide daily 0.8 https://clival.com/news/pfizer-talzenna-in-combo-with-xtandi-gets-european-approval-to-treat-patients-with-metastatic-castration-resistant-prostate-cancer daily 0.8 https://clival.com/news/pfizer-asks-for-formal-us-approval-of-oral-covid-treatment-paxlovid daily 0.8 https://clival.com/news/terumo-india-launches-treo-abdominal-stent-graft-system daily 0.8 https://clival.com/news/phasebio-pharmaceuticals-and-biovectra-enter-into-supply-agreement-to-support-development-and-commercialization-of-bentracimab daily 0.8 https://clival.com/news/cipla-receives-us-fda-approval-for-generic-nexium daily 0.8 https://clival.com/news/spero-therapeutics-ends-exclusive-license-pact-with-gsk-for-tebipenem-hbr daily 0.8 https://clival.com/news/eilean-therapeutics-acquires-ness-therapeutics daily 0.8 https://clival.com/news/biocon-climbs-4-as-pharma-giants-arm-launches-cancer-treatment-product-abevmy daily 0.8 https://clival.com/news/probiogen-mapp-collab-to-afucosylated-antibody daily 0.8 https://clival.com/news/sun-pharma-cosmo-expand-license-and-supply-agreements-for-winlevi-to-include-japan-australia-new-zealand-brazil-mexico-and-russia daily 0.8 https://clival.com/news/avicanna-inks-agreement-with-chilean-pharma-knop-laboratorios-to-supply-range-of-cannabinoid-based-api daily 0.8 https://clival.com/news/pharmamar-signs-lurbinectedin-licensing-and-commercialization-agreement-with-lotus-pharmaceutical-in-taiwan daily 0.8 https://clival.com/news/voydeya-gets-approval-as-add-on-therapy-to-ravulizumab-or-eculizumab daily 0.8 https://clival.com/news/daiichi-announces-positive-results-from-phase-12-trial-of-ds-5141-to-treat-duchenne-muscular-dystrophy daily 0.8 https://clival.com/news/alvotech-jamp-pharma-expand-exclusive-partnership-adding-two-biosimilar-candidates-for-canadian-market daily 0.8 https://clival.com/news/orion-bayer-prostate-cancer-drug-gets-fda-approval daily 0.8 https://clival.com/news/junshi-biosciences-phase-iii-jupiter-06-study-of-toripalimab-in-combo-with-chemotherapy-to-treat-escc-reaches-primary-endpoints daily 0.8 https://clival.com/news/bayer-collabs-with-samsung-for-sleep-disturbances-associated-with-menopause daily 0.8 https://clival.com/news/closed-loop-medicine-and-pharmanovia-enter-into-partnership daily 0.8 https://clival.com/news/ionis-and-astrazeneca-close-deal-to-develop-and-commercialize-eplontersen daily 0.8 https://clival.com/news/iks-health-acquires-aquity-solutions-to-provide-comprehensive-administrative-clinical-and-financial-services-for-healthcare-organizations-in-us daily 0.8 https://clival.com/news/us-fda-approves-astellas-veozah-for-treatment-of-vasomotor-symptoms-due-to-menopause daily 0.8 https://clival.com/news/halozyme-to-acquire-specialty-pharmaceutical-company-antares-pharma-for-960-million daily 0.8 https://clival.com/news/nurix-therapeutics-granted-fast-track-designation-by-the-us-fda-for-nx-5948-in-the-treatment-of-relapsed-or-refractory-cll-and-sll daily 0.8 https://clival.com/news/tencent-deepens-collaboration-with-who-to-combat-covid-19 daily 0.8 https://clival.com/news/gc-biopharma-announces-fda-orphan-drug-designation-for-gc1126a daily 0.8 https://clival.com/news/novartis-fabhalta-phase-iiib-improved-hemoglobin-in-pnh-patients daily 0.8 https://clival.com/news/foghorn-therapeutics-to-present-clinical-data-from-phase-1-study-of-fhd-286-at-ash-annual-meeting-in-san-diego daily 0.8 https://clival.com/news/pharmalink-acquires-pharmareturns daily 0.8 https://clival.com/news/cynata-finishes-patient-enrolment-for-phase-1-trial-of-cyp-006tk daily 0.8 https://clival.com/news/merck-strengthens-immunology-pipeline-with-acquisition-of-prometheus-biosciences daily 0.8 https://clival.com/news/ec-approves-pfizers-velsipity-for-ulcerative-colitis daily 0.8 https://clival.com/news/daiichi-sankyo-to-present-new-clinical-research-across-its-dxd-adc-portfolio-in-multiple-types-of-cancer-at-esmo23-congress daily 0.8 https://clival.com/news/fda-approves-first-drug-for-treatment-of-peanut-allergy-for-children daily 0.8 https://clival.com/news/innocare-pharma-begins-patient-dosing-in-phase-iii-registrational-trial-of-orelabrutinib-for-treatment-of-itp-in-china daily 0.8 https://clival.com/news/bioxcel-receives-european-patent-for-sublingual-dexmedetomidine daily 0.8 https://clival.com/news/us-fda-granted-accelerated-approval-to-novartis-tafinlar-mekinist-for-first-tumour-agnostic-indication-for-braf-v600e-solid-tumours daily 0.8 https://clival.com/news/aarvik-therapeutics-announces-a-global-novel-payload-agreement-with-nj-bio-inc daily 0.8 https://clival.com/news/ultromics-partners-with-pfizer-to-expedite-development-of-echo-ai-algorithm-to-detect-cardiac-amyloidosis daily 0.8 https://clival.com/news/us-fda-approves-jazzs-xywav-oral-solution-for-cataplexy-excessive-daytime-sleepiness-associated-with-narcolepsy daily 0.8 https://clival.com/news/amoydx-collaborates-with-astrazeneca-for-multiple-companion-diagnostics-in-china daily 0.8 https://clival.com/news/lupin-gets-health-canada-marketing-approval-for-generic-spiriva-to-treat-copd daily 0.8 https://clival.com/news/beigene-and-eusa-pharma-announce-china-nmpa-approval-of-qarzibaa-dinutuximab-beta-for-patients-with-high-risk-neuroblastoma daily 0.8 https://clival.com/news/glenmark-pharma-gets-usfda-nod-for-prostate-cancer-treatment-drug daily 0.8 https://clival.com/news/cufa-adj-diabetes-brasil-and-merck-promote-red-card-day-for-diabetes-with-blood-glucose-testing-in-heliopolis daily 0.8 https://clival.com/news/sermonix-pharma-receives-chinese-approval-of-ind-application-for-isofoxifene daily 0.8 https://clival.com/news/dr-reddys-laboratories-announces-settlement-of-us-revlimid-lenalidomide-capsules-patent-litigation-with-celgene-a-bristol-myers-squibb-company daily 0.8 https://clival.com/news/neurocline-biosciences-and-takeda-announce-collaboration-to-develop-and-commercialize-drug-candidates-for-mental-illness daily 0.8 https://clival.com/news/fda-advisory-committee-votes-in-support-of-approval-for-pfizers-vaccine-candidate-to-help-prevent-rsv-in-infants-through-maternal-immunization daily 0.8 https://clival.com/news/yiling-pharma-receives-first-international-approval-for-herbal-covid-19-medicine daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-privo-technologies-cisplatin-to-treat-cis-of-anterior-23-of-oral-cavity daily 0.8 https://clival.com/news/gannex-announces-positive-clinical-trial-results-in-overweight-obese-subjects-for-thr daily 0.8 https://clival.com/news/fda-grants-breakthrough-therapy-designation-to-pfizers-group-b-streptococcus-vaccine-candidate daily 0.8 https://clival.com/news/menarini-obtains-european-commission-approval-for-the-use-of-elzonris-tagraxofusp-in-the-treatment-of-plasmacetoid-blast-dendritic-cell-neoplasm-nc daily 0.8 https://clival.com/news/helsinn-group-launches-akynzeo-injection-in-us-market daily 0.8 https://clival.com/news/subcutaneously-administered-pd-l1-antibody-asc22-envafolimab-is-safe-and-well-tolerated-in-phase-iia-hbv-study daily 0.8 https://clival.com/news/qiagen-enhances-syndromic-testing-in-malaysia-with-mda-approval daily 0.8 https://clival.com/news/maharashtras-plan-to-buy-drug-from-bangladesh-irks-local-companies daily 0.8 https://clival.com/news/exero-medicals-smart-sensor-granted-fda-breakthrough-designation daily 0.8 https://clival.com/news/merck-keytruda-gets-european-approval-for-adjuvant-treatment-for-adults-with-nsclc-at-high-risk-of-recurrence-following-complete-resection-and-platinum-based-chemotherapy daily 0.8 https://clival.com/news/jupiter-hospital-launches-bone-marrow-transplant-centre-in-pune daily 0.8 https://clival.com/news/baxter-expands-pharma-portfolio-with-launching-five-injectable-products-in-us daily 0.8 https://clival.com/news/everest-medicines-announces-acceptance-of-new-drug-application-by-china-nmpa-for-xerava-for-the-treatment-of-complicated-intra-abdominal-infections daily 0.8 https://clival.com/news/ema-recommends-approval-of-mercks-keytruda-plus-padcev daily 0.8 https://clival.com/news/wuxi-xdc-and-hkstp-partner-to-foster-growth-in-hong-kong-bioconjugate-drug-sector daily 0.8 https://clival.com/news/dr-reddys-laboratories-launches-sorafenib-tablets-in-uk-market daily 0.8 https://clival.com/news/glenmark-receives-us-fda-approval-for-generic-vimpat-tablets daily 0.8 https://clival.com/news/sihuan-pharma-obtains-production-approval-for-gabapentin-capsules daily 0.8 https://clival.com/news/cipla-all-set-to-launch-favipiravir-drug-for-treatment-of-covid-patients-csir daily 0.8 https://clival.com/news/obi-992-secures-fda-approval-to-commence-phase-iii-clinical-trials daily 0.8 https://clival.com/news/alembic-pharma-gets-final-usfda-nod-for-infection-treatment-drug daily 0.8 https://clival.com/news/pierre-fabre-selects-agc-biologics-as-cdmo-to-manufacture-the-orphan-drug-er-004 daily 0.8 https://clival.com/news/thermo-fisher-starts-mycoplasma-and-biosafety-testing daily 0.8 https://clival.com/news/rockwells-partner-drogsan-pharma-seeks-marketing-approval-for-triferic-avnu-from-turkish-mmda daily 0.8 https://clival.com/news/clene-nanomedicine-announces-positive-results-from-phase-2-covid-19-study-of-cnm-znag daily 0.8 https://clival.com/news/nevakar-and-zhaoke-ophthalmology-enter-into-licensing-agreement-for-nvk-002-atropine-for-the-treatment-of-the-progression-of-myopia-in-children daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval daily 0.8 https://clival.com/news/mercks-phase-3-keynote-671-trial-of-keytruda-meets-primary-endpoint-of-efs-in-patients-with-resectable-stage-ii-iiia-or-iiib-nsclc daily 0.8 https://clival.com/news/asc40-tvb-2640-phase-2-nash-trial-completed-patient-enrollment-in-china daily 0.8 https://clival.com/news/cardiac-dimensions-receives-australian-tga-approval-of-carillon-system-to-treat-functional-mitral-regurgitation daily 0.8 https://clival.com/news/enlivex-receives-authorizations-from-french-and-belgian-regulatory-agencies-to-expand-its-phase-ii-sepsis-clinical-trial-into-france-and-belgium daily 0.8 https://clival.com/news/glaxosmithklines-jemperli-receives-us-fda-approval-for-women-with-recurrent-or-advanced-dmmr-endometrial-cancer daily 0.8 https://clival.com/news/lupin-launches-us-fda-approved-generic-vivlodex-capsules daily 0.8 https://clival.com/news/efa-technologies-goes-in-brazilian-market-post-anvisa-approval daily 0.8 https://clival.com/news/ucb-and-ariceum-therapeutics-sign-a-strategic-research-collaboration daily 0.8 https://clival.com/news/everest-medicines-announces-first-drug-approval-of-trodelvy daily 0.8 https://clival.com/news/alembic-gets-usfda-nod-for-ointment-to-treat-skin-disease daily 0.8 https://clival.com/news/sri-international-announces-collaboration-agreement-with-janssen daily 0.8 https://clival.com/news/ractigen-therapeutics-advances-to-clinical-stage-with-revolutionary-sarna-medication-rag-01 daily 0.8 https://clival.com/news/pfizer-voluntarily-withdraws-oxbryta-from-worldwide-markets daily 0.8 https://clival.com/news/nih-launches-programme-to-advance-research-led-by-native-american-communities-on-substance-use-and-pain daily 0.8 https://clival.com/news/roche-joins-the-fda-accelerated-approval-revamp-team-nixing-a-tecentriq-bladder-cancer-nod daily 0.8 https://clival.com/news/us-fda-accepts-caliways-cbl-514-ind-application-for-phase-2-study-to-treat-dercums-disease daily 0.8 https://clival.com/news/cordenpharma-and-certest-ink-partnership-on-ionizable-lipids-in-lnp-formulation daily 0.8 https://clival.com/news/radiopharm-theranostics-expands-supply-agreement-with-terthera-for-terbium-161-isotope-use-in-prostate-cancer daily 0.8 https://clival.com/news/south-african-firm-aspen-to-acquire-sandoz-china-business daily 0.8 https://clival.com/news/arzeda-announces-collaboration-with-w-l-gore-and-associates-to-drive-innovation-in-materials-research-with-designer-proteins daily 0.8 https://clival.com/news/life-spines-plateau-x-ti-lateral-lumbar-spacer-system-receives-us-fda-marketing-approval daily 0.8 https://clival.com/news/novo-nordisks-ozempic-20-mg-receives-us-fda-approval-to-treat-type-2-diabetes daily 0.8 https://clival.com/news/fda-withdraws-accelerated-approval-for-pepaxto daily 0.8 https://clival.com/news/takeda-announces-us-fda-grants-priority-review-for-new-drug-application-for-mobocertinib-tak-788-as-a-treatment-for-egfr-exon20-insertion-metastati daily 0.8 https://clival.com/news/glenmark-gets-russian-health-ministrys-nod-to-market-allergic-rhinitis-tablets daily 0.8 https://clival.com/news/abbott-recalls-batch-of-thyronorm-tablets daily 0.8 https://clival.com/news/sanofi-to-discontinue-phase-3-carmen-lc03-trial-of-tusamitamab-ravtansine daily 0.8 https://clival.com/news/briori-biotech-inc-granted-patent-for-topical-formulation-of-vioxx daily 0.8 https://clival.com/news/jcr-pharmaceuticals-announces-research-collaboration-option-and-license-agreement-with-alexion-to-develop-a-therapy-using-j-brain-cargo-for-neurodegenerative-disease daily 0.8 https://clival.com/news/proscia-and-visiopharm-partner-to-deliver-ai-powered-pathology-to-drive-insight-in-cancer-diagnosis daily 0.8 https://clival.com/news/bactiguard-ab-and-zimmer-biomet-expand-global-license-partnership daily 0.8 https://clival.com/news/nih-begins-patient-dosing-in-phase-1-trial-of-universal-flu-vaccine-candidate daily 0.8 https://clival.com/news/henlius-novel-anti-pd-1-mab-hansizhuang-serplulimab-approved-for-the-treatment-of-es-sclc daily 0.8 https://clival.com/news/simulations-plus-extends-agreement-with-niehs daily 0.8 https://clival.com/news/biontech-begins-patient-dosing-in-phase-2-trial-of-mrna-based-bnt111-in-combo-with-libtayo-to-treat-rr-advanced-melanoma daily 0.8 https://clival.com/news/ainos-nisshinbo-micro-devices-inabata-begin-phase-2-of-voc-co-development-powered-by-ai-nose-accelerating-the-digitalization-of-smell daily 0.8 https://clival.com/news/glenmark-inks-licensing-pact-with-hikma-for-commercialisation-of-nasal-spray-ryaltris-in-us daily 0.8 https://clival.com/news/neovii-fosun-pharma-ink-exclusive-agreement-to-develop-and-commercialize-grafalon-in-china daily 0.8 https://clival.com/news/nestle-health-science-collaborates-with-iapen-to-strengthen-awareness-on-gut-health-management daily 0.8 https://clival.com/news/temasek-to-acquire-an-additional-41-stake-in-manipal-health-enterprises daily 0.8 https://clival.com/news/chugai-obtains-japanese-approval-for-phesgo-the-fixed-dose-subcutaneous-combination-of-perjeta-herceptin-for-her2-positive-breast-and-colorectal-cancer daily 0.8 https://clival.com/news/aviceda-gets-us-fda-clearance-to-begin-phase-2-trials-of-avd-104-for-treatment-of-geographic-atrophy-from-macular-degeneration daily 0.8 https://clival.com/news/hataali-and-reef-group-enter-into-strategic-partnership-for-atmp-smart-labs daily 0.8 https://clival.com/news/bayers-phase-i-trial-bay3498264-for-kras-mutated-advanced-tumors daily 0.8 https://clival.com/news/eisai-and-seikagaku-enter-into-agreement-for-the-co-development-and-marketing-alliance-of-si-613-a-treatment-of-osteoarthritis-in-china daily 0.8 https://clival.com/news/us-fda-approves-marinus-pharmas-lead-drug-to-treat-genetic-disorder daily 0.8 https://clival.com/news/iveric-bio-delsitech-ink-license-agreement-to-develop-commercialize-sustained-release-zimura daily 0.8 https://clival.com/news/mandala-phase-iii-trial-of-pt027-a-new-fdc-of-albuterol-and-budesonide daily 0.8 https://clival.com/news/us-fda-approves-bayers-astepro-allergy-nasal-spray-to-treat-respiratory-allergies-in-us daily 0.8 https://clival.com/news/bayer-to-acquire-exclusive-license-from-cedilla-therapeutics-on-selective-inhibitors-in-pre-clinical-precision-oncology daily 0.8 https://clival.com/news/bristol-myers-squibb-2seventy-bio-announce-positive-results-from-karmma-3-phase-3-study-of-abecma-compared-with-standard-combination-regimens-to-treat-multiple-myeloma daily 0.8 https://clival.com/news/akums-drugs-ventures-into-nasal-sprays-market daily 0.8 https://clival.com/news/merck-and-gphl-collaborate-on-business-innovation-and-development daily 0.8 https://clival.com/news/us-fda-approves-abbvies-dalvance-to-treat-absssi-in-pediatric-patients daily 0.8 https://clival.com/news/swissmedic-approves-vfmcrp-and-caras-kapruvia-to-treat-moderate-to-severe-pruritus-associated-with-ckd daily 0.8 https://clival.com/news/msn-labs-launches-urinary-incontinence-drug-fesobig daily 0.8 https://clival.com/news/hitgen-and-uppthera-extend-protac-research-collaboration-after-hit-finding-success-on-undruggable-targets daily 0.8 https://clival.com/news/galderma-gets-health-canada-approval-for-restylane-shaype-a-new-hyaluronic-acid-injectable-designed-for-augmenting-the-chin-region daily 0.8 https://clival.com/news/henlius-novel-anti-pd-1-mab-hansizhuang-serplulimab-approved-for-the-treatment-of-escc daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-approval-for-generic-remodulin-injection daily 0.8 https://clival.com/news/graymatters-health-launches-new-fda-cleared-self-neuromodulation-ptsd-therapy-in-the-united-states daily 0.8 https://clival.com/news/boehringer-enriches-cancer-immunology-portfolio-with-amal-therapeutics-acquisition daily 0.8 https://clival.com/news/accutar-biotechnology-announces-first-patient-dosed-in-china-with-ac0682-in-phase-1-study-in-er-positive-breast-cancer daily 0.8 https://clival.com/news/sartorius-collaborates-with-sanofi-to-commercialize-end-to-end-platform-for-downstream-process-intensification daily 0.8 https://clival.com/news/covant-therapeutics-collaborates-with-boehringer-ingelheim daily 0.8 https://clival.com/news/lupin-launches-generic-antidepressant-tablets-in-us daily 0.8 https://clival.com/news/huidagene-therapeutics-gets-us-fda-clearance-for-hg202 daily 0.8 https://clival.com/news/lupin-gets-us-fda-tentative-approval-for-dapagliflozin-tablets daily 0.8 https://clival.com/news/biolinerx-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-motixafortide-for-cd34-hematopoietic-stem-cell-mobilization-for-gene-therapies-in-sickle-cell-disease daily 0.8 https://clival.com/news/china-cde-clears-elpisciences-ind-for-es014-to-initiate-phase-1-study-to-treat-advanced-solid-tumours daily 0.8 https://clival.com/news/gsk-and-curevac-announce-strategic-mrna-technology-collaboration daily 0.8 https://clival.com/news/china-approves-gc-pharmas-greengene-f-as-a-therapy-to-treat-haemophilia-a daily 0.8 https://clival.com/news/pfizer-biontech-report-positive-topline-results-from-phase-12-study-of-mrna-based-combination-vaccine-program-against-influenza-and-covid-19 daily 0.8 https://clival.com/news/akoya-biosciences-to-partner-with-acrivon-therapeutics-for-the-clinical-development-of-acrivon daily 0.8 https://clival.com/news/neurocrine-biosciences-receives-orphan-drug-designation-for-valbenazine-as-a-treatment-for-chorea-associated-with-huntington-disease daily 0.8 https://clival.com/news/us-fda-approves-gsk-menveo-in-a-new-single-vial-presentation-to-help-prevent-disease-caused-by-meningococcal-bacteria-serogroups-a-c-y-and-w daily 0.8 https://clival.com/news/ekf-life-sciences-and-abec-partner-for-us-biomanufacturing-expansion daily 0.8 https://clival.com/news/daiichi-sankyo-seeks-japanese-approval-for-trastuzumab-to-treat-her2-positive-metastatic-breast-cancer daily 0.8 https://clival.com/news/indian-pharma-major-lupin-inks-partnership-agreement-with-foncoo-for-china daily 0.8 https://clival.com/news/recbio-receives-pharmaceutical-production-license-from-jiangsu-medical-products-administration-for-production-of-covid-19-vaccine daily 0.8 https://clival.com/news/daiichi-sankyo-and-american-regent-announce-approval-of-injectafer daily 0.8 https://clival.com/news/merck-and-orna-therapeutics-collaborate-to-advance-ornas-next-generation-of-rna-technology daily 0.8 https://clival.com/news/shanghai-genechem-co-ltd-genechem-announces-global-collaboration-on-bispecific-antibodies daily 0.8 https://clival.com/news/bgi-genomics-receives-eua-from-fda-for-sars-cov-2-detection-kit daily 0.8 https://clival.com/news/cipla-to-collaborate-with-kemwell-biopharma-manipal-medical-group-to-form-jv-in-us daily 0.8 https://clival.com/news/astrazeneca-announces-positive-results-from-phase-iii-champion-mg-trial-of-ultomiris-in-adults-with-generalised-myasthenia-gravis daily 0.8 https://clival.com/news/ascentage-pharma-announces-clinical-trial-application-for-olverembatinib-hqp1351-approved-in-canada daily 0.8 https://clival.com/news/roche-announces-phase-iii-centerstone-study-of-xofluza-significantly-reduces-the-transmission-of-influenza-viruses daily 0.8 https://clival.com/news/nona-biosciences-and-pfizer-have-entered-into-a-worldwide-license-agreement-for-hbm9033-an-antibody-drug-conjugate-adc-targeting-msln daily 0.8 https://clival.com/news/amgen-successfully-completes-acquisition-of-chemocentryx daily 0.8 https://clival.com/news/nanotics-to-collaborate-with-mass-general-cancer-center-mgcc-on-novel-nanomedicine-for-treating-cancer daily 0.8 https://clival.com/news/amgen-gets-us-fda-approval-for-kyprolis-in-combo-with-darzalex-faspro-and-dexamethasone-for-patients-with-multiple-myeloma-at-first-or-subsequent-relapse daily 0.8 https://clival.com/news/moderna-announces-ecs-approval-of-advance-purchase-agreement-for-initial-80-million-doses-of-mrna-vaccine-against-covid-19 daily 0.8 https://clival.com/news/china-nmpa-approves-ascletis-ind-application-of-oral-rdrp-inhibitor-asc10-for-covid-19 daily 0.8 https://clival.com/news/strides-receives-us-fda-approval-for-generic-fioricet-with-codeine-capsules daily 0.8 https://clival.com/news/glenmark-pharma-receives-2nd-us-fda-tentative-approval-for-generic-onglyza-tablets daily 0.8 https://clival.com/news/amarin-partner-eddingpharm-gets-china-nmpa-approval-for-vascepa-for-cardiovascular-risk-reduction daily 0.8 https://clival.com/news/nexturn-bio-inc-acquired-a-50-stake-in-rosvivo-therapeutics-inc daily 0.8 https://clival.com/news/one-up-one-down-allecra-scores-fda-nod-for-antibiotic-combo-after-venatorx-hit-with-rejection daily 0.8 https://clival.com/news/roche-initiates-phase-iii-clinical-trial-of-actemra-roactemra-plus-remdesivir-in-hospitalised-patients-with-severe-covid-19-pneumonia daily 0.8 https://clival.com/news/samsung-biologics-signs-development-agreement-with-panolos-for-solid-tumor-treatment daily 0.8 https://clival.com/news/pfizer-biontech-announce-positive-results-from-phase-3-study-of-covid-19-mrna-based-vaccine-candidate-bnt162b2 daily 0.8 https://clival.com/news/pfizer-announces-positive-results-from-phase-3-affine-study-of-haemophilia-a-gene-therapy-candidate daily 0.8 https://clival.com/news/innovent-secures-fast-track-status-from-the-fda-for-ibi343 daily 0.8 https://clival.com/news/addex-indivior-select-clinical-candidates-from-gabab-positive-allosteric-modulator-research-collaboration daily 0.8 https://clival.com/news/cidara-therapeutics-receives-us20-million-milestone-payment-following-fda-approval-of-rezzayo daily 0.8 https://clival.com/news/strides-receives-us-fda-approval-for-icosapent-ethyl-capsules daily 0.8 https://clival.com/news/pharmaceutical-news-lima-corporate-gets-us-fda-nod-to-begin-clinical-trial-of-smr-stem-less-reverse-shoulder-system daily 0.8 https://clival.com/news/merus-begins-patient-dosing-in-liger-hn2-a-phase-3-trial-evaluating-petosemtamab-in-23l-rm-hnscc daily 0.8 https://clival.com/news/china-nmpa-approves-label-updation-for-astrazenecas-lokelma-for-patients-with-hyperkalaemia-on-chronic-haemodialysis daily 0.8 https://clival.com/news/envision-pharma-launches-envisionone-insights-to-harness-power-of-big-data-in-medical-affairs-technology daily 0.8 https://clival.com/news/lumenis-moses-technology-wins-2020-medtech-breakthrough-award-for-innovation-in-surgical-technology daily 0.8 https://clival.com/news/radiaction-medical-ltd-receives-fda-clearance-for-its-innovative-radiation-protection-system-and-secures-10m-for-us-launch-and-commercialization daily 0.8 https://clival.com/news/abbott-launches-vitamin-d-supplement-arachitol-gummies daily 0.8 https://clival.com/news/ultradx-gains-first-clinical-approval-for-single-molecule-analyzer-in-china daily 0.8 https://clival.com/news/fosun-pharmas-licensed-covid-19-vaccine-receives-nmpa-acceptance daily 0.8 https://clival.com/news/labcorp-launches-new-test-to-identify-and-confirm-neurodegenerative-disease daily 0.8 https://clival.com/news/bayer-receives-breakthrough-therapy-designation-in-china-for-bay-2927088 daily 0.8 https://clival.com/news/biomed-x-institute-ono-pharma-launch-new-collaboration-in-cancer-research daily 0.8 https://clival.com/news/tyligand-bioscience-announces-first-patient-dosed-in-phase-12-clinical-trial-of-tsn1611 daily 0.8 https://clival.com/news/sanofi-announces-waiting-period-expires-under-hsr-act-for-acquisition-of-synthorx daily 0.8 https://clival.com/news/tff-pharmaceuticals-enters-into-worldwide-licensing-agreement-with-union-therapeutics-for-its-thin-film-freezing-technology-in-combination-with-niclos daily 0.8 https://clival.com/news/astrazenecas-truqap-combination-in-pten-deficient-mhspc-shows-significant-improvement-in-trial daily 0.8 https://clival.com/news/glenmark-gets-usfda-nod-for-contraceptive-tablets daily 0.8 https://clival.com/news/avicanna-expands-its-epilepsy-research-program-with-a-new-collaboration-with-the-university-of-toronto daily 0.8 https://clival.com/news/hiro-acquires-us-based-full-service-clinical-research-provider-courante-oncology daily 0.8 https://clival.com/news/sn-bioscience-and-boryung-announce-the-licensing-agreement-on-generic-version-of-abraxane daily 0.8 https://clival.com/news/cansino-biologics-and-precision-nanosystems-announce-collaboration-to-co-develop-a-covid-19-rna-vaccine daily 0.8 https://clival.com/news/bavarian-nordic-monkeypox-vaccine-wins-eu-approval daily 0.8 https://clival.com/news/tg-immunopharma-receives-fda-approval-to-initiate-clinical-trial-for-tgi-6-bispecific-antibody daily 0.8 https://clival.com/news/bioasis-enters-into-research-collaboration-with-janssen daily 0.8 https://clival.com/news/ascentage-pharma-receives-clearance-from-us-fda-to-proceed-with-phase-iii-clinical-trial-for-lisaftoclax-apg-2575 daily 0.8 https://clival.com/news/glenmark-pharma-reaches-settlement-agreement-with-pfizer-for-axitinib-tablets-1-mg-and-5-mg daily 0.8 https://clival.com/news/biocytogen-announces-renlite daily 0.8 https://clival.com/news/brii-biosciences-soon-to-acquire-vbis-ip-rights-in-brii-179 daily 0.8 https://clival.com/news/strata-oncology-announces-expansion-of-clinical-collaboration-with-pfizer-for-strata-path-trial-into-early-stage-cancer daily 0.8 https://clival.com/news/fresenius-kabi-targets-treatment-of-certain-seizures-with-launch-of-generic-lacosamide-injection daily 0.8 https://clival.com/news/nhs-medicines-shortage-putting-lives-at-risk-pharmacists-warn daily 0.8 https://clival.com/news/bayer-initiates-phase-iii-finearts-hf-study-for-finerenone-in-patients-with-heart-failure-and-preserved-ejection-fraction daily 0.8 https://clival.com/news/gilead-sciences-signs-new-joint-procurement-agreement-with-the-european-commission-for-veklury daily 0.8 https://clival.com/news/us-fda-accepts-astrazeneca daily 0.8 https://clival.com/news/vivani-medical-to-initiate-clinical-study-in-australia-for-miniature-npm-115 daily 0.8 https://clival.com/news/us-fda-accepts-and-grant-priority-review-status-to-humacyte-bla-for-human-acellular-vessel-to-treat-vascular-trauma daily 0.8 https://clival.com/news/gsk-path-bharat-biotech-sign-product-transfer-agreement-to-help-ensure-long-term-supply-of-rtssas01e-malaria-vaccine daily 0.8 https://clival.com/news/canbridge-to-present-positive-data-from-phase-12-trial-of-can008-plus-temozolomideradiotherapy-in-glioblastoma-multiforme-at-esmo-congress-in-switzerland daily 0.8 https://clival.com/news/mednovation-inks-cooperation-agreement-with-life-science-intelligence-to-support-innovation-in-chinese-medtech-market daily 0.8 https://clival.com/news/gracell-biotechnologies-fastcar-t-gc012f-receives-fda-clearance-for-phase-12-trial-in-refractory-systemic-lupus-erythematosus daily 0.8 https://clival.com/news/autifony-enters-exclusive-global-license-collaboration-agreement-with-jazz-pharma-on-two-ion-channel-targets-for-neurological-disorders daily 0.8 https://clival.com/news/granules-india-gets-us-fda-approval-for-loperamide-hydrochloride-and-simethicone-tablets daily 0.8 https://clival.com/news/european-commission-approves-novartis daily 0.8 https://clival.com/news/lapix-therapeutics-announces-positive-results-from-phase-1-trial-of-lpx-ti641 daily 0.8 https://clival.com/news/sun-pharma-and-philogen-enter-into-global-licensing-agreement-for-fibromun daily 0.8 https://clival.com/news/abiogen-pharma-completes-acquisition-of-swiss-company-effrx-pharma daily 0.8 https://clival.com/news/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions daily 0.8 https://clival.com/news/transcenta-holding-announces-approval-to-initiate-phase-ii-clinical-trial-of-tst002-blosozumab daily 0.8 https://clival.com/news/boehringer-ingelheim-gains-approval-for-supply-of-eu-and-us-markets daily 0.8 https://clival.com/news/astellas-and-go-therapeutics-enter-into-strategic-research-and-license-agreement-to-develop-novel-antibodies-for-immuno-oncology daily 0.8 https://clival.com/news/cytomed-therapeutics-announces-china-research-collaboration-to-enhance-its-allogeneic-car-ghd-t-in-vivo-persistency daily 0.8 https://clival.com/news/proteinqure-collaborates-with-astrazeneca-to-develop-new-therapeutic-peptides daily 0.8 https://clival.com/news/bavarian-nordic-monkeypox-vaccine-gets-preliminary-nod-from-eu-drug-regulator daily 0.8 https://clival.com/news/innovent-begins-patient-dosing-in-higher-dose-cohort-of-phase-2-trial-of-mazdutide-in-chinese-adults-with-obesity daily 0.8 https://clival.com/news/astrazeneca-covid-19-vaccine-vaxzevria-authorised-for-emergency-use-in-japan daily 0.8 https://clival.com/news/bergenbio-enters-clinical-trial-collaboration-with-ut-health-san-antonio-and-sobi daily 0.8 https://clival.com/news/viromed-medical-launches-second-pioneering-study-on-use-of-cold-plasma daily 0.8 https://clival.com/news/us-fda-approves-abbotts-heartmate-3-heart-pump-to-help-patients-avoid-open-heart-surgery daily 0.8 https://clival.com/news/zydus-cadila-gets-nod-for-phase-2-clinical-study-in-caps-patients-in-australia daily 0.8 https://clival.com/news/prothena-and-novo-nordisk-announce-acquisition-agreement-for-prothenas-attr-amyloidosis-programme daily 0.8 https://clival.com/news/us-fda-approves-leqselvi-deuruxolitinib-an-oral-jak-inhibitor daily 0.8 https://clival.com/news/ideaya-reports-positive-interim-phase-1-expansion-data-of-ide397-fro-urothelial-and-lung-cancer daily 0.8 https://clival.com/news/biocomposites-launches-two-new-phase-ii-trials daily 0.8 https://clival.com/news/springworks-to-present-long-term-efficacy-and-safety-data-from-phase-3-defi-trial-of-ogsiveo daily 0.8 https://clival.com/news/takeda-hyqvia-gets-european-approval-for-maintenance-therapy-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy daily 0.8 https://clival.com/news/us-fda-approves-merck-keytruda-plus-gemcitabine-cisplatin-to-treat-patients-with-locally-advanced-unresectable-or-metastatic-bct daily 0.8 https://clival.com/news/roche-requests-dcgi-to-check-gaps-in-the-clinical-trial-of-perjeta daily 0.8 https://clival.com/news/after-prior-rejection-iterum-nabs-long-sought-fda-nod-for-oral-uti-drug-orlynvah daily 0.8 https://clival.com/news/biocytogen-officially-launches-renmice-series daily 0.8 https://clival.com/news/viva-biotech-acquires-major-stake-in-chinese-cdmo daily 0.8 https://clival.com/news/abcam-announces-successful-acquisition-of-expedeons-proteomics-and-immunology-business-enhancing-its-conjugation-capability daily 0.8 https://clival.com/news/eyenovia-strategic-partner-arctic-vision-enrolls-first-patient-in-phase-iii-clinical-trial-of-arvn003-microline-for-presbyopia-in-china daily 0.8 https://clival.com/news/prenetics-acquires-act-genomics-creating-a-leader-in-comprehensive-cancer-genetics-and-precision-oncology daily 0.8 https://clival.com/news/health-canada-approves-ascentage-pharmas-phase-ib-study-application-for-olverembatinib-to-treat-patients-with-refractory-cml-or-ph-all daily 0.8 https://clival.com/news/curateq-gets-phase-1-positive-results-for-bp11 daily 0.8 https://clival.com/news/innocares-btk-inhibitor-orelabrutinib-gets-china-nmpa-priority-review-status-to-treat-rr-marginal-zone-lymphoma daily 0.8 https://clival.com/news/us-fda-approves-abbvies-interleukin-23-inhibitor-skyrizi-to-treat-moderately-to-severely-active-crohns-disease daily 0.8 https://clival.com/news/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3-presbyopia-trial-of-lnz100 daily 0.8 https://clival.com/news/ani-pharmaceuticals-launches-us-fda-approved-estradiol-gel daily 0.8 https://clival.com/news/novartis-presents-data-from-fabhalta-at-asn-kidney-week-2024-data-sustained-clinically-meaningful-results-at-1-year-in-phase-iii-c3-glomerulopathy-trial daily 0.8 https://clival.com/news/us-fda-clears-tyra-biosciences-ind-application-for-tyra-300-in-paediatric-achondroplasia daily 0.8 https://clival.com/news/cynosure-enters-into-partnership-agreement-with-jeisys-medical-japan daily 0.8 https://clival.com/news/us-fda-accepts-astrazeneca-and-mercks-snda-for-lynparza-in-combo-with-abiraterone-and-prednisone-or-prednisolone-to-treat-patients-with-mcrpc daily 0.8 https://clival.com/news/thermo-fisher-collaborates-with-wuxi-diagnostics daily 0.8 https://clival.com/news/biocryst-announces-approval-of-orladeyo daily 0.8 https://clival.com/news/chipscreen-newway-first-patient-dosed-in-phase-1-trial-of-the-bispecific-antibody-nwy001-a-next-generation-tumor-immunotherapy-in-patients-with-advanced-solid-tumors daily 0.8 https://clival.com/news/us-china-collab-to-deliver-multiplexed-solutions-for-mrna-vaccine-and-cell-gene-therapy daily 0.8 https://clival.com/news/chimeric-therapeutics-signs-strategic-manufacturing-partnership-with-wuxi-atu daily 0.8 https://clival.com/news/rapid-medical-announces-japanese-approval-and-exclusive-partnership-with-kaneka-for-tigertriever-the-worlds-only-adjustable-thrombectomy-device daily 0.8 https://clival.com/news/innovent-announces-first-participant-dosed-in-phase-1-clinical-study-of-ibi333-vegf-avegf-c-bispecific-fusion-protein-in-patients-with-neovascular-age-related-macular-degeneration daily 0.8 https://clival.com/news/bristol-myers-squibb-gets-us-fda-approval-for-opdivo-yervoy-to-treat-patients-with-hcc-previously-treated-with-sorafenib daily 0.8 https://clival.com/news/bioarctic-partner-eisai-receives-chinese-approval-for-leqembi-to-treat-alzheimer-disease daily 0.8 https://clival.com/news/myriad-genetics-partners-with-ncche-for-clinical-trials daily 0.8 https://clival.com/news/china-adagene-partners-with-french-firm-sanofi-for-immuno-oncology daily 0.8 https://clival.com/news/chime-biologics-and-hope-medicine-enter-manufacturing-agreement-to-speed-up-the-launch-of-first-in-class-antibody-drug-hmi-115-targeting-endometriosis-and-androgenic-alopecia daily 0.8 https://clival.com/news/pfizer-to-acquire-seattle-based-biotech-company-seagen-for-43-billion daily 0.8 https://clival.com/news/nuvalent-enters-phase-2-trials-for-nvl-655 daily 0.8 https://clival.com/news/senti-bio-and-celest-therapeutics-announce-new-collaboration-for-clinical-development-of-senti-301a-in-china daily 0.8 https://clival.com/news/aston-sci-gets-us-fda-nod-to-begin-phase-2-trial-of-therapeutic-cancer-vaccine-ast-301-in-patients-with-her2-12-breast-cancer daily 0.8 https://clival.com/news/bliss-biopharmaceutical-enters-into-a-clinical-trial-collaboration-agreement-with-an-option-of-strategic-collaboration-with-eisai-for-bb-1701 daily 0.8 https://clival.com/news/roche-and-hitachi-high-tech-extend-their-long-standing-partnership daily 0.8 https://clival.com/news/akeso-completes-patient-enrollment-in-phase-iii-trial-of-ivonescimab-in-combo-with-chemotherapy-in-egfr-tki-resistant-nsq-nsclc daily 0.8 https://clival.com/news/apex-labs-launches-advanced-supra-bioavailable-itraconazole-65-130-mg-capsules daily 0.8 https://clival.com/news/kite-to-acquire-tmunity-therapeutics-to-pursue-next-generation-car-t-cell-therapy-advancements-in-cancer daily 0.8 https://clival.com/news/licensing-partner-of-shenzhen-chipscreen-biosciences-huyabio-international-receives-regulatory-approval-for-chidamide-monotherapy-of-peripheral-t-cell-lymphoma-ptcl-in-japan daily 0.8 https://clival.com/news/shilpa-medicares-jadcherla-facility-receives-us-fda-warning-letter daily 0.8 https://clival.com/news/us-fda-grants-emergency-use-authorization-to-novavax-2024-2025-formula-covid-19-vaccine daily 0.8 https://clival.com/news/maharishi-ayurveda-launches-ayurdefence-av daily 0.8 https://clival.com/news/strides-receives-us-fda-approval-for-sevelamer-carbonate-for-oral-suspension daily 0.8 https://clival.com/news/cipla-unit-inks-agreement-for-anti-psychotic-drug daily 0.8 https://clival.com/news/biosyngen-gets-china-nmpa-nod-to-begin-phase-ii-trial-of-brg01 daily 0.8 https://clival.com/news/xenetic-biosciences-inc-and-the-university-of-virginia-have-initiated-a-research-agreement-to-advance-their-oncology-platform-based-on-dnase-technology daily 0.8 https://clival.com/news/relief-therapeutics-provides-update-from-collaboration-partner-acer-therapeutics-on-commercial-launch-activities-for-olpruva daily 0.8 https://clival.com/news/meihua-international-medical-technologies-co-ltd-enters-into-strategic-partnership-with-getein-biotech-inc-to-jointly-produce-and-sell-covid-19-antigen-test-kits-and-ivds daily 0.8 https://clival.com/news/european-medicines-agency-validates-type-ii-variation-application-for-padcev-enfortumab-vedotin-with-keytrudapembrolizumab-for-first-line-treatment-of-advanced-bladder-cancer daily 0.8 https://clival.com/news/innovent-announces-successful-phase-3-trial-results-for-mazdutide-in-china daily 0.8 https://clival.com/news/ionis-announces-phase-3-neuro-ttransform-study-of-eplontersen-in-patients-with-attrv-pn-meets-co-primary-and-secondary-endpoints daily 0.8 https://clival.com/news/roches-ocrevus-sc-injection-receives-eu-chmp-positive-opinion daily 0.8 https://clival.com/news/eusa-pharma-announces-fda-approves-phase-3-clinical-trial-of-silvoximab-for-covid-19-related-acute-respiratory-distress-syndrome-patients daily 0.8 https://clival.com/news/vergent-bioscience-presents-phase-2-data-showing-vgt-309-visualizes-tumours-in-lung-during-surgery-at-the-sts-annual-meeting daily 0.8 https://clival.com/news/genequantum-and-wuxi-xdc-to-empower-innovative-bioconjugates-development daily 0.8 https://clival.com/news/oncolytics-biotech-announces-investigator-sponsored-phase-2-trial-evaluating-pelareorep-anti-pd-1-combination-treatment-in-triple-negative-breast-canc daily 0.8 https://clival.com/news/gilead-and-merck-announce-phase-2-for-islatravir-and-lenacapavir daily 0.8 https://clival.com/news/maxcyte-inks-strategic-platform-license-with-curamys-to-enable-cell-gene-therapies-to-treat-rare-intractable-diseases daily 0.8 https://clival.com/news/ideaya-pfizer-expand-clinical-collaboration-supply-agreements-for-darovasertib-and-crizotinib-combo-in-metastatic-uveal-melanoma-and-additional-cmet-driven-tumours daily 0.8 https://clival.com/news/biocytogen-pharmaceuticals-and-pheon-therapeutics-announced-a-license-agreement daily 0.8 https://clival.com/news/adm-korea-launches-first-clinical-trial-of-niclosamide-based-anticancer-drug-for-prostate-cancer daily 0.8 https://clival.com/news/fda-accepts-eisai-filing-of-a-supplemental-biologics-license-application-and-grants-priority-review-for-traditional-approval-of-leqembi daily 0.8 https://clival.com/news/mhra-grants-approval-for-astrazenecas-evusheld-in-the-uk daily 0.8 https://clival.com/news/rhythm-announces-expansion-in-setmelanotide-trials daily 0.8 https://clival.com/news/merck-announces-receipt-of-antitrust-clearance-in-germany-and-austria-relating-to-tender-offer-to-acquire-acceleron-pharma-inc daily 0.8 https://clival.com/news/gsk-cambridge-university-announce-new-five-year-collaboration-in-kidney-and-respiratory-disease daily 0.8 https://clival.com/news/deka-biosciences-gets-us-fda-clearance-for-dk210-egfr-ind-application daily 0.8 https://clival.com/news/antengene-inks-clinical-collaboration-with-msd-to-evaluate-atg-037-in-combo-with-keytruda-in-patients-with-locally-advanced-or-metastatic-solid-tumours daily 0.8 https://clival.com/news/zydus-receives-us-fda-approval-for-zituvio-to-treat-adult-patients-with-type-2-diabetes-mellitus daily 0.8 https://clival.com/news/quris-ai-expands-collaboration-with-merck-kgaa-darmstadt daily 0.8 https://clival.com/news/venus-remedies-gets-coveted-gmp-certification-from-libya daily 0.8 https://clival.com/news/gc-biopharma-concludes-agreement-with-acuitas-therapeutics-for-lipid-nanoparticle-delivery-system-for-use-in-mrna-vaccines-and-therapeutics daily 0.8 https://clival.com/news/venus-remedies-receives-marketing-approvals-for-docetaxel-from-israel-and-cytarabine-from-colombia daily 0.8 https://clival.com/news/us-fda-accepts-and-grants-priority-review-status-to-cti-biopharmas-nda-for-pacritinib-to-treat-myelofibrosis daily 0.8 https://clival.com/news/aethlon-medical-receives-second-ethics-committee-approval-for-hemopurifier-cancer-trial daily 0.8 https://clival.com/news/us-fda-approves-amgen-astrazenecas-tezspire-to-treat-severe-asthma daily 0.8 https://clival.com/news/fda-approves-alembic-pharmaceuticals-macitentan-tablets daily 0.8 https://clival.com/news/bayer-acquires-noria-and-psma-therapeutics-to-expand-portfolio-in-prostate-cancer daily 0.8 https://clival.com/news/dr-reddys-laboratories-announces-the-launch-of-methylprednisolone-sodium-succinate-for-injection-usp-in-the-us-market daily 0.8 https://clival.com/news/us-fda-grants-expanded-label-approval-for-mercks-anti-pd-1-therapy-keytruda-in-locally-advanced-cutaneous-squamous-cell-carcinoma daily 0.8 https://clival.com/news/apellis-pharma-syfovre-gets-us-fda-approval-to-treat-geographic-atrophy daily 0.8 https://clival.com/news/tavotek-announces-a-research-agreement-with-genmab-for-the-development-of-bispecific-antibodies daily 0.8 https://clival.com/news/innogi-technologies-collabs-with-simulations-plus-for-oral-drug-performance daily 0.8 https://clival.com/news/redhill-biopharma-announces-fda-grant-of-5-year-us-market-exclusivity-for-talicia-with-ip-protection-running-to-2034 daily 0.8 https://clival.com/news/astellas-presents-positive-results-from-phase-3-spotlight-trial-of-zolbetuximab-at-2023-asco-gi-cancers-symposium daily 0.8 https://clival.com/news/usfda-grants-orphan-drug-designation-to-carsgen-therapeutics daily 0.8 https://clival.com/news/chugai-presents-updated-results-from-phase-iii-alex-study-of-alecensa-vs-crizotinib-in-untreated-advanced-alk-nsclc-at-asco-programme daily 0.8 https://clival.com/news/gannex-gets-china-nmpa-nod-for-phase-ii-and-iii-protocols-of-asc42-to-treat-primary-biliary-cholangitis daily 0.8 https://clival.com/news/advaxis-updates-on-phase-1-clinical-trial-of-adxs-504-to-treat-early-prostate-cancer daily 0.8 https://clival.com/news/renalys-pharma-is-introduced-to-bring-groundbreaking-medicines-to-patients-in-japan-and-various-asian-countries daily 0.8 https://clival.com/news/bayer-seeks-eu-japanese-approvals-for-aflibercept-for-retinopathy-of-prematurity-in-premature-babies daily 0.8 https://clival.com/news/skye-bioscience-receives-central-irb-approval-to-begin-phase-2-trial-with-sbi-100-ophthalmic-emulsion daily 0.8 https://clival.com/news/us-fda-and-ema-accepts-sandoz-bla-for-proposed-multiple-sclerosis-biosimilar-natalizumab daily 0.8 https://clival.com/news/amerisourcebergen-to-expand-global-biopharma-services-platform-with-acquisition-of-pharmalex daily 0.8 https://clival.com/news/senti-bio-enters-collaboration-with-spark-therapeutics-to-develop-next-generation-precision-gene-therapies daily 0.8 https://clival.com/news/kura-oncology-doses-first-subject-in-phase-iii-hnscc-drug-trial daily 0.8 https://clival.com/news/harbour-biomed-announces-dosing-of-first-patient-in-australia-for-phase-ibiia-clinical-study-of-its-next-generation-anti-ctla-4-antibody daily 0.8 https://clival.com/news/cytelabs-launches-dish-testing-an-us-fda-approved-technique-for-breast-cancer-with-reduced-waiting-time-for-treatment-access daily 0.8 https://clival.com/news/daiichi-sankyo-begins-phase-3-trial-of-mutant-strain-covid-19-vaccine-ds-5670-in-japan daily 0.8 https://clival.com/news/md-anderson-obsidian-get-us-fda-clearance-to-begin-phase-i-study-of-novel-til-therapy-obx-115-to-treat-solid-tumours daily 0.8 https://clival.com/news/andall-biosciences-launches-ovary-care-capsule-23well daily 0.8 https://clival.com/news/lupins-vizag-api-facility-receives-eir-from-us-fda daily 0.8 https://clival.com/news/us-fda-approves-medtronics-diamondtemp-ablation-system-to-treat-patients-with-atrial-fibrillation daily 0.8 https://clival.com/news/astrazenecas-batura-phase-iiib-trial-of-airsupra-in-asthma-patients-meets-its-primary-endpoint daily 0.8 https://clival.com/news/us-fda-510k-clearance-for-the-company-5008x-hemodialysis-system daily 0.8 https://clival.com/news/renalys-pharma-begins-patient-dosing-in-registrational-phase-iii-trial-of-sparsentan daily 0.8 https://clival.com/news/uk-mhra-grants-marketing-authorization-to-pierre-fabres-vibegron daily 0.8 https://clival.com/news/bdr-pharma-launches-generic-antibiotic-combo-of-ceftazidime-and-avibactum daily 0.8 https://clival.com/news/nuvectis-pharma-announces-fda-clearance-of-nxp900-ind daily 0.8 https://clival.com/news/japanese-mhlw-grants-marketing-approval-for-eylea-8-mg-for-neovascular-wet-age-related-macular-degeneration-and-dme daily 0.8 https://clival.com/news/lupins-brazilian-subsidiary-medquimica-acquires-rights-to-nine-brands-from-bausch-health daily 0.8 https://clival.com/news/eisai-wren-therapeutics-ink-research-agreement-to-advance-discovery-of-novel-small-molecules-targeting-alpha-synuclein-to-treat-synucleinopathies daily 0.8 https://clival.com/news/westgene-to-proceed-to-clinical-trials-after-obtaining-two-ind-approvals daily 0.8 https://clival.com/news/daiichi-sankyo-astrazenecas-enhertu-gets-btd-from-us-fda daily 0.8 https://clival.com/news/anixa-biosciences-begins-patient-dosing-in-phase-1-trial-of-novel-car-t-therapy daily 0.8 https://clival.com/news/wuxi-apptec-peptide-facility-receives-pmda-approval daily 0.8 https://clival.com/news/beigene-receives-10th-approval-for-pd-1-inhibitor-tislelizumab-in-china daily 0.8 https://clival.com/news/astrazeneca-daiichi-sankyos-tropion-lung01-phase-iii-trial-of-datopotamab-deruxtecan-meets-dual-primary-endpoint-of-pfs-in-patients-with-advanced-nsclc daily 0.8 https://clival.com/news/pacbio-and-ucla-health-announce-research-collaboration-for-whole-genome-sequencing-in-rare-diseases daily 0.8 https://clival.com/news/agilent-technologies-enters-digital-pathology-scanner-distribution-agreement-with-hamamatsu daily 0.8 https://clival.com/news/verisim-life-and-total-brain-announce-strategic-collaboration-agreement-applying-ai-to-develop-new-drugs-for-neurological-disorders daily 0.8 https://clival.com/news/us-fda-accepts-bristol-myers-squibbs-bla-for-subcutaneous-nivolumab daily 0.8 https://clival.com/news/neurobo-pharma-submits-ind-application-to-us-fda-for-phase-1-trial-of-da-1726-to-treat-obesity daily 0.8 https://clival.com/news/galapagos-collaborates-with-novalix daily 0.8 https://clival.com/news/sunbird-bio-merges-with-glympse-bio-to-accelerate-development-of-proprietary-protein-based-diagnostic-technologies daily 0.8 https://clival.com/news/first-patient-dosed-in-canbridge-pharmaceuticals-can103-phase-12-trial-for-the-treatment-of-gaucher-disease-in-china daily 0.8 https://clival.com/news/adagene-to-present-interim-results-of-masked-anti-ctla-4-safebody-adg126-muzastotug-in-combination-with-pembrolizumab-in-mss-crc-at-asco-gi-symposium daily 0.8 https://clival.com/news/akums-enters-into-industry-academia-partnership-with-sgt-university daily 0.8 https://clival.com/news/asieris-obtained-ind-approval-from-us-fda-for-apl-1401-a-new-drug-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis daily 0.8 https://clival.com/news/gsk-launches-shingles-vaccine-shingrix-in-india daily 0.8 https://clival.com/news/metropolis-healthcare-launches-the-nextgen-hla-for-hematopoietic-stem-cell-transplant-and-solid-organ-transplantation daily 0.8 https://clival.com/news/alembics-subsidiary-aleor-receives-us-fda-approval-for-generic-abreva-cream daily 0.8 https://clival.com/news/fortress-biotech-gets-us-fda-rare-pediatric-disease-designation-for-cutx-101-to-treat-menkes-disease daily 0.8 https://clival.com/news/chugai-pharma-mosunetuzumab-achieves-primary-endpoint-in-expansion-cohort-of-japanese-phase-i-study-for-rr-follicular-lymphoma daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-gan-and-lees-malignant-glioma-drug-glr2007 daily 0.8 https://clival.com/news/galvanize-announces-license-agreement-and-partnership-with-energenx-medical-for-its-technologies-in-china daily 0.8 https://clival.com/news/gsk-issues-seroxat-warning-letter daily 0.8 https://clival.com/news/csl-enters-licensing-agreement-with-arcturus-therapeutics-for-next-generation-mrna-vaccine-technology daily 0.8 https://clival.com/news/fda-approves-novartis-kisqali-to-reduce-risk-of-recurrence-in-early-breast-cancer daily 0.8 https://clival.com/news/biomed-x-institute-and-merck-extend-collaboration-to-continue-novel-research-in-oncology-and-autoimmunity daily 0.8 https://clival.com/news/oncology-pharma-and-ribera-solutions-signed-a-licensing-agreement-for-the-use-of-riberas-clinical-trials-platform-connect2med daily 0.8 https://clival.com/news/narayana-health-forges-strategic-partnership-with-clearmedi-healthcare-to-implement-his daily 0.8 https://clival.com/news/providence-medical-technology-gets-us-fda-clearance-of-corus-navigation-access-system daily 0.8 https://clival.com/news/owkin-inks-collaboration-agreement-with-merck-to-develop-and-commercialize-ai-powered-diagnostics-for-cancer daily 0.8 https://clival.com/news/ec-approves-novavax-covid-19-vaccine-for-active-immunization-to-prevent-covid-19-caused-by-sars-cov-2-in-individuals-aged-12-older daily 0.8 https://clival.com/news/immunogen-announces-research-collaboration-with-oxford-biotherapeutics-to-develop-novel-antibody-drug-conjugates daily 0.8 https://clival.com/news/transperfect-life-sciences-and-innovaderm-research-expand-trial-interactive-partnership daily 0.8 https://clival.com/news/bayer-launches-industry-first-public-database-listing-companys-science-collaborations-and-partnerships-in-the-us daily 0.8 https://clival.com/news/johnson-johnson-announces-advance-purchase-agreement-with-the-african-vaccine-acquisition-trust daily 0.8 https://clival.com/news/boehringer-ingelheim-receives-us-fda-approval-for-spesolimab-as-a-treatment-option-for-generalized-pustular-psoriasis-flares-in-adults daily 0.8 https://clival.com/news/china-approves-astrazenecas-forxiga-for-ckd-in-patients-with-and-without-type-2-diabetes daily 0.8 https://clival.com/news/biocon-licenses-3-generic-drugs-to-china-medical-system-holdings daily 0.8 https://clival.com/news/valneva-announces-european-commission-approval-of-advance-purchase-agreement-for-up-to-60-million-doses-of-inactivated-covid-19-vaccine-vla2001 daily 0.8 https://clival.com/news/bayer-and-salus-optima-partner-on-ai-enabled-healthy-aging-journey daily 0.8 https://clival.com/news/everest-medicines-gets-nmpa-acceptance-for-nefecon-supplementary-application daily 0.8 https://clival.com/news/ideaya-biosciences-announces-phase-2-expansion-dose-for-ide397-monotherapy daily 0.8 https://clival.com/news/gsk-dreamm-3-phase-iii-trial-of-blenrep-to-treat-relapsedrefractory-multiple-myeloma-fails-to-meet-primary-endpoint daily 0.8 https://clival.com/news/astrazenecas-bevespi-aerosphere-gets-chinese-approval-to-treat-patients-with-copd daily 0.8 https://clival.com/news/amgen-request-for-full-approval-of-lumakras-in-lung-cancer-denied-by-fda daily 0.8 https://clival.com/news/us-fda-approves-janssens-of-darzalex-faspro-in-combo-with-pomalidomide-dexamethasone-for-patients-with-mm-after-first-or-subsequent-relapse daily 0.8 https://clival.com/news/advent-international-to-acquire-controlling-stake-in-zcl-chemicals daily 0.8 https://clival.com/news/pfizer-acquires-amplyx-pharmaceuticals daily 0.8 https://clival.com/news/gc-cells-promising-ab-201-cancer-treatment-to-begin-phase-1-trials-using-lunit-ai-platform daily 0.8 https://clival.com/news/maps-launches-psychedelic-fundamentals-an-online-education-curriculum-from-leading-psychedelic-organization daily 0.8 https://clival.com/news/aytu-bioscience-announces-definitive-agreement-to-acquire-innovus-pharmaceuticals daily 0.8 https://clival.com/news/biosion-enters-research-collaboration-with-immunogen-to-create-novel-antibody-drug-conjugates daily 0.8 https://clival.com/news/roche-and-regeneron-collaborate-to-significantly-increase-global-supply-of-regn-cov2-investigational-antibody-combination-for-covid-19 daily 0.8 https://clival.com/news/bayer-scores-eu-approval-for-ckd-drug-kerendia daily 0.8 https://clival.com/news/novartis-mmv-announce-decision-to-move-to-phase-3-study-for-novel-ganaplacidelumefantrine-sdf-combination-in-adults-and-children-with-malaria daily 0.8 https://clival.com/news/abbisko-therapeutics-announced-the-entry-into-a-licensing-agreement-for-pimicotinib-absk021-with-merck daily 0.8 https://clival.com/news/aitia-enters-into-collaboration-with-servier daily 0.8 https://clival.com/news/technoderma-medicines-completes-phase-1-dose-escalation-clinical-trial-of-tdm-180935-for-atopic-dermatitis daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-to-market-generic-hypertension-drug daily 0.8 https://clival.com/news/venus-remedies-receives-marketing-authorisation-from-azerbaijan-for-anticoagulant-enoxaparin daily 0.8 https://clival.com/news/gicell-announces-research-collaboration-with-hk-innon-for-next-generation-car-nk-therapy daily 0.8 https://clival.com/news/eiger-and-partner-anges-receive-approval-for-zokinvy-lonafarnib-for-hutchinson-gilford-progeria-syndrome-and-processing-deficient-progeroid-laminopathies-in-japan daily 0.8 https://clival.com/news/eisai-launches-antiepileptic-drug-in-china daily 0.8 https://clival.com/news/sanofi-launches-dedicated-vaccines-mrna-center-of-excellence daily 0.8 https://clival.com/news/ginkgo-bioworks-announces-collaboration-with-merck-to-improve-active-pharmaceutical-ingredient-manufacturing daily 0.8 https://clival.com/news/datopotamab-deruxtecan-demonstrates-clinically-significant-increase-in-overall-survival daily 0.8 https://clival.com/news/soligenix-extends-patent-protection-for-its-filovirus-vaccine daily 0.8 https://clival.com/news/mgi-inks-partnership-with-genos-medica-tcl-group-to-expand-presence-in-latin-america daily 0.8 https://clival.com/news/ferring-ramps-up-bladder-cancer-drug-launch-with-royalty-deal-worth-up-to-500m daily 0.8 https://clival.com/news/mylan-biocon-launch-biosimilar-of-cancer-drug-herceptin-in-us daily 0.8 https://clival.com/news/senzime-an-fukuda-denshi-launching-the-first-integrated-tetragraph-module daily 0.8 https://clival.com/news/amgen-collaborates-with-tscan-therapeutics daily 0.8 https://clival.com/news/zydus-receives-final-approval-from-the-usfda-for-varenicline-tablets daily 0.8 https://clival.com/news/ausperbio-announces-fda-clearance-of-ind-application-of-ahb-137-in-chronic-hepatitis-b-treatment daily 0.8 https://clival.com/news/sanofi-and-biovac-spearhead-polio-vaccine-manufacturing-capabilities-in-africa daily 0.8 https://clival.com/news/ligand-announces-icagens-expansion-of-collaboration-with-roche-to-develop-and-commercialize-therapies-for-neurological-diseases daily 0.8 https://clival.com/news/4p-pharma-delta-4-sign-agreement-to-identify-and-develop-treatments-for-rare-autoimmune-chronic-liver-disease daily 0.8 https://clival.com/news/astrazeneca-and-msds-lynparza-gets-chinese-approval-for-1st-line-maintenance-treatment-with-bevacizumab-for-hrd-positive-advanced-ovarian-cancer daily 0.8 https://clival.com/news/gsk-and-vir-biotechnology-announce-continuing-progress-of-the-comet-clinical-development-programme-for-sotrovimab daily 0.8 https://clival.com/news/alembic-gets-usfda-nod-for-doxycycline-hyclate-tablets daily 0.8 https://clival.com/news/pfizer-announces-positive-results-from-phase-3-talapro-2-study-of-talzenna-in-combo-with-xtandi-to-treat-mcrpc daily 0.8 https://clival.com/news/china-nmpa-approves-chugai-pharma daily 0.8 https://clival.com/news/telix-pharmaceuticals-announces-licence-agreement-with-lilly-for-olaratumab daily 0.8 https://clival.com/news/verrica-pharmaceuticals-announces-fda-filing-acceptance-of-new-drug-application-for-vp-102 daily 0.8 https://clival.com/news/medimap-signs-partnership-with-wrha-to-improve-emergency-room-wait-times daily 0.8 https://clival.com/news/vanflyta-first-flt3-inhibitor-approved-in-the-usa-specifically-for-patients-with-newly-diagnosed-flt3-itd-positive-aml daily 0.8 https://clival.com/news/agena-bioscience-enters-into-partnership-with-nrichdx daily 0.8 https://clival.com/news/aleor-dermaceuticals-receives-final-usfda-approval-for-cold-sore-drug daily 0.8 https://clival.com/news/akums-receives-dcgi-approval-for-triple-combination-diabetes-treatment daily 0.8 https://clival.com/news/innovent-announces-first-patient-dosed-in-phase-2-pivotal-trial-of-ibi310-ctla-4-combined-with-tyvyt-sintilimab-injection-for-the-treatment-of-s daily 0.8 https://clival.com/news/pfizer-wellcome-launches-surveillance-programme-to-combat-growing-threat-of-amr-in-low-and-middle-income-countries daily 0.8 https://clival.com/news/phase-1-clinical-trial-of-potential-universal-flu-vaccine-opens-at-nih-clinical-center daily 0.8 https://clival.com/news/genscript-and-innobation-enter-into-the-agreement-for-car-t-therapy daily 0.8 https://clival.com/news/prelude-therapeutics-announces-clinical-trial-collaboration-with-beigene daily 0.8 https://clival.com/news/acepodia-announces-fda-clearance daily 0.8 https://clival.com/news/merck-announces-positive-results-from-phase-3-keynote-966-trial-of-keytruda-in-combo-with-chemotherapy-to-treat-advanced-or-unresectable-biliary-tract-cancer daily 0.8 https://clival.com/news/bristol-myers-squibbs-breyanzi-receives-us-fda-approval-for-adults daily 0.8 https://clival.com/news/kalivir-immunotherapeutics-astellas-ink-research-agreement-to-develop-and-commercialise-vet2-l2-novel-oncolytic-virus daily 0.8 https://clival.com/news/inxmed-enters-license-agreement-with-escugen-to-develop-next-generation-adcs daily 0.8 https://clival.com/news/merck-to-collaborate-with-donghao-lansheng-to-pilot-new-import-policy-in-china daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-kyverna-therapeutics-cd19-car-t-cell-product-candidate-kyv-101-to-treat-refractory-progressive-ms daily 0.8 https://clival.com/news/fda-approves-abbvie-pfizer-drugs-for-eczema-creating-competition-for-sanofi daily 0.8 https://clival.com/news/pfizer-and-biontech-announce-an-agreement-with-us-government-for-up-to-600-million-doses-of-mrna-based-vaccine-candidate-against-sars-cov-2 daily 0.8 https://clival.com/news/serres-group-receives-18-million-research-grant-from-business-finland daily 0.8 https://clival.com/news/uks-first-norovirus-mrna-vaccine-trial-launched daily 0.8 https://clival.com/news/pfizer-opens-analytics-gateway-in-india-to-propel-growth daily 0.8 https://clival.com/news/resync-bio-launches-to-automate-data-and-operations-in-drug-discovery daily 0.8 https://clival.com/news/lung-cancer-research-foundation-announces-new-research-collaboration-with-bayer-pharma daily 0.8 https://clival.com/news/mercks-keytruda-plus-chemotherapy-approved-by-fda daily 0.8 https://clival.com/news/keybioscience-announces-extension-of-strategic-collaboration-with-lilly daily 0.8 https://clival.com/news/angle-signs-agreement-with-recursion-pharma-to-expand-pharma-services-business daily 0.8 https://clival.com/news/alkem-labs-signs-a-non-exclusive-patent-license-agreement-with-takeda daily 0.8 https://clival.com/news/seegene-partners-with-springer-nature-to-launch-nature-awards-mdx-impact-grants daily 0.8 https://clival.com/news/merck-presents-positive-results-from-phase-2b3-trial-of-clesrovimab daily 0.8 https://clival.com/news/omeicos-therapeutics-completes-enrollment-in-phase-2a-pmd-option-study daily 0.8 https://clival.com/news/bayer-submits-marketing-authorization-application-for-elinzanetant-to-ema daily 0.8 https://clival.com/news/insilico-medicine-reports-positive-phase-iia-results-for-ism001-055 daily 0.8 https://clival.com/news/immorta-bio-announces-a-significant-breakthrough-in-treatment-of-liver-failure daily 0.8 https://clival.com/news/find-therapeutics-initiates-patient-dosing-in-phase-1-study-of-ftx-101 daily 0.8 https://clival.com/news/ractigen-therapeutics-gains-fts-for-pioneering-sarna-therapy-rag-01 daily 0.8 https://clival.com/news/eterna-therapeutics-collabs-with-factor-bioscience-to-speed-up-cell-therapy-development daily 0.8 https://clival.com/news/abbott-announces-positive-data-from-life-btk-trial-of-esprit-btk-system daily 0.8 https://clival.com/news/zeon-lifesciences-forays-into-b2c-segment-with-launch-of-nutraceutical-products-zeonutra daily 0.8 https://clival.com/news/arrayplex-selected-by-immunome-for-targeted-cancer-therapies daily 0.8 https://clival.com/news/enanta-pharma-announces-top-line-results-for-edp-323-in-phase-2a-study daily 0.8 https://clival.com/news/bharat-biotech-collaborates-with-alopexx-to-develop-and-commercialize-av0328 daily 0.8 https://clival.com/news/sinovac-inks-new-agreements-for-covid-19-vaccine-cooperation daily 0.8 https://clival.com/news/sanofi-radiomedix-orano-med-enter-licensing-agreement-ofor-rare-cancers daily 0.8 https://clival.com/news/oncoinvent-announces-positive-interim-results-from-phase-12a-studies-of-radspherin daily 0.8 https://clival.com/news/dr-reddys-facility-assessment-concludes-successfully-after-us-fdas-vai-inspection daily 0.8 https://clival.com/news/indian-immunologicals-launches-multiple-indigenous-in-vitro-fertilization-media-for-embryo-transfer daily 0.8 https://clival.com/news/citiustech-partners-with-novant-health-to-support-enterprise-decision-intelligence-drive-outcomes daily 0.8 https://clival.com/news/vir-biotechnology-completes-exclusive-license-agreement-with-sanofi-for-t-cell-engager-therapies daily 0.8 https://clival.com/news/j-j-seeks-us-fda-approval-for-subcutaneous-tremfya-in-ulcerative-colitis daily 0.8 https://clival.com/news/chi-med-to-present-final-analysis-of-savolitinib-in-phase-ib-tatton-study-at-wclc-2020-on-jan-28-31 daily 0.8 https://clival.com/news/cipher-pharma-reports-moberg-pharmas-mob-015-fails-phase-3-primary-endpoint daily 0.8 https://clival.com/news/ge-healthcare-completes-phase-i-clinical-programme-for-macrocyclic-mri-contrast-agent daily 0.8 https://clival.com/news/takeda-receives-japanese-nod-to-manufacture-and-market-fruzaqla-for-colorectal-cancer daily 0.8 https://clival.com/news/hongene-biotech-recibiopharm-collaborate-to-enhance-gene-editing-drug-manufacturing-capabilities daily 0.8 https://clival.com/news/us-fda-approves-astrazenecas-tagrisso-for-stage-iii-egfr-mutated-lung-cancer daily 0.8 https://clival.com/news/regenxbio-reports-positive-results-from-phase-iiiiii-campsiite-trial-of-rgx-121 daily 0.8 https://clival.com/news/theriva-announces-positive-outcome-of-dsmc-review-in-phase-1b2a-trial-of-ribaxamase daily 0.8 https://clival.com/news/merck-eyebio-initiate-phase-2b3-trial-for-restoret-to-treat-diabetic-macular-edema daily 0.8 https://clival.com/news/daiichi-sankyo-astrazeneca-announced-results-from-the-tropion-lung01-phase-3-trial daily 0.8 https://clival.com/news/annji-pharmaceutical-announced-a-licensing-agreement-with-avenue-therapeutics-to-develop-and-commercialize-aj201-a-first-in-class-clinical-asset-for-the-treatment-of-kennedy-disease daily 0.8 https://clival.com/news/cytomx-therapeutics-announces-probody daily 0.8 https://clival.com/news/gsk-announces-phase-iii-therapeutic-herpes-simplex-virus-vaccine-trial-fail-in-1ry-test daily 0.8 https://clival.com/news/bristol-myers-squibb-janssen-collaboration-launches-pivotal-phase-3-librexia-trial-programme-evaluating-milvexian daily 0.8 https://clival.com/news/gujarat-fdca-grants-manufacturing-approval-to-several-cos-for-amphotericin-b-to-treat-black-fungus daily 0.8 https://clival.com/news/indoco-remedies-baddi-facility-unit-i-receives-gmp-certification-from-eu-health-authority daily 0.8 https://clival.com/news/mercks-zilovertamab-vedotin-r-chp-yields-100-crr-in-phase-2-dlbcl daily 0.8 https://clival.com/news/check-cap-receives-us-fda-ide-approval-to-begin-pivotal-study-of-c-scan-in-us daily 0.8 https://clival.com/news/stealth-biotherapeutics-to-receive-fara-grant-to-develop-mitochondrial-therapeutic-sbt-589 daily 0.8 https://clival.com/news/johnson-and-johnson-opens-first-satellite-center-for-global-health-discovery-in-asia-pacific-at-duke-nus-to-advance-dengue-research daily 0.8 https://clival.com/news/hitgen-enters-research-agreement-with-nitrase-therapeutics-focused-on-dna-encoded-library-based-drug-discovery daily 0.8 https://clival.com/news/china-nmpa-approves-mercks-welireg-for-von-hippel-lindau-disease-associated-tumours daily 0.8 https://clival.com/news/beximco-pharma-introduces-generic-version-of-pfizers-paxlovid-the-first-us-fda-approved-oral-therapy-for-covid-19-treatment daily 0.8 https://clival.com/news/china-nmpa-approves-mercks-welireg-to-treat-von-hippel-lindau-disease-associated-tumours daily 0.8 https://clival.com/news/merck-reports-positive-results-from-phase-3-keynote-859-trial-of-keytruda-in-combo-with-chemotherapy-to-treat-her2-negative-gastric-or-gej-adenocarcinoma daily 0.8 https://clival.com/news/pfizers-braftovimektovi-shows-positive-results-in-braf-v600e-mutant-metastatic-nsclc daily 0.8 https://clival.com/news/shilpa-medicare-completes-phase-1-trial-for-rha daily 0.8 https://clival.com/news/chugai-launches-phesgo-subcutaneous-combination-in-japan-to-treat-her2-positive-breast-and-colorectal-cancer daily 0.8 https://clival.com/news/genome-and-company-enters-clinical-trial-collaboration-with-msd-to-evaluate-gen-001-in-combo-with-keytruda-in-phase-2-trial-in-biliary-tract-cancer-patients daily 0.8 https://clival.com/news/sparc-signs-pact-with-bioprojet-to-acquire-exclusive-rights-for-drug-to-treat-auto-immune-diseases daily 0.8 https://clival.com/news/biocartis-enters-agreement-with-astrazeneca-to-develop-market-companion-diagnostic-test-for-tagrisso daily 0.8 https://clival.com/news/chugai-pharma-announces-positive-results-from-phase-iii-haven-7-study-of-hemlibra-to-treat-infants-with-severe-haemophilia-a daily 0.8 https://clival.com/news/unraveling-the-science-behind-vicks-vaporub-therapeutic-vapours daily 0.8 https://clival.com/news/ema-committee-recommends-expanded-indication-approval-for-vifor-fresenius-medicals-velphoro-to-treat-children-with-ckd daily 0.8 https://clival.com/news/ema-accepts-for-review-vfmcrp-and-chemocentryxs-maa-for-avacopan-to-treat-anca-associated-vasculitis-and-microscopic-polyangiitis daily 0.8 https://clival.com/news/bioatla-and-beigene-revise-global-development-and-commercialization-agreement-for-novel-conditionally-active-biologic-ctla-4-candidate-ba3071 daily 0.8 https://clival.com/news/cstone-pharmaceuticals-and-jiangsu-hengrui-pharmaceuticals-announce-strategic-partnership-and-exclusive-licensing-agreement-on-anti-ctla-4-monoclonal-antibody-cs1002-in-greater-china daily 0.8 https://clival.com/news/who-approves-chinas-sinovac-covid19-vaccine-for-emergency-use daily 0.8 https://clival.com/news/smartcella-obtains-approval-for-gmp daily 0.8 https://clival.com/news/us-fda-pada-committee-recommends-approval-of-pt027-to-treat-asthma-in-people-aged-18-years-and-older daily 0.8 https://clival.com/news/innocare-announces-first-prescription-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-under-boao-hope-citys-early-access-program daily 0.8 https://clival.com/news/spago-nanomedical-gets-regulatory-approval-to-begin-phase-iia-study-trial-with-mri-contrast-agent-sn132d-in-endometriosis daily 0.8 https://clival.com/news/antares-pharma-enters-into-a-global-development-agreement-with-idorsia-pharmaceuticals-ltd daily 0.8 https://clival.com/news/assembly-bio-shares-interim-phase-1b-results-for-abi-4334-in-hepatitis-b daily 0.8 https://clival.com/news/bristol-myers-announces-positive-results-from-phase-3-checkmate-8hw-trial-of-opdivo-plus-yervoy-in-patients-with-msi-h-or-dmmr-metastatic-colorectal-cancer daily 0.8 https://clival.com/news/argenx-gains-japan-approval-for-vyvdura-in-cidp-treatment-for-adults daily 0.8 https://clival.com/news/japanese-mhlw-approves-solasias-organoarsenic-drug-darvias-injection-to-treat-relapsed-or-refractory-ptcl daily 0.8 https://clival.com/news/lupin-launches-generic-lipitor-tablets daily 0.8 https://clival.com/news/moderna-and-chiesi-group-sign-agreement-to-develop-treatment-for-pulmonary-arterial-hypertension-pah daily 0.8 https://clival.com/news/prothera-biologics-and-takeda-enter-global-licensing-agreement-to-develop-novel-plasma-derived-therapy-based-on-inter-alpha-inhibitor-proteins-iaip daily 0.8 https://clival.com/news/innovent-announces-first-patient-dosed-in-ph-1-clinical-trial-of-bispecific-antibody daily 0.8 https://clival.com/news/lupin-launches-generic-myfortic-delayed-release-tablets daily 0.8 https://clival.com/news/agreement-with-cheplapharm-for-rights-to-seroquel-and-seroquel-xr-in-europe-and-russia-completed daily 0.8 https://clival.com/news/x-guide-receives-eu-mdr-certification daily 0.8 https://clival.com/news/asieris-photocure-enter-into-a-license-agreement-for-development-and-commercialization-of-cevira daily 0.8 https://clival.com/news/lupin-launches-generic-truvada-tablets daily 0.8 https://clival.com/news/theramex-announces-an-agreement-with-enzene-biosciences-limited-to-develop-and-commercialize-tocilizumab-a-biosimilar-for-the-treatment-of-rheumatoid-arthritis daily 0.8 https://clival.com/news/biocon-subsidiary-acquires-research-facility-from-pfizer-healthcare daily 0.8 https://clival.com/news/netsurf-launches-three-new-products-under-its-healthcare-range-to-deal-with-lifestyle-disorders daily 0.8 https://clival.com/news/gentibio-announces-collaboration-with-bristol-myers-squibb-to-pioneer-engineered-treg-therapies-for-inflammatory-bowel-diseases daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-for-astrazenecas-trixeo-aerosphere-for-maintenance-treatment-of-copd daily 0.8 https://clival.com/news/mersana-therapeutics-announces-research-collaboration-and-license-agreement-with-janssen-to-advance-novel-antibody-drug-conjugates daily 0.8 https://clival.com/news/bayer-bristol-myers-squibb-and-ono-pharmaceutical-enter-into-a-clinical-collaboration-agreement daily 0.8 https://clival.com/news/china-based-haplox-partners-with-illumina-to-build-benchtop-sequencing-system daily 0.8 https://clival.com/news/gc-biopharmanovel-pharmas-sanfilippo-syndrome-treatment-obtains-fda-ind-approval daily 0.8 https://clival.com/news/gilead-and-evoq-therapeutics-announce-collaboration-to-advance-immunotherapies daily 0.8 https://clival.com/news/us-fda-approves-pfizer-braftovi-mektovi-for-braf-v600e-mutant-metastatic-non-small-cell-lung-cancer daily 0.8 https://clival.com/news/cipla-acquires-additional-stake-in-digital-tech-startup-goapptive daily 0.8 https://clival.com/news/abbvie-umoja-biopharma-enter-collaboration-to-develop-novel-in-situ-car-t-cell-therapies daily 0.8 https://clival.com/news/wuxi-biologics-gets-good-manufacturing-practice-certification-from-brazils-anvisa daily 0.8 https://clival.com/news/bayer-extends-partnership-with-peking-university-to-foster-pharmaceutical-innovation-in-china daily 0.8 https://clival.com/news/ocular-therapeutix-reports-interim-10-month-data-from-ongoing-us-phase-1-trial-evaluating-otx-tki-to-treat-wet-amd daily 0.8 https://clival.com/news/pfizer-buys-arena-in-67bn-deal-to-broaden-immuno-inflammatory-portfolio daily 0.8 https://clival.com/news/lanova-medicines-announces-initiation-of-phase-1-clinical-trial-of-bispecific-antibody-lm-299 daily 0.8 https://clival.com/news/takeda-announces-approval-of-cuvitru-subcutaneous-immunoglobulin-in-japan-for-patients-with-agammaglobulinemia-or-hypogammaglobulinemia daily 0.8 https://clival.com/news/lupin-launches-varenicline-tablets-in-the-united-states daily 0.8 https://clival.com/news/castle-creek-pharmaceutical-holdings-announces-agreement-to-acquire-fibrocell daily 0.8 https://clival.com/news/zydus-gets-tentative-us-fda-approval daily 0.8 https://clival.com/news/biogen-bio-thera-ink-agreement-to-develop-manufacture-and-commercialize-bat1806-to-treat-rheumatoid-arthritis daily 0.8 https://clival.com/news/lipocine-announces-positive-topline-results-from-phase-2-study-of-lpcn-1148-to-treat-cirrhosis daily 0.8 https://clival.com/news/us-fda-approves-alnylam-amvuttra-to-treat-polyneuropathy-of-hereditary-transthyretin-mediated-amyloidosis-in-adults daily 0.8 https://clival.com/news/boston-pharma-inks-3-year-out-licenses-and-option-agreement-with-gsk-for-advancement-of-multiple-pre-phase-2-programmes daily 0.8 https://clival.com/news/merck-to-discontinue-phase-3-keyvibe-008-trial-for-vibostolimab-and-pembrolizumab-combination daily 0.8 https://clival.com/news/sitero-acquires-clarios-eclinical-technology-suite-to-enhance-clinical-trial-delivery daily 0.8 https://clival.com/news/hansa-biopharma-completes-enrollment-in-phase-2-study-of-imlifidase-in-amr-episodes-post-kidney-transplantation daily 0.8 https://clival.com/news/global-group-inc-launches-innovative-salivary-testing-pilot-to-combat-oral-health-disparities daily 0.8 https://clival.com/news/genome-and-company-announces-clinical-trial-collaboration-with-msd-to-evaluate-gen-001-in-combination-of-keytruda daily 0.8 https://clival.com/news/liscure-gets-clearance-to-start-phase-2-trial-for-lb-p8 daily 0.8 https://clival.com/news/stevanato-launches-ez-fill-kit-and-laboratory-fill-and-finish-service-to-support-small-batch-drug-development-and-commercialization daily 0.8 https://clival.com/news/caredxs-alloseq-tx-17-gets-ce-mark-approval-to-enable-global-availability-of-innovative-hc-technology-hla-testing-for-transplant-patients daily 0.8 https://clival.com/news/thermo-scientific-launches-cultimaxx daily 0.8 https://clival.com/news/sihuan-receives-nmpa-approval-for-exclusive-medical-aesthetic-product-letybo daily 0.8 https://clival.com/news/entasis-therapeutics-receives-acquisition-proposal-from-existing-majority-stockholder-innoviva-inc daily 0.8 https://clival.com/news/lilly-buys-fda-approved-new-injectable-medicine-from-nexus-pharma daily 0.8 https://clival.com/news/zai-lab-and-innoviva-announce-nmpa-approval-for-xacduro daily 0.8 https://clival.com/news/janssen-seeks-us-fda-expanded-indication-approval-for-edurant-to-include-treatment-of-hiv-1-infection-in-children daily 0.8 https://clival.com/news/medigenes-im-tcr-technology-receives-japanaese-patent daily 0.8 https://clival.com/news/vor-biopharma-and-metagenomi-to-collaborate-on-engineered-hematopoietic-stem-cell-therapies daily 0.8 https://clival.com/news/alembic-pharma-receives-us-fda-approval-for-generic-macrodantin-capsules daily 0.8 https://clival.com/news/sanofi-regeneron-announce-second-phase-3-trial-of-dupixent-to-treat-prurigo-nodularis-met-primary-and-key-secondary-endpoints daily 0.8 https://clival.com/news/valneva-pfizer-announce-positive-phase-2-paediatric-data-for-lyme-disease-vaccine-candidate daily 0.8 https://clival.com/news/lupin-gets-usfda-nod-to-market-its-mania-and-epilepsy-treatment-drug-in-us daily 0.8 https://clival.com/news/pfizer-elrexfio-receives-us-fda-accelerated-approval-for-relapsed-or-refractory-multiple-myeloma daily 0.8 https://clival.com/news/alembic-pharma-receives-us-fda-approval-for-fulvestrant-injection daily 0.8 https://clival.com/news/hempstreet-partners-with-gynica-to-bolster-combined-rd-for-womens-health-with-cannabinoid-based-phytomedicine daily 0.8 https://clival.com/news/pfizer-biontech-seek-us-fda-emergency-use-authorization-for-omicron-ba4ba5-adapted-bivalent-vaccine-booster-in-children-5-through-11-years-of-age daily 0.8 https://clival.com/news/hansoh-announces-strategic-collaboration-with-eqrx-for-almonertinib daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-ganirelix-acetate-injection daily 0.8 https://clival.com/news/bioarctics-partner-eisai-receives-us-fda-fast-track-designation-for-lecanemab-to-treat-alzheimers-disease daily 0.8 https://clival.com/news/leica-biosystems-and-leap-therapeutics-partner-on-companion-diagnostic-to-advance-care-for-cancer-patients daily 0.8 https://clival.com/news/mankind-pharma-launches-justoza daily 0.8 https://clival.com/news/thurston-group-launches-modis-dental-partners daily 0.8 https://clival.com/news/us-fda-approves-asieris-pharma-ind-application-for-oral-drug-apl-1401-to-treat-moderately-to-severely-active-uc daily 0.8 https://clival.com/news/agilent-gets-korean-mfds-approval-for-companion-diagnostic-pd-l1-ihc-22c3-pharmdx-on-dako-omnis-to-detect-nsclc daily 0.8 https://clival.com/news/chugai-in-licenses-rnai-therapeutic-zilebesiran-for-hypertension daily 0.8 https://clival.com/news/china-nmpa-approves-gsks-nucala-for-use-in-severe-asthma-with-an-eosinophilic-phenotype daily 0.8 https://clival.com/news/lanova-medicines-enters-exclusive-license-agreement-with-astrazeneca-for-novel-gprc5d-targeting-antibody-drug-conjugate-lm-305 daily 0.8 https://clival.com/news/astellas-pharma-and-kate-therapeutics-enter-into-licence-agreement-for-kt430 daily 0.8 https://clival.com/news/sorrento-announces-positive-results-from-phase-1b-study-of-epidural-resiniferatoxin-injection-to-treat-intractable-cancer-pain daily 0.8 https://clival.com/news/ascletis-announces-ind-approval-of-oral-viral-polymerase-inhibitor-asc10-for-monkeypox-indication-by-china-nmpa daily 0.8 https://clival.com/news/shionogi-receives-us-fda-fast-track-designation-for-ensitrelvir-fumaric-acid-an-investigational-oral-antiviral-for-covid-19 daily 0.8 https://clival.com/news/eu-approves-astrazeneca-daiichi-sankyo-enhertu-to-treat-patients-with-unresectable-or-metastatic-her2-low-metastatic-breast-cancer daily 0.8 https://clival.com/news/scisparc-signs-collaboration-agreement-with-polyrizon-for-brain-targeting-using-intranasal-hydrogel-systems daily 0.8 https://clival.com/news/glenmark-looks-to-license-out-second-drug-asset daily 0.8 https://clival.com/news/bla-for-datopotamab-deruxtecan-accepted-in-us daily 0.8 https://clival.com/news/sanofi-regenerons-libtayo-snags-lung-cancer-nod-taking-a-stab-at-keytrudas-megablockbuster-lead daily 0.8 https://clival.com/news/remegen-announces-publication-of-results-from-two-phase-ii-studies-for-disitamab-vedotin-in-latest-issue-of-journal-of-clinical-oncology-jco daily 0.8 https://clival.com/news/lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-immunometabolic-medicines daily 0.8 https://clival.com/news/sanofi-enters-agreement-with-janssen-to-develop-commercialise-vaccine-candidate-for-extraintestinal-pathogenic-e-coli daily 0.8 https://clival.com/news/neurocrine-biosciences-gets-us-fda-breakthrough-therapy-designation-for-crinecerfont-in-congenital-adrenal-hyperplasia daily 0.8 https://clival.com/news/indian-immunologicals-receives-dcgi-approval-for-measles-rubella-vaccine daily 0.8 https://clival.com/news/astrazeneca-completes-transfer-of-global-rights-to-eklira-duaklir-to-covis-pharma daily 0.8 https://clival.com/news/amphastar-receives-fda-tentative-approval-for-vasopressin daily 0.8 https://clival.com/news/wuxi-xdc-partners-with-multitude-therapeutics-hyslink-in-novel-linker-payload-technology-enabling-clients-to-speed-up-adc-discovery-and-development daily 0.8 https://clival.com/news/geneoscopy-seeks-us-fda-premarket-approval-for-noninvasive-colorectal-cancer-rna-biomarker-screening-test daily 0.8 https://clival.com/news/biolinerx-begins-phase-2-trial-for-motixafortide daily 0.8 https://clival.com/news/astrazenecas-severe-asthma-treatment-approved-in-eu-for-self-administration daily 0.8 https://clival.com/news/shanghai-public-health-clinical-center-completed-the-first-patient-dosing-in-clinical-study-of-pd-l1-antibody-asc22-in-combination-with-chidamide-for-functional-cure-of-hiv-infection daily 0.8 https://clival.com/news/bd-acquires-vancouver-washington-based-leading-rfid-pharmacy-technology-company-gsl-solutions daily 0.8 https://clival.com/news/innovent-announces-publication-of-mazdutide-ibi362-phase-2-full-results-in-chinese-patients-with-overweight-or-obesity-in-nature-communications daily 0.8 https://clival.com/news/indoco-remedies-receives-us-fda-tentative-approval-for-canagliflozin-tablets daily 0.8 https://clival.com/news/biomotiv-and-bristol-myers-squibb-announce-the-launch-of-anteros-pharmaceuticals daily 0.8 https://clival.com/news/herbolea-biotech-ink-agreement-granting-iberfar-the-rights-to-utilize-its-extraction-and-purification-technologies-in-portugal daily 0.8 https://clival.com/news/tarveda-therapeutics-and-sciclone-pharmaceuticals-international-establish-licensing-agreement-for-pen-866-in-greater-china daily 0.8 https://clival.com/news/aptar-pharmas-airless-system-delivers-china-nmpa-approved-rosacea-treatment daily 0.8 https://clival.com/news/roche-gets-us-fda-nod-for-first-companion-diagnostic-to-identify-patients-with-her2-low-metastatic-breast-cancer-eligible-for-enhertu daily 0.8 https://clival.com/news/fda-advisers-back-new-endpoint-for-myeloma-approvals daily 0.8 https://clival.com/news/innate-pharma-gets-us-fda-clearance-to-begin-phase-1-study-of-nectin-4-adc daily 0.8 https://clival.com/news/lilly-omvoh-receives-us-fda-approval-for-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis daily 0.8 https://clival.com/news/lupin-launches-generic-fosaprepitant-injection-in-us daily 0.8 https://clival.com/news/shivalik-rasayan-ltd-have-successfully-submitted-usmdf-for-api-palbociclib-to-us-fda daily 0.8 https://clival.com/news/johnson-johnson-to-buy-shockwave-medical daily 0.8 https://clival.com/news/turnstone-biologics-announces-til-therapy-research-collaboration-with-the-university-of-montreal-hospital-research-centre daily 0.8 https://clival.com/news/argenx-and-zai-lab-announces-biologics-licence-application-bla-for-vyvgart daily 0.8 https://clival.com/news/formosa-pharmaceuticals-announces-licensing-agreement-with-eyenovia-inc-for-the-commercialization-of-app13007-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery daily 0.8 https://clival.com/news/xtalpi-and-ck-life-sciences-to-collaborate-in-ai-empowered-tumour-vaccine-research-and-development-opening-a-new-paradigm-for-scientific-innovation daily 0.8 https://clival.com/news/lonza-acquires-synaffix daily 0.8 https://clival.com/news/achillion-receives-breakthrough-therapy-designation-from-fda-for-danicopan-for-treatment-of-paroxysmal-nocturnal-hemoglobinur daily 0.8 https://clival.com/news/subcutaneous-injection-pen-for-methotrexate-gains-approval daily 0.8 https://clival.com/news/shouti-introduces-basecamp-bio-as-a-wholly-owned-subsidiary-to-expand-pipeline-and-partnerships daily 0.8 https://clival.com/news/lupin-receives-us-fda-marketing-approval-for-generic-welchol-tablets daily 0.8 https://clival.com/news/gemini-therapeutics-and-avitide-enter-into-exclusive-license-agreement daily 0.8 https://clival.com/news/syngene-to-acquire-unit-3-of-stelis-biopharma-to-add-20000-liters-of-installed-biologics-drug-substance-manufacturing-capacity daily 0.8 https://clival.com/news/shanghai-henlius-biotech-expands-collaboration-with-kgbio-genexine-biologics daily 0.8 https://clival.com/news/opiant-pharmaceuticals-and-aptar-pharma-expand-long-term-collaboration-for-the-manufacture-of-unidose-nasal-spray-for-opnt003-nasal-nalmefene daily 0.8 https://clival.com/news/pfizer-shares-top-line-results-from-phase-23-epic-pep-study-of-paxlovid-for-post-exposure-prophylactic-use daily 0.8 https://clival.com/news/vicore-pharma-inks-licensing-agreement-with-nippon-shinyaku-to-develop-and-commercialize-drug-candidate-c21-in-japan daily 0.8 https://clival.com/news/scisparc-submits-ind-application-to-us-fda-for-phase-iib-trial-for-tourette-syndrome daily 0.8 https://clival.com/news/ablaze-pharma-enters-agreement-with-yonghe-pharma-to-develop-series-of-targeted-radiopharmaceutical-therapy-products daily 0.8 https://clival.com/news/jacobio-pharma-announces-breakthrough-therapy-designation-from-china-cde-for-kras-g12c-inhibitor-glecirasib-for-the-treatment-of-pancreatic-cancer daily 0.8 https://clival.com/news/rational-vaccines-and-shenzhen-mellow-hope-pharm-industrial-co-ltd-establish-collaboration-for-the-development-of-herpes-vaccines-in-china daily 0.8 https://clival.com/news/aleor-gets-us-fda-approval-for-nystatin-and-triamcinolone-acetonide-cream-usp daily 0.8 https://clival.com/news/biogens-aduhelm-already-battling-us-skepticism-faces-likely-european-rejection daily 0.8 https://clival.com/news/sirio-soon-to-launch-personalised-womens-health-platform daily 0.8 https://clival.com/news/indocos-api-kilo-lab-manufacturing-facility-and-ias-division-completes-fda-inspection daily 0.8 https://clival.com/news/oxford-biomedica-announces-that-sio-gene-therapies-intends-to-cease-the-license-agreement-for-gene-therapy-programme-in-parkinsons-disease daily 0.8 https://clival.com/news/phase-2-results-for-amlitelimab-shows-positive-signs-for-ad daily 0.8 https://clival.com/news/acumen-pharma-begins-dosing-in-altitude-ad-phase-2-trial-of-sabirnetug daily 0.8 https://clival.com/news/goldfinch-bio-announces-licensing-agreement-with-takeda-for-cb1-monoclonal-antibody-for-the-treatment-of-rare-and-metabolic-kidney-diseases daily 0.8 https://clival.com/news/acerus-announces-closing-of-acquisition-of-serenity-pharmaceuticals-llc-and-acquisition-of-global-rights-to-noctiva daily 0.8 https://clival.com/news/elsevier-launches-first-branch-of-traditional-chinese-medicine-taxonomy daily 0.8 https://clival.com/news/mgi-tech-eurofins-genomics-partner-for-dnbseq-t202-sequencer daily 0.8 https://clival.com/news/abbvie-acquires-djs-antibodies-further-strengthening-immunology-pipeline daily 0.8 https://clival.com/news/aribio-granted-ema-authorization-for-phase-3-clinical-trial-of-ar1001 daily 0.8 https://clival.com/news/scisparc-to-acquire-automax daily 0.8 https://clival.com/news/sorrento-enters-into-merger-agreement-to-acquire-smartpharm-and-develop-pipeline-of-gene-encoded-therapeutic-antibodies-starting-with-neutralizing-an daily 0.8 https://clival.com/news/primerx-launches-new-pharmacy-technology-focused-podcast daily 0.8 https://clival.com/news/mannkind-announces-clinical-data-for-conference daily 0.8 https://clival.com/news/dupixent-sbla-accepted-for-fda-priority-review-for-treating-chronic-rhinosinusitis daily 0.8 https://clival.com/news/tarsier-pharma-receives-fda-agreement-under-special-protocol-assessment-spa-for-tarsier-04-phase-3-trial-of-trs01-ophthalmic-solution-for-the-treatment-of-non-infectious-uveitis-including-uveitic-glaucoma daily 0.8 https://clival.com/news/vanda-pharmaceuticals-announces-fda-update-for-supplemental-nda-for-hetlioz-in-the-treatment-of-insomnia daily 0.8 https://clival.com/news/wuxi-biologics-enter-agreement-to-acquire-pfizer-chinas-biologics-ds-dp-manufacturing-facilities daily 0.8 https://clival.com/news/us-fda-places-partial-clinical-hold-of-sanofi-phase-3-studies-of-tolebrutinib-in-ms-and-myasthenia-gravis daily 0.8 https://clival.com/news/cambrex-to-acquire-snapdragon-chemistry-a-leader-in-continuous-flow-api-development-services daily 0.8 https://clival.com/news/chinese-biotech-startup-lanova-medicines-inks-600-m-deal-with-astrazeneca daily 0.8 https://clival.com/news/biocept-receives-canadian-patent-entitled-methods-and-reagents-for-signal-amplification daily 0.8 https://clival.com/news/merck-crispr-gene-editing-technology-receives-us-patent daily 0.8 https://clival.com/news/astrazeneca-durvalumab-receives-cdsco-approval-for-treatment-of-biliary-tract-cancer daily 0.8 https://clival.com/news/eisai-enters-industry-academia-government-joint-research-agreement-with-four-universities-in-japan daily 0.8 https://clival.com/news/novo-nordisk-to-acquire-obesity-drug-developer-inversago daily 0.8 https://clival.com/news/pfizer-and-biontech-announce-positive-early-data-from-clinical-trial-of-omicron-ba4ba5-adapted-bivalent-booster-in-individuals-18-years-and-older daily 0.8 https://clival.com/news/redhill-announces-fda-snda-approval-for-talicia daily 0.8 https://clival.com/news/charles-river-labs-curigin-collaborate-to-produce-oncolytic-rnai-gene-therapy daily 0.8 https://clival.com/news/medtronic-receives-approval-for-first-rdn-system daily 0.8 https://clival.com/news/astrazenecas-ultomiris-receives-european-approval-to-adults-with-generalised-myasthenia-gravis daily 0.8 https://clival.com/news/eisai-submits-sbla-for-iv-maintenance-dosing-of-leqembi daily 0.8 https://clival.com/news/sarepta-therapeutics-receives-fast-track-designation-for-srp-9001-micro-dystrophin-gene-therapy-for-the-treatment-of-duchenne-muscular-dystrophy daily 0.8 https://clival.com/news/plagued-by-production-issues-pfizer-aims-to-shift-epipen-work-to-mylan-upjohn-merger daily 0.8 https://clival.com/news/alexion-dodges-soliris-biosimilar-bullet-for-now-with-amgen-patent-settlement daily 0.8 https://clival.com/news/us-fda-approves-two-opdivo-based-regimens-as-first-line-treatments-for-unresectable-advanced-or-metastatic-escc daily 0.8 https://clival.com/news/exelixis-arcus-biosciences-enter-clinical-trial-collaboration-to-evaluate-zanzalintinib-in-combo-with-ab521-in-patients-with-advanced-rcc daily 0.8 https://clival.com/news/xenetic-tokyo-medical-university-signs-aggrement-for-advancing-of-dnase-based-oncology-platform daily 0.8 https://clival.com/news/nmpa-approves-oral-formulation-of-akynzeo-in-china daily 0.8 https://clival.com/news/merck-plans-to-begins-trial-for-hpv-vaccine-gardasil-9 daily 0.8 https://clival.com/news/abbott-launches-hbsag-next-assay-in-india-to-accelerate-early-and-enhanced-detection-of-hepatitis-b daily 0.8 https://clival.com/news/qiagens-syndromic-qiastat-dx-test-fda-clearance-for-ard-diagnosis daily 0.8 https://clival.com/news/astrazenecas-fasenra-receives-fda-approval daily 0.8 https://clival.com/news/citius-pharma-collaborates-with-university-of-pittsburgh-for-phase-1-investigator-initiated-study-to-evaluate-iontak-in-combo-with-pembrolizumab-in-solid-tumours daily 0.8 https://clival.com/news/bavarian-nordic-launches-mpox-vaccine-jynneos-in-us-market daily 0.8 https://clival.com/news/natera-and-bgi-genomics-announce-commercial-launch-of-the-bgi-natera-signatera-assay-in-china daily 0.8 https://clival.com/news/fda-approves-priority-review-status-to-ptc-therapeutics-bla-for-upstaza daily 0.8 https://clival.com/news/knight-therapeutics-enters-into-exclusive-licensing-agreement-with-supernus-pharmaceuticals-for-qelbree-viloxazine-in-canada daily 0.8 https://clival.com/news/gsk-announces-phase-iii-ruby-trial-of-jemperli-plus-chemotherapy-meets-endpoint-of-os-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer daily 0.8 https://clival.com/news/mirum-pharmaceuticals-and-gc-pharma-enter-into-exclusive-licensing-agreement-to-develop-and-commercialize-maralixibat-for-rare-liver-diseases-in-south daily 0.8 https://clival.com/news/epizyme-and-hutchmed-announce-strategic-collaboration-to-develop-and-commercialize-tazverika-tazemetostat-in-greater-china daily 0.8 https://clival.com/news/amneal-enters-us-biosimilars-market-with-approval-of-releukotm-filgrastim-ayow daily 0.8 https://clival.com/news/curasight-accelerates-phase-iiia-trials-to-include-5-types-of-cancer daily 0.8 https://clival.com/news/venkat-pharmas-clinical-trials-on-herbovir-show-high-antiviral-immune-boosting-properties-to-treat-covid-19-patients daily 0.8 https://clival.com/news/alembic-pharma-receives-us-fda-tentative-approval-for-generic-pradaxa-capsules daily 0.8 https://clival.com/news/fierce-pharma-asia-lilly-innovents-pd-1-review-takeda-bayer-patent-settlement daily 0.8 https://clival.com/news/bio-techne-announces-partnership-with-lunaphore daily 0.8 https://clival.com/news/sentynl-therapeutics-nulibry-injection-gets-uk-mhra-approval-for-mocd-type-a daily 0.8 https://clival.com/news/pistoia-alliance-partners-with-matador daily 0.8 https://clival.com/news/astrazenecas-imfinzilynparza-regimens-granted-ec-approval-to-treat-endometrial-cancer daily 0.8 https://clival.com/news/bayer-begins-phase-ii-confidence-study-of-initial-combo-therapy-of-finerenone-with-empagliflozin-in-patients-with-ckd-type-2-diabetes daily 0.8 https://clival.com/news/merck-opens-enrollment-in-new-phase-3-trials-with-once-daily-islatravir-in-combo-with-doravirine-to-treat-hiv-1-infection daily 0.8 https://clival.com/news/eucure-biopharma-a-subsidiary-of-biocytogen-announces-partnership-with-isu-abxis-for-the-development-of-tri-specific-antibodies-using-yh003-antibody-sequence daily 0.8 https://clival.com/news/fda-launches-new-clinical-trial-center-to-improve-innovation-communication daily 0.8 https://clival.com/news/zynex-receives-fda-clearance daily 0.8 https://clival.com/news/cambridge-biotherapies-launches-ketamine-infusions-for-pain-and-headache-management daily 0.8 https://clival.com/news/umoja-biopharma-and-iaso-biotherapeutics-announce-research-collaboration-to-bring-off-the-shelf-therapies-to-patients-with-hematological-malignancies daily 0.8 https://clival.com/news/bayer-begins-phase-ii-study-of-soluble-guanylate-cyclase-activator-bay3283142 daily 0.8 https://clival.com/news/lilly-announces-phase-3-study-positive-results-of-mirikizumab-compared-to-ustekinumab daily 0.8 https://clival.com/news/libtayo-cemiplimab-receives-positive-chmp-opinion-for-the-treatment-in-europe-of-two-advanced-cancers daily 0.8 https://clival.com/news/inhibrx-receives-fda-orphan-drug-designation-for-inbrx-101-for-the-treatment-of-alpha-1-antitrypsin-deficiency daily 0.8 https://clival.com/news/us-fda-approves-daiichi-sankyos-vanflyta-for-patients-with-newly-diagnosed-flt3-itd-positive-aml daily 0.8 https://clival.com/news/i-mab-accelerates-clinical-development-of-anti-cd47-monoclonal-antibody-lemzoparlimab-in-us-china daily 0.8 https://clival.com/news/raysearch-expands-collaboration-with-bebig-medical daily 0.8 https://clival.com/news/merck-gets-antitrust-clearance-in-germany-austria-for-pending-acquisition-of-acceleron-pharma daily 0.8 https://clival.com/news/tivdak-receives-approval-to-treat-recurrent-or-metastatic-cervical-cancer daily 0.8 https://clival.com/news/rarestone-group-received-approval-for-pitolisant-wakix-by-china-nmpa daily 0.8 https://clival.com/news/sk-bioscience-bolsters-strategic-partnership-with-novavax-through-equity-investment daily 0.8 https://clival.com/news/takeda-announced-positive-topline-results-from-a-randomized daily 0.8 https://clival.com/news/natco-pharma-seeks-us-fda-approval-for-generic-erdafitinib-tablets daily 0.8 https://clival.com/news/nagaland-government-and-vitamin-angels-collabs-to-improve-vit-a-supplementation-coverage daily 0.8 https://clival.com/news/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-bellus-health daily 0.8 https://clival.com/news/pfizer-reports-positive-results-from-phase-3-trial-of-etrasimod-to-treat-ulcerative-colitis daily 0.8 https://clival.com/news/reithera-exothera-collaborate-to-develop-large-scale-low-cost-per-dose-manufacturing-process-to-deliver-novel-vaccines-to-low-and-middle-income-countries daily 0.8 https://clival.com/news/edigene-announces-completion-of-last-patient-dosing-in-phase-i-clinical-trial-of-et-01-its-investigational-gene-editing-hematopoietic-stem-cell-therapy-for-transfusion-dependent-thalassemia daily 0.8 https://clival.com/news/legochem-biosciences-and-iksuda-enter-licensing-agreement-for-antibody-drug-conjugate-program daily 0.8 https://clival.com/news/arcutis-huadong-enter-collaboration-agreement-to-develop-manufacture-commercialize-topical-roflumilast-in-greater-china-southeast-asia daily 0.8 https://clival.com/news/ranbaxy-recalls-generic-lipitor-in-us daily 0.8 https://clival.com/news/novocure-begins-patient-enrollment-in-ef-33-phase-2-pilot-trial-of-tumor-treating-fields-delivered-utilizing-high-intensity-transducer-arrays daily 0.8 https://clival.com/news/pharmabcine-announces-safety-approval-for-4mg-single-dose-for-pmc-403-in-phase-i-trial daily 0.8 https://clival.com/news/pfizer-vaccines-launches-global-centers-of-excellence-network daily 0.8 https://clival.com/news/united-biopharma-announces-latest-results-of-ub-221-monoclonal-antibody-in-phase-i-single-dose-clinical-trial-with-csu-patients daily 0.8 https://clival.com/news/novartis-launches-first-of-its-kind-not-for-profit-portfolio-of-medicines-for-symptomatic-treatment-of-covid-19 daily 0.8 https://clival.com/news/partner-therapeutics-leukine-sargramostim-gets-approval-in-japan daily 0.8 https://clival.com/news/nascent-hypospray-join-hands-to-develop-an-alternative-delivery-for-pritumumab daily 0.8 https://clival.com/news/cidara-therapeutics-announces-agreement-with-janssen-to-develop-and-commercialize-avcs-for-the-prevention-and-treatment-of-influenza daily 0.8 https://clival.com/news/xvivo-receives-us-fda-approval-to-include-dcd-hearts-in-ide-clinical-trial daily 0.8 https://clival.com/news/antengene-gets-australian-hrec-nod-to-initiate-phase-i-trial-of-atg-018-to-treat-advanced-solid-tumours-and-hematologic-malignancies daily 0.8 https://clival.com/news/eisai-has-entered-into-an-agreement-with-gilead-sciences-inc daily 0.8 https://clival.com/news/epizyme-announces-fda-acceptance-of-new-drug-application-for-filing-with-priority-review-for-tazverik daily 0.8 https://clival.com/news/teva-and-natco-announce-launch-of-additional-strengths-for-the-generic-version-of-revlimid daily 0.8 https://clival.com/news/bc-platforms-partners-with-eu-funded-ai-driven-cancer-data-initiative daily 0.8 https://clival.com/news/us-fda-clears-lysogenes-ind-application-to-initiate-gene-therapy-clinical-trial-with-lys-gm101-to-treat-gm1-gangliosidosis daily 0.8 https://clival.com/news/clarity-receives-fda-fast-track-designation-for-64cu-sar-bispsma daily 0.8 https://clival.com/news/ipsen-announces-results-from-phase-iii-resilient-trial-evaluating-onivyde daily 0.8 https://clival.com/news/astellas-to-buy-iveric-bio-for-us-59-billion daily 0.8 https://clival.com/news/bayer-acquires-asklepios-biopharmaceutical-to-broaden-innovation-base-in-cell-and-gene-therapy daily 0.8 https://clival.com/news/patent-infringements-are-inevitable-in-pharma-sector-origiin-ip daily 0.8 https://clival.com/news/pfizer-reports-positive-results-from-phase-3-talapro-2-study-of-oral-parp-inhibitor-talzenna daily 0.8 https://clival.com/news/vaxart-announces-agreement-with-hvivo-to-develop-worlds-first-human-omicron-challenge-model daily 0.8 https://clival.com/news/mgi-tech-opens-customer-experience-center-in-brazil daily 0.8 https://clival.com/news/caris-life-sciences-xencor-ink-discovery-collaboration-and-license-agreement-for-novel-xmab-bispecific-antibodies daily 0.8 https://clival.com/news/dosing-begins-in-clinical-study-of-yolt-101-for-fh-therapy daily 0.8 https://clival.com/news/glenmark-receives-us-fda-approval-for-acetaminophen-and-ibuprofen-tablets daily 0.8 https://clival.com/news/wuxi-sta-passes-the-first-us-fda-drug-product-pre-approval-inspection-at-its-shanghai-waigaoqiao daily 0.8 https://clival.com/news/implicity-receives-us-fda-510k-clearance-for-signalhf daily 0.8 https://clival.com/news/bio-thera-solutions-expands-partnership-with-biomm-in-brazil-with-addition-of-bat2206-a-stelara daily 0.8 https://clival.com/news/jjs-rybrevant-combo-gets-fda-approval-as-first-chemo-free-treatment-for-nsclc daily 0.8 https://clival.com/news/lupin-introduces-doxycycline-for-injection-usp-in-us-market daily 0.8 https://clival.com/news/ginkgo-bioworks-collaborates-with-merck-to-improve-biologic-manufacturing daily 0.8 https://clival.com/news/maharashtra-fda-minister-holds-emergency-meeting-to-augment-supply-of-remdesivir-injection-medical-oxygen daily 0.8 https://clival.com/news/theriva-gets-idmc-recommendation daily 0.8 https://clival.com/news/hansa-biopharmas-idefirix-receives-european-approval-for-highly-sensitized-kidney-transplants-patients daily 0.8 https://clival.com/news/moderna-iavi-enter-collaboration-to-tackle-broad-global-health-priorities-using-mrna-for-vaccines-and-antibodies daily 0.8 https://clival.com/news/akron-biotech-inks-agreement-with-octapharma-to-produce-virally-inactivated-human-ab-serum-derived-from-octaplas-for-cell-therapy-market daily 0.8 https://clival.com/news/exagen-inc-and-queen-mary-university-of-london-announce-exclusive-license-and-collaboration-to-develop-novel-patented-molecular-signatures-for-rheumatoid-arthritis-biologic-therapeutic-selection daily 0.8 https://clival.com/news/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-fluoxetine-oral-solution-usp daily 0.8 https://clival.com/news/pfizer-announces-approval-of-abrysvo daily 0.8 https://clival.com/news/biocon-biologics-receives-eu-gmp-certification-for-its-new-manufacturing-unit-for-mabs daily 0.8 https://clival.com/news/chugai-receives-japanese-indication-approval-for-evrysdi-in-pre-symptomatic-sma daily 0.8 https://clival.com/news/bd-to-buy-edwards-lifesciences-critical-care-product-group-for-42-billion daily 0.8 https://clival.com/news/mankind-pharma-collaborates-with-russian-rdif-for-distribution-of-sputnik-v-in-india daily 0.8 https://clival.com/news/overland-adct-biopharma-announces-biologics-license-application-for-zynlonta daily 0.8 https://clival.com/news/sn-bioscience-gets-fta-for-small-cell-lung-cancer-therapy daily 0.8 https://clival.com/news/sebias-capillarys-3-dbs-devices-gets-grant-clearance daily 0.8 https://clival.com/news/us-fda-committee-to-review-amgen-data-supporting-snda-for-full-approval-of-lumakras-to-treat-kras-g12c-mutated-nsclc daily 0.8 https://clival.com/news/reform-biologics-and-milliporesigma-announce-a-licensing-agreement-for-excipient-development-and-commercialization daily 0.8 https://clival.com/news/anheart-therapeutics-to-acquire-rights-to-two-clinical-stage-oncology-candidates-from-daiichi-sankyo daily 0.8 https://clival.com/news/sirius-begins-patient-dosing-in-phase-1-trial daily 0.8 https://clival.com/news/context-therapeutics-gets-clearance-of-ind-for-phase-1-clinical-trial-of-ctim-76 daily 0.8 https://clival.com/news/samsung-biologics-signs-additional-development-and-manufacturing-agreement-with-stcube daily 0.8 https://clival.com/news/adcendo-gets-us-fda-clearance-to-begin-adcelerate-01-phase-iii-trial-of-adce-d01 daily 0.8 https://clival.com/news/teva-reaches-agreement-with-texas-to-settle-the-states-opioid-related-claims daily 0.8 https://clival.com/news/sanofi-dndi-hat-r-acc-consortium-announce-ema-committee-recommends-approval-of-fexinidazole-winthrop-to-treat-acute-form-of-sleeping-sickness daily 0.8 https://clival.com/news/ideaya-going-to-present-ide397-phase-1-expansion-results-at-eortc-nci-aacr-symposium daily 0.8 https://clival.com/news/storm-therapeutics-begins-patient-dosing-in-phase-1-study-of-oral-mettl3-inhibitor-stc-15-to-treat-solid-tumour daily 0.8 https://clival.com/news/biohaven-and-pfizer-announce-positive-topline-results-of-pivotal-trial-of-rimegepant-for-the-acute-treatment-of-migraine-in-china-and-south-korea daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-phanes-therapeutics-pt217 daily 0.8 https://clival.com/news/exelixis-ryvu-enter-license-agreement-to-develop-novel-sting-agonist-based-targeted-cancer-therapies daily 0.8 https://clival.com/news/cho-plus-announces-research-collaboration-agreement-with-janssen daily 0.8 https://clival.com/news/merck-receives-us-fda-expanded-indication-approval-for-keytruda-plus-padcev-to-treat-locally-advanced-or-metastatic-urothelial-cancer daily 0.8 https://clival.com/news/health-canada-approves-new-indication-for-mercks-prevymis daily 0.8 https://clival.com/news/mckesson-corporation-extends-pharmaceutical-distribution-agreement-with-cvs-health daily 0.8 https://clival.com/news/adcentrx-therapeutics-announces-china-nmpas-ind-grant-for-adrx-0706 daily 0.8 https://clival.com/news/resilience-acquires-swiftscale-biologics-a-leader-in-cell-free-protein-synthesis-technology daily 0.8 https://clival.com/news/seagen-genmab-seek-us-fda-approval-for-tisotumab-vedotin-to-treat-recurrentmetastatic-cervical-cancer daily 0.8 https://clival.com/news/gsk-vir-biotech-announce-joint-procurement-agreement-with-ec-to-supply-up-to-220000-doses-of-sotrovimab-to-treat-covid-19 daily 0.8 https://clival.com/news/cipla-usa-acquires-anti-infective-zemdri-from-achaogen-inc daily 0.8 https://clival.com/news/xnk-therapeutics-receives-ema-scientific-recommendation-for-evencaleucel-as-an-advanced-therapy-medicinal-product daily 0.8 https://clival.com/news/chinese-firms-to-advance-drug-development-for-hard-to-drug-molecular-targets daily 0.8 https://clival.com/news/merck-to-buy-cancer-drug-developer-arqule-for-27-bln-in-cash daily 0.8 https://clival.com/news/bioatla-receives-fda-clearance-for-ind-application-for-ba3361 daily 0.8 https://clival.com/news/shionogi-requests-approval-for-sdt-001-app daily 0.8 https://clival.com/news/syntheticgestalt-and-enamine-forge-partnership-to-develop-ai-driven-model-for-streamlining-drug-discovery daily 0.8 https://clival.com/news/i-mab-announces-china-nmpa-approval-for-phase-1b-trial-of-felzartamab-in-systemic-lupus-erythematosus daily 0.8 https://clival.com/news/european-medicines-agency-accepts-astellas-marketing-authorization-application-for-zolbetuximab daily 0.8 https://clival.com/news/green-valley-obtains-ind-approval-from-us-fda-for-sodium-oligomannates-global-phase-ii-clinical-trial-in-treating-parkinsons-disease daily 0.8 https://clival.com/news/azura-ophthalmics-presents-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction-at-ophthalmology-innovation-summit-xii daily 0.8 https://clival.com/news/astellas-collabs-with-yaskawa-to-create-an-innovative-cell-therapy-ecosystem daily 0.8 https://clival.com/news/osr-holdings-sillajen-collabs-to-develop-new-therapies-for-us-market-extension daily 0.8 https://clival.com/news/angelini-pharma-and-jcr-pharmaceuticals-announce-global-collaboration-for-the-development-and-commercialization-of-novel-biologic-therapies-in-epilepsy daily 0.8 https://clival.com/news/university-of-nottingham-enter-into-partnership-with-touchlight-to-accelerate-zika-vaccine-development daily 0.8 https://clival.com/news/fda-expects-to-convene-discussion-on-trailblazer-alz-2-study-of-donanemab daily 0.8 https://clival.com/news/anheart-licenses-two-clinical-stage-oncology-candidates-from-daiichi-sankyo daily 0.8 https://clival.com/news/ignis-stadas-britannia-partner-to-develop-commercialize-subcutaneous-apomorphine-in-mainland-china daily 0.8 https://clival.com/news/biogen-and-innocare-announce-license-and-collaboration-agreement-for-orelabrutinib-an-innovative-cns-penetrant-btk-inhibitor-for-the-potential-treatm daily 0.8 https://clival.com/news/ascletis-receives-china-nmpa-approval-to-begin-phase-iia-trial-of-asc10-to-treat-rsv-infection daily 0.8 https://clival.com/news/us-fda-approves-novartis-oral-monotherapy-fabhalta-to-treat-adults-with-paroxysmal-nocturnal-hemoglobinuria daily 0.8 https://clival.com/news/rhizen-pharmaceuticals-sa-and-curon-biopharmaceutical-limited-announce-an-exclusive-licensing-agreement-to-develop-and-commercialize-tenalisib-a-dual daily 0.8 https://clival.com/news/bristol-myers-phase-3-yellowstone-trial-of-zeposia-fails-in-result daily 0.8 https://clival.com/news/phosplatin-in-collaboration-with-nih-begin-patient-dosing-in-phase-2-trial-of-pt-112-for-thymoma-and-thymic-carcinoma daily 0.8 https://clival.com/news/fda-approves-hydrogel-injection-for-stress-urinary-incontinence daily 0.8 https://clival.com/news/sunho-announces-first-patient-dosed-in-phase-iii-clinical-trial-of-a-potential-first-in-class-immunocytokine-ibb0979 daily 0.8 https://clival.com/news/ideaya-reports-positive-interim-phase-2-data-for-darovasertib daily 0.8 https://clival.com/news/fda-prioritizes-review-of-sarclisa-for-newly-diagnosed-multiple-myeloma-patients daily 0.8 https://clival.com/news/roches-phase-iii-skyscraper-02-study-of-tiragolumab-plus-tecentriq-and-chemotherapy-to-treat-people-with-es-sclc-fails-to-meet-co-primary-endpoint daily 0.8 https://clival.com/news/pfizer-recalls-some-lots-of-blood-pressure-drug-due-to-potential-carcinogen daily 0.8 https://clival.com/news/china-nmpa-accepts-innovent-eli-lillys-snda-for-tyvyt-in-combo-with-gemcitabine-and-platinum-as-first-line-therapy-in-squamous-nsclc daily 0.8 https://clival.com/news/astrazenecas-tezspire-receives-european-approval-to-treat-severe-asthma daily 0.8 https://clival.com/news/valneva-completes-lot-to-lot-phase-3-trial-of-single-shot-chikungunya-vaccine-candidate daily 0.8 https://clival.com/news/primary-endpoint-met-in-phase-iii-clinical-trial-of-trilaciclib-in-chinese-patients-with-small-cell-lung-cancer daily 0.8 https://clival.com/news/alkem-labs-collaborates-with-biosergen-to-develop-anti-infective-for-severe-fungal-infections daily 0.8 https://clival.com/news/clinical-trial-ind-for-bioray-pharmaceuticals-br105-injection-receives-fda-approval daily 0.8 https://clival.com/news/exicure-inc-announces-termination-of-abbvie-and-ipsen-collaboration-agreements daily 0.8 https://clival.com/news/glenmark-and-strides-pharma-cipla-recall-products-in-the-us daily 0.8 https://clival.com/news/chugai-pharmaceuticals-and-omron-collaborate-to-enhance-automation-in-drug-discovery-research daily 0.8 https://clival.com/news/biosion-announces-research-collaboration-with-immunogen-to-create-novel-antibody-drug-conjugates daily 0.8 https://clival.com/news/us-fda-accepts-and-grants-priority-review-status-to-astrazeneca-snda-for-tagrisso-in-combo-with-chemotherapy-for-patients-with-egfr-mutated-advanced-lung-cancer daily 0.8 https://clival.com/news/dr-reddys-laboratories-announces-the-launch-of-doxycycline-capsules daily 0.8 https://clival.com/news/nurix-therapeutics-presents-positive-results-from-phase-1a1b-trial-of-btk-degrader-nx-5948 daily 0.8 https://clival.com/news/quoin-pharmaceuticals-signs-exclusive-distribution-agreement-with-er-kim-for-its-lead-asset-qrx003-for-netherton-syndrome daily 0.8 https://clival.com/news/endo-introduces-us-fda-approved-neostigmine-glycopyrrolate-combination-pre-filled-syringe-prevduo-in-us-market daily 0.8 https://clival.com/news/astellas-receives-positive-chmp-recommendation-for-zolbetuximab-combo-with-chemotherapy daily 0.8 https://clival.com/news/supriya-lifescience-ink-agreement-to-manufacture-and-market-plasma-nutritions-ioprotein-in-india daily 0.8 https://clival.com/news/fda-approves-additional-indication-for-fibryga daily 0.8 https://clival.com/news/daiichi-sankyo-seeks-japanese-approval-for-valemetostat-to-treat-for-patients-with-adult-t-cell-leukaemialymphoma daily 0.8 https://clival.com/news/axion-biosystems-expands-operations-with-acquisition-of-m-solv-manufacturing-limited daily 0.8 https://clival.com/news/t-knife-and-catalent-sign-technology-transfer-and-manufacturing-agreement-for-autologous-t-cell-receptor-based-cell-therapy daily 0.8 https://clival.com/news/dutch-biotech-argenx-claims-18bn-licensing-deal-with-jj daily 0.8 https://clival.com/news/moderna-receives-israelis-ministry-of-health-approval-to-import-covid-19-vaccine daily 0.8 https://clival.com/news/afya-limited-announces-the-acquisition-of-glic daily 0.8 https://clival.com/news/novartis-canada-clarius-partner-for-psoriatic-arthritis-care-in-canada daily 0.8 https://clival.com/news/genkore-announces-collaboration-with-a-us-based-company-on-in-vivo-gene-editing-therapy daily 0.8 https://clival.com/news/genenta-science-announces-extension-of-licence-agreement-with-ospedale-san-raffaele daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-genprex-reqorsa-immunogene-therapy-for-sclc-treatment daily 0.8 https://clival.com/news/leo-pharma-signs-agreement-to-divest-emollients-and-proctology-portfolio-to-karo-pharma daily 0.8 https://clival.com/news/nykode-therapeutics-announces-positive-results-from-phase-2-trial-with-vb1016-in-combo-with-atezolizumab-in-advanced-cervical-cancer daily 0.8 https://clival.com/news/gl-scientific-launches-bespoke-a-new-tailor-made-service-for-small-and-emerging-pharma-and-biotech-companies daily 0.8 https://clival.com/news/eu-approves-bayer-iodine-based-contrast-agent-ultravist-for-contrast-enhanced-mammography daily 0.8 https://clival.com/news/beckley-psytech-announces-phase-iia-results-bpl-003 daily 0.8 https://clival.com/news/mycovia-pharma-announces-partner-jiangsu-hengrui-pharma daily 0.8 https://clival.com/news/genworks-us-fda-approved-eva-colposcope-stethoscope-is-portable-non-invasive-for-cervical-exams daily 0.8 https://clival.com/news/gsk-vir-biotech-announce-comet-tail-phase-iii-trial-of-iv-administration-of-sotrovimab-for-early-treatment-of-covid-19-meets-primary-endpoint daily 0.8 https://clival.com/news/truveta-inks-strategic-collaboration-with-pfizer-to-accelerate-safety-insights-in-real-time daily 0.8 https://clival.com/news/palatin-announces-direct-to-consumer-telehealth-partnership-with-upscripthealth-for-vyleesi daily 0.8 https://clival.com/news/lupin-receives-us-fda-marketing-approval-for-turqoz-tablets daily 0.8 https://clival.com/news/calliditas-announces-positive-phase-2-results-from-setanaxib-trial daily 0.8 https://clival.com/news/beigene-launches-us-biologics-manufacturing-and-rd-facility daily 0.8 https://clival.com/news/pfizer-announces-topline-phase-2b-results-of-oral-glp-1r-agonist-danuglipron-in-adults-with-obesity daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-bristol-myers-repotrectinib daily 0.8 https://clival.com/news/us-fda-grants-marketing-auhtorisation-to-caption-healths-ai-guided-image-acquisition-system daily 0.8 https://clival.com/news/us-fda-clears-obi-pharma-ind-application-for-phase-12-study-of-obi-992 daily 0.8 https://clival.com/news/melanoma-research-alliance-welcomes-approval-for-amtagvi daily 0.8 https://clival.com/news/rona-therapeutics-announces-exclusive-licensing-transaction-from-sanofi-for-its-broad-sirna-therapeutic-portfolio-and-technology-platform daily 0.8 https://clival.com/news/brii-biosciences-and-qpex-biopharma-enter-into-agreement-to-acquire-global-rights-for-brii-693 daily 0.8 https://clival.com/news/merck-ervebo-gets-us-fda-expanded-indication-approval-for-zaire-ebolavirus-in-individuals-12-months-of-age-and-older daily 0.8 https://clival.com/news/eu-drug-watchdog-approves-first-rsv-infant-elderly-vaccine daily 0.8 https://clival.com/news/uks-life-sciences-sector-to-receive-a-279-million-boost-to-tackle-significant-health-challenges daily 0.8 https://clival.com/news/lupin-expects-increase-in-industry-collaborations-and-in-licensing-alliances-in-pharma-sector-in-2021 daily 0.8 https://clival.com/news/zhejiang-doer-biologics-announces-phase-i-trial-of-dr10624 daily 0.8 https://clival.com/news/enhertu-approved-in-the-eu-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer daily 0.8 https://clival.com/news/hangzhou-chance-pharmaceuticals-expands-pipeline-with-in-licensing-of-aer901-from-aerami-therapeutics daily 0.8 https://clival.com/news/menarini-group-and-insilico-medicine-enter-global-exclusive-license-agreement-for-novel-kat6-inhibitor-for-potential-breast-cancer-treatment-and-other-oncology-indications daily 0.8 https://clival.com/news/j-j-receives-fda-approval-for-opsynvi daily 0.8 https://clival.com/news/dr-reddys-lab-inks-pact-to-acquire-nimbus-health daily 0.8 https://clival.com/news/enhertu daily 0.8 https://clival.com/news/us-fda-approves-pfizers-pneumococcal-20-valent-conjugate-vaccine-prevnar-20-for-adults daily 0.8 https://clival.com/news/epcoritamab-epkinly-fda-approved-for-patients-with-relapsed-or-refractory-follicular-lymphoma daily 0.8 https://clival.com/news/sun-pharma-signs-voluntary-licensing-agreement-with-eli-lilly-for-expanding-access-to-baricitinib-to-help-alleviate-the-burden-of-covid-19-in-india daily 0.8 https://clival.com/news/us-fda-accepts-lupins-snda-for-solosec-to-treat-trichomoniasis daily 0.8 https://clival.com/news/ascentage-pharma-announces-ind-approval-in-china-for-phase-i-study-of-apg-5918-in-patients-with-advanced-solid-tumors-or-hematologic-malignancies daily 0.8 https://clival.com/news/astellas-snda-for-izervay-receives-approval daily 0.8 https://clival.com/news/beigene-asieris-ink-collaboration-to-evaluate-safety-and-efficacy-of-oral-apl-1202-in-combo-with-tislelizumab daily 0.8 https://clival.com/news/orameds-oral-insulin-candidate-fails-to-meet-phase-3-targets daily 0.8 https://clival.com/news/caliway-to-present-cbl-514-phase-2-study-results-for-subcutaneous-fat-reduction-at-imcas-2024 daily 0.8 https://clival.com/news/technoderma-medicines-phase-2-clinical-trial daily 0.8 https://clival.com/news/cytek-biosciences-gains-approval-for-1-laser-and-2-laser-6-color-tbnk-reagents-for-clinical-use-in-china daily 0.8 https://clival.com/news/applied-dna-gets-contract-from-hdt-bio-for-vaccine-development daily 0.8 https://clival.com/news/ascletis-and-suzhou-alphamab-expand-their-partnership-into-worldwide-license-agreement-for-asc22-envafolimab-to-treat-hepatitis-b-and-other-viral-diseases daily 0.8 https://clival.com/news/cytokinetics-royalty-pharma-expand-collaboration-for-launch-of-aficamten daily 0.8 https://clival.com/news/tropion-lung01-head-to-head-phase-3-trial-initiated-to-evaluate-datopotamab-deruxtecan-versus-docetaxel-in-previously-treated-patients-with-advanced-o daily 0.8 https://clival.com/news/synchrons-stentrode-receives-us-fda-breakthrough-device-designation daily 0.8 https://clival.com/news/immviras-mvr-t3011-obtained-nmpas-approval-for-intravenous-administration-iv-phase-i-clinical-trial daily 0.8 https://clival.com/news/bluerock-bitbio-enter-collaboration-agreement-to-discover-and-manufacture-of-regulatory-t-cell-based-therapies daily 0.8 https://clival.com/news/alcon-launches-systane-complete-eye-drops-in-europe daily 0.8 https://clival.com/news/bridgewest-group-launches-novacina-new-sterile-injectable-cdmo daily 0.8 https://clival.com/news/krystal-aim-for-global-expansion-with-vyjuvek daily 0.8 https://clival.com/news/roche-wins-approval-for-cancer-drug-kadcyla-in-fast-growing-china-market daily 0.8 https://clival.com/news/accord-healthcare-launches-additional-strengths-of-hydroxychloroquine-tablets daily 0.8 https://clival.com/news/alterity-therapeutics-receives-uk-mhra-nod-to-proceed-phase-2-trial-of-ath434-to-treat-multiple-system-atrophy daily 0.8 https://clival.com/news/iages-collaborates-with-technology-leaders-in-robotic-surgery-conducts-national-conference-in-coimbatore daily 0.8 https://clival.com/news/moderna-thermo-fisher-scientific-ink-long-term-strategic-partnership-to-manufacture-covid-19-vaccine-spikevax-in-us daily 0.8 https://clival.com/news/dyve-biosciences-announces-research-and-development-collaboration-with-moffitt-cancer-center daily 0.8 https://clival.com/news/chugai-obtained-approval-from-the-ministry-of-health daily 0.8 https://clival.com/news/sun-pharma-inks-licensing-pact-with-csir-iict-hyderabad daily 0.8 https://clival.com/news/merck-keytruda-plus-chemoradiotherapy-to-treat-patients-with-figo-2014-stage-iii-iva-cervical-cancer-receives-us-fda-approval daily 0.8 https://clival.com/news/sanofi-and-regeneron-announce-dupixent-significantly-reduced-copd-exacerbations-in-second-positive-phase-3-trial daily 0.8 https://clival.com/news/strides-pharma-recalls-over-6-lakhbottles-of-blood-pressure-treatmenttablets-in-us daily 0.8 https://clival.com/news/avistone-gets-approval-for-vebreltinib-as-initial-met-tki-therapy daily 0.8 https://clival.com/news/senhwa-biosciences-receives-us-fda-approval-to-begin-phase-1b-study-of-cx-5461-to-treat-brca2-or-palb2-solid-tumors daily 0.8 https://clival.com/news/amylyx-pharmaceuticals-announces-health-canada-approval-of-albrioza daily 0.8 https://clival.com/news/evox-therapeutics-announces-a-multi-target-rnai-and-antisense-research-collaboration-and-license-agreement-with-lilly daily 0.8 https://clival.com/news/hebecell-and-logomix-announce-collaboration-for-the-development-of-next-gen-genomically-engineered-psc-nk-cells daily 0.8 https://clival.com/news/alembic-pharma-gets-4-observations-from-us-fda-for-panelav-facility daily 0.8 https://clival.com/news/fujifilm-india-launches-synapse-3d-at-the-prestigious-abip daily 0.8 https://clival.com/news/affamed-therapeutics-licensee-of-dextenza daily 0.8 https://clival.com/news/akums-launches-lasmiditan-tablet-to-confront-migraine-challenges daily 0.8 https://clival.com/news/abbvie-says-multiple-parties-vying-for-assets-related-to-allergan-deal-approval daily 0.8 https://clival.com/news/enhertu-receives-japanese-approval-for-patients-with-previously-treated-her2-positive-metastatic-breast-cancer daily 0.8 https://clival.com/news/cansinobio-receives-european-gmp-certification-for-its-covid-19-vaccine-convidecia daily 0.8 https://clival.com/news/phase-3-trial-evaluating-antiviral-tecovirimat-with-monkeypox-infection-begins-in-us daily 0.8 https://clival.com/news/ehave-signs-licensing-agreement-to-enhance-its-telemedicine-platform daily 0.8 https://clival.com/news/moderna-announces-amendment-to-current-supply-agreement-with-uk-govt-for-additional-2-million-doses-of-mrna daily 0.8 https://clival.com/news/perfuzes-millipede-070-aspiration-catheter-millipede-088-access-catheter-receive-us-fda-approval-to-treat-acute-ischemic-stroke daily 0.8 https://clival.com/news/launch-of-tiopronin-delayed-release-tablets-with-patient-support-for-cystinuria-treatment daily 0.8 https://clival.com/news/telix-announces-licence-agreement-with-lilly-for-olaratumab daily 0.8 https://clival.com/news/hitgen-announces-license-agreement-with-merck-co-inc-kenilworth-nj-usa-to-access-compounds-for-potential-development-of-a-novel-class-of-drugs daily 0.8 https://clival.com/news/astellas-poseida-therapeutics-ink-research-collab-to-develop-allogeneic-cell-therapies-in-oncology daily 0.8 https://clival.com/news/astrazenecas-tagrisso-approved-to-add-with-chemotherapy daily 0.8 https://clival.com/news/daiichi-sankyo-announces-enhertu-approved-in-japan-as-first-her2-directed-therapy-for-patients-with-her2-mutant-metastatic-nsclc daily 0.8 https://clival.com/news/nucleai-and-debiopharm-launch-research-collaboration-utilizing-nucleais-ai-powered-biomarker-platform daily 0.8 https://clival.com/news/longeveron-announces-nhlbi-funded-phase-2-elpis-ii-trial-of-lomecel-b-in-hypoplastic-left-heart-syndrome-surpasses-50-enrollment-threshold daily 0.8 https://clival.com/news/nona-biosciences-enters-collaboration-with-alayabio-to-advance-car-t-cell-therapy daily 0.8 https://clival.com/news/solid-biosciences-announces-closing-of-acquisition-of-aavantibio-and-concurrent-75-million-private-placement daily 0.8 https://clival.com/news/oramed-pharmaceuticals-announces-results-from-phase-3-clinical-trial-of-ormd-0801-to-treat-type-2-diabetes daily 0.8 https://clival.com/news/aurobindo-pharma-arm-receives-usfda-nod-for-triamcinolone-acetonide-injectable-suspension daily 0.8 https://clival.com/news/clearpoint-neuro-receives-clearance-its-prism-bone-anchor-accessory daily 0.8 https://clival.com/news/fordoz-enters-contract-manufacturing-agreement-for-oncology-liposomal-product-with-lipomedix daily 0.8 https://clival.com/news/obseva-announces-sale-of-ebopiprant-license-agreement-to-xoma-for-up-to-113-million daily 0.8 https://clival.com/news/twist-bioscience-launches-kit-for-liquid-biopsy daily 0.8 https://clival.com/news/illumina-receives-european-commission-approval-to-divest-grail daily 0.8 https://clival.com/news/allergan-sightsavers-and-iapb-launch-keep-sight-india-initiative-to-prevent-glaucoma daily 0.8 https://clival.com/news/tectonic-therapeutic-to-present-positive-phase-1a-results-of-tx45-a-long-acting-fc-relaxin-fusion-protein-at-aha-2024 daily 0.8 https://clival.com/news/eyeing-600m-in-peak-sales-scynexis-preps-ambitious-launch-for-antifungal-brexafemme daily 0.8 https://clival.com/news/paragon-28-phantom-activcore-nail-system-receives-510k-clearance daily 0.8 https://clival.com/news/recursion-and-bayer-expand-fibrosis-collaboration-to-include-inferential-search-capabilities daily 0.8 https://clival.com/news/drug-maker-lupin-inks-licensing-pact-with-axantia-for-pegfilgrastim daily 0.8 https://clival.com/news/relief-therapeutics-partner-neurorx-seeks-us-fda-approval-to-begin-phase-23-trial-of-inhaled-rlf-100-to-treat-non-acute-lung-injury daily 0.8 https://clival.com/news/quantro-therapeutics-imp-enter-research-collaboration-to-accelerate-transcriptomic-drug-discovery daily 0.8 https://clival.com/news/nk-celltech-obtains-fda-clearance-for-nk010-clinical-trial daily 0.8 https://clival.com/news/p360-launches-edenhelp-a-novel-ai-powered-platform-for-healthcare-professionals-and-patients daily 0.8 https://clival.com/news/owl-therapeutics-inks-clinical-collaboration-with-abliva-to-advance-neurostat-for-traumatic-brain-injury daily 0.8 https://clival.com/news/argenx-and-zai-lab-announce-approval-of-efgartigimod-alfa-injection daily 0.8 https://clival.com/news/hansa-biopharma-announces-exclusive-agreement-with-sarepta-therapeutics-to-develop-and-promote-imlifidase daily 0.8 https://clival.com/news/gsk-gets-positive-results-from-dreamm-8-phase-iii-trial daily 0.8 https://clival.com/news/chiesi-group-and-haisco-pharmaceutical-collaborate-on-new-bronchiectasis-treatment daily 0.8 https://clival.com/news/m8-pharmaceuticals-and-vectans-pharma-signed-an-exclusive-licensing-agreement-of-loramyc-miconazole-lauriad-for-mexico-and-brazil daily 0.8 https://clival.com/news/savannah-phase-ii-trial-shows-tagrisso-plus-savolitinib-demonstrated-49-objective-response-rate-in-lung-cancer-patients-with-high-levels-of-met-overexpression-andor-amplification daily 0.8 https://clival.com/news/lupin-launches-us-fda-approved-generic-cellcept-tablets daily 0.8 https://clival.com/news/alnylam-pharma-medison-expand-collaboration-to-a-multi-regional-partnership-to-commercialize-rnai-therapeutics daily 0.8 https://clival.com/news/tcbp-shows-first-agreement-to-acquire-nk-platform-technologies daily 0.8 https://clival.com/news/uk-mhra-grants-marketing-approval-for-roches-ocrelizumab daily 0.8 https://clival.com/news/aspens-drug-to-prevent-preterm-birth-approved-by-fda daily 0.8 https://clival.com/news/fresenius-medical-care-launches-new-dialysis-machine-in-china daily 0.8 https://clival.com/news/orasure-technologies-omnigene-gut-dx-microbiome-collection-device-gets-de-novo-authorization-from-us-fda daily 0.8 https://clival.com/news/china-nmpa-approves-roches-tecentriq-in-combo-with-avastin-to-treat-people-with-most-common-form-of-liver-cancer daily 0.8 https://clival.com/news/polyu-launches-first-dedicated-interdisciplinary-master-programme-in-medical-physics daily 0.8 https://clival.com/news/boehringer-ingelheim-inks-agreement-with-chinese-startup-for-oncology-companion-diagnostics daily 0.8 https://clival.com/news/amneal-pharma-receives-fda-approval-for-naloxone-hci-nasal-spray daily 0.8 https://clival.com/news/biocon-biologics-completes-acquisition-of-viatris-global-biosimilars-business daily 0.8 https://clival.com/news/elevar-therapeutics-and-jiangsu-hengrui-pharma-partner-for-worldwide-licensing-of-camrelizumab-and-rivoceranib-for-unresectable-hepatocellular-carcinoma daily 0.8 https://clival.com/news/novartis-to-spin-off-generics-business-sandoz daily 0.8 https://clival.com/news/fermion-tyk2-jh2-inhibitor-fz007-119-received-ind-approval-from-china-nmpa daily 0.8 https://clival.com/news/nabriva-therapeutics-announces-first-patient-enrolled-in-phase-1-trial-of-xenleta daily 0.8 https://clival.com/news/bukwang-introduces-latuda-for-schizophrenia-and-bipolar-i-disorder-depression-treatment daily 0.8 https://clival.com/news/astrazenecas-dapagliflozin-shown-to-reduce-cv-fatality-in-deliver-phase-iii-trial daily 0.8 https://clival.com/news/merck-to-begin-new-phase-3-clinical-programme-with-lower-dose-of-daily-oral-islatravir-in-combo-with-doravirine-to-treat-hiv-1-infection daily 0.8 https://clival.com/news/wision-ai-receives-ce-mdr-mark-for-ai-colonoscopy-device daily 0.8 https://clival.com/news/anheart-therapeutics-announces-exclusive-license-agreement-with-nippon-kayaku-for-taletrectinib-in-japan daily 0.8 https://clival.com/news/fermion-announces-ind-approval-of-non-addictive-pain-relief-drug-fz008-145-by-china-nmpa daily 0.8 https://clival.com/news/blade-therapeutics-expands-anti-fibrotic-pipeline-with-acquisition-of-atxco-and-its-autotaxin-inhibitor-pat-409 daily 0.8 https://clival.com/news/medicure-announces-us-fda-provides-complete-approval-to-enroll-patients-in-pivotal-phase-3-trial-to-treat-rare-paediatric-disease daily 0.8 https://clival.com/news/angelini-pharma-collaborates-with-jcr-pharmaceuticals daily 0.8 https://clival.com/news/china-nmpa-approves-skyline-therapeutics-skg0106-for-neovascular-age-related-macular-degeneration-gene-therapy daily 0.8 https://clival.com/news/bio-thera-and-stada-reach-exclusive-agreement-for-bat2506 daily 0.8 https://clival.com/news/coya-therapeutics-announces-agreement-with-dr-reddys-laboratories daily 0.8 https://clival.com/news/us-fda-clears-jubilant-therapeutics-ind-for-novel-dual-lsd1-hdac6-inhibitor-jbi-802-for-treatment-of-solid-tumours daily 0.8 https://clival.com/news/fda-clearance-of-corus-navigation-access-system daily 0.8 https://clival.com/news/top-10-most-anticipated-drug-launches-of-2024 daily 0.8 https://clival.com/news/akcea-ionis-begin-neuro-ttransform-phase-3-trial-for-akcea-ttr-lrx-in-patients-with-polyneuropathy-driven-by-hereditary-ttr-amyloidosis daily 0.8 https://clival.com/news/fda-approves-phase-ii-study-of-ruxoprubart-for-anca-associated-vasculitis daily 0.8 https://clival.com/news/tiumbio-and-hansoh-pharma-announce-clinical-trial-approval-of-hs-10518tu2670 daily 0.8 https://clival.com/news/emoneeds-partners-with-new-venture-fund-and-naadam-to-provide-free-mental-health-treatment daily 0.8 https://clival.com/news/us-fda-approves-vertex-casgevy-to-treat-transfusion-dependent-beta-thalassemia daily 0.8 https://clival.com/news/alembic-pharma-gets-final-usfda-nod-for-fenofibrate-tablets daily 0.8 https://clival.com/news/roches-actemraroactemra-receives-us-fda-emergency-use-authorization-for-the-treatment-of-covid-19-in-hospitalised-adults-and-children daily 0.8 https://clival.com/news/gc-biopharma-signs-agreement-with-catalyst-biosciences-for-the-acquisition-of-rare-disease-pipeline-in-hematology daily 0.8 https://clival.com/news/arena-bioworks-launches-as-self-sustaining-centre-of-excellence-to-streamline-drug-development daily 0.8 https://clival.com/news/biogen-sets-to-realign-resources-for-alzheimer-disease-franchise daily 0.8 https://clival.com/news/andelyn-biosciences-selects-viral-vector-manufacturing-partner-for-cirm-accelerating-medicines-partnership-bgtc daily 0.8 https://clival.com/news/j-ints-bio-launches-ai-supercomputing-alliance-to-transform-cancer-therapy daily 0.8 https://clival.com/news/sol-gel-technologies-enters-into-licence-agreement-with-searchlight-pharma daily 0.8 https://clival.com/news/dynacure-receives-us-patent-for-investigational-antisense-product-candidate-dyn101-to-treat-myotubular-and-centronuclear-myopathies daily 0.8 https://clival.com/news/britains-gsk-to-buy-affinivax-for-up-to-33-bln-in-vaccines-push daily 0.8 https://clival.com/news/granules-india-receives-us-fda-approval-for-glycopyrrolate-oral-solution daily 0.8 https://clival.com/news/aslan-pharmaceuticals-and-thermo-fisher-scientific-announce-partnership-to-manufacture-high-concentration-formulation-of-eblasakimab-for-future-studies daily 0.8 https://clival.com/news/astrazenecas-ondexxya-receives-japanese-approval-for-reversal-of-acute-major-bleeds-in-patients-on-factor-xa-inhibitors daily 0.8 https://clival.com/news/vertex-pharma-soon-to-acquire-alpine-immune-sciences daily 0.8 https://clival.com/news/alcon-to-acquire-aerie-pharmaceuticals-inc-enhancing-its-ophthalmic-pharmaceutical-portfolio daily 0.8 https://clival.com/news/oclean-launches-worlds-smallest-smart-oral-irrigator daily 0.8 https://clival.com/news/innovent-announces-phase-1b-study-results-of-mazdutide-ibi362-in-chinese-patients-with-type-2-diabetes-published-in-nature-communications daily 0.8 https://clival.com/news/shionogi-and-gardp-or-chai-sign-license-and-collaboration-agreements-to-treat-bacterial-infections-by-expanding-access-to-cefiderocol-in-135-countries daily 0.8 https://clival.com/news/shilpa-medicare-gets-us-fda-nod-for-erlotinib-tablets daily 0.8 https://clival.com/news/novartis-partners-with-american-society-of-haematology-to-fight-sickle-cell-disease-in-sub-saharan-africa daily 0.8 https://clival.com/news/menarini-looks-east-with-invida-acquisition daily 0.8 https://clival.com/news/fdc-launches-favipiravir-oral-suspension-to-treat-covid-19-in-india daily 0.8 https://clival.com/news/eisai-co-ltd-entered-into-an-agreement-with-gilead-sciences-inc daily 0.8 https://clival.com/news/kintor-pharma-announces-first-patient-dosing-of-phase-iii-clinical-trial-of-kx-826-pyrilutamide-for-treating-androgenic-alopecia-patients-in-china daily 0.8 https://clival.com/news/enzene-biosciences-launches-its-first-manufacturing-base-in-the-us daily 0.8 https://clival.com/news/alligator-bioscience-signs-antibody-agreement-for-greater-china daily 0.8 https://clival.com/news/chance-pharmaceuticals-and-acorda-therapeutics-announce-agreement-to-provide-inbrija daily 0.8 https://clival.com/news/rajiv-gandhi-ayurveda-medical-college-in-mahe-pondicherry-gets-licence-to-manufacture-medicines daily 0.8 https://clival.com/news/lupin-introduces-mirabegron-er-tablets-in-us-markets daily 0.8 https://clival.com/news/gardp-and-mitsubishi-tanabe-pharma-corporation-announce-partnership-in-search-for-new-antibiotics daily 0.8 https://clival.com/news/enzene-biosciences-launches-first-manufacturing-base-in-us daily 0.8 https://clival.com/news/kyowa-kirin-and-mei-pharma-announce-first-patient-dosed-in-japanese-pivotal-phase-2-study-of-zandelisib-in-patients-with-indolent-b-cell-non-hodgkins daily 0.8 https://clival.com/news/ampath-labs-inks-strategic-partnership-with-emami-frank-ross daily 0.8 https://clival.com/news/bridgebio-keeps-fda-approval-spree-rolling-this-time-with-nod-for-targeted-bile-duct-cancer-med daily 0.8 https://clival.com/news/ascletis-begins-patient-dosing-in-phase-iii-trial-of-asc40-for-treatment-of-acne daily 0.8 https://clival.com/news/visen-gets-bla-for-lonapegsomatropin-in-china daily 0.8 https://clival.com/news/astrazenecas-phase-iii-tulip-2-trial-of-anifrolumab-to-treat-systemic-lupus-erythematosus-meets-primary-endpoint daily 0.8 https://clival.com/news/bayer-new-eylea-8-mg-receives-european-marketing-approval-to-treat-namd-and-diabetic-macular-edema daily 0.8 https://clival.com/news/mesoblast-resubmits-bla-to-us-fda-for-approval-of-ryoncil-in-children-with-sr-agvhd daily 0.8 https://clival.com/news/avexegen-therapeutics-gets-294-million-nihs-sbir-grant-to-develop-oral-neuregulin-4-based-therapy-for-ibd daily 0.8 https://clival.com/news/sandoz-receives-european-marketing-approval-for-biosimilar-tyruko-for-multiple-sclerosis daily 0.8 https://clival.com/news/gator-bio-inks-distribution-agreement-with-i-and-l-biosystems daily 0.8 https://clival.com/news/wuxi-biologics-congratulates-amicus-therapeutics-on-us-fda-approval-for-new-treatment-for-pompe-disease daily 0.8 https://clival.com/news/wuxi-biologics-launches-wuxia-adcc-plus-to-advance-the-development-and-manufacturing-of-afucosylated-antibodies-enhancing-adcc-effect daily 0.8 https://clival.com/news/bayer-buys-bluerock-in-600-mln-bet-on-stem-cell-therapies daily 0.8 https://clival.com/news/inventiva-and-hepalys-pharma-announce-licence-agreement-to-commercialize-lanifibranor daily 0.8 https://clival.com/news/eisai-gets-japanese-orphan-drug-designation-for-ultrahigh-dose-mecobalamin-with-prospective-indication-for-delaying-progression-of-disease-and-functional-impairment-of-als daily 0.8 https://clival.com/news/henlius-deepens-collaboration-with-intas-to-bring-henlius-novel-anti-pd-1-mab-serplulimab-to-europe-and-india daily 0.8 https://clival.com/news/bayer-initiates-oasis-4-phase-iii-study-of-elinzanetant-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy daily 0.8 https://clival.com/news/aayush-wellness-board-approved-10-for-1-stock-split-and-esop daily 0.8 https://clival.com/news/lead-pharma-enters-into-a-research-collaboration-and-license-agreement-with-roche-to-develop-oral-small-molecules-for-immune-mediated-diseases daily 0.8 https://clival.com/news/shinobi-therapeutics-launches-with-completion-of-51m-series-a-to-advance-hypoimmune-ips-t-cell-therapy-platform daily 0.8 https://clival.com/news/oncoheroes-biosciences-inc-out-licences-volasertib-to-notable-labs-for-the-global-adult-development-of-its-anticancer-therapy daily 0.8 https://clival.com/news/element-biosciences-launches-the-aviti daily 0.8 https://clival.com/news/biostar-stem-cell-research-institute-developed-stem-cell-therapy-gets-japanese-approval-to-begin-treatment-for-parkinson-disease-patients daily 0.8 https://clival.com/news/colorcon-completes-acquisition-of-controlled-atmosphere-packaging-specialist-airnov-healthcare-packaging daily 0.8 https://clival.com/news/first-commercial-drug-manufactured-via-ajinomoto-bio-pharma-services-ajiphase-technology-receives-fda-approval daily 0.8 https://clival.com/news/gsk-reports-positive-results-from-dreamm-7-head-to-head-phase-iii-trial-for-blenrep-in-relapsedrefractory-multiple-myeloma daily 0.8 https://clival.com/news/icotec-ags-kong-tl-and-the-kong-c-vertebral-body-replacement-systems-receives-us-fda-and-european-approvals daily 0.8 https://clival.com/news/acurx-pharma-presents-ibezapolstat-phase-2-trial-results-for-cdi-at-scientific-conference daily 0.8 https://clival.com/news/oncohost-announces-clinical-trial-collaboration-with-roswell-park-comprehensive-cancer-center-to-analyze-immunotherapy-resistance daily 0.8 https://clival.com/news/jubilant-therapeutics-announces-first-patient-dosing-in-global-clinical-trials-for-jbi-802-and-jbi-778 daily 0.8 https://clival.com/news/bioversys-joins-eu-funded-respirintm-programme-for-its-broad-spectrum-drug-candidates daily 0.8 https://clival.com/news/mercks-keytruda-pembrolizumab-approved-in-china-for-escc-tumors daily 0.8 https://clival.com/news/usfda-issues-6-observations-to-natco-pharmas-api-facility-near-hyderabad daily 0.8 https://clival.com/news/discovery-life-sciences-acquires-allcells daily 0.8 https://clival.com/news/takedas-vedolizumab-gains-approval-for-crohns-disease daily 0.8 https://clival.com/news/genscript-probio-and-rvac-medicines-announce-strategic-partnership-for-gmp-plasmid-dna-manufacturing-for-mrna-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/astrazeneca-ionis-eye-us-approval-after-positive-trial-data daily 0.8 https://clival.com/news/mabwell-announces-first-patient-dosed-in-phase-ibii-trial-of-its-novel-nectin-4-targeting-adc-in-combination-with-pd-1-inhibitor daily 0.8 https://clival.com/news/roche-receives-european-approval-for-tecentriq-in-combo-with-abraxane-to-treat-people-with-pd-l1-positive-tnbc daily 0.8 https://clival.com/news/us-fda-approves-chiesi-global-rare-diseases-lamzede-for-alpha-mannosidosis daily 0.8 https://clival.com/news/singlera-genomics-announces-research-collaboration-with-astellas-pharma-pursuing-methylation-based-tools-to-better-understand-biological-reactions-to-pharmaceuticals daily 0.8 https://clival.com/news/cellectis-ucart22-granted-odd-and-rpdd-status-by-fda daily 0.8 https://clival.com/news/vestige-launches-absorvit-sublingual-oral-spray-to-address-vitamin-deficiency daily 0.8 https://clival.com/news/thermo-fisher-scientific-collaborates-with-arsenal-biosciences daily 0.8 https://clival.com/news/evusheld-long-acting-antibody-combination-approved-in-the-eu-for-the-treatment-of-covid-19 daily 0.8 https://clival.com/news/cnd-life-sciences-receives-24-mn-phase-ii-nih-sbir-grant-to-advance-diagnostic-technology-for-neurodegenerative-diseases daily 0.8 https://clival.com/news/enlivexs-immunotherapy-product-candidate-allocetra-receives-us-patent-to-treat-gout-inflammatory-bowel-disease-crohns-disease-ulcerative-colitis daily 0.8 https://clival.com/news/ionis-pharma-inks-licensing-agreement-with-bicycle-therapeutics-to-increase-delivery-capabilities-of-advanced-lica-medicines daily 0.8 https://clival.com/news/lupin-receives-health-canada-approval-for-generic-inderal-la-capsules daily 0.8 https://clival.com/news/myonex-completes-acquisition-of-hubertus-clinical-trial-and-packaging-business daily 0.8 https://clival.com/news/boehringer-ingelheim-kyowa-kirin-enter-license-agreement-to-develop-novel-first-in-class-treatment-for-fibro-inflammatory-diseases daily 0.8 https://clival.com/news/tivdak-supplemental-biologics-license-application-accepted-for-priority-review-by-fda-for-patients-with-recurrent-or-metastatic-cervical-cancer daily 0.8 https://clival.com/news/us-fda-grants-510k-clearance-to-babson-diagnostics-betterway-blood-testing-ecosystem daily 0.8 https://clival.com/news/blk-max-hospital-collaborates-with-sgei-to-discuss-the-advanced-endoscopic-practices daily 0.8 https://clival.com/news/carsgen-presents-data-from-china-pivotal-phase-ii-trial-of-bcma-car-t-zevor-cel-ct053-at-2022-ash-annual-meeting daily 0.8 https://clival.com/news/daiichi-sankyo-demonstrates-breadth-and-depth-of-oncology-portfolio-across-multiple-cancers-with-new-data-at-esmo-asia-sabcs-ash daily 0.8 https://clival.com/news/astrazeneca-receives-cdsco-approval-to-import-and-market-andexanet-alfa-in-india daily 0.8 https://clival.com/news/eton-pharmaceuticals-announces-fda-acceptance-of-nda-for-et-400 daily 0.8 https://clival.com/news/valneva-begins-vaccination-in-paediatric-patients-in-phase-2-trial-of-single-shot-chikungunya-vaccine-ixchiq daily 0.8 https://clival.com/news/hitachi-high-tech-and-invivoscribe-partner-to-advance-molecular-diagnostics-and-precision-medicine daily 0.8 https://clival.com/news/sunshine-biopharma-inks-agreement-with-university-of-arizona-to-advance-anti-coronavirus-drug-development-programme daily 0.8 https://clival.com/news/junshi-biosciences-gets-approval-of-snda-for-toripalimab-and-bevacizumab-combination-therapy daily 0.8 https://clival.com/news/telix-and-nucliber-sign-distribution-agreement-for-prostate-cancer-imaging-in-spain daily 0.8 https://clival.com/news/pfizer-and-biontech-announce-data-from-preclinical-studies-of-mrna-based-vaccine-candidate-against-covid-19 daily 0.8 https://clival.com/news/us-fda-approves-abbott-new-lab-automation-system-glp-systems-track daily 0.8 https://clival.com/news/us-fda-approves-dupixent-as-first-and-only-treatment-indicated-for-children-aged-1-year-and-older-with-eosinophilic-esophagitis daily 0.8 https://clival.com/news/akcda-to-launch-exclusive-generic-segment-in-trade-on-the-lines-of-pmbjp-stores daily 0.8 https://clival.com/news/biohaven-begins-patient-enrollment-in-phase-3-trial-of-troriluzole-to-treat-obsessive-compulsive-disorder daily 0.8 https://clival.com/news/mankind-pharma-launches-posaconazole-gastro-resistant-tablets daily 0.8 https://clival.com/news/granules-india-gets-usfda-nod-for-generic-product daily 0.8 https://clival.com/news/asieris-pharma-gets-china-nmpa-approval-to-begin-phase-trial-of-hexvix-to-treat-bladder-cancer daily 0.8 https://clival.com/news/alniche-launched-novel-product-in-collaboration-with-dpsru daily 0.8 https://clival.com/news/sirona-biochem-inks-research-collaboration-with-icgeb-to-advance-antiviral-library-of-compounds daily 0.8 https://clival.com/news/hyloris-pharma-receives-us-fda-approval-for-maxigesic-iv-for-mild-to-moderate-pain daily 0.8 https://clival.com/news/tetra-bio-pharma-enters-into-a-strategic-partnership-with-avicanna daily 0.8 https://clival.com/news/somalogic-announces-license-agreement-with-oncohost-for-the-development-of-precision-cancer-diagnostics daily 0.8 https://clival.com/news/us-fda-approves-xeris-biopharmas-recorlev-to-treat-endogenous-hypercortisolemia-in-patients-with-cushings-syndrome daily 0.8 https://clival.com/news/pfizer-opkos-ngenla-to-treat-paediatric-growth-hormone-deficiency-receives-japanese-approval daily 0.8 https://clival.com/news/novartis-to-buy-morphosys-ag daily 0.8 https://clival.com/news/novocure-announces-clinical-trial-collaboration-with-msd-to-evaluate-tumor-treating-fields-together-with-keytrudaa daily 0.8 https://clival.com/news/dragonfly-expands-research-collaboration-with-abbvie-to-develop-novel-therapeutic-candidates-for-immune-mediated-diseases daily 0.8 https://clival.com/news/sun-pharma-enters-licensing-pact-with-lundbeck-to-launch-novel-anti-depressant-pill-in-india daily 0.8 https://clival.com/news/hitgen-inks-agreement-with-mitsubishi-tanabe daily 0.8 https://clival.com/news/lipella-pharma-doses-first-two-patients-in-phase-2a-oral-lichen-planus-clinical-trial daily 0.8 https://clival.com/news/shanghai-genchem-announces-global-collaboration-with-i-mab-on-bispecific-antibodies daily 0.8 https://clival.com/news/johnson-johnson-announces-submission-of-application-to-the-us-fda-for-emergency-use-authorization-of-its-investigational-single-shot-janssen-covid daily 0.8 https://clival.com/news/ec-grants-msds-prevymis-orphan-product-designation daily 0.8 https://clival.com/news/daewoong-pharmaceuticals-fexuprazan-enters-africa-in-partnership-with-cooper-pharma daily 0.8 https://clival.com/news/pfizer-receives-us-fda-emergency-use-authorization-for-novel-covid-19-oral-antiviral-treatment daily 0.8 https://clival.com/news/aethlon-medical-enters-agreement-with-namsa-to-advance-hemopurifier-clinical-programmes-in-cancer daily 0.8 https://clival.com/news/aucta-pharma-and-oakrum-pharma-announce-launch-of-generic-version-of-jadenu-r-sprinkle-deferasirox-granules daily 0.8 https://clival.com/news/alembic-pharma-receives-eight-us-fda-approvals-in-q3fy24 daily 0.8 https://clival.com/news/astellas-to-air-new-veozah-fezolinetant-tv-spot-during-the-super-bowl daily 0.8 https://clival.com/news/knight-signs-new-exclusive-agreement-for-ambisome-with-gilead-in-brazil daily 0.8 https://clival.com/news/akceas-tegsedi-approved-in-spain-to-treat-polyneuropathy-in-hereditary-transthyretin-amyloidosis daily 0.8 https://clival.com/news/calliditas-partner-stada-seeks-uk-mhra-full-marketing-authorization-for-kinpeygo-to-treat-iga-nephropathy daily 0.8 https://clival.com/news/sirona-biochem-signs-international-partnership-agreement-with-wanbang-biopharmaceuticals daily 0.8 https://clival.com/news/european-patent-office-grants-key-exosome-patent-to-evox-therapeutics daily 0.8 https://clival.com/news/adalvo-receives-european-approval-for-liraglutide-pre-filled-pen-to-treat-type-2-diabetes daily 0.8 https://clival.com/news/qihan-biotech-announces-nmpa-approval-of-investigational-new-drug-ind-application-for-qn-019a-a-multi-locus-gene-editing-cell-therapy-product-to-treat-cd19-positive-b-cell-lymphoma daily 0.8 https://clival.com/news/lupin-receives-us-fda-tentative-approval-for-generic-briviact-tablets daily 0.8 https://clival.com/news/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-non-pancreatic-neuroendocrine-tumors daily 0.8 https://clival.com/news/revive-therapeutics-announces-research-collaboration-with-pharmather-for-development-of-psilocybin-in-cancer-and-discovery-of-novel-uses-of-psychedeli daily 0.8 https://clival.com/news/layoffs-persist-glp-1s-launch-for-weight-loss-in-china daily 0.8 https://clival.com/news/epi-health-a-novan-company-enters-into-exclusive-license-agreement-with-sato-pharmaceutical-co-ltd-for-rhofade daily 0.8 https://clival.com/news/vertex-pharmaceuticals-announces-licencing-agreement-with-crispr-therapeutics daily 0.8 https://clival.com/news/thermo-fisher-scientific-enhances-clinical-research-solutions-in-collaboration-with-matrix-clinical-trials daily 0.8 https://clival.com/news/novartis-vijoice-gets-us-fda-accelerated-approval-for-select-patients-with-pik3ca-related-overgrowth-spectrum daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-to-market-generic-tecfidera-dr-capsules daily 0.8 https://clival.com/news/halia-therapeutics-starts-phase-ii-trial-for-ht-6184 daily 0.8 https://clival.com/news/edwards-evoque-valve-replacement-system-first-transcatheter-therapy-to-earn-fda-approval-for-tricuspid-valve daily 0.8 https://clival.com/news/brii-biosciences-expands-license-agreements-with-vbi-vaccines-in-hepatitis-b-virus-field daily 0.8 https://clival.com/news/prestige-biopharma-and-teva-israel-announce-license-and-supply-agreement-to-commercialize-prestiges-trastuzumab-biosimilar-tuznue-in-israel daily 0.8 https://clival.com/news/bayer-askbio-initiates-phase-ii-genephit-trial-in-congestive-heart-failure-chf daily 0.8 https://clival.com/news/abbvies-rinvoq-receives-european-approval-to-treat-active-psoriatic-arthritis daily 0.8 https://clival.com/news/astrazeneca-acquires-gracell-biotechnologies daily 0.8 https://clival.com/news/biophytis-receives-us-fda-approval-to-initiate-sara-31-phase-3-study-in-sarcopenia daily 0.8 https://clival.com/news/us-fda-accepts-basf-pharma-solutions-excipient-soluplus-into-its-pilot-programme daily 0.8 https://clival.com/news/aucta-pharma-licenses-vigabatrin-for-oral-solution-in-china daily 0.8 https://clival.com/news/oragenics-completes-acquisition-of-odyssey-health-neurological-assets daily 0.8 https://clival.com/news/diabetes-drug-maker-novo-nordisk-buys-pill-factory-in-north-carolina daily 0.8 https://clival.com/news/foldax-receives-approval-for-clinical-trial-of-tria-biopolymer-surgical-aortic-heart-valve-in-india daily 0.8 https://clival.com/news/novavax-and-sk-bioscience-expand-manufacturing-agreement daily 0.8 https://clival.com/news/tonix-pharmaceuticals-extends-research-collaboration-with-the-university-of-alberta-to-develop-antiviral-drugs-against-sars-cov-2 daily 0.8 https://clival.com/news/astrazeneca-sanofi-beyfortus-receives-chinese-approval-for-prevention-of-rsv-disease-in-infants daily 0.8 https://clival.com/news/fda-approves-tofidence-tocilizumab-bavi-a-biosimilar-of-actemra-developed-by-bio-thera-solutions daily 0.8 https://clival.com/news/innocare-announces-clearance-of-clinical-trial-of-bcl2-inhibitor-icp-248-by-us-fda daily 0.8 https://clival.com/news/scisparc-to-seek-us-fda-nod-to-begin-phase-iib-trial-with-sci-110-to-treat-tourette-syndrome daily 0.8 https://clival.com/news/truveta-announces-strategic-collaboration-with-pfizer-to-accelerate-safety-insights-in-real-time daily 0.8 https://clival.com/news/everest-medicines-begins-dosing-in-china-for-global-phase-2b-trial-of-zetomipzomib daily 0.8 https://clival.com/news/qdx-announces-collaboration-with-prelude-therapeutics-on-novel-oncology-programs daily 0.8 https://clival.com/news/who-issues-emergency-use-validation-for-pfizerbiontechs-covid-19-vaccine-comirnaty-and-emphasizes-need-for-equitable-global-access daily 0.8 https://clival.com/news/samr-thermo-fisher-collab-to-create-center-of-excellence daily 0.8 https://clival.com/news/germany-agrees-deal-with-curevac-gsk-for-mrna-vaccines-until-2029 daily 0.8 https://clival.com/news/edap-completes-enrollment-in-phase-3-study-of-focal-one-hifu-therapy-to-treat-deep-infiltrating-rectal-endometriosis daily 0.8 https://clival.com/news/sanofi-to-acquire-translate-bio-advances-deployment-of-mrna-technology-across-vaccines-and-therapeutics-development daily 0.8 https://clival.com/news/china-nmpa-accepts-for-review-of-sobis-maa-for-emapalumab-to-treat-primary-hlh daily 0.8 https://clival.com/news/arqule-wanted-a-partner-merck-wanted-control-solution-a-buyout-deal daily 0.8 https://clival.com/news/syneos-health-collaborates-with-microsoft daily 0.8 https://clival.com/news/sanofi-goes-all-in-on-parkinsons-with-groundbreaking-abl-bio-deal daily 0.8 https://clival.com/news/oxford-bio-collaborates-with-agenus-to-support-clinical-development-of-obts-antibody-drug-conjugate-obt076-in-combo-with-agenus-cpi-balstilimab daily 0.8 https://clival.com/news/innocare-announces-approval-of-clinical-trial-of-shp2-inhibitor-icp-189-in-combination-with-egfr-inhibitor-furmonertinib daily 0.8 https://clival.com/news/sk-bioscience-and-vaxxas-enter-joint-development-agreement daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-nod-for-generic-doryx-tablets daily 0.8 https://clival.com/news/gujarat-fdca-approves-layout-designs-of-240-drug-manufacturing-units-post-gst daily 0.8 https://clival.com/news/exact-sciences-oncxerna-ink-license-agreement-to-bring-oncxernas-xerna-tme-panel-lab-services-to-more-us-patients daily 0.8 https://clival.com/news/fda-accepts-biogens-aducanumab-biologics-license-application-for-alzheimers-disease-with-priority-review daily 0.8 https://clival.com/news/reunion-neuroscience-begins-patient-dosing-in-phase-2-trial-of-re104-for-treatment-of-postpartum daily 0.8 https://clival.com/news/regenerons-evkeeza-to-treat-ultra-rare-inherited-form-of-high-cholesterol-gets-us-fda-approval daily 0.8 https://clival.com/news/lupin-gets-us-fda-approval-for-chlorpromazine-hcl-tablets-usp daily 0.8 https://clival.com/news/clarity-pharma-begin-patient-dosing-in-phase-iii-prostate-cancer-trial-with-cu-64-sar-bispsma daily 0.8 https://clival.com/news/ultragenyx-launches-dojolvi-in-us-market-to-treat-long-chain-fatty-acid-oxidation-disorders daily 0.8 https://clival.com/news/veeda-clinical-research-acquires-stake-in-bioneeds daily 0.8 https://clival.com/news/us-fda-approves-hope-biosciences-phase-ii-trial-of-hb-admscs-to-provide-immune-support-against-covid-19 daily 0.8 https://clival.com/news/nmpa-approves-mabwells-new-drug-application-for-8mw0511-injection daily 0.8 https://clival.com/news/roche-inks-agreement-to-use-molecular-yous-comprehensive-molecular-profiling-technology daily 0.8 https://clival.com/news/cipla-quality-chemical-industries-signs-business-transfer-agreement-with-qcl daily 0.8 https://clival.com/news/junshi-biosciences-announces-nejm-publication-of-results-of-phase-3-study-of-vv116-versus-paxlovid-for-adults-at-high-risk-for-progression-to-severe-covid-19 daily 0.8 https://clival.com/news/sandoz-receives-regulatory-approval-from-nmpa-for-rosuvastatin daily 0.8 https://clival.com/news/novartis-unwraps-15b-gene-therapy-buyout-beefing-up-arsenal-against-retinal-diseases daily 0.8 https://clival.com/news/merck-phase-3-keynote-921-trial-of-keytruda-plus-chemotherapy-in-patients-with-mcrpc-fails-to-meet-dual-primary-endpoints daily 0.8 https://clival.com/news/gt-healthcare-capital-partners-launches-ai-driven-drug-development-company daily 0.8 https://clival.com/news/oziva-launches-bioactive-gluta-fizzy-for-skin-damage daily 0.8 https://clival.com/news/who-launches-new-online-course-for-health-workers-on-caring-for-refugee-and-migrant-populations daily 0.8 https://clival.com/news/china-nmpa-grants-conditional-approval-for-beigenes-brukinsa-to-treat-waldenstroms-macroglobulinemia daily 0.8 https://clival.com/news/elpiscience-astellas-enter-research-collaboration-and-license-agreement-for-novel-bispecific-macrophage-engager daily 0.8 https://clival.com/news/durect-and-innocoll-announce-a-136-million-us-licensing-agreement-for-posimir daily 0.8 https://clival.com/news/aurobindo-sun-pharma-recall-products-in-us-market daily 0.8 https://clival.com/news/ers-genomics-and-lepton-pharma-ink-crisprcas9-license-agreement daily 0.8 https://clival.com/news/biocytogen-enters-into-antibody-agreement-with-ona-therapeutics-to-develop-adc-targeting-solid-tumours daily 0.8 https://clival.com/news/lupin-under-usfda-glare-for-lapses-at-three-plants daily 0.8 https://clival.com/news/fosun-pharma-receives-fda-emergency-use-authorization-eua-for-its-covid-19-rt-pcr-detection-kit daily 0.8 https://clival.com/news/illumina-launches-global-health-access-initiative-to-support-acceleration-of-pathogen-sequencing-in-low-and-middle-income-countries daily 0.8 https://clival.com/news/recursion-announces-transformational-collaboration-with-roche-and-genentech-in-neuroscience-and-oncology daily 0.8 https://clival.com/news/china-nmpa-grants-priority-review-designation-to-innovent-and-ascentage-pharmas-nda-for-olverembatinib-to-treat-drug-resistant-cml daily 0.8 https://clival.com/news/lilly-eva-pharma-collaborate-to-enhance-sustainable-access-to-affordable-insulin-in-africa daily 0.8 https://clival.com/news/brainstorm-receives-european-australian-and-israel-patents-for-allogeneic-exosome-platform-product-in-neurological-disorder-treatments daily 0.8 https://clival.com/news/abbvies-phase-3-trial-of-upadacitinib-to-treat-ulcerative-colitis-meets-primary-and-secondary-endpoints daily 0.8 https://clival.com/news/health-net-federal-services-gains-recognition-with-the-renewal-of-urac-accreditations daily 0.8 https://clival.com/news/aurinia-pharmas-lupkynis-receives-us-fda-approval-to-treat-adult-patients-with-active-lupus-nephritis daily 0.8 https://clival.com/news/echosens-and-novo-nordisk-announce-partnership-to-increase-awareness-and-advance-early-diagnosis-of-nash daily 0.8 https://clival.com/news/us-fda-approves-astrazeneca-and-daiichi-sankyos-enhertu-as-first-her2-directed-therapy-for-patients-with-previously-treated-her2-mutant-metastatic-nsclc daily 0.8 https://clival.com/news/luye-pharma-enters-into-agreement-with-cipla-medpro daily 0.8 https://clival.com/news/novartis-cosentyx-receives-us-fda-approval-to-treat-moderate-to-severe-hidradenitis-suppurativa-in-adults daily 0.8 https://clival.com/news/bayer-to-buy-uk-based-biotech-kandy-therapeutics-for-us-875-million daily 0.8 https://clival.com/news/telix-and-uniquest-to-collaborate-on-radiolabelled-immune-targeting-peptide daily 0.8 https://clival.com/news/lupin-partner-caplin-receives-us-fda-approval-for-rocuronium-bromide-injection daily 0.8 https://clival.com/news/bharat-biotechs-covaxin-gets-sec-approval-on-its-phase-3-trials-efficacy-data daily 0.8 https://clival.com/news/ipsens-cabometyx-in-combo-with-opdivo-receives-european-approval-to-treat-patients-living-with-advanced-rcc daily 0.8 https://clival.com/news/us-fda-clears-galapagos-ind-application-for-phase-12-atalanta-1-study-of-cd19-car-t-glpg5101 daily 0.8 https://clival.com/news/ventus-inks-exclusive-development-and-license-agreement-with-novo-nordisk-for-nlrp3-inhibitor-programme daily 0.8 https://clival.com/news/triastek-receives-fda-ind-clearance-for-3d-printed-medicine-for-the-treatment-of-ulcerative-colitis daily 0.8 https://clival.com/news/update-to-contractual-arrangements-between-astrazeneca-swedish-orphan-biovitrum-ab-and-sanofi daily 0.8 https://clival.com/news/apollomics-inc-and-iterion-therapeutics-announce-exclusive-collaboration-and-license-agreement-to-develop-and-commercialize-tegavivint-in-greater-chin daily 0.8 https://clival.com/news/aptitude-gets-up-to-54-million-partnership-with-barda-to-develop-diagnostics-for-point-of-care-and-at-home-use daily 0.8 https://clival.com/news/zai-lab-and-argenx-secure-chinese-approval-for-vyvgart-hytrulo-in-treating-cidp daily 0.8 https://clival.com/news/enanta-pharma-announces-positive-data-from-phase-1-study-of-oral-3cl-protease-inhibitor-edp-235-for-treatment-of-covid-19 daily 0.8 https://clival.com/news/gero-enters-research-collaboration-with-pfizer-to-discover-potential-targets-for-fibrotic-diseases daily 0.8 https://clival.com/news/jj-submits-sbla-to-us-fda-for-approval-of-guselkumab daily 0.8 https://clival.com/news/covaxin-approved-for-emergency-use-in-13-countries-mos-for-health-bharati-pravin-pawar daily 0.8 https://clival.com/news/legochem-biosciences-and-amgen-enter-into-a-multi-target-research-collaboration-and-license-agreement-for-the-development-of-antibody-drug-conjugates daily 0.8 https://clival.com/news/rigel-pharmaceuticals-and-md-anderson-establish-strategic-collaboration-to-progress-rezlidhia-olutasidenib-in-aml-and-other-cancer-forms daily 0.8 https://clival.com/news/terracon-acquired-by-chargepoint-technology daily 0.8 https://clival.com/news/biomx-completes-patient-dosing-in-phase-1b2a-study-for-bx004-in-cystic-fibrosis daily 0.8 https://clival.com/news/kintor-pharma-announces-dosing-of-first-subject-in-us-phase-i-clinical-trial-of-gt20029-for-androgenic-alopecia-and-acne daily 0.8 https://clival.com/news/pfizer-announces-global-licensing-deal-signed-with-an-un-backed-group daily 0.8 https://clival.com/news/newamsterdam-pharma-receives-us-patent-for-obicetrapib-extend-it-till-july-2043 daily 0.8 https://clival.com/news/nxera-pharma-to-get-us-35-mn-from-neurocrine-for-completing-phase-2-trial-with-nbi-1117568 daily 0.8 https://clival.com/news/innovent-bio-and-iaso-biotechnology-announced-national-medical-products-administration-approval-for-fucaso daily 0.8 https://clival.com/news/immunesensor-therapeutics-gets-australian-regulatory-nod-to-begin-phase-1-trial-of-imsb301 daily 0.8 https://clival.com/news/a-chinese-mrna-covid-vaccine-is-approved-for-the-first-time-in-indonesia daily 0.8 https://clival.com/news/microba-enters-agreement-with-sonic-healthcare-to-distribute-microbas-advanced-infectious-disease-test-metapanel-in-australia daily 0.8 https://clival.com/news/us-FDA-approves-eli-lillys-alzheimers-drug-donanemab daily 0.8 https://clival.com/news/nicox-announces-last-patients-complete-final-visit-in-ncx-470-phase-3-mont-blanc-glaucoma-trial daily 0.8 https://clival.com/news/us-fda-approves-ascletis-ind-application-of-oral-3clpro-inhibitor-asc11-for-covid-19 daily 0.8 https://clival.com/news/abbisko-announces-positive-results-from-phase-3-maneuver-study-of-pimicotinib daily 0.8 https://clival.com/news/sanofi-plans-to-split-consumer-health-unit-to-narrow-focus daily 0.8 https://clival.com/news/innovent-begins-patient-dosing-in-phase-3-trial-of-pemigatinib-to-treat-unresectable-or-metastatic-cholangiocarcinoma-in-china daily 0.8 https://clival.com/news/evofem-biosciences-to-receive-two-us-patents-for-phexxi daily 0.8 https://clival.com/news/samsung-biologics-reaches-agreement-with-biogen-to-acquire-full-ownership-of-samsung-bioepis daily 0.8 https://clival.com/news/noxopharm-in-licenses-novel-rna-technology-from-hudson-institute-of-medical-research daily 0.8 https://clival.com/news/eu-approves-bristol-myers-car-t-cell-therapy daily 0.8 https://clival.com/news/us-fda-approves-jjs-rybrevant-plus-standard-of-care-as-first-and-only-targeted-regimen daily 0.8 https://clival.com/news/alembic-pharma-receives-4-observations-from-usfda-for-panelav-facility daily 0.8 https://clival.com/news/immunogen-collaborates-with-takeda-to-develop-and-commercialize-elahere-in-japan daily 0.8 https://clival.com/news/gc-cell-inks-first-licensing-agreement-for-immuncell-lc daily 0.8 https://clival.com/news/windtree-therapeutics-announces-kl4-surfactant-and-aerosurf daily 0.8 https://clival.com/news/pulse-biosciences-cardiac-surgery-system-treatment-gets-breakthrough-device-designation daily 0.8 https://clival.com/news/kintor-pharma-announces-its-trial-for-androgenetic-alopecia-reaches-primary-endpoint daily 0.8 https://clival.com/news/ge-healthcare-partners-with-biofourmis-for-patient-monitoring daily 0.8 https://clival.com/news/galmed-receives-european-patent-for-aramchol-resmetirom-combo daily 0.8 https://clival.com/news/sciwind-biosciences-begins-patient-dosing-in-phase-3-trials-of-ecnoglutide-to-treat-type-2-diabetes-in-china daily 0.8 https://clival.com/news/wuxi-biologics-buys-manufacturing-facilities-from-pfizer-china daily 0.8 https://clival.com/news/fujitsu-and-riken-develop-ai-technology-for-predicting-protein-structural-changes daily 0.8 https://clival.com/news/china-nmpa-grants-breakthrough-designation-to-innovents-ibi351-for-previously-treated-advanced-colorectal-carcinoma daily 0.8 https://clival.com/news/us-fda-grants-fast-track-orphan-drug-designations-to-rocket-pharma-rp-a601-gene-therapy-for-pkp2-arrhythmogenic-cardiomyopathy daily 0.8 https://clival.com/news/fda-grants-orphan-drug-designation-to-phenylketonuria-treatment daily 0.8 https://clival.com/news/dr-reddys-soon-to-market-pharmazzs-centhaquine-in-india daily 0.8 https://clival.com/news/biontech-matinas-biopharma-ink-research-collaboration-to-evaluate-novel-delivery-technology-for-mrna-based-vaccines daily 0.8 https://clival.com/news/roches-ventana-cldn18-43-14a-rxdx-assay-to-identify-patients-with-gastric-or-gej-cancer daily 0.8 https://clival.com/news/eu-approves-astrazeneca-imfinzi-plus-imjudo-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers daily 0.8 https://clival.com/news/cocrystal-pharma-announces-further-development-of-influenza-ab-antiviral-compounds-by-merck-under-exclusive-worldwide-license-and-collaboration-agree daily 0.8 https://clival.com/news/hong-kong-department-of-health-accepts-eisais-nda-for-new-anti-insomnia-drug-dayvigo daily 0.8 https://clival.com/news/recbio-and-rongsheng-biotech-collaborate-for-adjuvant-vaccine daily 0.8 https://clival.com/news/janssen-korea-jj-innovation-launch-seoul-innovation-quickfire-challenge-in-smart-healthcare-in-collaboration-with-seoul-metropolitan-government-kh daily 0.8 https://clival.com/news/super-trillion-common-light-chain-antibody-discovery-platform-launched daily 0.8 https://clival.com/news/johnson-and-johnson-vision-launches-intraocular-lens-for-patients-with-astigmatism-in-india daily 0.8 https://clival.com/news/vanflyta daily 0.8 https://clival.com/news/roche-to-acquire-berkeley-california-based-carmot-therapeutics-for-us-27-billion daily 0.8 https://clival.com/news/nerviano-medical-sciences-inks-licensing-agreement-with-italfarmaco-to-develop-and-commercialize-a-novel-peptide-drug-conjugate daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-of-sandozs-biosimilar-trastuzumab-to-treat-breast-gastric-cancer daily 0.8 https://clival.com/news/pierre-fabre-laboratories-receives-eca-for-braftovi-in-combination-with-mektovi daily 0.8 https://clival.com/news/idorsia-pharma-seeks-japanese-pmda-approval-for-dual-orexin-receptor-antagonist-daridorexant-to-treat-insomnia daily 0.8 https://clival.com/news/wuxi-biologics-and-toregem-biopharma-sign-mou-for-development-of-anti-usag-1-antibody daily 0.8 https://clival.com/news/biobot-surgical-gets-us-fda-510k-clearance-for-new-robotic-assisted-transperineal-needle-guidance-system-isrobot-mona-lisa-20-for-prostate-biopsy-cancer-ablations daily 0.8 https://clival.com/news/peptidream-inks-new-research-and-collaboration-with-eli-lilly-to-discover-novel-peptide-drug-conjugates daily 0.8 https://clival.com/news/zuellig-pharma-announces-agreement-with-regeneron-to-introduce-libtayo daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-midostaurin-capsules daily 0.8 https://clival.com/news/amgen-and-generate-biomedicines-announce-multi-target-multi-modality-research-collaboration-agreement daily 0.8 https://clival.com/news/bioarctic-partner-eisai-to-present-new-data-from-phase-3-clarity-ad-study-of-leqembi-to-treat-alzheimer-disease-ctad-conference daily 0.8 https://clival.com/news/sanofi-announces-riliprubart-one-year-follow-up-from-phase-2-study daily 0.8 https://clival.com/news/thermo-fisher-scientific-to-acquire-the-binding-site-group daily 0.8 https://clival.com/news/venus-remedies-receives-approval-to-supply-cephalosporin daily 0.8 https://clival.com/news/us-fda-grants-510k-clearance-for-baebies-g6pd-test-on-finder-platform daily 0.8 https://clival.com/news/philogen-receives-swissmedic-approval-to-begin-phase-ii-study-of-nidlegy-in-nonmelanoma-skin-cancer daily 0.8 https://clival.com/news/transgene-gets-french-regulatory-approval-to-begin-phase-i-trial-of-tg6050-a-novel-il-12-armed-oncolytic-virus-given-by-intravenous-administration daily 0.8 https://clival.com/news/lyra-therapeutics-begins-dosing-in-phase-2-beacon-trial-of-lyr-220-in-post-surgical-chronic-rhinosinusitis-patients daily 0.8 https://clival.com/news/iaso-bio-and-umoja-biopharma-establish-a-novel-partnership-for-advancing-ex-vivo-and-in-vivo-cell-and-gene-therapies daily 0.8 https://clival.com/news/zydus-lifesciences-receives-finalusfda-approval-for-pemetrexed-achemotherapy-drug daily 0.8 https://clival.com/news/jacobio-pharma-receives-ind-approval-for-parp7-inhibitor-jab-26766-in-china daily 0.8 https://clival.com/news/sugam-portal-approves-134298-out-of-total-151724-applications-related-to-medical-devices-and-drugs-during-lockdown-period daily 0.8 https://clival.com/news/us-fda-approves-ultragenyx-pharmas-crysvita-for-rare-disease-that-causes-low-phosphate-blood-levels-bone-softening daily 0.8 https://clival.com/news/fda-grants-breakthrough-therapy-designation-for-dizal-pharmaceuticals-dzd9008-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-harboring-egfr-exon20-insertion daily 0.8 https://clival.com/news/bristol-myers-snda-for-krazati-and-cetuximab-gets-approval daily 0.8 https://clival.com/news/eisai-to-merge-with-kan-research-institute-inc daily 0.8 https://clival.com/news/beigene-gets-approval-to-transit-from-biotech-chapter-of-hkex-to-a-general-listing daily 0.8 https://clival.com/news/regeneron-to-acquire-checkmate-pharmaceuticals-and-its-investigational-immune-activator daily 0.8 https://clival.com/news/strides-pharma-gets-us-fda-approval-for-loratadine-softgel-capsule daily 0.8 https://clival.com/news/lavie-bio-announces-licensing-agreement-for-bio-fungicides-with-corteva-agriscience daily 0.8 https://clival.com/news/zydus-cadila-gets-us-fda-tentative-marketing-nod-for-droxidopa-capsules daily 0.8 https://clival.com/news/scantox-acquires-leading-cro-qps-neuropharmacology daily 0.8 https://clival.com/news/waters-and-bioinfra-establish-the-asean-academy-for-bioanalysis-to-promote-analytical-skills-development daily 0.8 https://clival.com/news/nxera-pharma-announces-supply-and-distribution-agreement-for-pivlaz daily 0.8 https://clival.com/news/sedana-medical-gets-us-fda-fast-track-status-for-isoflurane-via-sedaconda-acd-s-device-for-sedation-of-mechanically-ventilated-patients-in-icu-setting daily 0.8 https://clival.com/news/gsks-bepirovirsen-fast-tract-approval-for-hepatitis-b daily 0.8 https://clival.com/news/senhwas-silmitasertib-receives-us-fda-orphan-drug-designation-for-the-treatment-of-biliary-tract-cancer daily 0.8 https://clival.com/news/polydex-pharmaceuticals-announces-collaboration-with-termanox-water-treatment-solutions-for-novel-use-of-native-dextran daily 0.8 https://clival.com/news/enlivex-initiates-phase-iii-trial-for-allocetra-for-knee-osteoarthritis daily 0.8 https://clival.com/news/alembic-pharma-gets-vai-classification-from-usfda-for-its-panelav-facility daily 0.8 https://clival.com/news/paige-and-flagship-biosciences-announce-partnership-to-expand-access-to-immuno-oncology-biomarker-analysis-tools daily 0.8 https://clival.com/news/beigene-announces-positive-results-from-phase-3-sequoia-trial-of-brukinsa-in-combo-with-bendamustine-and-rituximab-to-treat-cll-or-sll daily 0.8 https://clival.com/news/redhill-announces-new-uspto-patent-grant-for-talicia-for-h-pylori-treatment-through-2042 daily 0.8 https://clival.com/news/insilico-medicine-signs-strategic-research-collaboration-with-sanofi-worth-12-b daily 0.8 https://clival.com/news/alx-oncology-holdings-announces-clinical-trial-collaboration-with-sanofi daily 0.8 https://clival.com/news/takeda-announces-us-fda-acceptance-of-biologics-licence-application-bla-for-tak-755 daily 0.8 https://clival.com/news/bristol-myers-abecma-gets-approval-for-relapsed-or-refractory-multiple-myeloma daily 0.8 https://clival.com/news/calliditas-therapeutics-to-receive-us-patent-covering-tarpeyo daily 0.8 https://clival.com/news/glenmark-pharma-launches-generic-sunitinib-oral-capsules daily 0.8 https://clival.com/news/transthera-receives-fast-track-designation-from-fda-for-its-core-product-tt-00420-to-treat-cholangiocarcinoma daily 0.8 https://clival.com/news/lilly-signs-125bn-collaboration-deal-with-mina-therapeutics daily 0.8 https://clival.com/news/pfizer-launches-rimegepant-in-hong-kong-first-market-in-asia-for-migraine-management daily 0.8 https://clival.com/news/samsung-biologics-partners-with-legochem-biosciences daily 0.8 https://clival.com/news/akums-launches-rabeprazolelevosulpiride-sr-capsules-in-india daily 0.8 https://clival.com/news/astrazenecas-ultomiris-receives-jpanese-approval-for-prevention-of-relapses-in-patients-with-nmosd daily 0.8 https://clival.com/news/kenvue-collabs-with-api-for-recommendations-on-oral-fluid-electrolytes daily 0.8 https://clival.com/news/iovance-biotherapeutics-and-cellectis-enter-into-a-research-collaboration-and-exclusive-worldwide-license-agreement daily 0.8 https://clival.com/news/specialised-therapeutics-signs-partnership-agreement-with-akeso-inc-and-cttq-akeso-to-commercialise-new-anti-pd1-antibody-in-australia-and-southeast-asia daily 0.8 https://clival.com/news/mercks-capvaxive-gets-us-fda-approval-for-prevention-of-pneumococcal-diseases daily 0.8 https://clival.com/news/kiniksa-pharmaceuticals-and-huadong-medicine-announce-strategic-collaboration daily 0.8 https://clival.com/news/sustained-hepatitis-b-surface-antigen-loss-in-chronic-hepatitis-b-patients-with-subcutaneous-pd-l1-antibody-asc22-treatment-interim-results-of-phase-iib-study daily 0.8 https://clival.com/news/solvias-acquires-netherlands-based-cergentis-to-bolster-biologics-and-cell-gene-therapy-capabilities daily 0.8 https://clival.com/news/merck-announces-positive-results-from-pivotal-phase-3-stellar-trial-of-sotatercept-to-treat-adults-with-pah daily 0.8 https://clival.com/news/akston-biosciences-begins-patient-dosing-in-phase-ii-trial-of-covid-19-vaccine-candidate-aks-452-in-india daily 0.8 https://clival.com/news/k-mhra-grants-marketing-approval-for-ganaxolone daily 0.8 https://clival.com/news/arcutis-partners-with-sato-for-topical-roflumilast daily 0.8 https://clival.com/news/zydus-us-subsidiary-acquires-speciality-drug-asset-in-us daily 0.8 https://clival.com/news/sun-pharma-lupin-recall-products-in-us-market daily 0.8 https://clival.com/news/alembic-pharma-gets-final-usfda-approval-for-lacosamide-tablet-lacosamide-tablet daily 0.8 https://clival.com/news/glenmark-launches-teneligliptin-dapagliflozin-fdc-for-adults-with-type-2-diabetes-having-comorbidities daily 0.8 https://clival.com/news/aurobindo-pharma-plunges-9-as-usfda-issues-14-observations daily 0.8 https://clival.com/news/zenyaku-kogyo-chugai-pharma-announce-japanese-approval-for-rituxan-for-suppression-and-treatment-of-antibody-mediated-rejection-in-organ-transplantation daily 0.8 https://clival.com/news/thermo-fisher-inks-cdx-agreement-with-hengrui-therapeutics daily 0.8 https://clival.com/news/becton-dickinson-and-biocorp-ink-agreement-traceability-to-self-administered-injectable-drugs daily 0.8 https://clival.com/news/bayer-and-broad-institute-of-mit-and-harvard-extend-research-collaboration-to-develop-new-cancer-therapies daily 0.8 https://clival.com/news/kura-oncology-begins-human-trial-for-ko-2806-and-cabozantinib-combo daily 0.8 https://clival.com/news/novartis-phase-iii-steer-study-meets-endpoint-for-sma-treatment-in-children daily 0.8 https://clival.com/news/rokote-partners-with-exothera-to-bring-fincovac-20-to-clinical-phase-iii-trials daily 0.8 https://clival.com/news/eterna-inks-option-and-license-agreement-with-lineage-cell-therapeutics-to-develop-ipsc-lines-for-multiple-neurology-indications daily 0.8 https://clival.com/news/dr-reddys-labs-gets-dcgi-approval-to-begin-phase-3-trial-for-sputnik-v-vaccine-in-india daily 0.8 https://clival.com/news/union-health-minister-launches-second-phase-of-nationwide-bi-annual-mda-campaign-2024 daily 0.8 https://clival.com/news/radiopharm-announces-strategic-co-development-partnership-with-lantheus-for-australia daily 0.8 https://clival.com/news/porton-advanced-and-biomap-establish-a-strategic-partnership-for-ai-driven-advancements-in-aav-gene-therapy-development daily 0.8 https://clival.com/news/ono-enters-into-collaboration-agreement-with-evqlv-to-generate-novel-antibodies-against-multiple-targets-utilizing-evqlvs-ai-powered-antibody-design-engine-for-development-of-innovative-antibody-drugs daily 0.8 https://clival.com/news/epic-bio-novel-genetic-medicine-candidate-epi-321-to-treat-fshd-receives-us-fda-orphan-drug-designation daily 0.8 https://clival.com/news/lupin-digital-health-launches-lyfe-digital-therapeutic-solution daily 0.8 https://clival.com/news/sun-pharma-acquires-disperzyme daily 0.8 https://clival.com/news/junshi-biosciences-receives-fda-breakthrough-therapy-designation-for-toripalimab-for-the-treatment-of-nasopharyngeal-carcinoma-first-anti-pd-1-antibod daily 0.8 https://clival.com/news/nephron-and-sharps-announce-manufacturing-and-research-partnership daily 0.8 https://clival.com/news/fda-approves-xolair-for-food-allergies daily 0.8 https://clival.com/news/felzartamab-granted-breakthrough-therapy-designation-for-primary-membranous-nephropathy-pmn-by-the-us-fda daily 0.8 https://clival.com/news/seelos-therapeutics-receives-european-orphan-drug-designation-for-sls-005-trehalose-in-amyotrophic-lateralsclerosis-als daily 0.8 https://clival.com/news/peptidream-inks-collaboration-and-licensing-pact-with-genentech-to-discover-develop-novel-peptide-radioisotope-drug-conjugates daily 0.8 https://clival.com/news/structured-alpha-lp-to-acquire-all-issued-and-outstanding-common-shares-of-liminal-biosciences daily 0.8 https://clival.com/news/glenmark-pharma-launches-favipiravir-drug-for-covid-19-treatment-priced-at-rs-103-a-tablet daily 0.8 https://clival.com/news/johnson-johnson-seeks-us-eu-approvals-for-darzalex-fasprodarzalex-for-multiple-myeloma daily 0.8 https://clival.com/news/huma-partners-with-merck-kgaa-to-develop-digital-solution-to-support-cancer-care daily 0.8 https://clival.com/news/bayer-launches-new-collaboration-with-oerth-bio-to-further-advance-innovations-in-crop-protection daily 0.8 https://clival.com/news/sirnaomics-announces-positive-interim-data-from-phase-iib-clinical-trial-of-stp705-in-adults-with-cutaneous-squamous-cell-carcinoma-in-situ daily 0.8 https://clival.com/news/brii-biosciences-announces-commercial-launch-of-its-amubarvimabromlusevimab-combination-therapy-for-covid-19-in-china daily 0.8 https://clival.com/news/gestalt-language-acquisition-to-help-children-with-asd daily 0.8 https://clival.com/news/astrazeneca-pursues-mrna-signs-vaccine-manufacturing-deal-with-china-cansino daily 0.8 https://clival.com/news/centhaquine-to-enter-us-fda-approved-phase-3-clinical-trial-in-us-and-europe-says-pharmazz-india daily 0.8 https://clival.com/news/breckenridge-signs-new-product-agreement-with-pts-pharma daily 0.8 https://clival.com/news/gsks-respiratory-syncytial-virus-vaccine-arexvy-for-adults-geta-approval daily 0.8 https://clival.com/news/basilea-enters-exclusive-license-and-option-agreement-for-tonabacase-with-intron-biotechnology daily 0.8 https://clival.com/news/logistics4pharma-launches-ultra-low-temperature-dry-shipper-services daily 0.8 https://clival.com/news/shanghai-argo-unveils-multiple-rnai-licensing-agreements-and-establishes-strategic-collaborations-with-novartis daily 0.8 https://clival.com/news/olix-pharmaceuticals-begins-phase-1-trial-for-olx75016 daily 0.8 https://clival.com/news/sun-pharma-announces-settlement-of-patent-litigation-for-generic-revlimida daily 0.8 https://clival.com/news/lilly-receives-us-fda-fast-track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity-or-overweight-with-weight-related-comorbidities daily 0.8 https://clival.com/news/stada-alvotech-introduce-uzpruvo-the-first-approved-ustekinumab-biosimilar-to-stelara daily 0.8 https://clival.com/news/orexo-receives-us-patent-for-its-nasal-epinephrine-powder-product-ox640 daily 0.8 https://clival.com/news/bharat-serums-and-vaccines-acquires-key-women-health-brand-tidilan-from-jagdale-industries daily 0.8 https://clival.com/news/bluerock-gets-positive-phase-i-trial-data-for-bemdaneprocel daily 0.8 https://clival.com/news/concept-medical-gets-approval-for-sirolimus-drug-coated-balloon daily 0.8 https://clival.com/news/csafe-launches-reusable-silverpod-pallet-shipper-to-hit-sustainability-targets daily 0.8 https://clival.com/news/y-biologics-3d-medicines-collaborate-to-develop-novel-cancer-therapeutics-for-china daily 0.8 https://clival.com/news/pfizer-completes-acquisition-of-biotech-company-seagen daily 0.8 https://clival.com/news/emblaveo-receives-european-marketing-approval-for-multidrug-resistant-infections daily 0.8 https://clival.com/news/novartis-acquires-san-diego-based-preclinical-stage-biotech-company-dtx-pharma daily 0.8 https://clival.com/news/teva-and-alvotech-introduce-simlandi-injection-in-us-markets daily 0.8 https://clival.com/news/indoco-remedies-receives-us-fda-final-approval-for-pregabalin-capsules daily 0.8 https://clival.com/news/cytovia-therapeutics-licenses-productivity-boosting-manufacturing-technology-for-its-nk-engager-multifunctional-antibodies-from-proteonic daily 0.8 https://clival.com/news/xbiome-acquires-exclusive-development-and-commercial-rights-to-aurealis-clinical-stage-dfu-drug-candidate-aup-16-in-greater-china daily 0.8 https://clival.com/news/cynata-therapeutics-treated-first-patient-with-cyp-001 daily 0.8 https://clival.com/news/biocity-biopharma-cd3egfr-bispecific-antibody-granted-fda-clearance-for-ind-application daily 0.8 https://clival.com/news/abbvie-and-immunome-announce-strategic-collaboration-to-discover-multiple-novel-oncology-targets daily 0.8 https://clival.com/news/ec-approves-vertexs-kalydeco-to-treat-infants-with-cystic-fibrosis daily 0.8 https://clival.com/news/clasado-biosciences-collaborates-with-leading-scientists-to-advance-prebiotics-in-medical-nutrition-field daily 0.8 https://clival.com/news/sobi-receives-european-marketing-authorisation-for-altuvoct-to-treat-haemophilia-a daily 0.8 https://clival.com/news/phc-corporation-and-cyfuse-enter-into-agreement daily 0.8 https://clival.com/news/daiichi-sankyo-and-gustave-roussy-enter-innovative-research-collaboration-for-dxd-adcs-ds-1062-and-patritumab-deruxtecan daily 0.8 https://clival.com/news/phillips-medisize-enters-agreement-with-global-pharmaceutical-company-to-acquire-exclusive-ownership-of-patents-for-an-innovative-mini-tablet-dispense daily 0.8 https://clival.com/news/china-nmpa-approves-ind-for-equecabtagene-autoleucel daily 0.8 https://clival.com/news/eubiologics-phase-iii-clinical-trial-ind-approval-of-eucorvac-19-covid-19-vaccine-candidate-in-south-korea daily 0.8 https://clival.com/news/astellas-company-iveric-bio-receives-us-fda-approval-for-izervay-to-treat-geographic-atrophy daily 0.8 https://clival.com/news/ascentage-pharma-announces-its-9th-orphan-drug-designation-from-the-us-fda-in-2020-setting-a-record-for-chinese-biopharmaceutical-companies daily 0.8 https://clival.com/news/annoviss-buntanetap-improves-unified-parkinsons-disease-rating-scale-and-cognitive-function daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-ns-pharmas-ns-089ncnp-02-to-reat-duchenne-muscular-dystrophy daily 0.8 https://clival.com/news/akebia-receives-approval-for-vafseo-to-treat-anaemia daily 0.8 https://clival.com/news/biovaxys-bioelpida-collaborate-to-begin-bioproduction-of-vaccine-candidate-against-stage-iii-and-iv-ovarian-cancer daily 0.8 https://clival.com/news/basilea-partners-with-glioblastoma-foundation-for-oncology-candidate-lisavanbulin daily 0.8 https://clival.com/news/galecto-starts-phase-2-trial-by-dosing-in-investigator-initiated-study-combining-gb1211 daily 0.8 https://clival.com/news/sirio-to-launch-pureorganix-range-of-gummies-at-vitafoods-europe daily 0.8 https://clival.com/news/verona-pharma-gets-us-fda-approval-for-ohtuvayre-to-treat-copd daily 0.8 https://clival.com/news/ascletis-announces-positive-results-from-phase-i-study-for-asc47-to-treat-obesity daily 0.8 https://clival.com/news/citius-pharmaceuticals-to-accelerate-phase-3-mino-lok-trial-by-expanding-trial-sites-internationally daily 0.8 https://clival.com/news/vir-biotechnology-announces-positive-results-from-phase-1-trial-of-vir-3434-in-patients-with-chronic-hepatitis-b-virus daily 0.8 https://clival.com/news/wuxi-atu-gains-approval-to-manufacture-amtagvi daily 0.8 https://clival.com/news/inspira-technologies-signs-a-strategic-agreement-in-the-us daily 0.8 https://clival.com/news/us-fda-approves-invivoscribes-leukostrat-cdx-flt3-mutation-assay-to-select-patients-with-flt3-itd-positive-aml-to-treat-with-vanflyta daily 0.8 https://clival.com/news/abbvies-skyrizi-receives-us-fda-approval-to-treat-adults-with-active-psoriatic-arthritis daily 0.8 https://clival.com/news/bayer-receives-us-fda-fast-track-designation-for-asundexian-atrial-fibrillation-program daily 0.8 https://clival.com/news/soleno-therapeutics-secures-btd-for-dccr-extended-release-tablets daily 0.8 https://clival.com/news/us-fda-approves-medtronics-inceptiv-closed-loop-spinal-cord-stimulator daily 0.8 https://clival.com/news/abbvie-cugene-ink-exclusive-worldwide-license-option-agreement-in-autoimmune-diseases daily 0.8 https://clival.com/news/merck-and-eisai-share-crucial-phase-3-trial-results-for-advanced-endometrial-carcinoma-treatment daily 0.8 https://clival.com/news/hummingbird-bioscience-initiates-hmbd-001-phase-ib-trials-in-australia-and-partners-with-omico daily 0.8 https://clival.com/news/amgen-presents-new-lumakras-sotorasib-plus-vectibix-panitumumab-data-in-patients-with-kras-g12c-mutated-metastatic-colorectal-cancer daily 0.8 https://clival.com/news/european-commission-approves-abbvie-skyrizi-to-treat-moderate-to-severe-active-crohns-disease daily 0.8 https://clival.com/news/usfda-issues-warning-letter-to-intas-pharma-for-sanand-plant daily 0.8 https://clival.com/news/almirall-has-announced-that-lebrikizumab-achieves-skin-clearance-in-pivotal-phase-3-atopic-dermatitis-trials daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-status-to-avactas-lead-pre-cision-drug-candidate-ava6000-to-treat-soft-tissue-sarcoma daily 0.8 https://clival.com/news/kura-oncology-begins-trial-of-ko-2806-plus-cabozantinib daily 0.8 https://clival.com/news/ec-approves-sobis-aspaveli-for-pnh daily 0.8 https://clival.com/news/adcentrx-and-avantgen-enter-a-new-partnership-with-a-three-year-multi-target-collaboration-to-discover-antibodies-for-novel-antibody-drug-conjugates daily 0.8 https://clival.com/news/vertex-announces-fda-clearance-of-investigational-new-drug-application-for-vx-264 daily 0.8 https://clival.com/news/asymchem-acquires-snapdragon-chemistry daily 0.8 https://clival.com/news/bio-techne-enters-new-distribution-agreement-with-thermo-fisher-scientific daily 0.8 https://clival.com/news/gsk-beats-merck-to-first-pd-1-approval-in-newly-diagnosed-endometrial-cancer daily 0.8 https://clival.com/news/bd-expands-from-cancer-discovery-and-diagnosis-into-post-treatment-monitoring-by-acquiring-cytognos daily 0.8 https://clival.com/news/scisparc-gets-renewal-for-autism-clinical-trial-by-israeli-cannabis-agency daily 0.8 https://clival.com/news/fda-grants-orphan-drug-designation-to-micurxs-mrx-5-for-ntm-infections daily 0.8 https://clival.com/news/axsome-posts-mixed-phase-iii-data-in-alzheimers-agitation-plans-fda-filing daily 0.8 https://clival.com/news/acelyrin-to-present-phase-2-data-phase-3-design-for-lonigutamab-online daily 0.8 https://clival.com/news/vyne-therapeutics-receives-fda-clearance-for-ind-application-of-vyn202 daily 0.8 https://clival.com/news/chugai-introduces-piasky-for-injection-340-mg daily 0.8 https://clival.com/news/telix-acquires-uk-based-medical-device-company-lightpoint-medical-and-its-sensei-radio-guided-surgery-business daily 0.8 https://clival.com/news/abbvie-presents-long-term-data-further-supporting-the-efficacy-and-safety-profile-of-rinvoq-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis daily 0.8 https://clival.com/news/nmpa-approves-xacduro-for-habpvabp-caused-by-acinetobacter-baumannii-calcoaceticus-complex daily 0.8 https://clival.com/news/ventus-collabs-with-novo-nordisk-starts-phase-1-clinical-study-for-nnc6022-0001 daily 0.8 https://clival.com/news/sec-recommends-waiver-of-local-phase-iii-and-iv-trials-for-sanofi-orphan-drug-to-treat-pompe-disease daily 0.8 https://clival.com/news/alvotech-and-dr-reddy-patners-for-commercialization-of-avt03-denosumab daily 0.8 https://clival.com/news/leucid-bio-lonza-ink-collaboration-to-leverage-cocoon-platform-for-automated-manufacturing-of-personalised-car-t-cells daily 0.8 https://clival.com/news/iveric-bio-announces-fda-has-granted-breakthrough-therapy-designation-for-avacincaptad-pegol-for-geographic-atrophy daily 0.8 https://clival.com/news/glenmark-launches-affordable-priced-ryaltris-az-nasal-spray-in-india-to-treat-allergic-rhinitis daily 0.8 https://clival.com/news/novo-nordisk-announces-positive-results-from-phase-3-essence-trial-of-semaglutide daily 0.8 https://clival.com/news/arcellx-and-kite-reveal-an-extended-collaboration-within-their-strategic-partnership daily 0.8 https://clival.com/news/novozymes-linusbio-collaborate-to-test-new-non-invasive-technology-in-clinical-trial daily 0.8 https://clival.com/news/redhill-biopharma-announces-approval-for-talicia daily 0.8 https://clival.com/news/valneva-or-pfizer-ink-equity-subscription-agreement-and-update-terms-of-collaboration-pact-for-lyme-disease-vaccine-candidate-vla15 daily 0.8 https://clival.com/news/marinomed-biotech-forms-long-term-solv4u-partnership-with-shanghai-sph-sinae-pharmaceuticals daily 0.8 https://clival.com/news/kinarus-therapeutics-signs-agreement-with-chaodian-hangzhou-investment-management daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-abbvie-upadacitinib-to-treat-active-non-radiographic-axial-spondyloarthritis daily 0.8 https://clival.com/news/parexel-palantir-expand-collaboration-to-speed-up-clinical-data-delivery daily 0.8 https://clival.com/news/gland-pharma-partners-launch-anticoagulant-injection-in-usa daily 0.8 https://clival.com/news/lupin-gets-australian-tga-approval-for-tiotropium-powder-for-inhalation-for-management-of-copd daily 0.8 https://clival.com/news/abbvie-cures-sting-fever-with-mavupharma-acquisition daily 0.8 https://clival.com/news/goqii-uk-and-modality-partnership-transform-patient-care-in-the-uk daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-valbenazine-capsules daily 0.8 https://clival.com/news/eu-approves-astrazeneca-and-msds-lynparza-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer daily 0.8 https://clival.com/news/hox-therapeutics-announces-collaboration-with-vernalis daily 0.8 https://clival.com/news/lupin-receives-us-fda-tentative-approval-for-letermovir-tablets daily 0.8 https://clival.com/news/astellas-seagen-and-merck-announce-results-of-phase-1b2-ev-103-trial-of-padcev-with-keytruda-and-padcev-as-monotherapy-in-first-line-advanced-urothelial-cancer daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-arpraziquantel-for-treatment-of-schistosomiasis-in-preschool-aged-children daily 0.8 https://clival.com/news/us-fda-approves-modernas-an-mrna-respiratory-syncytial-virus-vaccine-mresvia daily 0.8 https://clival.com/news/scisparc-announces-irb-approval-to-conduct-its-phase-iib-trial-in-tourette-syndrome daily 0.8 https://clival.com/news/menarini-india-strengthens-its-dermatology-portfolio-by-entering-into-exclusive-partnership-agreement-with-pierre-fabre-laboratories daily 0.8 https://clival.com/news/zydus-cadila-gets-us-fda-approval-for-ranolazine-er-tablets daily 0.8 https://clival.com/news/abbvie-tentarix-collaborate-for-oncology-and-immunology daily 0.8 https://clival.com/news/hjb-ansun-enter-into-strategic-agreement-for-cmc-development daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-roche-subcutaneous-injection-tecentriq-for-multiple-cancer-types daily 0.8 https://clival.com/news/bristol-myers-squibb-gets-positive-phase-3-trial-results-for-zeposia daily 0.8 https://clival.com/news/novartis-phase-iiiii-study-of-tafinlarmekinist-demonstrates-unprecedented-efficacy-in-paediatric-patients-with-braf-v600-low-grade-gliomas daily 0.8 https://clival.com/news/lynparza-approved-in-the-us-as-a-1st-line-maintenance-treatment-of-germline-brca-mutated-metastatic-pancreatic-cancer daily 0.8 https://clival.com/news/daiichi-sankyo-receives-us-fda-approval-for-vanflyta-first-flt3-inhibitor daily 0.8 https://clival.com/news/biocity-biopharm-and-astrazeneca-enter-into-collaboration-agreement daily 0.8 https://clival.com/news/gsk-jemperli-gets-us-fda-full-approval-to-treat-patients-with-recurrent-or-advanced-mismatch-repair-deficient-endometrial-cancer daily 0.8 https://clival.com/news/westgenes-mrna-therapeutic-cancer-vaccine-receives-us-fda-approval daily 0.8 https://clival.com/news/efruxifermin-granted-fda-breakthrough-therapy-designation-for-nash daily 0.8 https://clival.com/news/basf-pharma-solutions-introduces-premium-services-to-its-vpas-digital-services-platform daily 0.8 https://clival.com/news/gilead-receives-fda-approval-for-biktarvy-label-update-with-data-for-pregnant-adults-with-hiv daily 0.8 https://clival.com/news/deepqure-receives-ide-approval-from-fda-for-its-efs-study-to-treat-resistant-hypertension daily 0.8 https://clival.com/news/abbott-introduces-neurosphere-virtual-clinic-first-of-its-kind-remote-neuromodulation-patient-care-technology-in-the-us daily 0.8 https://clival.com/news/intelgenx-begins-phase-2-montpark-trial-of-montelukast-versafilm daily 0.8 https://clival.com/news/twist-bioscience-and-kriya-sign-agreement-to-discover-novel-antibodies-for-applications-in-oncology-using-gene-therapy daily 0.8 https://clival.com/news/kyowa-kirin-mei-pharma-report-positive-data-from-phase-2-mirage-study-of-zandelisib-in-patients-with-indolent-b-cell-nhl daily 0.8 https://clival.com/news/atyr-pharma-receives-fda-fast-track-designation-for-efzofitimod-atyr1923-for-treatment-of-pulmonary-sarcoidosis daily 0.8 https://clival.com/news/medgenome-acquires-illuminas-novaseq-x-plus-and-launches-genome-sequencing-test-karyoseq daily 0.8 https://clival.com/news/us-fda-accepts-inmune-bios-ind-application-to-initiate-phase-2-trial-of-quellor-to-treat-covid-19 daily 0.8 https://clival.com/news/aurobindo-pharmas-subsidiary-receives-us-fda-approval-for-single-dose-plerixafor-injection daily 0.8 https://clival.com/news/cayman-chemical-expands-molecular-diagnostic-research-partnering-with-pcrassayscom daily 0.8 https://clival.com/news/cevidoplenib-gets-odd-for-itp daily 0.8 https://clival.com/news/cipla-to-acquire-21-pc-stake-in-achira-labs-for-rs-25-cr daily 0.8 https://clival.com/news/cipla-to-distribute-sanofis-cns-products-in-india daily 0.8 https://clival.com/news/compugen-announces-new-us-patent-for-methods-of-screening-for-anti-pvrig-antibodies daily 0.8 https://clival.com/news/endo-announces-positive-results-from-phase-2-study-of-collagenase-clostridium-histolyticum-in-participants-with-adhesive-capsulitis-of-shoulder daily 0.8 https://clival.com/news/enlivex-announces-positive-results-from-phase-ii-trial-of-allocetra daily 0.8 https://clival.com/news/zuellig-pharma-enters-into-agreement-with-gsk daily 0.8 https://clival.com/news/gilead-xilio-ink-exclusive-license-agreement-to-develop-xtx301 daily 0.8 https://clival.com/news/hookipa-announces-pivotal-phase-23-trial-design-for-hb-200-with-pembrolizumab daily 0.8 https://clival.com/news/hyundai-bioscience-shows-clinical-strategy-for-niclosamide-based-anticancer-treatment daily 0.8 https://clival.com/news/ipsen-skyhawk-therapeutics-collaborates-for-rare-neurological-diseases daily 0.8 https://clival.com/news/kintara-tuhura-ink-definitive-merger-agreement daily 0.8 https://clival.com/news/labcorp-gets-approval-for-first-companion-diagnostic-for-use-with-pfizers-newly-approved-gene-therapy daily 0.8 https://clival.com/news/lupin-digital-health-acc-collaborate-to-revolutionize-in-home-cardiovascular-care-in-india-with-digital-therapeutics daily 0.8 https://clival.com/news/mallinckrodt-announces-journal-publication-of-economic-evidence-for-terlivaz-terlipressin-for-injection-in-adults-with-hepatorenal-syndrome-hrs daily 0.8 https://clival.com/news/mission-bio-and-abiosciences-partner-to-co-develop-bioinformatics-for-clinical-research-applications-in-china daily 0.8 https://clival.com/news/n4-pharma-collabs-with-sri-to-target-and-treat-cells-in-human-body daily 0.8 https://clival.com/news/neoss-group-signs-collaboration-agreement-with-sweden-based-osstell-ab daily 0.8 https://clival.com/news/neurogene-and-neoleukin-enter-definitive-merger-agreement daily 0.8 https://clival.com/news/j-j-announces-positive-results-from-phase-3-cartitude-4-study-of-carvykti daily 0.8 https://clival.com/news/uk-mhra-grants-marketing-authorisation-to-curium-pharmas-piflufolastat daily 0.8 https://clival.com/news/lupins-subsidiary-novel-labs-receives-us-fda-approval-for-fluocinolone-acetonide-body-oil daily 0.8 https://clival.com/news/pfizer-announces-phase-3-trial-positive-results daily 0.8 https://clival.com/news/collplant-and-united-therapeutics-announce-exercise-of-option-that-will-expand-their-collaboration-to-include-3d-bioprinting-of-human-kidneys-for-tran daily 0.8 https://clival.com/news/sanofi-and-regeneron-dupixent-gets-european-approval-to-treat-severe-atopic-dermatitis-in-children-aged-6-months-to-5-years-old daily 0.8 https://clival.com/news/acentra-health-celebrates-us-india-technology-partnership-with-us-consul-general-in-chennai daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-astrazenecas-lynparza-imfinzi-combo daily 0.8 https://clival.com/news/innovent-biologics-and-md-anderson-announce-a-strategic-collaboration-to-develop-anti-pd-1-therapy-tyvyt-sintilimab-injection-in-rare-cancers daily 0.8 https://clival.com/news/bayers-kerendia-gets-updated-label-in-us-to-include-findings-from-phase-iii-figaro-dkd-cardiovascular-outcomes-study daily 0.8 https://clival.com/news/strides-receives-us-fda-approval-for-fluoxetine-tabs-10-mg-20-mg daily 0.8 https://clival.com/news/new-partnership-formed-for-improving-chinas-health daily 0.8 https://clival.com/news/novo-nordisk-to-buy-cardior-pharma-for-1025-billion-euros daily 0.8 https://clival.com/news/puretechs-lyt-200-gets-approval-for-head-and-neck-cancers daily 0.8 https://clival.com/news/renovorx-collaborates-with-imugene daily 0.8 https://clival.com/news/roches-blood-test-elecsys-ptau217-assay-gets-bdd daily 0.8 https://clival.com/news/roches-subcutaneous-formulation-of-tecentriq-demonstrates-positive-phase-iii-results daily 0.8 https://clival.com/news/rusan-pharmas-api-plant-in-ankleshwar-receives-us-fda-gmp-approval daily 0.8 https://clival.com/news/rznomics-inc-secures-orphan-drug-designation-from-fda-for-rz-001-in-hepatocellular-carcinoma daily 0.8 https://clival.com/news/sanofi-to-acquire-qunol-a-fast-growing-us-brand-in-healthy-aging-segment daily 0.8 https://clival.com/news/sebia-gains-fda-clearance-for-eia-tests daily 0.8 https://clival.com/news/soligenix-gets-odd-for-the-prevention-and-post-exposure-prophylaxis daily 0.8 https://clival.com/news/sosei-heptares-acquires-idorsias-pharmaceuticals-business-in-japan-and-apac daily 0.8 https://clival.com/news/specialised-therapeutics-acquires-commercialisation-rights-for-new-motor-neuron-disease-therapy daily 0.8 https://clival.com/news/takeda-speeds-narcolepsy-drug-to-late-stage-testing daily 0.8 https://clival.com/news/trials-of-lamassu-biotechs-cancer-treatment-protocol-gets-approval daily 0.8 https://clival.com/news/uk-mhra-approves-pfizerbiontechs-comirnaty-jn1-covid-19-vaccine daily 0.8 https://clival.com/news/us-fda-committee-to-review-astrazenecas-imfinzi-to-treat-resectable-nsclc daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-of-sn-biosciences-nano-anti-cancer-drug-snb-101-for-small-cell-lung-cancer daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-bcma-car-t-cell-therapy-co-developed-by-iaso-bio-and-innovent daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-status-to-kira-pharmas-bifunctional-antibody-fusion-protein-kp104-to-treat-paroxysmal-nocturnal-hemoglobinuria daily 0.8 https://clival.com/news/who-published-diagnostic-manual-for-icd-11-disorders daily 0.8 https://clival.com/news/xeris-biopharma-grants-fda-orphan-drug-exclusivity-for-recorlev daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-tentative-nod-for-dasatinib-tablets daily 0.8 https://clival.com/news/alnylam-announces-positive-results-from-phase-3-illuminate-a-study-of-lumasiran-to-treat-primary-hyperoxaluria-type-1 daily 0.8 https://clival.com/news/pure-biologics-chooses-to-collaborate-with-twist-bioscience-to-increase-its-potential-in-the-field-of-phage-display-technology daily 0.8 https://clival.com/news/arch-biopartners-univ-of-calgary-join-hands-for-lsalt-peptide-trial daily 0.8 https://clival.com/news/zydus-cadila-gets-permission-from-dcgi-for-phase-1-clinical-trial-of-novel-molecule-zyil1 daily 0.8 https://clival.com/news/zydus-lifesciences-subsidiary-zahil-acquires-stake-in-mylab-discovery-solutions daily 0.8 https://clival.com/news/boehringer-ingelheim-gets-us-fda-approval-for-senvelgo-the-first-oral-liquid-medication-for-diabetes-in-cats daily 0.8 https://clival.com/news/keravet-bio-partners-with-wellhaven-pet-health-and-pet-peace-of-mind daily 0.8 https://clival.com/news/trivitron-healthcare-launches-terrene-ct-scanner-becomes-1st-company-to-get-approval daily 0.8 https://clival.com/news/astellas-and-bmt-ctn-announce-topline-results-from-phase-3-morpho-trial-of-gilteritinib daily 0.8 https://clival.com/news/yikaida-car-t-cell-therapy-approved-as-a-second-line-therapy-for-new-indication daily 0.8 https://clival.com/news/boston-scientific-completes-acquisition-of-btg daily 0.8 https://clival.com/news/sanofi-completes-acquisition-of-kadmon daily 0.8 https://clival.com/news/astellas-to-acquire-propella-therapeutics daily 0.8 https://clival.com/news/adare-pharma-solutions-acquires-frontida-biopharm daily 0.8 https://clival.com/news/fujifilm-completes-acquisition-of-biogens-manufacturing-site-in-denmark daily 0.8 https://clival.com/news/bharat-biotech-biofabri-starts-clinical-trials-of-mtbvac daily 0.8 https://clival.com/news/sk-bioscience-receives-emergency-use-listing-for-skycovione daily 0.8 https://clival.com/news/xenetic-biosciences-inc-announces-research-and-development-collaboration-with-the-scripps-research-institute-to-advance-dnase-platform daily 0.8 https://clival.com/news/roche-inks-agreement-to-buy-lumiradxs-point-of-care-technology-for-usd-295-million daily 0.8 https://clival.com/news/iteos-gsk-initiate-galaxies-lung-301-phase-3-study-of-belrestotug-and-dostarlimab daily 0.8 https://clival.com/news/bayer-published-aflibercept-8-mg-in-the-lancet daily 0.8 https://clival.com/news/antengene-collaborates-with-wuxi-biologics-wuxi-sta-for-adc-asset daily 0.8 https://clival.com/news/qiagen-launches-new-secondary-analysis-solution-for-oncology-and-inherited-disease daily 0.8 https://clival.com/news/akums-drugs-receives-license-to-manufacture-ldl-cholesterol-drug-bempedoic-acid daily 0.8 https://clival.com/news/coya-therapeutics-announces-5-million-strategic-investment-by-the-alzheimers-drug-discovery-foundation daily 0.8 https://clival.com/news/fda-clears-intelivation-technologies-new-hammerdesis-interphalangeal-fusion-system daily 0.8 https://clival.com/news/samsung-biologics-completes-full-acquisition-of-samsung-bioepis daily 0.8 https://clival.com/news/merck-announces-positive-results-from-two-phase-3-trials-evaluating-21-valent-pneumococcal-conjugate-vaccine-v116-specifically-designed-for-adults daily 0.8 https://clival.com/news/nona-biosciences-does-agreement-with-astrazeneca-for-monoclonal-antibody daily 0.8 https://clival.com/news/sobi-acquires-cti-biopharma daily 0.8 https://clival.com/news/abbvie-announces-us-fda-approves-vraylar-as-an-adjunctive-treatment-for-mdd daily 0.8 https://clival.com/news/teva-confirms-efficacy-and-safety-of-ajovy-fremanezumab daily 0.8 https://clival.com/news/nammi-therapeutics-begins-patient-dosing-in-phase-1-study-of-qxl138am daily 0.8 https://clival.com/news/mindray-launches-new-automated-external-defibrillator daily 0.8 https://clival.com/news/eisai-initiates-rolling-biologics-license-application-to-us-fda-for-leqembi daily 0.8 https://clival.com/news/notable-announces-volasertib-phase-2-programme daily 0.8 https://clival.com/news/clover-reports-positive-results-from-phase-i-trial-of-scb-219m-to-treat-cancer-patients-with-chemotherapy-induced-thrombocytopenia daily 0.8 https://clival.com/news/gilead-to-acquire-all-remaining-rights-to-potential-first-in-class-immunotherapy-gs-1811-from-jounce-therapeutics daily 0.8 https://clival.com/news/halozyme-therapeutics-to-acquire-antares-pharma-in-all-cash-deal daily 0.8 https://clival.com/news/astellas-fezolinetant-reduces-frequency-and-severity-of-vms-associated-with-menopause-in-women-considered-unsuitable-for-hormone-therapy daily 0.8 https://clival.com/news/astellas-inks-research-collaboration-with-mass-general-brigham daily 0.8 https://clival.com/news/astex-and-cardiff-university-announce-new-drug-discovery-collaboration daily 0.8 https://clival.com/news/astrazenecas-pacific-phase-iii-trial-of-imfinzi-demonstrates-sustained-clinically-meaningful-os-and-pfs-benefit-at-5-years-in-patient-with-unresectabl daily 0.8 https://clival.com/news/ayush-ministry-clarifies-on-licensing-and-approval-of-various-dosage-forms-of-asu-products daily 0.8 https://clival.com/news/az-announces-us-fast-track-designation-for-il-5-inhibitor-fasenra daily 0.8 https://clival.com/news/biocon-receives-three-us-fda-observations-on-its-telangana-plant daily 0.8 https://clival.com/news/biocytogen-pharma-partners-with-gilead daily 0.8 https://clival.com/news/biogen-and-therapanacea-announce-new-collaboration-with-the-potential-to-advance-digital-health-for-personalized-medicine-in-neuroscience daily 0.8 https://clival.com/news/biontech-and-medigene-announce-global-collaboration-to-advance-t-cell-receptor-immunotherapies-against-cancer daily 0.8 https://clival.com/news/boehringer-ingelheim-3t-biosciences-collaborate-to-develop-next-generation-cancer-immunotherapies daily 0.8 https://clival.com/news/boehringer-ingelheim-announces-five-new-rd-partnerships daily 0.8 https://clival.com/news/calliditas-inks-agreement-with-viatris-to-register-and-commercialize-specialty-therapy-for-iga-nephropathy-in-japan daily 0.8 https://clival.com/news/catalent-and-ethicann-sign-development-and-license-agreement-for-new-fast-dissolve-cannabinoid-based-treatments daily 0.8 https://clival.com/news/cnmpa-approves-agilents-pd-l1-companion-diagnostic daily 0.8 https://clival.com/news/disc-medicines-bitopertin-to-treat-erythropoietic-protoporphyria-receives-us-fda-orphan-drug-designation daily 0.8 https://clival.com/news/dizal-pharmaceutical-receives-us-fda-fast-track-designation-for-dzd4205-golidocitinib-for-the-treatment-of-refractory-or-relapsed-peripheral-t-cell-lymphoma daily 0.8 https://clival.com/news/eisai-and-biogen-inc-announce-us-fda-grants-breakthough-therapy-designation-for-lecanemab-ban2401-an-anti-amyloid-beta-protofibril-antibody-for-the-tr daily 0.8 https://clival.com/news/eisai-biogens-injectable-leqembi-clears-toxic-protein-in-alzheimers-disease daily 0.8 https://clival.com/news/eisai-gets-japanese-orphan-drug-status-to-novel-fgf-receptor-selective-tki-e7090-with-prospective-indication-for-unresectable-biliary-tract-cancer-wit daily 0.8 https://clival.com/news/emd-serono-expands-neuroinflammatory-pipeline-with-acquisition-of-chord-therapeutics daily 0.8 https://clival.com/news/eris-lifesciences-acquires-trademark-zomelis-from-novartis-for-india-market daily 0.8 https://clival.com/news/erlysign-gets-cdsco-nod-for-trials-for-oral-cancer-detection-technology daily 0.8 https://clival.com/news/european-commission-grants-orphan-drug-designation-to-aura-biosciences-au-011-to-treat-uveal-melanoma daily 0.8 https://clival.com/news/evotec-completes-acquisition-of-rigenerand daily 0.8 https://clival.com/news/exscientia-announces-collaboration-with-charite daily 0.8 https://clival.com/news/fda-grants-rafael-pharmaceuticals-orphan-drug-designation-for-cpi-613-devimistat-for-treatment-of-soft-tissue-sarcoma daily 0.8 https://clival.com/news/fennec-pharmaceuticals-receives-us-fda-orphan-drug-exclusivity-for-pedmark daily 0.8 https://clival.com/news/fifth-annual-botox-cosmetic-onabotulinumtoxina-day-makes-history-as-the-biggest-day-ever daily 0.8 https://clival.com/news/genprex-partners-with-researchers-to-expand-nonclinical-programs daily 0.8 https://clival.com/news/genscript-biotech-collaborates-with-t-maximum-biotech daily 0.8 https://clival.com/news/granuless-unit-v-facility-successfully-completes-fda-inspection daily 0.8 https://clival.com/news/harrow-health-acquires-patented-ophthalmic-surgical-drug-candidate-from-sintetica daily 0.8 https://clival.com/news/ikena-acquires-cancer-startup-pionyr-after-gilead-passes-on-buyout daily 0.8 https://clival.com/news/innovent-eli-lilly-announce-final-clinical-results-and-biomarker-analysis-of-phase-ib-study-of-tyvyt-plus-bevacizumab-biosimilar-injection-for-advanced-hcc-at-asco-gi-symposium daily 0.8 https://clival.com/news/ipsen-to-acquire-rare-disease-specialist-albireo-in-deal-worth-over-950m daily 0.8 https://clival.com/news/isomorphic-collaborates-with-lilly-to-discover-therapeutics-against-multiple-targets-eli-lilly-launches-lillydirect-for-obesity-migraine-and-diabetic-patients daily 0.8 https://clival.com/news/jiangsu-alphamab-biopharmaceuticals-3d-medicines-beijing-and-glenmark-have-signed-a-license-agreement-for-kn035-envafolimab-to-be-distributed-globally daily 0.8 https://clival.com/news/jw-therapeutics-announces-nmpa-acceptance-of-the-supplemental-biological-license-application-for-carteyva-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma daily 0.8 https://clival.com/news/kenvue-partners-with-API-to-reapproach-cough-treatment daily 0.8 https://clival.com/news/lanxess-completes-acquisition-of-iffs-microbial-control-business daily 0.8 https://clival.com/news/lilly-and-proqr-to-expand-rna-editing-collaboration daily 0.8 https://clival.com/news/lilly-to-acquire-akouos-to-discover-and-develop-treatments-for-hearing-loss daily 0.8 https://clival.com/news/lilly-wins-breakthrough-designation-for-breast-cancer-drug daily 0.8 https://clival.com/news/lion-tcr-receives-fda-fast-track-designation-for-its-hbv-specific-tcr-t-cell-therapy-for-hepatocellular-carcinoma daily 0.8 https://clival.com/news/maiweijian-becomes-first-biosimilar-of-denosumab daily 0.8 https://clival.com/news/manufacturers-not-concerned-about-provisions-of-drug-labeling-and-packaging daily 0.8 https://clival.com/news/merck-keytruda-plus-concurrent-chemoradiotherapy-improved-pfs-vs-concurrent-chemoradiotherapy-alone-in-newly-diagnosed-high-risk-locally-advanced-cervical-cancer daily 0.8 https://clival.com/news/new-data-for-arexvy-gsks-rsv-vaccine-show-potential-to-help-protect-adults-aged-50-to-59-at-increased-risk-for-rsv-disease daily 0.8 https://clival.com/news/new-real-world-data-show-tremfya-guselkumab-was-associated-with-clinically-meaningful-improvements-in-patient-reported-outcomes-for-adults-living-with-active-psoriatic-arthritis daily 0.8 https://clival.com/news/novartis-drops-subpoena-request-in-trade-secret-spat-with-takeda daily 0.8 https://clival.com/news/novartis-to-pay-up-to-15bn-for-gyroscope daily 0.8 https://clival.com/news/novo-nordisk-announces-completion-of-dicerna-pharmaceuticals-acquisition daily 0.8 https://clival.com/news/okyo-pharma-gets-us-patent-for-lipid-conjugated-peptide-analogues-to-treat-ocular-pain-and-inflammation daily 0.8 https://clival.com/news/ono-pharma-gets-in-licensing-agreement-for-nxi-101 daily 0.8 https://clival.com/news/olympus-launches-visera-elite-iii-surgical-visualization-platform daily 0.8 https://clival.com/news/pfizer-to-buy-clinical-stage-biopharma-company-reviral-for-525-million daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-mercks-21-valent-pneumococcal-conjugate-vaccine-v116-to-treat-ipd-pneumococcal-pneumonia daily 0.8 https://clival.com/news/propella-therapeutics-announces-licensing-agreement-with-jiangsu-aosaikang-pharmaceutical-co-ltd-ask-pharm-for-development-and-commercial-rights-to-cgs-200-5-in-greater-china daily 0.8 https://clival.com/news/relief-announces-us-fda-denies-breakthrough-designation-to-nrx-pharma daily 0.8 https://clival.com/news/roche-announces-embark-trial-in-dmd-did-not-reach-primary-endpoint-but-shows-positive-efficacy-outcomes-on-all-timed-functional-key-endpoints daily 0.8 https://clival.com/news/sanyou-stal-platform-represents-a-groundbreaking-leap-forward-in-the-realm-of-drug-discovery daily 0.8 https://clival.com/news/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations daily 0.8 https://clival.com/news/sosei-heptares-and-lilly-enter-multi-target-collaboration-and-license-agreement-in-diabetes-and-metabolic-diseases daily 0.8 https://clival.com/news/strides-pharma-on-acquiredendo-portfolio-for-turnaround-of-itsus-business daily 0.8 https://clival.com/news/teva-wins-three-loses-six-in-patent-battle-over-migraine-drug daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-device-designation-for-curvebeam-ai-s-ossview-bone-fragility-software daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-device-designation-to-pulse-medicals daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-immunocores-tebentafusp-to-treat-unresectable-or-metastatic-uveal-melanoma daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-pfizers-gbs-vaccine-candidate-to-help-prevent-infection-in-infants-via-immunization-of-pregnant-women daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-status-to-biocrysts-bcx9930-to-treat-paroxysmal-nocturnal-hemoglobinuria daily 0.8 https://clival.com/news/usfda-grants-orphan-drug-status-to-mexiletine-hydrochloride-lupin daily 0.8 https://clival.com/news/varian-expands-cancer-care-solutions-portfolio-with-interventional-oncology-acquisitions daily 0.8 https://clival.com/news/verde-bio-holdings-inc-announces-acquisition-in-oil-rich-permian-basin daily 0.8 https://clival.com/news/willow-and-enterin-collaborate-to-develop-sustainable-intermediates-and-active-pharmaceutical-ingredients-apis daily 0.8 https://clival.com/news/wpd-pharmaceuticals-completed-the-acquisition-of-two-pancreatic-cancer-drug-candidates daily 0.8 https://clival.com/news/wuxi-apptec-completes-acquisition-of-uk-based-cro-oxgene daily 0.8 https://clival.com/news/wuxi-sta-completes-acquisition-of-bristol-myers-squibb-manufacturing-facility-in-couvet-switzerland daily 0.8 https://clival.com/news/xbiotech-announces-granting-of-canadian-patent-for-treatment-of-dermatological-pathologies daily 0.8 https://clival.com/news/xylazine-fentanyl-and-other-potentially-lethal-substances-frequently-found-together-report-from-more-than-160000-urine-drug-tests-demonstrates daily 0.8 https://clival.com/news/ymeworks-announces-new-multispecific-antibody-collaboration-with-merck daily 0.8 https://clival.com/news/zerion-pharma-and-hovione-extend-partnership-to-cover-use-of-the-dispersome daily 0.8 https://clival.com/news/zhimeng-biopharma-cb03-granted-orphan-drug-status-by-the-us-fda-for-amyotrophic-lateral-sclerosis-as-a-potassium-ion-channel-opener daily 0.8 https://clival.com/news/zuellig-pharma-becomes-stada-philippines-exclusive-distribution-partner daily 0.8 https://clival.com/news/hemogenyx-inks-partnership-with-wuxi-atu-to-manufacture-lentiviral-vectors-for-phase-i-trial-of-cutting-edge-hemo-car-t-programme daily 0.8 https://clival.com/news/merck-acquires-prometheus-biosciences-for-approximately-108-billion daily 0.8 https://clival.com/news/alexion-neurimmune-close-global-collaboration-and-licence-pact-to-develop-and-commercialise-ni006 daily 0.8 https://clival.com/news/neurophth-secures-australian-approval-for-ophthalmic-gene-therapy daily 0.8 https://clival.com/news/abm-therapeutics-announces-us-fda-orphan-drug-designation-to-abm-1310 daily 0.8 https://clival.com/news/pfizer-biontech-receive-us-fda-approval-authorization-for-omicron-kp2-adapted-covid-19-vaccine daily 0.8 https://clival.com/news/sartorius-stedim-biotech-completes-acquisition-of-novaseps-chromatography-division daily 0.8 https://clival.com/news/astrazeneca-amgens-tezspire-meets-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial daily 0.8 https://clival.com/news/teva-launches-generic-version-of-epipen-for-young-children daily 0.8 https://clival.com/news/doer-bio-completes-enrollment-in-phase-1b2a-trial-of-dr10624 daily 0.8 https://clival.com/news/farxiga-met-primary-endpoint-in-landmark-phase-iii-dapa-hf-trial-for-the-treatment-of-patients-with-heart-failure daily 0.8 https://clival.com/news/china-approves-anti-cancer-agent-by-eisai daily 0.8 https://clival.com/news/who-and-partners-launch-new-online-resource-to-advance-sti-vaccine-development daily 0.8 https://clival.com/news/alembic-pharma-acquires-aleor-dermaceuticals daily 0.8 https://clival.com/news/scg-cell-therapy-gets-us-fda-nod-to-initiate-phase-12-trial-for-scg142 daily 0.8 https://clival.com/news/scribe-therapeutics-to-collaborate-with-biogen-to-develop-crispr-based-genetic-medicines-for-neurological-diseases-including-amyotrophic-lateral-scle daily 0.8 https://clival.com/news/unichem-labs-gets-us-fda-marketing-approval-for-generic-celebrex-capsules daily 0.8 https://clival.com/news/lupin-to-buy-french-pharma-company-medisol daily 0.8 https://clival.com/news/roche-atezolizumab-receives-dcgi-approval-for-treatment-of-metastatic-triple-negative-breast-cancer-in-india daily 0.8 https://clival.com/news/chugai-obtains-japanese-approval-for-humanized-anti-pd-l1-monoclonal-antibody-tecentriq-to-treat-unresectable-advancedrecurrent-nsclc daily 0.8 https://clival.com/news/maharashtra-fda-issues-circular-empowering-dis-to-inspect-drug-retail-premises daily 0.8 https://clival.com/news/china-nmpa-approves-ascletis-pharmas-ind-for-hiv-drug-asc09f daily 0.8 https://clival.com/news/akums-acquires-drug-manufacturing-facility-from-ankur-drugs daily 0.8 https://clival.com/news/astellas-receives-positive-chmp-opinion-for-xtanditm-enzalutamide-for-patients-with-metastatic-hormone-sensitive-prostate-cancer daily 0.8 https://clival.com/news/astrazenecas-covid-19-vaccine-authorised-for-emergency-supply-in-the-uk daily 0.8 https://clival.com/news/telix-pharma-completes-patient-enrollment-in-zircon-phase-iii-kidney-cancer-imaging-study daily 0.8 https://clival.com/news/panacea-biotec-launches-diabetes-drug-in-india daily 0.8 https://clival.com/news/us-fda-approves-eton-pharmas-biorphen-injection daily 0.8 https://clival.com/news/lonza-and-dinaqor-ag-announce-strategic-collaboration-to-advance-gene-therapy-programs-for-patients-with-monogenic-cardiomyopathies daily 0.8 https://clival.com/news/greenlight-biosciences-and-samsung-biologics-announce-collaboration-to-build-capacity-for-messenger-rna-vaccine-manufacturing daily 0.8 https://clival.com/news/enzychem-to-partner-with-zydus-cadila-to-manufacture-covid-19-plasmid-dna-vaccine-in-korea daily 0.8 https://clival.com/news/abbott-announces-discovery-of-new-strain-of-hiv-keeping-global-health-community-a-step-ahead-of-the-virus daily 0.8 https://clival.com/news/scilex-holding-company-acquires-rights-to-us-fda-approved-elyxyb-in-us-canada-for-migraine-treatment daily 0.8 https://clival.com/news/junshi-biosciences-announces-fda-approval-of-investigational-new-drug-application-for-anti-cd112r-monoclonal-antibody-for-treatment-of-advanced-solid-tumors daily 0.8 https://clival.com/news/corbus-pharma-enters-agreement-with-cspc-megalith-biopharma-to-develop-and-commercialize-clinical-stage-nectin-4-targeting-adc daily 0.8 https://clival.com/news/glenmark-pharma-gets-us-fda-final-approval-for-generic-compazine-tablets daily 0.8 https://clival.com/news/eirgenixs-breast-cancer-biosimilar-receives-marketing-authorization-by-ec daily 0.8 https://clival.com/news/active-biotech-enters-into-global-patent-license-agreement-with-oncode-institute-for-tasquinimod-in-myelofibrosis daily 0.8 https://clival.com/news/uk-books-covid-19-vaccine-doses-from-jj-and-novavax-and-backs-new-clinical-trials daily 0.8 https://clival.com/news/us-fda-approves-takeda daily 0.8 https://clival.com/news/sorrento-enters-into-merger-agreement-to-acquire-late-stage-oncology-company-acea-therapeutics daily 0.8 https://clival.com/news/bristol-myers-announces-positive-results-from-poetyk-pso-1-phase-3-study-of-deucravacitinib-to-treat-severe-psoriasis-patients daily 0.8 https://clival.com/news/us-fda-authorizes-novavax-covid-19-vaccine-for-use-in-12-years-of-age-and-above daily 0.8 https://clival.com/news/junshi-biosciences-has-revealed-that-the-singapore-health-sciences-authority-has-accepted-the-new-drug-application-for-toripalimab daily 0.8 https://clival.com/news/dnanexus-and-twist-bioscience-collaborate-to-provide-data-analysis-software-for-ngs-workflow daily 0.8 https://clival.com/news/uk-mhra-approves-four-dose-mounjaro-kwikpen-for-diabetes-and-weight-management daily 0.8 https://clival.com/news/aurobindo-pharma-gets-usfda-nod-for-icatibant-injection daily 0.8 https://clival.com/news/hutchmed-china-receives-marketing-approval-for-fruquintinib-in-hong-kong-to-treat-metastatic-colorectal-cancer daily 0.8 https://clival.com/news/dcgi-approves-astrazenecas-lynparza-as-monotherapy-for-adjuvant-treatment-of-patients-with-high-risk-early-breast-cancer daily 0.8 https://clival.com/news/asieris-phase-iii-bridging-trial-of-hexvix-for-bladder-cancer-diagnosis-meets-primary-endpoint daily 0.8 https://clival.com/news/trigr-therapeutics-and-elpiscience-biopharmaceuticals-announce-117-million-exclusive-china-licensing-transaction-for-tr009-a-phase-1b-dual-angiogeni daily 0.8 https://clival.com/news/ascletis-announces-first-patient-dosed-in-the-phase-iii-clinical-trial-of-fasn-inhibitor-asc40-combined-with-bevacizumab-for-treatment-of-recurrent-glioblastoma daily 0.8 https://clival.com/news/innovent-announces-first-patient-dosing-of-claudin182cd3-bispecific-antibody-ibi389-in-phase-1a1b-clinical-trial-for-advanced-solid-tumor daily 0.8 https://clival.com/news/new-fda-warning-letters-show-indias-drugmakers-still-in-trouble daily 0.8 https://clival.com/news/an-actriia-fusion-protein-got-fda-approved-for-pah-treatment daily 0.8 https://clival.com/news/astrazenecas-phase-iii-olympus-and-rockies-trials-show-roxadustat-significantly-increases-haemoglobin-levels-for-ckd-patients-with-anaemia daily 0.8 https://clival.com/news/novartis-cosentyx-gets-european-expanded-approvals-for-use-in-childhood-arthritic-conditions daily 0.8 https://clival.com/news/vazyme-enters-into-global-strategic-collaboration-agreement-with-azenta daily 0.8 https://clival.com/news/amarin-and-lotus-pharmaceuticals-announce-exclusive-partnership-to-commercialize-vazkepa daily 0.8 https://clival.com/news/atara-biotherapeutics-enters-strategic-manufacturing-partnership-with-fujifilm daily 0.8 https://clival.com/news/bayer-and-atara-biotherapeutics-enter-strategic-collaboration-for-mesothelin-targeted-car-t-cell-therapies-for-solid-tumors daily 0.8 https://clival.com/news/biocytogen-and-ctm-bio-make-noteworthy-progress-in-collaborative-development-of-tcr-mimic-antibody-based-multi-specific-t-cell-engager-targeting-wt1hla-a02 daily 0.8 https://clival.com/news/breakthrough-discoveries-on-novel-features-of-omicron-variant-and-an-anti-omicron-antibody-jmb2002 daily 0.8 https://clival.com/news/bristol-myers-squibb-gains-rights-to-systimmune-adc-candidate-for-up-to-84bn daily 0.8 https://clival.com/news/bristol-myers-squibbs-krystal-12-for-krazati-meets-primary-endpoint daily 0.8 https://clival.com/news/centessa-pharmaceuticals-receives-us-fda-fast-track-designation-for-serpinpc-hemophilia-b daily 0.8 https://clival.com/news/chugai-pharmas-actemra-gets-japanese-approval-for-additional-indication-of-sars-cov-2-pneumonia daily 0.8 https://clival.com/news/chugai-pharmas-gazyva-gets-japanese-mhlw-approval-for-an-additional-indication-of-cd20-positive-cll daily 0.8 https://clival.com/news/cipla-dndi-launch-4-in-1-antiretroviral-treatment-for-children-with-hiv daily 0.8 https://clival.com/news/clinigen-adds-pharmacovigilance-capabilities-with-acquisition-of-drug-safety-navigator daily 0.8 https://clival.com/news/cnd-life-sciences-receives-third-nih-sbir-grant-to-study-syn-one-test-in-patients-diagnosed-with-rem-sleep-behaviour-disorder daily 0.8 https://clival.com/news/cordis-to-acquire-switzerland-based-medalliance daily 0.8 https://clival.com/news/creative-medical-seeks-us-fda-orphan-drug-designation-for-immcelz-platform-to-treat-brittle-type-1-diabetes daily 0.8 https://clival.com/news/daewoong-pharmaceutical-gets-first-korean-us-fda-fast-track-for-new-idiopathic-pulmonary-fibrosis-drug daily 0.8 https://clival.com/news/daiichi-sankyo-and-astrazeneca-enter-new-global-development-and-commercialization-collaboration-for-daiichi-sankyos daily 0.8 https://clival.com/news/daiichi-sankyo-and-astrazenecas-enhertu-receives-us-fda-breakthrough-therapy-designation-to-treat-patients-with-her2-low-metastatic-breast-cancer daily 0.8 https://clival.com/news/daiichi-sankyo-begins-patient-dosing-in-tropion-breast01-phase-3-trial-of-datopotamab-deruxtecan-in-patients-with-hr-positive-her2-negative-metastatic-breast-cancer daily 0.8 https://clival.com/news/decibel-therapeutics-gets-european-orphan-drug-designation-for-lead-gene-therapy-candidate-db-oto daily 0.8 https://clival.com/news/delhi-hc-seeks-clarification-from-cci-sebi-on-pharmeasys-acquisition-of-thyrocare daily 0.8 https://clival.com/news/delta-fly-pharma-inc-is-granted-orphan-drug-designation-by-us-food-and-drug-administration-for-dfp-10917 daily 0.8 https://clival.com/news/dr-reddy-laboratories-planningmergers-and-acquisitions-to-climbup-ladder daily 0.8 https://clival.com/news/enterobiotix-starts-phase-2-study-of-ebx-102-02 daily 0.8 https://clival.com/news/esperion-daiichi-sankyo-europe-announce-125-million-amendment-to-their-collaboration-including-resolution-of-pending-litigation daily 0.8 https://clival.com/news/everest-medicines-enters-into-agreement-with-gilead-sciences-for-trodelvy-in-asia-territories daily 0.8 https://clival.com/news/evotec-enters-into-agreement-with-janssen daily 0.8 https://clival.com/news/fda-grants-orphan-drug-designation-to-elamipretide-for-lhon daily 0.8 https://clival.com/news/fda-grants-orphan-drug-status-to-cellects-apograft daily 0.8 https://clival.com/news/fda-takes-key-action-in-fight-against-covid-19-by-issuing-emergency-use-authorization-for-first-covid-19-vaccine daily 0.8 https://clival.com/news/ferring-pharmaceuticals-and-gubra-announce-collaboration-within-inflammatory-bowel-disease-ibd daily 0.8 https://clival.com/news/genesis-medtech-acquires-world-first-drug-coated-balloon-technology-with-next-generation-angioplasty-architecture-for-the-treatment-of-peripheral-vasc daily 0.8 https://clival.com/news/gilead-sciences-and-gritstone-announce-collaboration-utilizing-gritstones-vaccine-platform-technology-for-hiv-cure daily 0.8 https://clival.com/news/gilead-sciences-completes-acquisition-of-mirobio daily 0.8 https://clival.com/news/ginkgo-to-acquire-zymergen daily 0.8 https://clival.com/news/grifols-inks-collaboration-and-licensing-pact-with-selagine-to-develop-immunoglobulin-eye-drops-to-treat-dry-eye-disease daily 0.8 https://clival.com/news/gsk-announces-expanded-collaboration-with-tempus-in-precision-medicine-to-accelerate-rd daily 0.8 https://clival.com/news/gsk-enters-licensing-deal-for-ards-enzyme daily 0.8 https://clival.com/news/gsk-microsoft-collaborate-with-the-centre-for-health-and-disease-studies-to-launch-disease-surveillance-project-in-nepal daily 0.8 https://clival.com/news/henlius-and-sermonix-announce-strategic-collaboration-and-exclusive-license-agreements-for-novel-endocrine-therapy-lasofoxifene daily 0.8 https://clival.com/news/i-mab-announces-positive-outcome-in-arbitration-relating-to-agreements-with-tracon-pharma daily 0.8 https://clival.com/news/iifl-amc-fund-acquires-minority-stake-in-omniactive-health-technologies daily 0.8 https://clival.com/news/impact-biotech-receives-fda-orphan-drug-designation-for-padeliporfin-vtp-in-pancreatic-cancer daily 0.8 https://clival.com/news/india-sun-pharma-acquires-us-based-concert-for-576-million daily 0.8 https://clival.com/news/innovent-and-xuanzhu-partner-on-sintilimab-combination-trial-for-advanced-solid-tumors-in-china daily 0.8 https://clival.com/news/inovio-receives-european-commission-orphan-drug-designation-for-ino-3107 daily 0.8 https://clival.com/news/isomorphic-labs-and-novartis-establish-strategic-collaboration-for-multi-target-research daily 0.8 https://clival.com/news/johnson-johnson-to-buy-clinical-stage-biopharma-company-ambrx-for-20-billion daily 0.8 https://clival.com/news/lupin-gets-usfda-nod-for-formoterol-fumarate-inhalation-solution daily 0.8 https://clival.com/news/lupin-receives-us-fda-tentative-approval-for-migalastat-capsules daily 0.8 https://clival.com/news/mankind-pharma-launches-drug-to-treat-black-fungus daily 0.8 https://clival.com/news/melior-pharmaceuticals-announces-execution-of-license-agreement-for-armesocarb-by-adhera-therapeutics daily 0.8 https://clival.com/news/notable-and-mds-foundation-announce-partnership-to-collaborate-on-clinical-mds-trials-and-advance-drug-therapies-for-mds-patients daily 0.8 https://clival.com/news/novartis-gsk-collaborate-to-support-scientific-research-into-genetic-diversity-in-africa daily 0.8 https://clival.com/news/pfizer-and-biontech-receive-expanded-us-fda-emergency-use-suthorization-of-covid-19-vaccine-booster-to-include-individuals-18-and-older daily 0.8 https://clival.com/news/protalix-chiesi-global-rare-diseases-announce-final-results-of-bright-phase-iii-trial-evaluating-prx-102-to-treat-fabry-disease daily 0.8 https://clival.com/news/recbio-and-rhegen-signed-an-mrna-vaccine-cooperation-agreement daily 0.8 https://clival.com/news/regenxbio-receives-fda-orphan-drug-designation-for-potential-duchenne-treatment daily 0.8 https://clival.com/news/sanegenebio-innovent-ink-collaboration-to-develop-sirna-drug-for-the-treatment-of-hypertension daily 0.8 https://clival.com/news/sanofi-to-acquire-immuno-oncology-company-amunix-for-1-billion daily 0.8 https://clival.com/news/scientific-innovation-and-collaboration-highlighted-at-aids-2022-as-gilead-extends-leadership-efforts-toward-ending-the-global-hiv-epidemic daily 0.8 https://clival.com/news/scisparc-announces-additional-positive-results-from-the-third-part-of-clearmind-medicine-inc-pre-clinical-study-for-cocaine-addiction-treatment daily 0.8 https://clival.com/news/sosei-heptares-partner-pfizer-progresses-its-oral-glp-1-receptor-agonist-pf-07081532-into-phase-2-clinical-trials-for-treating-type-2-diabetes-and-obesity daily 0.8 https://clival.com/news/takeda-to-acquire-exclusive-worldwide-license-of-hutchmed-fruquintinib-a-highly-selective-oral-vegfr123-tyrosine-kinase-inhibitor daily 0.8 https://clival.com/news/tata-1mg-vitonnix-uk-get-into-an-exclusive-partnership-in-india daily 0.8 https://clival.com/news/torrent-pharma-and-jb-chemicals-in-final-race-to-acquire-curatio-healthcare daily 0.8 https://clival.com/news/us-fda-approves-pfizer-and-biontechs-sbla-for-covid-19-vaccine-comirnaty-for-adolescents-12-through-15-years-of-age daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-gsks-neisseria-gonorrhoeae-investigational-vaccine daily 0.8 https://clival.com/news/vanda-pharma-receives-approval-for-fanapt daily 0.8 https://clival.com/news/voyager-inks-capsid-license-agreement-and-strategic-collaboration-with-novartis-to-advance-novel-gene-therapies daily 0.8 https://clival.com/news/wuxi-xdc-enters-into-partnership-agreement-with-intocell-enabling-clients-to-accelerate-adc-discovery-and-development daily 0.8 https://clival.com/news/synplogen-and-ginkgo-bioworks-announce-collaborative-efforts-to-boost-worldwide-dna-manufacturing-and-gene-therapy-platform-services-in-japan daily 0.8 https://clival.com/news/endo-acquires-six-development-stage-ready-to-use-injectable-product-candidates-from-nevakar daily 0.8 https://clival.com/news/major-breakthrough-achieved-in-smart-cell-design-innovation daily 0.8 https://clival.com/news/neumoras-phase-3-koastal-1-study-of-navacaprant-in-mdd-misses-endpoint daily 0.8 https://clival.com/news/capricor-seeks-fda-approval-for-deramiocel-to-treat-duchenne-muscular-dystrophy daily 0.8 https://clival.com/news/nona-biosciences-shares-update-on-dualitybio-and-beigenes-adc-collaboration daily 0.8 https://clival.com/news/beigene-launches-bioisland-innovation-center-in-guangzhou-china daily 0.8 https://clival.com/news/hansoh-pharmas-ameile-almonertinib-receives-marketing-authorization-in-china-for-second-line-treatment-for-patients-with-egfr-t790m-mutation-non-sma daily 0.8 https://clival.com/news/philips-ibex-medical-analytics-ink-collaboration-to-jointly-promote-ai-powered-digital-pathology daily 0.8 https://clival.com/news/nuance-pharma-announces-clearance-of-ind-application-for-ensifentrine-pivotal-clinical-trials-for-copd-in-china daily 0.8 https://clival.com/news/aribio-secures-exclusive-marketing-rights-of-ar1001-for-china daily 0.8 https://clival.com/news/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema daily 0.8 https://clival.com/news/astrazeneca-to-acquire-teneotwo-and-its-clinical-stage-t-cell-engager-strengthening-haematological-cancer-pipeline daily 0.8 https://clival.com/news/lilly-and-bill-melinda-gates-foundation-ink-agreement-to-supply-of-potential-covid-19-antibody-therapy-for-low-and-middle-income-countries daily 0.8 https://clival.com/news/regeneron-pharma-announces-phase-3-trial-of-evkeeza-in-children-aged-5-to-11-with-homozygous-familial-hypercholesterolemia-meets-primary-endpoint daily 0.8 https://clival.com/news/takeda-receives-positive-chmp-opinion-recommending-approval-of-dengue-vaccine-candidate-in-eu-and-dengue-endemic-countries daily 0.8 https://clival.com/news/collaboration-between-abbvie-biogen-and-pfizer-creates-worlds-largest-browsable-resource-linking-rare-protein-coding-genetic-variants-to-human-health daily 0.8 https://clival.com/news/biocon-biologics-receives-uk-mhra-marketing-approval-for-yesafili-a-biosimilar-of-aflibercept daily 0.8 https://clival.com/news/astrazeneca-to-acquire-vaccine-developer-icosavax-in-deal-worth-up-to-11bn daily 0.8 https://clival.com/news/xnk-therapeutics-gets-certificate-of-gmp-compliance-of-manufacturer-from-swedish-medical-products-agency daily 0.8 https://clival.com/news/chugai-pharma-to-transfer-japanese-marketing-authorization-of-anti-cancer-agent-xeloda-tablets-300-to-cheplapharm daily 0.8 https://clival.com/news/karuna-therapeutics-reports-positive-results-from-phase-1b-ambulatory-blood-pressure-monitoring-trial-of-karxt-in-schizophrenia daily 0.8 https://clival.com/news/carsgen-therapeutics-collaborates-with-moderna daily 0.8 https://clival.com/news/solvias-acquires-cergentis-to-bolster-biologics-and-cell-and-gene-therapy-capabilities daily 0.8 https://clival.com/news/alkem-labs-gets-eir-from-us-fda-for-baddi-facility daily 0.8 https://clival.com/news/everest-medicines-announces-approval-of-xerava-in-taiwan-for-the-treatment-of-complicated-intra-abdominal-infections-in-adult-patients daily 0.8 https://clival.com/news/eli-lilly-signs-licensing-pact-with-cipla-sun-lupin-for-covid19-drug daily 0.8 https://clival.com/news/pfizers-ticovac-vaccine-gets-us-fda-approval-for-active-immunization-to-prevent-tick-borne-encephalitis daily 0.8 https://clival.com/news/philogen-sun-pharma-announce-ema-validates-nidlegy-marketing-authorization-application daily 0.8 https://clival.com/news/sinovac-receives-product-license-for-23-valent-pneumonia-vaccine daily 0.8 https://clival.com/news/health-arx-technologies-launches-beato-to-address-vulnerable-population-of-covid-19-patients-with-diabetes daily 0.8 https://clival.com/news/ema-approves-dupixent-to-treat-eosinophilic-esophagitis-in-children-as-young-as-one-year daily 0.8 https://clival.com/news/almirall-and-wuxi-biologics-sign-strategic-collaboration-agreement-for-multiple-bispecific-antibodies-targeting-dermatology-diseases daily 0.8 https://clival.com/news/chime-biologics-mabgeek-advance-mg-k10-for-ad-and-asthma-therapies daily 0.8 https://clival.com/news/eton-pharma-acquires-galzin-fda-approved-treatment-for-wilson-disease daily 0.8 https://clival.com/news/gc-labs-and-two-clinical-diagnostic-companies-enter-the-collaboration-for-the-new-lab-testing-service daily 0.8 https://clival.com/news/sirnaomics-completes-second-cohort-of-phase-i-clinical-study-of-galnac-based-rnai-therapeutic-stp122g daily 0.8 https://clival.com/news/alora-pharmaceuticals-celebrates-acquisition-of-monarch-manufacturing-facility daily 0.8 https://clival.com/news/imugene-doses-first-australian-patient-in-b-cell-lymphoma-drug-trial daily 0.8 https://clival.com/news/moderna-to-acquire-oriciro-genomics-for-85-million daily 0.8 https://clival.com/news/abbott-completes-acquisition-of-cardiovascular-systems daily 0.8 https://clival.com/news/biotage-acquires-dna-synthesis-and-purification-company-atdbio daily 0.8 https://clival.com/news/positive-outcomes-revealed-in-interim-analysis-of-rec610-recbio-innovative-adjuvanted-recombinant-shingles-vaccine-clinical-trial-in-the-philippines daily 0.8 https://clival.com/news/us-fda-approves-astrazeneca-sanofi-beyfortus-for-prevention-of-rsv-lower-respiratory-tract-disease-in-infants daily 0.8 https://clival.com/news/ascentage-pharma-receives-commercialisation-approval-for-oncology-drug-in-macau-china daily 0.8 https://clival.com/news/mankind-pharma-launches-limit-white-india-campaign-for-bp-awareness daily 0.8 https://clival.com/news/boehringers-idiopathic-pulmonary-fibrosis-drug-gets-breakthrough-designation daily 0.8 https://clival.com/news/abbotts-breakthrough-dissolving-stent-esprit-btk-system-gets-fda-approval daily 0.8 https://clival.com/news/fda-approves-pfizer-ngenla daily 0.8 https://clival.com/news/pfizer-launches-pfizerforall-a-digital-platform-that-helps-simplify-access-to-healthcare daily 0.8 https://clival.com/news/ab-science-announces-the-results-of-phase-2-study-evaluating-masitinib-in-covid-19 daily 0.8 https://clival.com/news/daewoong-pharmaceutical-announces-us-fda-clearance-of-ind-application-for-dwp213388-first-in-class-irreversible-oral-dual-acting-inhibitor-for-autoimmune-diseases daily 0.8 https://clival.com/news/biocon-mylan-wins-sanofi-patent-litigation-for-insulin-glargine-device-in-us daily 0.8 https://clival.com/news/biocon-generics-acquires-eywa-pharma-oral-solid-dosage-manufacturing-facility-in-new-jersey-for-us-77-million daily 0.8 https://clival.com/news/eluminex-biosciences-acquires-zuretinol-acetate-from-retinagenix-holdings daily 0.8 https://clival.com/news/merck-completes-acquisition-of-prometheus-biosciences daily 0.8 https://clival.com/news/araris-biotech-enters-research-collaboration-with-taiho-pharma-to-develop-next-generation-adcs-using-araris-proprietary-linker-conjugation-technology daily 0.8 https://clival.com/news/us-fda-approves-springworks-ogsiveo-to-treat-adults-with-desmoid-tumours daily 0.8 https://clival.com/news/astrivax-begins-clinical-trials-for-innovative-vaccine-platform-technology daily 0.8 https://clival.com/news/astrazeneca-and-fibrogens-roxadustat-not-yet-filed-in-us-nabs-2nd-anemia-nod-in-china daily 0.8 https://clival.com/news/gsks-viiv-launches-first-campaign-for-new-hiv-med-dovato-with-real-patient-ambassadors daily 0.8 https://clival.com/news/merck-announces-positive-results-from-stride-3-phase-3-trial-of-21-valent-pvc-v116-compared-to-pcv20-in-adults-50-years-of-age-and-older daily 0.8 https://clival.com/news/mediwound-partners-with-3m-health-care-on-escharex-phase-iii-study-for-patients-with-venous-leg-ulcers daily 0.8 https://clival.com/news/us-fda-grants-rare-paediatric-designation-to-arthex-biotechs-atx-01 daily 0.8 https://clival.com/news/sanofi-and-translate-bio-expand-collaboration-to-develop-mrna-vaccines-across-all-infectious-disease-areas daily 0.8 https://clival.com/news/us-fda-approves-adma-biologics-bivigam-for-primary-humoral-immunodeficiency-in-paediatric-patients daily 0.8 https://clival.com/news/bostik-launches-smart-blister-packaging-solution-for-the-pharma-products daily 0.8 https://clival.com/news/sellas-life-sciences-signs-exclusive-license-agreement-with-genfleet-therapeutics-for-next-generation-highly-selective-cdk9-inhibitor daily 0.8 https://clival.com/news/novartis-phase-iii-orion-10-and-11-trials-show-high-consistency-in-lowering-ldl-c-in-individual-response-with-investigational-inclisiran daily 0.8 https://clival.com/news/fda-approves-pfizer-litfulo daily 0.8 https://clival.com/news/orchid-pharma-partners-with-cipla-to-introduce-antibiotic-cefepime-enmetazobactam-in-india daily 0.8 https://clival.com/news/pune-based-drug-discovery-firm-to-start-trial-on-anti-parasitic-drug-for-covid-19 daily 0.8 https://clival.com/news/zydus-lifesciences-arm-gets-usfda-tentative-approval-to-market-hypertension-drug daily 0.8 https://clival.com/news/astrazeneca-enters-collaboration-investment-agreement-with-cellectis-to-accelerate-cell-therapy-and-genomic-medicine-ambitions daily 0.8 https://clival.com/news/australias-ramsay-health-care-receives-proposal-for-asian-joint-venture daily 0.8 https://clival.com/news/cerveau-technologies-inc-signs-agreement-with-roche-to-provide-novel-tau-imaging-biomarker-for-disease-modifier-research daily 0.8 https://clival.com/news/epitomap-inc-animal-allergy-clinical-laboratories-inc-and-nippon-zenyaku-kogyo-co-ltd-enter-into-license-agreement daily 0.8 https://clival.com/news/fronteo-and-axcelead-ddp-forge-essential-ai-enabled-drug-discovery-support-partnership daily 0.8 https://clival.com/news/halozyme-acumen-pharma-ink-global-collaboration-and-license-agreement-to-develop-subcutaneous-formulation-of-acu193-with-enhanze-technology-in-ad daily 0.8 https://clival.com/news/innovent-biologics-and-sanofi-enter-strategic-collaboration-to-accelerate-development-of-oncology-medicines-and-expand-presence-in-china daily 0.8 https://clival.com/news/nanox-completes-merger-with-zebra-medical-vision-ltd-re-brand-as-nanoxai-and-acquisition-of-mdweb-llc-and-usarad-holdings-inc daily 0.8 https://clival.com/news/nec-oncoimmunity-acquires-vaximms-neoantigen-vaccine-development-assets daily 0.8 https://clival.com/news/on-heels-of-european-nod-merck-scores-fda-approval-for-ebola-vaccine-ervebo daily 0.8 https://clival.com/news/portage-biotech-acquires-tarus-therapeutics-a-developer-of-adenosine-receptor-antagonists daily 0.8 https://clival.com/news/rentschler-biopharma-and-vetter-unveil-xpert-alliance-a-joint-visualization-of-their-successful-strategic-collaboration daily 0.8 https://clival.com/news/roche-lilly-collaborate-to-develop-elecsys-amyloid-plasma-panel-for-early-diagnosis-of-alzheimer-disease daily 0.8 https://clival.com/news/sanofi-and-igm-biosciences-announce-collaboration-agreement-for-oncology-immunology-and-inflammation-targets daily 0.8 https://clival.com/news/sanofi-and-seagen-announce-collaboration-to-develop-and-commercialize-multiple-novel-antibody-drug-conjugates daily 0.8 https://clival.com/news/siemens-healthineers-and-nasscom-centre-of-excellence-announce-strategic-partnership-to-boost-india-healthcare-through-digital-innovations daily 0.8 https://clival.com/news/simcere-and-almirall-enter-into-a-licensing-agreement-for-il-2-mu-fc daily 0.8 https://clival.com/news/simcere-zaiming-announces-clinical-collaboration-to-evaluate-sim0235-a-tnfr2-monoclonal-antibody-in-combination-with-keytruda daily 0.8 https://clival.com/news/simnova-and-orna-therapeutics-collaborate-to-advance-ornas-next-generation-circular-rna-technology-in-china daily 0.8 https://clival.com/news/starpharma-signs-new-dep-research-agreement-with-msd daily 0.8 https://clival.com/news/telix-pharma-to-acquire-swiss-german-biotechnology-company-therapharm-gmbh daily 0.8 https://clival.com/news/usv-starts-new-manufacturing-plant-in-baddi daily 0.8 https://clival.com/news/valotx-acquires-peptichip-technology-enabling-rapid-identification-of-tumour-antigens-to-develop-personalized-immunotherapies daily 0.8 https://clival.com/news/zenas-biopharma-acquires-exclusive-worldwide-rights-to-obexelimab-from-xencor daily 0.8 https://clival.com/news/systimmune-bristol-myers-squibb-ink-licensing-agreement-to-co-develop-co-commercialise-bl-b01d1-in-us daily 0.8 https://clival.com/news/usda-approves-mercks-nobivac-nxt-canine-flu-h3n2-for-canine-influenza daily 0.8 https://clival.com/news/us-fda-approves-mercks-keytruda-plus-gemcitabine-cisplatin-to-treat-patients-with-locally-advanced-unresectable-or-metastatic-bct daily 0.8 https://clival.com/news/bioray-initiates-phase-i-clinical-trial-for-bry812-a-novel-antibody-drug-conjugate-targeting-liv-1 daily 0.8 https://clival.com/news/jazz-pharma-enrylaze-receives-european-marketing-approval-to-treat-all-and-lymphoblastic-lymphoma daily 0.8 https://clival.com/news/gsk-announced-results-from-an-interim-analysis-of-the-dreamm-7-phase-iii-trial daily 0.8 https://clival.com/news/ema-committee-recommends-revoking-of-conditional-marketing-authorisation-for-ocaliva daily 0.8 https://clival.com/news/dr-reddys-unveils-cancer-drug-in-us daily 0.8 https://clival.com/news/sorrento-therapeutics-announces-the-fda-ind-clearance-of-sti-1558-an-oral-mpro-and-cathepsin-l-inhibitor-to-treat-covid-19 daily 0.8 https://clival.com/news/adlai-nortye-announces-global-license-out-agreement-with-biotime-for-several-products-including-pd-l1-inhibitor-an4005-and-anti-htnfr2-antibody-an3025 daily 0.8 https://clival.com/news/uk-mhra-grants-marketing-authorization-to-astra-zenecas-capivasertib daily 0.8 https://clival.com/news/european-commission-approves-vertex-pharmas-kaftrio-in-combo-with-ivacaftor-to-treat-children-with-cystic-fibrosis-ages-2-through-5 daily 0.8 https://clival.com/news/zealand-pharma-completes-patient-enrollment-in-phase-3-trial-of-dasiglucagon-in-children-with-congenital-hyperinsulinism daily 0.8 https://clival.com/news/lupin-receives-usfda-approval-for-generic-drug-to-treat-bronchoconstriction-in-copd-patients daily 0.8 https://clival.com/news/roche-tecentriq-gets-european-approval-as-adjuvant-treatment-for-subset-of-people-with-early-stage-nsclc daily 0.8 https://clival.com/news/leo-pharma-enters-clinical-trial-partnership-with-icon daily 0.8 https://clival.com/news/pfizers-ticovac-vaccine-which-prevent-tick-borne-encephalitis-gets-us-fda-approval daily 0.8 https://clival.com/news/fda-panel-backs-approval-of-rexulti-for-alzheimer-related-agitation daily 0.8 https://clival.com/news/zydus-gets-us-fda-nod-to-begin-epics-iii-phase-2-trial-of-saroglitazar-mg-to-treat-primary-biliary-cholangitis daily 0.8 https://clival.com/news/gsk-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-candidate-vaccine daily 0.8 https://clival.com/news/rubryc-therapeutics-announces-research-collaboration-and-licensing-option-agreement-with-zai-labs daily 0.8 https://clival.com/news/aethlons-hemopurifier-technology-to-treat-cancer-receives-european-patent daily 0.8 https://clival.com/news/bioivt-acquires-specialty-global-contract-research-organization-xenotech daily 0.8 https://clival.com/news/uk-mhra-approves-gsk-vir-biotechnologys-xevudy-to-treat-covid-19 daily 0.8 https://clival.com/news/clearpoint-neuro-enters-into-licence-agreement-with-ucb daily 0.8 https://clival.com/news/hisky-launches-new-brand-ilivtouch daily 0.8 https://clival.com/news/china-nmpa-approves-bio-thera-solutions-bat1806-a-biosimilar-to-actemra daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-for-astrazenecas-saphnelo-to-treat-systemic-lupus-erythematosus daily 0.8 https://clival.com/news/humanigen-enters-into-agreement-with-pci-pharma-services-as-part-of-preparations-for-commercialization-in-the-united-kingdom daily 0.8 https://clival.com/news/chime-biologics-enters-into-agreement-with-kings-pharm daily 0.8 https://clival.com/news/bristol-myers-squibb-announces-phase-3-checkmate-8hw-trial-of-opdivo-plus-yervoy-compared-to-chemotherapy-in-msi-h-or-dmmr-mcrc-meets-dual-primary-endpoint daily 0.8 https://clival.com/news/astex-pharma-expands-drug-discovery-collaboration-with-merck daily 0.8 https://clival.com/news/zydus-vaccine-for-kids-above-12-to-come-up-for-approval-this-week daily 0.8 https://clival.com/news/gracell-biotechnologies-receives-fda-clearance-for-phase-1-clinical-trial-of-fastcar-t-gc012f-as-an-early-line-therapy-for-multiple-myeloma daily 0.8 https://clival.com/news/sun-pharma-acquires-rights-to-trademarks-of-three-diabetes-drug-brands-in-india-from-astrazeneca daily 0.8 https://clival.com/news/japan-mhlf-approves-gsk-shingrix-to-prevent-shingles-in-at-risk-adults-aged-18-and-over daily 0.8 https://clival.com/news/lilly-and-openai-collaborate-on-developing-new-treatments-for-drug-resistant-bacteria daily 0.8 https://clival.com/news/samsung-biologics-and-ichnos-sciences-announce-agreement-for-manufacture-of-isb-830 daily 0.8 https://clival.com/news/ractigen-therapeutics-receives-for-beginning-phase-1-trials-for-rag-17 daily 0.8 https://clival.com/news/olix-pharmaceuticals-announces-expansion-of-collaboration-with-laboratoires-thea-to-develop-sirna-therapeutics-for-ophthalmic-diseases daily 0.8 https://clival.com/news/maruho-introduces-mitchga-sc-injection-30mg-vials daily 0.8 https://clival.com/news/almirall-and-simcere-enter-into-a-licensing-agreement-for-il-2-mu-fc daily 0.8 https://clival.com/news/binnopharm-to-acquire-two-antibacterial-brands-from-dr-reddys daily 0.8 https://clival.com/news/nmd-pharma-gets-approval-to-begin-phase-2b-trial-of-nmd670 daily 0.8 https://clival.com/news/cansinobio-announces-approval-for-its-mcv4-product-menhycia daily 0.8 https://clival.com/news/cdsco-approves-boehringer-ingelheims-spevigo-to-treat-psoriasis daily 0.8 https://clival.com/news/ema-committee-recommends-expanded-indication-approval-for-blueprint-medicines-ayvakyt-to-treat-advanced-systemic-mastocytosis daily 0.8 https://clival.com/news/calliditas-phase-3-nefigard-trial-evaluating-nefecon-in-iga-nephropathy-meets-primary-endpoint daily 0.8 https://clival.com/news/us-fda-grants-breakthrough-therapy-designation-to-johnson-johnsons-tar-200-to-treat-high-risk-nmibc daily 0.8 https://clival.com/news/truenorth-launches-sensibiotics-in-india daily 0.8 https://clival.com/news/us-fda-approves-regeneron-pharma-libtayo-in-combination-with-chemotherapy-as-first-line-treatment-for-advanced-nsclc daily 0.8 https://clival.com/news/gsk-and-sk-biosciences-covid-vaccine-submitted-for-s-korea-approval daily 0.8 https://clival.com/news/takeda-acquires-maverick-therapeutics-to-advance-t-cell-activator-solid-tumor-treatments-and-expand-new-cancer-immunotherapy-portfolio daily 0.8 https://clival.com/news/us-fda-accepts-correvios-resubmitted-nda-for-brinavess daily 0.8 https://clival.com/news/strides-pharma-receives-us-fda-approval-for-generic-renvela-tablets daily 0.8 https://clival.com/news/comirnaty-omicron-gets-updated-license daily 0.8 https://clival.com/news/pharmadrugs-sairiyo-approved-for-phase-1-trial-of-reformulated-cepharanthine daily 0.8 https://clival.com/news/lupin-launches-luforbec-1006-for-adult-asthma-and-copd-treatment-in-germany daily 0.8 https://clival.com/news/sec-recommends-approval-to-mylan-for-import-marketing-of-mdr-tb-drug-delamanid-dispersible-tablets-25-mg daily 0.8 https://clival.com/news/biocon-biologics-gets-us-fda-nod-for-biosimilar-aflibercept-to-treat-different-types-of-ophthalmology-conditions daily 0.8 https://clival.com/news/pyxis-oncology-to-acquire-clinical-stage-biopharma-company-apexigen-for-16-million daily 0.8 https://clival.com/news/qilian-international-holding-group-limited-enters-into-exclusive-agency-agreement-with-kangzhiyuan-to-boost-sales-of-gan-di-xin daily 0.8 https://clival.com/news/redcliffe-labs-acquires-rajasthan-medicentre-sonography-and-clinical-lab daily 0.8 https://clival.com/news/rnagene-signs-a-collaborative-research-agreement-with-pharmabcine-to-develop-novel-mrna-therapeutics daily 0.8 https://clival.com/news/roche-bolsters-indias-fight-against-diabetes daily 0.8 https://clival.com/news/roche-launches-vabysmo-to-treat-vision-loss daily 0.8 https://clival.com/news/roche-prothena-plan-to-advance-prasinezumab-into-phase-2b-study-to-treat-parkinsons-disease daily 0.8 https://clival.com/news/rocket-pharmaceuticals-completes-acquisition-of-renovacor daily 0.8 https://clival.com/news/samsung-biologics-kurma-partners-enter-strategic-partnership-for-development-manufacturing-of-biologics-for-kurmas-portfolio-companies daily 0.8 https://clival.com/news/samyang-biopharm-usa-inc-and-talix-therapeutics-nv-announce-global-strategic-collaboration-to-advance-novel-immuno-oncology-therapeutic daily 0.8 https://clival.com/news/sanisure-acquires-gl-engineering daily 0.8 https://clival.com/news/sanskritech-launches-health-monitoring-bag-swandook daily 0.8 https://clival.com/news/sec-recommends-granting-permission-to-novartis-for-phase-iii-b-trial-of-inclisiran daily 0.8 https://clival.com/news/silo-pharma-inks-license-agreement-with-medspray-pharma-for-intranasal-technology-used-in-spc-15-treatment-for-ptsd daily 0.8 https://clival.com/news/sirius-medical-collaborates-with-ge-healthcare-to-showcase-the-pintuition-and-cem-combination-for-an-efficient-and-accurate-breast-cancer-care-pathway daily 0.8 https://clival.com/news/stride-gets-approval-for-gabapentin-tablet daily 0.8 https://clival.com/news/sun-pharma-zydus-enter-agreement-to-co-market-desidustat-to-treat-anaemia-associated-with-ckd-in-india daily 0.8 https://clival.com/news/syapse-extends-collaboration-with-pfizer-to-continue-to-generate-real-world-evidence-in-breast-cancer daily 0.8 https://clival.com/news/takeda-gets-approval-for-snda-for-iclusig daily 0.8 https://clival.com/news/takeda-signs-partnership-with-birac-in-india-to-foster-healthcare-innovation daily 0.8 https://clival.com/news/thermo-fisher-scientific-project-hope-collaborate-to-advance-health-equity-among-hiv-positive-youth-in-sub-saharan-africa daily 0.8 https://clival.com/news/us-fda-grants-import-discretion-of-braccos-iodinated-contrast-medium-iomeron-to-address-supply-shortages daily 0.8 https://clival.com/news/venus-medtech-acquires-cardiovalve-to-optimize-its-innovative-products-pipeline-of-mitral-and-tricuspid-valve-replacement daily 0.8 https://clival.com/news/xgeva-gets-approval-from-uk-mhra-in-a-month daily 0.8 https://clival.com/news/xtalpi-and-eddc-announce-a-fresh-collaboration-to-fuel-biomedical-advancements-with-the-integration-of-robotics-and-advanced-language-models daily 0.8 https://clival.com/news/xtalpi-and-the-university-of-hong-kong-advanced-biomedical-instrumentation-centre-establish-collaboration-to-accelerate-deep-tech-commercialization daily 0.8 https://clival.com/news/zhongchao-inc-collaborates-with-a-public-health-foundation-to-support-sustainable-and-effective-cancer-treatments daily 0.8 https://clival.com/news/biocytogen-enters-into-global-licensing-agreement-with-merck daily 0.8 https://clival.com/news/altos-biologics-a-subsidiary-of-alteogen-completed-patient-enrollment-in-global-phase-3-clinical-trial-of-eylea daily 0.8 https://clival.com/news/alx-oncology-and-quantum-leap-healthcare-collaborative daily 0.8 https://clival.com/news/amador-bioscience-completed-the-acquisition-of-ann-arbor-pharmacometrics-group daily 0.8 https://clival.com/news/arthex-gets-clearance-begin-phase-i-iia-arthemir-trial daily 0.8 https://clival.com/news/ascentage-pharma-and-astrazeneca-collaborate-on-phase-iii-study-for-first-line-cllsll-treatment-with-bcl-2-inhibitor-lisaftoclax-and-btk-inhibitor-acalabrutinib daily 0.8 https://clival.com/news/ascentage-pharma-announces-another-milestone-payment-from-its-licensee-unity-biotechnology-rapidly-advancing-the-clinical-development daily 0.8 https://clival.com/news/asep-medical-signs-joint-venture-agreement-with-sansure-biotech-in-china daily 0.8 https://clival.com/news/astellas-pharma-biolabs-and-mitsui-fudosan-collaborate-to-enhance-life-science-ecosystems-in-japan daily 0.8 https://clival.com/news/aws-announces-strategic-collaboration-with-novartis-to-accelerate-digital-transformation-of-its-business-operations daily 0.8 https://clival.com/news/beigene-and-medison-announce-approval-and-national-reimbursement-in-israel-for-brukinsa daily 0.8 https://clival.com/news/bharat-biotech-receives-dcgi-approval-for-phase-3-clinical-trials-of-its-intra-nasal-vaccine daily 0.8 https://clival.com/news/biocytogen-and-hansoh-pharma-announce-antibody-license-agreement-in-china daily 0.8 https://clival.com/news/takeda-announces-approval-of-nuvaxovid daily 0.8 https://clival.com/news/biotheus-signs-collaboration-agreement-with-hansoh-pharma-for-its-egfrmet-bispecific-antibody daily 0.8 https://clival.com/news/boehringer-ingelheims-diabetes-pill-jardiance-gets-cdsco-nod-for-use-against-heart-failure daily 0.8 https://clival.com/news/breakthrough-in-landmine-detection-enzymit-enabled-tnt-biosensor-developed-in-collaboration-with-hebrew-university daily 0.8 https://clival.com/news/bristol-myers-squibb-and-liantuo-biotech-enter-into-agreement-for-mavacamten-rights-in-china-and-asian-markets daily 0.8 https://clival.com/news/bristol-myers-squibb-to-buy-mirati-therapeutics-in-deal-worth-up-to-58-billion daily 0.8 https://clival.com/news/calliditas-begins-patient-dosing-in-phase-2-trial-of-setanaxib-in-head-and-neck-cancer daily 0.8 https://clival.com/news/canariabio-and-hikma-announce-the-signing-of-distribution-and-license-agreement-for-oregovomab-in-mena-region daily 0.8 https://clival.com/news/castle-biosciences-completes-acquisition-of-altheadx daily 0.8 https://clival.com/news/chugai-and-towa-launch-edirol-tablet-for-osteoporosis-treatment daily 0.8 https://clival.com/news/chugai-gets-approval-for-cancer-genomic-profile daily 0.8 https://clival.com/news/citiustech-acquires-wilco-source daily 0.8 https://clival.com/news/dr-reddys-launches-versavo-in-the-uk daily 0.8 https://clival.com/news/everest-medicines-enters-into-collaboration-and-license-agreement-with-kezar-life-sciences-to-develop-and-commercialize-zetomipzomib-in-greater-china-and-other-asian-markets daily 0.8 https://clival.com/news/fujirebio-sysmex-expand-cdmo-partnership-into-the-field-of-neurodegenerative-diseases-under-their-immunoassay-collaboration daily 0.8 https://clival.com/news/glaxosmithkline-inks-85-m-deal-with-china-hansoh-pharma daily 0.8 https://clival.com/news/glycotope-max-delbruck-center-ink-research-collaboration-to-explore-combination-of-glycotargets-and-car-technology daily 0.8 https://clival.com/news/gujarats-online-portal-for-ayurveda-drug-manufacturing-license-system-receives-thumping-response-from-ayush-industry daily 0.8 https://clival.com/news/hkbu-launches-online-consultation-and-delivery-services-of-chinese-medicines daily 0.8 https://clival.com/news/i2o-therapeutics-announces-research-collaboration-with-sanofi-to-enable-oral-delivery-of-nanobody-based-medicines daily 0.8 https://clival.com/news/igyxos-and-selexis-enter-service-agreement-to-advance-igyxos-first-in-class-monoclonal-antibody-for-the-treatment-of-human-infertility daily 0.8 https://clival.com/news/iktos-announces-research-collaboration-with-janssen-to-utilize-iktos-artificial-intelligence-technology-to-increase-speed-efficiency-of-small-molecu daily 0.8 https://clival.com/news/immetas-and-gc-biopharma-collaborate-on-mrna-therapeutics-for-autoimmune-diseases daily 0.8 https://clival.com/news/immuron-will-proceed-with-phase-3-trials-post-topline-results daily 0.8 https://clival.com/news/innovent-announces-phase-ib-results-of-higher-dose-mazdutide-in-chinese-participants-with-overweight-or-obesity-published-in-eclinicalmedicine daily 0.8 https://clival.com/news/intelgenx-announces-research-collaboration-with-renowned-neurologist daily 0.8 https://clival.com/news/jacobio-pharma-gets-approval-for-jab-30300 daily 0.8 https://clival.com/news/juniper-biologics-acquires-cell-mediated-gene-therapy-tg-c-ld-to-treat-knee-osteoarthritis daily 0.8 https://clival.com/news/jw-therapeutics-acquires-syracuse-biopharma-and-license-to-eureka-therapeutics-solid-tumor-technology-in-china daily 0.8 https://clival.com/news/lianbio-inks-350-m-deal-with-bristol-myers-squibb-to-provide-cardiac-drug-in-china-other-asian-markets daily 0.8 https://clival.com/news/lords-mark-industries-collaborates-with-sensing-self-to-launch-saliva-based-rapid-antigen-test-kit-with-99-accuracy-rate daily 0.8 https://clival.com/news/lupin-gets-marketing-approval-for-generic-vibramycin-injection daily 0.8 https://clival.com/news/lupin-receives-marketing-approval-for-aripiprazole-tablets-usp daily 0.8 https://clival.com/news/m3-expands-with-acquisition-of-vidal-group daily 0.8 https://clival.com/news/mcsaf-and-novasep-announce-their-successful-collaboration-to-produce-a-next-generation-antibody-drug-conjugate daily 0.8 https://clival.com/news/medibuddy-acquires-online-doctor-consultation-platform-clinix daily 0.8 https://clival.com/news/medilink-therapeutics-announces-strategic-collaboration-and-worldwide-license-agreement-with-biontech-to-develop-next-generation-anti-cancer-antibody-drug-conjugate daily 0.8 https://clival.com/news/merck-announces-positive-data-from-phase-3-studies-of-v116 daily 0.8 https://clival.com/news/merck-strengthens-oncology-pipeline-through-strategic-partnership-with-china-hengrui-pharma daily 0.8 https://clival.com/news/monash-university-partners-with-orio-therapeutics-to-transform-regenerative-medicine daily 0.8 https://clival.com/news/nektar-and-collaborators-present-preclinical-data-on-nktr-255-in-combo-with-car-cell-therapies-at-2022-tandem-meetings-of-astct-cibmtr daily 0.8 https://clival.com/news/nona-biosciences-enters-collaboration-agreement-with-lycia-therapeutics daily 0.8 https://clival.com/news/novo-nordisk-to-acquire-dicerna-pharmaceuticals-for-33b daily 0.8 https://clival.com/news/novocure-signs-agreement-with-stanford-university-to-set-up-ttfields-research-programme daily 0.8 https://clival.com/news/ono-pharma-enters-into-a-development-and-license-agreement-with-numab daily 0.8 https://clival.com/news/orchard-therapeutics-gets-approval-for-lenmeldy daily 0.8 https://clival.com/news/organon-to-acquire-forendo-pharma daily 0.8 https://clival.com/news/palvella-therapeutics-ligand-pharma-expand-partnership-to-speed-up-development-of-qtorin-rapamycin daily 0.8 https://clival.com/news/paradigm-and-bristol-myers-squibb-partner-to-build-a-new-model-for-clinical-trials daily 0.8 https://clival.com/news/pfizer-and-biontech-announce-new-agreement-with-us-government-to-provide-additional-doses-of-covid-19-vaccine daily 0.8 https://clival.com/news/pfizer-us-ink-529-bln-deal-for-covid-pills daily 0.8 https://clival.com/news/pharmabcine-signs-long-term-contract-manufacturing-organization-agreement-for-olinvacimab-with-binex daily 0.8 https://clival.com/news/porton-advanced-and-brl-medicine-build-strategic-partnership-to-accelerate-commercialization-of-gene-and-cell-therapies daily 0.8 https://clival.com/news/predictive-oncology-partners-with-cancer-research-horizons daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-nod-for-nifedipine-er-tablets daily 0.8 https://clival.com/news/lupin-receives-eir-from-us-fda-for-its-somerset-manufacturing-facility daily 0.8 https://clival.com/news/opko-receives-us-fda-approval-to-begin-phase-2-trial-with-rayaldee-to-treat-covid-19 daily 0.8 https://clival.com/news/hanchorbio-announces-approval-for-multi-regional-clinical-trial-of-hcb101 daily 0.8 https://clival.com/news/oxford-nanopore-twist-bioscience-partners-to-launch-pgx-beta-programme daily 0.8 https://clival.com/news/ascentage-pharma-presents-positive-results-from-phase-i-study-of-bcl-2-inhibitor-lisaftoclax-apg-2575-in-chinese-patients-with-rr-nhl-at-eha-2022-congress daily 0.8 https://clival.com/news/akili-gets-positive-response-from-phase-iii-trials daily 0.8 https://clival.com/news/biostar-pharma-secures-fda-approval-for-phase-2-trial-of-utidelone-injection-utd1 daily 0.8 https://clival.com/news/eu-approves-abbvies-rinvoq-as-an-oral-treatment-for-adults-with-active-non-radiographic-axial-spondyloarthritis daily 0.8 https://clival.com/news/tango-therapeutics-discontinued-development-of-tng348-clinical-program daily 0.8 https://clival.com/news/cstone-and-legochem-biosciences-enter-global-licensing-agreement-for-new-antibody-drug-conjugate daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-nod-for-pirfenidone-tablets daily 0.8 https://clival.com/news/aflibercept-8-mg-first-to-achieve-sustained-vision-gains-with-more-than-70-of-patients-extended-to-intervals-between-16-and-24-weeks-in-wet-age-related-macular-degeneration-at-two-years daily 0.8 https://clival.com/news/astrazeneca-dapagliflozin-meets-primary-endpoint-in-deliver-phase-iii-trial-reduces-cvd-fatality daily 0.8 https://clival.com/news/agilent-announces-collaboration-with-apc-on-real-time-process-monitoring daily 0.8 https://clival.com/news/amgen-announces-approval-of-aimovig-erenumab-in-japan-for-the-suppression-of-onset-of-migraine-attacks-in-adults daily 0.8 https://clival.com/news/vector-labs-going-to-merge-with-absolute-biotech-component-manufacturer-for-life-science-customers daily 0.8 https://clival.com/news/glenmark-pharmaceuticals-receives-anda-approval-for-saxagliptin-tablets-25-mg-and-5-mg daily 0.8 https://clival.com/news/us-fda-accepts-pfizer-snda-for-braftovi-mektovi-for-patients-with-metastatic-nsclc daily 0.8 https://clival.com/news/lupin-gets-us-fda-tentative-approval-for-dolutegravir-lamivudine-tenofovir-alafenamide-tablets daily 0.8 https://clival.com/news/astellas-pharma-phase-3-glow-trial-of-zolbetuximab-in-combo-with-capox-to-treat-claudin-182-positive-her2-negative-locally-advanced-unresectable-or-metastatic-gastric-and-gej-cancers-meets-primary-endpoint daily 0.8 https://clival.com/news/evopoint-biosciences-inks-clinical-trial-collaboration-with-msd-to-study-of-xnw5004-in-combo-with-keytruda-in-advanced-solid-tumours daily 0.8 https://clival.com/news/kites-new-state-of-the-art-car-t-cell-therapy-manufacturing-facility-in-maryland-gets-us-fda-approval daily 0.8 https://clival.com/news/amylyxs-als-drug-relyvrio-gets-off-the-ground-as-company-eyes-new-brain-disorder daily 0.8 https://clival.com/news/catalyst-clinical-research-acquires-genpro-research daily 0.8 https://clival.com/news/abbvie-terminates-collaboration-with-bioarctic-on-alpha-synuclein-portfolio daily 0.8 https://clival.com/news/us-fda-approves-rigel-pharma-rezlidhia-to-treat-relapsed-or-refractory-aml daily 0.8 https://clival.com/news/eisai-initiates-bla-submission-of-leqembi-with-us-fda daily 0.8 https://clival.com/news/south-koreas-nhis-approves-reimbursement-of-antengenes-xpovio daily 0.8 https://clival.com/news/revir-therapeutics-reaches-milestone-in-novel-splicing-therapy-development daily 0.8 https://clival.com/news/amgen-announces-positive-results-from-two-repatha-ole-studies-to-phase-3-fourier-cardiovascular-outcomes-trial daily 0.8 https://clival.com/news/patent-court-to-review-alexions-soliris-patents-on-amgen-challenge daily 0.8 https://clival.com/news/duoning-collaborates-with-bioelectronica-for-antibody-discovery daily 0.8 https://clival.com/news/mercks-keytruda-gets-european-approval-as-adjuvant-therapy-for-certain-patients-with-rcc-following-surgery daily 0.8 https://clival.com/news/csl-fails-its-phase-3-aegis-ii-trial-for-csl112 daily 0.8 https://clival.com/news/astrazeneca-sanofi-receives-nod-for-rsv-disease-prevention daily 0.8 https://clival.com/news/mauna-kea-technologies-and-tasly-pharma-launch-jv-in-china daily 0.8 https://clival.com/news/almirall-and-irb-barcelona-announce-new-research-collaboration daily 0.8 https://clival.com/news/zygofixs-zlock-lumbar-facet-fixation-system-receives-us-fda-clearance daily 0.8 https://clival.com/news/hasten-biopharma-acquires-commercial-rights-in-china-for-roche-antibiotic-rocephin-portfolio daily 0.8 https://clival.com/news/daiichi-sankyo-begins-patient-dosing-in-phase-2-trial-of-mrna-vaccine-ds-5670-against-covid-19 daily 0.8 https://clival.com/news/c4-therapeutics-signs-license-and-research-collaboration-with-merck-to-discover-degrader-antibody-conjugates daily 0.8 https://clival.com/news/granules-india-receives-us-fda-approval-for-generic-hyzaar-tablets-to-treat-hypertension daily 0.8 https://clival.com/news/valbiotis-gets-approval-to-launch-two-phase-iiiii-insight-insight-2-studies-on-totum-854-for-the-reduction-of-blood-pressure daily 0.8 https://clival.com/news/anx-robotica-is-pleased-to-announce-fda-clearance-for-expanded-indications-of-navicam-small-bowel-video-capsule-endoscopy daily 0.8 https://clival.com/news/integral-molecular-and-optimeos-life-sciences-enter-partnership-to-develop-mrna-and-dna-based-gene-therapies-using-molecular-targeting daily 0.8 https://clival.com/news/us-fda-approves-sage-therapeutics-biogens-zurzuvae-for-women-with-postpartum-depression-and-issues-a-crl-for-major-depressive-disorder daily 0.8 https://clival.com/news/antengene-enters-into-commercialization-partnership-with-hansoh-pharma-for-firstonly-in-class-xpo1-inhibitor-xpovioselinexor-in-the-mainland-of-china daily 0.8 https://clival.com/news/biolinerx-receives-fda-approval-of-aphexda-in-combination-with-filgrastim-g-csf daily 0.8 https://clival.com/news/lupin-launches-its-erectile-dysfunction-tablets-in-us daily 0.8 https://clival.com/news/qiagen-and-inovio-expand-collaboration-to-develop-ngs-companion-diagnostics-for-inovios-vgx-3100-for-advanced-cervical-dysplasia daily 0.8 https://clival.com/news/hanchorbio-announces-taiwan-fda-ind-approval-for-the-multi-regional-clinical-trial-of-hcb101-to-treat-solid-and-hematological-malignancies daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-nod-for-generic-brovana-inhalation-solution daily 0.8 https://clival.com/news/eg-427-receives-us-fda-clearance-to-initiate-phase-1b2a-study-of-eg110a daily 0.8 https://clival.com/news/innocare-announces-first-adolescent-patient-dosed-in-clinical-trial-of-pan-trk-inhibitor-icp-723-in-china daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-for-astrazenecas-qtrilmet-to-treat-type-2-diabetes daily 0.8 https://clival.com/news/alembic-pharma-gets-us-fda-tentative-nod-for-ivabradine-tablets daily 0.8 https://clival.com/news/allarity-therapeutics-and-fivephusion-announce-collaboration daily 0.8 https://clival.com/news/vimgreen-pharma-completes-enrollment-in-phase-2-trial-of-vg081821ac daily 0.8 https://clival.com/news/compugen-begins-patient-dosing-in-anti-pvrig-antibody-phase-1-trial-of-com701 daily 0.8 https://clival.com/news/us-fda-approves-abbotts-proclaim-xr-spinal-cord-stimulation-system-to-treat-painful-diabetic-peripheral-neuropathy daily 0.8 https://clival.com/news/antengene-seeks-south-korean-mfds-approval-for-selinexor-to-treat-rrmm-and-rrdlbcl daily 0.8 https://clival.com/news/china-us-collaboration-to-advance-novel-biotherapies-for-cancer-treatment daily 0.8 https://clival.com/news/amcor-expands-healthcare-platform-in-apac-with-acquisition-of-china-based-mdk daily 0.8 https://clival.com/news/mirus-announces-launch-of-molybdenum-rhenium-low-profile-atlas-more-foot-and-ankle-plating-system daily 0.8 https://clival.com/news/artizan-biosciences-announces-multi-year-research-collaboration-with-the-university-medical-center-utrecht-and-microviable-therapeutics-sl daily 0.8 https://clival.com/news/aveo-oncology-announces-positive-results-from-phase-portion-of-deductive-trial-of-fotivda-in-combo-with-imfinzi-to-treat-patients-with-advanced-or-met daily 0.8 https://clival.com/news/bactiguard-collaborates-with-quintess-medical-to-launch-wound-care-products-in-uk-ireland daily 0.8 https://clival.com/news/beigene-innorna-enter-strategic-research-collaboration-to-jointly-discover-novel-mrna-therapies daily 0.8 https://clival.com/news/bms-inks-deal-with-immatics-on-cancer-bispecific daily 0.8 https://clival.com/news/chinese-startups-cure-genetics-and-frametact-ink-60-m-deal-to-develop-gene-therapy-for-familial-neurological-diseases daily 0.8 https://clival.com/news/grifols-to-acquire-alkahest-to-enhance-discovery-research-and-development-to-identify-innovative-therapies daily 0.8 https://clival.com/news/happiness-biotech-receives-usfda-approval-for-hand-sanitizer daily 0.8 https://clival.com/news/lotus-clinical-research-expands-partnership-with-veeva-to-accelerate-clinical-trials daily 0.8 https://clival.com/news/mabwell-and-wuxi-xdc-sign-long-term-adc-strategic-collaboration-to-accelerate-global-layout-of-innovative-biologics daily 0.8 https://clival.com/news/otsuka-pharmaceutical-collaborates-with-shapetx daily 0.8 https://clival.com/news/pfizer-biontech-report-positive-early-data-from-phase-23-trial-of-omicron-ba4ba5-adapted-bivalent-booster-in-individuals-18-years-and-older daily 0.8 https://clival.com/news/scandi-pharma-swede-deal-for-psyros-diagnostics daily 0.8 https://clival.com/news/shuwen-biotech-collaborates-with-perkinelmer daily 0.8 https://clival.com/news/todos-medical-announces-distribution-agreement-with-adial-pharmaceuticals-to-market-the-fda-eua-authorized daily 0.8 https://clival.com/news/verge-genomics-enters-ai-enabled-drug-discovery-collaboration-with-alexion-for-rare-neurodegenerative-and-neuromuscular-diseases daily 0.8 https://clival.com/news/virtual-incision-gains-fda-marketing-authorization daily 0.8 https://clival.com/news/achilles-therapeutics-announces-manufacturing-expansion-in-the-uk-and-partnership-for-manufacturing-in-the-us daily 0.8 https://clival.com/news/abbvie-and-jacobio-announce-strategic-collaboration-to-advance-shp2-inhibitors daily 0.8 https://clival.com/news/marengo-asia-healthcare-karkinos-healthcare-collaborate-to-revolutionize-cancer-care-in-india daily 0.8 https://clival.com/news/shanton-pharma-reaches-full-enrollment-in-phase-2b-refractorytophaceous-gout-study-with-sap-001 daily 0.8 https://clival.com/news/zhejiang-doer-biologics-announces-licence-agreement-with-biontech daily 0.8 https://clival.com/news/johnson-johnson-acquires-taris-biomedical-with-focus-on-transforming-the-treatment-of-bladder-cancer daily 0.8 https://clival.com/news/vj-farma-seeks-dcgia daily 0.8 https://clival.com/news/mhra-grants-approval-for-pfizers-oral-covid-19-antiviral-pill daily 0.8 https://clival.com/news/avrobio-and-magenta-therapeutics-announce-collaboration-to-evaluate-targeted-antibody-drug-conjugate-as-a-potential-conditioning-regimen-for-lentivira daily 0.8 https://clival.com/news/walgreens-hit-with-lawsuit-after-fda-warning-over-eyedrops daily 0.8 https://clival.com/news/mayo-clinic-and-mercy-collaborate-to-globally-transform-patient-care daily 0.8 https://clival.com/news/broncus-to-acquire-100-equity-interest-in-hangzhou-jingliang daily 0.8 https://clival.com/news/biosyngen-announces-fda-fast-track-designation-for-bst02-in-treatment-of-liver-cancer daily 0.8 https://clival.com/news/agi-group-acquires-chemtrix-to-expand-into-the-large-scale-flow-chemistry-market daily 0.8 https://clival.com/news/alkermes-completes-acquisition-of-rodin-therapeutics daily 0.8 https://clival.com/news/innoviva-to-acquire-la-jolla-pharmaceutical-company daily 0.8 https://clival.com/news/innovent-announces-first-patient-dosed-with-cd73-antibody-in-phase-1a1b-clinical-trial-for-advanced-solid-tumor daily 0.8 https://clival.com/news/alkem-laboratories-launches-ibuprofen-famotidine-tablets-in-us-market daily 0.8 https://clival.com/news/granules-receives-us-fda-approval-for-sildenafil-for-oral-suspension-to-treat-pulmonary-arterial-hypertension daily 0.8 https://clival.com/news/germkill-indias-citrobioshield-clinical-trials-proven-effective-against-covid-19-for-use-across-hospitals daily 0.8 https://clival.com/news/hitgen-has-successfully-completed-a-three-year-collaboration-with-mtpc-to-discover-novel-hit-compounds-for-multiple-drug-targets daily 0.8 https://clival.com/news/moderna-and-catalent-announce-collaboration-for-fill-finish-manufacturing-of-modernas-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/polaryx-therapeutics-gets-us-fda-approval-to-begin-study-of-plx-200-to-treat-juvenile-neuronal-ceroid-lipofuscinosis daily 0.8 https://clival.com/news/abvc-biopharma-inks-licensing-agreement-with-oncox daily 0.8 https://clival.com/news/abbott-expands-agreement-with-mabxience-holdings-to-commercialize-several-biosimilar-molecules-in-key-emerging-markets daily 0.8 https://clival.com/news/better-therapeutics-seeks-us-fda-breakthrough-device-designation-for-digital-therapeutic-platform-to-treat-liver-disease daily 0.8 https://clival.com/news/bridge-biotherapeutics-receives-fda-authorization-to-proceed-with-phase-2-study-of-bbt-877 daily 0.8 https://clival.com/news/wuxi-biologics-partners-with-pharmadule-morimatsu daily 0.8 https://clival.com/news/taiho-pharmaceutical-and-phost-in-therapeutics-announce-licence-agreement-on-gnt-v-inhibitor-phox430 daily 0.8 https://clival.com/news/quoin-pharma-to-begin-clinical-study-in-new-zealand-to-evaluate-qrx003-to-treat-paediatric-patient-with-peeling-skin-syndrome daily 0.8 https://clival.com/news/beigene-and-ensem-therapeutics-announce-partnership-to-advance-differentiated-cdk2-inhibitor daily 0.8 https://clival.com/news/aurobindo-pharma-acquires-domestic-formulations-business-of-veritaz-healthcare-for-rs-171-crore daily 0.8 https://clival.com/news/abelzeta-pharma-and-astrazeneca-announce-collaboration-for-the-joint-development-of-an-original-glypican-3-gpc3-armored-car-t-therapy-in-china daily 0.8 https://clival.com/news/spero-therapeutics-announces-closing-of-exclusive-license-agreement-with-gsk-for-tebipenem-hbr daily 0.8 https://clival.com/news/calliditas-receives-approval-orphan-drug-exclusivity-of-7-years-for-nefecon daily 0.8 https://clival.com/news/harbour-biomeds-subsidiary-nona-biosciences-inks-license-and-collaboration-agreement-with-moderna daily 0.8 https://clival.com/news/samsung-bioepis-announces-health-canada-approval-of-150mg-single-use-vial-and-440mg-multi-dose-vial-of-ontruzant daily 0.8 https://clival.com/news/alcami-and-tanvex-cdmo-collaborate-fro-comprehensive-solutions daily 0.8 https://clival.com/news/westvac-biopharma-receives-emergency-use-authorisation-eua-for-coviccine daily 0.8 https://clival.com/news/bruker-acquires-optimal-companies-for-pharma-pat-software-and-biopharma-manufacturing-automation-expertise-and-technologies daily 0.8 https://clival.com/news/us-fda-grants-accelerated-approval-to-janssen-pharmas-first-in-class-bispecific-therapy-talvey-to-treat-heavily-pretreated-multiple-myeloma daily 0.8 https://clival.com/news/harbour-biomed-licenses-sars-cov-2-neutralizing-ab-to-abbvie-for-covid-19-treatment daily 0.8 https://clival.com/news/astellas-subsidiary-xyphos-go-therapeutics-ink-research-and-license-agreement-to-develop-novel-antibodies-for-immuno-oncology daily 0.8 https://clival.com/news/twist-bioscience-and-ildong-pharmaceutical-enter-into-a-collaboration-to-enhance-antibody-discovery-for-applications-in-immuno-oncology daily 0.8 https://clival.com/news/us-fda-approves-mylan-generic-of-lilly-lung-cancer-drug-alimta daily 0.8 https://clival.com/news/glooko-acquires-xbird-a-medical-artificial-intelligence-company-based-in-germany daily 0.8 https://clival.com/news/akums-drugs-and-pharma-gets-dcgi-approval-for-anti-epilepsy-drug-perampanel-oral-suspension daily 0.8 https://clival.com/news/blueprint-medicines-to-expand-precision-therapy-leadership-in-lung-cancer-with-acquisition-of-lengo-therapeutics daily 0.8 https://clival.com/news/daiichi-sankyo-vanflyta-receives-european-approval-for-patients-with-newly-diagnosed-flt3-itd-positive-aml daily 0.8 https://clival.com/news/sun-pharma-recalls-over-24k-prefilled-syringes-of-generic-medication-in-the-us-due-to-a-manufacturing-issue daily 0.8 https://clival.com/news/integra-biosciences-acquires-california-based-miroculus-to-accelerate-genomics daily 0.8 https://clival.com/news/foresee-pharmaceuticals-and-trpharm-announce-license-and-co-development-agreement daily 0.8 https://clival.com/news/astrazeneca-and-sanofi-beyfortus-gets-european-approval-for-prevention-of-rsv-lower-respiratory-tract-disease-in-infants daily 0.8 https://clival.com/news/xtalpi-ck-life-sciences-collaborate-to-jointly-develop-ai-empowered-tumour-vaccine-rd-platform daily 0.8 https://clival.com/news/innovent-receives-china-nmpa-approval-for-pemazyre-to-treat-locally-advanced-or-metastatic-cholangiocarcinoma-with-a-fgfr2-fusion daily 0.8 https://clival.com/news/ascletis-gets-us-fda-approval-to-conduct-phase-iia-trial-of-asc10-to-treat-respiratory-syncytial-virus-infection daily 0.8 https://clival.com/news/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3kd-selective-inhibitor-in-relapsed-or-refractory-follicular-l daily 0.8 https://clival.com/news/boehringer-ingelheim-inks-option-agreement-to-acquire-san-diego-based-trutino-biosciences daily 0.8 https://clival.com/news/chugai-obtains-japanese-approval-for-foundationone-liquid-cdx-cancer-genomic-profile-as-a-companion-diagnostic-for-capmatinib-to-treat-advanced-andor-recurrent-unresectable-nsclc daily 0.8 https://clival.com/news/genkyotex-announces-positive-phase-1-data-of-high-dose-setanaxib-in-primary-biliary-cholangitis-patients daily 0.8 https://clival.com/news/pfizer-biontech-receive-us-fda-approval-for-2023-2024-covid-19-vaccine daily 0.8 https://clival.com/news/mercks-keytruda-scores-solo-lymphoma-nod-but-analysts-are-fixed-on-seagens-combo-potential daily 0.8 https://clival.com/news/novartis-wins-fda-approval-for-new-heart-drug-but-faces-uphill-sales-battle daily 0.8 https://clival.com/news/fda-approves-alembic-pharmaceuticals-aleor-dermaceuticals-nystatin-triamcinolone-acetonide-ointment daily 0.8 https://clival.com/news/strides-receives-us-fda-approval-for-ursodiol-tablets daily 0.8 https://clival.com/news/niagara-phase-iii-trial-of-astrazenecas-imfinzi-demonstrates-clinically-meaningful-improvementr daily 0.8 https://clival.com/news/gensight-seeks-european-marketing-approval-for-lumevoq-gene-therapy-to-treat-vision-loss-due-to-leber-hereditary-optic-neuropathy daily 0.8 https://clival.com/news/karyopharm-and-menarini-group-enter-into-exclusive-license-agreement-to-commercialize-nexpovio daily 0.8 https://clival.com/news/bayers-bay-2927088-gets-breakthrough-therapy-designation daily 0.8 https://clival.com/news/viiv-healthcare-mpp-sign-new-voluntary-licensing-agreement-to-expand-access-to-innovative-long-acting-hiv-prevention-medicine daily 0.8 https://clival.com/news/wuxi-biologics-launches-an-integrated-biologics-crdmo-center-in-fengxian-shanghai daily 0.8 https://clival.com/news/jubilant-life-sciences-seeks-nod-to-roll-out-remdesivir-tablet daily 0.8 https://clival.com/news/china-nmpa-approves-biogens-tecfidera-to-treat-multiple-sclerosis daily 0.8 https://clival.com/news/jacobio-pharma-receives-centre-for-drug-evaluation-approval-for-pivotal-study-of-glecirasib-in-pancreatic-cancer daily 0.8 https://clival.com/news/zydus-receives-final-usfda-approval-for-bortezomib-injection daily 0.8 https://clival.com/news/pfizer-applies-for-fda-authorization-for-omicron-retooled-vaccine-booster-in-kids-under-5 daily 0.8 https://clival.com/news/chinas-sanyou-bio-launches-comprehensive-monkeypox-product-line daily 0.8 https://clival.com/news/novavax-fdb-ink-agreement-to-begin-large-scale-manufacturing-of-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/azurity-pharmaceuticals-inc-announces-fda-approval-of-fleqsuvy daily 0.8 https://clival.com/news/apellis-and-beam-therapeutics-enter-exclusive-research-collaboration-to-apply-base-editing-to-discover-novel-therapies-for-complement-driven-diseases daily 0.8 https://clival.com/news/arisglobal-inks-agreement-to-acquire-amplexor-life-sciences daily 0.8 https://clival.com/news/avinger-expands-international-presence-with-first-commercial-launch-of-lumivascular-products-in-chile daily 0.8 https://clival.com/news/bavarian-nordic-receives-european-approval-of-extension-of-vaccine-label-to-include-monkeypox daily 0.8 https://clival.com/news/biolinerx-phase-12a-study-of-anti-tumour-vaccine-agi-134-in-metastatic-solid-tumours-meets-primary-endpoint daily 0.8 https://clival.com/news/biovaxys-enters-bioproduction-agreement-with-wuxi-biologics-for-covid-19-vaccine daily 0.8 https://clival.com/news/citeline-connect-and-proofpilot-announce-strategic-partnership daily 0.8 https://clival.com/news/eisai-gains-approval-in-japan-for-fycompa daily 0.8 https://clival.com/news/ema-recommends-mercks-keytruda-combo-with-chemotherapy daily 0.8 https://clival.com/news/enterome-inks-rd-collaboration-with-nestl daily 0.8 https://clival.com/news/fda-oks-valeants-psoriasis-drug-siliq-with-black-box-warning daily 0.8 https://clival.com/news/fda-revokes-emergency-use-authorization-for-chloroquine-and-hydroxychloroquine daily 0.8 https://clival.com/news/fda-revokes-emergency-use-authorization-for-monoclonal-antibody-bamlanivimab daily 0.8 https://clival.com/news/flatiron-health-announces-rwd-partnership-with-japan daily 0.8 https://clival.com/news/focus-x-therapeutics-a-viva-biotech-portfolio-company-successfully-reached-an-acquisition-agreement-with-full-life-technologies daily 0.8 https://clival.com/news/graybug-and-calcimedica-enter-into-definitive-merger-agreement daily 0.8 https://clival.com/news/gsk-and-vir-biotechnology-expand-coronavirus-collaboration-to-advance-new-therapeutics-for-influenza-and-other-respiratory-viruses daily 0.8 https://clival.com/news/biofrontera-inc-enters-into-agreements-to-purchase-options-of-biofrontera-ag daily 0.8 https://clival.com/news/zydus-gets-final-us-fda-nod-for-methylene-blue-injection daily 0.8 https://clival.com/news/delcath-systems-announces-us-launch-and-first-commercial-treatment-utilizing-hepzato-kit daily 0.8 https://clival.com/news/clover-launches-quadrivalent-seasonal-influenza-vaccine-in-mainland-china daily 0.8 https://clival.com/news/health-tech-firm-indegene-acquires-us-based-culthealth daily 0.8 https://clival.com/news/immune-onc-therapeutics-initiates-expansion-cohorts-for-io-108-and-enters-into-clinical-supply-agreement-with-regeneron daily 0.8 https://clival.com/news/innovent-announces-first-patient-dosed-in-a-phase-2-clinical-study-of-ibi112-il-23p19-monoclonal-antibody-in-patients-with-moderate-to-severe-active-ulcerative-colitis daily 0.8 https://clival.com/news/insilico-enters-into-a-collaboration-with-aprinoia-to-apply-novel-generative-ai-powered-system daily 0.8 https://clival.com/news/itm-inks-clinical-supply-agreement-with-y-mabs-therapeutics-for-nca-lutetium-177 daily 0.8 https://clival.com/news/larkspur-health-acquisition-corporation-announces-closing-of-75-million-initial-public-offering daily 0.8 https://clival.com/news/local-fixe-llc-issues-allergy-alert-on-undeclared-wheat-in-classic-lasagna-sheets-soup-noodles-dinner-rolls-pie-dough-squid-ink-fettucine-and-fresh-flour-tortillas daily 0.8 https://clival.com/news/merck-eisai-provide-update-on-phase-3-leap-010-trial-evaluating-keytruda-plus-lenvima-in-patients-with-certain-types-of-recurrent-or-metastatic-hnscc daily 0.8 https://clival.com/news/mercks-keytruda-inches-toward-another-biomarker-based-approval daily 0.8 https://clival.com/news/moderna-recalls-over-760k-covid-19-vaccine-doses-in-europe daily 0.8 https://clival.com/news/omnicell-completes-acquisition-of-recept daily 0.8 https://clival.com/news/oncotelic-therapeutics-announces-partnership-with-vectara daily 0.8 https://clival.com/news/orchid-pharmas-enmetazobactam-receives-us-fda-approval daily 0.8 https://clival.com/news/parse-biosciences-announces-partnership-with-molecular-diagnostics-korea daily 0.8 https://clival.com/news/pasithea-therapeutics-announces-comprehensive-settlement-agreement-with-the-camac-group daily 0.8 https://clival.com/news/polybio-launches-new-longcovid-research-consortium daily 0.8 https://clival.com/news/roche-concludes-acquisition-of-spark-therapeutics-inc-to-strengthen-presence-in-gene-therapy daily 0.8 https://clival.com/news/sanofi-completes-acquisition-of-synthorx-inc daily 0.8 https://clival.com/news/sanofi-completes-principia-biopharma-inc-acquisition daily 0.8 https://clival.com/news/sarepta-therapeutics-and-codiak-biosciences-collaborate-to-research-and-develop-exosome-based-therapeutics-for-rare-diseases daily 0.8 https://clival.com/news/sosei-heptares-doses-first-subject-in-clinical-trial-with-new-drug-candidate-nominated-from-multi-target-drug-discovery-collaboration-with-pfizer daily 0.8 https://clival.com/news/strides-pharma-acquires-manufacturing-facility-from-us-based-micelle-biopharma daily 0.8 https://clival.com/news/teva-and-alvotech-biosimilar-simlandi-gets-approval daily 0.8 https://clival.com/news/velsipity-gains-european-marketing-approval daily 0.8 https://clival.com/news/vipergen-establishes-dna-encoded-library-del-based-drug-discovery-partnership-with-theseus-pharmaceuticals-focused-on-targeted-cancer-therapies daily 0.8 https://clival.com/news/vir-biotechnology-announces-collaboration-agreement-with-gsk daily 0.8 https://clival.com/news/voydeya-gets-eu-recommends-for-marketing-approval daily 0.8 https://clival.com/news/xnk-therapeutics-inks-research-collaboration-with-karolinska-university-hospital-in-acute-myeloid-leukaemia daily 0.8 https://clival.com/news/zimmer-biomet-receives-fda-clearance-for-rosa daily 0.8 https://clival.com/news/zydus-inks-licensing-agreement-with-cms-to-develop-commercialise-desidustat-in-greater-china daily 0.8 https://clival.com/news/usfda-pulls-up-aurobindo-pharma-for-manufacturing-lapses-at-api-plant daily 0.8 https://clival.com/news/sandoz-launches-new-global-act4biosimilars-initiative-to-improve-patient-access-and-increase-adoption-by-at-least-30-in-30-countries-by-2030 daily 0.8 https://clival.com/news/ema-accepts-sandozs-marketing-authorization-applications-for-proposed-biosimilar-denosumab daily 0.8 https://clival.com/news/ascletis-announces-positive-phase-iia-hbv-results-on-subcutaneously-administered-pd-l1-antibody-asc22-envafolimab daily 0.8 https://clival.com/news/scisparc-receives-approval-to-conduct-its-clinical-trial-in-children-with-autism-spectrum-disorder-at-the-soroka-medical-center daily 0.8 https://clival.com/news/astrazeneca-launches-evinova-a-health-tech-business-to-accelerate-innovation-across-life-sciences-sector-the-delivery-of-clinical-trials-and-better-health-outcomes daily 0.8 https://clival.com/news/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate-against-covid-19-and-commence-pivotal-phase-23-global-study daily 0.8 https://clival.com/news/azure-pharmaceuticals-launched-a-high-quality-generic-range-campaign daily 0.8 https://clival.com/news/angle-signs-commercial-agreement-with-large-pharma daily 0.8 https://clival.com/news/akeso-announced-that-ivonescimab-granted-priority-review-of-nda-by-china-nmpa daily 0.8 https://clival.com/news/amgens-otezla-bags-expanded-fda-nod-in-psoriasis-i-mab-ceo-hits-the-exit-amid-shakeup-at-chinese-firm daily 0.8 https://clival.com/news/fujifilm-launches-new-branding-campaign-focusing-on-technologies-to-enable-people-to-move-beyond-their-health-challenges daily 0.8 https://clival.com/news/astrazeneca-in-collaboration-with-indian-society-of-nephrology-launches-ckd-academy daily 0.8 https://clival.com/news/lupin-launches-lyfe-its-digital-therapeutic-solution-for-holistic-heart-care daily 0.8 https://clival.com/news/boehringer-ingelheims-investigational-treatment-for-cognitive-impairment-associated-with-schizophrenia-receives-fda-breakthrough-therapy-designation daily 0.8 https://clival.com/news/health-canada-approves-dexcom-g7-continuous-glucose-monitoring-system-for-people-with-all-types-of-diabetes daily 0.8 https://clival.com/news/novartis-says-knew-about-zolgensma-data-problems-before-us-approval daily 0.8 https://clival.com/news/roche-pharma-india-and-skcc-usa-launch-acmo-in-india-for-oncologistspathologists daily 0.8 https://clival.com/news/gilead-announces-positive-results-from-phase-3-tropics-02-study-of-trodelvy-versus-comparator-chemotherapy-in-patients-with-hrher2-metastatic-breast-cancer daily 0.8 https://clival.com/news/dr-reddys-launches-generic-opioid-antagonist-injection-in-us daily 0.8 https://clival.com/news/twist-bioscience-and-biotia-receive-expanded-emergency-use-authorization-to-report-genetic-variants-of-sars-cov-2 daily 0.8 https://clival.com/news/lifespin-acibadem-forge-etabolomics-partnership-to-advance-personalized-medicine daily 0.8 https://clival.com/news/lupin-gets-gmp-certificate-from-japanese-agency daily 0.8 https://clival.com/news/compugen-to-host-conference-call-to-discuss-exclusive-license-agreement-with-gilead-for-com503-novel-immuno-oncology-pre-clinical-program-harnessing-il-18-biology daily 0.8 https://clival.com/news/us-fda-grants-expanded-approval-of-illuminoss-photodynamic-bone-stabilization-system-for-use-in-femur-and-tibia-fractures-as-supplemental-fixation daily 0.8 https://clival.com/news/dr-reddys-gets-3-observations-from-usfda-for-us-based-api-plant daily 0.8 https://clival.com/news/actavis-completes-705bn-allergan-acquisition daily 0.8 https://clival.com/news/european-commission-approves-teysuno-in-metastatic-colorectal-cancer daily 0.8 https://clival.com/news/mabwell-announces-the-cde-approval-of-novel-nectin-4-targeting-adc-for-phase-iii-clinical-trial daily 0.8 https://clival.com/news/carsgen-announces-first-patient-enrollment-in-the-confirmatory-phase-ii-clinical-trial-of-ct041-in-china daily 0.8 https://clival.com/news/roches-elecsys-gdf-15-assay-as-a-companion-diagnostic-in-cancer-treatment-receives-us-fda-breakthrough-device-designation daily 0.8 https://clival.com/news/phathom-pharma-vonoprazan-tablets-gets-us-fda-approval-for-treatment-of-erosive-esophagitis daily 0.8 https://clival.com/news/haystack-oncology-inks-collaboration-with-rutgers-cancer-institute-to-use-haystack-mrd-in-clinical-study-of-early-stage-triple-negative-breast-cancer daily 0.8 https://clival.com/news/us-fda-grants-510k-clearance-to-avingers-tigereye-st-image-guided-cto-crossing-system daily 0.8 https://clival.com/news/china-nmpa-accepts-antengenes-nda-for-atg-010-to-treat-rr-multiple-myeloma daily 0.8 https://clival.com/news/carsgen-ct011-achieves-ind-clearance-from-the-nmpa-for-the-gpc3-positive-stage-3-a-hepatocellular-carcinoma-at-high-risk-of-recurrence-after-surgical-resection daily 0.8 https://clival.com/news/beigenes-brukinsa-gets-health-canada-approval-to-treat-waldenstroms-macroglobulinemia daily 0.8 https://clival.com/news/dr-reddy-s-laboratories-announces-the-launch-of-difluprednate-ophthalmic-emulsion-005-in-the-us-market daily 0.8 https://clival.com/news/chinas-nmpa-approved-astellas-pharmas-padcev daily 0.8 https://clival.com/news/sino-biological-acquires-signalchem-biotech daily 0.8 https://clival.com/news/basilea-pharmaceutica-reports-positive-results-of-phase-3-eradicate-study-of-ceftobiprole-in-staphylococcus-aureus-bacteremia daily 0.8 https://clival.com/news/lupin-receives-tentative-approval-from-us-fda-for-tenofovir-alafenamide-tablets daily 0.8 https://clival.com/news/beacon-reports-positive-12-month-data-from-phase-2-skyline-trial-of-agtc-501-in-patients-with-x-linked-retinitis-pigmentosa daily 0.8 https://clival.com/news/merck-eisais-keytruda-lenvima-combo-rides-strong-data-to-fda-nod-in-kidney-cancer-and-its-bad-news-for-pfizer daily 0.8 https://clival.com/news/soligenix-signs-partnership-with-serb-pharma-to-supply-its-novel-ricin-antigen daily 0.8 https://clival.com/news/zydus-lifesciences-gets-usfda-nod-to-market-generic-high-blood-pressure-drug daily 0.8 https://clival.com/news/bristol-myers-part-2-of-phase-3-checkmate-227-trial-of-opdivo-plus-chemotherapy-in-patients-with-nsclc-fails-to-meet-primary-endpoint daily 0.8 https://clival.com/news/abclonal-biotechnology-acquires-yurogen-biosystems-to-better-serve-diagnostic-and-pharmaceutical-researchers-worldwide daily 0.8 https://clival.com/news/pfizer-and-morphosys-an-incyte-enter-into-clinical-trial-collaboration-for-monjuvi daily 0.8 https://clival.com/news/smt-receives-ce-mark-approval-for-hydra-tavr-system-to-treat-aortic-stenosis daily 0.8 https://clival.com/news/biocon-biologics-concludes-integration-of-acquired-biosimilars-business-in-120-countries daily 0.8 https://clival.com/news/medtronic-expand-partnership-with-cosmo-pharma-to-use-ai-to-improve-endoscopic-software daily 0.8 https://clival.com/news/cancervax-enters-agreement-with-flashpoint-therapeutics daily 0.8 https://clival.com/news/affamed-therapeutics-drug-gets-approval daily 0.8 https://clival.com/news/novo-holdings-soonto-acquire-majority-stake-in-single-use-support daily 0.8 https://clival.com/news/astrazeneca-acquires-caelum-biosciences-for-rare-disease-antibody daily 0.8 https://clival.com/news/arcatron-partners-with-orbimed-for-growth daily 0.8 https://clival.com/news/glaxosmithkline-enters-exclusive-license-agreement-with-hansoh-for-hs-20093 daily 0.8 https://clival.com/news/highlife-receives-ide-approval-to-initiate-us-pivotal-clinical-study-for-treatment-of-mr daily 0.8 https://clival.com/news/alivedx-multiplexed-autoimmune-diagnostics-solution-receives-three-ivdr-ce-marks daily 0.8 https://clival.com/news/arvinas-gets-in-strategic-license-agreement-with-novartis-for-protac-ar-degrader daily 0.8 https://clival.com/news/heartbeam-seeks-us-fda-approval-for-its-heartbeam-aimigo-vecg-system daily 0.8 https://clival.com/news/ocugen-announces-publication-of-positive-paediatric-phase-23-study-results-in-children-aged-2-18-years-for-covid-19-vaccine-covaxin-in-the-lancet daily 0.8 https://clival.com/news/roche-announces-us-fda-approval-of-polivy-in-combination-with-r-chp daily 0.8 https://clival.com/news/mgi-tech-and-seqone-collaborate-to-advance-complete-genomic-analysis daily 0.8 https://clival.com/news/dcgi-approved-themis-medicares-viralex-effective-against-covid19-viral-respiratory-infections daily 0.8 https://clival.com/news/niaidnih-recognizes-the-potency-of-ub-421-against-multi-drug-resistant-hiv-and-receives-the-fda-approval-to-conduct-a-phase-2-clinical-trial-with-ub-421 daily 0.8 https://clival.com/news/janssen-seeks-european-marketing-approval-for-lazertinib-in-combo-with-rybrevant-to-treat-patients-with-egfr-mutated-nsclc daily 0.8 https://clival.com/news/sun-pharma-recalls-products-in-us-market daily 0.8 https://clival.com/news/azurity-pharmaceuticals-inc-announces-fda-approval-of-eprontiatm-topiramate-oral-solution daily 0.8 https://clival.com/news/fennec-receives-us-patent-entitled-anhydrous-sodium-thiosulfate-and-formulations-thereof daily 0.8 https://clival.com/news/fda-approves-cti-biopharmas-bone-marrow-cancer-drug daily 0.8 https://clival.com/news/supriya-lifesciences-to-raise-inr-1200-crore-from-its-ipo-on-december-16-2021-has-chosen-lifescience-intellipedia-as-one-of-its-data-sourcing-partners-for-its-dhrp daily 0.8 https://clival.com/news/uk-mhra-approves-novavaxs-covid-19-vaccine-nuvaxovid daily 0.8 https://clival.com/news/egle-therapeutics-identifies-first-novel-regulatory-t-cell-targets-in-research-alliance-with-takeda daily 0.8 https://clival.com/news/nugen-medical-devices-insulin-specific-needle-free-injection-system-insujet-receives-health-canada-approval daily 0.8 https://clival.com/news/india-approves-two-vaccines-and-one-drug-against-covid-19-in-single-day daily 0.8 https://clival.com/news/astrazeneca-soon-to-acquire-amolyt-pharma daily 0.8 https://clival.com/news/eyestem-research-seeks-cdsco-approval-to-begin-first-in-human-trials-for-its-product-to-treat-geographic-atrophy daily 0.8 https://clival.com/news/astellas-vyloy-receives-regulatory-approval-in-japan daily 0.8 https://clival.com/news/viatris-gets-us-fda-tentative-nod-for-a-paediatric-formulation-of-abacavir-a-once-daily-for-hiv-children daily 0.8 https://clival.com/news/ascletis-announces-us-fda-approval-for-conducting-a-phase-iia-clinical-trial daily 0.8 https://clival.com/news/europes-largest-initiative-launches-to-accelerate-therapy-development-for-covid-19-and-future-coronavirus-threats daily 0.8 https://clival.com/news/european-drug-regulator-approves-biocons-malaysia-insulin-facility daily 0.8 https://clival.com/news/baudax-bio-reports-positive-outcome-of-interim-analysis-of-phase-ii-randomized-trial-for-bx1000-in-patients-undergoing-elective-surgery daily 0.8 https://clival.com/news/china-nmpa-approves-antengenes-xpovio-as-monotherapy daily 0.8 https://clival.com/news/topical-ibuprofen-companies-get-fda-warning daily 0.8 https://clival.com/news/union-health-ministry-issues-updated-clinical-management-protocol-for-managing-covid-19-cases daily 0.8 https://clival.com/news/junshis-phase-iii-jupiter-02-study-of-toripalimab-in-combo-with-gemcitabine-to-treat-recurrent-or-metastatic-nasopharyngeal-carcinoma-meets-primary-en daily 0.8 https://clival.com/news/china-wuxi-biologics-announces-research-service-agreement-worth-20-m-with-biontech daily 0.8 https://clival.com/news/medinol-receives-fda-approval-for-next-generation-elunir-perl-drug-eluting-coronary-stent-system daily 0.8 https://clival.com/news/eu-approves-astrazenecas-tagrisso-with-addition-of-chemotherapy-as-new-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-for-novartis-scemblix-to-treat-adult-patients-with-chronic-myeloid-leukaemia daily 0.8 https://clival.com/news/us-fda-grants-accelerated-approval-to-gileada daily 0.8 https://clival.com/news/icecure-medicals-prosense-cryoablation-system-receives-regulatory-approval-in-brazil daily 0.8 https://clival.com/news/janssen-phase-3-cartitude-4-study-of-carvykti-to-treat-relapsed-and-refractory-multiple-myeloma-meets-primary-endpoint daily 0.8 https://clival.com/news/union-cabinet-approves-rs330-crore-loan-to-help-three-psu-pharma-cos daily 0.8 https://clival.com/news/astrazeneca-gets-us-fda-approval-for-ultomiris daily 0.8 https://clival.com/news/sutro-biopharma-achieves-first-in-human-milestone-in-cytokine-derivatives-collaboration-with-merck daily 0.8 https://clival.com/news/china-nmpa-accepts-innovent-eli-lillys-snda-for-sintilimab-in-combo-with-alimta-and-platinum-to-treat-non-squamous-nsclc daily 0.8 https://clival.com/news/cage-bio-begins-phase-2b-clinical-trial-for-cgb-500-a-breakthrough-topical-jak-inhibitor-for-moderate-to-severe-atopic-dermatitis daily 0.8 https://clival.com/news/us-fda-approves-sanofi-regeneron-dupixent-to-treat-adults-and-children-aged-12-and-older-with-eosinophilic-esophagitis daily 0.8 https://clival.com/news/ema-accepts-first-china-developed-biosimilar-henlius-hlx02-maa-for-review daily 0.8 https://clival.com/news/harbour-biomed-and-windward-bio-partner-on-anti-tslp-antibody-hbm9378 daily 0.8 https://clival.com/news/crinetics-pharma-reports-positive-phase-2-results-for-atumelnant-trial daily 0.8 https://clival.com/news/promis-neurosciences-starts-phase-1b-trial-of-pmn310-for-alzheimers-disease daily 0.8 https://clival.com/news/bayer-reports-positive-phase-iii-results-for-gadoquatrane-in-mri-imaging daily 0.8 https://clival.com/news/nektar-completes-enrollment-for-rezolve-ad-phase-2b-trial-in-dermatitis daily 0.8 https://clival.com/news/fda-approval-eli-lillys-weight-loss-drug-zepbound-arrives-to-challenge-novo-nordisk daily 0.8 https://clival.com/news/novartis-wins-fda-approval-for-leqvio-on-second-try daily 0.8 https://clival.com/news/provepharm-receives-us-fda-approval-to-produce-apis-for-us-market daily 0.8 https://clival.com/news/ema-committee-recommends-approval-for-novartis-entresto-for-paediatric-heart-failure daily 0.8 https://clival.com/news/biogens-tofidence-a-biosimilar-referencing-actemra-receives-us-fda-approval-to-treat-rheumatoid-arthritis-pjia-sjia daily 0.8 https://clival.com/news/glenmark-launches-covid-19-drug-after-dcgi-nod daily 0.8 https://clival.com/news/ipsen-sohonos-capsules-receives-us-fda-approval-to-treat-fibrodysplasia-ossificans-progressiva daily 0.8 https://clival.com/news/lupin-diagnostics-launches-reference-laboratory-in-ranchi daily 0.8 https://clival.com/news/stada-alvotech-receive-european-marketing-approval-for-uzpruvo-a-biosimilar-to-stelara daily 0.8 https://clival.com/news/roche-pharma-launches-phesgo-in-india-for-the-treatment-of-her-2-positive-breast-cancer daily 0.8 https://clival.com/news/genequantum-and-biomap-form-strategic-collaboration-to-advance-next-generation-adc-therapeutics daily 0.8 https://clival.com/news/agex-therapeutics-enters-research-collaboration-with-japanese-biopharma-company-to-generate-hypoimmunogenic-cells daily 0.8 https://clival.com/news/genentecha daily 0.8 https://clival.com/news/sciwind-biosciences-to-highlight-positive-results-for-ecnoglutide-ecnoglutide daily 0.8 https://clival.com/news/us-fda-grants-emergency-use-authorization-to-oceanits-assure-100-rapid-covid-19-home-test daily 0.8 https://clival.com/news/3b-scientific-acquires-innoging-medical daily 0.8 https://clival.com/news/after-infants-death-fda-sends-new-warning-about-probiotics-for-premature-babies-in-the-hospital daily 0.8 https://clival.com/news/roches-tecentriq-receives-european-approval-for-initial-treatment-for-adults-with-metastatic-nsclc daily 0.8 https://clival.com/news/bayer-initiates-nirvana-phase-ii-study-of-elinzanetant-in-women-with-sleep-disturbances-associated-with-menopause daily 0.8 https://clival.com/news/novartis-kisqali-natalee-analysis-reinforces-25-reduction-in-risk-of-recurrence-across-broad-population-of-patients-with-early-breast-cancer daily 0.8 https://clival.com/news/lupin-gets-us-fda-tentative-approval-for-dolutegravir-emtricitabine-and-tenofovir-alafenamide-tablets daily 0.8 https://clival.com/news/china-nmpa-approves-ascentages-phase-ibii-study-of-mdm2-p53-inhibitor-apg-115-in-combo-with-pd-1pd-l1-to-treat-advanced-lps-or-other-advanced-solid daily 0.8 https://clival.com/news/arrivent-announces-a-multi-target-adc-collaboration-with-alphamab daily 0.8 https://clival.com/news/kangpu-begins-patient-dosing-in-phase-iia-trial-of-neomides-molecular-glue-kpg-818-in-systemic-lupus-erythematosus daily 0.8 https://clival.com/news/ayala-pharmaceuticals-and-advaxis-enter-into-merger-agreement daily 0.8 https://clival.com/news/alembic-pharma-gets-final-nod-from-usfda-for-generic-drug-to-treat-parkinsons-disease daily 0.8 https://clival.com/news/aspect-biosystems-enter-into-partnership-with-novo-nordisk daily 0.8 https://clival.com/news/novartis-issues-voluntary-us-nationwide-recall-of-two-lots-of-sandimmune-oral-solution-100-mgml-due-to-crystallization daily 0.8 https://clival.com/news/astrazeneca-and-merck-announce-positive-results-from-phase-3-paola-1-and-solo-1-trials-of-lynparza-in-combo-with-bevacizumab-to-treat-first-line-advanced-ovarian-cancer daily 0.8 https://clival.com/news/astrazeneca-announces-aegean-phase-iii-trial-of-imfinzi-shows-significantly-improved-efs-for-patients-with-resectable-early-stage-nsclc daily 0.8 https://clival.com/news/deliver-phase-iii-trial-shows-astrazeneca-farxiga-improved-symptom-burden-and-health-related-quality-of-life-in-patients-with-mildly-reduced-or-preserved-ejection-fraction daily 0.8 https://clival.com/news/glaxosmithkline-once-a-day-oral-jak1jak2-and-acvr1-inhibitor-omjjara-receives-european-marketing-approval daily 0.8 https://clival.com/news/iregene-therapeutics-multicenter-clinical-trial-for-novel-parkinson-disease-therapy daily 0.8 https://clival.com/news/licensing-deal-for-np213-nail-fungus-treatment-is-another-key-milestone-for-novabiotics daily 0.8 https://clival.com/news/moonlake-immunotherapeutics-signs-development-and-manufacturing-agreement-with-vetter-pharma-international-gmbh daily 0.8 https://clival.com/news/novo-nordisk-and-flagship-pioneering-to-collaborate-on-new-research-programmes daily 0.8 https://clival.com/news/syndax-pharmaceuticals-announces-closing-of-global-collaboration-and-license-agreement-for-axatilimab daily 0.8 https://clival.com/news/takeda-announces-us-fda-acceptance-of-biologics-licence-application-bla-for-tak-75 daily 0.8 https://clival.com/news/abbotts-new-coronary-imaging-software-powered-by-artificial-intelligence-launched-in-india daily 0.8 https://clival.com/news/gilead-sciences-signs-joint-procurement-agreement-with-the-european-commission-for-veklurya daily 0.8 https://clival.com/news/telix-partners-with-curium-pharma-for-scintimun-marketing-and-distribution daily 0.8 https://clival.com/news/immunoforge-gets-fda-mfds-approvals-for-pemziviptadil-kf1601-trials daily 0.8 https://clival.com/news/stada-announces-us-fda-approves-norbitec-biotech-facility-in-uetersen-germany-to-supply-retacrit-to-patients-in-us daily 0.8 https://clival.com/news/thermo-fisher-launches-make-in-india-air-quality-monitoring-systems daily 0.8 https://clival.com/news/ocugen-announces-positive-phase-23-study-results-of-its-covid-19-vaccine-candidate-covaxin daily 0.8 https://clival.com/news/flagship-pioneering-and-quotient-therapeutics-forge-agreement-to-discover-novel-targets daily 0.8 https://clival.com/news/zinzino-acquires-assets-in-xeliss-in-southern-europe-and-in-the-microalgae-spirulina daily 0.8 https://clival.com/news/hutchmed-completes-patient-enrollment-in-eslim-01-phase-iii-trial-of-sovleplenib-to-treat-primary-immune-thrombocytopenia daily 0.8 https://clival.com/news/lupin-launches-fixed-dose-triple-combination-drug-vilfuro-g-for-copd-management-in-india daily 0.8 https://clival.com/news/category/product-related-updates daily 0.8 https://clival.com/news/category/certificates-accreditation daily 0.8 https://clival.com/news/category/approval-launch daily 0.8 https://clival.com/news/category/clinical-trial-update daily 0.8 https://clival.com/news/category/licensing-collaboration-deal daily 0.8 https://clival.com/news/category/odd-bta-fta-status daily 0.8 https://clival.com/news/category/merger-acquisition daily 0.8 https://clival.com/news/category/warning-recalls daily 0.8 https://clival.com/news/dozee-and-midmark-to-launch-india-first-intelligent-connected-bed-to-propel-remote-patient-monitoring daily 0.8 https://clival.com/news/fda-approves-telixs-prostate-cancer-imaging-product-illuccix daily 0.8 https://clival.com/news/therma-bright-seeks-health-canada-approval-for-acuvid-covid-19-rapid-antigen-saliva-test-for-poc daily 0.8 https://clival.com/news/daiichi-sankyo-gets-japanese-approval-for-daichirona-for-intramuscular-injection-for-booster-vaccination-against-covid-19 daily 0.8 https://clival.com/news/exothera-collaborates-with-logicbio-therapeutics-and-polyplus-to-develop-highly-scalable-aav-manufacturing-platform daily 0.8 https://clival.com/news/mabwell-updates-on-clinical-trial-development-of-9mw2821-for-triple-negative-breast-cancer daily 0.8 https://clival.com/news/zealand-pharma-expands-its-peptide-platform-with-acquisition-of-encycle-therapeutics daily 0.8 https://clival.com/news/innovent-releases-phase-3-results-of-tyvyt-sintilimab-injection-in-combination-with-byvasda-bevacizumab-biosimilar-injection-as-first-line-treatment-i daily 0.8 https://clival.com/news/tenaya-therapeutics-gets-us-fda-clearance-to-initiate-clinical-testing-of-tn-401-gene-therapy-to-treat-pkp2-associated-arvc daily 0.8 https://clival.com/news/akums-launches-novel-combikit-for-treatment-of-duodenal-ulcer-and-h-pylori-infection daily 0.8 https://clival.com/news/fda-approval-melanoma-clinical-trials-after-anti-lag-3-approval daily 0.8 https://clival.com/news/illumina-launches-new-oncology-menu-for-novaseq-x-series-customers daily 0.8 https://clival.com/news/sentynl-acquires-zokinvy-to-treat-hutchinson-gilford-progeria-syndrome daily 0.8 https://clival.com/news/exonate-in-collaboration-with-janssen-begins-patient-dosing-in-phase-ibii-trial-for-exn-407in-diabetic-macular-oedema daily 0.8 https://clival.com/news/mylan-biocon-launch-biosimilar-of-cancer-drug-herceptin-in-australia daily 0.8 https://clival.com/news/oncolytics-biotech-announces-positive-long-term-survival-data-from-phase-1b-glioblastoma-multiforme-trial daily 0.8 https://clival.com/news/glenmark-becomes-the-firstpharmaceutical-company-tolaunch-teneligliptin-pioglitazonefixed-dose-combination-drug-fortype-2-diabetes-in-india daily 0.8 https://clival.com/news/viiv-healthcare-receives-european-marketing-approval-for-vocabria-in-combo-with-rekambys-and-edurant-to-treat-hiv-1-infection daily 0.8 https://clival.com/news/annexon-completes-enrollment-in-archer-phase-2-trial-of-novel-c1q-inhibitor-anx007-to-treat-geographic-atrophy daily 0.8 https://clival.com/news/digene-gel-recall-goa-state-warns-abbott-india-on-antacid-license-suspension daily 0.8 https://clival.com/news/orasure-technologies-gets-us-fda-approval-for-oracollect-dx-saliva-collection-device-for-otc-use daily 0.8 https://clival.com/news/uk-mhra-supports-launch-of-innovate-uk-first-of-its-kind-initiative-to-fund-new-rsin daily 0.8 https://clival.com/news/astrazeneca-to-acquire-teneotwo-and-its-clinical-stage-t-cell-engager daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-generic-esbriet-tablets daily 0.8 https://clival.com/news/boston-medical-center-to-offer-first-us-fda-approved-gene-therapies-for-sickle-cell-disease daily 0.8 https://clival.com/news/daiichi-sankyo-begins-patient-dosing-in-tropion-lung07-phase-3-trial-to-evaluate-datopotamab-deruxtecan-in-combo-with-pembrolizumab-to-treat-patients-with-previously-untreated-metastatic-nsclc daily 0.8 https://clival.com/news/astrazeneca-msd-present-final-results-of-key-secondary-os-endpoint-from-phase-iii-propel-trial-at-asco-gu-cancers-symposium daily 0.8 https://clival.com/news/ultimovacs-to-present-update-of-nipu-phase-ii-trial-in-patients-with-malignant-mesothelioma daily 0.8 https://clival.com/news/amgens-lumykras-receives-european-conditional-marketing-approval-for-patients-with-kras-g12c-mutated-advanced-nsclc daily 0.8 https://clival.com/news/apex-labs-receive-regulatory-approval-for-oral-antiviral-clevira-tablets daily 0.8 https://clival.com/news/us-fda-approves-pharming-joenja-to-treat-apds-in-adult-and-paediatric-patients-12-years-of-age-and-older daily 0.8 https://clival.com/news/lilly-entos-pharma-ink-research-collaboration-to-support-development-of-innovative-therapies-in-multiple-neurologic-indications daily 0.8 https://clival.com/news/astrazeneca-receives-chinese-marketing-nod-for-lynparza daily 0.8 https://clival.com/news/luxa-bio-announces-first-participant-dosed-in-phase-12a-clinical-trial-of-adult-rpesc-rpe-4w-for-dry-age-related-macular-degeneration daily 0.8 https://clival.com/news/sun-pharma-awaiting-regulator-nod-to-launch-covid-19-drug-in-india daily 0.8 https://clival.com/news/ascletis-begins-patient-dosing-in-us-phase-i-trial-of-oral-pd-l1-small-molecule-inhibitor-prodrug-asc61-to-treat-solid-tumours daily 0.8 https://clival.com/news/us-fda-grants-priority-review-to-merck-new-bla-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-to-protect-adults daily 0.8 https://clival.com/news/sotio-announces-first-patient-dosed-in-part-b-of-phase-11b-study-with-so-c101-in-combination-with-pembrolizumab-in-patients-with-solid-tumors daily 0.8 https://clival.com/news/gannex-galmed-enter-into-research-agreement-for-nash-treatment daily 0.8 https://clival.com/news/kite-licenses-antibodies-and-establishes-collaboration-with-teneobio-in-multiple-myeloma daily 0.8 https://clival.com/news/eirgenix-breast-cancer-biosimilar-secures-marketing-authorization-from-the-european-commission daily 0.8 https://clival.com/news/novartis-shareholders-approve-the-proposed-100-spin-off-of-sandoz daily 0.8 https://clival.com/news/innovent-receives-china-national-medical-products-administration-approval-for-olverembatinib daily 0.8 https://clival.com/news/beigene-signs-licensing-agreement-for-singlomics-neutralizing-covid-19-ab daily 0.8 https://clival.com/news/affamed-therapeutics-announces-clinical-trial-application-approval-in-mainland-china-for-risuteganib-luminate-first-in-class-candidate-for-the-treatment-of-intermediate-dry-amd daily 0.8 https://clival.com/news/fda-takes-key-action-by-approving-second-covid-19-vaccine daily 0.8 https://clival.com/news/neuroplast-announces-positive-results-from-phase-i-trial-with-neuro-cells-stem-cell-treatment-for-traumatic-spinal-cord-injury daily 0.8 https://clival.com/news/chugai-pharma-seeks-japanese-approval-for-humanized-anti-cd20-monoclonal-antibody-gazyva-to-treat-cll daily 0.8 https://clival.com/news/glenmark-pharma-gets-us-fda-approval-for-generic-cardene-capsules daily 0.8 https://clival.com/news/uk-mhra-grants-marketing-authorization-to-sk-biosciences-covid-19-vaccine-skycovion daily 0.8 https://clival.com/news/the-european-commission-approves-label-update-for-takhzyro-lanadelumab-expanding-its-use-to-a-broader-group-of-paediatric-patients-with-recurrent-attacks-of-hereditary-angioedema-hae daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-mercks-keytruda-as-adjuvant-treatment-for-adult-and-adolescent-patients-with-stage-iib-or-iic-melanoma-following-complete-resection daily 0.8 https://clival.com/news/pulsesight-seeks-french-approval-for-phase-i-trial-of-pst-611-for-dry-amd daily 0.8 https://clival.com/news/novartis-receives-us-fda-accelerated-approval-for-fabhalta daily 0.8 https://clival.com/news/vivoryon-strengthens-rd-pipeline-for-kidney-disease-development-progress daily 0.8 https://clival.com/news/teva-partners-with-formycon-to-commercialize-fyb203-biosimilar-in-europe-israel daily 0.8 https://clival.com/news/health-canada-approves-medmiras-reveal-g4-rapid-hiv-test-for-point-of-care daily 0.8 https://clival.com/news/aurobindo-pharmas-unit-vii-facility-gets-oai-from-us-fda daily 0.8 https://clival.com/news/acticor-biotech-begins-patient-enrollment-in-phase-23-actisave-study-of-glenzocimab-to-treat-acute-ischemic-stroke daily 0.8 https://clival.com/news/us-fda-approves-santhera-pharmas-agamree-to-treat-dmd-in-patients-2-years-of-age-and-older daily 0.8 https://clival.com/news/astrazeneca-drug-saphnelo-anifrolumab-has-been-approved-in-the-eu daily 0.8 https://clival.com/news/janssen-announces-positive-results-from-phase-3-mariposa-study-of-rybrevant-in-combo-with-lazertinib-versus-osimertinib-to-treat-patients-with-egfr-mutated-nsclc daily 0.8 https://clival.com/news/supriya-lifescience-attains-prestigious-gmp-certification-from-anvisa-brazil daily 0.8 https://clival.com/news/csl-arcturus-therapeutics-self-amplifying-mrna-vaccine-arct-154-receives-japanese-approval-for-covid-in-adults daily 0.8 https://clival.com/news/us-fda-declines-to-approve-spectrum-pharmaceuticals-lung-cancer-drug daily 0.8 https://clival.com/news/csir-iict-enters-licensing-agreement-with-lee-pharma-for-synthesis-of-2-deoxy-d-glucose daily 0.8 https://clival.com/news/lupin-receives-us-fda-marketing-approval-for-generic-esbriet-capsules daily 0.8 https://clival.com/news/coforge-launches-authorization-rules-centre-solution-for-the-healthcare-industry daily 0.8 https://clival.com/news/alvotech-announces-approval-in-japan-of-avt04-ustekinumab-a-biosimilar-to-stelara daily 0.8 https://clival.com/news/us-fda-grants-emergency-use-authorization-to-moderna-covid-19-vaccine-for-children-6-months-of-age-and-older daily 0.8 https://clival.com/news/novavax-set-for-india-launch-with-sii-as-mfg-partner daily 0.8 https://clival.com/news/novartis-cosentyx-receives-us-fda-approval-for-treatment-of-psoriatic-arthritis-ankylosing-spondylitis-nr-axspa daily 0.8 https://clival.com/news/ema-receives-application-for-conditional-marketing-authorisation-of-covid-19-vaccine-astrazeneca daily 0.8 https://clival.com/news/humanigen-executes-licensing-agreement-for-lenzilumab-in-covid-19-with-kpm-techtelcon-rf-pharmaceutical-for-south-korea-and-the-philippines daily 0.8 https://clival.com/news/wuxi-biologics-medigene-ink-research-collaboration-for-off-the-shelf-tcr-guided-t-cell-engagers daily 0.8 https://clival.com/news/astrazeneca-msds-lynparza-receives-japanese-approval-to-treat-advanced-ovarian-prostate-and-pancreatic-cancers daily 0.8 https://clival.com/news/asahi-kasei-to-acquire-bionova-scientific daily 0.8 https://clival.com/news/daiichi-sankyo-launches-ezharmia-in-japan-as-first-dual-ezh1-ezh2-inhibitor-therapy-for-patients-with-adult-t-cell-leukaemia-lymphoma daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-status-to-immunomedics-trodelvy-to-treat-glioblastoma daily 0.8 https://clival.com/news/health-canada-grants-marketing-approval-to-heron-therapeutics-zynrelef-for-management-of-postoperative-pain daily 0.8 https://clival.com/news/pfizers-rituxan-biosimilar-bags-fda-approval daily 0.8 https://clival.com/news/venus-remedies-ltd-remedies-receives-marketing-approvals-from-philippines-saudi-arabia-for-three-drugs daily 0.8 https://clival.com/news/catalent-to-acquire-erytech-pharma-us-cell-therapy-manufacturing-facility-for-us-445-million daily 0.8 https://clival.com/news/us-fda-approves-daiichi-sankyos-treatment-for-rare-joint-tumor daily 0.8 https://clival.com/news/check-cap-announces-fda-approval-of-amended-ide-application-for-pivotal-study-of-c-scan daily 0.8 https://clival.com/news/leads-biolabs-receives-approval-for-first-in-human-clinical-trials-of-lbl-034-in-relapsedrefractory-multiple-myeloma daily 0.8 https://clival.com/news/lexogen-launches-luthor-high-definition-single-cell-3-mrna-seq-kit-paving-the-way-for-a-revolution-in-single-cell-rna-sequencing daily 0.8 https://clival.com/news/natco-pharmas-partner-alvogen-gets-us-fda-tentative-approval-for-generic-imbruvica daily 0.8 https://clival.com/news/sun-pharma-recalls-over-10000-bottles-of-generic-anti-depression-drug-in-us daily 0.8 https://clival.com/news/novartis-to-proceed-with-phase-iii-trial-to-evaluate-the-use-of-hydroxychloroquine-to-treat-hospitalized-patients-with-covid-19-disease daily 0.8 https://clival.com/news/alembic-pharmaceuticals-receives-final-approval-from-usfda-for-its-clarithromycin-tablets daily 0.8 https://clival.com/news/merck-ridgeback-sign-long-term-supply-agreement-with-unicef-for-oral-antiviral-covid-19-medicine-molnupiravir daily 0.8 https://clival.com/news/us-fda-approves-mediwounds-nexobrid-to-treat-severe-thermal-burns-in-adults daily 0.8 https://clival.com/news/pulmatrix-seeks-us-fda-approval-to-to-initiate-phase-2-trial-of-investigational-drug-pur3100-to-treat-acute-migraine daily 0.8 https://clival.com/news/eisai-presents-late-breaker-updates-on-lecanemab-clinical-biomarker-and-safety-data-from-phase-2b-study-core-and-open-label-extension-across-five-years-at-clinical-trials-on-alzheimers-disease-ctad-conference daily 0.8 https://clival.com/news/astellas-and-poseida-therapeutics-partners-to-develop-novel-allogeneic-cell-therapies daily 0.8 https://clival.com/news/gilead-and-macrogenics-announce-oncology-collaboration-to-develop-bispecific-antibodies daily 0.8 https://clival.com/news/zydus-to-initiate-phase-ii-a-trial-of-zyil1-in-patients-with-caps-in-australia daily 0.8 https://clival.com/news/innovent-announces-the-nmpa-granted-new-indication-approval-for-byvasda-bevacizumab-biosimilar daily 0.8 https://clival.com/news/us-fda-approves-biomarins-voxzogo-vosoritide-for-children-under-5-years-with-achondroplasia daily 0.8 https://clival.com/news/us-fda-accepts-for-review-amgens-snda-for-otezla-to-treat-adults-with-mild-to-moderate-plaque-psoriasis daily 0.8 https://clival.com/news/amrutanjan-healthcare-launches-physical-store-world-of-amrutanjan-in-chennai daily 0.8 https://clival.com/news/glenmark-launches-triple-fdc-of-teneligliptin-pioglitazone-metformin-in-india-for-adults-with-type-2-diabetes-high-insulin-resistance daily 0.8 https://clival.com/news/synaptogenix-cleveland-clinic-seek-us-fda-approval-to-initiate-phase-1-trial-of-bryostatin-1-in-multiple-sclerosis daily 0.8 https://clival.com/news/new-image-group-has-acquired-nutrimetics-from-tupperware-brands daily 0.8 https://clival.com/news/us-fda-ema-accept-roches-sbla-for-ocrevus-shorter-2-hour-infusion-time-to-treat-ms daily 0.8 https://clival.com/news/orthoxel-receives-us-fda-510k-clearance-for-its-vertex-hip-fracture-nail daily 0.8 https://clival.com/news/sonivie-receives-ide-approval-from-fda-for-its-pilot-study-to-treat-hypertension-with-its-renal-artery-denervation-tivus daily 0.8 https://clival.com/news/i-mab-jumpcan-enter-agreement-to-develop-manufacture-and-commercialize-eftansomatropin-alfa daily 0.8 https://clival.com/news/daiichi-sankyo-begins-phase-3-trial-of-mrna-covid-19-vaccine-ds-5670-in-unvaccinated-individuals-in-japan daily 0.8 https://clival.com/news/mira-pharmaceuticals-and-memorial-sloan-in-talks-to-become-partner daily 0.8 https://clival.com/news/us-fda-approves-harm-reduction-therapeutics-rivive-an-otc-naloxone-nasal-spray daily 0.8 https://clival.com/news/mabwell-announces-the-nmpa-approval-of-novel-trop-2-adc-9mw2921 daily 0.8 https://clival.com/news/fda-grants-strides-pharma-approval-for-amantadine-hydrochloride-softgel-capsules-100mg daily 0.8 https://clival.com/news/dokasch-temperature-solutions-announces-united-cargo-grants-technical-approval-for-opticooler-rkn daily 0.8 https://clival.com/news/beigene-receives-european-commission-approval-for-brukinsa daily 0.8 https://clival.com/news/astrazeneca-to-acquire-icosavax daily 0.8 https://clival.com/news/amgen-soon-to-seek-european-marketing-authorization-for-teprotumumab daily 0.8 https://clival.com/news/fulcrum-collabs-with-sanofi-to-develop-and-commercialize-of-losmapimod-in-fshd daily 0.8 https://clival.com/news/techmah-cmf-llc-receives-fda-510k-approval-for-new-tmcmf-solution daily 0.8 https://clival.com/news/european-commission-approves-abbvies-skyrizifor-to-treat-adults-with-active-psoriatic-arthritis daily 0.8 https://clival.com/news/abbvie-and-plexium-enter-into-multi-target-strategic-collaboration-to-develop-and-commercialize-targeted-protein-degradation-therapies-for-neurological-conditions daily 0.8 https://clival.com/news/astellas-dosing-in-highlight-1-phase-3-study-of-fezolinetant-for-vms-for-breast-cancer daily 0.8 https://clival.com/news/biogen-announces-us-approval-for-qalsody daily 0.8 https://clival.com/news/mhra-grants-marketing-approval-for-viiv-healthcares-cabotegravir-formulations daily 0.8 https://clival.com/news/saluda-medical-receives-fda-approval-for-evoke-system-mri-labeling daily 0.8 https://clival.com/news/merck-and-proxygen-partner-in-deal-worth-up-to-25bn daily 0.8 https://clival.com/news/asgard-therapeutics-collaborates-with-exothera-to-advance-at-108-into-clinical-trials daily 0.8 https://clival.com/news/azurity-pharmaceuticals-inc-announces-fda-approval-of-zonisade daily 0.8 https://clival.com/news/direct-biologics-gets-us-fda-nod-to-proceed-with-phase-3-trial-of-ev-drug-exoflo-to-treat-ards-due-to-covid-19 daily 0.8 https://clival.com/news/amgen-was-believed-for-its-obesity-pipeline daily 0.8 https://clival.com/news/biocytogen-enters-agreement-with-ctm-bio-to-co-develop-tcr-mimic-antibody-based-multi-specific-t-cell-engagers daily 0.8 https://clival.com/news/applied-pharmaceutical-science-inc-announces-fda-approval-of-investigational-new-drug-application-for-aps03118-a-next-generation-ret-original-new-drug-for-unlimited-cancers daily 0.8 https://clival.com/news/gsk-receives-japanese-mhlw-approval-for-nucala-to-treat-chronic-rhinosinusitis daily 0.8 https://clival.com/news/latecomer-glaxosmithkline-ushers-in-7th-pd-1l1-with-fda-nod-for-jemperli-treading-on-keytrudas-ground daily 0.8 https://clival.com/news/abbvie-announces-european-commission-approval-of-rinvoq daily 0.8 https://clival.com/news/annogen-collabs-with-orchard-therapeutics-for-development-of-cns-cell-specific-promoters daily 0.8 https://clival.com/news/ani-pharmaceuticals-acquires-andas-from-oakrum-pharma-llc daily 0.8 https://clival.com/news/mei-pharma-and-kyowa-kirin-announces-me-401-phase-1b-study-to-be-highlighted-in-a-presentation-at-the-virtual-edition-of-the-25th-european-hematology daily 0.8 https://clival.com/news/astellas-pantherna-ink-agreement-for-research-to-generate-mrna-based-regenerative-medicine-programmes-using-direct-reprogramming daily 0.8 https://clival.com/news/us-fda-approves-lillys-retevmo-to-treat-adult-patients-with-advanced-ret-driven-lung-thyroid-cancers daily 0.8 https://clival.com/news/prestige-biopharmas-herceptin-biosimilar-tuznue daily 0.8 https://clival.com/news/ionis-pharma-completes-enrollment-in-phase-3-cardio-ttransform-study-of-eplontersen-in-patients-with-ttr-mediated-amyloid-cardiomyopathy daily 0.8 https://clival.com/news/sun-pharma-subsidiary-presents-positive-5-year-phase-3-data-of-ilumya-from-combined-resurface-extension-studies-at-eadv-congress daily 0.8 https://clival.com/news/novo-nordisk-snags-high-dose-ozempic-approval-turning-up-the-heat-on-lillys-trulicity daily 0.8 https://clival.com/news/ema-recommends-bluevac-3-and-syvazul-btv-3-vaccines-for-bluetongue-in-sheep daily 0.8 https://clival.com/news/fda-approves-zydus-phase-iib-trial-of-usnoflast-for-als-treatment daily 0.8 https://clival.com/news/fermion-simcere-partner-to-develop-sstr4-pain-treatment-asset-fz002-037 daily 0.8 https://clival.com/news/antengene-announces-xpovio daily 0.8 https://clival.com/news/novartis-scemblix-shows-superior-mmr-rates-vs-standard-of-care-tkis-in-phase-iii-trial-for-newly-diagnosed-patients-with-chronic-myeloid-leukaemia daily 0.8 https://clival.com/news/astrazeneca-has-completed-the-acquisition-of-neogene-therapeutics-inc daily 0.8 https://clival.com/news/lonza-and-bioqube-ventures-sign-a-framework-agreement-for-the-future-development-of-biologics-and-small-molecules-for-bioqubes-portfolio-companies daily 0.8 https://clival.com/news/innocare-keymed-partner-with-prolium-for-cd20xcd3-antibody-icp-b02 daily 0.8 https://clival.com/news/yoltech-launches-yolt-204-gene-therapy-trial-for-beta-thalassemia daily 0.8 https://clival.com/news/spravato-approved-as-first-monotherapy-for-treatment-resistant-depression daily 0.8 https://clival.com/news/arrowhead-pharma-gets-fda-approval-for-plozasiran-in-chylomicronemia-syndrome daily 0.8 https://clival.com/news/duoning-and-bioelectronica-collaborate-to-launch-advanced-single-cell-sorting-system daily 0.8 https://clival.com/news/chromadex-inks-distribution-agreement-with-sinopharm-xingsha-to-accelerate-cross-border-sales-of-tru-niagen-into-mainland-china daily 0.8 https://clival.com/news/astrazeneca-partners-with-alveofit-to-scale-up-diagnosis-and-treatment-of-lung-diseases-in-india daily 0.8 https://clival.com/news/astrazeneca-to-buy-china-based-clinical-stage-biopharma-company-gracell-for-12-billion daily 0.8 https://clival.com/news/mallinckrodt-announces-us-fda-clearance-of-inomax-evolve-ds-delivery-system-and-approval-of-inomax-mini-cylinder daily 0.8 https://clival.com/news/basilea-acquires-novel-clinical-stage-antifungal-to-treat-aspergillus-mold-infections-from daily 0.8 https://clival.com/news/sun-pharma-and-philogen-enter-into-an-exclusive-distribution-licence-and-supply-agreement-for-nidlegy daily 0.8 https://clival.com/news/humanigen-and-cenexi-announce-collaboration-to-manufacture-lenzilumab-in-france daily 0.8 https://clival.com/news/ascletis-reports-positive-us-phase-ia-results-for-glp-1r-agonist-asc40-in-obesity daily 0.8 https://clival.com/news/astrazeneca-closes-global-development-commercialisation-agreement-with-ionis-pharma-for-eplontersen daily 0.8 https://clival.com/news/biophytis-askhelpu-partner-to-treat-rare-neuromuscular-diseases-in-china daily 0.8 https://clival.com/news/poxel-secures-chinese-patent-for-imeglimin-use-in-type-2-diabetes-with-renal-issues daily 0.8 https://clival.com/news/dyne-therapeutics-gains-fda-fast-track-for-dyne-101-in-myotonic-dystrophy daily 0.8 https://clival.com/news/astrazeneca-signs-licence-agreement-with-rq-biotechnology-for-monoclonal-antibodies-against-covid-19 daily 0.8 https://clival.com/news/merck-collaborates-with-innovative-biotech-to-support-establishment-of-first-vaccine-production-facility-in-nigeria daily 0.8 https://clival.com/news/merck-orion-ink-collaboration-to-develop-and-commercialize-investigational-steroid-synthesis-inhibitor-odm-208-to-treat-mcrpc daily 0.8 https://clival.com/news/biocon-biologics-to-acquire-viatris-biosimilars-assets daily 0.8 https://clival.com/news/sony-and-astellas-pharma-enter-into-collaborative-research-agreement daily 0.8 https://clival.com/news/anabios-acquires-cell-systems-expands-human-cell-portfolio-for-drug-discovery daily 0.8 https://clival.com/news/lutris-pharma-completes-enrollment-of-part-two-of-its-phase-12-trial-of-lut014-to-treat-radiation-dermatitis-in-patients-with-breast-cancer daily 0.8 https://clival.com/news/fda-grants-breakthrough-therapy-status-to-brelovitug-for-hepatitis-delta daily 0.8 https://clival.com/news/ena-respiratory-advances-inna-051-trials-in-older-and-young-adults daily 0.8 https://clival.com/news/solid-biosciences-sgt-212-for-friedreichs-ataxia-gets-fda-fast-track daily 0.8 https://clival.com/news/zydus-usnoflast-gets-fda-orphan-drug-status-for-als-treatment daily 0.8 https://clival.com/news/taho-completes-pivotal-trial-of-tah3311-first-oral-film-anticoagulant daily 0.8 https://clival.com/news/windtree-therapeutics-and-lees-pharmaceuticals-license-istaroxime-dual-serca2a-activators-and-rostafuroxin-for-greater-chinaasia-pacific daily 0.8 https://clival.com/news/akums-acquires-new-facility-in-baddi-to-elevate-tablet-manufacturing-capacity daily 0.8 https://clival.com/news/aptar-pharma-acquires-worldwide-rights-to-pharmaxis-orbital-high-payload-dry-powder-inhaler daily 0.8 https://clival.com/news/novo-holdings-to-acquire-denmark-based-ellab-from-eqt daily 0.8 https://clival.com/news/polypid-announces-500th-patient-enrolled-in-shield-i-phase-3-clinical-trial-of-d-plex-in-abdominal-surgery daily 0.8 https://clival.com/news/sirnaomics-establishes-a-strategic-partnership-with-edirna-inc-an-rna-editing-therapeutic-company daily 0.8 https://clival.com/news/kelun-biotechs-tagitanlimab-approved-for-second-line-npc-therapy daily 0.8 https://clival.com/news/attovia-begins-phase-1-trial-of-atto-1310-for-chronic-pruritus-treatment daily 0.8 https://clival.com/news/lupin-gets-us-fda-nod-for-generic-triumeq-pd-tablets-to-treat-hiv-1 daily 0.8 https://clival.com/news/advaxis-and-ayala-pharmaceuticals-complete-merger daily 0.8 https://clival.com/news/shionogi-maze-gets-into-exclusive-worldwide-license-agreement-for-mze001 daily 0.8 https://clival.com/news/takeda-and-hutchmed-announce-fda-new-drug-application-nda-for-fruquintinib daily 0.8 https://clival.com/news/astrazeneca-gets-cdsco-nod-to-market-its-triple-drug-combination-inhalation-aerosol-for-copd-care daily 0.8 https://clival.com/news/abbvie-collaboration-with-neomorph-to-develop-molecular-glue-degraders daily 0.8 https://clival.com/news/fda-approves-leqembi-iv-maintenance-dosing-for-early-alzheimers-treatment daily 0.8 https://clival.com/news/bayer-and-hurdle-launch-precision-health-strategic-partnership daily 0.8 https://clival.com/news/bgi-genomics-launches-spearheading-innovation-in-uruguay daily 0.8 https://clival.com/news/uni-of-dundee-eisai-join-forces-for-cancer-drug-discovery daily 0.8 https://clival.com/news/novo-nordisk-reports-positive-phase-1b2a-results-for-amycretin-in-obesity daily 0.8 https://clival.com/news/ocugen-announces-fda-approval-of-ocu500-inhaled-vaccine-for-covid-19 daily 0.8 https://clival.com/news/nippon-shinyaku-ab2-bio-partner-to-commercialize-tadekinig-alfa-in-the-us daily 0.8 https://clival.com/news/transcenta-begins-phase-i-trial-of-claudin182-targeting-monoclonal-antibody-tst001-in-china daily 0.8 https://clival.com/news/haemalogix-and-lonza-collaborate-to-manufacture-kappamab-a-multiple-myeloma-drug-candidate daily 0.8 https://clival.com/news/us-fda-approves-iaso-bio-clinical-trial-application-for-bcma-car-t-ct103a-for-relapsedrefractory-multiple-myeloma daily 0.8 https://clival.com/news/ema-reviews-gsks-maa-for-depemokimab-in-asthma-and-crswnp-treatment daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-generic-atrovent-nasal-spray daily 0.8 https://clival.com/news/anavex-2-73-secures-us-patent-for-neurodegenerative-disorder-treatment daily 0.8 https://clival.com/news/inventia-life-science-unveils-rastrum-allegro-for-advanced-3d-cell-culture daily 0.8 https://clival.com/news/verona-pharmas-partner-nuance-pharma-gets-clearance-to-begin-phase-1-and-phase-3-studies-with-ensifentrine-for-copd-in-china daily 0.8 https://clival.com/news/merck-waters-to-collaborate-on-extractables-and-leachables-reference-library daily 0.8 https://clival.com/news/gsks-depemokimab-applications-under-review-in-china-japan-for-asthma daily 0.8 https://clival.com/news/beckman-coulter-gets-fda-breakthrough-status-for-alzheimers-blood-test daily 0.8 https://clival.com/news/supernus-fda-approves-qelbree-label-update-with-new-data-guidance daily 0.8 https://clival.com/news/neurocrine-biosciences-starts-phase-3-trial-of-osavampator-for-mdd daily 0.8 https://clival.com/news/lupin-receives-us-fda-tentative-approval-for-generic-invokamet-xr-tablets daily 0.8 https://clival.com/news/nabriva-therapeutics-expands-xenleta daily 0.8 https://clival.com/news/jb-chemicals-to-acquire-brands-from-sanzyme-for-rs-628-crore daily 0.8 https://clival.com/news/hikma-acquires-teligent-sterile-injectable-assets-for-4575m daily 0.8 https://clival.com/news/anthos-therapeutics-abelacimab-receives-us-fda-fast-track-designation-to-prevent-stroke-and-systemic-embolism-in-patients-with-atrial-fibrillation daily 0.8 https://clival.com/news/the-key-registration-phase-iii-study-of-neriq daily 0.8 https://clival.com/news/celltrions-avtozma-biosimilar-gains-fda-approval-for-ra-gca-more daily 0.8 https://clival.com/news/eu-approves-viivs-long-acting-vocabria-rekambys-for-hiv-in-adolescents daily 0.8 https://clival.com/news/delta4-secures-european-patents-for-fsgs-treatment-candidate-compounds daily 0.8 https://clival.com/news/fda-clears-lupins-edaravone-facility-in-somerset-with-no-observations daily 0.8 https://clival.com/news/ema-recommends-approval-of-bavarian-nordics-chikungunya-vaccine-vimkunya daily 0.8 https://clival.com/news/takeda-pharmaceuticals-announces-fda-acceptance-of-biologics-licence-application-for-entyvio daily 0.8 https://clival.com/news/supernus-wins-fda-approval-for-parkinsons-infusion-pump-onapgo daily 0.8 https://clival.com/news/rsv-human-challenge-trial-contract-signed-with-inhalon-biopharma daily 0.8 https://clival.com/news/alivedxs-mosaiq-aiplex-ctdplus-assay-earns-ivdr-ce-mark-for-aiird daily 0.8 https://clival.com/news/apogee-begins-dosing-in-phase-2-apex-trial-of-apg777-for-dermatitis daily 0.8 https://clival.com/news/dd-pharmatech-completes-enrollment-for-48-week-phase-2-mash-trial daily 0.8 https://clival.com/news/dr-reddys-laboratories-announces-the-launch-of-valsartan-tablets-usp-in-the-us-market daily 0.8 https://clival.com/news/aurobindo-pharma-receives-us-fda-approval-for-generic-precedex daily 0.8 https://clival.com/news/trilink-biotechnologies-aldevron-partner-for-cleancap-mrna-technology daily 0.8 https://clival.com/news/harbour-biomeds-hbm9378skb378-approved-for-copd-treatment daily 0.8 https://clival.com/news/hcw-biologics-gets-fda-approval-for-phase-1-trial-of-hcw9302-for-alopecia daily 0.8 https://clival.com/news/algiax-pharma-reports-positive-phase-2a-results-for-ap-325-in-neuropathic-pain daily 0.8 https://clival.com/news/astellas-seeks-japan-approval-for-avacincaptad-pegol-in-geographic-atrophy daily 0.8 https://clival.com/news/venus-remedies-gets-uk-marketing-authorization-for-bleomycin-15000-iu daily 0.8 https://clival.com/news/shionogi-jordans-guardian-angels-launch-first-neurodevelopment-trial daily 0.8 https://clival.com/news/fda-approves-supernus-onapgo-for-advanced-parkinsons-treatment daily 0.8 https://clival.com/news/alumis-acelyrin-merge-to-advance-therapies-for-immune-diseases daily 0.8 https://clival.com/news/keymed-biosciences-stapokibart-approved-for-seasonal-allergic-rhinitis daily 0.8 https://clival.com/news/equillium-biocon-report-positive-phase-2-results-for-itolizumab-in-uc daily 0.8 https://clival.com/news/lipella-pharma-gets-fda-nod-for-expanded-access-of-lp-310-oral-rinse daily 0.8 https://clival.com/news/revalesio-shares-new-phase-2-rescue-study-analyses-for-rns60-in-stroke daily 0.8 https://clival.com/news/takeda-augments-io-portfolio-with-third-build-to-buy-acquisition-in-a-year daily 0.8 https://clival.com/news/roche-releases-phase-iii-regency-trial-analysis-of-gazyva-for-lupus daily 0.8 https://clival.com/news/eli-lilly-shares-positive-omvoh-data-from-vivid-2-crohns-study daily 0.8 https://clival.com/news/nuance-pharma-gains-approval-for-ohtuvayre-to-treat-copd daily 0.8 https://clival.com/news/cenexel-announces-its-role-in-vertex-pharmas-studies-in-journavx-and-celebrates-us-fda-approval daily 0.8 https://clival.com/news/abbvies-emblaveo-gets-fda-approval-for-complex-intra-abdominal-infections daily 0.8 https://clival.com/news/senseonics-submits-ce-mark-for-eversense-365-longest-lasting-cgm-system daily 0.8 https://clival.com/news/pliant-therapeutics-pauses-beacon-ipf-trial-enrollment-for-bexotegrast daily 0.8 https://clival.com/news/bayer-seeks-eu-approval-for-6-month-eylea-8-mg-dosing-in-namd-dme daily 0.8 https://clival.com/news/neodynamics-introduces-us-fda-approved-pulse-biopsy-technology-neonavia-for-breast-and-axillary-lymph-node-biopsies daily 0.8 https://clival.com/news/canbridge-announces-approval-of-can108-for-rare-liver-disease-alagille-syndrome-under-the-early-and-pilot-implementation-policy-in-boao-lecheng-international-medical-tourism-pilot-zone daily 0.8 https://clival.com/news/alzecures-acd856-for-alzheimers-disease-gets-patent daily 0.8 https://clival.com/news/beigenes-phase-2-trial-of-brukinsa-in-patients-with-respiratory-symptoms-of-covid-19-fails-to-meet-co-primary-endpoints daily 0.8 https://clival.com/news/usfda-approves-injectable-form-of-gsk-hiv-prevention-drug daily 0.8 https://clival.com/news/clearside-shares-new-cls-ax-phase-2b-data-at-angiogenesis-2025-meeting daily 0.8 https://clival.com/news/inmune-bio-to-submit-bla-for-cordstrom-to-treat-pediatric-rdeb daily 0.8 https://clival.com/news/lion-tcrs-liocyx-m004-gets-fda-clearance-for-global-phase-2-hbv-trial daily 0.8 https://clival.com/news/boehringers-phase-iii-study-of-nerandomilast-meets-pulmonary-fibrosis-goal daily 0.8 https://clival.com/news/everest-medicines-announces-china-nmpas-approval-of-nefecon-for-the-treatment-of-primary-iga-nephropathy-in-adult-patients daily 0.8 https://clival.com/news/aim-vaccine-uses-ai-for-mrna-shingles-vaccine-submits-trial-application daily 0.8 https://clival.com/news/pfizers-adcetris-combo-approved-by-fda-for-large-b-cell-lymphoma-treatment daily 0.8 https://clival.com/news/gensight-biologics-reports-lumevoq-phase-iii-study-results-for-efficacy daily 0.8 https://clival.com/news/endo-introduces-ibuprofen-famotidine-tablets daily 0.8 https://clival.com/news/takeda-announces-topline-results-of-phase-3-admire-cd-ii-trial-of-alofisel-darvadstrocel-in-complex-crohns-perianal-fistulas daily 0.8 https://clival.com/news/uk-mhra-approves-sobis-efanesoctocog-alfa-for-haemophilia-a-treatment daily 0.8 https://clival.com/news/askbio-begins-genephit-phase-2-trial-for-ab-1002-in-heart-failure-treatment daily 0.8 https://clival.com/news/bayer-seeks-japan-approval-for-finerenone-to-treat-chronic-heart-failure daily 0.8 https://clival.com/news/fda-grants-fast-track-to-nkgens-natural-killer-therapy-for-alzheimers daily 0.8 https://clival.com/news/natco-pharma-announces-launch-of-first-generic-of-top-selling-cancer-drug-revlimid daily 0.8 https://clival.com/news/eris-lifesciences-acquires-oaknet-healthcare-for-650cr daily 0.8 https://clival.com/news/shenzhen-kexing-pharma-gets-fda-nod-for-gb05-clinical-trial-for-rsv-in-kids daily 0.8 https://clival.com/news/gsks-5-in-1-meningococcal-vaccine-penmenvy-wins-us-fda-approval daily 0.8 https://clival.com/news/samsung-bioepis-wins-ec-approval-for-denosumab-biosimilar-obodence-xbryk daily 0.8 https://clival.com/news/bayer-and-exscientia-collaborate-to-leverage-the-potential-of-artificial-intelligence-in-cardiovascular-and-oncology-drug-discovery daily 0.8 https://clival.com/news/fda-grants-breakthrough-designation-to-innate-pharmas-lacutamab-for-szary daily 0.8 https://clival.com/news/taho-reports-positive-results-for-tah3311-oral-dissolving-anticoagulant daily 0.8 https://clival.com/news/limmatech-begins-phase-1-study-for-staphylococcus-aureus-vaccine-lbt-sa7 daily 0.8 https://clival.com/news/supernus-reports-phase-2b-results-for-treatment-resistant-depression daily 0.8 https://clival.com/news/boehringer-ingelheim-acquires-swiss-biotech-company-t3-pharma-for-450-million-chf daily 0.8 https://clival.com/news/quizartinib-recommended-for-approval-in-eu-by-chmp-for-patients-with-newly-diagnosed-flt3-itd-positive-aml daily 0.8 https://clival.com/news/askbios-gene-therapy-ab-1005-gets-fda-rmat-for-parkinsons-treatment daily 0.8 https://clival.com/news/fda-accepts-sanofi-regenerons-dupixent-sbla-for-bullous-pemphigoid daily 0.8 https://clival.com/news/chimerix-announces-fda-priority-review-for-dordaviprone-in-h3-k27m-glioma daily 0.8 https://clival.com/news/fda-approves-novartis-cosentyx-as-first-intravenous-iv-formulation-interleukin-17a-antagonist-for-rheumatic-diseases daily 0.8 https://clival.com/news/adalimumab-adbm-boehringer-ingelheim-interchangeable-biosimilar-to-humira-now-available-at-low-wholesale-acquisition-cost daily 0.8 https://clival.com/news/abzena-launches-labzient daily 0.8 https://clival.com/news/boehringer-ingelheim-begins-lenticlair-1-trial-for-cystic-fibrosis-therapy daily 0.8 https://clival.com/news/harbour-biomed-insilico-partner-for-ai-driven-antibody-development daily 0.8 https://clival.com/news/jj-reports-positive-phase-3-astro-results-for-tremfya-in-ulcerative-colitis daily 0.8 https://clival.com/news/recce-pharma-reports-positive-phase-ii-results-for-recce-327-gel-in-absssi daily 0.8 https://clival.com/news/fda-approves-roches-evrysdi-as-first-tablet-for-spinal-muscular-atrophy daily 0.8 https://clival.com/news/perrigo-receives-us-fda-approval-for-opill-otc-daily-oral-contraceptive daily 0.8 https://clival.com/news/sensei-biotherapeutics-submits-ind-application-to-us-fda-for-phase-12-trial-of-sns-101-to-treat-patients-with-solid-tumours daily 0.8 https://clival.com/news/altamira-partners-with-univercells-for-mrna-vaccines daily 0.8 https://clival.com/news/roches-lunsumio-gets-us-fda-approval-to-treat-people-with-rr-follicular-lymphoma daily 0.8 https://clival.com/news/fujifilm-launches-60-million-vc-fund-for-early-stage-biotech daily 0.8 https://clival.com/news/amgen-and-plexium-announce-new-research-collaboration-worth-over-500m daily 0.8 https://clival.com/news/takeda-takhzyro daily 0.8 https://clival.com/news/us-fda-clears-abk-biomedicals-easi-vue-embolic-microspheres-for-embolization-of-arteriovenous-malformations-and-hypervascular-tumours daily 0.8 https://clival.com/news/sanofi-brain-penetrant-btk-inhibitor-meets-primary-endpoint-of-phase-2-trial-in-relapsing-multiple-sclerosis daily 0.8 https://clival.com/news/seegenes-allplex daily 0.8 https://clival.com/news/us-fda-approves-zoetis-solensia-to-control-osteoarthritis-pain-in-cats daily 0.8 https://clival.com/news/emcure-pharmaceuticals-launches-750-mg-injectable-ferric-carboxymaltose daily 0.8 https://clival.com/news/us-fda-approves-glaxosmithkline-ojjaara-for-treatment-of-myelofibrosis-patients-with-anaemia daily 0.8 https://clival.com/news/molbio-diagnostics-launches-cdsco-approved-truenat-hsv-12-test-for-herpes-simplex-virus daily 0.8 https://clival.com/news/bayer-initiates-oceanic-afina-phase-iii-study-of-asundexian-in-patients-with-af-ineligible-for-oral-anticoagulant-treatment daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-iaso-bio daily 0.8 https://clival.com/news/us-fda-approves-sandoz-biosimilar-tyruko-for-relapsing-forms-of-multiple-sclerosis daily 0.8 https://clival.com/news/daiichi-sankyo-begins-patient-dosing-phase-1-trial-of-garp-directed-immuno-oncology-therapy-ds-1055-to-treat-advanced-metastatic-solid-tumors daily 0.8 https://clival.com/news/us-fda-grants-accelerated-approval-to-cti-biopharmas-vonjo-to-treat-myelofibrosis-and-thrombocytopenia daily 0.8 https://clival.com/news/bristol-myers-squibb-acquires-karuna-therapeutics daily 0.8 https://clival.com/news/us-fda-grants-marketing-authorization-to-fujirebio-diagnostics-lumipulse-g daily 0.8 https://clival.com/news/astrazeneca-to-acquire-biopharma-company-fusion-pharma daily 0.8 https://clival.com/news/granules-india-received-us-fda-approval-for-pantoprazole-sodium-delayed-release-tablets daily 0.8 https://clival.com/news/roches-first-fda-approved-tumour-agnostic-medicine daily 0.8 https://clival.com/news/us-fda-approves-granules-indias-otc-equivalent-of-advil-dual-action-tablets daily 0.8 https://clival.com/news/centrum-launched-in-india daily 0.8 https://clival.com/news/lupin-introduces-diazepam-rectal-gel-in-us-markets daily 0.8 https://clival.com/news/daiichi-sankyo-inks-clinical-research-collaboration-with-merck daily 0.8 https://clival.com/news/leucine-rich-bio-launches-oral-microbiome-firm-crown-biome-in-us daily 0.8 https://clival.com/news/senju-pharmaceutical-and-novaliq-enter-into-licence-agreement daily 0.8 https://clival.com/news/discovery-life-sciences-acquires-reachbio-research-labs daily 0.8 https://clival.com/news/lavie-bio-receives-canadian-regulatory-approval-for-thrivus daily 0.8 https://clival.com/news/solvay-collaborates-with-ginkgo-bioworks daily 0.8 https://clival.com/news/todoc-to-launch-low-cost-artificial-cochlear-implant-system-sullivan-at-ces-2022 daily 0.8 https://clival.com/news/us-fda-approves-lannetts-branded-anesthetic-product-cocaine-hcl-nasal-solution-4 daily 0.8 https://clival.com/news/novartis-phase-iii-psmafore-study-of-pluvicto-a-psma-targeted-radioligand-therapy-meets-primary-endpoint daily 0.8 https://clival.com/news/canadian-veteran-receives-approval-for-apexs-psilocybin-therapy-through-health-canada-special-access-program daily 0.8 https://clival.com/news/aristea-begins-patient-dosing-in-phase-2a-trial-of-rist4721-in-hidradenitis-suppurativa daily 0.8 https://clival.com/news/salipro-biotech-gets-us-and-chinese-patents-for-direct-extraction-of-membrane-proteins-and-library-generation daily 0.8 https://clival.com/news/boehringer-ingelheim-sosei-heptares-collab-for-treatment-of-schizophrenia daily 0.8 https://clival.com/news/bioduro-neox-to-create-next-gen-ab-discovery-platform daily 0.8 https://clival.com/news/astrazenecas-farxiga-nabs-first-cv-approval-from-the-fda-will-a-bigger-one-follow daily 0.8 https://clival.com/news/vfl-sciences-launches-penguin-classic-laboratory-freeze-dryerlyophilizer daily 0.8 https://clival.com/news/bioinvent-completes-planned-dose-escalation-in-phase-12a-trial-of-bi-1808-in-advanced-malignancies daily 0.8 https://clival.com/news/teva-pharmaceuticals-collaborates-with-rimidi daily 0.8 https://clival.com/news/innocare-begins-patient-dosing-in-phase-ii-trial-using-orelabrutinib-for-itp-treatment daily 0.8 https://clival.com/news/amgen-and-arrakis-therapeutics-announce-multi-target-collaboration-to-identify-novel-rna-degrader-small-molecule-therapeutics daily 0.8 https://clival.com/news/lupin-launches-thiamine-hydrochloride-injection-usp-in-the-united-states daily 0.8 https://clival.com/news/free-labxchange-science-education-accelerator-launched-by-amgen-foundation-and-harvards-faculty-of-arts-and-sciences daily 0.8 https://clival.com/news/acliv-obtains-us-epa-approval daily 0.8 https://clival.com/news/xeris-bags-us-approval-for-cushings-syndrome-drug-recorlev daily 0.8 https://clival.com/news/synthego-launches-engineered-cell-libraries-to-validate-targets-with-speed-and-accelerate-drug-discovery daily 0.8 https://clival.com/news/daiichi-sankyo-receives-us-fda-approval-for-vanflyta daily 0.8 https://clival.com/news/bristol-myers-squibb-announces-positive-data-from-two-phase-3-psoriasis-studies-demonstrating-superiority-of-deucravacitinib-compared-to-placebo-and-o daily 0.8 https://clival.com/news/us-fda-approves-first-generic-maropitant-citrate-tablets-for-use-in-dogs-to-prevent-vomiting daily 0.8 https://clival.com/news/telstar-launches-a-new-range-of-modular-design-gmp-freeze-dryers-lyozeta daily 0.8 https://clival.com/news/gunze-launches-tenaleaf daily 0.8 https://clival.com/news/boston-scientific-acquires-obsidio daily 0.8 https://clival.com/news/novo-adds-another-cardio-win-for-wegovy-shows-benefits-in-heart-failure daily 0.8 https://clival.com/news/nx-ireland-achieves-gdp-certification-for-captive-warehouse daily 0.8 https://clival.com/news/amgen-and-plexium-announce-multi-year-drug-discovery-collaboration-to-identify-novel-targeted-protein-degradation-therapies daily 0.8 https://clival.com/news/alivecor-launches-clinically-validated-personal-ecg-device-kardiamobile-6l daily 0.8 https://clival.com/news/ascensias-partner-senseonics-receives-ce-mark-approval-for-eversense-e3-continuous-glucose-monitoring-system daily 0.8 https://clival.com/news/bristol-myers-squibb-phase-3-commands-trial-of-reblozyl-meets-primary-endpoint daily 0.8 https://clival.com/news/us-fda-grants-marketing-authorization-to-appliedvr daily 0.8 https://clival.com/news/japan-to-legalise-cannabis-based-medicines daily 0.8 https://clival.com/news/boehringer-ingelheims-emperor-reduced-phase-ii-trial-of-empagliflozin-in-adults-with-heart-failure-meets-primary-endpoint daily 0.8 https://clival.com/news/fujirebio-europe-launches-the-roboblot daily 0.8 https://clival.com/news/thermo-fisher-scientific-launches-enhanced-applied-biosystems-hiv-1-genotyping-kit daily 0.8 https://clival.com/news/us-fda-grants-priority-review-status-to-merck-sbla-for-keytruda-plus-padcev-to-treat-locally-advanced-or-metastatic-urothelial-cancer daily 0.8 https://clival.com/news/agilent-acquires-artificial-intelligence-technology-to-enhance-lab-productivity daily 0.8 https://clival.com/news/us-fda-issues-warning-letter-to-torrent-pharma-arm-for-violations-of-gmp daily 0.8 https://clival.com/news/us-fda-lifts-partial-clinical-hold-on-dbv-technologies-vitesse-phase-3-pivotal-trial daily 0.8 https://clival.com/news/us-approval-for-astellas daily 0.8 https://clival.com/news/boston-scientific-closes-acquisition-of-baylis-medical-company daily 0.8 https://clival.com/news/alembic-pharma-gets-tentative-usfda-nod-for-fesoterodine-fumarate-extended-release-tablets daily 0.8 https://clival.com/news/eisai-enters-into-agreement-with-national-cancer-centre daily 0.8 https://clival.com/news/sun-pharma-to-launch-oral-lipid-lowering-drug-brillo-in-india daily 0.8 https://clival.com/news/us-fda-approves-revances-botox-rival daily 0.8 https://clival.com/news/us-fda-approves-jardiance-for-the-treatment-of-adults-with-chronic-kidney-disease daily 0.8 https://clival.com/news/sun-pharma-alembic-recall-drugs-in-us-market daily 0.8 https://clival.com/news/us-fda-approves-lexicon-pharmas-inpefa-for-treatment-of-heart-failure daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-avstera daily 0.8 https://clival.com/news/us-fda-approves-lexicon-pharmas-drug-for-heart-failure daily 0.8 https://clival.com/news/thermo-fisher-scientific-launches-ce-ivd-marked-panel-to-detect-most-common-gastrointestinal-bacteria daily 0.8 https://clival.com/news/astellas-pharma-announce-priority-review-of-us-fda-licence-application-for-zolbetuxima daily 0.8 https://clival.com/news/sanofi-receives-marketing-approval-for-dupixent-in-india daily 0.8 https://clival.com/news/sun-pharma-recalls-antidepressant-in-us daily 0.8 https://clival.com/news/thermo-fisher-symphogen-extend-collaboration-to-advance-biopharmaceutical-discovery-development daily 0.8 https://clival.com/news/evotec-partners-with-bristol-myers daily 0.8 https://clival.com/news/us-fda-approves-vertexs-kalydeco-to-treat-eligible-infants-with-cf-ages-1-month-and-older daily 0.8 https://clival.com/news/chugai-pharma daily 0.8 https://clival.com/news/venus-remedies-partners-with-infex-for-met-x-development-in-india daily 0.8 https://clival.com/news/nektar-announces-trial-for-rezpegaldesleukin-in-type-1-diabetes daily 0.8 https://clival.com/news/us-fda-approves-mirums-ctexli-tablets-for-cerebrotendinous-xanthomatosis daily 0.8 https://clival.com/news/kineticos-launches-kinvard-bio-to-develop-next-gen-antibiotics-for-amr daily 0.8 https://clival.com/news/redhill-licenses-rhb-102-globally-to-hyloris-pharma-for-up-to-60m daily 0.8 https://clival.com/news/hbm-alpha-therapeutics-partners-to-advance-novel-endocrine-therapies daily 0.8 https://clival.com/news/akeso-initiates-phase-3-trial-for-ivonescimab-vs-tislelizumab-in-first-line-squamous-nsclc-treatment daily 0.8 https://clival.com/news/bristol-myers-squibb-acquires-karuna-therapeutics-for-14-billion-boosting-neuroscience-portfolio daily 0.8 https://clival.com/news/bristol-myers-squibb-to-buy-radiopharmaceutical-company-rayzebio-for-approx-41-billion daily 0.8 https://clival.com/news/astrazeneca-to-buy-us-based-clinical-stage-biopharma-company-cincor-pharma-for-18-billion daily 0.8 https://clival.com/news/bristol-myers-squibb-to-showcase-data-across-its-innovative-cardiovascular-portfolio-at-the-european-society-of-cardiology-congress-2023 daily 0.8 https://clival.com/news/servier-showcases-leadership-in-mutant-isocitrate-dehydrogenase-idh-inhibition-through-new-data-spotlighting-real-world-treatment-patterns-and-clinical-outcomes-of-tibsovo-use-at-ash-2023 daily 0.8 https://clival.com/news/regeneron-announces-us-fda-approves-eylea-hd-injection-8-mg-to-treat-wet-amd-dme-and-diabetic-retinopathy daily 0.8 https://clival.com/news/astrazeneca-completes-acquisition-of-teneotwo daily 0.8 https://clival.com/news/astellas-receives-positive-chmp-opinion-for-veoza-fezolinetant daily 0.8 https://clival.com/news/kyowa-kirin-to-present-new-research-on-x-linked-hypophosphatemia-xlh-at-asbmr-annual-meeting daily 0.8 https://clival.com/news/vueway-gadopiclenol-recibe-un-dictamen-positivo-del-chmp daily 0.8 https://clival.com/news/pfizer-and-biontech-announce-positive-topline-data-for-mrna-based-combination-vaccine-program-against-influenza-and-covid-19 daily 0.8 https://clival.com/news/yamo-pharma-begins-patient-enrollment-in-phase-2-study-of-l1-79-in-autism-spectrum-disorder daily 0.8 https://clival.com/news/faron-pharma-gets-us-fda-fimea-approvals-to-begin-phase-iii-bexmarilimab-combination-study-in-hematologic-malignancies daily 0.8 https://clival.com/news/vedas-cure-launches-ayurvedic-composition-gerd-reflux-care-for-patients-facing-regular-heartburn-and-indigestion daily 0.8 https://clival.com/news/once-weekly-altuviiio-approved-in-japan-as-a-new-class-of-factor-viii-therapy-for-hemophilia-a daily 0.8 https://clival.com/news/mdoloris-medical-systems-mindray-announce-the-ce-mark-and-launch-of-their-analgesia-nociception-index-mr-module-in-europe daily 0.8 https://clival.com/news/revelation-biosciences-inc-announces-initiation-of-a-phase-2b-study-to-assess-efficacy-of-intranasal-revtx-99-for-the-prevention-of-h3n2-influenza daily 0.8 https://clival.com/news/lillys-mounjaro-injection-to-treat-adults-with-type-2-diabetes-receives-us-fda-approval daily 0.8 https://clival.com/news/biomx-announces-positive-results-from-part-1-of-the-phase-1b2a-study-evaluating-bx004-for-treatment-of-chronic-pulmonary-infections-in-patients-with-cystic-fibrosis daily 0.8 https://clival.com/news/merck-to-discontinue-phase-3-keylynk-008-trial-of-keytruda-plus-lynparza-to-treat-metastatic-squamous-nsclc daily 0.8 https://clival.com/news/dr-reddys-completes-phase-1-study-of-drl-tc-proposed-biosimilar-of-tocilizumab daily 0.8 https://clival.com/news/immuron-gets-us-fda-approval-to-proceed-with-clinical-evaluation-of-travelan daily 0.8 https://clival.com/news/strides-gets-usfda-nod-forgeneric-drug-with-180-dayexclusivity daily 0.8 https://clival.com/news/janssen-announces-positive-interim-data-from-phase-2-galaxi-1-study-of-tremfya-to-treat-crohns-disease daily 0.8 https://clival.com/news/sanofi-and-gsk-initiate-global-phase-3-clinical-efficacy-study-of-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/full-life-technologies-announces-land-purchase-in-belgium-to-establish-gmp-manufacturing-facility daily 0.8 https://clival.com/news/bayer-hits-major-roundup-set-back-again-as-judge-rejects-unreasonable-2b-settlement daily 0.8 https://clival.com/news/astellas-4d-molecular-ink-license-agreement-to-use-4dmts-proprietary-intravitreal-r100-vector-for-rare-ophthalmic-targets daily 0.8 https://clival.com/news/asieris-unveiled-results-of-its-phase-iii-clinical-study-for-apl-1706-an-imaging-drug-for-diagnosis-or-surgery-of-bladder-cancer-at-the-siu-2023-congress daily 0.8 https://clival.com/news/am-pharma-reports-positive-data-from-phase-1b-trial-evaluating-ilofotase-alfa-in-hypophosphatasia-patients daily 0.8 https://clival.com/news/novartis-takes-on-regeneron-roche-blockbusters-with-beovu-approval daily 0.8 https://clival.com/news/teva-announces-launch-of-first-to-market-generic-version-of-narcan daily 0.8 https://clival.com/news/astrazeneca-or-daiichi-sankyo-enhertu-gets-eu-approval-for-her2-positive-metastatic-breast-cancer-treated-with-one-or-more-prior-anti-her2-based-regimens daily 0.8 https://clival.com/news/us-fda-approves-palette-life-sciences-barrigel-rectal-spacer-to-protect-during-radiation-therapy-treatment-for-prostate-cancer daily 0.8 https://clival.com/news/novartis-phase-iiib-argon-study-meets-primary-endpoint-in-a-comparison-of-enerzair-breezhaler-vs-free-combo-of-two-existing-inhaled-treatments-in-unco daily 0.8 https://clival.com/news/jazz-pharmaceuticals-plc-announced-the-us-food-and-drug-administration-fda-approval-of-a-supplemental-biologics-license-application daily 0.8 https://clival.com/news/us-fda-issues-12-observations-for-ciplas-goa-manufacturing-facility daily 0.8 https://clival.com/news/bioinvent-begins-patient-recruitment-in-phase-2a-trial-of-single-agent-bi-1808-to-treat-advanced-malignancies daily 0.8 https://clival.com/news/indoco-gets-eir-from-us-fda-for-its-solid-dosages-facility-plant-i-in-verna-goa daily 0.8 https://clival.com/news/alembic-pharma-gets-tentative-usfda-approval-for-depressive-disorder-drug daily 0.8 https://clival.com/news/college-of-medicine-launches-beyond-pills-campaign-to-tackle-overprescribing-in-uk-health-system daily 0.8 https://clival.com/news/indoco-remedies-launches-generic-azopt-in-us-market daily 0.8 https://clival.com/news/daiichi-sankyos-her2-directed-adc-enhertu-receives-prime-ministers-award-from-japan-techno-economics-society daily 0.8 https://clival.com/news/cytvia-and-nucleus-biologics-collaborate-on-custom-media-formulation-and-fulfillment-solutions daily 0.8 https://clival.com/news/nature-ally-launches-indias-first-natural-extract-antioxidant-blend-based-multivitamins daily 0.8 https://clival.com/news/bioxcel-therapeutics-begins-phase-3-trial-for-acute-agitation-in-alzheimers-patients daily 0.8 https://clival.com/news/indoco-remedies-receives-us-fda-approval-for-generic-vimpat-tablets daily 0.8 https://clival.com/news/astrazenecas-39b-alexion-buyout-scores-eu-blessing-but-still-awaits-key-nod-from-the-uk daily 0.8 https://clival.com/news/amgen-novartis-amend-aimovig-licensing-and-collaboration-agreement daily 0.8 https://clival.com/news/us-fda-approves-eli-lillys-jaypirca-to-treat-cllsll-who-have-received-at-least-two-prior-lines-of-therapy-including-a-btk-inhibitor-and-a-bcl-2-inhibitor daily 0.8 https://clival.com/news/lupin-diagnostics-expands-presence-in-south-india-with-new-regional-reference-laboratory-in-chennai daily 0.8 https://clival.com/news/transgene-bioinvent-dose-first-patient-in-part-b-of-phase-i-clinical-trial-assessing-oncolytic-virus-bt-001-in-combination-with-pembrolizumab daily 0.8 https://clival.com/news/enzene-biosciences-launches-cetuximab-biosimilar-of-cancer-drug-erbitux daily 0.8 https://clival.com/news/zydus-cadila-gets-usfda-nod-to-market-generic-cholesterol-lowering-drug daily 0.8 https://clival.com/news/abbvie-rinvoq-nabs-eu-approval-in-crohn-disease daily 0.8 https://clival.com/news/dr-reddys-labs-launches-bortezomib-injection-in-us-market daily 0.8 https://clival.com/news/oculogica-introduces-us-fda-approved-new-eyebox-device-for-diagnosis-of-concussion daily 0.8 https://clival.com/news/gensci-launches-global-innovation-hub-in-shanghai daily 0.8 https://clival.com/news/biocept-inks-agreement-with-quest-diagnostics-to-provide-target-selector-ngs-based-liquid-biopsy-testing-for-patients-with-lung-cancer daily 0.8 https://clival.com/news/china-nmpa-approves-antengenes-ind-application-for-atg-019-in-patients-with-advanced-solid-tumors-or-nhl daily 0.8 https://clival.com/news/pfizer-receives-all-required-regulatory-approvals-to-complete-the-acquisition-of-seagen daily 0.8 https://clival.com/news/gsks-long-acting-hiv-shot-approved-for-preventive-use daily 0.8 https://clival.com/news/fda-approves-boehringers-lung-disease-drug daily 0.8 https://clival.com/news/biosplice-announces-interim-data-from-phase-3-long-term-extension-trial-in-knee-osteoarthritis-and-initiates-new-phase-3-trial daily 0.8 https://clival.com/news/european-commission-approves-menarini-groups-orserdu-elacestrant-for-the-treatment-of-patients-with-er-her2-locally-advanced-or-metastatic-breast-cancer-with-an-activating-esr1-mutation daily 0.8 https://clival.com/news/trigone-pharma-announces-the-initiation-of-a-phase-2-clinical-trial-of-trg-100-in-patients-with-interstitial-cystitisbladder-pain-syndrometrg-100-is-now-being-evaluated-in-broad-range-of-bladder-disorders daily 0.8 https://clival.com/news/lupin-gets-us-fda-tentative-marketing-approval-for-generic-xywav-oral-solution daily 0.8 https://clival.com/news/biosyngen-announces-fda-approval-of-phase-iii-clinical-trials-for-brl03 daily 0.8 https://clival.com/news/zydus-cadila-receives-us-fda-approval-to-market-glycopyrrolate-injection daily 0.8 https://clival.com/news/verge-genomics-begins-patient-dosing-in-phase-1-trial-of-vrg50635-a-novel-therapeutic-for-als daily 0.8 https://clival.com/news/icmr-set-to-develop-centres-for-phase-i-clinical-trial daily 0.8 https://clival.com/news/glenmark-pharma-gets-usfda-approval-for-skin-cream-generic daily 0.8 https://clival.com/news/us-fda-approves-bristol-myers-squibbs-zeposia-to-treat-active-ulcerative-colitis daily 0.8 https://clival.com/news/breakthrough-discovery-aims-to-reduce-wound-healing-treatment-cost daily 0.8 https://clival.com/news/ampath-labs-launches-android-mobile-app-to-ease-accessibility-and-digital-presence daily 0.8 https://clival.com/news/eli-lilly-nixes-verzenios-phase-3-her2-positive-early-breast-cancer-trial daily 0.8 https://clival.com/news/concept-medicals-sirolimus-coated-magictouch-group-of-products-receives-ce-certification daily 0.8 https://clival.com/news/us-fda-clears-armata-pharmas-ind-application-to-start-phase-2-trial-of-ap-pa02-in-non-cystic-fibrosis-bronchiectasis daily 0.8 https://clival.com/news/wuxi-biologics-announces-gmp-release-of-48000l-commercial-drug-substance-manufacturing-facility-in-hebei-china daily 0.8 https://clival.com/news/lupin-collaborates-with-enzene-biosciences-to-launch-cetuximab-in-india-to-treat-head-and-neck-cancer daily 0.8 https://clival.com/news/ayala-pharmaceuticals-announces-al102-receives-orphan-drug-designation-for-desmoid-tumors daily 0.8 https://clival.com/news/acadia-pharma-gets-crl-from-us-fda-for-snda-for-pimavanserin-to-treat-hallucinations-and-delusions-associated-with-adp daily 0.8 https://clival.com/news/thermo-fisher-scientifics-amplitude-solution-receives-fda-authorization-for-covid-19-testing daily 0.8 https://clival.com/news/orum-begins-patient-dosing-in-a-phase-1-trial-of-orm-5029-to-treat-her2-expressing-advanced-solid-tumours daily 0.8 https://clival.com/news/biolinerx-announces-updated-phase-2a-data-from-triple-combination-arm-of-combatkeynote-202-study-in-patients-with-second-line-metastatic-pancreatic-c daily 0.8 https://clival.com/news/zeon-lifesciences-launches-liquid-filled-capsules-to-enhance-bioavailability-and-absorption-rates daily 0.8 https://clival.com/news/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat8007-an-antibody-drug-conjugate-targeting-nectin-4-for-the-treatment-of-advanced-solid-tumors daily 0.8 https://clival.com/news/antengene-receives-china-nmpa-approval-to-initiate-phase-ibii-study-of-eltanexor-in-patients-with-advanced-solid-tumors daily 0.8 https://clival.com/news/china-nmpa-approves-astrazeneca-soliris-to-treat-adults-with-refractory-generalised-myasthenia-gravis daily 0.8 https://clival.com/news/emas-committee-recommends-conditional-marketing-approval-for-roches-bispecific-antibody-mosunetuzumab-to-treat-rr-follicular-lymphoma daily 0.8 https://clival.com/news/meiji-seika-pharma-presents-positive-findings-from-phase-ii-study-of-me3183-novel-highly-potent-selective-pde4-inhibitor-in-patients-with-plaque-psoriasis-at-eadv-congress-2023 daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-mercks-prevymis-for-prophylaxis-of-cmv-disease-in-adult-kidney-transplant-recipients-at-high-risk daily 0.8 https://clival.com/news/lupin-lunches-rocuronium-bromide-injection-in-us-markets daily 0.8 https://clival.com/news/telix-announces-health-canada-approves-illuccix-for-prostate-cancer-imaging daily 0.8 https://clival.com/news/wuxi-launches-integrated-biologics-crdmo-centre-in-fengxian-shanghai daily 0.8 https://clival.com/news/biogen-to-buy-early-stage-potential-alzheimers-parkinsons-treatment-from-pfizer daily 0.8 https://clival.com/news/jubilant-life-sciences-arm-receives-eir-from-us-fda-for-us-salisbury-facility daily 0.8 https://clival.com/news/ambio-receives-us-fda-approval-for-generic-version-of-forteo-to-treat-osteoporosis daily 0.8 https://clival.com/news/senhwa-announces-first-patient-successfully-dosed-in-phase-i-study-of-pindnarulex-in-combination-with-pfizers-talazoparib-for-the-treatment-of-prostate-cancer daily 0.8 https://clival.com/news/teva-and-medincell-announce-fda-approval-of-uzedy daily 0.8 https://clival.com/news/ascletis-gets-pharmaceutical-trade-license-and-gsp-certificate daily 0.8 https://clival.com/news/zydus-lifesciences-gets-usfda-nod-for-generic-acne-treating-drug daily 0.8 https://clival.com/news/hnz-lifesciences-launches-its-new-brand-amio-wellness daily 0.8 https://clival.com/news/granules-pharma-receives-us-fda-approval-for-generic-adderall-xr-er-capsules daily 0.8 https://clival.com/news/us-fda-approves-aethlon-medicals-hemopurifier-covid-19-study-protocol-amendment daily 0.8 https://clival.com/news/zydus-receives-us-fda-approval-for-zituvimet-to-treat-adult-patients-with-type-2-diabetes-mellitus daily 0.8 https://clival.com/news/brii-biosciences-announces-positive-results-from-phase-1-study-of-brii-296-to-treat-postpartum-depression daily 0.8 https://clival.com/news/kamada-announces-us-fda-approval-of-its-application-to-manufacture-cytogam daily 0.8 https://clival.com/news/aligos-therapeutics-starts-patient-dosing-in-phase-1-study-with-nash-drug-candidate-alg-055009 daily 0.8 https://clival.com/news/bio-thera-solutions-announces-first-patient-dosed-in-phase-1-study-for-bat8008-an-antibody-drug-conjugate-targeting-trop2-for-the-treatment-of-advanced-solid-tumors daily 0.8 https://clival.com/news/glenmark-becomes-the-first-company-to-launch-type-2-diabetes-fixed-dose-combination-drug-in-india daily 0.8 https://clival.com/news/merck-reports-welireg-phase-3-litespark-005-trial-meets-primary-endpoint-of-pfs-in-certain-previously-treated-patients-with-advanced-rcc daily 0.8 https://clival.com/news/genes2me-launches-rtpcr-testing-lab-in-gurgaon daily 0.8 https://clival.com/news/pulse-biosciences-announces-fda-510k-clearance-for-the-treatment-of-sebaceous-hyperplasia daily 0.8 https://clival.com/news/frontera-therapeutics-begins-patient-dosing-in-phase-1-trial-of-gene-therapy-ft-001-to-treat-leber-congenital-amaurosis-2 daily 0.8 https://clival.com/news/kintor-pharma-announces-dosing-of-first-patient-in-phase-ii-clinical-trial-of-kx-826-for-the-treatment-of-androgenic-alopecia-female-patients-in-china daily 0.8 https://clival.com/news/sab-biotherapeutics-reports-update-to-phase-3-nih-activ-2-trial-design-evaluating-sab-185-for-covid-19-treatment daily 0.8 https://clival.com/news/maharashtra-fda-launches-prosecution-against-trisis-ventures-for-non-compliance-to-drugs-act daily 0.8 https://clival.com/news/ionis-pharma-announces-us-fda-accepts-new-drug-application-for-tofersen-to-treat-rar-genetic-form-of-als daily 0.8 https://clival.com/news/us-fda-approves-foundation-medicine-foundationone daily 0.8 https://clival.com/news/teva-pharma-launches-biosimilar-truxima-injection-for-rheumatoid-arthritis-in-us-market daily 0.8 https://clival.com/news/innovent-announces-the-nmpa-approval-of-sintbilo-tafolecimab-injection-for-the-treatment-of-adult-patients-with-primary-hypercholesterolemia-and-mixed-dyslipidemia daily 0.8 https://clival.com/news/strides-receives-us-fda-approval-for-efavirenz-emtricitabine-tenofovir-disoproxil-fumurate-tablets-for-hiv-1-infection daily 0.8 https://clival.com/news/zydus-gets-final-usfda-nod-to-market-cariprazine-capsules daily 0.8 https://clival.com/news/tot-biopharm-announces-nmpa-granted-marketing-approval-for-pusintin daily 0.8 https://clival.com/news/bristol-myers-squibb-2seventy-bio-report-positive-results-from-karmma-3-trial-of-abecma-in-relapsed-and-refractory-mm daily 0.8 https://clival.com/news/phase-i-clinical-trial-of-pac-1-in-patients-with-end-stage-cancers-shows-promising-results daily 0.8 https://clival.com/news/novartis-gets-european-approval-for-tabrecta-to-treat-metex14-skipping-advanced-non-small-cell-lung-cancer daily 0.8 https://clival.com/news/chains-xjtlu-launches-new-academy-of-pharmacy daily 0.8 https://clival.com/news/ascletis-begins-patient-dosing-in-phase-iii-trial-of-fasn-inhibitor-asc40-in-combo-with-bevacizumab-to-treat-recurrent-glioblastoma daily 0.8 https://clival.com/news/galderma-phase-iii-olympia-2-trial-of-nemolizumab-in-patients-with-prurigo-nodularis-meets-primary-and-secondary-endpoints daily 0.8 https://clival.com/news/pnb-vesper-successfully-completes-phase-2-clinical-trials-of-gpp-baladol-on-covid-19-patients-to-submit-data-to-dcgi daily 0.8 https://clival.com/news/xvivo-gains-regulatory-approval-in-china-for-perfadexr-plus-the-global-gold-standard-for-lung-preservation daily 0.8 https://clival.com/news/roche-announces-positive-results-from-phase-iii-haven-6-study-of-hemlibra-in-people-with-moderate-or-mild-haemophilia-a daily 0.8 https://clival.com/news/jazz-pharmaceuticals-announces-new-research-collaboration-with-redx-pharma-to-discover-and-develop-two-targeted-cancer-therapies daily 0.8 https://clival.com/news/mindset-pharma-progresses-plans-for-clinical-trials-of-its-advanced-pre-clinical-psychedelic-msp-1014 daily 0.8 https://clival.com/news/innocare-receives-hong-kong-approval-for-tafasitamab-in-combo-with-lenalidomide-to-treat-rr-diffuse-large-b-cell-lymphoma daily 0.8 https://clival.com/news/wipro-ge-healthcare-launches-made-in-india-ct-system-to-strengthen-access-to-quality-healthcare-across-india daily 0.8 https://clival.com/news/altamira-therapeutics-announces-launch-of-bentrio-in-hong-kong-by-its-partner-nuance-pharma daily 0.8 https://clival.com/news/olipass-announces-commencement-of-dosing-in-phase-2a-trial-for-pain-killer-olp-1002 daily 0.8 https://clival.com/news/calliditas-therapeutics-submits-snda-to-us-fda-seeking-full-approval-of-tarpeyo daily 0.8 https://clival.com/news/ark-biopharmaceuticals-ak0610-receives-ind-approval-for-rsv-antibody daily 0.8 https://clival.com/news/phase-i-study-of-car-t-cell-therapy-in-paediatric-leukaemia-adult-lymphoma-patients-at-tata-hospital-shows-positive-results daily 0.8 https://clival.com/news/nmpa-approves-chinas-first-trastuzumab-biosimilar daily 0.8 https://clival.com/news/cilag-gmbh-international-discontinues-collaboration-and-license-agreement-with-argenx-for-cusatuzumab daily 0.8 https://clival.com/news/eisais-new-anti-insomnia-drug-dayvigo-approved-in-hong-kong daily 0.8 https://clival.com/news/daiichi-begins-patient-dosing-in-phase-12-study-of-ds-1594-to-treat-rr-acute-myeloid-leukemia-and-acute-lymphoblastic-leukemia daily 0.8 https://clival.com/news/biophore-its-subsidiary-zenara-pharma-receive-first-approval-for-cannabidiol-in-india daily 0.8 https://clival.com/news/cyclo-therapeutics-signs-master-services-agreement-with-worldwide-clinical-trials daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-bristol-myers-opdivo-plus-yervoy-with-two-cycles-of-chemotherapy-to-treat-metastatic-nsclc daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-tg-therapeutics-briumvi-to-treat-relapsing-forms-of-multiple-sclerosis-in-adults daily 0.8 https://clival.com/news/takedas-exkivity daily 0.8 https://clival.com/news/us-fda-grants-rare-paediatric-disease-designation-to-sensorion-otof-gt-to-treat-otoferlin-gene-mediated-hearing-loss daily 0.8 https://clival.com/news/sanofi-and-gsk-covid-19-vaccine-candidate-demonstrates-strong-immune-responses-across-all-adult-age-groups-in-phase-2-trial daily 0.8 https://clival.com/news/angion-biomedica-gets-us-fda-clearance-to-initiate-phase-1b-study-of-ang-3070-in-patients-with-ipf daily 0.8 https://clival.com/news/remegens-telitacicept-demonstrates-positive-results-in-phase-ii-trial-in-treatment-of-primary-sj daily 0.8 https://clival.com/news/accutar-biotechnology-announces-fda-approval-of-ind-application-for-phase-1-clinical-trial-of-ac0176-for-prostate-cancer daily 0.8 https://clival.com/news/gracell-biotechnologies-receives-ind-approval-from-china-nmpa-for-gc019f-a-fastcar-enabled-car-t-therapy-for-the-treatment-of-relapsed-or-refractory daily 0.8 https://clival.com/news/inmagene-hutchmed-begin-patient-dosing-in-phase-1-trial-of-img-007-to-treat-atopic-dermatitis daily 0.8 https://clival.com/news/biomarin-announces-positive-results-from-phase-3-gener8-1-study-of-valoctocogene-roxaparvovec-to-treat-severe-haemophilia-a daily 0.8 https://clival.com/news/ahmedabad-based-troikaa-pharma-receives-us-patent-for-pain-relief-formula daily 0.8 https://clival.com/news/incyte-presents-phase-3-data-from-true-ad-programme-of-ruxolitinib-to-treat-atopic-dermatitis-at-rad-virtual-symposium daily 0.8 https://clival.com/news/arcellx-and-kite-continue-anito-cel-multiple-myeloma-program daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-jr-441-for-the-treatment-of-mucopolysaccharidosis-type-iiia-mps-iiia daily 0.8 https://clival.com/news/krystal-biotech-seeks-us-fda-approval-for-b-vec-to-treat-patients-with-dystrophic-epidermolysis-bullosa daily 0.8 https://clival.com/news/european-commission-grants-marketing-approval-for-karyopharm-and-menarinis-nexpovio-to-treat-patients-with-mm-after-at-least-one-prior-therapy daily 0.8 https://clival.com/news/antengene-announces-first-patient-dosed-in-phase-ii-trial-of-atg-008-onatasertib-in-patients-with-advanced-solid-tumors-with-specific-genetic-altera daily 0.8 https://clival.com/news/astellas-pharma-seagen-announce-positive-results-from-phase-3-ev-302-trial-of-padcev-in-combo-with-keytruda-versus-chemotherapy-in-patients-with-previously-untreated-advanced-bladder-cancer daily 0.8 https://clival.com/news/gilead-and-galapagos-phase-2b-3-trial-of-oral-once-daily-jak1-inhibitor-filgotinib-to-treat-ulcerative-colitis-meets-primary-endpoint daily 0.8 https://clival.com/news/first-of-its-kind-global-collaboration-launched-to-develop-transformative-treatment-regimens-for-tuberculosis daily 0.8 https://clival.com/news/aquestive-therapeutics-expands-licence-and-supply-agreement-with-atnahs-pharma daily 0.8 https://clival.com/news/abbott-launches-freestyle-librelink-mobile-app-in-india daily 0.8 https://clival.com/news/fda-approves-novel-treatment-to-target-abnormality-in-sickle-cell-disease daily 0.8 https://clival.com/news/junshi-biosciences-begins-phase-i-study-of-sars-cov-2-neutralizing-antibody-js016-in-china daily 0.8 https://clival.com/news/mankind-pharma-gets-cdsco-panel-nod-for-phase-i-trial-of-anti-diabetic-drug-mkp10241 daily 0.8 https://clival.com/news/sanofi-enters-agreement-with-merck-to-conduct-phase-2-trial-of-thor-707-in-combo-with-keytruda-for-new-treatment-option-in-oncology daily 0.8 https://clival.com/news/glenmark-pharmaceuticals-receives-anda-approval-for-lacosamide-tablet daily 0.8 https://clival.com/news/chugai-phase-iii-alina-study-of-alecensa-compared-with-platinum-based-chemotherapy-to-treat-alk-positive-early-stage-lung-cancer-meets-primary-endpoint daily 0.8 https://clival.com/news/gsk-launches-anti-shingles-vaccine-in-india daily 0.8 https://clival.com/news/aurobindo-units-recall-products-in-us-market-for-manufacturing-issues daily 0.8 https://clival.com/news/navin-fluorine-launches-navin-molecular-a-new-brand-for-its-future-thinking-cdmo-business daily 0.8 https://clival.com/news/zydus-receives-final-fda-approval-for-type-2-diabetes-drug daily 0.8 https://clival.com/news/astrazenecas-triple-combination-therapy-gets-approval-in-china-for-copd daily 0.8 https://clival.com/news/icecures-prosense-deepens-regulatory-approval-in-india daily 0.8 https://clival.com/news/lexicon-pharma-shares-plummet-after-fda-denies-appeal-against-drug-rejection daily 0.8 https://clival.com/news/karnataka-gets-four-of-the-six-genome-sequencing-labs-approved-by-dbt daily 0.8 https://clival.com/news/sanofi-receives-marketing-approval-for-its-diabetes-drug-soliqua-in-india daily 0.8 https://clival.com/news/eisai-and-biogen-announces-acceptance-of-new-drug-submission-nds-for-lecanemab daily 0.8 https://clival.com/news/takeda-receives-positive-chmp-opinion-for-pre-filled-syringe-presentation-of-takhzyro-lanadelumab-for-use-as-a-preventive-treatment-for-hereditary-ang daily 0.8 https://clival.com/news/cancer-research-uk-and-ucb-have-announced-a-clinical-development-collaboration daily 0.8 https://clival.com/news/china-approves-yiling-pharmaceuticals-patent-depression-resolving-drug daily 0.8 https://clival.com/news/astrazeneca-shares-rise-on-early-us-approval-for-leukaemia-drug daily 0.8 https://clival.com/news/sanofi-bioverativ-deal-begins-to-pay-dividends-with-first-new-drug-approval daily 0.8 https://clival.com/news/startoon-labs-physiotherapy-monitoring-device-pheezee-receives-us-fda-approval daily 0.8 https://clival.com/news/jw-therapeutics-announces-ind-approval-for-the-clinical-trial-of-relma-cel-in-patients-with-moderately-or-severely-refractory-systemic-lupus-erythematosus daily 0.8 https://clival.com/news/bdr-pharma-launches-enzalutamide-80mg-to-treat-mcrpc daily 0.8 https://clival.com/news/alzheimers-drugmakers-seek-accelerated-fda-review-despite-us-coverage-decision daily 0.8 https://clival.com/news/regrow-biosciences-receives-us-fda-approval-to-begin-phase-ii-trials-of-ossgrow-to-treat-osteonecrosis daily 0.8 https://clival.com/news/kinnate-biopharma-inc-announces-fda-clearance-of-investigational-drug-application-for-kin-3248 daily 0.8 https://clival.com/news/anglo-french-drugs-launches-lyber-range daily 0.8 https://clival.com/news/gujarat-fdca-issues-licenses-to-610-cos-between-april-1-2020-and-feb-9-2021 daily 0.8 https://clival.com/news/antengene-announces-hrec-approval-in-australia-for-the-phase-i-trial-of-the-small-molecule-cd73-inhibitor-atg-037 daily 0.8 https://clival.com/news/mercks-keytruda-receives-european-approval-to-treat-patients-with-msi-h-or-dmmr-tumours-in-five-different-types-of-cancer daily 0.8 https://clival.com/news/promis-neurosciences-starts-phase-1b-dosing-in-precise-ad-trial daily 0.8 https://clival.com/news/fda-approves-first-human-milk-based-fortifier-for-infants-with-gastroschisis daily 0.8 https://clival.com/news/wuxi-biologics-drug-substance-and-drug-product-facilities-again-approved-by-us-fda-and-ema daily 0.8 https://clival.com/news/dr-reddys-labs-launches-generic-sapropterin-dihydrochloride-tablets daily 0.8 https://clival.com/news/astrazenecas-dapagliflozin-receives-dcgi-marketing-approval-to-treat-patients-with-heart-failure daily 0.8 https://clival.com/news/us-fda-clears-transcentas-ind-to-initiate-phase-i-trial-for-bi-functional-anti-pd-l1tgf daily 0.8 https://clival.com/news/antengenes-xpovio-gets-australian-tga-approval-to-treat-rr-mm-triple-class-refractory-multiple-myeloma daily 0.8 https://clival.com/news/us-fda-grants-marketing-authorization-to-moximeds-misha-knee-system-for-people-suffering-from-knee-osteoarthritis daily 0.8 https://clival.com/news/iveric-bio-announces-positive-24-month-topline-results-from-phase-3-study-of-izervay-avacincaptad-pegol-intravitreal-solution-for-geographic-atrophy daily 0.8 https://clival.com/news/pharmablock-obtained-iso-50001-certification-advancing-sustainable-development daily 0.8 https://clival.com/news/shepherd-therapeutics-and-mayo-clinic-announce-collaboration-to-advance-research-in-rhabdomyosarcoma-using-shepherds-precision-oncology-platform-delve daily 0.8 https://clival.com/news/lupins-inhalation-research-center-florida-receives-eir-from-us-fda daily 0.8 https://clival.com/news/zydus-cadila-gets-tentative-usfda-nod-to-market-anti-cancer-drug daily 0.8 https://clival.com/news/roches-vabysmo-gets-european-approval-to-treat-namd-and-visual-impairment-due-to-dme daily 0.8 https://clival.com/news/us-fda-approves-ellipses-pharma-ind-application-for-ep0042-for-treatment-of-acute-myeloid-leukaemia daily 0.8 https://clival.com/news/zydus-cadila-receives-us-fda-approval-for-mesalamine-er-capsules daily 0.8 https://clival.com/news/akeso-completes-enrollment-in-phase-iii-trial-of-pd-1vegf-bispecific-antibody-ak112-combined-with-chemotherapy-in-egfr-tki-resistant-nsq-nsclc daily 0.8 https://clival.com/news/apotex-corporation-launches-teriparatide-injectable-for-osteoporosis-treatment-in-the-united-states daily 0.8 https://clival.com/news/bristol-myers-squibb-and-janssen-pharmaceuticals-collaborate-to-receive-fda-fast-track-designation-for-milvexian daily 0.8 https://clival.com/news/kyowa-kirin-announces-approval-of-phozevel-for-improvement-of-hyperphosphatemia-in-chronic-kidney-disease-patients-on-dialysis-in-japan daily 0.8 https://clival.com/news/lytix-biopharma-gets-regulatory-approval-to-commence-atlas-it-05-study-in-3-european-countries daily 0.8 https://clival.com/news/dcgi-approves-market-authorisation-for-siis-covid-vaccine-covovax-as-heterologous-booster-dose daily 0.8 https://clival.com/news/beigene-begins-patient-dosing-in-phase-1-trial-of-investigational-tyk2-inhibitor-bgb-23339 daily 0.8 https://clival.com/news/bdr-pharma-launches-furmecil daily 0.8 https://clival.com/news/glenmark-launches-sacu-vtm-to-treat-chronic-heart-failure daily 0.8 https://clival.com/news/teva-launches-first-generic-versions-of-hiv-1-treatments-truvadaa daily 0.8 https://clival.com/news/singapore-hsa-approves-specialised-therapeutics-qinlock-to-treat-patients-with-gist daily 0.8 https://clival.com/news/lynk-pharmaceuticals-gets-clinical-approval-in-china-for-class-i-new-drug-lnk01004 daily 0.8 https://clival.com/news/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-in-china-for-the-treatment-of-androgenetic-alopecia-in-female-patients daily 0.8 https://clival.com/news/ayala-pharmaceuticals-announces-first-patient-dosed-with-al102-in-phase-3-segment-of-ringside-trial-in-desmoid-tumors daily 0.8 https://clival.com/news/aiocd-seeks-amendments-in-pharmacy-act-1948-to-ensure-hassle-free-renewal-of-pharmacists-licences-in-jk daily 0.8 https://clival.com/news/astrazeneca-gets-us-fda-complete-response-letter-on-sbla-for-farxiga-in-type-1-diabetes daily 0.8 https://clival.com/news/transcenta-received-ind-clearance-from-fda-for-its-best-in-class-masp2-targeting-antibody-tst004-for-the-treatment-of-iga-nephropathy daily 0.8 https://clival.com/news/scisparc-begins-patient-recruitment-in-phase-iia-trial-of-sci-110-to-treat-alzheimers-disease daily 0.8 https://clival.com/news/global-phase-3-trial-of-beigenes-pd-1-inhibitor-tislelizumab-in-combination-with-chemotherapy-meets-primary-endpoint-in-first-line-advanced-esophageal-squamous-cell-carcinoma daily 0.8 https://clival.com/news/ascentage-pharma-gets-china-nmpa-approval-for-phase-iia-study-of-apg-115-single-agent-or-in-combo-with-apg-2575-to-treat-relapsedrefractory-t-cell-pr daily 0.8 https://clival.com/news/china-approves-worlds-first-comprehensive-myeloprotection-drug-against-chemo-damage daily 0.8 https://clival.com/news/indoco-remedies-gets-eir-from-usfda-for-2-plants-in-goa daily 0.8 https://clival.com/news/lords-the-hygiene-india-launches-thimovement-campaign-to-foster-a-health-hygiene-culture-in-india daily 0.8 https://clival.com/news/astrazeneca-to-discontinue-stabilize-ckd-and-dialize-outcomes-phase-iii-trials-for-lokelma daily 0.8 https://clival.com/news/glenmark-pharma-receives-us-fda-approval-for-generic-cleocin-hydrochloride-capsules daily 0.8 https://clival.com/news/biorestorative-awarded-an-sttr-phase-i-grant-to-explore-therapeutic-effects-of-peg-peptide-hydrogel-encapsulated-hypoxic-bone-marrow-stem-cells daily 0.8 https://clival.com/news/bharat-biotech-announces-phase-3-results-of-covaxin daily 0.8 https://clival.com/news/sequana-medical-completes-patient-enrollment-in-phase-2a-sahara-i-dsr-study-dsr-10-for-congestive-heart-failure-treatment daily 0.8 https://clival.com/news/chugai-pharma-obtains-japanese-approval-for-polivy-to-treat-rr-diffuse-large-b-cell-lymphoma daily 0.8 https://clival.com/news/pfizers-lorviqua-receives-ec-approval-for-treatment-of-advanced-lung-cancer daily 0.8 https://clival.com/news/revelation-biosciences-doses-first-patient-in-prime-phase-1b-ckd-study daily 0.8 https://clival.com/news/hexvix daily 0.8 https://clival.com/news/global-registrational-phase-iii-study-of-bcl-2-inhibitor-lisaftoclax-in-treatment-naive-patients-with-cllsll-approved-by-the-china-cde daily 0.8 https://clival.com/news/bristol-myers-squibb-cellares-announces-agreement-for-car-t-cell-therapies-manufacturing daily 0.8 https://clival.com/news/daiichi-sankyo-scri-announce-phase-12-trial-of-ds-7300-continues-to-show-promising-durable-response-in-patients-with-several-types-of-advanced-cancer daily 0.8 https://clival.com/news/prenetics-launches-200-m-jv-for-multi-cancer-early-detection-in-hong-kong daily 0.8 https://clival.com/news/dr-reddys-glenmark-recall-products-in-us-due-to-manufacturing-issues daily 0.8 https://clival.com/news/gsk-launches-ps6-million-programme-to-boost-stem-career-progression-for-young-people-from-under-represented-groups-in-uk daily 0.8 https://clival.com/news/neurobo-pharma-begins-patient-dosing-in-phase-2a-trial-of-da-1241-for-nonalcoholic-steatohepatitis-treatment daily 0.8 https://clival.com/news/myhealthcare-launches-an-integrated-healthcare-financing-solution-for-patients-named-myhealthfin daily 0.8 https://clival.com/news/precigen-announces-us-fda-confirmation-that-the-ongoing-phase-12-study-of-prgn-2012-adenoverse-immunotherapy-will-serve-as-pivotal-study-to-support-accelerated-approval daily 0.8 https://clival.com/news/novartis-receives-european-approval-for-piqray-in-combo-with-fulvestrant-to-treat-hrher2-locally-advanced-or-metastatic-breast-cancer-with-pik3ca-mu daily 0.8 https://clival.com/news/elgans-infant-malabsorption-treatment-reduces-complications-in-phase-iii daily 0.8 https://clival.com/news/valenzabio-and-novelty-nobility-announce-exclusive-license-agreement-for-potential-best-in-class-anti-c-kit-monoclonal-antibody daily 0.8 https://clival.com/news/oncolytics-biotech-reports-interim-results-from-phase-12-goblet-study-showing-a-70-orr-in-pancreatic-cancer-at-sitc-meeting daily 0.8 https://clival.com/news/china-nmpa-approves-bayer-kerendia-to-treat-ckd-associated-with-type-2-diabetes daily 0.8 https://clival.com/news/everest-medicines-announces-approval-of-xerava-in-china-for-the-treatment-of-complicated-intra-abdominal-infections-in-adult-patients daily 0.8 https://clival.com/news/hutchmed-initiates-phase-ibii-study-of-hmpl-453-in-combination-with-chemotherapy-or-toripalimab-for-advanced-solid-tumors-in-china daily 0.8 https://clival.com/news/ascletis-announces-dosing-of-4-healthy-subjects-of-the-first-cohort-in-multiple-dose-escalation-phase-i-clinical-trial-of-oral-3clpro-inhibitor-asc11-for-covid-19 daily 0.8 https://clival.com/news/first-patient-dosed-in-canbridge-pharmaceuticals-can103-phase-2-trial-for-the-treatment-of-gaucher-disease-in-china daily 0.8 https://clival.com/news/strides-receives-tentative-us-fda-approval-for-dolutegravir-lamivudinetenofovir-disproxil-fumurate-tablets daily 0.8 https://clival.com/news/us-fda-grants-510k-clearance-to-abm-respiratory-care-biwaze-clear-system daily 0.8 https://clival.com/news/jb-chemicals-receives-us-fda-approval-for-loratadine-tablets daily 0.8 https://clival.com/news/foresee-pharmaceuticals-announces-first-patient-dosed-in-the-casppian-phase-3-clinical-trial-of-leuprolide-fp-001-injectable-emulsion-42-mg-for-the-treatment-of-central-precocious-puberty-patients daily 0.8 https://clival.com/news/molecular-targeting-technologies-inc-thomas-jefferson-university-and-north-china-pharmaceutical-co-ltd-announced-the-chinese-approval-for-a-rabies-drug daily 0.8 https://clival.com/news/bio-thera-solutions-announces-initiation-of-phase-i-clinical-trials-for-bat6026-a-monoclonal-antibody-targeting-ox40 daily 0.8 https://clival.com/news/mda-celebrates-the-approval-of-mtpas-radicava-ors-to-treat-als daily 0.8 https://clival.com/news/antengene-begins-patient-dosing-in-phase-iii-hatch-trial-of-eltanexor-to-treat-myelodysplastic-syndrome daily 0.8 https://clival.com/news/bristol-myers-squibb-announces-positive-results-from-phase-2-study-of-lpa1-antagonist-bms-986278-in-patients-with-idiopathic-pulmonary-fibrosis daily 0.8 https://clival.com/news/biological-e-receives-dcgi-approval-for-administration-of-corbevax-in-children-aged-12-to-18-years daily 0.8 https://clival.com/news/radius-health-announces-agreement-to-be-acquired-by-gurnet-point-capital-and-patient-square-capital daily 0.8 https://clival.com/news/gc-pharma-announces-publication-of-results-from-phase-iii-clinical-trial-of-gc5107-immune-globulin-in-frontiers-in-immunology daily 0.8 https://clival.com/news/sk-biopharma-begins-a-phase-3-clinical-trial-of-cenobamate-in-asia-to-treat-partial-onset-seizures daily 0.8 https://clival.com/news/ipsen-announces-phase-iii-resilient-trial-evaluating-onivyde-in-second-line-monotherapy-for-sclc-fails-to-meet-primary-endpoint daily 0.8 https://clival.com/news/pfizer-receives-european-approval-for-cibinqo-to-treat-moderate-to-severe-atopic-dermatitis daily 0.8 https://clival.com/news/addex-therapeutics-completes-patient-enrollment-in-phase-2a-study-of-dipraglurant-to-treat-blepharospasm daily 0.8 https://clival.com/news/genmab-announces-approval-of-epkinlytm-to-treat-relapsed-or-refractory-large-b-cell-lymphoma daily 0.8 https://clival.com/news/promis-neurosciences-announces-fda-clearance-of-investigational-new-drug-ind-application-for-pmn310 daily 0.8 https://clival.com/news/lupin-launches-merzee-capsules-in-us-market daily 0.8 https://clival.com/news/bdr-pharmaceutical-launches-zisavel-capsules-to-treat-invasive-aspergillosis-mucormycosis daily 0.8 https://clival.com/news/glaxosmithkline-pauses-maternal-respiratory-syncytial-virus-vaccine-clinical-trials-and-to-provide-update-soon daily 0.8 https://clival.com/news/bridge-biotherapeutics-presents-phase-2a-clinical-trial-results-for-bbt-401-a-drug-candidate-to-treat-ulcerative-colitis daily 0.8 https://clival.com/news/jacobio-announces-first-patient-dosed-in-phase-iii-clinical-trial-of-kras-g12c-inhibitor-for-solid-tumor daily 0.8 https://clival.com/news/correcting-and-replacing-senju-pharmaceutical-and-novaliq-enter-into-license-agreement-for-nov03-perfluorohexyl-octane-ophthalmic-solution-for-the-treatment-of-dry-eye-disease-in-japan daily 0.8 https://clival.com/news/abbvies-rinvoq-tops-dupixent-in-eczema-showdown-but-safety-issues-will-limit-use-analysts-say daily 0.8 https://clival.com/news/roches-xofluza-receives-us-fda-approval-to-treat-influenza-in-children-aged-five-years-and-older daily 0.8 https://clival.com/news/akesos-ligufalimab-and-ivonescimab-obtained-approval-to-initiate-a-phase-ii-trial daily 0.8 https://clival.com/news/china-nmpa-recommends-breakthrough-therapy-status-to-ascentages-olverembatinib-to-treat-chronic-phase-chronic-myeloid-leukemia daily 0.8 https://clival.com/news/eisai-preps-for-launch-with-insomnia-med-dayvigo-after-buying-out-purdue daily 0.8 https://clival.com/news/genfleet-gets-china-nmpa-approval-for-two-phase-ii-combination-studies-of-tgf daily 0.8 https://clival.com/news/sunovion-takes-urovants-overactive-bladder-med-gemtesa-to-primary-care-docs-as-promo-partnership-launches daily 0.8 https://clival.com/news/ascentage-pharma-to-present-results-from-three-clinical-studies-of-bcl-2-inhibitor-lisaftoclax-apg-2575-including-the-first-data-in-aml-and-mm daily 0.8 https://clival.com/news/lupin-launches-combination-drug-sacubitril-valsartan-in-india-for-heart-failure-patients daily 0.8 https://clival.com/news/seekin-receives-ce-mark-approval-for-seekincare daily 0.8 https://clival.com/news/hepatx-namocell-and-takara-bio-usa-complete-second-phase-of-collaboration-on-single-cell-analysis-for-cell-therapy-to-treat-late-stage-liver-diseases daily 0.8 https://clival.com/news/us-fda-approves-viiv-healthcare-dispersible-single-tablet-regimen-containing-dolutegravir-triumeq-pd-to-treat-children-living-with-hiv daily 0.8 https://clival.com/news/eledon-reports-positive-results-from-phase-2a-trial-of-tegoprubart-in-patients-with-amyotrophic-lateral-sclerosis daily 0.8 https://clival.com/news/zydus-lifesciences-launches-drug-for-treating-bad-cholesterol daily 0.8 https://clival.com/news/bristol-myers-squibb-phase-3-checkmate-76k-trial-of-opdivo-in-patients-with-stage-iibc-melanoma-meets-its-primary-endpoint daily 0.8 https://clival.com/news/aivita-biomedical-completes-treatment-of-patients-in-phase-2-trial-of-av-gbm-1-to-treat-glioblastoma daily 0.8 https://clival.com/news/cadila-pharma-launches-generic-ocaliva-to-treat-primary-biliary-cholangitis daily 0.8 https://clival.com/news/lincoln-pharma-receives-indian-patent-for-diclofenac-rectal-spray daily 0.8 https://clival.com/news/hitgen-uppthera-enter-drug-discovery-research-pact-to-identify-small-molecule-hits-against-previous-known-to-be-undruggable-targets-and-novel-e3-ligas daily 0.8 https://clival.com/news/antengene-receives-australia-approval-to-initiate-phase-i-stamina-trial-of-atg-037-to-treat-locally-advanced-or-metastatic-solid-tumours daily 0.8 https://clival.com/news/novartis-announces-plan-to-initiate-clinical-trial-of-canakinumab-for-patients-with-covid-19-pneumonia daily 0.8 https://clival.com/news/first-patient-dosed-in-australia-in-atg-101-first-in-human-trial daily 0.8 https://clival.com/news/dcgi-approves-biological-es-14-valent-pneumococcal-conjugate-vaccine daily 0.8 https://clival.com/news/european-commission-approves-astellas-veoza-for-treatment-of-vasomotor-symptoms-associated-with-menopause daily 0.8 https://clival.com/news/alzecure-pharma-begins-patient-dosing-in-phase-ii-trial-in-neuropathic-pain-with-non-opioid-acd440 daily 0.8 https://clival.com/news/activist-launches-nutrition-supplement-malt-hb-spread daily 0.8 https://clival.com/news/dupixent-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis daily 0.8 https://clival.com/news/nih-to-launch-public-private-partnership-to-speed-covid-19-vaccine-and-treatment-options daily 0.8 https://clival.com/news/ns-pharma-begins-patient-enrollment-in-phase-2-study-of-ns-018-for-myelofibrosis-treatment daily 0.8 https://clival.com/news/abyrx-receives-fda-clearance-for-montage-settable-bone-putty-for-use-in-cardiothoracic-surgery daily 0.8 https://clival.com/news/innocare-begins-patient-dosing-in-clinical-trial-of-novel-shp2-allosteric-inhibitor-icp-189-in-china daily 0.8 https://clival.com/news/us-fda-approves-otsuka-lundbecks-abilify-asimtufii-the-first-two-month-lai-to-treat-schizophrenia-or-maintenance-monotherapy-treatment-of-bipolar-i-disorder-in-adults daily 0.8 https://clival.com/news/crown-aesthetics-announces-expanded-launch-of-biojuve-living-skin-biome-care daily 0.8 https://clival.com/news/i-mab-announces-ind-approval-from-china-nmpa-for-phase-2-clinical-trial-of-enoblituzumab-in-combination-with-pembrolizumab-in-solid-tumors daily 0.8 https://clival.com/news/china-nmpa-approves-cstone-and-pfizer-sugemalimab-in-patients-with-unresectable-stage-iii-nsclc daily 0.8 https://clival.com/news/natco-pharma-launches-novel-fixed-dose-combination-drug-for-colorectal-gastric-cancer daily 0.8 https://clival.com/news/innocare-receives-china-nmpa-approval-to-initiate-phase-ii-trial-using-orelabrutinib-to-treat-nmosd daily 0.8 https://clival.com/news/nsg-biolabs-drives-biotech-innovation-in-singapore-and-southeast-asia daily 0.8 https://clival.com/news/us-fda-approves-azurity-pharma-fleqsuvy-for-treatment-of-spasticity-from-multiple-sclerosis daily 0.8 https://clival.com/news/us-fda-grants-approval-to-granules-india-for-its-generic-amphetamine-mixed-salts daily 0.8 https://clival.com/news/dr-reddys-laboratories-says-its-andhra-plant-gets-two-observations-from-usfda daily 0.8 https://clival.com/news/glenmark-pharma-receives-us-fda-approval-for-apremilast-tablets-10-mg-20-mg-30-mg daily 0.8 https://clival.com/news/daiichi-sankyo-astrazeneca-initiate-tropion-lung05-phase-2-trial-of-datopotamab-deruxtecan-in-patients-with-advancedmetastatic-nsclc-with-actionable daily 0.8 https://clival.com/news/solid-biosciences-announces-stockholder-approval-of-acquisition-of-aavantibio daily 0.8 https://clival.com/news/zydus-cadila-receives-us-fda-approval-to-market-macitentan-tablets daily 0.8 https://clival.com/news/unichem-laboratories-gets-usfda-nod-for-hypertension-management-drug daily 0.8 https://clival.com/news/fda-grants-accelerated-approval-for-alzheimer-disease-treatment daily 0.8 https://clival.com/news/fda-approves-roche-evrysdi-for-use-in-babies-under-two-months-with-spinal-muscular-atrophy-sma daily 0.8 https://clival.com/news/transcenta-holding-receives-fda-clearance-to-proceed-with-global-phase-iii-trial-of-osemitamab daily 0.8 https://clival.com/news/chinese-biotech-startup-receives-80-m-in-series-b-funding daily 0.8 https://clival.com/news/immunos-therapeutics-gets-tga-approval-to-begin-first-in-human-trial-of-ios-1002 daily 0.8 https://clival.com/news/reven-holdings-a-privately-held-clinical-stage-biotechnology-and-pharmaceutical-company-announced-that-the-us-food-and-drug-administration-fda-has daily 0.8 https://clival.com/news/us-fda-approves-intramuscular-administration-for-mercks-mmrv-family-of-vaccines-m-m-rii-varivax-proquad daily 0.8 https://clival.com/news/allergan-aesthetics-receives-us-fda-approval-for-juvederm-voluma-xc-for-augmentation-of-chin-region daily 0.8 https://clival.com/news/dr-reddys-laboratories-launches-favipiravir-in-india daily 0.8 https://clival.com/news/janssen-presents-positive-data-from-phase-3-voyager-pad-study-of-xarelto-in-combo-with-asprin-to-treat-patients-with-pad-after-lower-extremity-revascu daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-astrazenecas-forxiga-for-symptomatic-chronic-heart-failure daily 0.8 https://clival.com/news/roches-phase-iii-opera-i-opera-ii-studies-show-that-ocrevus-treatment-reduces-risk-of-disease-and-disability-progression-in-rms-and-ppms daily 0.8 https://clival.com/news/cipla-receives-us-fda-approval-for-generic-imitrex daily 0.8 https://clival.com/news/inmagene-receives-fda-ind-clearance-for-a-third-generation-btk-inhibitor-targeting-immunological-diseases daily 0.8 https://clival.com/news/viking-therapeutics-begins-phase-2-venture-trial-of-dual-glp-1gip-receptor-agonist-vk2735-in-patients-with-obesity daily 0.8 https://clival.com/news/china-nmpa-approves-astrazeneca-imfinzi-plus-chemotherapy-to-treat-locally-advanced-or-metastatic-biliary-tract-cancer daily 0.8 https://clival.com/news/algernon-pharmaceuticals-announces-last-patient-treated-in-phase-2-study-of-ipf-and-chronic-cough daily 0.8 https://clival.com/news/us-fda-approves-first-rsv-vaccine-from-gsk daily 0.8 https://clival.com/news/280-bio-receives-ind-approval-from-the-fda-for-yl-17231 daily 0.8 https://clival.com/news/antengene-announces-ind-approval-in-china-for-a-phase-ii-study-of-eltanexor-atg-016-in-patients-with-high-risk-myelodysplastic-syndromes daily 0.8 https://clival.com/news/akesos-cadonilimab-pd-1ctla-4-bi-specific-antibody-combined-with-ivonescimab-obtained-approval-to-initiate-a-phase-ibii-clinical-trial daily 0.8 https://clival.com/news/insilico-announces-nomination-of-preclinical-candidate-targeting-kat6a-for-erher2-breast-cancer-therapy daily 0.8 https://clival.com/news/lupin-receives-us-fda-nod-for-generic-edarbi-tablets daily 0.8 https://clival.com/news/ppd-expands-clinical-capabilities-in-china daily 0.8 https://clival.com/news/novartis-to-test-novel-launch-strategy-for-cholesterol-drug-leqvio daily 0.8 https://clival.com/news/us-fda-approves-taigens-ind-for-tg-1000-to-treat-influenza-a-and-b daily 0.8 https://clival.com/news/caring-cross-and-immunoact-signs-agreement-to-commercialize-tricar-t-cell-immunotherapy daily 0.8 https://clival.com/news/receptor-life-sciences-announces-fda-acceptance-of-ind-application-for-rls103-inhaled-dry-powder-cbd-and-initiation-of-ind-opening-clinical-safety-and-efficacy-study daily 0.8 https://clival.com/news/genfleet-receives-ema-approval-for-phase-ibii-study-of-gfh925-kras-g12c-inhibitor-in-combination-with-erbitux daily 0.8 https://clival.com/news/dr-reddys-launches-generic-oral-anti-epileptic-drug-in-us daily 0.8 https://clival.com/news/astrazeneca-india-partners-with-roche-diagnostics-india-to-improve-diagnostic-testing-for-breast-cancer-patients daily 0.8 https://clival.com/news/otsuka-pharma-reports-positive-results-from-two-pivotal-phase-3-trials-of-centanafadine-to-treat-adolescents-and-children-with-adhd daily 0.8 https://clival.com/news/antengene-announces-ind-approval-in-china-for-a-global-phase-iii-trial-of-selinexor-in-advanced-or-recurrent-endometrial-cancer daily 0.8 https://clival.com/news/spains-esteve-to-buy-german-pharma-firm-riemser-from-ardian daily 0.8 https://clival.com/news/gsk-gets-fda-nod-for-wider-use-of-ovarian-cancer-drug-zejula daily 0.8 https://clival.com/news/sihuan-pharma-launched-equity-incentive-plan-to-inject-new-impetus daily 0.8 https://clival.com/news/galecto-begins-patient-enrollment-in-phase-2-trial-of-gb1211-in-combo-with-atezolizumab-to-treat-nsclc daily 0.8 https://clival.com/news/strides-gets-usfda-nod-for-generic-oxybutynin-chloride-tablets daily 0.8 https://clival.com/news/tscan-announces-collaboration-with-novartis-on-the-discovery-and-development-of-novel-t-cell-receptor-therapies-for-the-treatment-of-solid-tumors daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-immunocores-kimmtrak-to-treat-unresectable-or-metastatic-uveal-melanoma daily 0.8 https://clival.com/news/qiagen-receives-cdsco-approval-for-neumodx-hiv-1-hbv-and-hcv-quant-assays-in-india-for-blood-borne-virus-testing daily 0.8 https://clival.com/news/novo-nordisk-has-announced-fiasp-approved-for-children-in-europe daily 0.8 https://clival.com/news/sun-pharma-receives-china-nmpa-approval-for-ilumetri-to-treat-adults-with-moderate-to-severe-plaque-psoriasis daily 0.8 https://clival.com/news/biogen-buys-into-fast-advancing-roche-cancer-drug daily 0.8 https://clival.com/news/visen-pharma-announces-positive-results-from-phase-3-trial-of-once-weekly-lonapegsomatropin-in-children-with-growth-hormone-deficiency daily 0.8 https://clival.com/news/amgen-gets-us-fda-full-approval-for-blincyto-to-treat-minimal-residual-disease-positive-b-cell-precursor-all daily 0.8 https://clival.com/news/glenmark-pharma-receives-us-fda-approval-for-generic-prograf-capsules daily 0.8 https://clival.com/news/us-fda-issues-warning-letters-to-boiron-inc-marketing-unapproved-eye-products daily 0.8 https://clival.com/news/incytes-pemazyre-receives-japanese-approval-to-treat-patients-with-myeloidlymphoid-neoplasms daily 0.8 https://clival.com/news/virica-biotech-oxford-biomedica-enter-rd-partnership daily 0.8 https://clival.com/news/avantgen-enters-a-strategic-collaboration-agreement-to-develop-novel-anti-cancer-therapeutic-with-its-nk-cell-engager-technology daily 0.8 https://clival.com/news/chinese-firm-sensetime-receives-ce-mark-for-ai-based-medical-solution daily 0.8 https://clival.com/news/us-fda-approves-tg-therapeutics-multiple-sclerosis-drug daily 0.8 https://clival.com/news/kaneka-files-patent-infringement-lawsuit-against-cocrystal daily 0.8 https://clival.com/news/genequantum-healthcares-two-next-generation-bioconjugate-drugs-gq1005-and-gq1007-have-been-approved-for-clinical-trials-in-australia daily 0.8 https://clival.com/news/masina-hospital-launches-tobacco-cessation-clinic daily 0.8 https://clival.com/news/remynd-announces-positive-data-from-phase-1-study-of-alzheimer-programme daily 0.8 https://clival.com/news/us-fda-approves-myovant-and-pfizers-myfembree-a-once-daily-therapy-for-management-of-moderate-to-severe-pain-associated-with-endometriosis daily 0.8 https://clival.com/news/a-biotech-wins-the-first-fda-drug-approval-in-a-rare-type-of-eye-cancer daily 0.8 https://clival.com/news/dr-reddys-laboratories-announces-the-launch-of-pemetrexed-for-injection-usp-in-the-usa-market daily 0.8 https://clival.com/news/bayer-bicycle-therapeutics-ink-collaboration-to-develop-novel-targeted-radionuclide-therapies-in-oncology daily 0.8 https://clival.com/news/ariceum-therapeutics-doses-first-patient-with-its-first-in-class-targeted-radiopharmaceutical-drug-satoreotide-in-its-phase-ib-study-in-small-cell-lung-cancer daily 0.8 https://clival.com/news/askbio-begins-patient-dosing-in-phase-1-trial-of-ab-1005-gene-therapy-for-multiple-system-atrophy-parkinsonian-type daily 0.8 https://clival.com/news/amgen-to-present-results-from-phase-4-foremost-study-of-otezla-to-treat-early-oligoarticular-psoriatic-arthritis-at-acr-2023 daily 0.8 https://clival.com/news/us-fda-approves-otsuka-lundbecks-snda-for-rexulti-to-treat-agitation-associated-with-dementia-due-to-alzheimers-disease daily 0.8 https://clival.com/news/novartis-returns-tislelizumab-to-beigene-as-pd-1-gains-first-european-nod daily 0.8 https://clival.com/news/us-fda-approves-takedaa daily 0.8 https://clival.com/news/stada-xbrane-get-uk-mhra-marketing-approval-for-ximluci-biosimilar-referencing-lucentis daily 0.8 https://clival.com/news/lupin-introduces-rufinamide-oral-suspension-in-us-market daily 0.8 https://clival.com/news/canbridge-announces-marketing-approval-of-can108-livmarli-in-taiwan-for-the-treatment-of-cholestatic-pruritus-in-patients-with-alagille-syndrome-algs daily 0.8 https://clival.com/news/perkinelmer-to-buy-uk-based-oxford-immunotec-global daily 0.8 https://clival.com/news/positive-phase-12-study-results-of-rilzabrutinib-in-people-with-immune-thrombocytopenia-published-in-the-new-england-journal-of-medicine daily 0.8 https://clival.com/news/sedana-medical-receives-ind-approval-for-us-trial daily 0.8 https://clival.com/news/reddys-laboratories-launches-generic-version-of-fesoterodine-fumarate-tablets-in-us daily 0.8 https://clival.com/news/cstone-announces-first-patient-dosed-in-the-phase-i-bridging-registrational-study-of-ivosidenib daily 0.8 https://clival.com/news/mindrank-announces-first-in-human-phase-1-study-of-mdr-001-in-china daily 0.8 https://clival.com/news/lupins-subsidiary-novel-labs-gets-us-fda-approval-for-diazepam-rectal-gel daily 0.8 https://clival.com/news/olix-pharmaceuticals-announces-ind-submission-to-us-fda-to-evaluate-safety-and-tolerability-of-olx10212-in-phase-1-clinical-trial daily 0.8 https://clival.com/news/wuxi-biologics-to-open-clinical-manufacturing-facility-in-us daily 0.8 https://clival.com/news/alligator-presents-positive-phase-i-trial-data-with-4-1bb-drug-candidate-ator-1017-1017-to-treat-metastatic-cancer-at-asco-meeting daily 0.8 https://clival.com/news/natco-pharma-gets-eir-from-usfda-for-kothur-facility daily 0.8 https://clival.com/news/china-nmpa-approves-koselugo-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas daily 0.8 https://clival.com/news/pfizer-announces-positive-results-from-phase-3-study-of-20vpnc-in-pneumococcal-vaccine-naive-adults-18-through-49-years-of-age daily 0.8 https://clival.com/news/elgan-pharma-announces-positive-results-from-its-phase-iii-study-of-elgn-gi-in-preterm-infants-for-treatment-of-intestinal-malabsorption daily 0.8 https://clival.com/news/brainstorm-cell-therapeutics-announces-the-presentation-of-new-analyses-from-the-phase-3-trial-of-nurown daily 0.8 https://clival.com/news/aneurotech-gets-positive-feedback-from-us-fda-for-pivotal-phase-iiib-development-programme-for-ant-01-as-an-adjunctive-anti-depression-drug-for-mdd daily 0.8 https://clival.com/news/pfizer-bails-on-irish-pension-overhaul-after-workers-union-rejection daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-akebia-vafseo-to-treat-symptomatic-anaemia-associated-with-ckd-in-adults-on-chronic-maintenance-dialysis daily 0.8 https://clival.com/news/mercks-keytruda-gets-european-approval-as-adjuvant-treatment-for-adult-and-adolescent-patients-with-stage-iib-or-iic-melanoma-following-complete-resection daily 0.8 https://clival.com/news/alk-abello-and-x-chem-announce-drug-discovery-collaboration daily 0.8 https://clival.com/news/who-lpa-unit-in-collaboration-with-searo-wpro-to-organize-vaccine-manufacturing-workshop-for-sear-wpr-on-feb-21-22 daily 0.8 https://clival.com/news/glenmark-pharma-receives-us-fda-approval-for-generic-prolixin-tablets-usp-1-mg-25-mg-5-mg-10-mg daily 0.8 https://clival.com/news/soliris-receives-japanese-approval-for-paediatric-patients-with-generalised-myasthenia-gravis daily 0.8 https://clival.com/news/bayers-gadavist-receives-us-fda-approval-for-use-in-cardiac-mri-in-patients-with-coronary-artery-disease daily 0.8 https://clival.com/news/medicago-gsk-initiate-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/immunoforge-doses-first-patient-in-phase-2-clinical-trial-of-froniglutide-for-dermatomyositispolymyositis daily 0.8 https://clival.com/news/lupin-gets-us-fda-nod-for-desvenlafaxine-er-tablets daily 0.8 https://clival.com/news/eisai-files-marketing-authorization-application-for-lecanemab-as-treatment-for-early-alzheimers-disease-in-south-korea daily 0.8 https://clival.com/news/chinas-nmpa-approves-bayers-larotrectinib-to-treat-advanced-solid-tumours-that-harbour-ntrk-gene-fusion daily 0.8 https://clival.com/news/gracell-biotechnologies-announces-fda-clearance-of-ind-application-for-phase-12-clinical-trial-of-fastcar-t-gc012f-for-the-treatment-of-refractory-systemic-lupus-erythematosus daily 0.8 https://clival.com/news/novartis-molecular-partners-announce-empathy-phase-2-study-for-ensovibep-a-darpin-antiviral-therapeutic-for-covid-19-meets-primary-endpoint daily 0.8 https://clival.com/news/mgc-pharma-in-collaboration-with-hempstreet-launches-artemic daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-for-ultomiris-to-treat-adults-with-neuromyelitis-optica-spectrum-disorder daily 0.8 https://clival.com/news/genentech-announces-phase-iii-imscin001-study-of-subcutaneous-formulation-of-tecentriq-meets-co-primary-endpoints daily 0.8 https://clival.com/news/zydus-receives-usfda-approval-to-market-roflumilast-tablets daily 0.8 https://clival.com/news/cambrian-biopharma-launches-new-pipeline-company-isterian-biotech daily 0.8 https://clival.com/news/sanofi-regeneron-announce-positive-data-from-phase-2-trial-of-libtayo-in-patients-with-advanced-basal-cell-carcinoma daily 0.8 https://clival.com/news/glenmark-launches-fdc-asthma-medication-in-india daily 0.8 https://clival.com/news/sciwind-biosciences-announces-initiation-of-dosing-in-phase-1-clinical-trial-evaluating-xw004-an-oral-tablet-formulation-of-its-proprietary-glp-1-analogue-ecnoglutide daily 0.8 https://clival.com/news/viiv-healthcare-gets-japanese-marketing-approval-for-vocabria-used-in-combo-with-rekambys-to-treat-hiv daily 0.8 https://clival.com/news/zydus-cadila-gets-us-fda-approval-to-market-sevelamer-carbonate-tablets daily 0.8 https://clival.com/news/novartis-to-present-positive-phase-iii-results-from-junipera-study-of-cosentyx-as-a-potential-treatment-in-jia-population-at-eular-2021 daily 0.8 https://clival.com/news/kromatid-launches-pinpoint-fish-tp53cep17-kit-for-synthetic-oligonucleotide-based-fish-assay daily 0.8 https://clival.com/news/alligator-seeks-regulatory-approval-to-begin-phase-ii-optimize-1-study-of-mitazalimab-in-combo-with-chemotherapy-to-treat-metastatic-pancreatic-cancer daily 0.8 https://clival.com/news/zoetis-india-discontinues-6-vet-products-meant-for-livestock-to-tackle-antimicrobial-resistance daily 0.8 https://clival.com/news/glenmark-specialty-sa-switzerland-receives-nda-approval-by-the-united-states-food-and-drug-administration-fda-for-ryaltris daily 0.8 https://clival.com/news/chinas-wuxi-sta-forms-strategic-partnership-with-coherent-biopharma daily 0.8 https://clival.com/news/hutchmed-initiates-phase-i-study-of-btk-inhibitor-hmpl-760-in-patients-with-previously-treated-b-cell-non-hodgkin-lymphoma-in-china daily 0.8 https://clival.com/news/us-fda-approves-bristol-myers-squibb-new-state-of-the-art-cell-therapy-manufacturing-facility-in-devens-massachusetts daily 0.8 https://clival.com/news/ribomic-announces-preliminary-topline-data-from-phase-2-trials-of-rbm-007-for-wet-age-related-macular-degeneration daily 0.8 https://clival.com/news/us-fda-grants-accelerated-approval-for-qalsody-to-treat-als-in-adults-who-have-a-mutation-in-sod1-gene daily 0.8 https://clival.com/news/novavax-covid-19-vaccine-adjuvanted-gets-expanded-approval-in-us daily 0.8 https://clival.com/news/the-phase-3-clinical-trial-for-first-line-ls-sclc-utilizing-henlius-anti-pd-1-mab-serplulimab-begins-patient-dosing-in-europe daily 0.8 https://clival.com/news/dcgi-approves-msds-drug-keytruda-for-the-treatment-of-triple-negative-breast-cancer-and-renal-cell-carcinoma daily 0.8 https://clival.com/news/hkust-researchers-show-promising-breakthroughs-in-early-diagnostics-and-therapeutic-treatment-of-alzheimers-disease daily 0.8 https://clival.com/news/aslans-shot-at-approval-jumps-in-gastric-cancer-after-phase-iiiii-completion daily 0.8 https://clival.com/news/idorsia-receives-us-fda-approval-of-quviviq-daridorexant-25-and-50-mg-for-the-treatment-of-adults-with-insomnia daily 0.8 https://clival.com/news/new-phase-iii-data-shows-investigational-antibody-cocktail-casirivimab-and-imdevimab-reduced-hospitalisation-or-death-by-70-in-non-hospitalised-patie daily 0.8 https://clival.com/news/genenta-science-presents-new-clinical-data-from-phase-iiia-study-of-temferon-in-patients-affected-by-gbm-at-asgct-meeting daily 0.8 https://clival.com/news/china-nmpa-accepts-beigenes-sbla-for-pd-1-inhibitor-tislelizumab-in-patients-with-first-line-unresectable-or-metastatic-hcc daily 0.8 https://clival.com/news/eisai-and-biogen-announced-the-results-from-large-global-phase-3-confirmatory-clarity-ad-clinical-study-of-lecanemab daily 0.8 https://clival.com/news/antengene-announces-first-patient-dosed-in-the-phase-iii-swatch-study-of-xpovio daily 0.8 https://clival.com/news/corium-gets-us-fda-approval-for-adlarityto-treat-patients-with-alzheimers-disease daily 0.8 https://clival.com/news/sun-pharma-announces-health-canada-approval-of-prwinlevi-clascoterone-cream-1-for-topical-treatment-of-acne daily 0.8 https://clival.com/news/dr-reddys-labs-launches-generic-uloric-tablets daily 0.8 https://clival.com/news/cadila-healthcare-board-approves-transfer-of-animal-healthcare-biz-to-subsidiary daily 0.8 https://clival.com/news/abbvie-announces-european-commission-approval-of-aquipta-atogepant-for-the-preventive-treatment-of-migraine-in-adults daily 0.8 https://clival.com/news/dr-reddys-labs-gets-dcgi-nod-to-launch-molnupiravir-in-india daily 0.8 https://clival.com/news/alimera-announces-approval-and-pricing-granted-for-iluvien-for-uveitis-in-italy daily 0.8 https://clival.com/news/us-fda-grants-pma-approval-for-artivion-perclot-for-use-to-control-bleeding-in-certain-open-and-laparoscopic-surgical-procedures daily 0.8 https://clival.com/news/redhill-biopharma-initiates-phase-3-study-of-rhb-204-for-first-line-treatment-of-ntm-disease daily 0.8 https://clival.com/news/rybelsus-recommended-for-approval-for-the-treatment-of-adults-with-type-2-diabetes-by-the-european-regulatory-authorities daily 0.8 https://clival.com/news/zydus-cadila-gets-usfda-nod-for-overactive-bladder-treatment-drug daily 0.8 https://clival.com/news/i-mab-receives-ind-approval-for-phase-1-clinical-trial-of-bispecific-antibody-tj-cd4b-in-solid-tumors-in-china daily 0.8 https://clival.com/news/phase-3-trials-for-covaxin-reaches-final-stage-as-investigators-at-nims-give-booster-dose-to-participating-volunteers daily 0.8 https://clival.com/news/overland-adct-biopharma-announces-first-patient-dosed-in-china-with-zynlonta daily 0.8 https://clival.com/news/dop-rejects-sun-pharmaa daily 0.8 https://clival.com/news/antengene-announces-first-patient-dosed-in-phase-iii-trial-of-eltanexor-for-the-treatment-of-myelodysplastic-syndrome daily 0.8 https://clival.com/news/pfizer-penbraya-vaccine-receives-us-fda-approval-for-prevention-of-five-most-common-serogroups-causing-meningococcal-disease-in-adolescents daily 0.8 https://clival.com/news/remegen-announces-us-fda-clearance-of-ind-application-to-initiate-phase-ii-clinical-trial-in-urothelial-cancer daily 0.8 https://clival.com/news/usfda-grants-approval-for-aduhelm-as-the-first-and-only-alzheimera daily 0.8 https://clival.com/news/astrazeneca-breast-cancer-treatment-gets-fda-priority-review daily 0.8 https://clival.com/news/kato-wins-fda-approval-for-human-studies-of-drug-for-retinal-disorders daily 0.8 https://clival.com/news/jazz-pharma-announces-positive-results-from-phase-3-study-of-xywav-to-treat-idiopathic-hypersomnia daily 0.8 https://clival.com/news/gatehouse-bio-collaborates-with-astrazeneca-to-accelerate-new-drug-discovery daily 0.8 https://clival.com/news/biovaxys-enters-a-bioproduction-agreement-with-wuxi-biologics daily 0.8 https://clival.com/news/sciwind-biosciences-announces-initiation-of-patient-dosing-in-phase-3-clinical-trials-of-ecnoglutide-xw003-a-long-acting-glp-1-analog-for-the-treatment-of-type-2-diabetes-in-china daily 0.8 https://clival.com/news/terns-pharmaceuticals-initiates-ph1-clinical-trial-of-tern-101 daily 0.8 https://clival.com/news/arrowhead-starts-phase-iii-trial-of-complement-mediated-disease-asset daily 0.8 https://clival.com/news/tezspire-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-severe-asthma daily 0.8 https://clival.com/news/cirm-awards-685-million-grant-to-excision-bio-to-support-ongoing-phase-12-trial-of-ebt-101-as-potential-cure-for-hiv daily 0.8 https://clival.com/news/sun-pharma-presents-phase-4-data-of-cequa-showing-sustained-improvement-in-dry-eye-disease-symptom daily 0.8 https://clival.com/news/fda-approves-gsks-voltaren-arthritis-pain-for-over-the-counter-use-in-the-united-states daily 0.8 https://clival.com/news/navidea-biopharmaceuticals-announces-launch-of-phase-3-clinical-trial-in-rheumatoid-arthritis daily 0.8 https://clival.com/news/alzecure-selects-cd-and-enters-next-development-phase-with-alzstatin-acd680-against-alzheimers daily 0.8 https://clival.com/news/glenmark-pharma-receives-us-fda-approval-for-generic-tecfidera-dr-capsules daily 0.8 https://clival.com/news/moderna-and-merck-announces-mrna-4157-v940-in-combination-with-keytrudar-pembrolizumab-demonstrated-superior-results daily 0.8 https://clival.com/news/i-mab-to-kick-off-clinical-trials-for-monoclonal-antibody-tjm2-in-china daily 0.8 https://clival.com/news/the-first-hormone-replacement-therapy-for-hypoparathyroidism-in-china-obtains-ind-approval-for-phase-iii-clinical-trial daily 0.8 https://clival.com/news/ascentage-pharma-hosts-ceremony-marking-the-launch-of-olverembatinib-in-newly-approved-indication-and-the-dispatch-of-first-batch-for-the-new-indication daily 0.8 https://clival.com/news/ayala-pharmaceuticals-announces-completion-of-enrollment-in-part-a-of-ringside-a-pivotal-phase-23-study-of-al102-in-desmoid-tumorsinterim-results-expected-mid-2022 daily 0.8 https://clival.com/news/innocare-announces-first-patient-dosed-in-phase-ii-registrational-trial-of-tafasitamab-in-combination-with-lenalidomide-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-china daily 0.8 https://clival.com/news/us-fda-approves-astrazeneca-truqap-in-combo-with-faslodex-to-treat-patients-with-advanced-hr-positive-breast-cancer daily 0.8 https://clival.com/news/zydus-cadila-gets-usfda-approval-to-market-generic-version-of-deferasirox-tablets daily 0.8 https://clival.com/news/ema-committee-recommends-approval-for-astrazenecas-forxiga-to-treat-chronic-kidney-disease daily 0.8 https://clival.com/news/jacobio-receives-ind-approval-for-combination-therapy-of-kras-g12c-and-cetuximab-injection-in-china daily 0.8 https://clival.com/news/medicenna-therapeutics-administers-initial-dose-in-phase-2-monotherapy-dose-expansion-component-of-ability-study-for-assessment-of-mdna11-in-specific-solid-tumor-varieties daily 0.8 https://clival.com/news/medivir-announces-positive-interim-data-from-phase-1b2a-study-of-fostrox-in-combo-with-lenvima-to-treat-hcc daily 0.8 https://clival.com/news/foresee-pharmaceuticals-to-present-phase-12-fanconi-anemia-clinical-study-design-for-its-aldh2-activator-fp-045-at-the-fanconi-anemia-research-fund-2023-scientific-symposium daily 0.8 https://clival.com/news/glenmark-pharma-gets-us-fda-approval-for-generic-taytulla-capsules daily 0.8 https://clival.com/news/china-nmpa-accepts-junshi-biosciences-snda-for-toripalimab-in-combo-with-chemotherapy-to-treat-recurrent-or-metastatic-nasopharyngeal-carcinoma daily 0.8 https://clival.com/news/viiv-healthcare-receives-china-nmpa-approval-for-vocabria-in-combo-with-rekambys-the-first-and-only-complete-long-acting-hiv-1-injectable-treatment daily 0.8 https://clival.com/news/us-fda-approves-glaxosmithkline-respiratory-syncytial-virus-vaccine-arexvy-for-older-adults daily 0.8 https://clival.com/news/pfizer-enters-into-agreement-with-acuitas-therapeutics-for-lipid-nanoparticle-delivery-system-for-use-in-mrna-vaccines-and-therapeutics daily 0.8 https://clival.com/news/telix-pharmaceuticals-announces-us-fda-expanded-indication-for-illuccix daily 0.8 https://clival.com/news/strides-arm-receives-eir-for-its-us-facility daily 0.8 https://clival.com/news/smartcardia-launches-one-of-its-kind-7-lead-cardiac-monitoring-patch-to-provide-insights-into-patients-health daily 0.8 https://clival.com/news/biocytogen-signs-renmab daily 0.8 https://clival.com/news/rigenerand-inks-agreement-with-lacopa-to-distribute-vitvo-3d-cell-culture-technology-across-central-asian-regions-of-russia-kazakhstan-belarus daily 0.8 https://clival.com/news/fujifilm-india-launches-on-ground-breast-cancer-screening-and-awareness-campaign-on-national-cancer-awareness-day daily 0.8 https://clival.com/news/china-nmpa-approves-henlius-ind-applications-of-hlx42-hlx43-to-treat-advancemetastatic-solid-tumours daily 0.8 https://clival.com/news/us-fda-grants-510k-clearance-to-accelus-flarehawk-tihawk11-interbody-fusion-system daily 0.8 https://clival.com/news/china-nmpa-approves-astrazenecas-forxiga-cardiovascular-outcomes-benefit daily 0.8 https://clival.com/news/us-fda-approves-krystal-biotechs-redosable-gene-therapy-vyjuvek-to-treat-dystrophic-epidermolysis-bullosa daily 0.8 https://clival.com/news/lupin-launches-first-reference-lab-in-kolkata daily 0.8 https://clival.com/news/unichem-labs-receives-us-fda-approval-for-generic-tenoretic daily 0.8 https://clival.com/news/hutchmed-initiates-a-phase-i-trial-of-hmpl-653-in-patients-with-advanced-malignant-solid-tumors-and-tgct-in-china daily 0.8 https://clival.com/news/genexine-kgbio-receive-indonesian-marketing-approval-for-novel-long-acting-erythropoietin-efepoetin-alfa-to-treat-ckd-induced-anaemia-in-non-dialysis-patients daily 0.8 https://clival.com/news/eu-approves-label-expansion-of-roche-hemlibra-to-include-people-with-moderate-haemophilia-a daily 0.8 https://clival.com/news/gsk-begins-patient-dosing-in-phase-3-study-of-rsv-candidate-vaccine-for-maternal-immunisation daily 0.8 https://clival.com/news/immuno-cure-secures-hk8-m-funding-support-for-hiv-vaccine-clinical-trial daily 0.8 https://clival.com/news/lupin-receives-sanda-approval-from-usfda-for-levothyroxine-sodium-tablets daily 0.8 https://clival.com/news/fda-accepts-gmp-plasmid-dmf-of-obio-technology daily 0.8 https://clival.com/news/assembly-biosciences-and-door-pharmaceuticals-sign-collaboration-and-option-agreement-to-develop-a-novel-class-of-hbv-core-protein-modulators daily 0.8 https://clival.com/news/global-roundup-celltrion-prepares-to-trap-covid-19-in-phase-iii daily 0.8 https://clival.com/news/sec-asks-emcure-sandoz-to-submit-more-data-for-further-approval-of-ophthalmic-injections daily 0.8 https://clival.com/news/caplin-point-gets-us-fda-approval-for-generic-amidate daily 0.8 https://clival.com/news/aum-biosciences-receives-human-research-ethics-committee-approval-to-commence-phase-ii-clinical-trial-of-aum001-for-treatment-of-metastatic-colorectal-cancer-in-australia daily 0.8 https://clival.com/news/glenmark-pharmaceuticals-secures-anda-approval-for-003-per-cent-tacrolimus-ointment daily 0.8 https://clival.com/news/unichem-gets-usfda-nod-for-generic-medication daily 0.8 https://clival.com/news/i-mab-announces-completion-of-patient-enrollment-in-phase-iii-clinical-trial-of-eftansomatropin-alfa-for-treatment-of-pediatric-growth-hormone-deficiency daily 0.8 https://clival.com/news/qurient-announces-us-fda-clearance-of-ind-application-for-q901-a-novel-cancer-therapy daily 0.8 https://clival.com/news/teneobio-announces-us-fda-clearance-of-investigational-new-drug-application-for-tnb-486-and-the-initiation-of-phase-i-clinical-studies-in-patients-wit daily 0.8 https://clival.com/news/innocare-receives-singapore-health-authority-approval-for-hibruka-to-treat-mantle-cell-lymphoma daily 0.8 https://clival.com/news/mercks-keytruda-receives-fda-approval-for-advanced-endometrial-cancer daily 0.8 https://clival.com/news/antengene-begins-patient-dosing-in-phase-ii-trial-of-atg-008-to-treat-advanced-solid-tumors-with-specific-genetic-alterations daily 0.8 https://clival.com/news/antengene-announces-clearance-of-us-ind-for-the-phase-i-trial-of-first-in-class-anti-cd24-monoclonal-antibody-atg-031 daily 0.8 https://clival.com/news/sibionics-launches-the-breakthrough-sibio-ks1-ckm-for-ketone-level-monitoring daily 0.8 https://clival.com/news/maharashtra-fda-issues-guidelines-for-blood-donation-camps-to-341-registered-blood-banks-in-state-in-wake-of-covid-19-scenario daily 0.8 https://clival.com/news/bayer-rivaroxaban-receives-japanese-approval-to-treat-patients-with-pad-after-revascularisation daily 0.8 https://clival.com/news/antengene-announces-approval-of-first-ph-i-trial-of-atg-017 daily 0.8 https://clival.com/news/bayer-launches-verquvo-in-india-a-novel-treatment-approved-to-reduce-the-risk-of-cvd-fatalities daily 0.8 https://clival.com/news/adc-therapeutics-announces-positive-results-from-phase-2-trial-of-camidanlumab-tesirine-in-rr-hodgkin-lymphoma daily 0.8 https://clival.com/news/sterrx-llc-issues-voluntary-nationwide-recall-of-certain-sterrx-products daily 0.8 https://clival.com/news/asieris-announces-nda-acceptance-for-regulatory-review-of-cevira-in-china daily 0.8 https://clival.com/news/health-ministry-to-mandate-medical-device-import-licence-holders-towards-susar-reporting daily 0.8 https://clival.com/news/takeda-pharmaceutical-announces-approval-to-manufacture-and-market-entyvio daily 0.8 https://clival.com/news/northwest-biotherapeutics-receives-mhra-approval-of-license-for-gmp-manufacturing-in-uk daily 0.8 https://clival.com/news/health-ministry-directs-state-govts-to-restrain-panic-buying-of-hcq-and-azithromycin-in-the-wake-of-covid-19 daily 0.8 https://clival.com/news/tonix-pharma-gets-us-fda-nod-to-begin-phase-2-proof-of-concept-study-using-tnx-102-sl-to-treat-alcohol-use-disorder daily 0.8 https://clival.com/news/pfizer-receives-us-fda-approval-for-ulcerative-colitis-drug daily 0.8 https://clival.com/news/novartis-phase-iii-combi-i-study-evaluating-spartalizumab-in-combo-with-tafinlar-and-mekinist-fails-to-meet-primary-endpoint daily 0.8 https://clival.com/news/actinium-reports-positive-data-from-pivotal-phase-3-sierra-trial-in-patients-with-active-relapsed-or-refractory-aml daily 0.8 https://clival.com/news/us-fda-denies-approval-of-alvotechs-stelara-biosimilar-as-manufacturing-problems-at-site daily 0.8 https://clival.com/news/sandoz-to-begin-patient-enrollment-in-phase-iii-mylight-study-of-biosimilar-aflibercept-to-treat-neovascular-age-related-macular-degeneration daily 0.8 https://clival.com/news/medivirs-patent-application-for-fostrox-approved-in-china daily 0.8 https://clival.com/news/luye-pharma-rykindo-gets-us-fda-nod-to-treat-schizophrenia-and-bipolar-disorder daily 0.8 https://clival.com/news/doceree-launches-next-marketing-lab-for-pharma-marketers daily 0.8 https://clival.com/news/cara-therapeutics-announces-approval-of-korsuva-iv-injection-syringe-in-japan-for-the-treatment-of-pruritus-in-hemodialysis-patients daily 0.8 https://clival.com/news/leading-womens-wellness-brand-o-positiv-announces-the-launch-of-uro-bladder-control daily 0.8 https://clival.com/news/phase-2-tyvyt-orient-2-study-meets-primary-endpoint-of-overall-survival-in-second-line-treatment-of-patients-with-advancedmetastatic-escc daily 0.8 https://clival.com/news/mumbai-pharma-company-gets-licence-for-breakthrough-tb-drug daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-regeneron-sanofi daily 0.8 https://clival.com/news/enlivex-receives-clearance-from-spanish-agency-of-medicines-and-medical-devices-for-treatment-of-patients-with-advanced-solid-malignancies-in-the-ongoing-allocetra-phase-iii-clinical-trial daily 0.8 https://clival.com/news/ascentage-pharma-gets-china-nmpa-approval-to-begin-registrational-pivotal-phase-iii-study-of-olverembatinib-to-treat-patients-with-ph-all daily 0.8 https://clival.com/news/astrazeneca-announces-positive-results-from-mandara-phase-iii-trial-of-fasenra-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis daily 0.8 https://clival.com/news/philips-launches-ultrasound-3300-system-in-india-for-obgyn-general-and-cardiovascular-procedures daily 0.8 https://clival.com/news/thermo-fisher-scientific-launches-a-more-sustainable-solution-for-large-scale-cell-culture-harvesting daily 0.8 https://clival.com/news/tscan-therapeutics-announces-fda-clearance-of-three-investigational-new-drug-applications daily 0.8 https://clival.com/news/nmpa-grants-approval-for-sugemalimab-as-first-line-treatment-for-esophageal-squamous-cell-carcinoma-as-announced-by-cstone daily 0.8 https://clival.com/news/allergan-scores-year-end-fda-nod-for-cgrp-migraine-med-ubrelvy-plans-early-2020-launch daily 0.8 https://clival.com/news/novartis-phase-iii-canopy-a-study-evaluating-canakinumab-as-adjuvant-treatment-in-nsclc-fails-to-meet-primary-endpoint daily 0.8 https://clival.com/news/fda-grants-approval-to-orasis-pharmaceuticals-for-qlosi-in-the-management-of-presbyopia daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-tiotropium-dry-powder-inhaler daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-for-novo-nordisks-once-weekly-sogroya-to-treat-aghd daily 0.8 https://clival.com/news/novartis-phase-iii-kestrel-kite-studies-of-beovu-show-potential-for-fluid-resolution-in-more-dme-patients-with-fewer-injections-versus-aflibercept daily 0.8 https://clival.com/news/provention-bio-announces-initiation-of-the-phase-2a-prevail-2-study-of-prv-3279-cd32b daily 0.8 https://clival.com/news/antengene-announces-ind-approval-in-china-for-a-phase-iii-study-of-selinexor-atg-010-in-patients-with-non-hodgkin-lymphoma daily 0.8 https://clival.com/news/transcenta-announces-first-patient-dosed-in-phase-iia-study-of-claudin182-monoclonal-antibody-tst001-combined-with-cisplatin-and-gemcitabine-for-the-first-line-treatment-of-biliary-tract-cancer daily 0.8 https://clival.com/news/alpha-biopharma-announces-completion-of-its-everest-phase-iiiii-clinical-study-of-zorifertinib-in-non-small-cell-lung-cancer-patients-with-central-nervous-system-metastases daily 0.8 https://clival.com/news/iaso-bio-receives-fda-approval-of-ind-application-for-iaso-782-for-treatment-of-autoimmune-disease daily 0.8 https://clival.com/news/fda-approves-lilly-and-incytes-olumiant daily 0.8 https://clival.com/news/dcgi-approves-entod-pharma-phase-iii-study-of-005-per-cent-atropine-eye-drops daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-rufinamide-tablets daily 0.8 https://clival.com/news/omnix-medical-receives-us-fda-approval-of-a-phase-ii-trial-of-its-next-generation-anti-infective-omn6 daily 0.8 https://clival.com/news/novartis-kymriah-gets-european-approval-as-first-car-t-cell-therapy daily 0.8 https://clival.com/news/pall-corporation-launches-3-new-allegro-connect-systems daily 0.8 https://clival.com/news/zydus-cadila-receives-us-fda-tentative-approval-for-dapagliflozin-linagliptin-tablets daily 0.8 https://clival.com/news/trivitron-healthcare-launches-eksahishuruat-an-initiative-to-raise-awareness-on-newborn-screening-in-india daily 0.8 https://clival.com/news/japans-mhlw-approves-argenxs-vyvgart-to-treat-generalized-myasthenia-gravis daily 0.8 https://clival.com/news/spine-care-chain-anssi-wellness-launches-new-spine-clinic-in-pune daily 0.8 https://clival.com/news/novartis-provides-update-on-phase-iii-stand-trial-assessing-crizanlizumab daily 0.8 https://clival.com/news/abbott-gets-us-fda-approval-for-hpv-test-to-run-on-alinity-m-offering-primary-hpv-screening-and-assessment-of-high-risk-cancer-causing-types-of-hpv daily 0.8 https://clival.com/news/zydus-cadila-receives-usfda-approval-to-market-generic-cancer-drug-in-us daily 0.8 https://clival.com/news/novartis-blockbuster-heart-med-entresto-snags-fda-approval-in-larger-patient-group daily 0.8 https://clival.com/news/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate-phase-12a-clinical-trial-to-begin-in-second-half-of-july daily 0.8 https://clival.com/news/sec-approves-msd-pembrolizumab-injunction-for-additional-indications-of-cervical-and-esophageal-cancers daily 0.8 https://clival.com/news/evoke-pharma-receives-us-patent-covering-nasal-formulation-of-metoclopramide-gimoti daily 0.8 https://clival.com/news/glenmark-launches-minocycline-4-gel-minym-gel-to-treat-moderate-to-severe-acne-in-india daily 0.8 https://clival.com/news/alkem-labs-partners-with-hospitals-for-its-reliever-free-india-initiative-on-world-asthma-day daily 0.8 https://clival.com/news/mainz-biomed-receives-irb-approval-to-begin-reconaasense-pivotal-study-in-us daily 0.8 https://clival.com/news/simcere-pharmaceutical-group-announces-research-agreement-with-mass-general-brigham daily 0.8 https://clival.com/news/kadimastem-receives-israel-patent-to-develop-isletrx-for-diabetes daily 0.8 https://clival.com/news/linepharma-international-files-for-manufacturing-marketing-approval-of-the-abortion-pill-in-japan daily 0.8 https://clival.com/news/abbisko-therapeutics-completed-dosing-of-first-patient-for-its-first-in-class-highly-selective-fgfr23-inhibitor-absk061 daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-for-bayer-darolutamide-to-treat-metastatic-hormone-sensitive-prostate-cancer daily 0.8 https://clival.com/news/dong-a-st-beactica-therapeutics-to-terminate-oncology-collaboration-and-licensing-agreement daily 0.8 https://clival.com/news/bavencio-approved-in-us-for-maintenance-treatment-of-patients-with-locally-advanced-or-metastatic-urothelial-carcinoma daily 0.8 https://clival.com/news/astrazenecas-calquence-receives-japanese-approval-for-adult-patients-with-treatment-naive-cll daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-bristol-myers-squibbs-camzyos-to-treat-symptomatic-obstructive-hcm daily 0.8 https://clival.com/news/neoimmunetech-announces-clinical-collaboration-with-bristol-myers-squibb daily 0.8 https://clival.com/news/abbvie-seeks-us-fda-european-approvals-for-upadacitinib-to-treat-non-radiographic-axial-spondyloarthritis daily 0.8 https://clival.com/news/bayer-and-orions-nubeqa-phase-iii-arasens-trial-in-metastatic-hormone-sensitive-prostate-cancer-meets-primary-endpoint daily 0.8 https://clival.com/news/laurus-labs-signs-memorandum-of-agreement-moa-with-iit-kanpur-for-novel-gene-therapy-assets daily 0.8 https://clival.com/news/novartis-eyes-1b-sales-with-fda-nod-for-targeted-sickle-cell-disease-drug-adakveo daily 0.8 https://clival.com/news/bristol-myers-squibb-announces-us-fda-approves-addition-of-positive-data-from-phase-3-valor-hcm-study-to-camzyos-label daily 0.8 https://clival.com/news/lupin-announces-fda-approval-of-solosec-secnidazole daily 0.8 https://clival.com/news/lupin-gets-us-fda-approval-for-doxycycline-hyclate-delayed-release-tablets-usp daily 0.8 https://clival.com/news/orasis-pharmaceuticals-announces-csf-1-eye-drop-successfully-met-primary-endpoint-in-phase-2b-clinical-study-in-presbyopia daily 0.8 https://clival.com/news/c4xd-inks-worldwide-licensing-pact-with-astrazeneca-worth-up-to-402-mn-to-develop-commercialise-nrf2-activator-programme daily 0.8 https://clival.com/news/china-nmpa-approves-tyvyt-in-combo-with-chemotherapy-to-treat-esophageal-squamous-cell-carcinoma daily 0.8 https://clival.com/news/atamyo-therapeutics-announces-first-patient-dosed-with-ata-100-gene-therapy-in-lgmd-r9-clinical-trial daily 0.8 https://clival.com/news/frontera-therapeutics-doses-first-patient-in-a-clinical-trial-of-ft-003-gene-therapy-for-the-treatment-of-wet-amd daily 0.8 https://clival.com/news/ian-and-birac-partner-to-launch-bioangels daily 0.8 https://clival.com/news/number-1-brand-in-combating-pain-launches-formula-that-promises-to-revolutionize-the-analgesic-market daily 0.8 https://clival.com/news/coherus-biosciences-announces-us-launch-of-udenyca daily 0.8 https://clival.com/news/pharmnxt-biotech-launches-first-integrated-manufacturing-unit-for-single-use-bioprocessing-systems daily 0.8 https://clival.com/news/medical-devices-with-certificate-of-sale-from-uk-to-get-import-licence-without-clinical-investigation daily 0.8 https://clival.com/news/sinovac-beijing-settled-litigation-of-its-business-license-and-seals daily 0.8 https://clival.com/news/cassiopea-scores-fda-approval-for-winlevi-the-first-novel-acne-med-in-decades daily 0.8 https://clival.com/news/hutchmed-begins-patient-dosing-in-phase-i-trial-of-hmpl-a83-in-patients-with-advanced-malignant-neoplasms-in-china daily 0.8 https://clival.com/news/cerevel-therapeutics-begins-patient-dosing-in-phase-3-trials-of-tavapadon-to-treat-parkinsons-disease daily 0.8 https://clival.com/news/orthospin-receives-us-fda-approval-for-smart-robotic-external-fixation-system-for-orthopaedic-treatments daily 0.8 https://clival.com/news/amphista-therapeutics-achieves-first-discovery-milestone-in-collaboration-with-bristol-myers-squibb daily 0.8 https://clival.com/news/sibionics-achieves-milestone-receiving-ce-mark-for-its-groundbreaking-gs1-continuous-glucose-monitoring-system daily 0.8 https://clival.com/news/innocare-announces-approval-of-clinical-trial-of-bcl2-inhibitor-icp-248-in-china daily 0.8 https://clival.com/news/us-fda-approves-senhwa-biosciences-phase-ii-ind-application-of-silmitasertib-to-treat-patients-with-cap-associated-with-viral-infection daily 0.8 https://clival.com/news/amgen-launched-humira-biosim-to-its-own-detriment daily 0.8 https://clival.com/news/roche-announces-results-from-phase-iii-balaton-and-comino-studies-evaluating-faricimab-in-macular-edema daily 0.8 https://clival.com/news/us-fda-approves-polarean-imagings-drug-device-combination-product-xenoview daily 0.8 https://clival.com/news/hitgen-and-evotec-se-enter-into-drug-discovery-research-collaboration daily 0.8 https://clival.com/news/us-fda-accepts-gc-pharmas-biologics-license-application-for-immune-globulin-gc5107 daily 0.8 https://clival.com/news/strides-pharma-gets-usfda-approval-for-generic-ibuprofen-oral-suspension daily 0.8 https://clival.com/news/sec-approves-import-and-marketing-of-eli-lillys-anti-cancer-drug-selpercatinib daily 0.8 https://clival.com/news/fda-verging-on-its-first-covid-booster-approval-pfizer-and-moderna-will-have-to-recalibrate-revenues-again daily 0.8 https://clival.com/news/daiichi-sankyo-takes-oncology-shift-into-next-phase-with-new-global-business-unit daily 0.8 https://clival.com/news/roches-phesgo-to-treat-her2-positive-breast-cancer-gets-us-fda-approval daily 0.8 https://clival.com/news/a-greater-bay-area-company-launches-first-handheld-covid-19-nucleic-acid-test daily 0.8 https://clival.com/news/visen-pharmaceuticals-announces-first-time-detailed-clinical-data-from-phase-3-trial-of-lonapegsomatropin daily 0.8 https://clival.com/news/glenmark-pharma-gets-tentative-nod-from-usfda-for-anticoagulant-drug daily 0.8 https://clival.com/news/ionis-pharma-announces-positive-results-from-phase-2-study-of-antisense-medicine-donidalorsen daily 0.8 https://clival.com/news/kbi-biopharma-launches-suremab-monoclonal-antibody-offering daily 0.8 https://clival.com/news/laekna-therapeutics-and-innovent-biologics-obtain-ind-approval-for-combination-therapy-in-patients-with-specific-types-of-solid-tumors-who-have-been-refractory-to-treatment-with-pd-1pd-l1-inhibitors daily 0.8 https://clival.com/news/spear-bio-receives-iso-134852016-certification daily 0.8 https://clival.com/news/takeda-seals-62bn-shire-deal-autolus-ipo-gottlieb-warning daily 0.8 https://clival.com/news/stada-and-calliditas-seek-european-marketing-approval-for-kinpeygo-to-treat-primary-iga-nephropathy daily 0.8 https://clival.com/news/japan-approves-covaxin-booster-dose-for-travellers-bharat-biotech daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-trastuzumab-deruxtecan-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen daily 0.8 https://clival.com/news/fda-approves-genentechs-vabysmo-to-treat-two-causes-of-vision-loss daily 0.8 https://clival.com/news/jj-launches-innovation-challenge-in-china daily 0.8 https://clival.com/news/alnylams-rare-genetic-disorder-drug-gets-early-us-approval daily 0.8 https://clival.com/news/ict-begins-patient-dosing-in-phase-i-trial-of-gcc19cart-for-relapsedrefractory-metastatic-colorectal-cancer daily 0.8 https://clival.com/news/bluebird-cleared-for-zynteglo-launch-aims-to-dose-first-patients-soon daily 0.8 https://clival.com/news/glenmark-pharma-receives-us-fda-approval-for-sodium-phenylbutyrate-tablets-usp-500-mg daily 0.8 https://clival.com/news/inari-medical-announces-first-patient-enrollment-in-the-defiance-clinical-trial daily 0.8 https://clival.com/news/cyclo-therapeutics-signs-agreement-with-worldwide-clinical-trials-to-conduct-alzheimera daily 0.8 https://clival.com/news/astrazeneca-announces-approval-of-ultomiris-ravulizumab-in-the-european-union-eu daily 0.8 https://clival.com/news/incannex-healthcare-gets-us-fda-approval-to-begin-ihl-42x-phase-23-trial-to-treat-obstructive-sleep-apnoea daily 0.8 https://clival.com/news/caris-life-hummingbird-bioscience-ink-collaboration-to-advance-clinical-development-of-anti-her3-therapy-hmbd-001 daily 0.8 https://clival.com/news/us-fda-approves-viatris-ocuphire-pharma-ryzumvl-075-eye-drops-to-treat-pharmacologically-induced-mydriasis-produced-by-adrenergic-agonists-or-parasympatholytic-agents daily 0.8 https://clival.com/news/elpiscience-announces-first-patient-dosed-for-phase-1-clinical-trial-of-first-in-class-anti-cd39xtgf-bispecific-antibody-es014 daily 0.8 https://clival.com/news/telix-begins-patient-dosing-in-phase-iii-prostact-global-study-of-antibody-based-prostate-cancer-therapy-candidate-tlx591 daily 0.8 https://clival.com/news/nuance-pharma-announces-clearance-of-ind-application-for-respiratory-syncytial-virus-rsv-vaccine-in-china daily 0.8 https://clival.com/news/jw-therapeutics-announces-ind-approval-for-the-pivotal-clinical-trial-of-carteyva daily 0.8 https://clival.com/news/takeda-launches-launcheshemophilia-drug-adynovate-inindia daily 0.8 https://clival.com/news/relief-enters-definitive-agreement-with-meta-healthcare-to-acquire-us-fda-approved-novel-dosage-form-of-aprescription-drug-to-treat-pku daily 0.8 https://clival.com/news/scisparc-gets-israeli-regulatory-approval-to-begin-clinical-trial-with-sci-210-in-children-with-autism-spectrum-disorder daily 0.8 https://clival.com/news/roche-announces-positive-results-from-phase-iii-ocarina-ii-trial-of-ocrevus-twice-a-year-10-minute-subcutaneous-injection-in-patients-with-multiple-sclerosis daily 0.8 https://clival.com/news/us-fda-approves-pfizers-talzenna-in-combo-with-xtandi-to-treat-adult-patients-with-hrr-gene-mutated-mcrpc daily 0.8 https://clival.com/news/chinas-beigene-gets-fda-approval-for-drug-to-treat-rare-form-of-lymphoma daily 0.8 https://clival.com/news/julius-group-noble-biomaterials-to-launch-high-quality-antiviral-ppe daily 0.8 https://clival.com/news/xeris-pharmas-low-blood-sugar-treatment-wins-fda-approval daily 0.8 https://clival.com/news/biomark-diagnostics-announces-update-from-clinical-trial-on-lung-cancer-liquid-biopsy-test daily 0.8 https://clival.com/news/bharat-biotech-dossier-under-review-for-covaxin-emergency-use-listing-who daily 0.8 https://clival.com/news/lupin-announces-positive-top-line-results-from-phase-3-study-of-single-dose-solosec-to-treat-trichomoniasis daily 0.8 https://clival.com/news/us-fda-approves-mitsubishi-tanabe-pharma daily 0.8 https://clival.com/news/hutchmed-completes-patient-enrollment-of-fresco-2-in-phase-iii-trial-of-fruquintinib-in-metastatic-colorectal-cancer daily 0.8 https://clival.com/news/chemomab-reports-top-line-results-from-cm-101-phase-2a-liver-fibrosis-biomarker-trial-in-nash-patients daily 0.8 https://clival.com/news/bioinvents-bi-1206-to-advance-into-expansion-stage-of-phase-12a-study-in-nhl-after-productive-end-of-phase-1-us-fda-meeting daily 0.8 https://clival.com/news/sol-gel-technologies-and-galderma-announce-fda-approval-of-epsolay daily 0.8 https://clival.com/news/glaxosmithkline-works-to-get-shingrix-back-on-track-an-fda-approval-increases-the-key-vaccines-reach daily 0.8 https://clival.com/news/nanobiotix-begins-patient-dosing-in-nanoray-312-phase-3-trial-evaluating-radioenhancer-nbtxr3-in-head-and-neck-cancer daily 0.8 https://clival.com/news/ntc-seeks-european-marketing-approval-for-kleerkol-for-bowel-preparation-for-colonoscopy daily 0.8 https://clival.com/news/lupin-launches-sildenafil-for-oral-suspension-in-us-market daily 0.8 https://clival.com/news/us-antitrust-enforcers-give-roche-approval-to-buy-spark-therapeutics daily 0.8 https://clival.com/news/blueprint-medicines-announces-partial-clinical-hold-for-phase-12-vela-trial-of-blu-222-due-to-visual-adverse-events daily 0.8 https://clival.com/news/precigen-announces-positive-phase-1-dose-escalation-data-for-autologous-prgn-3006-ultracar-t-in-rr-aml daily 0.8 https://clival.com/news/dr-reddys-labs-launches-fosaprepitant-for-injection-in-us-market daily 0.8 https://clival.com/news/bharat-rubber-to-receive-eu-mdr-certification daily 0.8 https://clival.com/news/bdr-pharma-varenyam-launch-sugammadex-anaesthesia-drugs-in-india daily 0.8 https://clival.com/news/everest-medicines-receives-approval-of-investigational-new-drug-application-from-china-nmpa-for-ever001-a-novel-btk-inhibitor-in-development-for-treatment-of-renal-diseases daily 0.8 https://clival.com/news/vanda-pharmaceuticals-announces-that-us-fda-accepts-new-drug-application-for-tradipitant-for-the-treatment-of-gastroparesis daily 0.8 https://clival.com/news/eisais-anti-insomnia-drug-dayvigo-gets-approval-in-hong-kong daily 0.8 https://clival.com/news/alkermes-receives-fda-fast-track-designation-for-nemvaleukin-alfa-for-the-treatment-of-mucosal-melanoma daily 0.8 https://clival.com/news/us-fda-approves-pfizer-snda-for-cibinqo-expanding-its-indication-to-include-adolescents-with-refractory-moderate-to-severe-ad daily 0.8 https://clival.com/news/cellect-biotechnology-receives-canadaian-patent-for-apograft daily 0.8 https://clival.com/news/astrazeneca-completes-equity-investment-agreement-with-cellectis daily 0.8 https://clival.com/news/gannex-announces-completion-of-the-us-phase-i-trial-of-asc43f-an-in-house-developed-first-in-class-dual-targeting-fixed-dose-combination-tablet-for-nash daily 0.8 https://clival.com/news/dorian-and-hitgen-announce-research-collaboration-focused-on-dna-encoded-library-based-drug-discovery daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-loteprednol-etabonate-ophthalmic-suspension-02 daily 0.8 https://clival.com/news/biogen-brings-in-a-successor-to-spinraza daily 0.8 https://clival.com/news/beigene-announces-china-nmpa-approval-of-brukinsa-zanubrutinib-for-the-treatment-of-patients-with-relapsed-or-refractory-waldenstroms-macroglobulin daily 0.8 https://clival.com/news/shineco-subsidiary-receives-marketing-approval-from-china-regulatory-body-for-its-cardiac-5-minute-test daily 0.8 https://clival.com/news/aridis-phama-begins-enrollment-of-covid-19-patient-in-phase-3-trial-of-ar-301-for-ventilator-associated-pneumonia daily 0.8 https://clival.com/news/i-mab-announces-first-patient-dosed-in-china-phase-2-clinical-trial-of-efineptakin-alfa-in-combination-with-pembrolizumab-in-advanced-solid-tumors daily 0.8 https://clival.com/news/avistone-announces-the-first-approval-of-vebreltinib-for-met-exon-14-skipping-non-small-cell-lung-cancer-opening-a-new-chapter-in-met-targeted-treatment-of-lung-cancer daily 0.8 https://clival.com/news/icpa-launches-mucofibro-softgel-capsules-to-aid-in-healing-of-oral-lesions-precancerous-conditions daily 0.8 https://clival.com/news/lupin-launches-softovac-liquifibre-a-first-of-its-kind-liquid-fibre daily 0.8 https://clival.com/news/daiichi-sankyo-sarah-cannon-begin-patient-dosing-in-phase-1-study-of-ds-6000-to-treat-advanced-renal-cell-carcinoma-or-ovarian-cancer daily 0.8 https://clival.com/news/who-grants-prequalification-to-gsks-malaria-vaccine-mosquirix daily 0.8 https://clival.com/news/lilly-opens-libretto-431-phase-3-trial-of-selpercatinib-for-treatment-naive-ret-fusion-positive-nsclc daily 0.8 https://clival.com/news/sanofi-launches-global-health-brand-with-non-profit-treatments daily 0.8 https://clival.com/news/dcgi-approves-glenmarks-novel-molecule-grc-54276-for-phase-1-clinical-trial daily 0.8 https://clival.com/news/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine daily 0.8 https://clival.com/news/us-fda-grants-eua-for-cepheid-xpert-mpox-test-for-use-in-a-point-of-care-setting daily 0.8 https://clival.com/news/altesa-biosciences-to-initiate-clinical-trials-of-promising-antiviral daily 0.8 https://clival.com/news/bristol-mayers-phase-3-checkmate-274-trial-of-opdivo-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-dfs-in-muscle-in daily 0.8 https://clival.com/news/zydus-gets-us-fda-final-nod-for-febuxostat-tablets-for-treating-high-uric-acid daily 0.8 https://clival.com/news/zydus-bags-us-fda-final-approval-to-market-dapagliflozin-tablets daily 0.8 https://clival.com/news/strides-pharma-science-arm-gets-usfda-nod-for-drug-to-treat-overactive-bladder daily 0.8 https://clival.com/news/glenmark-pharma-launches-generic-banzel-tablets daily 0.8 https://clival.com/news/china-approves-astrazenecas-lokelma-to-treat-hyperkalaemia daily 0.8 https://clival.com/news/rigenerand-receives-italian-medicine-authority-approval-for-gene-therapy-production daily 0.8 https://clival.com/news/ascendis-pharma-seeks-us-fda-approval-to-initiate-transcon-tlr78-agonist-clinical-programme daily 0.8 https://clival.com/news/jacobio-receives-ind-approval-for-aurora-a-inhibitor-jab-2485-from-fda daily 0.8 https://clival.com/news/cdsco-approves-four-more-medical-device-testing-labs daily 0.8 https://clival.com/news/us-fda-approves-novartis-tafinlarmekinist-for-paediatric-patients-with-braf-v600e-low-grade-glioma daily 0.8 https://clival.com/news/spectrum-pharma-begins-patient-dosing-in-clinical-trial-of-rolontis-on-same-day-as-chemotherapy daily 0.8 https://clival.com/news/dr-reddys-launches-otc-store-brand-equivalent-of-allegra-d-24-hr-in-us-market daily 0.8 https://clival.com/news/china-nmpa-approves-soliris-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder daily 0.8 https://clival.com/news/biontech-gets-rolling-with-mrna-production-at-former-novartis-site-in-marburg daily 0.8 https://clival.com/news/insempra-launches-fermentation-based-functional-ingredient-for-consumer-products daily 0.8 https://clival.com/news/bayer-eylea-receives-japanese-approval-to-treat-preterm-infants-with-retinopathy-of-prematurity daily 0.8 https://clival.com/news/mercks-keytruda-plus-chemotherapy-gets-european-nod-as-neoadjuvant-treatment-then-continued-as-adjuvant-monotherapy-after-surgery-for-locally-advanced-or-early-stage-tnbc daily 0.8 https://clival.com/news/glenmark-pharmaceuticals-receives-anda-approval-for-prostate-cancer-tablets daily 0.8 https://clival.com/news/merck-initiates-first-clinical-trial-of-tlr7-and-8-inhibitor-as-a-potential-treatment-for-severe-symptoms-of-covid-19-infection daily 0.8 https://clival.com/news/altimmune-completes-enrollment-in-phase-1b-clinical-trial-of-nasoshield-a-single-dose-intranasal-anthrax-vaccine-candidate daily 0.8 https://clival.com/news/medtronic-davita-launch-new-independent-kidney-health-technology-company-mozarc-medical daily 0.8 https://clival.com/news/brainstorm-initiates-nurown-expanded-access-programme-for-als-patients-who-completed-all-phase-3-trial-assessments-and-meet-specific-eligibility-crite daily 0.8 https://clival.com/news/inmagene-receives-fdas-ind-clearance-for-ox40-antagonist daily 0.8 https://clival.com/news/eyenovia-announces-fda-approval-of-mydcombi daily 0.8 https://clival.com/news/incannex-healthcare-receives-bellberry-hrec-approval-to-begin-babe-trial-of-ihl-42x-to-treat-obstructive-sleep-apnoea daily 0.8 https://clival.com/news/us-fda-grants-orphan-drug-designation-to-beactica-therapeutics-bea-17-for-glioblastoma-treatment daily 0.8 https://clival.com/news/actinium-reports-positive-results-from-pivotal-phase-3-sierra-trial-of-iomab-b-in-patients-with-active-relapsed-or-refractory-aml daily 0.8 https://clival.com/news/molecular-partners-begins-patient-dosing-in-phase-2a-trial-of-ensovibep-to-treat-covid-19 daily 0.8 https://clival.com/news/european-commission-grants-marketing-authorization-for-beigene-brukinsa-to-treat-relapsed-or-refractory-follicular-lymphoma daily 0.8 https://clival.com/news/arrowhead-concludes-enrolment-in-phase-iib-mixed-dyslipidemia-trial daily 0.8 https://clival.com/news/seegene-to-launch-new-covid-19-pcr-test-with-a-reduced-turnaround-time-optimized-for-mass-testing daily 0.8 https://clival.com/news/zydus-completes-enrollment-in-three-phase-iii-saroglitazar-trials-to-treat-nash daily 0.8 https://clival.com/news/us-fda-approves-novartis-millburn-facility-for-us-commercial-production-of-pluvicto daily 0.8 https://clival.com/news/blade-therapeutics-announces-positive-results-from-phase-1-study-of-cudetaxestat-to-treat-idiopathic-pulmonary-fibrosis daily 0.8 https://clival.com/news/emerald-health-pharmaceuticals-initiates-phase-i-clinical-study-on-its-oral-drug-candidate-derived-from-cannabidiol daily 0.8 https://clival.com/news/aveta-biomics-and-csir-cdri-announce-license-to-aveta-biomics-for-the-development-and-commercialization-of-first-in-class-bone-health-drugs daily 0.8 https://clival.com/news/dr-reddys-announces-the-launch-of-vasopressin-inj-generic-version-of-vasostrict-in-the-us-market daily 0.8 https://clival.com/news/china-approves-first-and-only-therapy-available-for-patients-with-egfr-exon20-insertion-nsclc daily 0.8 https://clival.com/news/insilico-medicine-raises-60-m-to-launch-ai-powered-drug-discovery-robotics-lab daily 0.8 https://clival.com/news/sab-biotherapeutics-announces-sab-185-to-first-patient-treatment-for-covid-19-in-phase-1b-clinical-trial daily 0.8 https://clival.com/news/beigene-announces-approval-for-brukinsa-zanubrutinib-by-swissmedic-for-treatment-of-adult-patients-with-waldenstr daily 0.8 https://clival.com/news/certara-customers-received-90-percent-of-us-fda-novel-drug-approvals-for-8th-consecutive-year daily 0.8 https://clival.com/news/allurion-launches-its-world-leading-weight-management-solution-in-india daily 0.8 https://clival.com/news/kintor-pharma-announces-first-patient-dosing-in-china-in-phase-iii-clinical-trial-of-proxalutamide-for-the-treatment-of-covid-19-outpatients daily 0.8 https://clival.com/news/a-442m-failure-after-years-of-work-and-an-fda-rejection-novartis-calls-it-quits-on-advair-copy daily 0.8 https://clival.com/news/ema-committee-recommends-marketing-approval-for-biocon-biologics-viatris-biosimilar-bevacizumab daily 0.8 https://clival.com/news/ranok-therapeutics-announces-us-fda-clearance-to-proceed-with-its-first-in-human-trial-of-rnk05047-in-patients-with-advanced-solid-tumor-cancers-and-lymphomas-champ-1 daily 0.8 https://clival.com/news/enzene-biosciences-launches-ranibizumab-as-an-affordable-alternative-to-treat-neovascular-amd daily 0.8 https://clival.com/news/genesis-drug-discovery-and-development-expands-its-presence-in-the-clinical-space-by-acquiring-statking-clinical-services daily 0.8 https://clival.com/news/cci-approves-bharat-biotech-international-eastman-exports-deal daily 0.8 https://clival.com/news/pfizer-and-astellas-xtandi-approved-by-us-fda-in-earlier-prostate-cancer-treatment-setting daily 0.8 https://clival.com/news/lupin-launches-regional-reference-laboratory-in-patna-bihar daily 0.8 https://clival.com/news/who-launches-global-registry-on-human-genome-editing daily 0.8 https://clival.com/news/strides-receives-us-fda-approval-for-generic-neoral-capsules daily 0.8 https://clival.com/news/glenmark-pharma-gets-tentative-usfda-nod-for-generic-anti-diabetes-tablets daily 0.8 https://clival.com/news/icpa-launches-herbal-drug-pilon-for-piles daily 0.8 https://clival.com/news/pandemic-response-lab-launches-novel-triple-target-monkeypox-tests daily 0.8 https://clival.com/news/eoflow-seeks-us-fda-approval-for-wearable-insulin-pump-eopatch daily 0.8 https://clival.com/news/regenxbio-inc-to-file-bla-using-us-fda-accelerated-approval-pathway-for-rgx-121-to-treat-mps-ii daily 0.8 https://clival.com/news/sirnaomics-doses-first-subject-in-phase-i-clinical-trial-of-stp707-for-the-treatment-of-liver-fibrosis-in-primary-sclerosing-cholangitis daily 0.8 https://clival.com/news/harbour-biomed-announces-ind-clearance-for-first-in-class-anti-b7h7-antibody-by-the-us-fda daily 0.8 https://clival.com/news/china-approves-astrazeneca-drug-to-treat-anaemia-in-ckd-patients daily 0.8 https://clival.com/news/aslan-pharmaceuticals-enters-into-licencing-agreement-with-zenyaku-kogyo daily 0.8 https://clival.com/news/abl-bio-announces-publication-of-preclinical-data-demonstrating-safety-and-efficacy-of-abl503tj-l14b-a-novel-anti-pd-l1-x-4-1bb-bispecific-antibody daily 0.8 https://clival.com/news/boehringer-ingelheim-receives-european-approval-for-senvelgo-an-oral-liquid-medication-for-diabetic-cats daily 0.8 https://clival.com/news/gilead-sciences-launches-asia-pacific-rainbow-grant-2021 daily 0.8 https://clival.com/news/bioarctics-new-antibodies-targeting-alzheimers-disease-receives-japanese-patent daily 0.8 https://clival.com/news/sutro-biopharma-announces-encouraging-interim-phase-1-clinical-data-for-a-dose-escalation-study-of-stro-002-antibody-drug-conjugate-in-ovarian-cancer daily 0.8 https://clival.com/news/bayer-partners-with-population-health-research-institute-phri-on-global-clinical-research-evaluating-covid-19-treatments daily 0.8 https://clival.com/news/venus-remedies-launches-consumer-healthcare-division daily 0.8 https://clival.com/news/abivax-gets-us-fda-nod-to-begin-phase-2b-trial-of-abx464-to-treat-moderate-to-severe-uc daily 0.8 https://clival.com/news/ascellahealth-launches-q3-2023-specialty-rare-pipeline-digest-expert-resource-for-fda-approval-status-of-specialty-pharmaceuticals-and-cell-gene-therapies daily 0.8 https://clival.com/news/4d-pharma-inks-clinical-trial-collaboration-and-supply-pact-with-merck-kgaa-pfizer-to-evaluate-mrx0518-in-combo-with-bavencio-to-treat-urothelial-ca daily 0.8 https://clival.com/news/biocon-gets-8-observations-for-2-new-biologics-manufacturing-units-in-bengaluru daily 0.8 https://clival.com/news/telix-commences-phase-iii-clinical-trial-of-prostate-cancer-therapy daily 0.8 https://clival.com/news/caladrius-biosciences-and-cend-therapeutics-announce-closing-of-merger-and-the-emergence-of-lisata-therapeutics daily 0.8 https://clival.com/news/eu-approves-lynparza-for-patients-with-germline-brca-mutated-metastatic-pancreatic-cancer daily 0.8 https://clival.com/news/systimmune-gets-us-fda-nod-to-begin-phase-1-trials-of-bl-b01d1-in-subjects-with-metastaticunresectable-non-small-cell-lung-cancer daily 0.8 https://clival.com/news/hansoh-pharma-and-atomwise-start-strategic-collaboration-on-ai-drug-discovery-for-multiple-therapeutic-areas daily 0.8 https://clival.com/news/lupin-gets-usfda-nod-to-market-generic-product daily 0.8 https://clival.com/news/dr-reddys-launches-heartburn-capsules-in-us-market daily 0.8 https://clival.com/news/us-fda-grants-510k-clearance-to-irras-next-generation-irraflow-control-unit daily 0.8 https://clival.com/news/beigene-announces-approval-in-canada-of-brukinsa-zanubrutinib-for-the-treatment-of-patients-with-mantle-cell-lymphoma daily 0.8 https://clival.com/news/pfizer-is-in-discussions-with-the-us-fda-about-altering-its-safety-warnings-on-viagra daily 0.8 https://clival.com/news/glenmark-pharma-gets-us-fda-approval-for-generic-zytiga-tablets daily 0.8 https://clival.com/news/novotech-cro-tapped-for-two-informa-citeline-awards-for-excellence-in-asia-pacific-clinical-trials daily 0.8 https://clival.com/news/us-fda-approves-new-therapy-for-rare-form-of-blood-cancers-called-myelodysplastic-syndromes daily 0.8 https://clival.com/news/us-fda-approves-amarins-vascepa-to-reduce-cardiovascular-risk daily 0.8 https://clival.com/news/sanofi-and-regeneron-provide-update-on-kevzara-sarilumab-phase-3-us-trial-in-covid-19-patients daily 0.8 https://clival.com/news/beigene-receives-manufacturing-approval-for-biologics-facility-in-china daily 0.8 https://clival.com/news/algernon-begins-phase-2-ifenprodil-ipf-and-chronic-cough-human-study-in-australia daily 0.8 https://clival.com/news/orthox-receives-uk-mhra-nod-to-begin-fflex-study-of-knee-cartilage-repair-fibrofix-product-platform daily 0.8 https://clival.com/news/tracon-pharmaceuticals-reports-regulatory-approval-of-envafolimab-in-china daily 0.8 https://clival.com/news/venus-remedies-chemotherapy-drug-cisplatin-receives-uk-mhra-marketing-approval daily 0.8 https://clival.com/news/trivitron-launches-kiran-health-shield-range-of-hand-sanitizers-protective-coverall daily 0.8 https://clival.com/news/bioinvent-and-transgene-receive-ind-approval-from-the-us-fda-for-bt-001-a-novel-oncolytic-virus-for-the-treatment-of-solid-tumors daily 0.8 https://clival.com/news/starton-therapeutics-reports-positive-results-from-phase-1-study-evaluating-star-lld-continuous-delivery-lenalidomide daily 0.8 https://clival.com/news/mainz-biomed-announces-commercial-partnership-for-coloalert-with-israel-based-fugene-genetics daily 0.8 https://clival.com/news/takeda-launches-cinryze-in-india-for-prophylaxis-in-hereditary-angioedema-patients daily 0.8 https://clival.com/news/biohaven-and-pfizer-complete-collaboration-transaction-for-commercialization-of-rimegepant-zavegepant-outside-us daily 0.8 https://clival.com/news/denali-therapeutics-biogen-initiate-phase-2b-study-of-lrrk2-inhibitor-in-parkinsons-disease daily 0.8 https://clival.com/news/hkbu-discovers-new-treatment-for-nasopharyngeal-cancer daily 0.8 https://clival.com/news/hightide-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-htd1801-in-type-2-diabetes-mellitus daily 0.8 https://clival.com/news/walgreens-boehringer-ingelheim-collaborate-to-improve-diversity-in-clinical-trials daily 0.8 https://clival.com/news/glenmark-receives-anda-approval-for-topical-treatment-of-plaque-psoriasis-in-adults daily 0.8 https://clival.com/news/daiichi-sankyo-begins-patient-dosing-in-phase-2-trial-of-pexidartinib-to-treat-tenosynovial-giant-cell-tumor daily 0.8 https://clival.com/news/syneos-health-announces-partnership-with-fosun-pharma-usa-to-launch-serplulimab daily 0.8 https://clival.com/news/us-fda-approves-boostrix-vaccine-for-use-during-third-trimester-of-pregnancy-to-prevent-whooping-cough-in-infants-younger-than-two-months-of-age daily 0.8 https://clival.com/news/astrazeneca-india-gets-cdsco-marketing-approval-for-palivizumab-a-preventive-therapy-for-rsv daily 0.8 https://clival.com/news/elpiscience-announces-first-patient-dosed-in-us-phase-i-clinical-trial-of-anti-cd39-monoclonal-antibody-es002-for-treatment-of-advanced-solid-tumors daily 0.8 https://clival.com/news/vtx-801-receives-us-fda-fast-track-designation-for-the-treatment-of-wilson-disease daily 0.8 https://clival.com/news/moberg-pharma-completes-enrollment-in-phase-3-study-for-mob-015-in-north-america daily 0.8 https://clival.com/news/pfizer-biontech-vaccine-induces-immune-response-in-early-phase-trial daily 0.8 https://clival.com/news/china-nmpa-accepts-beigenes-sbla-for-tislelizumab-to-treat-locally-msi-h-or-dmmr-solid-tumors daily 0.8 https://clival.com/news/qci-launches-wash-standard-for-assessment-of-workplaces-to-mitigate-the-risk-of-covid-19-infection daily 0.8 https://clival.com/news/ascletis-receives-ind-approval-for-its-nash-drug daily 0.8 https://clival.com/news/bayer-wins-fda-approval-for-gadavist daily 0.8 https://clival.com/news/daiichi-begins-phase-12-trial-of-mrna-covid19-vaccine-ds-5670-in-japan daily 0.8 https://clival.com/news/biorchestra-sk-biopharmaceuticals-collaborate-to-develop-mirna-targeted-therapeutics daily 0.8 https://clival.com/news/novartis-presents-positive-results-from-phase-iii-hawk-and-harrier-trials-of-beovu-to-treat-wet-amd-at-euretina-2020 daily 0.8 https://clival.com/news/biophytis-reports-positive-post-hoc-analysis-of-phase-2-3-cova-study-strongly-supporting-therapeutic-potential-of-sarconeos-in-covid-19 daily 0.8 https://clival.com/news/pfizers-once-daily-jak1-inhibitor-cibinqo-receives-us-fda-approval-to-treat-with-moderate-to-severe-atopic-dermatitis daily 0.8 https://clival.com/news/torrent-pharma-gets-warning-letter-from-usfda-for-gujarat-facility daily 0.8 https://clival.com/news/medison-pharma-announces-the-expansion-of-its-partnership-with-albireo-to-a-multi-regional-agreement-to-commercialize-odevixibat-in-canada-and-israel daily 0.8 https://clival.com/news/dr-reddys-gets-4-observations-from-usfda-for-srikakulam-plant daily 0.8 https://clival.com/news/bdr-pharma-launches-generic-drug-zisavel-to-treat-invasive-aspergillosis-mucormycosis daily 0.8 https://clival.com/news/nuance-pharma-announces-license-and-supply-agreement-with-bavarian-nordic-on-the-development-and-commercialization-of-respiratory-syncytial-virus-rsv-vaccine-for-adults-in-china daily 0.8 https://clival.com/news/us-fda-accepts-immunomedics-bla-resubmission-for-sacituzumab-govitecan-to-treat-metastatic-triple-negative-breast-cancer daily 0.8 https://clival.com/news/roches-tecentriq-grabs-i-o-s-first-win-in-post-surgery-lung-cancer-but-its-limited-and-an-fda-approval-could-be-too daily 0.8 https://clival.com/news/us-fda-approves-biogens-plegridy-to-treat-multiple-sclerosis daily 0.8 https://clival.com/news/twinstrand-biosciences-launches-duplex-sequencing-technology daily 0.8 https://clival.com/news/sanofi-regenerons-phase-3-trial-of-libtayo-monotherapy-in-advanced-cervical-cancer-stopped-early-for-positive-result-on-overall-survival daily 0.8 https://clival.com/news/pfizers-talzenna daily 0.8 https://clival.com/news/sparrow-pharma-begin-patient-dosing-in-phase-2-trial-of-hsd-1-inhibitor-spi-62-to-treat-polymyalgia-rheumatica daily 0.8 https://clival.com/news/amyris-signs-agreement-with-croda-for-supply-of-sustainable-squalene daily 0.8 https://clival.com/news/volitionrx-commences-lung-cancer-clinical-study-with-fosun-in-china daily 0.8 https://clival.com/news/bioversys-expands-collaboration-with-gsk daily 0.8 https://clival.com/news/us-fda-approves-qiagens-quantiferon-tb-gold-plus-assay-for-use-on-diasorins-automated-liaison-xs-platform-for-tb-testing daily 0.8 https://clival.com/news/merck-begins-phase-3-clinical-programme-for-oral-pcsk9-inhibitor-candidate-mk-0616-to-treat-adults-with-hypercholesterolemia daily 0.8 https://clival.com/news/bayer-in-frame-to-win-first-eu-nod-for-high-precision-cancer-drug daily 0.8 https://clival.com/news/zydus-cadila-launches-insomnia-drug-in-us-market daily 0.8 https://clival.com/news/granules-india-gets-us-fda-approval-for-penicillamine-capsules daily 0.8 https://clival.com/news/oncohost-prophet-platform-to-support-henlius-us-based-phase-iii-trial-for-patients-with-extensive-stage-small-cell-lung-cancer daily 0.8 https://clival.com/news/glenmark-pharma-launches-generic-nintedanib-to-treat-pulmonary-fibrosis-in-india daily 0.8 https://clival.com/news/fda-approves-first-therapy-for-rare-type-of-non-cancerous-tumors daily 0.8 https://clival.com/news/frontera-therapeutics-doses-first-patient-in-phase-1-clinical-trial-for-gene-therapy-ft-001-for-the-treatment-of-leber-congenital-amaurosis-2 daily 0.8 https://clival.com/news/avesthagen-inks-strategic-alliance-with-wipro-launches-genetic-testing-portfolio-for-cancers-neurological-and-rare-diseases daily 0.8 https://clival.com/news/cstone-eqrx-s-sugemalimab-scores-os-win-in-first-line-lung-cancer-trial daily 0.8 https://clival.com/news/merck-and-ridgebacks-covid-19-pill-receives-special-approval-in-japan daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-stada-alvotechs-uzpruvo-a-biosimilar-candidate-to-stelara daily 0.8 https://clival.com/news/beigenes-brutons-tyrosine-kinase-inhibitor-brukinsa-gets-china-nmpa-approval daily 0.8 https://clival.com/news/niper-mohali-gets-patent-for-its-invention-for-new-anti-tb-compound daily 0.8 https://clival.com/news/uk-mhra-grants-marketing-authorization-to-gbts-oxbryta-to-treat-haemolytic-anaemia-in-patients-with-scd-age-12-years-and-older daily 0.8 https://clival.com/news/neoimmunetech-begins-patient-dosing-in-phase-2a-portion-of-phase-1b2a-trial-of-nt-i7-in-combo-with-keytruda-to-treat-rr-advanced-solid-tumors daily 0.8 https://clival.com/news/fda-approves-takedas-alunbrig-a daily 0.8 https://clival.com/news/bms-drug-gets-first-us-approval-to-prevent-acute-gvhd daily 0.8 https://clival.com/news/zydus-gets-us-fda-marketing-approval-for-generic-vanos-cream daily 0.8 https://clival.com/news/us-pharma-firm-gilead-sciences-likely-to-seek-nod-to-market-anti-viral-drug-remdesivir-in-india daily 0.8 https://clival.com/news/neucyte-licenses-promising-novel-compound-for-treatment-of-refractory-epilepsy-and-related-neurological-disorders daily 0.8 https://clival.com/news/ema-committee-recommends-approval-of-karyopharm-menarinis-nexpovioto-treat-patients-with-refractory-multiple-myeloma daily 0.8 https://clival.com/news/calliditas-therapeutics-partner-everest-medicines-introduces-nefecon-in-china daily 0.8 https://clival.com/news/absstem-technologies-invests-rs-30-million-to-launch-new-business-focused-on-nitrogen-plants-in-india daily 0.8 https://clival.com/news/usfda-issues-warning-letter-to-lantech-pharma-for-manufacturing-violations-at-andhra-plant daily 0.8 https://clival.com/news/transcode-gets-us-fda-nod-to-proceed-with-first-in-human-trial-of-ttx-mc138-to-treat-advanced-solid-tumours daily 0.8 https://clival.com/news/glaucoma-research-foundation-launches-catalyst-for-a-cure-initiative-to-prevent-and-cure-neurodegeneration daily 0.8 https://clival.com/news/beigene-launches-proposed-public-offering-by-selling-shareholders daily 0.8 https://clival.com/news/bayer-launches-daily-immunity-booster-supradyn-immuno daily 0.8 https://clival.com/news/omron-healthcare-india-collaborates-with-alivecor-india daily 0.8 https://clival.com/news/mhra-approves-epidyolex-cannabidiol-for-tsc-seizure-treatment daily 0.8 https://clival.com/news/caplin-steriles-gets-us-fda-approval-for-generic-bloxiverz-injection daily 0.8 https://clival.com/news/granules-pharma-gets-us-fda-approval-for-generic-rozerem-tablets daily 0.8 https://clival.com/news/belite-bio-shares-phase-3-dragon-trial-interim-results-for-tinlarebant daily 0.8 https://clival.com/news/ema-recommends-approval-of-abbvies-upadacitinib-for-giant-cell-arteritis daily 0.8 https://clival.com/news/glenmark-pharma-acquires-launches-acetylcysteine-injection-200-mgml daily 0.8 https://clival.com/news/abbvie-gubra-partner-to-develop-amylin-analog-for-obesity-treatment daily 0.8 https://clival.com/news/fda-grants-fast-track-status-to-latigos-ltg-001-for-acute-pain-treatment daily 0.8 https://clival.com/news/infinx-acquires-medreceivables-to-boost-pathology-revenue-solutions daily 0.8 https://clival.com/news/wuxi-biologics-unveils-effix-for-advanced-microbial-biologics-production daily 0.8 https://clival.com/news/pfizer-announces-fda-approval-of-paxlovid daily 0.8 https://clival.com/news/akesos-ngf-monoclonal-antibody-ak115-approved-to-initiate-clinical-trial-in-pain-including-cancer-pain daily 0.8 https://clival.com/news/ideaya-attmos-partner-to-advance-aiml-driven-oncology-drug-discovery daily 0.8 https://clival.com/news/regenxbio-partners-with-nippon-shinyaku-for-mps-disease-treatments daily 0.8 https://clival.com/news/astellas-yaskawa-form-joint-venture-for-cell-therapy-manufacturing daily 0.8 https://clival.com/news/bioheng-therapeutics-wins-approval-for-cd7-ucar-t-therapy-in-t-alllbl daily 0.8 https://clival.com/news/fda-ema-grant-orphan-drug-status-to-bioxodes-stroke-therapy-biox-101 daily 0.8 https://clival.com/news/persica-pharma-reports-positive-phase-1b-trial-for-pp353-in-back-pain daily 0.8 https://clival.com/news/biocon-biologics-civica-partner-to-expand-insulin-aspart-access-in-us daily 0.8 https://clival.com/news/zydus-lifesciences-unveils-breakthrough-drug-for-transplant-patients daily 0.8 https://clival.com/news/lupin-launches-rivaroxaban-tablets-usp-25mg-in-the-us-market daily 0.8 https://clival.com/news/novavax-becomes-australias-5thapproved-covid-19-vaccine daily 0.8 https://clival.com/news/cadila-pharma-launches-esomeprazole-tablets-for-treatment-of-hyperacidity daily 0.8 https://clival.com/news/beneq-exosens-partner-on-lead-free-mcps-with-ald-for-enhanced-performance daily 0.8 https://clival.com/news/roche-opens-genentech-innovation-center-boston-at-harvards-research-hub daily 0.8 https://clival.com/news/sun-pharma-to-acquire-checkpoint-therapeutics-in-strategic-expansion daily 0.8 https://clival.com/news/uk-mhra-approves-vertexs-alyftrek-for-cystic-fibrosis-treatment daily 0.8 https://clival.com/news/sensorion-completes-enrollment-in-notoxis-phase-2a-trial-for-sens-401 daily 0.8 https://clival.com/news/astrazeneca-india-secures-cdsco-nod-for-durvalumab-in-ls-sclc-treatment daily 0.8 https://clival.com/news/clivallundbecks-amlenetug-gains-japanese-orphan-drug-status-for-msa-treatment daily 0.8 https://clival.com/news/amgen-kyowa-kirin-report-positive-phase-3-rocatinlimab-ignite-results daily 0.8 https://clival.com/news/positive-adept-phase-23-results-for-dupixent-in-bullous-pemphigoid-at-aad daily 0.8 https://clival.com/news/bms-presents-phase-3-poetyk-psa-2-data-showing-sotyktus-superiority daily 0.8 https://clival.com/news/salvat-laboratories-announces-submission-of-new-drug-application-to-the-us-fda-for-clobetasol-nanoemulsion-for-treating-inflammation-and-pain-after-ocular-surgery daily 0.8 https://clival.com/news/austedo daily 0.8 https://clival.com/news/idma-hails-approval-of-three-bulk-drug-parks-to-strengthen-domestic-api-industry daily 0.8 https://clival.com/news/durect-reports-positive-results-from-phase-2b-ahfirm-trial-of-larsucosterol-in-alcohol-associated-hepatitis daily 0.8 https://clival.com/news/oxilio-quotient-sciences-receive-uk-mhra-nod-to-begin-clinical-trial-with-oxl001 daily 0.8 https://clival.com/news/mercks-phase-3-trials-show-doravirineislatravir-maintains-hiv-1-suppression daily 0.8 https://clival.com/news/alpha-teknova-pluristyx-partner-to-launch-plurifreeze-for-cell-therapies daily 0.8 https://clival.com/news/harbour-biomed-launches-elance-therapeutics-for-obesity-therapies daily 0.8 https://clival.com/news/bayer-hurdle-announce-major-breakthrough-in-aging-research daily 0.8 https://clival.com/news/ema-recommends-approval-of-hepizovac-vaccine-for-cattle-disease daily 0.8 https://clival.com/news/peptris-licenses-indias-first-ai-discovered-drug-to-revio-therapeutics daily 0.8 https://clival.com/news/innovent-biologics-sycume-gets-china-nmpa-approval-for-thyroid-eye-disease daily 0.8 https://clival.com/news/eton-pharma-reports-positive-et-600-bioequivalence-study-results daily 0.8 https://clival.com/news/astrazenecas-calypso-trial-shows-eneboparatide-normalizes-serum-calcium daily 0.8 https://clival.com/news/enterobiotix-reports-positive-phase-2a-trial-results-for-ebx-102-02-in-ibs-c daily 0.8 https://clival.com/news/rona-therapeutics-gets-fda-clearance-for-phase-2-study-of-rn0361-sirna daily 0.8 https://clival.com/news/opko-health-entera-bio-partner-to-advance-oral-glp-1-tablet-for-obesity daily 0.8 https://clival.com/news/health-canada-grants-expanded-authorization-to-novavaxs-covid-19-vaccine-nuvaxovid-xbb15-vaccine daily 0.8 https://clival.com/news/vigil-health-announces-interim-order-for-acquisition-by-assa-abloy daily 0.8 https://clival.com/news/lupin-receives-us-fda-approval-for-fluconazole-tablets-usp daily 0.8 https://clival.com/news/meridian-bioscience-introduces-lyo-ready-qpcr-saliva-specific-master-mixes-for-dna-rna-direct-detection daily 0.8 https://clival.com/news/specialty-injectables-maker-exela-issues-recall-after-particles-turn-up-in-3-different-drugs daily 0.8 https://clival.com/news/cansinobios-convidecia daily 0.8 https://clival.com/news/biotage-launches-new-automated-platform-for-plasmid-dna-purification daily 0.8 https://clival.com/news/vanda-pharma-phase-iii-study-of-tradipitant-in-gastroparesis-fails-to-meet-prespecified-primary-endpoint daily 0.8 https://clival.com/news/frusica-2-trial-meets-primary-endpoint-for-rcc-in-china-with-sintilimab-fruquintinib daily 0.8 https://clival.com/news/usv-launches-empagliflozin-combos-for-diabetes-care-in-india daily 0.8 https://clival.com/news/fda-grants-fast-track-to-jjs-nipocalimab-for-sjgrens-disease-treatment daily 0.8 https://clival.com/news/lilly-launches-mounjaro-in-india-for-obesity-and-type-2-diabetes-treatment daily 0.8 https://clival.com/news/sobi-announces-gamifant-sepsis-research-collaboration-at-isicem-congress daily 0.8 https://clival.com/news/altesa-biosciences-gets-fda-clearance-for-vapendavir-to-treat-rhinovirus daily 0.8 https://clival.com/news/alnylam-wins-fda-approval-for-amvuttra-to-treat-cardiomyopathy daily 0.8 https://clival.com/news/glenmark-gets-us-fda-approval-for-olopatadine-hydrochloride-solution daily 0.8 https://clival.com/news/us-fda-approves-novartis-fabhalta-for-c3-glomerulopathy-treatment daily 0.8 https://clival.com/news/pharming-doses-first-patient-in-phase-ii-trial-of-leniolisib-for-cvid daily 0.8 https://clival.com/news/uk-mhra-approves-pfizerbiontech-bivalent-covid-19-booster-vaccine daily 0.8 https://clival.com/news/united-labs-novo-nordisk-sign-2b-deal-for-obesity-diabetes-treatment daily 0.8 https://clival.com/news/health-canada-approves-hikmas-kloxxado-nasal-spray-for-opioid-overdose daily 0.8 https://clival.com/news/yaqrit-secures-22m-nihr-grant-for-dialive-liver-support-trials daily 0.8 https://clival.com/news/tempero-bio-starts-phase-2-trial-with-tmp-301-for-alcohol-use-disorder daily 0.8 https://clival.com/news/clearminds-fda-approved-cmnd-100-trial-moves-forward-in-the-us daily 0.8 https://clival.com/news/clover-biopharma-begins-rsv-vaccine-trial-after-us-fda-ind-clearance daily 0.8 https://clival.com/news/fda-grants-priority-review-to-sanofis-tolebrutinib-for-multiple-sclerosis daily 0.8 https://clival.com/news/biovica-clia-laboratory-receives-cap-accreditation daily 0.8 https://clival.com/news/united-laboratories-novo-nordisk-sign-global-license-deal-for-ubt251 daily 0.8 https://clival.com/news/actinium-pharma-partners-with-eckert-ziegler-for-ac-225-supply-agreement daily 0.8 https://clival.com/news/bio-thera-partners-with-dr-reddys-for-biosimilar-deal-in-southeast-asia daily 0.8 https://clival.com/news/fapon-biopharma-anti-cd47-antibody-fp002-earns-ind-approval-from-fda daily 0.8 https://clival.com/news/sineugene-gets-fda-clearance-for-snug01-to-treat-als daily 0.8 https://clival.com/news/merck-signs-2b-deal-with-hengrui-pharma-for-cardiovascular-drug daily 0.8 https://clival.com/news/adjutec-pharma-venus-remedies-partner-to-evaluate-apc-148-for-amr daily 0.8 https://clival.com/news/roche-launches-covid-19-pcr-test-for-omicron-sub-variant daily 0.8 https://clival.com/news/skb107-wins-china-nmpa-nod-for-bone-metastases-therapy daily 0.8 https://clival.com/news/bayer-puhe-biopharma-ink-global-license-agreement-for-clinical-phase-i-prmt5-inhibitor daily 0.8 https://clival.com/news/us-fda-grants-fast-track-designation-to-sanofis-mrna-vaccine-candidate-for-prevention-of-chlamydia-infection daily 0.8 https://clival.com/news/iaso-bio-secures-nda-approval-on-equecabtagene-autoleucel-for-multiple-myeloma-in-macau daily 0.8 https://clival.com/news/roches-actemra-wins-approval-for-hospitalized-covid-patients daily 0.8 https://clival.com/news/sol-gel-gets-fda-approval-for-encapsulated-skin-disease-drug daily 0.8 https://clival.com/news/biocon-biologics-bengaluru-facility-gets-eu-gmp-certification-for-bevacizumab daily 0.8 https://clival.com/news/alnylam-pharma-gains-approval-for-qfitlia-fitusiran-for-hemophilia daily 0.8 https://clival.com/news/exclusive-licensing-deal-link-healthcare-to-market-cefiderocol-in-aus-nz daily 0.8 https://clival.com/news/astrazenecas-azd0780-shows-significant-ldl-reduction-in-phase-iib-trial daily 0.8 https://clival.com/news/akums-unveils-ripasudiltimolol-combo-for-glaucoma-ocular-hypertension daily 0.8 https://clival.com/news/pfizers-abrysvo-wins-eu-approval-to-protect-adults-against-rsv daily 0.8 https://clival.com/news/china-nmpa-grants-breakthrough-therapy-status-to-innovents-ibi363-for-melanoma daily 0.8 https://clival.com/news/erbc-menarini-biotech-partner-to-fast-track-biopharma-development daily 0.8 https://clival.com/news/biomarins-phase-3-pegasus-trial-for-palynziq-meets-efficacy-goal daily 0.8 https://clival.com/news/novartis-wins-fda-nod-for-vanrafia-first-selective-endothelin-a-blocker daily 0.8 https://clival.com/news/sanofis-rilzabrutinib-gets-fda-orphan-drug-status-for-rare-diseases daily 0.8 https://clival.com/news/vera-therapeutics-completes-enrollment-in-origin-phase-3-igan-trial daily 0.8 https://clival.com/news/pacira-starts-phase-2-trial-of-pcrx-201-for-knee-osteoarthritis daily 0.8 https://clival.com/news/intellia-doses-first-patient-in-magnitude-2-phase-3-nexiguran-trial daily 0.8 https://clival.com/news/uk-mhra-approves-eplontersen-for-treating-rare-nerve-disorder daily 0.8 https://clival.com/news/tr1x-gets-8m-cirm-grant-for-trx103-phase-12a-gvhd-clinical-trial daily 0.8 https://clival.com/news/ethris-lonza-partner-to-develop-room-temp-mrna-respiratory-vaccines daily 0.8 https://clival.com/news/axsome-to-present-positive-phase-3-axs-05-axs-12-results-at-aan-2025 daily 0.8 https://clival.com/news/erbc-menarini-biotech-partner-to-advance-biopharma-to-human-trials daily 0.8 https://clival.com/news/vluye-pharma-launches-erzofri-er-in-us-for-schizophrenia-treatment daily 0.8 https://clival.com/news/valneva-limmatech-start-phase-2-pediatric-trial-for-s4v2-vaccine daily 0.8 https://clival.com/news/gc-biopharma-gets-mfds-nod-for-worlds-first-recombinant-anthrax-shot daily 0.8 https://clival.com/news/sanofis-tolebrutinib-shows-ms-disability-benefit-in-nejm-phase-3-data daily 0.8 https://clival.com/news/lexeo-reports-positive-phase-12-results-for-lx2006-in-fa-cardiomyopathy daily 0.8 https://clival.com/news/ethris-lonza-to-develop-spray-dried-mrna-vaccines-for-respiratory-care daily 0.8 https://clival.com/news/aviditys-delpacibart-gets-japan-orphan-drug-status-for-dm1 daily 0.8 https://clival.com/news/fda-clears-science-37s-dtp-site-in-phase-3-asthma-trial-inspection daily 0.8 https://clival.com/news/valneva-limmatech-begin-phase-2-infant-trial-for-shigella-vaccine daily 0.8 https://clival.com/news/fda-oks-vyvgart-hytrulo-syringe-for-gmg-and-cidp-self-injection daily 0.8 https://clival.com/news/worldwide-clinical-trials-unveils-ai-tool-for-smarter-trial-optimization daily 0.8 https://clival.com/news/zydus-gets-usfda-nod-to-marketgeneric-antifungal-medication daily 0.8 https://clival.com/news/theriva-shares-phase-1b2a-ribaxamase-data-in-transplant-patients daily 0.8 https://clival.com/news/mhra-review-of-uk-trial-applications-reveals-new-breakthrough-paths daily 0.8 https://clival.com/news/orexo-reports-positive-results-for-amorphox-based-intranasal-vaccine daily 0.8 https://clival.com/news/cagent-vascular-begins-enrollment-for-serranator-oct-angioplasty-study daily 0.8 https://clival.com/news/janssen-seeks-us-fda-approval-of-investigational-single-tablet-combo-therapy-of-macitentan-tadalafil-to-treat-pulmonary-arterial-hypertension daily 0.8 https://clival.com/news/boehringer-cue-biopharma-partner-for-autoimmune-drug-development daily 0.8 https://clival.com/news/galderma-launches-sculptra-in-china-to-boost-aesthetics-market-growth daily 0.8 https://clival.com/news/sanofi-advances-respiratory-pipeline-with-asthma-data-copd-trials daily 0.8 https://clival.com/news/bajaj-healthcare-launches-generic-favipiravir-tablets-for-covid-19-treatment daily 0.8 https://clival.com/news/nexalin-gets-us-patent-for-brain-stimulation-tech-in-substance-abuse daily 0.8 https://clival.com/news/bristol-myers-camzyos-phase-3-trial-fails-to-meet-key-endpoints daily 0.8 https://clival.com/news/xellsmarts-ipsc-cell-therapies-for-parkinsons-als-get-fda-nod daily 0.8 https://clival.com/news/chipscreen-new-cs32582-capsules-granted-clinical-approval-for-psoriasis-treatment daily 0.8 https://clival.com/news/chime-polpharma-biologics-team-up-to-accelerate-biosimilar-development daily 0.8 https://clival.com/news/csl-launches-andembry-for-hereditary-angioedema-treatment-in-japan daily 0.8 https://clival.com/news/cullinan-gets-ema-nod-for-phase-1-trial-of-cd19-t-cell-engager-cln-978 daily 0.8 https://clival.com/news/wayfinder-biosciences-partners-with-daiichi-sankyo-to-develop-therapies-for-neurodegenerative-diseases daily 0.8 https://clival.com/news/ono-and-jorna-therapeutics-partner-to-develop-innovative-rna-editing-therapies daily 0.8 https://clival.com/news/boehringer-cue-biopharma-partner-on-autoimmune-disease-treatment daily 0.8 https://clival.com/news/viatris-seeks-mhlw-nod-for-effexor-sr-to-treat-anxiety-disorder daily 0.8 https://clival.com/news/china-nmpa-approves-ronas-ind-for-rn1871-sirna-drug-for-hypertension daily 0.8 https://clival.com/news/fda-approves-minder-first-implantable-continuous-eeg-monitor-in-us daily 0.8 https://clival.com/news/roche-gets-ce-mark-for-chest-pain-algorithm-to-detect-acs-faster daily 0.8 https://clival.com/news/redhills-aemcolo daily 0.8 https://clival.com/news/zealand-pharma-begins-phase-2b-zupreme-2-trial-for-petrelintide daily 0.8 https://clival.com/news/gene-solutions-and-element-biosciences-collaboration-to-enhance-ngs-technology daily 0.8 https://clival.com/news/invivoscribes-flt3-itd-mrd-assay-approved-by-ny-state-health-dept daily 0.8 https://clival.com/news/aclaris-gets-fda-nod-to-begin-phase-1a1b-trial-of-ati-052-therapy daily 0.8 https://clival.com/news/doer-biologics-begins-phase-2-dosing-for-dr10624-in-mash-treatment daily 0.8 https://clival.com/news/augurexs-spinestat-approved-in-uk-for-axial-spondyloarthritis-testing daily 0.8 https://clival.com/news/lupin-gets-us-fda-approval-for-tolvaptan-tablets-for-hyponatremia daily 0.8 https://clival.com/news/sun-pharma-moebius-publish-phase-2b-data-on-mm-ii-for-osteoarthritis daily 0.8 https://clival.com/news/baebies-gets-fda-breakthrough-status-for-heparin-monitoring-test daily 0.8 https://clival.com/news/entod-pharma-gets-cdsco-approval-for-eye-drop-to-slow-myopia-in-children daily 0.8 https://clival.com/news/sebela-pharma-announces-positive-results-from-phase-3-triumph-programme-of-tegoprazan-in-gerd daily 0.8 https://clival.com/news/biogens-omaveloxolone-approved-by-uk-mhra-for-treating-friedreichs-ataxia daily 0.8 https://clival.com/news/fda-approves-pfizerbiontech-and-modernas-adapted-covid-19-vaccines daily 0.8 https://clival.com/news/first-clinical-data-released-for-yolt-101-base-editing-therapy-by-yoltech daily 0.8 https://clival.com/news/bioversys-hosts-virtual-kol-event-on-bv100-phase-2-vabp-study daily 0.8 https://clival.com/news/bioxodes-reports-positive-phase-2a-results-for-biox-101-in-stroke-treatment daily 0.8 https://clival.com/news/orion-criceto-to-develop-and-commercialize-aporon-for-parkinsons-off daily 0.8 https://clival.com/news/ipsen-to-present-elafibranor-phase-ii-data-at-easl-congress-2025 daily 0.8 https://clival.com/news/ema-panel-backs-argenxs-vyvgart-sc-injection-for-treating-cidp daily 0.8 https://clival.com/news/uk-mhra-approves-bayers-acoramidis-for-cardiomyopathy-treatment daily 0.8 https://clival.com/news/eu-approves-filspari-by-csl-vifor-travere-for-iga-nephropathy-treatment daily 0.8 https://clival.com/news/innovent-doses-first-patient-in-phase-1-study-of-ibi3020-for-cancer daily 0.8 https://clival.com/news/biohaven-grabs-a-foothold-with-600m-windfall-from-oberland-capital daily 0.8 https://clival.com/news/alcon-introduces-precision1-contact-lenses-in-india-with-a-new-launch-campaign daily 0.8 https://clival.com/news/abbvie-gets-fda-nod-for-rinvoq-to-treat-adults-with-giant-cell-arteritis daily 0.8 https://clival.com/news/alcresta-mgh-begin-trial-of-relizorb-in-pancreatitis-patients daily 0.8 https://clival.com/news/uk-mhra-approves-bridgebios-beyonttra-for-treating-attr-cm daily 0.8 https://clival.com/news/satsuma-gets-fda-nod-for-atzumi-nasal-powder-to-treat-migraine daily 0.8 https://clival.com/news/obi-pharma-gets-fda-clearance-for-phase-12-ind-of-trop-2-adc-obi-902 daily 0.8 https://clival.com/news/dimerix-enters-into-agreement-with-amicus-therapeutics-for-dmx-200-to-treat-fsgs daily 0.8 https://clival.com/news/addex-enters-into-agreement-with-sinntaxis-to-develop-mglu5-inhibitors-in-brain-injury-recovery daily 0.8 https://clival.com/news/okyo-pharmas-urcosimod-gets-fda-fast-track-for-corneal-pain-treatment daily 0.8 https://clival.com/news/astrazenecas-breztri-meets-phase-iii-endpoints-in-asthma-trials daily 0.8 https://clival.com/news/genmab-to-submit-sbla-to-fda-for-epcoritamab-with-r2-combination daily 0.8 https://clival.com/news/fda-reviews-application-for-first-oral-glp-1-obesity-treatment-25mg daily 0.8 https://clival.com/news/fda-clears-ind-for-nts071-nutshells-p53-y220c-reactivator-therapy daily 0.8 https://clival.com/news/enterobiotix-to-present-impulce-trial-results-on-ebx-102-at-easl-2025 daily 0.8 https://clival.com/news/dianthus-completes-enrollment-in-phase-2-magic-trial-for-dnth103 daily 0.8 https://clival.com/news/alteritys-ath434-gets-fda-fast-track-for-multiple-system-atrophy daily 0.8 https://clival.com/news/vanda-submits-bysanti-nda-to-fda-decision-anticipated-in-early-2026 daily 0.8 https://clival.com/news/jj-shares-new-tremfya-phase-3-data-for-ulcerative-colitis-treatment daily 0.8 https://clival.com/news/agc-biologics-novelty-nobility-partner-for-antibody-drug-development daily 0.8 https://clival.com/news/genprex-inks-sponsored-research-agreement-with-the-university-of-pittsburgh-to-study-diabetes-gene-therapy-in-type-1-and-type-2-diabetes daily 0.8 https://clival.com/news/everest-medicines-announces-nmpa-full-approval-of-nefecon-for-the-treatment-of-primary-immunoglobulin-a-nephropathy-igan-in-adults-at-risk-of-disease-progression daily 0.8 https://clival.com/news/lilly-deepens-als-pipeline-with-415m-alchemab-licensing-deal daily 0.8 https://clival.com/news/data-from-its-ongoing-phase-2-ensure-study-at-easl-congress-2025-suggesting-brii-179s-role-in-advancing-higher-hbsag-loss daily 0.8 https://clival.com/news/boehringer-starts-phase-ii-trial-for-oral-drug-in-geographic-atrophy daily 0.8 https://clival.com/news/gsks-glisten-phase-iii-trial-of-linerixibat-meets-primary-endpoint daily 0.8 https://clival.com/news/lillys-zepbound-beats-wegovy-in-weight-loss-trial-results daily 0.8 https://clival.com/news/amneal-apiject-expand-bfs-to-boost-us-sterile-drug-production daily 0.8 https://clival.com/news/mesoblast-submits-clinical-efficacy-and-safety-data-to-us-fda-in-rolling-bla-for-remestemcel-l-to-treat-children-with-sr-agvhd daily 0.8 https://clival.com/news/abbisko-to-present-phase-2-irpagratinib-data-at-2025-esmo-gi-congress daily 0.8 https://clival.com/news/novo-nordisk-shares-positive-phase-3-real8-data-on-sogroya-at-espeese daily 0.8 https://clival.com/news/abli-therapeutics-launches-with-novel-parkinsons-therapy daily 0.8 https://clival.com/news/trixeo-aerosphere-approved-in-uk-with-eco-friendly-propellant daily 0.8 https://clival.com/news/rein-therapeutics-begins-phase-2-renew-trial-of-lti-03-for-ipf daily 0.8 https://clival.com/news/vaxart-approved-by-barda-to-start-dosing-in-phase-2b-covid-19-trial daily 0.8 https://clival.com/news/gene-solutions-newcl-partner-to-boost-genetic-testing-in-taiwan daily 0.8 https://clival.com/news/foresee-starts-phase-2-windward-trial-of-mirivadelgat-for-ph-ild daily 0.8 https://clival.com/news/gene-solutions-newcl-partner-to-advance-genetic-testing-in-taiwan daily 0.8 https://clival.com/news/china-nmpa-approves-canbridges-velaglucerase-beta-for-gaucher-disease daily 0.8 https://clival.com/news/fda-approves-fujirebios-plasma-test-to-detect-alzheimers-pathology daily 0.8 https://clival.com/news/porton-hualong-partner-to-advance-matc-cell-therapy-for-tumors daily 0.8 https://clival.com/news/phase-3-trial-of-ifinatamab-deruxtecan-starts-for-advanced-escc daily 0.8 https://clival.com/news/armata-reports-positive-phase-1b2a-data-for-ap-sa02-in-s-aureus daily 0.8 https://clival.com/news/cortechsai-alz-net-partner-to-advance-alzheimers-care-with-ai daily 0.8 https://clival.com/news/ayush-ministry-directs-state-licensing-authorities-to-consider-and-accept-stability-data-for-asu-drugs daily 0.8 https://clival.com/news/boehringers-nerandomilast-shows-promise-in-phase-iii-ipf-ppf-trials daily 0.8 https://clival.com/news/brainstorm-wins-fda-ok-for-phase-3b-nurown-trial-in-als-treatment daily 0.8 https://clival.com/news/bharat-biotechs-hillchol-shows-success-in-phase-iii-cholera-vaccine-trial daily 0.8 https://clival.com/news/accropeutics-ac-201-shows-promise-in-phase-2-psoriasis-trial daily 0.8 https://clival.com/news/lupus-nexus-launches-to-advance-personalized-lupus-treatments-and-cure daily 0.8 https://clival.com/news/bayer-begins-phase-i-trial-of-girk4-inhibitor-for-atrial-fibrillation daily 0.8 https://clival.com/news/chugai-pharma-reports-phase-iii-success-for-tecentriq-avastin-in-liver-cancer daily 0.8 https://clival.com/news/roche-broad-labs-partner-to-speed-sbx-sequencing-adoption daily 0.8 https://clival.com/news/fda-grants-breakthrough-status-to-tinlarebant-for-stargardt-disease daily 0.8 https://clival.com/news/ani-pharma-starts-phase-4-trial-of-cortrophin-gel-for-gout-flares daily 0.8 https://clival.com/news/medicus-gets-uae-ok-for-phase-2-trial-of-sknjct-004-for-skin-cancer daily 0.8 https://clival.com/news/bayer-launches-centafore-imaging-core-lab-for-trials-and-samd daily 0.8 https://clival.com/news/roche-broad-clinical-labs-partner-to-advance-sbx-sequencing-adoption daily 0.8 https://clival.com/news/oncolytics-biotech-updates-clinical-development-operations-activities-during-covid-19-pandemic daily 0.8 https://clival.com/news/sun-pharma-gets-dcgi-approval-for-clinical-trial-with-nafamostat-in-covid-19-patients daily 0.8 https://clival.com/news/iavi-moderna-launch-first-in-africa-clinical-trial-of-mrna-hiv-vaccine-development-programme daily 0.8 https://clival.com/news/uk-mhra-approves-polihexanide-to-treat-acanthamoeba-keratitis daily 0.8 https://clival.com/news/china-oks-1st-ipsc-cell-therapy-by-xellsmart-for-spinal-cord-injury daily 0.8 https://clival.com/news/twist-element-biosciences-partner-on-end-to-end-ngs-solutions daily 0.8 https://clival.com/news/canada-approves-pfizer-covid-vaccine-for-kids-under daily 0.8 https://clival.com/news/zhiyi-biotech-received-clinical-approval-from-us-fda-for-sk10-in-chemotherapy-induced-diarrhea daily 0.8 https://clival.com/news/lupin-shares-fall-4-after-usfda-issues-form-483-for-pithampur-plant daily 0.8 https://clival.com/news/wuxi-bios-drug-substance-and-drug-product-facilities-receives-european-and-us-fda-approvals daily 0.8 https://clival.com/news/transgene-nec-announce-positive-data-from-phase-i-studies-of-tg4050-a-novel-individualized-neoantigen-cancer-vaccine daily 0.8 https://clival.com/news/us-fda-committee-votes-against-approval-of-acadia-pharma-pimavanserin-to-treat-alzheimers-disease-psychosis daily 0.8 https://clival.com/news/pfizer-and-biontech-announce-publication-of-results-from-landmark-phase-3-trial-of-bnt162b2-covid-19-vaccine-candidate-in-the-new-england-journal-of-m daily 0.8 https://clival.com/news/novartis-phase-ii-open-label-extension-orion-3-trial-of-leqvio-provides-effective-ldl-c-reduction-over-four-year-period daily 0.8 https://clival.com/news/gsk-seeks-health-canada-ok-for-depemokimab-in-asthma-sinusitis daily 0.8 https://clival.com/news/innovents-phase-3-glory-1-obesity-study-published-in-nejm daily 0.8 https://clival.com/news/huonslab-reaches-lpi-in-phase-1-trial-for-hyaluronidase-ph20 daily 0.8 https://clival.com/news/phanes-starts-dosing-patients-in-mavrostobart-chemo-combo-study daily 0.8 https://clival.com/news/lilly-to-expand-its-pain-pipeline-with-acquisition-of-siteone-therapeutics daily 0.8 https://clival.com/news/rein-therapeutics-begins-dosing-in-phase-2-trial-of-lti-03-for-ipf daily 0.8 https://clival.com/news/fda-halts-rocket-pharmas-rp-a501-trial-for-danon-disease daily 0.8 https://clival.com/news/immuteps-efti-combo-hits-phase-ii-goal-in-soft-tissue-sarcoma-trial daily 0.8 https://clival.com/news/innocare-wins-ok-to-trial-bcl2-drug-mesutoclax-for-mds daily 0.8 https://clival.com/news/biogen-partners-with-city-therapeutics-to-develop-select-novel-rnai-based-therapies daily 0.8 https://clival.com/news/china-nmpa-grants-priority-review-to-carsgens-satri-cel-for-ggeja daily 0.8 https://clival.com/news/us-fda-approves-modernas-covid-19-vaccine-mnexspike daily 0.8 https://clival.com/news/roches-fenebrutinib-curbs-ms-activity-disability-for-2-years daily 0.8 https://clival.com/news/sanofi-regeneron-itepekimab-meets-1-of-2-copd-phase-3-goals daily 0.8 https://clival.com/news/astellas-licenses-adc-xnw27011-from-evopoint-targeting-cldn182 daily 0.8 https://clival.com/news/trinity-ontada-use-analytics-insights-to-boost-oncology-outreach daily 0.8 https://clival.com/news/circode-biomed-gets-fda-nod-for-worlds-first-circular-rna-drug-hm2002 daily 0.8 https://clival.com/news/xellsmart-gets-fda-ok-for-3-ipsc-cell-therapies-for-key-cns-diseases daily 0.8 https://clival.com/news/eli-lillys-omvoh-recommended-by-nice-to-treat-crohns-disease-in-adults daily 0.8 https://clival.com/news/jenscare-shares-trinity-30-day-jensclip-1-year-results-at-europcr daily 0.8 https://clival.com/news/terumo-neuro-launches-sofia-flow-88-stroke-catheter-in-emea daily 0.8 https://clival.com/news/daewoong-shares-phase-2-bersiporocin-data-global-demographics-at-ats daily 0.8 https://clival.com/news/insilico-reports-phase-iia-ipf-results-of-ai-designed-rentosertib daily 0.8 https://clival.com/news/ascletis-phase-iii-denifanstat-trial-for-acne-meets-all-endpoints daily 0.8 https://clival.com/news/neuronata-r-als-phase-3-data-supports-fda-accelerated-approval-bid daily 0.8 https://clival.com/news/nasus-pharma-publishes-positive-phase-2-results-for-intranasal-ns002 daily 0.8 https://clival.com/news/singapore-grants-interim-approval-for-modernas-bivalent-covid-19-booster-vaccine daily 0.8 https://clival.com/news/fda-grants-orphan-drug-status-to-sanofis-rilzabrutinib-for-scd daily 0.8 https://clival.com/news/mycovia-starts-phase-2-study-for-cryptococcal-meningitis-enrollment daily 0.8 https://clival.com/news/canaglu daily 0.8 https://clival.com/news/elgan-pharma-chiesi-dose-first-infants-in-elgn-2112-phase-3-trial daily 0.8 https://clival.com/news/halia-completes-phase-2a-trial-enrollment-for-mds-drug-ht-6184 daily 0.8 https://clival.com/news/futureceuticals-vitalign-boosts-cellular-health-immunity daily 0.8 https://clival.com/news/yoltech-gets-fda-ind-ok-for-yolt-101-to-treat-familial-hypercholesterolemia daily 0.8 https://clival.com/news/finerenone-sglt-2-inhibitor-combo-shows-positive-results-in-ckd-with-type-2-diabetes daily 0.8 https://clival.com/news/sobi-apellis-aspaveliempaveli-demonstrates-sustained-one-year-efficacy-for-kd daily 0.8 https://clival.com/news/astrivax-begins-clinical-development-of-avx70371-with-launch-it-technology daily 0.8 https://clival.com/news/phase-iii-pulmonary-fibrosis-drug-trial-fails daily 0.8 https://clival.com/news/yoltechs-ind-application-for-yolt-101-gets-approval-from-fda daily 0.8 https://clival.com/news/klotho-neuroscience-aims-to-enhance-longevity-via-gene-replacement daily 0.8 https://clival.com/news/acurx-pharma-presents-dna-pol-iiic-inhibitor-findings-at-faseb-conference daily 0.8 https://clival.com/news/vivavision-gets-positive-fda-comments-for-type-c-meeting-regarding-vvn461ld-for-post-operative-infalmmation daily 0.8 https://clival.com/news/eluminex-biosciences-announces-phase-1b-results-for-eb-105-in-patients-with-dme daily 0.8 https://clival.com/news/nosopharm-brings-antibiotic-one-step-closer-to-clinical-development daily 0.8 https://clival.com/news/bayer-seeks-us-fda-ema-marketing-approval-for-finerenone-to-treat-chronic-kidney-disease-and-type-2-diabetes daily 0.8 https://clival.com/news/patanjalis-coronil-has-no-regulatory-approvals-ima daily 0.8 https://clival.com/news/hemab-therapeutics-to-present-clinical-and-preclinical-data-in-the-isth-2025-congress daily 0.8 https://clival.com/news/vanda-pharmaceuticals-announces-first-patient-dosed-in-a-trial-evaluating-vca-894a daily 0.8 https://clival.com/news/sanofi-presents-positive-results-from-discover-phase-4-study-of-dupixent daily 0.8 https://clival.com/news/bexorg-biohaven-collaborate-on-ai-driven-cns-drug-innovation daily 0.8 https://clival.com/news/nuevocor-receives-fda-clearance-for-ind-application-of-nvc-001-for-dialted-cardiomyopathy daily 0.8 https://clival.com/news/novartis-fabhalta-shows-meaningful-results-in-haemoglobin-in-new-population-of-patients-with-pnh daily 0.8 https://clival.com/news/bioarctic-to-initiate-next-cohorts-in-exidavnemab-phase-2a-study-after-positive-safety-review daily 0.8 https://clival.com/news/novavaxs-covid-19-influenza-vaccines-show-strong-phase-3-results daily 0.8 https://clival.com/news/keymed-biosciences-announces-latest-results-from-cm336-clinical-trial daily 0.8 https://clival.com/news/merck-initiates-mobilize-1-phase-3-study-evaluating-dengue-vaccine-candidate-v181 daily 0.8 https://clival.com/news/bristol-myers-squibb-announces-positive-phase-3-poetyk-psa-1-trial-results daily 0.8 https://clival.com/news/vaxarts-2nd-generation-vaccine-technology-shows-greater-antibody-response daily 0.8 https://clival.com/news/merry-life-launches-global-phase-ii-trial-of-tml-6-for-therapy-of-alzheimers-disease daily 0.8 https://clival.com/news/telomir-1-boosts-organ-recovery-in-wilsons-disease-preclinical-study daily 0.8 https://clival.com/news/roche-to-advance-prasinezumab-into-phase-iii-development-for-early-stage-parkinsons-disease daily 0.8 https://clival.com/news/halia-therapeutics-completes-first-in-human-phase-1-study-of-ht-4253 daily 0.8 https://clival.com/news/clover-begins-phase-i-trial-for-rsv-hmpv-piv3-combo-vaccine-candidates daily 0.8 https://clival.com/news/everest-phase-4-study-of-dupixent-shows-positive-reults-over-xolair daily 0.8 https://clival.com/news/ascletis-doses-first-participants-in-us-phase-i-trial-of-asc50-an-oral-il-17-inhibitor-for-psoriasis daily 0.8 https://clival.com/news/emory-micron-start-first-human-trial-of-rotavirus-vaccine-via-dissolvable-microneedle-patch daily 0.8 https://clival.com/news/skyhawk-therapeutics-announces-sky-0515-dosing-in-phase-23-falcon-hd-trial daily 0.8 https://clival.com/news/innovent-completes-first-patient-dosing-in-seventh-phase-3-trial-glory-osa-of-mazdutide daily 0.8 https://clival.com/news/abbvie-atogepant-outperforms-topiramate-in-phase-3-migraine-prevention-study daily 0.8 https://clival.com/news/dyne-therapeutics-gets-btd-for-dyne-101-in-myotonic-dystrophy-type-1-dm1 daily 0.8 https://clival.com/news/scholar-rock-drug-preserves-muscle-in-obesity-trial daily 0.8 https://clival.com/news/camurus-announces-positive-results-from-positano-phase-2b-study-of-octreotide-sc-depot daily 0.8 https://clival.com/news/eccogene-enters-exclusive-license-agreement-with-astrazeneca-to-develop-and-commercialize-small-molecule-glp-1-receptor-agonist-ecc5004-for-cardiometabolic-diseases daily 0.8 https://clival.com/news/lillys-insulin-efsitora-alfa-demonstrated-a1c-reduction-and-a-safety-profile-across-3-phase daily 0.8 https://clival.com/news/fda-clears-pearlmatrix-as-first-lumbar-fusion-accelerator daily 0.8 https://clival.com/news/mifepristone-shown-to-reduce-a1c-in-patients-with-difficult-to-control-type-2-diabetes-and-hypercortisolism daily 0.8 https://clival.com/news/zealand-pharma-announces-positive-topline-results-from-28-week-phase-1b-trial-for-dapiglutide daily 0.8 https://clival.com/news/cumberlands-phase-2-trial-shows-ifetroban-improves-heart-function-in-dmd-patients daily 0.8 https://clival.com/news/india-imposes-anti-dumping-duty-on-four-chinese-chemicals-this-month daily 0.8 https://clival.com/news/chugai-pharma-presents-positive-data-from-nxtage-phase-iii-study-of-nxt007 daily 0.8 https://clival.com/news/mercks-phase-3-hyperion-study-of-winrevair-meets-primary-endpoint-for-pah daily 0.8 https://clival.com/news/spinogenix-announces-full-enrollment-in-its-phase-2-trial-evaluating-spg302 daily 0.8 https://clival.com/news/viking-therapeutics-initiates-vanquish-phase-3-obesity-clinical-programme-with-glp-1gip-agonist-vk2735 daily 0.8 https://clival.com/news/amgen-announces-phase-2-obesity-study-results-of-maritide daily 0.8 https://clival.com/news/stuart-therapeutics-gives-initial-results-of-phase-iii-clinical-trial-for-st-100-ophthalmic-solution daily 0.8 https://clival.com/news/pfizers-hympavzi-shows-good-results-in-phase-3-basis-study daily 0.8 https://clival.com/news/aspire-biopharma-completes-phase-1-enrollment-for-its-fast-acting-sublingual-aspirin daily 0.8 https://clival.com/news/novartis-completes-acquisition-of-regulus-therapeutics daily 0.8 https://clival.com/news/lipocine-announces-first-patient-dosed-in-phase-3-clinical-trial-for-lpcn-1154-in-postpartum-depression daily 0.8 https://clival.com/news/alebunds-ap301-hits-phase-3-goal-for-serum-phosphorus-control-in-dialysis daily 0.8 https://clival.com/news/edgewise-therapeutics-announces-positive-results-on-sevasemten-programme-for-becker-and-duchenne-muscular-dystrophies daily 0.8 https://clival.com/news/galderma-starts-phase-2-trials-of-nemolizumab-for-systemic-sclerosis daily 0.8 https://clival.com/news/argenx-advances-clinical-development-of-argx-119-in-congenital-myasthenic-syndromes daily 0.8 https://clival.com/news/bavarian-nordic-initiates-clinical-trials-of-mpox-vaccine-in-infants-and-pregnant-women daily 0.8 https://clival.com/news/gemz-phase-3-study-of-fenfluramine-shows-positive-response-states-ucb daily 0.8 https://clival.com/news/nicox-announces-last-patient-completes-the-ncx-470-denali-phase-3-clinical-trial daily 0.8 https://clival.com/news/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-trial-evaluating-nbip-01435 daily 0.8 https://clival.com/news/actinogen-confirms-100th-participant-in-xanamia-phase-2b3-alzheimers-disease-trial-and-interim-analysis-timeline daily 0.8 https://clival.com/news/atai-life-sciences-beckley-psytech-announce-positive-results-from-phase-2b-study-of-bpl-003 daily 0.8 https://clival.com/news/klotho-neurosciences-advances-manufacturing-of-als-gene-therapy daily 0.8 https://clival.com/news/moderna-reports-positive-results-from-phase-3-efficacy-study-of-p304-for-seasonal-influenza-vaccine daily 0.8 https://clival.com/news/gain-therapeutics-completes-enrollment-in-phase-1b-study-to-evaluate-gt-02287-in-pd daily 0.8 https://clival.com/news/novartis-provides-update-on-phase-iii-gcaptain-study-of-cosentyx-in-giant-cell-arteritis-gca daily 0.8 https://clival.com/news/repronovo-announces-enrollment-in-us-phase-2-trial-of-rpn-001-to-treat-male-infertility daily 0.8 https://clival.com/news/everest-reports-positive-early-data-for-ever001-in-primary-membranous-nephropathy daily 0.8 https://clival.com/news/ascletis-begins-dosing-in-us-phase-iia-trial-of-oral-glp-1r-agonist-asc30 daily 0.8 https://clival.com/news/clearmind-gets-irb-approval-for-cmnd-100-alcohol-use-disorder-trial daily 0.8 https://clival.com/news/nuravax-imm-to-present-alzheimers-vaccine-data-at-ctad-2025 daily 0.8 https://clival.com/news/mind-lab-pros-cognitive-benefits-confirmed-in-a-uk-human-trial daily 0.8 https://clival.com/news/zhimeng-biopharmas-kcnq23-opener-cleared-for-als-phase-23-trial daily 0.8 https://clival.com/news/fda-accepts-mercks-nda-for-doravirineislatravir-to-treat-suppressed-hiv-1 daily 0.8 https://clival.com/news/verified-clinical-trials-starts-in-japan-with-mrj-jacic-to-prevent-duplicate-trial-subjects daily 0.8 https://clival.com/news/maplight-initiates-phase-2-zephyr-study-of-ml-007c-ma-to-treat-schizophrenia daily 0.8 https://clival.com/news/regenxbio-reports-preclinical-benefits-of-rgx-202-gene-therapy-for-duchenne daily 0.8 https://clival.com/news/ultragenyx-mereo-biopharma-announce-ux143-phase-3-orbit-study-for-osteogenesis-imperfecta daily 0.8 https://clival.com/news/earendil-labs-announces-initiation-of-a-phase-1-study-of-a-half-life-extended-novel-anti-tl1a-antibody daily 0.8 https://clival.com/news/cogent-biosciences-reports-positive-summit-trial-results-for-bezuclastinib daily 0.8 https://clival.com/news/osivax-publishes-phase-2a-results-of-ovx836-004-study daily 0.8 https://clival.com/news/crinetics-to-present-long-term-palsonify-data-at-endo-2025 daily 0.8 https://clival.com/news/abinopharm-and-egt-synbio-report-positive-clinical-results-for-oral-drergo-in-skin-health daily 0.8 https://clival.com/news/apogee-therapeutics-reports-positive-phase-2-results-for-atopic-dermatitis-drug daily 0.8 https://clival.com/news/bluerock-announces-first-patient-receives-investigational-therapy-in-clarico-phase-12a-trial daily 0.8 https://clival.com/news/revalesio-to-present-rns60-stroke-trial-data-at-snis-annual-meeting daily 0.8 https://clival.com/news/ascletis-completes-dosing-in-us-obesity-study-of-asc47-combined-with-semaglutide daily 0.8 https://clival.com/news/cerevance-to-present-data-of-kcnk13-inhibitor-at-alzheimers-association-international-conference-2025 daily 0.8 https://clival.com/news/palatin-announces-positive-preclinical-efficacy-data-for-oral-mc4r-agonist-pl7737-in-animal-model-of-obesity daily 0.8 https://clival.com/news/jiangsu-recbio-receives-uae-approval-to-initiate-phase-iiiii-study-of-sequential-booster-vaccination-for-covid-19-vaccine-recov daily 0.8 https://clival.com/news/anselamimab-misses-primary-endpoint-in-astrazenecas-phase-iii-cares-trial-for-al-amyloidosis daily 0.8 https://clival.com/news/takeda-announces-positive-results-from-two-pivotal-phase-3-studies-of-oveporexton-in-narcolepsy-type-1 daily 0.8 https://clival.com/news/merck-to-initiate-expressive-phase-3-trials-of-mk-8527-an-investigational-once-monthly-hiv-prevention-pill daily 0.8 https://clival.com/news/nanoviricides-designs-trial-protocol-for-phase-ii-mpox-clade-ia-with-a-novel-drug-nv-387-for-treating-mpox-disease daily 0.8 https://clival.com/news/baxdrostat-meets-primary-all-secondary-endpoints-in-baxhtn-phase-iii-trial-for-hypertension daily 0.8 https://clival.com/news/fda-halts-sarepta-therapeutics-elevidys-trials-for-multiple-gene-therapy-products-following-3-deaths daily 0.8 https://clival.com/news/sk-bioscience-seeks-korean-regulatory-approval-to-initiate-phase-12-trial-of-nbp607b daily 0.8 https://clival.com/news/us-fda-lifts-clinical-hold-on-portola-phase-2a-trial-of-kezar-life-sciences-for-evaluating-zetomipzomib daily 0.8 https://clival.com/news/viatris-provides-update-on-phase-3-study-of-mr-139-for-blepharitis daily 0.8 https://clival.com/news/rocket-pharma-gets-fda-regenerative-medicine-advanced-therapy-designation-for-rp-a601-gene-therapy daily 0.8 https://clival.com/news/roche-provides-update-on-astegolimab-in-chronic-obstructive-pulmonary-disease daily 0.8 https://clival.com/news/sun-pharma-announces-positive-phase-3-results-evaluating-tildrakizumab-100-mg-in-active-psoriatic-arthritis daily 0.8 https://clival.com/news/keros-begins-patient-dosing-in-phase-3-renew-trial-of-elritercept-for-mds daily 0.8 https://clival.com/news/ausperbio-receives-china-cde-clearance-to-advance-ahb-137-into-phase-iii-clinical-trial-for-chronic-hepatitis-b daily 0.8 https://clival.com/news/ocugen-doses-first-patient-in-phase-23-gardian3-trial-for-stargardt-disease-gene-therapy daily 0.8 https://clival.com/news/ausperbio-gets-china-cde-clearance-to-initiate-phase-iii-clinical-trial-of-ahb-137-for-chronic-hepatitis-b daily 0.8 https://clival.com/news/hillhurst-biopharmaceuticals-doses-first-subject-in-phase-2a-clinical-trial-of-hbi-002-a-novel-therapy-for-sickle-cell-disease daily 0.8 https://clival.com/news/cinainu-shows-promise-for-pediatric-alopecia-areata-in-landmark-raainbow-trial daily 0.8 https://clival.com/news/abivaxs-obefazimod-achieves-primary-endpoint-in-two-global-phase-3-trials-for-ulcerative-colitis daily 0.8 https://clival.com/news/gefurulimab-meets-all-endpoints-in-phase-iii-global-trial-for-generalised-myasthenia-gravis daily 0.8 https://clival.com/news/kiora-pharmaceuticals-secures-us-patent-for-kio-104-advancing-treatment-of-ocular-inflammatory-diseases daily 0.8 https://clival.com/news/shanton-pharmas-sap-001-receives-fda-fast-track-designation-for-refractory-gout daily 0.8 https://clival.com/news/ab-science-begins-confirmatory-phase-3-study-of-masitinib-for-als-in-europe-and-us daily 0.8 https://clival.com/news/ascletis-doses-first-patients-in-us-phase-iia-trial-of-asc30-for-obesity daily 0.8 https://clival.com/news/roche-unveils-new-alzheimers-research-at-aaic-across-portfolios daily 0.8 https://clival.com/news/south-rampart-srp-001-shows-central-non-toxic-pain-relief-in-study daily 0.8 https://clival.com/news/avidity-completes-phase-3-harbor-trial-enrollment-for-dm1-therapy daily 0.8 https://clival.com/news/bristol-myers-squibb-and-bain-capital-launch-new-biopharma-company-for-autoimmune-drug-innovation daily 0.8 https://clival.com/news/genethon-begins-phase-3-trials-of-gene-therapy-for-duchenne-muscular-dystrophy daily 0.8 https://clival.com/news/alfasigma-reports-positive-phase-3-results-for-filgotinib-in-axial-spondyloarthritis daily 0.8 https://clival.com/news/serina-therapeutics-advances-once-weekly-injectable-for-tardive-dyskinesia daily 0.8 https://clival.com/news/mounjaro-vs-trulicity-eli-lillys-landmark-diabetes-study-reveals-promising-results daily 0.8 https://clival.com/news/novavax-begins-phase-2-trial-for-covid-19-influenza-combination-and-stand-alone-influenza-vaccine-candidates daily 0.8 https://clival.com/news/aclaris-reports-strong-phase-2a-results-for-ati-2138-in-atopic-dermatitis daily 0.8 https://clival.com/news/raytone-biotech-doses-first-patient-in-clinical-trial-for-dry-eye-therapy-rtp-008 daily 0.8 https://clival.com/news/ouro-medicines-takes-bold-step-with-om336 daily 0.8 https://clival.com/news/legacy-healthcare-gets-pmda-green-light-for-phase-3-trial-of-cinainu-in-japan daily 0.8 https://clival.com/news/ascletis-pharma-completes-enrollment-for-phase-iia-study-of-oral-glp-1r-agonist-asc30-in-obesity-treatment daily 0.8 https://clival.com/news/innovent-biologics-secures-fda-nod-to-begin-phase-1-trials-for-oral-glp-1-agonist daily 0.8 https://clival.com/news/eth47-the-asthma-drug-that-could-redefine-respiratory-care daily 0.8 https://clival.com/news/metavia-extends-phase-1-study-of-obesity-drug-da-1726-to-8-weeks daily 0.8 https://clival.com/news/sublingual-minoxidil-enters-phase-3-trials-a-potential-game-changer-for-male-hair-loss daily 0.8 https://clival.com/news/eli-lillys-orforglipron-hits-phase-3-milestone-big-weight-loss-no-injections-required daily 0.8 https://clival.com/news/arch-biopartners-reaches-key-milestone-in-cardiac-surgery-kidney-injury-trial daily 0.8 https://clival.com/news/avobis-bio-seeks-rmat-designation-for-avb-114-after-positive-phase-ii-trial-results daily 0.8 https://clival.com/news/labconnect-partners-with-kits4life-to-reduce-clinical-trial-waste-and-boost-global-health daily 0.8 https://clival.com/news/phase-iii-win-for-boehringer-ingelheim-click-therapeutics-in-schizophrenia-digital-therapy daily 0.8 https://clival.com/news/novartis-hits-phase-iii-milestone-with-ianalumab-in-sjgrens-disease daily 0.8 https://clival.com/news/regenxbio-and-abbvie-advance-sura-vec-for-diabetic-retinopathy daily 0.8 https://clival.com/news/assembly-biosciences-reports-positive-interim-phase-1b-results-for-abi-5366-in-recurrent-genital-herpes daily 0.8 https://clival.com/news/fopecipidcgi-meet-strengthens-industry-regulator-collaboration-in-indian-pharma daily 0.8 https://clival.com/news/zydus-lifesciences-secures-usfda-approval-for-diltiazem-hydrochloride-tablets daily 0.8 https://clival.com/news/gc-biopharma-study-confirms-stability-of-alyglo-ivig-after-pooling daily 0.8 https://clival.com/news/ami-pharms-ayp-101-enters-phase-3-a-gentler-smarter-way-to-lose-the-double-chin daily 0.8 https://clival.com/news/biogen-and-stoke-kick-off-global-phase-3-emperor-study-for-dravet-syndrome-treatment daily 0.8 https://clival.com/news/abcentra-kicks-off-phase-2b-trial-for-game-changing-heart-inflammation-drug daily 0.8 https://clival.com/news/novartis-reports-positive-phase-iii-results-for-ianalumab-in-immune-thrombocytopenia-itp daily 0.8 https://clival.com/news/navamedic-secures-final-approvals-for-parkinsons-therapy-launch-in-the-nordics daily 0.8 https://clival.com/news/an2-therapeutics-hits-first-milestone-in-fight-against-chagas-disease daily 0.8 https://clival.com/news/ascletis-pharma-shows-strong-preclinical-data-for-obesity-drug-combo daily 0.8 https://clival.com/news/tonix-wins-fda-approval-for-tonmya-the-first-new-fibromyalgia-drug-in-15-years daily 0.8 https://clival.com/news/qilian-international-holding-group-limited-receives-approval-for-the-sale-of-its-newly-developed-nitrofurantoin-enteric-coated-tablets daily 0.8 https://clival.com/news/a-glimpse-of-hope-in-als-what-radicava-ors-could-mean-for-patients daily 0.8 https://clival.com/news/viking-therapeutics-just-dropped-phase-2-results-and-theyre-big daily 0.8 https://clival.com/news/enlivexs-allocetra-shows-promise-in-knee-osteoarthritis-trial daily 0.8 https://clival.com/news/arthrosi-therapeutics-reaches-full-enrollment-in-second-pivotal-phase-3-gout-trial daily 0.8 https://clival.com/news/jazz-saniona-a-new-bet-on-epilepsy-treatment daily 0.8 https://clival.com/news/biomed-x-and-novo-nordisk-team-up-to-transform-oral-peptide-delivery daily 0.8 https://clival.com/news/dynavaxs-new-shingles-vaccine-candidate-shows-strong-results-against-shingrix daily 0.8 https://clival.com/news/allos-pharma-advances-arbaclofen-program-for-autism-and-fragile-x daily 0.8 https://clival.com/news/keros-therapeutics-wins-fda-orphan-drug-designation-for-ker-065-in-duchenne-muscular-dystrophy daily 0.8 https://clival.com/news/492m-boost-for-alzheimers-research-lighthouse-pharmas-bold-bet-on-targeting-infection daily 0.8 https://clival.com/news/keros-therapeutics-secures-orphan-drug-designation-for-dmd-therapy daily 0.8 https://clival.com/news/terns-pharmaceuticals-prepares-investors-for-key-tern-701-data daily 0.8 https://clival.com/news/alkermes-to-showcase-phase-2-vibrance-1-data-on-alixorexton-at-world-sleep-congress-2025 daily 0.8 https://clival.com/news/givinostat-shows-long-term-benefits-for-duchenne-muscular-dystrophy daily 0.8 https://clival.com/news/argenx-reports-positive-phase-3-results-for-vyvgart-in-seronegative-gmg daily 0.8 https://clival.com/news/theravance-completes-enrollment-in-phase-3-cypress-trial-for-msa-patients-with-noh daily 0.8 https://clival.com/news/eli-lillys-oral-glp-1-pill-shows-strong-phase-3-results daily 0.8 https://clival.com/news/ascletis-receives-ind-approval-of-oral-pd-l1-small-molecule-inhibitor-asc61-from-china-nmpa-for-treatment-of-advanced-solid-tumours daily 0.8 https://clival.com/news/ascletis-asc30-shows-strong-pk-data-and-weight-loss-benefits-in-phase-ib-study daily 0.8 https://clival.com/news/evommune-starts-phase-2b-trial-of-evo756-in-atopic-dermatitis daily 0.8 https://clival.com/news/pfizer-gets-us-fda-approval-for-abrysvo-vaccine-to-prevent-rsv-in-infants-through-active-immunization-of-pregnant-individuals-32-36-weeks-of-gestational-age daily 0.8 https://clival.com/news/bristol-myers-squibb-to-present-new-cardiovascular-data-at-esc-congress-2025 daily 0.8 https://clival.com/news/correctseqs-cs-101-marks-first-base-editing-treatment-for-sickle-cell-disease-in-china daily 0.8 https://clival.com/news/zydus-therapeutics-saroglitazar-hits-phase-3-milestone-in-pbc-trial daily 0.8 https://clival.com/news/merck-shares-mixed-results-for-verquvo-in-heart-failure-trials daily 0.8 https://clival.com/news/ami-pharms-ayp-101-shows-strong-phase-2-results-for-double-chin-reduction daily 0.8 https://clival.com/news/oslo-university-hospital-launches-phase-2-trial-of-ilb-in-als-for-2026 daily 0.8 https://clival.com/news/mercks-oral-pcsk9-inhibitor-shows-promise-in-phase-3-trial daily 0.8 https://clival.com/news/oculis-to-showcase-late-stage-pipeline-at-major-retina-and-ophthalmology-meetings daily 0.8 https://clival.com/news/baxdrostat-phase-iii-trial-delivers-breakthrough-in-hard-to-control-hypertension daily 0.8 https://clival.com/news/citryll-doses-first-patient-in-phase-iia-citydream-trial-of-cit-013-for-rheumatoid-arthritis daily 0.8 https://clival.com/news/sanofi-to-showcase-broad-dermatology-and-immunology-data-at-eadv-2025 daily 0.8 https://clival.com/news/cage-bios-cgb-500-shows-best-in-class-results-in-atopic-dermatitis-phase-2b-trial daily 0.8 https://clival.com/news/sanofis-amlitelimab-hits-key-endpoints-in-phase-3-atopic-dermatitis-trial daily 0.8 https://clival.com/news/al-s-pharma-reports-positive-phase-2-results-of-ap-101-in-als daily 0.8 https://clival.com/news/accro-bioscience-to-present-phase-ii-results-of-oral-tyk2jak1-inhibitor-ac-201-in-psoriasis-at-eadv-2025 daily 0.8 https://clival.com/news/medgenome-launches-varminer-to-detect-genetic-variants-for-rare-diseases-and-inherited-cancers daily 0.8 https://clival.com/news/brazils-health-ministry-approves-china-sinovac-shot-for-some-children daily 0.8 https://clival.com/news/chinas-cansino-bio-advances-covid-19-vaccine-into-phase-2-on-preliminary-safety-data daily 0.8 https://clival.com/news/mankind-pharma-gets-cdsco-nod-for-first-in-human-trial-of-novel-jak-1-inhibitor daily 0.8 https://clival.com/news/pfizer-and-biontech-report-positive-phase-3-results-for-lp81-adapted-covid-19-vaccine daily 0.8 https://clival.com/news/fda-expands-takedas-vonvendi-approval-to-broader-range-of-von-willebrand-disease-patients daily 0.8 https://clival.com/news/novavax-announces-us-fda-vrbpa-committee-to-review-its-nvx-cov2373-covid-19-vaccine daily 0.8 https://clival.com/news/amgen-and-kyowa-kirin-report-positive-one-year-data-on-rocatinlimab-in-atopic-dermatitis daily 0.8 https://clival.com/news/takeda-reports-breakthrough-phase-3-results-for-oveporexton-in-narcolepsy-type-1 daily 0.8 https://clival.com/news/bayer-launches-colab-adventure-to-connect-biotech-startups-with-global-venture-capital daily 0.8 https://clival.com/news/us-fda-accepts-bla-for-sobis-nanoecapsulated-sirolimus-plus-pegadricase-for-patients-with-uncontrolled-gout daily 0.8 https://clival.com/news/alchemab-initiates-phase-1-trial-of-atlx-1282-and-announces-series-a-financing-extension daily 0.8 https://clival.com/news/endo-presents-plantar-fibromatosis-and-plantar-fasciitis-data-at-the-american-orthopaedic-foot-ankle-society-annual-meeting daily 0.8 https://clival.com/news/scipher-medicine-enters-into-partnership-with-maxymune-therapeutics-to-advance-autoimmune-and-inflammatory-disease-research daily 0.8 https://clival.com/news/merck-announces-positive-results-from-phase-3-stride-13-trial-of-capvaxive-to-treat-pneumococcal-disease daily 0.8 https://clival.com/news/tevas-emrusolmin-receives-us-fda-fast-track-designation-for-multiple-system-atrophy daily 0.8 https://clival.com/news/philips-and-masimo-renew-strategic-partnership-to-advance-next-generation-patient-monitoring daily 0.8 https://clival.com/news/seaport-therapeutics-doses-first-participant-in-phase-1-study-of-glyphago-for-generalized-anxiety-disorder daily 0.8 https://clival.com/news/kodiak-sciences-reports-positive-phase-1b-apex-study-results-for-ksi-101-in-mesi daily 0.8 https://clival.com/news/amo-pharma-reports-long-term-safety-data-for-amo-02-in-congenital-and-childhood-onset-dm1 daily 0.8 https://clival.com/news/argo-biopharma-secures-ind-approval-for-phase-ii-trial-of-bw-40202-in-pnh daily 0.8 https://clival.com/news/astrazenecas-saphnelo-hits-key-milestone-in-subcutaneous-lupus-trial daily 0.8 https://clival.com/news/remegens-telitacicept-ole-data-selected-for-oral-presentation-at-aanem-2025 daily 0.8 https://clival.com/news/corestemchemon-presents-phase-3-alsummit-trial-results-of-neuronata-r-at-pactals-2025 daily 0.8 https://clival.com/news/ascletis-presents-phase-iii-results-of-denifanstat-for-acne-at-eadv-2025 daily 0.8 https://clival.com/news/magicrna-publishes-first-clinical-data-of-in-vivo-car-t-therapy-in-sle daily 0.8 https://clival.com/news/orukas-orka-001-shows-100-day-half-life-paving-way-for-once-yearly-psoriasis-treatment daily 0.8 https://clival.com/news/maplight-launches-phase-2-study-of-novel-m1m4-agonist-for-alzheimers-psychosis daily 0.8 https://clival.com/news/astrazenecas-phase-iii-resolute-trial-of-fasenra-in-copd-misses-primary-endpoint daily 0.8 https://clival.com/news/ascletis-reports-strong-results-for-asc47-in-combination-with-semaglutide-in-obesity-trial daily 0.8 https://clival.com/news/evommune-presents-positive-phase-2-data-for-evo756-in-chronic-inducible-urticariastrong-early-efficacy daily 0.8 https://clival.com/news/eu-approves-tryngolza-for-familial-chylomicronemia-syndrome daily 0.8 https://clival.com/news/bayer-advances-dual-therapies-for-parkinsons-disease daily 0.8 https://clival.com/news/gc-biopharma-files-ind-for-phase-1-trial-of-covid-19-mrna-vaccine-candidate-gc4006a daily 0.8 https://clival.com/news/ausperbio-completes-enrollment-in-two-phase-ii-trials-for-hepatitis-b-candidate-ahb-137 daily 0.8 https://clival.com/news/bluerock-launches-phase-iii-trial-of-bemdaneprocel-for-parkinsons-disease daily 0.8 https://clival.com/news/new-kinect-pro-analysis-shows-ingrezza-achieves-high-remission-rates-in-tardive-dyskinesia daily 0.8 https://clival.com/news/fda-extends-review-of-sanofis-tolebrutinib-for-progressive-multiple-sclerosis daily 0.8 https://clival.com/news/celecors-phase-3-trial-of-disaggpro-shows-positive-results daily 0.8 https://clival.com/news/sanofi-regeneron-announce-preliminary-results-from-phase-23-trial-of-kevzara-in-hospitalised-covid-19-patients daily 0.8 https://clival.com/news/triveni-bio-doses-first-patient-in-phase-2-trial-of-triv-509-for-atopic-dermatitis daily 0.8 https://clival.com/news/novartis-presents-new-long-term-data-on-kesimpta-ofatumumab-in-relapsing-multiple-sclerosis daily 0.8 https://clival.com/news/replicate-bioscience-publishes-eight-month-follow-up-data-for-srrna-rabies-vaccine-candidate-rbi-4000 daily 0.8 https://clival.com/news/hansa-biopharma-reports-positive-phase-3-results-for-imlifidase-in-highly-sensitized-kidney-transplant-patients daily 0.8 https://clival.com/news/casi-pharmaceuticals-announces-market-approval-of-cnct19-by-china-nmpa daily 0.8 https://clival.com/news/bambusa-therapeutics-hits-two-major-milestones-with-bbt001 daily 0.8 https://clival.com/news/fda-clears-path-for-youthbios-first-in-human-alzheimers-trial-with-yb002 daily 0.8 https://clival.com/news/vanda-pharmaceuticals-publishes-positive-phase-3-insomnia-data-for-hetlioz-in-plos-one daily 0.8 https://clival.com/news/aspen-neuroscience-launches-cohort-3-in-parkinsons-trial-with-commercial-ready-anpd001 daily 0.8 https://clival.com/news/abbvie-files-fda-submission-for-tavapadon-in-parkinsons-disease daily 0.8 https://clival.com/news/itf-therapeutics-presents-new-givinostat-data-in-duchenne-muscular-dystrophy-at-2025-nmsg-annual-meeting daily 0.8 https://clival.com/news/csl-vifor-and-travere-welcome-kdigo-2025-guidelines-for-iga-nephropathy-highlight-filspari daily 0.8 https://clival.com/news/chugai-obtains-japanese-approval-for-foundationone-liquid-cdx-cancer-genomic-profile-as-liquid-biopsy-test-for-cgp-to-treat-solid-tumors daily 0.8 https://clival.com/news/chemomab-announces-fda-clearance-of-investigational-new-drug-application-for-phase-2-clinical-trial-of-cm-101-in-patients-with-systemic-sclerosis daily 0.8 https://clival.com/news/basilea-secures-barda-support-for-novel-oral-antibiotic-development daily 0.8 https://clival.com/news/varmx-receives-rare-phase-1-waiver-in-japan-for-vmx-c001-advances-directly-to-global-phase-3 daily 0.8 https://clival.com/news/eli-lillys-kisunla-approved-in-eu-for-early-alzheimers daily 0.8 https://clival.com/news/altesa-biosciences-vapendavir-shows-promise-in-preventing-copd-flare-ups daily 0.8 https://clival.com/news/novo-nordisk-resubmits-bla-for-awiqli-insulin-icodec-once-weekly-basal-insulin daily 0.8 https://clival.com/news/gene-therapy-amt-130-shows-dramatic-slowing-of-huntingtons-disease daily 0.8 https://clival.com/news/coya-therapeutics-completes-patient-enrollment-in-frontotemporal-dementia-study daily 0.8 https://clival.com/news/vascarta-completes-phase-1-trial-of-vas-101-vasceptor-for-knee-osteoarthritis daily 0.8 https://clival.com/news/wuxi-junuo-to-present-latest-clinical-study-data-of-benoda-at-2022-asco-meeting daily 0.8 https://clival.com/news/chugai-seeks-japanese-approval-for-polatuzumab-vedotin-to-treat-rr-diffuse-large-b-cell-lymphoma daily 0.8 https://clival.com/news/allrock-bio-reports-positive-phase-1-results-for-first-in-class-oral-rock-inhibitor-roc-101-at-ers-2025 daily 0.8 https://clival.com/news/rapt-therapeutics-receives-fda-clearance-to-initiate-phase-2b-trial-of-rpt904-for-food-allergy daily 0.8 https://clival.com/news/clear-scientifics-cs-1103-receives-fda-fast-track-designation-for-acute-methamphetamine-intoxication daily 0.8 https://clival.com/news/anji-pharma-launches-phase-3-trial-for-anj900-to-treat-type-2-diabetes-patients-with-kidney-disease daily 0.8 https://clival.com/news/collplant-announces-positive-results-from-non-clinical-studies-of-its-photocurable-regenerative-dermal-and-soft-tissue-filler daily 0.8 https://clival.com/news/landmark-phase-3-trial-vesalius-cv-meets-primary-endpoints-in-a-cardiovascular-primary-prevention-study-of-12000-patients daily 0.8 https://clival.com/news/japans-mhlw-grants-orphan-drug-designation-to-vicore-pharmas-buloxibutid-to-treat-idiopathic-pulmonary-fibrosis daily 0.8 https://clival.com/news/henlius-novel-anti-pd-1-mab-hansizhuang-serplulimab-receives-nmpa-approval-for-the-treatment-of-sqnsclc daily 0.8 https://clival.com/news/sitryx-therapeutics-receives-fda-clearance-for-phase-1b-trial-of-syx-5219-in-atopic-dermatitis daily 0.8 https://clival.com/news/avobis-bios-avb-114-receives-fda-rmat-designation-for-crohns-perianal-fistulas daily 0.8 https://clival.com/news/who-highlights-urgent-gaps-in-antibacterial-rd-and-diagnostics daily 0.8 https://clival.com/news/draig-therapeutics-to-initiate-phase-2-study-of-dt-101-for-major-depressive-disorder-following-fda-ind-clearance daily 0.8 https://clival.com/news/myrtelle-presents-encouraging-interim-phase-12-data-for-gene-therapy-in-canavan-disease-at-2025-cell-gene-meeting-on-the-mesa daily 0.8 https://clival.com/news/neurocrine-biosciences-reports-3-year-data-showing-sustained-chorea-improvement-with-ingrezza-in-huntingtons-disease daily 0.8 https://clival.com/news/abbvie-reports-positive-phase-2-elate-trial-results-for-botox-in-essential-tremor daily 0.8 https://clival.com/news/avidity-biosciences-to-present-new-duchenne-muscular-dystrophy-data-at-2025-world-muscle-society-congress daily 0.8 https://clival.com/news/neurosense-therapeutics-reports-positive-phase-2b-biomarker-data-for-primec-in-alzheimers-disease daily 0.8 https://clival.com/news/alteogens-tergase-novel-recombinant-human-hyaluronidase-injection-shows-excellent-immunogenicity-profile daily 0.8 https://clival.com/news/positive-phase-iii-bax24-results-show-baxdrostat-significantly-lowers-24-hour-blood-pressure-in-treatment-resistant-hypertension daily 0.8 https://clival.com/news/neurizon-therapeutics-announces-fda-clearance-to-advance-nuz-001-in-als-platform-trial daily 0.8 https://clival.com/news/skye-bioscience-reports-topline-26-week-phase-2a-cbeyond-results-for-nimacimab-in-obesity daily 0.8 https://clival.com/news/eccogene-receives-fda-clearance-to-initiate-phase-2a-mosaic-trial-for-mash daily 0.8 https://clival.com/news/bayer-and-bluerock-report-positive-36-month-phase-i-data-for-bemdaneprocel-in-parkinsons-disease daily 0.8 https://clival.com/news/sequence-lifescience-enrolls-first-patient-in-clinical-trial-evaluating-placental-membrane-grafts-for-diabetic-foot-ulcers daily 0.8 https://clival.com/news/neurelis-to-present-new-pediatric-data-on-valtoco-diazepam-nasal-spray-at-54th-child-neurology-society-annual-meeting daily 0.8 https://clival.com/news/us-fda-approves-revised-label-for-jazz-pharmas-vyxeos-to-include-new-indication-to-treat-secondary-acute-myeloid-leukemia-in-pediatric-patients daily 0.8 https://clival.com/news/navia-life-care-launches-video-consultation-platform-for-covid-19-patients daily 0.8 https://clival.com/news/fda-authorizes-emalex-biosciences-expanded-access-program-for-ecopipam-in-tourette-syndrome daily 0.8 https://clival.com/news/jubilant-pharmova-expands-us-injectable-capacity-with-new-sterile-fill-finish-line daily 0.8 https://clival.com/news/klifo-expands-clinical-trial-supply-capabilities-with-new-copenhagen-facility daily 0.8 https://clival.com/news/changxi-pharmaceutical-teams-up-with-huadong-medicine-to-commercialize-cxg87-in-china daily 0.8 https://clival.com/news/jubilant-hollisterstier-llc-enters-into-cooperative-agreement-of-1496-mn-with-us-government-to-expand-critical-vaccine-manufacturing-capacity daily 0.8 https://clival.com/news/ascletis-pharma-selects-asc35-as-once-monthly-glp-1gip-dual-agonist-candidate-for-obesity-treatment daily 0.8 https://clival.com/news/dr-reddys-and-zydus-lifesciences-initiate-us-recalls-over-manufacturing-issues daily 0.8 https://clival.com/news/cidara-therapeutics-cd388-receives-fda-breakthrough-therapy-designation daily 0.8 https://clival.com/news/quotient-sciences-and-biorasi-partner-to-deliver-fully-integrated-early-phase-clinical-trial-solutions daily 0.8 https://clival.com/news/fda-approves-ide-for-avisi-technologies-visiplate-glaucoma-device-sapphire-trial-to-begin-in-the-us daily 0.8 https://clival.com/news/merck-presents-new-phase-3-data-for-investigational-two-drug-hiv-regimen-doravirineislatravir daily 0.8 https://clival.com/news/clover-biopharmaceuticals-reports-positive-early-data-for-combination-respiratory-vaccine-candidates daily 0.8 https://clival.com/news/boehringer-ingelheim-and-click-therapeutics-report-positive-phase-iii-results-for-ct-155-in-schizophrenia daily 0.8 https://clival.com/news/calcimedica-and-telperian-collaborate-to-apply-ai-in-auxora-clinical-trial-analysis daily 0.8 https://clival.com/news/akesos-il-17a-monoclonal-antibody-gumokimab-completion-of-patient-enrollment-in-phase-ii-clinical-trial-for-the-treatment-of-ankylosing-spondylitis daily 0.8 https://clival.com/news/china-nmpa-approves-ascletis-ind-application-for-asc42-to-conduct-clinical-trials-for-chronic-hepatitis-b-indication daily 0.8 https://clival.com/news/novartis-reports-positive-phase-iii-results-for-cosentyx-in-polymyalgia-rheumatica daily 0.8 https://clival.com/news/gsk-reports-positive-phase-iii-results-for-low-carbon-ventolin-inhaler daily 0.8 https://clival.com/news/fda-grants-fast-track-designation-to-annjis-aj201-for-kennedy-disease daily 0.8 https://clival.com/news/cage-bio-initiates-clinical-trial-for-dna-aptamer-therapy-in-vitiligo daily 0.8 https://clival.com/news/johnson-johnson-reports-positive-phase-2-results-for-nipocalimab-in-sjgrens-disease daily 0.8 https://clival.com/news/neurotronic-to-present-first-clinical-outcomes-for-multi-organ-denervation-in-type-2-diabetes-and-hypertension daily 0.8 https://clival.com/news/halia-therapeutics-receives-fda-orphan-drug-designation-for-ofirnoflast-in-myelodysplastic-syndromes daily 0.8 https://clival.com/news/medtronic-reports-three-year-data-confirming-durable-blood-pressure-reduction-with-symplicity-spyral-rdn-system daily 0.8 https://clival.com/news/secarna-pharmaceuticals-and-scenic-biotech-join-forces-to-develop-novel-oligonucleotide-therapies-for-severe-genetic-diseases daily 0.8 https://clival.com/news/ucb-reports-three-year-data-showing-sustained-efficacy-of-bimzelx-across-psoriatic-arthritis-and-axial-spondyloarthritis daily 0.8 https://clival.com/news/lilly-and-incyte-report-positive-one-year-results-for-baricitinib-in-adolescents-with-severe-alopecia-areata daily 0.8 https://clival.com/news/johnson-johnson-presents-52-week-phase-3-data-for-icotrokinra-in-plaque-psoriasis daily 0.8 https://clival.com/news/sahyadri-hospital-hadapsar-becomes-first-in-the-region-to-receive-infuze-certification daily 0.8 https://clival.com/news/eli-lilly-reports-positive-data-on-omvoh-in-ulcerative-colitis-patients daily 0.8 https://clival.com/news/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/us-fda-accepts-enzychem-lifesciences-ind-for-phase-2-trial-of-ec-18-to-treat-ards-due-to-covid-19 daily 0.8 https://clival.com/news/johnson-johnson-reports-96-week-data-showing-long-term-efficacy-of-tremfya-in-crohns-disease daily 0.8 https://clival.com/news/jupiter-endovascular-reports-positive-first-in-human-results-from-spirare-i-study-evaluating-vertex-pulmonary-embolectomy-system daily 0.8 https://clival.com/news/philips-expands-collaboration-with-nicolab-to-advance-ai-powered-stroke-care-in-india daily 0.8 https://clival.com/news/evotec-receives-25-million-milestone-payment-from-bristol-myers-squibb-for-progress-in-neuroscience-partnership daily 0.8 https://clival.com/news/cipla-to-acquire-100-stake-in-inzpera-healthsciences-from-tata-industries daily 0.8 https://clival.com/news/ascletis-selects-asc36-as-once-monthly-amylin-receptor-agonist-candidate-for-obesity-treatment daily 0.8 https://clival.com/news/alys-pharmaceuticals-doses-first-subject-in-phase-11b-trial-of-aly-301-a-mast-cellselective-c-kit-inhibitor-for-cold-urticaria daily 0.8 https://clival.com/news/spinogenix-reports-positive-phase-2a-results-for-als-drug-candidate-spg302 daily 0.8 https://clival.com/news/metavia-presents-positive-phase-1-and-preclinical-data-for-dual-agonist-da-1726-at-obesityweek-2025 daily 0.8 https://clival.com/news/valneva-reports-positive-phase-1-results-for-second-generation-zika-vaccine-candidate-vla1601 daily 0.8 https://clival.com/news/aldeyra-therapeutics-reports-positive-liver-function-results-for-adx-629-refocuses-pipeline-on-next-generation-rasp-modulators daily 0.8 https://clival.com/news/gefurulimab-meets-primary-and-secondary-endpoints-in-phase-iii-prevail-trial-for-generalised-myasthenia-gravis daily 0.8 https://clival.com/news/fda-grants-orphan-drug-designation-to-calico-and-abbvies-investigational-adpkd-therapy daily 0.8 https://clival.com/news/vesper-bio-reports-promising-phase-ibiia-results-for-first-oral-therapy-in-frontotemporal-dementia daily 0.8 https://clival.com/news/amgen-to-present-new-data-on-repatha-and-cardiovascular-portfolio-at-aha-2025 daily 0.8 https://clival.com/news/gc-biopharma-publishes-phase-2-results-of-worlds-first-recombinant-anthrax-vaccine-in-vaccine daily 0.8 https://clival.com/news/regenxbio-completes-enrollment-in-pivotal-duchenne-gene-therapy-trial-and-produces-first-commercial-batches-of-rgx-202 daily 0.8 https://clival.com/news/otsuka-pharmaceutical-secures-exclusive-rights-to-4d-molecular-therapeutics-gene-therapy-for-eye-diseases-in-asia-and-oceania daily 0.8 https://clival.com/news/ascletis-showcases-promising-data-from-obesity-drug-candidates-at-obesityweek-2025 daily 0.8 https://clival.com/news/engulf-study-demonstrates-strong-safety-and-efficacy-for-e2s-hlo-thrombectomy-system-in-pulmonary-embolism daily 0.8 https://clival.com/news/new-findings-on-transdermal-curcumin-gel-show-promise-in-treating-acute-pain-in-sickle-cell-disease daily 0.8 https://clival.com/news/jenscare-showcases-positive-clinical-outcomes-for-lux-valve-plus-jensclip-and-ken-valve-at-tct-2025 daily 0.8 https://clival.com/news/chemdiv-extends-cmc-collaboration-for-ratutrelvir-an-oral-covid-19-antiviral-advancing-to-phase-2 daily 0.8 https://clival.com/news/acurx-pharmaceuticals-highlights-new-data-on-ibezapolstats-microbiome-sparing-activity-at-idweek-2025 daily 0.8 https://clival.com/news/shanghai-zhimeng-begins-phase-23-trial-of-novel-potassium-channel-opener-for-als daily 0.8 https://clival.com/news/avant-technologies-and-sgaustria-announce-joint-venture-to-develop-next-generation-diabetes-therapies daily 0.8 https://clival.com/news/argo-biopharma-to-present-phase-i-data-for-sirna-therapy-bw-20805-at-acaai-2025 daily 0.8 https://clival.com/news/moberg-pharma-and-karo-healthcare-partner-for-european-launch-of-mob-015-terclara-under-the-lamisil-brand daily 0.8 https://clival.com/news/tenpoint-therapeutics-and-zhaoke-ophthalmology-announce-nda-filing-for-brimochol-pf-in-south-korea daily 0.8 https://clival.com/news/cresilon-gets-agreement-for-vetigel-with-veterinary-product-suppliers daily 0.8 https://clival.com/news/nda-for-new-second-line-indication-of-car-t-cell-therapy-product-yikaida-axicabtagene-ciloleucel-injection-approved daily 0.8 https://clival.com/news/dupixent-shows-positive-phase-3-results-in-allergic-fungal-rhinosinusitis-afrs daily 0.8 https://clival.com/news/gsk-to-showcase-advances-in-liver-disease-pipeline-at-aasld-2025 daily 0.8 https://clival.com/news/rona-therapeutics-presents-phase-1-data-for-rn0361-a-long-acting-apoc3-sirna-at-aha-2025 daily 0.8 https://clival.com/news/cordis-reports-positive-phase-3-data-from-selution-denovo-and-selution4isr-trials-at-tct-2025 daily 0.8 https://clival.com/news/gilead-reports-long-term-data-on-livdelzi-reinforcing-safety-and-efficacy-in-pbc daily 0.8 https://clival.com/news/roche-reports-positive-phase-iii-results-for-fenebrutinib-in-multiple-sclerosis daily 0.8 https://clival.com/news/takeda-reports-stable-kidney-function-at-96-weeks-in-phase-1b-study-of-mezagitamab-for-iga-nephropathy daily 0.8 https://clival.com/news/australian-tga-approves-key-label-updates-to-camurus-buvidal-to-treat-opioid-dependence daily 0.8 https://clival.com/news/novartis-ganlum-achieves-phase-iii-success-marking-potential-first-major-malaria-treatment-breakthrough-in-25-years daily 0.8 https://clival.com/news/spyglass-pharma-reports-positive-results-from-clinical-trials-of-bim-iol-system-for-glaucoma-and-ocular-hypertension daily 0.8 https://clival.com/news/ascletis-announces-co-formulation-of-once-monthly-peptides-asc36-and-asc35-for-obesity-treatment-ind-filing-planned-for-q2-2026 daily 0.8 https://clival.com/news/fresenius-kabi-issues-voluntary-us-recall-of-three-lots-of-famotidine-injection-due-to-endotoxin-concerns daily 0.8 https://clival.com/news/phase-3-trial-of-investigational-heart-attack-drug-zalunfiban-shows-positive-results daily 0.8 https://clival.com/news/dbv-technologies-completes-last-patient-visit-in-phase-3-vitesse-trial-of-viaskin-peanut-patch daily 0.8 https://clival.com/news/bristol-myers-squibb-johnson-johnson-halt-phase-3-librexia-acs-trial-after-interim-review daily 0.8 https://clival.com/news/akeso-receives-nmpa-approval-to-begin-clinical-trials-for-ak152-a-first-in-china-bispecific-alzheimers-antibody daily 0.8 https://clival.com/news/ema-recommends-approval-of-teizeild-teplizumab-to-delay-onset-of-type-1-diabetes daily 0.8 https://clival.com/news/transcon-cnp-shows-promising-week-52-results-in-achondroplasia-new-data-published-in-jama-pediatrics daily 0.8 https://clival.com/news/resolve-therapeutics-to-present-platform-and-clinical-progress-on-cell-free-nucleic-acid-targeting daily 0.8 https://clival.com/news/vanda-reports-positive-results-for-tradipitant-in-study-on-glp-1induced-nausea-and-vomiting daily 0.8 https://clival.com/news/mercks-winrevair-shows-promise-in-cpcph-due-to-hfpef-key-takeaways-from-the-cadence-trial daily 0.8 https://clival.com/news/creatine-hcl-shows-promise-for-menopause-symptoms-in-new-vireo-systems-trial daily 0.8 https://clival.com/news/mycovias-vivjoa-shows-sustained-96-week-protection-against-recurrent-yeast-infections daily 0.8 https://clival.com/news/fda-grants-fast-track-status-to-vs-041-a-novel-mmp-inhibitor-for-hfpef daily 0.8 https://clival.com/news/new-tb-trial-data-shows-sorfequiline-could-dramatically-shorten-treatment-time daily 0.8 https://clival.com/news/merck-announces-positive-phase-3-results-for-two-drug-hiv-regimen-doravirineislatravir daily 0.8 https://clival.com/news/viking-therapeutics-completes-enrollment-for-phase-3-vanquish-1-obesity-trial-of-vk2735 daily 0.8 https://clival.com/news/theravance-biopharma-announces-virtual-kol-event-ahead-of-key-phase-3-results-for-ampreloxetine-in-msa-related-noh daily 0.8 https://clival.com/news/eli-lilly-joins-the-1-trillion-club-how-weight-loss-drugs-powered-a-historic-rise daily 0.8 https://clival.com/news/fda-grants-first-ever-eua-for-treating-new-world-screwworm-in-cats-what-pet-owners-need-to-know daily 0.8 https://clival.com/news/novavax-announces-positive-results-from-phase-12-trial-of-its-covid-19-influenza-combination-vaccine-candidate daily 0.8 https://clival.com/news/pipe-307-misses-key-endpoints-in-rrms-what-contineums-phase-2-vista-trial-really-tells-us daily 0.8 https://clival.com/news/mesoblast-and-nihs-bmt-ctn-launch-pivotal-trial-for-ryoncil-in-severe-adult-agvhd daily 0.8 https://clival.com/news/merils-myval-thv-proves-its-strength-in-landmark-global-trial-one-year-results-reveal-comparable-efficacy-and-superior-valve-stability daily 0.8 https://clival.com/news/bayer-posts-positive-phase-iii-results-for-asundexian-in-stroke-prevention daily 0.8 https://clival.com/news/new-19m-dod-funded-trial-aims-to-improve-swallowing-in-early-parkinsons-patients daily 0.8 https://clival.com/news/novo-nordisks-alzheimers-trials-miss-primary-endpoints-but-signal-a-new-era-of-pathobiology-driven-treatments daily 0.8 https://clival.com/news/innocan-pharma-publishes-promising-new-research-on-long-acting-liposomal-cbd-for-chronic-pain daily 0.8 https://clival.com/news/gemmabios-next-gen-sma1-gene-therapy-cleared-for-clinical-trials-in-brazil daily 0.8 https://clival.com/news/cornell-launches-new-study-on-once-weekly-glp-1-therapy-to-tackle-feline-obesity daily 0.8 https://clival.com/news/viking-therapeutics-to-join-piper-sandlers-37th-annual-healthcare-conference daily 0.8 https://clival.com/news/bayer-posts-strong-phase-iii-results-for-asundexian-in-stroke-prevention daily 0.8 https://clival.com/news/otsuka-files-nda-for-centanafadine-a-first-in-class-adhd-treatment-targeting-three-neurotransmitters daily 0.8 https://clival.com/news/neurosense-secures-fda-clearance-to-launch-pivotal-phase-3-trial-of-primec-for-als daily 0.8 https://clival.com/news/lighthouse-pharmaceuticals-showcases-new-precision-alzheimers-trial-at-ctad-2025 daily 0.8 https://clival.com/news/chugais-port-delivery-system-hits-key-milestone-in-japan daily 0.8 https://clival.com/news/innovents-mazdutide-9-mg-moves-one-step-closer-to-approval-in-china daily 0.8 https://clival.com/news/novo-nordisks-amycretin-delivers-strong-phase-2-results-in-type-2-diabetes daily 0.8 https://clival.com/news/cytiva-and-veeda-lifesciences-launch-hcp-services-center-to-strengthen-indias-biologics-ecosystem daily 0.8 https://clival.com/news/ascletis-selects-asc37-as-its-first-oral-triple-agonist-for-obesity-treatment daily 0.8 https://clival.com/news/generatebiomedicines-advances-gb-0895-into-phase-3-a-new-benchmark-in-ai-designed-asthma-therapies daily 0.8 https://clival.com/news/abbvies-atogepant-hits-key-milestones-in-phase-3-eclipse-trial daily 0.8 https://clival.com/news/spinogenix-secures-inn-approval-for-tazbentetol-a-new-era-in-synaptic-regeneration daily 0.8 https://clival.com/news/emas-positive-pip-decision-clears-new-path-for-aobiomes-b244-in-atopic-dermatitis daily 0.8 https://clival.com/news/adc-therapeutics-to-share-new-data-on-lotis-7-trial-evaluating-zynlonta-glofitamab daily 0.8 https://clival.com/news/fda-expands-dosing-options-for-omlyclo-what-the-new-300-mg-prefilled-syringe-means-for-patients daily 0.8 https://clival.com/news/recross-cardio-achieves-first-clinical-implantation-in-protea-pfo-study daily 0.8 https://clival.com/news/hoth-therapeutics-shares-major-pipeline-updates-whats-moving-whats-next daily 0.8 https://clival.com/news/als-association-awards-major-2025-grants-to-accelerate-early-stage-clinical-trials daily 0.8 https://clival.com/news/rentschler-biopharma-coriolis-pharma-announce-strategic-collaboration-to-deliver-end-to-end-biologics-development daily 0.8 https://clival.com/news/ionis-pharmaceuticals-secures-fda-breakthrough-therapy-designation-for-zilganersen-in-alexander-disease daily 0.8 https://clival.com/news/roche-reports-three-year-survival-gains-with-columvi-combo-in-relapsed-dlbcl daily 0.8 https://clival.com/news/askbios-gene-therapy-programs-earn-japans-sakigake-designation-what-it-means-for-parkinsons-and-heart-failure-treatment daily 0.8 https://clival.com/news/arrowhead-begins-phase-12a-trial-for-aro-mapt-a-new-rnai-therapy-targeting-alzheimers-disease daily 0.8 https://clival.com/news/pfizer-secures-global-rights-to-fosun-pharmas-oral-glp-1-program daily 0.8 https://clival.com/news/oral-semaglutide-shows-promising-weight-loss-and-heart-health-benefits-new-data-from-obesity-week-2025 daily 0.8 https://clival.com/news/scienture-and-blinkrx-partner-to-expand-access-to-arbli-the-first-ready-to-use-oral-losartan-suspension daily 0.8 https://clival.com/news/novo-nordisk-launches-ozempic-in-india-for-type-2-diabetes-care daily 0.8 https://clival.com/news/idma-urges-fssai-to-delink-foscos-licensing-from-product-details-submission daily 0.8 https://clival.com/news/dr-reddys-to-launch-anti-covid-drug-molnupiravir-at-rs-35-per-capsule daily 0.8 https://clival.com/news/hetero-launches-patient-compliant-pack-of-favivir-800200-for-covid-19-treatment daily 0.8 https://clival.com/news/argenx-permanently-grounds-studies-of-high-flying-vyvgart-in-thyroid-eye-disease daily 0.8 https://clival.com/news/novos-oral-semaglutide-edges-out-cagrisema-lillys-orforglipron-as-pcps-most-anticipated-obesity-med daily 0.8 https://clival.com/news/tevas-ophthalmology-biosimilar-ongavia-to-treat-age-related-macular-degeneration-receives-uk-mhra-approval daily 0.8 https://clival.com/news/china-nmpa-accepts-everest-medicines-ind-application-for-zetomipzomib-to-treat-a-range-of-immune-mediated-disorders daily 0.8 https://clival.com/news/bristol-myers-squibb-acceleron-announce-ec-approves-reblozyl-to-treat-transfusion-dependent-anemia-in-adult-with-mds-or-beta-thalassemia daily 0.8 https://clival.com/news/ascletis-begins-patient-dosing-in-phase-i-trial-of-asc42-to-treat-chronic-hepatitis-b-in-china daily 0.8 https://clival.com/news/glenmark-gets-usfda-nod-for-generic-lung-cancer-drug daily 0.8 https://clival.com/news/tempramed-secures-new-south-korea-patent-for-vivi-box-medication-storage-system daily 0.8 https://clival.com/news/gilead-moves-closer-to-filing-novel-hiv-combo-after-second-phase-3-win daily 0.8 https://clival.com/news/chugai-seeks-japanese-approval-for-crovalimab-to-treat-paroxysmal-nocturnal-hemoglobinuria daily 0.8 https://clival.com/news/hansa-biopharmas-imlifidase-stumbles-in-late-stage-anti-gbm-trial daily 0.8 https://clival.com/news/ionis-kicks-off-phase-3-angelman-syndrome-trial-with-public-awareness-push daily 0.8 https://clival.com/news/sandboxaq-and-maplight-therapeutics-team-up-to-develop-first-in-class-cns-therapies daily 0.8 https://clival.com/news/hyperfine-secures-cdsco-approval-to-launch-ai-powered-portable-mri-system-in-india daily 0.8 https://clival.com/news/fosun-pharma-inks-agreement-with-biontech-for-covid-19-vaccine-supply-in-china daily 0.8 https://clival.com/news/redhill-biopharma-gets-dsmb-recommendation-to-continue-phase-23-covid-19-study-of-opaganib daily 0.8 https://clival.com/news/gsk-sanofi-begin-phase-2-study-of-adjuvanted-recombinant-protein-based-covid-19-vaccine-candidate daily 0.8 https://clival.com/news/indian-pharma-backs-us-fdas-new-safety-reporting-guidance-for-babe-studies daily 0.8 https://clival.com/news/thermo-fisher-launches-global-real-world-registry-for-alzheimers-disease-research daily 0.8 https://clival.com/news/gc-biopharma-secures-south-korea-ind-approval-for-phase-1-mrna-covid-19-vaccine-trial daily 0.8 https://clival.com/news/emcure-launches-poviztra-a-new-semaglutide-option-for-weight-management-in-india daily 0.8 https://clival.com/news/ipsens-phase-ii-falkon-trial-fails-to-meet-primary-endpoint-in-fop daily 0.8 https://clival.com/news/novavax-covid-19-vaccine-nuvaxovid-receives-manufacturing-and-marketing-approval-from-korean-ministry-of-food-and-drug-safety-as-an-adult-booster daily 0.8 https://clival.com/news/ausperbio-completes-patient-enrollment-in-phase-iii-aushine-study-of-ahb-137-for-chronic-hepatitis-b daily 0.8 https://clival.com/news/sanofi-and-regeneron-receives-japanese-marketing-approval-for-dupixent-to-treat-bronchial-asthma-in-children-aged-6-to-11-years daily 0.8 https://clival.com/news/maharashtra-fda-approves-compensation-of-rs25-lakh-each-to-48-jj-faulty-hip-implant-affected-patients daily 0.8 https://clival.com/news/blue-lake-biotechnology-begins-patient-dosing-in-phase-1-trial-of-blb-201-intranasal-rsv-vaccine daily 0.8 https://clival.com/news/akesos-pcsk9-monoclonal-antibody-ebronucimab-early-completion-of-patient-enrollment-in-a-phase-iii-clinical-trial-for-primary-hypercholesterolemia-and-mixed-hyperlipidemia daily 0.8 https://clival.com/news/morepen-labs-gets-us-fda-approval-for-anti-allergy-drug-fexofinadine-hydrochloride daily 0.8 https://clival.com/news/mabwell-secures-us-fda-ind-clearance-for-anti-st2-antibody-in-copd daily 0.8 https://clival.com/news/caliway-files-us-ind-for-phase-2-study-combining-cbl-514-with-tirzepatide-in-obesity daily 0.8 https://clival.com/news/revolo-bio-gets-uk-mhra-nod-for-two-phase-2-trials-of-1805-in-autoimmune-diseases daily 0.8 https://clival.com/news/pharmakure-seeks-uk-mhra-nod-to-begin-phase-2a-trial-of-pk051-in-patients-with-mild-cognitive-impairment daily 0.8 https://clival.com/news/johnson-johnson-halts-development-of-jnj-5939-for-atopic-dermatitis daily 0.8 https://clival.com/news/irlab-secures-approvals-for-phase-ib-study-of-first-in-class-apathy-drug-in-parkinsons-disease daily 0.8 https://clival.com/news/johnson-and-johnson-single-dose-covid-19-vaccine-get-approval-for-eua-in-india daily 0.8 https://clival.com/news/nih-launches-clinical-trial-to-evaluate-investigational-preventative-vaccine-for-epstein-barr-virus daily 0.8 https://clival.com/news/gujarat-fdca-issues-test-license-to-hetero-to-manufacture-lyophilized-injection-of-remdesivir-to-treat-critically-ill-covid-19-patients daily 0.8 https://clival.com/news/oncoc4-doses-first-participant-in-ovarian-cancer-therapy-trial daily 0.8 https://clival.com/news/vidprevtyn-beta-covid-19-booster-vaccine-developed-by-sanofi-and-gsk-approved-for-use-in-great-britain daily 0.8 https://clival.com/news/taiwan-fda-approves-chugais-actemra-to-treat-covid-19-in-hospitalized-adults daily 0.8 https://clival.com/news/gc-biopharma-gets-south-korea-approval-to-start-phase-1-trial-of-mrna-covid-19-vaccine daily 0.8 https://clival.com/news/us-fda-warns-online-vendors-to-stop-selling-unapproved-weight-loss-drugs daily 0.8 https://clival.com/news/uk-mhra-authorizes-from-sk-chemicals-skycovion-covid-19-vaccine daily 0.8 https://clival.com/news/intas-brings-indias-first-needle-free-injection-technology-to-ivf-and-gynaecology daily 0.8 https://clival.com/news/edgewise-therapeutics-reports-positive-phase-2-progress-for-edg-7500-in-hypertrophic-cardiomyopathy daily 0.8 https://clival.com/news/foresee-pharmaceuticals-reports-positive-phase-3-results-for-fp-001-in-central-precocious-puberty daily 0.8 https://clival.com/news/diamyd-medical-accelerates-primary-efficacy-readout-by-9-months-in-type-1-diabetes-phase-3-trial-following-us-fda-alignment-and-guidance daily 0.8 https://clival.com/news/mabwell-announces-first-patient-dosed-in-phase-ii-trial-of-anti-il-11-antibody-for-pathological-scarring daily 0.8 https://clival.com/news/rosm-selected-to-lead-groundbreaking-clinical-trial-for-osteoarthritis-1m-grant-powers-search-for-disease-reversing-therapy daily 0.8 https://clival.com/news/tiziana-life-sciences-completes-clinical-trial-of-nasally-administered-foralumab-to-treat-covid-19-in-brazil daily 0.8 https://clival.com/news/ultragenyxs-setrusumab-misses-primary-endpoints-in-phase-3-oi-trials-shows-bone-density-gains daily 0.8 https://clival.com/news/immunoforge-heads-to-jpm-2026-to-seek-global-partners-for-fda-cleared-phase-2-assets daily 0.8 https://clival.com/news/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-receives-interim-authorization-from-health-canada-as-a-treatment-for-covid-19 daily 0.8 https://clival.com/news/i-mab-reports-positive-interim-analysis-from-phase-23-study-of-its-gm-csf-antibody-plonmarlimab-tjm2-to-treat-patients-with-severe-covid-19 daily 0.8 https://clival.com/news/scinopharm-becomes-the-first-taiwanese-company-to-win-us-fda-approval-for-glatiramer-acetate daily 0.8 https://clival.com/news/ascletis-secures-fda-ind-clearance-for-phase-ii-diabetes-study-of-oral-glp-1-asc30 daily 0.8 https://clival.com/news/astrazenecas-baxdrostat-shows-strong-phase-iii-results-in-resistant-hypertension daily 0.8 https://clival.com/news/delova-reports-positive-phase-3-results-for-long-acting-ropivacaine-qp-6211 daily 0.8 https://clival.com/news/geneditbio-secures-us-fda-ind-clearance-for-first-in-class-genome-editing-therapy-in-corneal-dystrophy daily 0.8 https://clival.com/news/metavias-da-1726-delivers-rapid-statistically-significant-weight-and-metabolic-benefits-in-phase-1 daily 0.8 https://clival.com/news/fda-grants-priority-review-to-tzield-for-early-childhood-type-1-diabetes daily 0.8 https://clival.com/news/endeavor-health-joins-trial-to-diagnose-cte-in-living-patients daily 0.8 https://clival.com/news/bambusa-therapeutics-doses-first-patient-with-bbt002-in-phase-ib-copd-trial daily 0.8 https://clival.com/news/gsk-secures-ec-approval-for-shingrix-in-a-prefilled-syringe daily 0.8 https://clival.com/news/phase-iii-tulip-sc-trial-confirms-subcutaneous-saphnelos-efficacy-in-lupus daily 0.8 https://clival.com/news/ascletis-secures-fda-ind-clearance-for-oral-glp-1-asc30-in-type-2-diabetes daily 0.8 https://clival.com/news/oxeia-biopharmaceuticals-launches-equity-crowdfunding-to-advance-first-potential-treatment-for-persistent-concussion-symptoms daily 0.8 https://clival.com/news/addex-spin-out-neurosterix-begins-phase-1-trial-of-novel-schizophrenia-drug-ntx-253 daily 0.8 https://clival.com/news/nimbus-therapeutics-and-eli-lilly-expand-partnership-to-develop-novel-oral-obesity-therapy daily 0.8 https://clival.com/news/muna-therapeutics-secures-1-million-alzheimers-association-grant-to-advance-trem2-targeting-therapy daily 0.8 https://clival.com/news/lillys-together-psa-trial-shows-dual-therapy-can-improve-psoriatic-arthritis-and-weight-outcomes daily 0.8 https://clival.com/news/zydus-cadila-gets-usfda-nod-to-market-generic-cancer-drug-in-us daily 0.8 https://clival.com/news/mrm-health-receives-us-fda-ind-clearance-to-initiate-phase-2b-trial-of-mh002-in-mild-to-moderate-ulcerative-colitis daily 0.8 https://clival.com/news/clover-initiates-phase-2-clinical-trial-for-rsv-hmpv-piv3-respiratory-combination-vaccine-candidates daily 0.8 https://clival.com/news/nrg-therapeutics-doses-its-first-in-human-phase-1-trial-for-nrg5051-to-treat-alsmnd-and-parkinsons-disease daily 0.8 https://clival.com/news/novavax-begins-phase-ii-study-for-covid-19-influenza-vaccines daily 0.8 https://clival.com/news/armata-cleared-to-advance-phage-therapy-ap-sa02-into-phase-3-for-complicated-s-aureus-bacteremia daily 0.8 https://clival.com/news/johnson-johnson-showcases-new-phase-3-neuropsychiatry-data-at-acnp-2026 daily 0.8 https://clival.com/news/thryv-initiates-wave-ii-pivotal-study-of-thrv-1268-in-long-qt-syndrome-type-2 daily 0.8 https://clival.com/news/merckgates-collaboration-advances-next-generation-tb-drug-candidate-tbd09 daily 0.8 https://clival.com/news/bristol-myers-squibb-reports-positive-phase-3-results-for-camzyos-in-adolescents-with-obstructive-hcm daily 0.8 https://clival.com/news/hyundai-bioscience-unveils-broad-spectrum-antiviral-strategy-as-it-enters-us-phase-2-trials daily 0.8 https://clival.com/news/askbio-secures-us-fda-ind-clearance-for-ab-1009-gene-therapy-in-late-onset-pompe-disease daily 0.8 https://clival.com/news/brenig-therapeutics-advances-two-cns-programs-into-key-clinical-milestones daily 0.8 https://clival.com/news/frontage-laboratories-brings-new-gmp-manufacturing-facility-fully-online daily 0.8 https://clival.com/news/verana-health-expands-site-explorer-with-real-world-urology-data daily 0.8 https://clival.com/news/ingrezza-shows-nearly-two-fold-higher-vmat2-target-occupancy-vs-austedo-xr daily 0.8 https://clival.com/news/sun-to-launch-mercks-covid-pill-molnupiravir-as-molxvir daily 0.8 https://clival.com/news/zylox-tonbridge-to-acquire-germanys-optimed-accelerating-global-vascular-expansion daily 0.8 https://clival.com/news/diabeloop-and-sequel-med-tech-partner-to-bring-closed-loop-insulin-delivery-to-the-us daily 0.8 https://clival.com/news/boston-scientific-to-acquire-penumbra-in-145b-deal-expanding-vascular-leadership daily 0.8 https://clival.com/news/fda-clears-first-acl-implant-label-claim-for-reduced-osteoarthritis-risk daily 0.8 https://clival.com/news/brenig-therapeutics-advances-two-cns-programs-into-the-clinic daily 0.8 https://clival.com/news/finger-prick-blood-test-could-transform-alzheimers-diagnosis daily 0.8 https://clival.com/news/insilico-medicine-and-hygtia-therapeutics-partner-to-advance-ai-discovered-nlrp3-inhibitor daily 0.8 https://clival.com/news/cannalean-completes-first-in-human-study-for-oral-cbd-based-dyslipidemia-therapy daily 0.8 https://clival.com/news/verb-biotics-clinical-trial-shows-probiotic-can-improve-sleep-and-reduce-stress daily 0.8 https://clival.com/news/fda-grants-de-novo-approval-to-bridge-to-lifes-vitasmart-hope-system-for-liver-transplantation daily 0.8 https://clival.com/news/alnylam-presents-positive-results-from-kardia-1-phase-2-study-of-zilebesiran-to-treat-hypertension-in-patients-at-high-cardiovascular-risk daily 0.8 https://clival.com/news/veloxis-vel-101-granted-fda-orphan-drug-designation-for-liver-transplant-rejection-prevention daily 0.8 https://clival.com/news/syngene-extends-long-standing-research-partnership-with-bristol-myers-squibb-to-2035 daily 0.8 https://clival.com/news/histoindex-partners-with-houston-research-institute-to-advance-ai-based-mash-diagnostics daily 0.8 https://clival.com/news/gujarat-fda-issues-licenses-to-12-more-oxygen-manufacturers-to-produce-medical-oxygen-to-cater-to-covid-19-patients daily 0.8 https://clival.com/news/jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease daily 0.8 https://clival.com/news/gillson-sciences-expands-into-environmental-health-with-sanair-acquisition daily 0.8 https://clival.com/news/agc-biologics-supports-commercial-launch-of-waskyra-after-fda-and-eu-approval daily 0.8 https://clival.com/news/trevi-therapeutics-nalbuphine-er-shows-significant-cough-reduction-in-ipf-patients daily 0.8 https://clival.com/news/histoindex-partners-with-houston-research-institute-to-advance-ai-enabled-mash-diagnostics daily 0.8 https://clival.com/news/european-commission-approves-ionis-and-otsukas-dawnzera-for-hereditary-angioedema-prevention daily 0.8 https://clival.com/news/sanofis-amlitelimab-delivers-positive-phase-3-data-in-moderate-to-severe-atopic-dermatitis daily 0.8 https://clival.com/news/novo-medi-sciences-launches-nexipox-plus-india-specific-upgraded-varicella-vaccine daily 0.8 https://clival.com/news/nuliv-science-preclinical-study-shows-astragin-supports-gut-barrier-function-and-probiotic-adhesion daily 0.8 https://clival.com/news/roches-ct-388-delivers-225-placebo-adjusted-weight-loss-in-phase-ii-obesity-trial daily 0.8 https://clival.com/news/bausch-healths-phase-3-red-c-program-for-rifaximin-ssd-misses-primary-endpoint-in-cirrhosis-related-hepatic-encephalopathy daily 0.8 https://clival.com/news/tetrapharm-reports-promising-preclinical-data-for-tpc-026-in-chronic-management-of-metabolic-disorders-and-obesity daily 0.8 https://clival.com/news/skyhawk-reports-positive-9-month-interim-data-for-sky-0515-in-huntingtons-disease-expands-global-phase-23-trial daily 0.8 https://clival.com/news/bayer-to-showcase-radiology-pipeline-advances-at-ecr-2026 daily 0.8 https://clival.com/news/opus-genetics-launches-gene-therapy-clinical-trial-for-mertk-related-retinitis-pigmentosa-in-abu-dhabi daily 0.8 https://clival.com/news/fda-clears-micurx-ind-for-mrx-5-to-enter-phase-2a-trial-in-m-abscessus-pulmonary-disease daily 0.8 https://clival.com/news/innovative-molecules-advances-adibelivir-into-phase-2-for-hsv-mediated-diseases daily 0.8 https://clival.com/news/boehringer-ingelheim-reports-positive-phase-ii-results-for-apecotrep-in-primary-fsgs daily 0.8 https://clival.com/news/mumbai-co-gets-ok-to-use-sepsis-drug-for-covid-clinical-trials daily 0.8 https://clival.com/news/pfizer-biontech-announce-new-agreement-to-supply-european-union-up-to-18-billion-additional-doses-of-covid-19-vaccine-comirnaty daily 0.8 https://clival.com/news/ena-respiratory-doses-first-participants-in-phase-ii-study-of-inna-051-to-protect-against-symptomatic-viral-respiratory-infections daily 0.8 https://clival.com/news/almiralls-seysara-receives-china-nmpa-approval-for-treatment-of-moderate-to-severe-acne daily 0.8 https://clival.com/news/tenpoint-therapeutics-yuvezzi-gets-us-fda-nod-the-first-and-only-combo-eye-drop-approved-to-treat-presbyopia daily 0.8 https://clival.com/news/crystalys-doses-first-patients-in-europe-for-phase-3-dotinurad-gout-trial daily 0.8 https://clival.com/news/mwyngil-therapeutics-initiates-phase-1-study-of-bt-409-for-neuroinflammatory-diseases daily 0.8 https://clival.com/news/japan-leads-asia-in-fda-novel-drug-approvals daily 0.8 https://clival.com/news/astrazeneca-signs-185-billion-licensing-deal-with-chinas-cspc daily 0.8 https://clival.com/news/redhill-biopharma-reports-positive-results-from-us-phase-2-study-with-opaganib-in-patients-hospitalized-with-covid-19-pneumonia daily 0.8 https://clival.com/news/affinia-therapeutics-secures-fda-ind-clearance-for-aftx-201-gene-therapy-in-bag3-dcm daily 0.8 https://clival.com/news/lumosa-reports-positive-phase-2-data-for-lt3001-in-acute-ischemic-stroke daily 0.8